<SEC-DOCUMENT>0001558370-20-012713.txt : 20201105
<SEC-HEADER>0001558370-20-012713.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105074250
ACCESSION NUMBER:		0001558370-20-012713
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14710
		FILM NUMBER:		201288724

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tmb-20200930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/5/2020 12:41:41 PM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: 952d31b7-3800-4097-9fdb-b8cae8c45754 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xoma="http://www.xoma.com/20200930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" xs:nil="true" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_9fZV6tGInEm0Q_FtG97kvg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" xs:nil="true" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Y_CFql4RikqDJzDMsiLOyQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_VjJVgvPwDkec6c4_FaXVnw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_6rFBxsxSGUqWrzXyiyTPaQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_qM6MJxl9CUKlygW0ppMF8g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_Vt48BbUiq06CvSGayf-8QA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_aSz0lyBNPk-MEGOiHfxTfg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_eU6K4_Z_lk2aE4zqKPrSgw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_BNB6kHviz0CsAKBxm_14mA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_dBHKRSLA002JHAMa878AjA">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityCentralIndexKey" id="Tc_PCfTgI7zUU6RVWqBWo-Hlg_2_1">0000791908</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:CurrentFiscalYearEndDate" id="Tc_5tUrkpsvjU2amZ1qdjVLwQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentFiscalYearFocus" id="Tc_5id4Yf-dpkuTgJ8dP_Ri_g_4_1">2020</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_zSQfT3WjbEmPtjRFfOqTlg_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:AmendmentFlag" id="Tc_TmsJzZ2QoE67KOQXsJj-MQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_0v2GnvbuBUGnfiOITD1bGQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_HtFobGvaM0a2AGcx3GzdcQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_wmNk2xC8k0S5yzE_7UsZ3w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_s4qMH8rVcku8i1uqsZgWBg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_9jDFZSkITEmOQWDHpi9lVg">6256</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_VlGnZTX-K0GzxN0CnUm8kQ">5003</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" xs:nil="true" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" name="us-gaap:PreferredStockValue" id="Hidden_pSbH5_Hu1UuaeDzOMSNqVg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" xs:nil="true" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" name="us-gaap:PreferredStockValue" id="Hidden_P4u2-aylQkOppw-2vXNJkA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_MGA0NvMgU0KJy_aFX1818A">9758583</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_wN9uB1ZuGk2FpHpwvpoRrA">11022143</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" sign="-" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" id="Hidden_h9_CU4N9hUeGKrZXcAoQxQ">1077000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" id="Hidden_GqyhXSrR5ky5_NPVxRDXDg">3178000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" sign="-" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" id="Hidden_Xa8_bVITYUiniHoTQl_7aA">9368000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" id="Hidden_v_w-0LV3PkSUVby9iBXvjg">2339000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A" decimals="4" name="xoma:PercentageOfAggregateSharesHeldRightAndOptionToSell" id="Hidden_5JMn34DvnkG2-h_9uI7tlA">0.3333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_IvzhjoQ1qkKnonNbFMwDHw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw" decimals="-5" name="us-gaap:ContractWithCustomerLiability" id="Hidden_6KcCQ2KmOUSERG_vOJUbuA">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VvqL6IhpekWtsweye5jZRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Lk396fUAR0mQ7Bxv2PCf3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_mQ-Twe7RO0Gh68dOSmYzIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_90hIlWqbgUaomWenCQwomg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pyJIa2rRckSbu4tMGZ7OQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_JlCyW65-O0OyudJIFvxeLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_bcq3GNUerEmVGRoYfGrnYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_uYjlieKTNEqKshJwUd9daQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TOYjkQxmGUCjZkjeSJlhUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_hVBra_ri2UOdlaAWOeBi1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_PlBfqshTSkaD5A1hfHjWOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyPurchaseAgreementMember_tYew2cGdwUWvjZAtJPwK7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_O7QrlKu98UGAIfv-vA1UQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-26</xbrli:startDate><xbrli:endDate>2019-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gkqI07hkKE2Ouf8ac3CdpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_WQB1V7-nwkm5651laM-Szg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_H1Cj_SIgjkCN0aYFMFbweg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_mi0xAnsFn0qDd9-F2V5_PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_qj2q9750f0eTH2ZT8YKEfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_0uPI2yU0iUS8hyjvd1t3XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NwHPINtT2E27syT0FERCZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DqK_86Lt2kGOZ5tETJSWVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_whotwsqlPUWlIpHCjIDEwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_tcvB75A62UqaD7Gz2Fyu6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ryahLRb460WZ_uEMdm-Gdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2008-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-03</xbrli:startDate><xbrli:endDate>2020-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sQZl0NJ6VEitMJ9UCcOjeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_9qNUOmhml0CM6tQxIvq-zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vF4M7itcq0qmDA1FQGsWbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_y28H4G623kys0zqGl3uk7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_HUFMmZpyxUmnf6MQcbwsUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_9_2020_To_10_9_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Wdtq6HhGbkyK1Ip4HHUIVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-09</xbrli:startDate><xbrli:endDate>2020-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2019_To_12_2_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_IZ5MZsXg_0uvXBtAPFu7OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-02</xbrli:startDate><xbrli:endDate>2019-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_QGXGPdezx06vh-Y7VCyZzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_St9i97mas0e22erorbJ1jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bl4vMQZQ1UG2x7-nwv1Wxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nFBHFZRpIkK4eK-sS_dY2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_RYA4JA0yrUCgyI6USQlccg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_J64v0Y9UbkWCwMWpG5hjQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_eVulBzUmCkKYuR7HDbiMhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-07</xbrli:startDate><xbrli:endDate>2019-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2017_To_2_28_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_zbfdDVr-vEikYw024muE5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_4_2019_To_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_5-XsEkqIb0O1_ILDeS9Gbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-04</xbrli:startDate><xbrli:endDate>2019-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2018_To_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_7DchDq9txkuakRpZQxN2Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-07</xbrli:startDate><xbrli:endDate>2018-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_1Myp4OOGqEKp2h3UVxadrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_QJfyk6LBB0y8TAEOtRhUbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_WyJEPykhS0yKbLZyNfLarQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nxvD1pY7ckS0UoRcs7ScvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-07</xbrli:startDate><xbrli:endDate>2019-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementX129Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2019-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_5lBpdkZpkEOX6-ywF04jcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_D0iNeUKX6UmzP9knxvEqaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-07</xbrli:startDate><xbrli:endDate>2018-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_j9t6d3XVyEWVqb-VBqtwnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_hAurvrTCL0uLGiyoscfcDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_m--qxWG3306IlcAtWJRFYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_EG_Q04r1k0GkBf-7UuDNjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2008_To_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_QfxCyr376USWRtXD17lOFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-09-01</xbrli:startDate><xbrli:endDate>2008-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_rxCwxf0QfUC9qk9Y_rh-eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_U6qdZrT-gUyphLqQMtHQng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_82L3K22qB0OdI0xUjjPm3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VjJ154auA0SD0BIHuZfOvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XaAWLwY770yBqnJd66HkrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-30</xbrli:startDate><xbrli:endDate>2019-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_Aq-O5Rvu_EG2xp_gxz4Gog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-05-01</xbrli:startDate><xbrli:endDate>2005-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2020_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_xoma_SeriesYConvertiblePreferredStockMember_Nj6TY6mgREyFvS2FQnthTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-03</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-30</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_ym6GLGOCy0yMN7HEESO78g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_2CZITBcVHU-Wgwh02jgIcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_MLU4k6KwO0e9m_Pf_os80w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_HrZIHs7O0UmWnhE2ICmFRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WqMgA-6e6kKmzgZNkJ6D0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ccfeS0VvmEuzUI-eiCKILw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFqqIoJL6E-YhthBhWYj6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_XDDor7baIkKyVKi2CJALuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_aD3k4_xk0EmzKHYfKIHIkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_44Jv_9l0yEu1_bEJhWroxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TyS4yAARRkOfhp3ZxgbyUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_R6x4VB5rkUSXD6oQWozXow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BpbgFdtUnke6KePzNaAfHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gWy-6Gw0aE-cAVIs8qB1-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hVEOeh5aZEmR21X1cz8YBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hlXDqQFb7UiKkqmKiwmObQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4A9-6p_84UiD0W2C5Za79Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_A4Fy7zVmnE2bfYQP0JYuiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pjxiTZywc0Wh6ZS22OYjuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sxxar2wWpEO_tGxnLsLLNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_s8s2F801V0SAntrBz7QyGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4N7F13h40ei1PNANLYZSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rP3tRAF8okybPM5hXTuJcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cY_riJ8ogEyCIjKm-1Dt3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uJ6C1JclfEqlTJ-BWfyYmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8THgqDdF-UuNoobclQVfIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jjydCrSLg0mxBT8T-UT6lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_AzRfCDaAQUKUmbmpbfVREg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BQMMHQz-90SmMzcNZJyNuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_osmPZAaeXEeF1lGAcFKPOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_Gh1sLtuoUk-sktvmIjYABQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xpsU-mpF3kaxH7Ar8BNhJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1ACuNNCz302yJVI99Iw5Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ROSrvWU66Eihc8UxuVEfvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_5cJagsvRIUaSv_KPMcQ3kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ECWY-fNR0Um4xrsyO9bRHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_GyucTZFnFU2YNGHx9ZQbnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zP13eTII7UilJItaI_yfUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bny-C6Pdi0WV2-8Z_Y4imQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_86zFUJxWa0Sowa2Y2-Beuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_b2BCEiFHZkqKPcE1gO60xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_RJ9Qlzbmi0O4zgEGElxXYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RUC_5NPG6ka8TvuxEM93Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QywYLWDewkuT4ebzmi68Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZtQmYwfNU6UL1F3kzpYtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_gPaYGyy2xkaDpvkBVLS-vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_spNgKpVzV0SFHWEoUU3GIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_bsRXsMH6rEOZqpfaU8z-Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_HlFFyZp90EKVNXtLD7WtKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_hayCoIN1Nki93_kbNGtPnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_9DVd9snmb02Tp8DZcf-2Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-21</xbrli:startDate><xbrli:endDate>2020-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_SXy_rcf1HE-sOiNkx-qqfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WNBaxopPiUiO0lekbTR3QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IT6QiO78xka2AQOOc1LOTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_qDUv8TEmVUiCki1cFKC_pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lg0H9jEOVUWKuKkJPri6jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UyMAk0h1pkWFrzI4SV59gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_aDDtU1Gqbk2yENmRPLeZEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_icqncM0pU0-kgas-GLplCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Ly6c31YnNUudvyfVl4nIcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_BU0vF3ofNkq6-z8Hkgq8qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eIy62rKGB0arkcYOhjzDlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_89o9tNvIJ0KB_EHx37NNug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27iut_LRX06eiWjddrdvbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_2tva6vIdREy4CHVmhj6hXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0nldtO9DMkyHVBM2GSo1qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_iK5dxlDC5kGuHLYJAFQjtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_D1p_zcUBUkyNi8tT3yY_hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GtNAno1Ke0iBcXqeK0kWoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_p6M7bhFzkEityaF4ZSk6kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_X8Vp97mKY0uNE717S6FXRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FWdasQOebUi4BvD0XzdauQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_JkbgTe29GU66NJfrMM3fWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-26</xbrli:startDate><xbrli:endDate>2019-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_xb_L_CetzU-uTJy5lWyAAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SecondTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7r0aHlZReUi3PqLdTuvGMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_1sIgH-TDmESIxi03ZCZdFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:FirstTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_6hHu9AeYSUi8Kjb-gsHXKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_z49RnI3stEODl-bB_4KFnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I1_FVLXQ30-8Ii9Rp4UaBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VR-z9bAmAEORRoi_pcVyOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Es2aTH6mzkmx8JPow1Wk5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BfyNiRBteUaq65VmnaTxwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lTYMNfRN7UyqGN9s3-87hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_55yjxRlLR0OOL8PFIxgQ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BvERxoSpn02VGxEAbYiLDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ROF4dELbnEKrkSBAq5Id-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_fc2DGhmLsU-P9b9i3fCa3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-qZT9POIkCNrG3Grph7dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_o9TKgo2PdkaRxCnPv5UwzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a30zLf3tz0OUKijReg49Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_K5wO4sN8QkaBiKw6ZJuixQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_WZsCIx7v_0eJCosFrT_7PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_j3P1UZ7onkKj9MeRA1L4Pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qRuzS7PxN0mhOpigbZVLcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-_VDIVr4EyNvxmIlDGnMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_NHx7oG_kKE65ICx_DXfo0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2005-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_SqIlV2-rakKVcalxYbzoAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_uWG4bPOtsk2Nwyko1KBEuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_hzEj56jCBEaI-AttEMG2SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_MNkxvd6px0Shg6qQPgSkhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_78opXNQ0QUCrlHhRR1n9Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_9TjQxVDWVkKyIj9TiaRkjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_pEtQLs5d2E-SAflZCpXZxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_o7vjlCxW1UuogpVKDCyxSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_1WJzW9HoPEib8xgIXL4tQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_eFRO3EsZIkmFH2cQ0wM35w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ZXd3cmpR10SClHLRFX8RSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_as3Q7AGP7kiK9uKgqvnZSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qrgth34a6EattwAKv19FyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_v4syz3rvHkSx0GCd0zfa9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2SoVfK-psE-uIiixwmUMVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_myPVpetgYkKI3zoBMnb_yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_T9kkdRE5TU2GA0x-StB7yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:OTCM</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RyfA1p37m0mqf8zUp_nppA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_mI7JO_tljkCY56R1erZxTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-CVgtfFe3U6W6zb4Ddth-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_0OemnNunTEaN1i6wIdopTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_QbXdq24V_UuHONHKjjaZgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:OTCM</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_U_gsaxcdB0WA9FXj8HId5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SecondTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_QpM51obSbEy_0dOTKgw2QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:FirstTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Jd47lV9m20mVoxI2mVnXeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-21</xbrli:startDate><xbrli:endDate>2020-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_AdKOII3dC0-c3gz97adv_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-07</xbrli:startDate><xbrli:endDate>2018-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Laye7qFdbkaWNAv5Y8KxEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-05-01</xbrli:startDate><xbrli:endDate>2005-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_MnJGbUR0Q0arUfSSoF2XOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_RE1e6CumO0O-2KGTFiCqsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_UmYPv4uBU0-L1_gmyTWzwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wW3g01I-CEqS98TMD6LhAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Vh-yAeDCzEam1o4LJU3R9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wOjQWoE-yEyfuioBK5aSsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v9GiP1Qyk0qx9_F2-bs0WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_w6FnUVgyxk-uu6eq_pVLjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4EvFxExj10OrmYqKm4c1sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NREQuj8uA0eP9aMHPRFc1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RVLPSZwwQEyCcFoXmWjm_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OT29fxEd0kmg6WxFKFQGSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:FiveYearWarrantsIssuedSecondRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:FiveYearWarrantsIssuedFirstRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201818Member_mlMnqtv8RUS5hgexXcSDqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BzIKlySpD0yINoAWGMbaLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3CadpqFg8UOOttt6X8zQ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_HmB3foWGM0Wj8z_XGGsBhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_mkImYFxDL0WhSR47srlVEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aQmUj8E-FUqSQDzVNxRfcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_0Cv-gufQXUiXoT0EaH7Cqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_uJR98_x7FUu-h9HgcgHodQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_cB3ANTnBg0OCmZf8uEBeTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_i4aGeX3zlkORauSmBIjKjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_UVoSolrPv0qV5x4CzEronQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ovP2h0yP-E6tctRS1ZBHeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NZcEoPXaI0iAyxKBC5cgCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_m0TV8U2aI0CDgV82mWs52g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0x8EMKzDr0a9bWPJF31vLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_HsRG2H4itkerF2L9Qw8I9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_ql4aVy4WmEur4m9MMRr5Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_p7ZWEJ2xMU2VC0KWzZIypg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1VjeaxaG8UOf7PR7WpN3Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_x1Y6PfrxfE2TlMaI8OC3hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_2_2020_5kIZ95MFdkGBcfQ2IYo9lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ"><xbrli:measure>xoma:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A"><xbrli:measure>xoma:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_7zKUzhL-x069Du3GTyKbRQ"><xbrli:measure>xoma:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw"><xbrli:measure>xoma:facility</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw"><xbrli:measure>xoma:Y</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA"><xbrli:measure>xoma:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg"><xbrli:measure>xoma:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_rMXTIUZ4Q0GOaNm0YP-bKA"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_AqtsOpMfTku-KpzgyKR7UQ"><xbrli:measure>xoma:period</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_LBF1-NCEGUqoBLW6Sito6A_7_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_v8RjykmcG06RZG0yBSfN8w_16_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_D4UqmmRuG0O1At5TqCYp8w_10_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2QusaOESx0ur2PFoam0Taw_6_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_Y_CFql4RikqDJzDMsiLOyQ" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_M6ssgo2M90642RA-IF9OCg_38_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gNXHDdUGOUGblWIvgAVenw_25_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_WtNHDEvBt06od3wj_CVkow_28_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9fPqO3HUnkWpBDZekGHmNg_32_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_m2RJdozbC0W-6_yBYsrafA_26_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GdgJoNAAc0KIhoRV97vELA_29_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kuGUR7hnm0uhzcSQMsH34A_23_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_X6GCUHcXrUKlhPczPH8d_A_30_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_GeyTclnuQ0qNX78tFlSPTg_12_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Hidden_P4u2-aylQkOppw-2vXNJkA" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vGy_7ECjK06v13AqRMdINQ_11_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5rG1U6AyMUinpVHKmveKig_40_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_v_kra4dIXUqGKGjoC1FCVA_13_6" toRefs="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_27d1f359_d503_486d_b352_5ba8de42f25e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C.&#160;20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentType" id="Narr_PjdEX2Z2cUeSme2L3Nxbeg"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_b0e9037d_c346_461e_89f8_cfde342bd282"></a><a id="Tc_XVSIwnmbxk6g_GL8ViX8Kw_1_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentQuarterlyReport" id="Tc_VWFLRcn6OUK1wcNuxtOXAw_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentPeriodEndDate" id="Narr_WaN98j5630-NT1Ug4LQ-NQ"><b style="font-weight:bold;">September 30, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_ecd3b331_91d2_4446_ab19_07ca508b12fd"></a><a id="Tc_RmLAZdqgFkuIDSMeRVdZVQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:DocumentTransitionReport" id="Tc_hAk3C7AizEq-F0_oPcimBg_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from __________to__________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityFileNumber" id="Narr_q84vPGbCnkKsaDnndQepvA"><b style="font-weight:bold;">0-14710</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityRegistrantName" id="Narr_Q8nTZ5JC5UWgV7cjePBEYg"><b style="font-weight:bold;">XOMA Corporation</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_15f1dce6_e2ae_4da9_a515_16aacd7b610f"></a><a id="Tc_-HL2DRhfCEOnbSw5vO5a6w_2_0"></a><a id="Tc_Y2Ucvy0cP0eQlcbU82xF4w_2_2"></a><a id="Tc_ePKy2wouaEiY9swchpkawg_3_0"></a><a id="Tc_jqopyjCTh0yIczw7KioctA_3_2"></a><a id="Tc_Lttaj-8ULk-PGmffaiVCXw_5_0"></a><a id="Tc_Gy46FZKOXESr9caCr3ov1w_6_0"></a><a id="Tc_dMIvDL2wu0GHbjph70Jbsg_7_0"></a><a id="Tc_CIjpu6ks6UmyBH6Iq7pZEA_7_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_d2vEn6RSqkeDgyRdLy0Rng_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityTaxIdentificationNumber" id="Tc_XwVT9O9yS0utGUl6Mcp2SA_1_2"><b style="font-weight:bold;">52-2154066</b></ix:nonNumeric></p></td></tr><tr style="height:8.65pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityAddressAddressLine1" id="Narr_KcLiusEReEmYxslDRf0fgQ"><b style="font-weight:bold;">2200 Powell Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityAddressAddressLine2" id="Narr_q4yeoUKay0mXCKSUzEX6bA"><b style="font-weight:bold;">Suite&#160;310</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityAddressCityOrTown" id="Narr_s1AiYu8gS0G3BAyezsFLBQ"><b style="font-weight:bold;">Emeryville</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityAddressStateOrProvince" id="Narr_0OKKcgb0K0e4z6m3kMb6lw"><b style="font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityAddressPostalZipCode" id="Tc_kiCSIju9d0GMNbylpSnK6A_6_2"><b style="font-weight:bold;">94608</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:CityAreaCode" id="Narr_gcEX9hLYlkCXHWt1-E_3Og"><b style="font-weight:bold;">510</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:LocalPhoneNumber" id="Narr_9BKmzQEZuEGfx_UBWHoIaA"><b style="font-weight:bold;">204-7200</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_710ebf75_8d52_4e15_8ec6_fb992f85cba5"></a><a id="Tc_YAfYLCncWE2QZCpRpKxAwQ_1_0"></a><a id="Tc_LHvUTbzUQUCi4h0LzTq7bA_1_1"></a><a id="Tc_rNoyVj5LoUefiyjlaLKS3A_1_2"></a><a id="Tc_8boA31S0sEaYPoDPKtuTqg_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.65pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:12.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Title of each class:</b></p></div></div></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:12.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Trading symbol(s):</b></p></div></div></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:12.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered:</b></p></div></div></td></tr><tr style="height:16.6pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:Security12bTitle" id="Narr_np0WsH2gxEi0VzppZJw3eA"><span style="font-size:9pt;">Common Stock</span></ix:nonNumeric><span style="font-size:9pt;">, $0.0075 par value</span></p></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:TradingSymbol" id="Tc_sgNkcz2BFUCJiAug52mYjg_2_1"><span style="font-size:9pt;">XOMA</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:SecurityExchangeName" id="Tc_3C5MqUBAukWgQwMI-TyX2g_2_2"><span style="font-size:9pt;">The Nasdaq Global Market </span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160; &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityCurrentReportingStatus" id="Narr_pwvdNW_smk-HEHzp3eCYrg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160; </span><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityInteractiveDataCurrent" id="Narr__htFWruhSEy4_k2zH-IpbQ"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_cb8630ca_c154_44da_8da1_f73b5a94b661"></a><a id="Tc_vGLg5ugfgk2c2UiMWW3xyA_1_0"></a><a id="Tc_hS2xNKnFAE2TCP4j7BGcOg_1_1"></a><a id="Tc_5W8ocgE4jUuox8u6Sg-sRQ_1_4"></a><a id="Tc_DT-_K8kMkEyqPEg22j0MfQ_2_0"></a><a id="Tc_VT4LFkrQG0OVmgHNnpJ1yQ_2_1"></a><a id="Tc_9PKf-HEfmkiKaw40VoO2Tw_2_3"></a><a id="Tc_YDrv22fG7E62sDzPswObcg_3_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityFilerCategory" id="Tc_W6rr8l_h1kOoM0u84dYnmA_1_3"><span style="font-size:9pt;">Accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Non-accelerated filer</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntitySmallBusiness" id="Tc_MN000lvHVU6JUaWm4QPgOg_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:20.83%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityEmergingGrowthCompany" id="Tc_6hWDl_EoQUie5q4GZf48TQ_3_1"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.84%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="dei:EntityShellCompany" id="Narr_MqbbgiFPVUuMy7DshUKVEg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt;">As of November 2, 2020, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_2_2020_5kIZ95MFdkGBcfQ2IYo9lw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_j3J_Rx8aZEqsjLxDp1DsQw">11,022,143</ix:nonFraction> shares of common stock, $0.0075 par value per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:24.5pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_627e543a_eedc_4520_bc72_a697b18f5f28"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">XOMA CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM&#160;10-Q</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.75pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_600368"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;I</b></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_600368"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_68199"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December&#160;31, 2019</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the Three and Nine Months Ended September 30, 2020 and 2019 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Nine&#160;Months Ended September 30, 2020 and 2019 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows for the Nine&#160;Months Ended September 30, 2020 and 2019 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Condensed Consolidated Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr style="height:7.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_732379"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_732379"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_840286"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;II</b></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_840286"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_81705"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_81705"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_925437"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_925437"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">42</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_154961"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_154961"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_257142"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_257142"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosure</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_588036"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_588036"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_976152"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_976152"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td colspan="3" style="vertical-align:bottom;width:91.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_103825"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6376651c_6bb8_47c1_b027_44204a427e5d"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_600368"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I&#160;-&#160;FINANCIAL INFORMATION</p><a id="ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_68199"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_fbd15a45_a8be_4563_8de3_e920eb5d6c94"></a><a id="Tc_ODVPi-CZsEaHF0It13WpjA_1_2"></a><a id="Tc_0zELD9r-B0e6EH2MWesUjw_1_5"></a><a id="Tc_CHucK5vOPUCuL8LuMxSXTw_2_2"></a><a id="Tc_j-GvoFn_I0yeBuuqnasDjA_2_5"></a><a id="Tc_5slqP57s10S_Ql90PagZbQ_3_2"></a><a id="Tc_hO3BFvC3N0ioQBhkG2QrzQ_3_5"></a><a id="Tc_Wp65ImIQD0aajTvGt1K8UQ_4_0"></a><a id="Tc_04yNNn5jHUua9lWU1NVHyw_5_0"></a><a id="Tc_VvyNeEsIqE-VE6o9Kcj67g_6_0"></a><a id="Tc_4t3iHdVh_USYA3mlDj-C2Q_6_2"></a><a id="Tc_sxNPnVSccU6fUp88YbgWKA_6_5"></a><a id="Tc_vUIrKiX6_E6Psynp6MiJGQ_7_0"></a><a id="Tc_rNSLP10_CE6tYPzzVRuwgA_8_0"></a><a id="Tc_ItL9D9Z1x0CddV_WX_gY5g_8_6"></a><a id="Tc_tzvwdH1060u8XNHmEzsNTg_9_0"></a><a id="Tc_ztpxA-Ul0E-RbJFXYqLyZQ_10_0"></a><a id="Tc_0DC6dkvTxkW9yXOsN1xqFg_11_0"></a><a id="Tc_sC5bQB3KsEasIDbvfDCaMg_12_0"></a><a id="Tc_qg6U7ccHJEyW0109VW8AcA_13_0"></a><a id="Tc_BSVC8_Zm5Um6jbr8co2Uow_14_0"></a><a id="Tc_tWSy6cRctEqDK_fKsbdWQg_15_0"></a><a id="Tc_KOizbaIr2EOmiCwCgc8mjA_16_0"></a><a id="Tc_-978BHWJ-Uieivu3GsZ1UQ_16_2"></a><a id="Tc_tLSgDgjgoUSuLZCyqMGh7A_16_5"></a><a id="Tc_cIvu87q4qE2K9ex4ba2A8w_18_0"></a><a id="Tc_G1iY05euW0mte0rhrm6kWg_19_0"></a><a id="Tc_SHavekc0MESVLMv3qXDa9Q_20_0"></a><a id="Tc_b8JLesEvRUK0-Ld7yFFYew_20_2"></a><a id="Tc_yfcvdpCQxkWvRV3NN33Qpw_20_5"></a><a id="Tc_usVXxX9DsUywK2jsyykd9w_21_0"></a><a id="Tc_QhcgIk8jR0SAKhLsZuo_oA_22_0"></a><a id="Tc_tLUp97Y-JUaXiqHgPigeZQ_23_0"></a><a id="Tc_eQ-2xlhEhUyKJPlz9OKW9Q_24_0"></a><a id="Tc_0WijNZ2fx0-4v9kcOMa51w_25_0"></a><a id="Tc_E1BOzZI_EEiSE4znBADRcA_26_0"></a><a id="Tc_4Mzql0mCNUy3u6vu1JhyYw_27_0"></a><a id="Tc_wWlIKn9eYkCPRpkEVzE3iA_28_0"></a><a id="Tc_zJg2vU3Yf06JgvS4RlOmxw_29_0"></a><a id="Tc_x8Kuhi5YQEWyywqBjNh80w_30_0"></a><a id="Tc_bIKJIcVC8EC_eQnQHBxI-A_31_0"></a><a id="Tc_N9FJy_JAkUKn2WJo_4RyKw_32_0"></a><a id="Tc_a29gzT7GQkGHJcHawn73aQ_34_0"></a><a id="Tc_W03eKn3GcUuQ4dNdz-tABg_36_0"></a><a id="Tc_NYwq7_CgU0ypbjuItd--Tg_37_0"></a><a id="Tc_--s9dwg8ZEeCrvoMickoDw_38_0"></a><a id="Tc_FkORe9vzw0S4QaOJ5GB-hQ_39_0"></a><a id="Tc_2WxxwgO4P02Oj0DpaeVeKQ_40_0"></a><a id="Tc_6tV-MMwkn0y6sEnnIS0YXQ_41_0"></a><a id="Tc_0sPYyvc1Lk-foHbNAHTWVQ_42_0"></a><a id="Tc_x9JBDbx-m0CsaOIHbNaZdg_42_2"></a><a id="Tc_GHjInPuMukWXyg7LgSbaOA_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Note 1)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="Tc_N3PCQBUsUUOd7CtYnj45Xg_6_3">45,725</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="Tc_2QusaOESx0ur2PFoam0Taw_6_6">56,688</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Trade and other receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_HS65OOS-3kaWYR7H9uq5XQ_7_3">222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_LBF1-NCEGUqoBLW6Sito6A_7_6">2,933</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Income tax receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="Tc_C0dfnV4xdkiIfMRelNgJwQ_8_3">1,526</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_i16S-heXYE6hv0Mgwm1I5Q_9_3">671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6">352</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Vey0yC-yU06HdJh0_I_FYg_10_3">48,144</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_D4UqmmRuG0O1At5TqCYp8w_10_6">59,973</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_F52JZngr2UqXrc9hJPZx9w_11_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_vGy_7ECjK06v13AqRMdINQ_11_6">34</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_-JvaULAnME2BcDvH3UixCg_12_3">398</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_GeyTclnuQ0qNX78tFlSPTg_12_6">510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Long-term royalty receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="3" id="Tc_mVhc9mj1skettGGDS3BYpA_13_3">34,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="3" id="Tc_v_kra4dIXUqGKGjoC1FCVA_13_6">34,375</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:EquitySecuritiesFvNiNonCurrent" scale="3" id="Tc_MvmA2agzEkqx0AvgR8kGTQ_14_3">2,572</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="xoma:EquitySecuritiesFvNiNonCurrent" scale="3" id="Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6">681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_kvA9DDCMKUuCMt5R-XoGhg_15_3">215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6">151</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_cf8UTROuP0Wj8h6DRqgtSQ_16_3">85,728</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_v8RjykmcG06RZG0yBSfN8w_16_6">95,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_1stLr7aVUUyjRTbDCiRbPQ_20_3">450</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6">614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_gcCVlr-O5USkZ6kzzYmoaQ_21_3">466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6">945</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under royalty purchase agreements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="3" id="Tc_4e6uCov1bE-ERumGzLSYTw_22_3">75</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="3" id="Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6">75</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_hp12ClTSyEyTwT8TcCjkdw_23_3">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kuGUR7hnm0uhzcSQMsH34A_23_6">163</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Unearned revenue recognized under units-of-revenue method</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_2_ODOdGkZUi-1uUO2KMpPA_24_3">1,409</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6">1,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_sf7_rdnIDUK-Ep_nWVltTg_25_3">798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_gNXHDdUGOUGblWIvgAVenw_25_6">798</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Current portion of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_-UTGHkHbH0a92-MaKVr11w_26_3">8,962</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_m2RJdozbC0W-6_yBYsrafA_26_6">5,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_7nkpZHp9eEeYgNRvxeZG8w_27_3">12,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6">8,875</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Unearned revenue recognized under units-of-revenue method &#8211; long-term</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_rVntGiWrSky9GY67thNFJQ_28_3">13,952</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_WtNHDEvBt06od3wj_CVkow_28_6">15,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_ZGg83IryT0isZwvzXyFCTw_29_3">20,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_GdgJoNAAc0KIhoRV97vELA_29_6">27,093</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Long-term operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_Mn5AHFzwLEi_3-Vq1XGHyw_30_3">275</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_X6GCUHcXrUKlhPczPH8d_A_30_6">408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other liabilities &#8211; long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_Nv6fjvsxPUGimh1k92vRzA_31_3">134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6">43</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_kG8cjDJ0qEGXS0y3fOzzng_32_3">47,686</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_9fPqO3HUnkWpBDZekGHmNg_32_6">51,736</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commitments and Contingencies (Note 10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;">Convertible preferred stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_AIyElOeG3Uenm-1WndONGg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_jcr0GVhHyUaS3UPxB2WnxA">0.05</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Wyr4uQHdk06jmDybyg2oMQ"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_dz_BRu6cmUef03R2QLHWOQ">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_a8Ksc08o0UqVNwspBBP77g">5,003</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_2vT89XmhE0q_mBhNmvfA5w">6,256</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_9jDFZSkITEmOQWDHpi9lVg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_VlGnZTX-K0GzxN0CnUm8kQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span><span style="font-size:8pt;"> at September&#160;30,&#160;2020 and December 31, 2019, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_pSbH5_Hu1UuaeDzOMSNqVg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_P4u2-aylQkOppw-2vXNJkA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:right;"> &#8212;</span></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;">Common stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0PqcfniucE2o_pd2ZzCYFg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_LFIWRWs-vUWMyZyQd7Jjqg">0.0075</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_oimf3P2yqk6au8FP-JRT3g"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3S9In2N8RkeqGZcpEZAalw">277,333,332</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Lv7_42sqgkKEOcurH8fwRA">11,022,143</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_GmAoKruxxUGht20CNXJzNQ">9,758,583</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_MGA0NvMgU0KJy_aFX1818A"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_wN9uB1ZuGk2FpHpwvpoRrA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span><span style="font-size:8pt;"> at September&#160;30,&#160;2020 and December 31, 2019, respectively</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_uuU1MbVxYEKkCOUfB73alA_38_3">83</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_M6ssgo2M90642RA-IF9OCg_38_6">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_eBzb24q93E62nsqRuJTyHw_39_3">1,241,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6">1,238,299</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ASGkU4h-XUmmHuVZ0Cjg9g_40_3">1,203,752</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_5rG1U6AyMUinpVHKmveKig_40_6">1,194,384</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tSOOQ7dSFUOT7huE2fTLGg_41_3">38,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6">43,988</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_89IQwm5q1EeC47wZQr817g_42_3">85,728</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6">95,724</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">(Note&#160;1) </i><ix:footnote xml:lang="en-US" id="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_76af203a_d6af_4372_8e22_a408fc0b07b7"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8a79dbb6_9c17_4dbd_ab6d_1703915d0735"></a><a id="Tc_QzDWkDvJ80qETAmqg5_P5Q_1_2"></a><a id="Tc_LELlwsv1g0CN9_V09c94cA_1_8"></a><a id="Tc_NbeYJ9PpDE-iTHTI09ogXg_2_2"></a><a id="Tc_b_avIEpJYEKNMGjWCOrU_Q_2_5"></a><a id="Tc_6M5h1wKn70-AUtzvNN3yXg_2_8"></a><a id="Tc_ZsmdsuP4jk-v3fHEF9Hkjw_2_11"></a><a id="Tc_AmQwAFWOl0ygSQS1RO8dIA_3_0"></a><a id="Tc_T4baaz3PY0ClaAGATe5X5w_4_0"></a><a id="Tc_4KIqx8Efa0-cI-_60KtP6w_4_2"></a><a id="Tc_lcpJCDbOBE6O3Wui2Nlb_g_4_5"></a><a id="Tc_cmH4aAvrmk6j8i6rs3UwxQ_4_8"></a><a id="Tc_IJoRY2xv-E6-nlsm7re33A_4_11"></a><a id="Tc_78X1hse92UqUDQfJoYupIg_5_0"></a><a id="Tc_O2boY61TcEuq1x5ckqmtpQ_6_0"></a><a id="Tc_Zf_bddOjcEmbvAyJsbYD8g_8_0"></a><a id="Tc_kjh8eZgT7EO3fVeiDH02Eg_9_0"></a><a id="Tc_Vr2JwdsJKk-8Z-5BgtR_pg_10_0"></a><a id="Tc_KRNgFCPRXEaOrh2pCH9lDg_11_0"></a><a id="Tc_2pcFUF-Ej0aE1pAVf8Sr4Q_13_0"></a><a id="Tc_LBCP8DOaXEK-eij-x2MVZA_15_0"></a><a id="Tc_kgYAUhSaOk2jevkI2z2VQw_16_0"></a><a id="Tc_ixPVvfP5vkeSvLMFE9Cybw_17_0"></a><a id="Tc_IrmUMcht-kSXKH_0PX_gLQ_18_0"></a><a id="Tc_Be0Ih-bGf0-iqmyu0LH1xw_19_0"></a><a id="Tc_p0x4y9rGtUqKwbfHiowcbg_19_3"></a><a id="Tc_5L7wUbz0yk67v5veW2clsQ_19_6"></a><a id="Tc_EL6ygNBjPUyBSk4xWMp8VA_19_12"></a><a id="Tc_GuMe6xuj2EGumYwziNBrww_20_0"></a><a id="Tc_zmyuj9SUL0uhSXcHQ8eQcw_21_0"></a><a id="Tc_lxVwdsMNpUKtUsh_4Hpciw_21_2"></a><a id="Tc_I8etiStgLU-opcLJluvVmw_21_5"></a><a id="Tc_HpFq86QF2E62r-Y-0ANYcQ_21_8"></a><a id="Tc_wT2yuC_K002vgO16ymHFEg_21_11"></a><a id="Tc_NnaMRn6jcE2MYnF7r0WhZg_22_0"></a><a id="Tc_DSbmU-yGVkeYIvkSC7Q0lQ_22_2"></a><a id="Tc_80lVusXq4kegUyk9pRdFDQ_22_5"></a><a id="Tc_vHl165LEdU6xeg8cCGZ0Pw_22_8"></a><a id="Tc_t1p9cR_BOEaxGRL_LvF93g_22_11"></a><a id="Tc_T16rqQLIfkm6_4GG_vQGww_23_0"></a><a id="Tc_g5RNfqQLVE670PLD46bDPQ_23_2"></a><a id="Tc_9T9Xh7HNREiVQYuXAR9-uA_23_5"></a><a id="Tc_d-PIHerzkEynXNqFUzfIHg_23_8"></a><a id="Tc_iFKxEl5RhEqRCQQmpNjK-g_23_11"></a><a id="Tc_l_hV8ctYGEWd4H8j3_alVQ_24_0"></a><a id="Tc_Fa9etunys0iMKnhW3CLVuw_24_2"></a><a id="Tc_sIWnH7f6Ik6Hs3GTyAnN7g_24_5"></a><a id="Tc_3K-kuxv90EWRKVX9DVt-iA_24_8"></a><a id="Tc_wg41sJnBDk2BUjMbZ9oa1Q_24_11"></a><a id="Tc_Ld167xzsG0S6dQ_Ko_UCyA_25_0"></a><a id="Tc_-L54kmVjqE2DJ7TurIS7pA_26_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revenues:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc__bmQcLavmkiqIpMoe3QHmw_4_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_OKEV0VgxD0uxRYdlovwk5Q_4_6">8,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_7vQzuBmni0KFoeT80z3jDQ_4_9">753</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Pkq93CKuKESClXRivxS5xQ_4_12">17,176</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Revenue recognized under units-of-revenue method</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_9D89koMId0mjfIQMaJYndw_5_3">357</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_DxzFEPWdZUSv66MySV0zFg_5_6">330</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_KuN7pgopqEWTK8Q8eY6eJA_5_9">1,051</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_xY0jB1L0HUWfYabHEaP00w_5_12">772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc__eR8nf4iT0u3aKrXYTepDQ_6_3">557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_0ENloJszI0Gl_AK07SLcqw_6_6">8,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_sH0FgrutH0ODkY9QbNHM_Q_6_9">1,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ex-ffHADOUuuNH5HLGPUbQ_6_12">17,948</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_hbx4rXo0YEq4GENxR6Rh2A_9_3">34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Uy2W223X1UiAUfyUlaln2A_9_6">143</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_ldNmc4SCEECnZ-9ESWL2_g_9_9">134</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_og8JuhsUok25urlOE08TnQ_9_12">1,123</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_d1s15ay210GjKUnqdXiw1g_10_3">3,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5Wder3-v_ESm8VOX2Wh0BA_10_6">5,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Q5DKwB5lwEu83UHv6pwxgg_10_9">13,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_iEYufruCukS2A9EC_WDQSA_10_12">16,709</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Q9C47mnVH0CAfhc-zmb7iw_11_3">3,246</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_c4clvqkqLUKxg788gmqfhg_11_6">5,964</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_inrW3_bI9UyXPNU-iK7Tvg_11_9">13,260</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_sJo_OF55-Emk6r9YduJ7gg_11_12">17,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">(Loss) income from operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_hxD76l-0ak-oDmd_uUxejA_13_3">2,689</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_bX0XnGYf-0-YM1YmzRppIg_13_6">2,891</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_-VEX6F9jvUCd2tbl23jB4g_13_9">11,456</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_AY8Yw1jJ7ke0_vmSXeYJEg_13_12">116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other income (expense), net:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_HoMQkdep50SPZVi4XYii_g_16_3">434</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_FTQClJdcnkGqC-E3N_xFpg_16_6">484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_HfZpFg-jikWuYSDDOJLtBQ_16_9">1,484</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_JyT6iPDCCEi1vjwCOTt_JQ_16_12">1,336</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_2wUscXXx5EW2_ZcQ2UXzPw_17_3">2,046</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_QO-zQjNoO0y-cj4oBryF5A_17_6">771</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_fxIBxKmpUkK5kghwi6tLMw_17_9">2,046</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_BVzDa4Fd-U-DXEpyQPwC7w_17_12">3,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">(Loss) income before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_H9dftLV-n0uVFIxnpQRWXQ_18_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_qCTJQNvltku9FPoHH8xV0Q_18_6">3,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_F14Gc7n35EWwmrK671fbmA_18_9">10,894</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_t1Gre71MfUK_QrCE3tOQtw_18_12">2,339</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Income tax benefit </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_t10Lk5Y4rkiHCQIR0FkOlA_19_9">1,526</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Net (loss) income and comprehensive (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_h9_CU4N9hUeGKrZXcAoQxQ"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_NxBWIzkE50u2HxuWM0yEBg_20_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_GqyhXSrR5ky5_NPVxRDXDg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_X8X5UTcUHk-0jDeqDfMang_20_6">3,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Xa8_bVITYUiniHoTQl_7aA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jx0w0TIBO0eyLA7laEUBfw_20_9">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_v_w-0LV3PkSUVby9iBXvjg"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_Ew8WNRB4v0OcJmcJ1WbKHw_20_12">2,339</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net (loss) income and comprehensive (loss) income available to common stockholders, basic</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_hpeZHvWihECG0OcyuafySQ_21_3">1,077</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_6vhQHUSBbkG5Vjvy5kNNGQ_21_6">1,851</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_xFWn6SvquECCteXola9rAw_21_9">9,368</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_edtu8djfEE-kj3dy4nZhNg_21_12">1,362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net (loss) income and comprehensive (loss) income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_ZZVT1NXFBUG91bv7f0VJMA_22_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_a6byQqzjDEKuF9lbj2hNrA_22_6">1,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_A-eSFcrxBkOhwYdOGXqIVg_22_9">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_qEoe_Q23bUGx6fjEBEMQQA_22_12">1,403</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Basic net (loss) income per share available to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_qiYNbIEgME26Ue77Nvyp9Q_23_3">0.10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_EOD33HRdEU-sKqQHRUDdYw_23_6">0.21</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_67mhh2Y4Nke6BF8x4MzA9A_23_9">0.89</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_95kU8mBsPUqGPXS7_LdZJQ_23_12">0.16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Diluted net (loss) income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_GZf4Tf72tEOS-cyxe4peyA_24_3">0.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc__gSd0SvnpU6J45Q00aWPmw_24_6">0.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_pAG8euVOI0-FVbE8K2-sJQ_24_9">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_xF5KuBAHSUWAke2yJTw4dg_24_12">0.15</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_kKyJzsfLsUeOFmPVryxN4Q_25_3">11,019</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_5OWq_GosEkuFwDCDeRKB6Q_25_6">8,731</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_rL1QhSY27kKkjVeBTN6ahQ_25_9">10,537</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_LdSqR3jN0UyEbnC441B75A_25_12">8,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_zcefCODvZkOA1JkkNfGUWw_26_3">11,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_89pRMmmWX0eqEauHoMofsQ_26_6">9,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_mV5QCcpIMkSTlfp0zZ1hyQ_26_9">10,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_kRonUj9tWkq8JooregCRIw_26_12">9,379</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3bc930d0_0c2f_4dc8_818d_e79794b489a3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f7eeb721_2197_4d64_9ec1_2863d9854351"></a><a id="Tc_VzscoSjQzUykNnmMzjJgTA_1_2"></a><a id="Tc_sXj2C8kMW0mq88j_IegS5A_2_2"></a><a id="Tc_Axkg7dZ5JEy0yIue34msSA_2_12"></a><a id="Tc_B2Ihe9QYIkGfxE_aovY5TA_2_18"></a><a id="Tc_I4RSaJnXbUCJbunhKOjtQA_3_2"></a><a id="Tc_bUU3qhlgb0Ks1x4jdi3kfg_3_7"></a><a id="Tc_BgOklh5E-kaU1EO4PRWSVA_3_12"></a><a id="Tc_rzwobaEM4UqVjR5vaCjltw_3_15"></a><a id="Tc_ZPFiw3iQu0Kh9bHa292LLg_3_18"></a><a id="Tc_SM84j0mDzUWQvRLrXCAVCQ_4_2"></a><a id="Tc_WyWLeael20yUvv0DUumQzw_4_4"></a><a id="Tc_9BxMn9OD4UahEixrWCQi4w_4_7"></a><a id="Tc_zDjQeNoj_0WzY5gMbQAGHg_4_9"></a><a id="Tc_8OJAAX2FIkeNjUYQxWoWDw_4_12"></a><a id="Tc_TI-ufjs1ekCksO9rK1AdHA_4_15"></a><a id="Tc__tbrQzQI6kmkf8rXRIskbA_4_18"></a><a id="Tc_E2RHQZxKLUm24pJ5U9Ni6A_5_0"></a><a id="Tc_GZF5zgpkaEC3bukH9kaJ4A_5_4"></a><a id="Tc_JtREHaG_-0e-dfAW2DnoKw_5_5"></a><a id="Tc_aqxxha56g0SDLqUuDBGvSQ_5_9"></a><a id="Tc_bCgvvE6_HUmWy4Y4p87ijA_5_12"></a><a id="Tc_UnwOv0glGkulL43jp4ErzQ_5_15"></a><a id="Tc_6apg7664VkOgZ1iEpm1xrA_5_18"></a><a id="Tc_yNFB2B7JMkGHr4l79e_r4Q_6_0"></a><a id="Tc_pVkILMlzbUG5dkyIxyajcA_6_2"></a><a id="Tc_qE8antYXF02tMKcB7VlAhQ_6_5"></a><a id="Tc_cwEASs63rkyByMPy4aJr0A_6_10"></a><a id="Tc_69aIcWwLaEieC6KI-tuaGQ_6_16"></a><a id="Tc_xFqOvkGA2U-qY2t7T9B_9w_7_0"></a><a id="Tc_HdkMbJlb2Eqrvhxn52mwWA_7_2"></a><a id="Tc_GTW9_Dz4J0iQB_aJ5-mXIw_7_5"></a><a id="Tc_Gfjk8-E3WkakUoDXZGXGew_7_7"></a><a id="Tc_92yeAz_mpEqs_pWQ7f6cwg_7_10"></a><a id="Tc_84K4rm9TXEm3r9HLU_4QbQ_7_16"></a><a id="Tc_Rcyub-5xjUuyyE7zAxq7Fg_8_0"></a><a id="Tc_OzMOznbzDkuiXUDC52tA7Q_8_2"></a><a id="Tc_4sRTf2NHJESUBgmDQaJv5w_8_5"></a><a id="Tc_lR456jT99UGm6NE4d6lbtA_8_7"></a><a id="Tc_0Yd1__cJtEuIS2zTAUy5rg_8_10"></a><a id="Tc_dX50PulaGE-R1udxZ-3Zvg_8_16"></a><a id="Tc_bNpansBtZ0eoON33J0ooLg_9_0"></a><a id="Tc_YQIzlfFhA0uOuQTA1WlZ-g_9_2"></a><a id="Tc_V20M2G1FQkiTsP_bqBLC9Q_9_5"></a><a id="Tc_Ff0i35OQRkO77PagR0ZDaA_9_7"></a><a id="Tc_zhFsHv-FfkGYy-09XLSr0w_9_10"></a><a id="Tc_G7vZKvOXFE2V_UINUwwiUg_9_13"></a><a id="Tc_bk1UcH8BuEWNaZLXqTf11g_10_0"></a><a id="Tc_Rz8iJNl-BEuZ_bhXGgdPOw_10_5"></a><a id="Tc_uu2kAPh4AEi4bhh3nbPFoQ_11_0"></a><a id="Tc_alfBuzYF80q5GKCx0mgWMg_11_2"></a><a id="Tc_WZFv1uPLckO3L4sDlqmvVw_11_5"></a><a id="Tc_bs0_tU7A-Um2V_yOtO6Gng_11_10"></a><a id="Tc_HGGsUmsCYE6rJGFDmJzDcg_11_16"></a><a id="Tc_2_FjuC747UC8Jytt2kJKwg_12_0"></a><a id="Tc_46CZgHMeLk-i1hHcwzoj3Q_12_2"></a><a id="Tc_PmN0VQdW7Ueh7YJhWwhwzg_12_5"></a><a id="Tc_BR_yw_ssW066_fFHSTLFoA_12_10"></a><a id="Tc_-u8pAieTh0-lMVEqBwHPfA_12_16"></a><a id="Tc_Zua1uZKqcUGGfTsdZasSsA_13_0"></a><a id="Tc_pPur34cF0EaU3bH1h4k_LA_13_5"></a><a id="Tc_4csxz7ngiUelsjUGCRvNmQ_13_19"></a><a id="Tc_KJCe-ue2SkG0ZugXpSHpwg_14_0"></a><a id="Tc_KC82EnF7GkahK1_Gxlbbqw_14_2"></a><a id="Tc_CUFHPP7vWEmqCdVIHr5hjA_14_5"></a><a id="Tc_6KyNYvE3bkep2usc8cRRzw_14_7"></a><a id="Tc_NbWlmh0LikqBoEd5bJPLlw_14_10"></a><a id="Tc_9TUnHaVDkEOn1VXHTnsDkg_14_16"></a><a id="Tc_MLgOeAFO4kGhtbg9GYVFMg_15_0"></a><a id="Tc_pYmmIaW5k0y4n496t_lcIg_15_2"></a><a id="Tc_lESKSz5fWk-WJ2BZ-RSmRw_15_5"></a><a id="Tc_m6kslXpkuUmOKELSwzQhGg_15_7"></a><a id="Tc_PDMbJdWxG0iix0kSm9gMoQ_15_10"></a><a id="Tc_T50Ksy1ks0-As40OevTP_w_15_13"></a><a id="Tc_ZabH3bsAiEqb17vxqlBciA_16_0"></a><a id="Tc_m5ZJui36gUen-qFxGP8ptg_16_5"></a><a id="Tc_y2_Adg9aLEWNCylPnbtyFw_17_0"></a><a id="Tc_gaSySzqQMEGXjoyNNLs6Mw_17_2"></a><a id="Tc_5Xdjc2MvRUafOgoTJu3eYg_17_5"></a><a id="Tc_IzmuFn-C2UuTsOXrdO2O2g_17_10"></a><a id="Tc_K3BZVNHzpkWVtN2rW4pahQ_17_16"></a><a id="Tc_2dTR5MLpkE6-SbGPcaIl5g_18_0"></a><a id="Tc_Z0bDyYk5eUOHSUaAqeDK8A_18_2"></a><a id="Tc_3Y-zopPlq0um-o_R8qXGQg_18_5"></a><a id="Tc_4OjXPCX9LU2m2TYPQWI0lA_18_7"></a><a id="Tc_4DezitMBv0eprxZvG9jICA_18_10"></a><a id="Tc_S6n8rqeFukab55e6n070jA_18_16"></a><a id="Tc_Yf8ER3sGXUazE24CV1MCvg_19_0"></a><a id="Tc_7SAiWMIN9Eu257GipLAa9w_19_2"></a><a id="Tc_btaWK_8YRk2cwcMB0a2Ojg_19_5"></a><a id="Tc_3goljULZE0i44TV8wLAQAA_19_7"></a><a id="Tc_o0XnknD6YUK_n7lvpqEesQ_19_10"></a><a id="Tc_YiLYGnyt8UmTdJCuULW77w_19_13"></a><a id="Tc_NspKiRJh7kKlTZ7qE4OeGw_20_0"></a><a id="Tc_Nt3JcMxDCEibzRPXmB25CQ_20_4"></a><a id="Tc_4rydR2hJVUCZkr6d0aPTjw_20_5"></a><a id="Tc_wc6zvSvCwU2up_Ekaa6Sew_20_9"></a><a id="Tc_hByzEBPAv0On5qjsrdxqrw_20_12"></a><a id="Tc_tjbmwRazAEygccGPMXvuUg_20_15"></a><a id="Tc_VQrnGBYHIkm186mqB-gIvA_20_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="18" style="vertical-align:bottom;white-space:nowrap;width:63.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible&#160;Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_GyucTZFnFU2YNGHx9ZQbnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_NQEboWyyt0mGOBGmwFItYQ_5_2">6</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_a5HsRJB3hUSUDPMrJoQJ2w_5_7">9,759</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rKfifFs_2USlxxP8zeoXuw_5_10">73</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rP3tRAF8okybPM5hXTuJcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3DkLqdVZMUyZZsYnjWaURQ_5_13">1,238,299</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4N7F13h40ei1PNANLYZSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cvd8EcnRtU6s5YYKhBkV_g_5_16">1,194,384</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_N6thasIIak6VbTJ-nZO7YQ_5_19">43,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFqqIoJL6E-YhthBhWYj6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="Tc_QsDpQ7SP3kOrAJZ1Ocn6aA_6_7">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_Cl_6oFxwT0qfAr7SpUmDaQ_6_13">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_pelV70ndO0uwzryDcLAfVg_6_19">88</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lbjdW0-Fu0Gr3PlCzO53Mw_7_13">1,788</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_dLmq35yfoEy17J2VSmTRGQ_7_19">1,788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Disgorgement of stockholder&#39;s short-swing profits </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement" scale="3" id="Tc_sa-YJpUzSU-yubyxfW0Sqg_8_13">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement" scale="3" id="Tc_HrHiVd7Im02FfF2_XEUk2w_8_19">13</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Es2aTH6mzkmx8JPow1Wk5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qASed3bfAkKw1AZG-LVqYg_9_16">4,758</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lnJ5sZRTw0et4EO50XWxqg_9_19">4,758</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, March&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ECWY-fNR0Um4xrsyO9bRHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_9GOcjakEWUu47pQGQmQlVQ_10_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_4uEPyzpxeU6KlWAJkHsGDg_10_7">9,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_StDRkcVEsESVjGesVz-s2g_10_10">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sxxar2wWpEO_tGxnLsLLNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OiCZVrpMfUKFFnWQHafRKw_10_13">1,240,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pjxiTZywc0Wh6ZS22OYjuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_DSyXln_Er0arQ8xTNLC2ww_10_16">1,199,142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2020_s8s2F801V0SAntrBz7QyGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7c0T6bn0skGn9y6Im96JWA_10_19">41,119</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_OnShDLVahEK-OxPPiNnV-g_11_7">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fseiRmOvD0Cw3sPQJvZ6Ag_11_13">10</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_1JOKGYaz10C1QFAmQu62ww_11_19">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Tc_NXKR3UqCzU-l2Yr3avj-QA_12_7">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_EXUW4l-Nt0-M_Ap35wL-GA_12_13">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_x_xvhsaZeUGOunfjRP-jhg_12_19">26</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to Series Y preferred stock conversion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BpbgFdtUnke6KePzNaAfHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_6NBPimJvKEGNABYIYfmWqg_13_2">1</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="Tc_x5lEo3ZEO0y8wPOkpt3zrw_13_7">1,253</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_BydsyKrl-Ue-xcLb-zDCzQ_13_10">10</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_c9r70P7jEUOaNOqIp1Glbw_13_13">10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XreE1JByTk6waH54-XGsjw_14_13">773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FW76vxZN4kOPZSpqOt3mkQ_14_19">773</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VR-z9bAmAEORRoi_pcVyOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FNVn10NSAUO0DvcZC-9CCQ_15_16">3,533</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sTjPssxRZUCTqJPXGbQlxQ_15_19">3,533</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_5cJagsvRIUaSv_KPMcQ3kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_cu7vobWr20a5xs1OD4s2IA_16_2">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_MAu4Pz-VUkaUCmKsj2wflg_16_7">11,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FKmEUpEwuEqG4w6nhimijg_16_10">83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4A9-6p_84UiD0W2C5Za79Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HJjC3RICQkGyCeZ4xjjieQ_16_13">1,240,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hlXDqQFb7UiKkqmKiwmObQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GLgSIPfN-0OqspqVC79FOA_16_16">1,202,675</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2020_A4Fy7zVmnE2bfYQP0JYuiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uGibXeiKe0edlDrusBrxLg_16_19">38,395</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WqMgA-6e6kKmzgZNkJ6D0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_0EdfEAd0DUGlZ7ipcuwAvw_17_7">4</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_pqSuWyZNFEmrgh2dsHwv1Q_17_13">16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_rzRAsA6V40uPcy8_jlLu-Q_17_19">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-pqGp5gvU02dQUzNd_5eOw_18_13">708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_r4VRrTj7CUGMqG0DIgx12A_18_19">708</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I1_FVLXQ30-8Ii9Rp4UaBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EOnmy3CDHUGNZMc1xwYATw_19_16">1,077</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_AbKRe6aTlUaM8AfKgtMX8g_19_19">1,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ROSrvWU66Eihc8UxuVEfvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_La50Q-p-MEeKh0zxZouU9A_20_2">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_qSihX8-kEk-L2l9QW26BbQ_20_7">11,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_20tbeRI_Vkm0cf_ogLsIXw_20_10">83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hVEOeh5aZEmR21X1cz8YBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_lSt28omn60i3zWbhTZWX9A_20_13">1,241,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gWy-6Gw0aE-cAVIs8qB1-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_s_AYsrBsIEi4O3n60GpQtw_20_16">1,203,752</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xAiViHSKW0yq3FSCNu0p_w_20_19">38,042</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d1a950cb_baa2_497b_945c_97724bc4e8d8"></a><a id="Tc_Kjsm7Xtshkueor1xI-gJkQ_1_2"></a><a id="Tc_0m7nMjP6SEeRcGz0jrXiwA_2_2"></a><a id="Tc_nxW4Kxk5N0S2abGMpOilug_2_12"></a><a id="Tc_9wX_Xy2UlUOQsKxs7aqfdw_2_18"></a><a id="Tc_n1D-lsaa50K58dRubFfOlg_3_2"></a><a id="Tc_DB4haMgda0KQeq4gM643kA_3_7"></a><a id="Tc_6ogH1QAnE0ClVQn-zpaTWw_3_12"></a><a id="Tc_fN1duL8G5Eq7CfYpLNflrw_3_15"></a><a id="Tc_6MRHSMTEaEGiF6UutbTLcw_3_18"></a><a id="Tc_kvAW3hmQBk6C1sdKmTqjhg_4_2"></a><a id="Tc_z_0GH6OXEke4AwlOEPuDrA_4_4"></a><a id="Tc_zEgU6rgytk-gOItw_Fnq_Q_4_7"></a><a id="Tc_M6lXBLZ0K0uEjxR6RCkSOw_4_9"></a><a id="Tc_KAWEeJeSmkq2ohcLEl3yog_4_12"></a><a id="Tc_0A8kOsBhVkOljqNKN9EsDg_4_15"></a><a id="Tc_0OIHSJbIQEGzGHHdoj6EkQ_4_18"></a><a id="Tc_ectLN7TNgEa_2_l_H1SSNw_5_0"></a><a id="Tc_axUftofUmE-cL6CgD1--NQ_5_4"></a><a id="Tc_7IZFraIXgUWavHh4PwOAbA_5_5"></a><a id="Tc_F6pUMtgjIU-vHVryb2qHjw_5_9"></a><a id="Tc_sRopQI2nUEu5fuf-QW2cIg_5_12"></a><a id="Tc_lEEUNDWsyEyrYXlJV1WfWQ_5_15"></a><a id="Tc_3mZOt33XYUWncpDB_S9iyw_5_18"></a><a id="Tc_QbbPzpIJ1U2y0qP9zABWAg_6_0"></a><a id="Tc_cOMzdrsv7kOUZGFpCzN6og_6_2"></a><a id="Tc_U5xUcg_uMkm3Y_84Q_V_Lw_6_5"></a><a id="Tc_YuzYZJ27C0Ct9uXqcddixw_6_10"></a><a id="Tc_NaJWnNp7zEO3Ua2BWxK6_g_6_16"></a><a id="Tc_lFyIipli-Ei3i3ls4f-XpQ_7_0"></a><a id="Tc_Cjx0jczUQEOV0XH01MhIpQ_7_2"></a><a id="Tc__5fvVqfRtkiWjKXgj7LDJQ_7_5"></a><a id="Tc_-XGOE1nl8kmmF7Us0u3iIw_7_10"></a><a id="Tc_ke1QB8L5DE-HQRPJb8qFzQ_7_16"></a><a id="Tc_9Fun3QsTe0atI7_jkTYA8Q_8_0"></a><a id="Tc_6R8O7pSB8kawtNqscwxoGQ_8_2"></a><a id="Tc_uSFojjz0DE2Krk9s6-UkNg_8_5"></a><a id="Tc_826iTeQ8Q0qxjsiOVzN2Qw_8_10"></a><a id="Tc_a9Lz_G7fUUmM_uKuXRqykg_8_13"></a><a id="Tc_1GGe1In0Z0qB6-hhq43k1A_8_16"></a><a id="Tc_WOBoqLvdhU-YfikUSHLLlg_8_19"></a><a id="Tc_IXFob7UoRUuMdynQCC6ODg_9_0"></a><a id="Tc_qzSZmOKe6EGJ6wQtM81MdA_9_2"></a><a id="Tc_GvEXnZ7n_ECFl9ceqD8w9g_9_5"></a><a id="Tc_zJIUZjRqDku-CM_u0fVC4A_9_7"></a><a id="Tc_bquQxVGDaEu9z8h0YaPoAA_9_10"></a><a id="Tc_RttlBAs_r0uz0BjaB3SFdg_9_16"></a><a id="Tc_HCe49NRiFUCQGZYIQnJlCA_10_0"></a><a id="Tc_FBVZ-7CbskC3nvgbujQ3LA_10_2"></a><a id="Tc_uCnNkgAc5EWRIbJzSyF1MQ_10_5"></a><a id="Tc_UtS9HQtn80aNkbOzUWrH_Q_10_7"></a><a id="Tc_lLdZxxxr_0eBNdbQB9YDGw_10_10"></a><a id="Tc_EFxrGKnkLUmlzWtJScdtJQ_10_16"></a><a id="Tc_U2CLUqXvaEGy1RzmKk-u6w_11_0"></a><a id="Tc_WovsfjVFUEG-mzIvljw1qw_11_2"></a><a id="Tc_vusaoRAosUmzBuGTF8W2Jw_11_5"></a><a id="Tc_KDrlv0-YU0KwXV567K8SLA_11_7"></a><a id="Tc_CFfvFADesUadw9kSjk4iKQ_11_10"></a><a id="Tc_OuO767YhA0-f2EGP5sEX0w_11_13"></a><a id="Tc_c2rx01c-UkClO_bE4qDhgQ_12_0"></a><a id="Tc_1vot3b4KJEOBWKuCo5Az5A_12_5"></a><a id="Tc_Fzya1qhn5E63cNlPkJqepA_13_0"></a><a id="Tc_ZmN2aSxEnkumKvkv0E10dw_13_2"></a><a id="Tc_AVu6UUUgVUK0Qr9_xoGSVQ_13_5"></a><a id="Tc_RBYWe2LbOEuN1ljW0X9W5A_13_10"></a><a id="Tc_OCMBzjJ8wUaZMD5cN9dNkg_13_16"></a><a id="Tc_hFFT4i6cIkuC01FG_7LXNA_14_0"></a><a id="Tc_GgmX8iaFb0elGsEEX_lfZQ_14_2"></a><a id="Tc_b7GG7UDyg0WQSY7pTkfctQ_14_5"></a><a id="Tc_jKHtBCq4VEa4krlGEhQsUg_14_10"></a><a id="Tc_J5vauChgMUO9RkUCJIllww_14_16"></a><a id="Tc_gMvXWDDp1EitRmw31yIspA_15_0"></a><a id="Tc_xLmuUPdbD0yf0kjhylyThQ_15_2"></a><a id="Tc_NeXY8PqWdUKo0UN57dPbBw_15_5"></a><a id="Tc_W1wVjSZe70Gz7C1R6EnBnQ_15_7"></a><a id="Tc_NjzfoY9Ep0OPKrRDai6gNw_15_10"></a><a id="Tc_RVqacPFOL067Hx8dwjNPgw_15_16"></a><a id="Tc_7FQjdZPmq06hjFwmZea6Gw_16_0"></a><a id="Tc_JR9Nj5OePUa1mxVINq9KHg_16_2"></a><a id="Tc_FA0f-wmCUk-BSCB-1kUVOw_16_5"></a><a id="Tc_zga_v2QTo06bvBHMKjLGJw_16_7"></a><a id="Tc_t0p6jhRGiEyqlS-QIG1gog_16_10"></a><a id="Tc_VV-83fHhe0uIGaJ_Y4E9SQ_16_13"></a><a id="Tc_PnhrMk3q1EWHuKGh1yoPlQ_17_0"></a><a id="Tc_Z_F-3Quxb0W9ZZDsbzOO7Q_17_5"></a><a id="Tc_MsYYQa5UCUS3pb3JWrkrew_18_0"></a><a id="Tc_URS2BrOjHECXXx2rdMal3A_18_2"></a><a id="Tc_OhdsxXNse0O4I1psmaB3Lw_18_5"></a><a id="Tc_1erbon5EmEuGrT9C6F6zEA_18_10"></a><a id="Tc_MrbbmFo7SE-B0iOiTHDY_g_18_16"></a><a id="Tc_UVNtzuzTAUm_B7v3091d5g_19_0"></a><a id="Tc_dTYQADNHrUym-1GZFEfCDg_19_2"></a><a id="Tc_vpObkrnMIE6hIcv59SMSpw_19_5"></a><a id="Tc_jB1BTAi-jE26inX9qg6q4Q_19_7"></a><a id="Tc_dL1naGtuI0m1lpsVbEYwbw_19_10"></a><a id="Tc_RvLVMp0K30iygiFH3W2zbA_19_16"></a><a id="Tc_rm1CTJJK9kmoLSBuu0Vc4Q_20_0"></a><a id="Tc_8BpBK47_hEW7XATJgY-Lew_20_2"></a><a id="Tc_CRFsQGVutk2tlv5omoSBHQ_20_5"></a><a id="Tc_P_lBNwOGGkKJApR5e6feKg_20_7"></a><a id="Tc_0IBbOf_rnE2JzbeX5qEg2Q_20_10"></a><a id="Tc_CWncELdmCkKZ5TYe6QBOYg_20_13"></a><a id="Tc_uUv5-KlJckCwxKYEN04TGw_21_0"></a><a id="Tc__adQ-IzickWYghVl5QHk_g_21_4"></a><a id="Tc_1Q8j4ZbKvEyjYA1cBqm3zQ_21_5"></a><a id="Tc_6dwPgiSn4UWjZOmVYW8yiQ_21_9"></a><a id="Tc_-2ST2_SvnEKq9Z7bgb1Emg_21_12"></a><a id="Tc_Zn4j3RJtdEi8TeGyz223qw_21_15"></a><a id="Tc_9gEUdE9We0e1ifmAAjLCUg_21_18"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="18" style="vertical-align:bottom;white-space:nowrap;width:63.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible&#160;Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_b2BCEiFHZkqKPcE1gO60xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_-OmNXZRqEkOqBfwe0VtWkg_5_2">6</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_9thb2HNCbkaFMCrJ84fOMw_5_7">8,691</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SuOC0dqJfUSE8bObo4wcSA_5_10">65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1ACuNNCz302yJVI99Iw5Cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cCVCkJ8Jj0S1Jqq5HGGyAg_5_13">1,211,122</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xpsU-mpF3kaxH7Ar8BNhJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AZdF5qj_f0GnXQ05cyh6eQ_5_16">1,192,402</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_p5Ri9YTdOEOdh-jQlAoqEQ_5_19">18,785</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_SpTGX14CIUSt-c7cR2pZFg_6_7">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4R-71N3fCUuuo-5gn0JAgQ_6_13">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_alT4RHBE5k2Sl3Ex49JXbw_6_19">115</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="Tc_dNR366h8P0yIQxweTH9rnA_7_7">7</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_zRS6GieSWkqzn8RJmgfkSw_7_13">102</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_h_wCzu7Dx0WGYiLZI7lTPA_7_19">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:SharesReleasedOfRestrictedStockUnits" scale="3" id="Tc_P2wfi3K7q06MX1xT7fkAMA_8_7">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_s8P0nrC3uke_6RRqZFxSPQ_9_13">1,728</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_r4-wScUJRkyKrGOPhbt_EA_9_19">1,728</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_wwlCpJFNk02GrTti7hm75w_10_13">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_fWX8a53x6EqTfX-wwzzjVg_10_19">66</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net income and comprehensive income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_55yjxRlLR0OOL8PFIxgQ3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_h91QF0dHfEuNaIUUEBEtIA_11_16">3,233</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_DM1VA_q0RU-OW9t2v7mI3g_11_19">3,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, March&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_86zFUJxWa0Sowa2Y2-Beuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_w7MA-ikXdUCGbvNtMuk63A_12_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_CzNDPkeMcEC7r0qJPK05wg_12_7">8,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fnCdIED_ZE--U4_aoj7hLQ_12_10">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_osmPZAaeXEeF1lGAcFKPOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zr_JRJiQNUOEbVy6T6GE6w_12_13">1,213,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BQMMHQz-90SmMzcNZJyNuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_v4ydJ5FOQEq4Pp6sQOeXAw_12_16">1,189,169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2019_Gh1sLtuoUk-sktvmIjYABQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ixW5ONZNqkOBoZQ3sSMrTA_12_19">24,029</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_KsiZHViAXkW0uxgsXUgbIA_13_7">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_6NZxPQ_-BU26srzlcFPf4w_13_13">8</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_lsDKyFoa7kGnfUXoU1A6cg_13_19">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Tc_t6te9bW9dEKy5itsQWIIww_14_7">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_l-Fot0MZLUue1Ty3_LHdMA_14_13">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_M3Cl_9FhRU2D57KCaSz3kA_14_19">16</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_JP7lLoQxPkGuWL_DtdH-uw_15_13">1,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_fjktyJpXRUyrK78Gf-2xtg_15_19">1,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lTYMNfRN7UyqGN9s3-87hA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cFOxxciaTkOt37tbkjb_YQ_16_16">4,072</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jqFJurnVfkyQT1pERXvclg_16_19">4,072</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, June&#160;30,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bny-C6Pdi0WV2-8Z_Y4imQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_8pH-4wHdLkistGVeixdACQ_17_2">6</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_O0InrZ_Na0OXt1hnGmVxxQ_17_7">8,728</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Z5rA90MXoUut8N1AavlNdw_17_10">65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jjydCrSLg0mxBT8T-UT6lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ogyn6LvhjkKEPm_Nf5NR5w_17_13">1,214,168</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8THgqDdF-UuNoobclQVfIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YoSGFcm4L0W4kBuG9j5Rjg_17_16">1,193,241</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2019_AzRfCDaAQUKUmbmpbfVREg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-ih9gI-zz0iDS3j_mrtCSA_17_19">20,992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ccfeS0VvmEuzUI-eiCKILw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_xpZqXLMIT0qMfQh7hKVoTA_18_7">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_VCA2_FzPUkKk7AMJc677mA_18_13">122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_eDVzdOMRmUG_plSARS9KQg_18_19">122</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_DBTyj825DUinaW85RNQosQ_19_13">1,494</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kJMuMvygj0qjYL-ZcCleiw_19_19">1,494</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net income and comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BfyNiRBteUaq65VmnaTxwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_gxv0Pf162E6RSU8kW27YCQ_20_16">3,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_H6o16gCgx0WoGv0julspsg_20_19">3,178</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:34.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, September&#160;30,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zP13eTII7UilJItaI_yfUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_k97Jx1RYbkOQsnNsxKO9vQ_21_2">6</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_jjGtBPzgfUqY5fgQoD94gw_21_7">8,752</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oKmN-FdUZU-Genw5usvR2A_21_10">65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uJ6C1JclfEqlTJ-BWfyYmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9K2sotVbokC_-1TzWX7-IQ_21_13">1,215,784</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cY_riJ8ogEyCIjKm-1Dt3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LciqlLFCqUOerdJZvTbzSw_21_16">1,190,063</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iM8dX_RcY0-I5ARf7vcOTw_21_19">25,786</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9fabc02b_51a7_4e48_8f5f_4ba42f5c3260"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_738e2f0e_6d7b_4f81_a7ca_18ba09573448"></a><a id="Tc_KJ-kpBUFjUSrOzLoYns7eg_1_2"></a><a id="Tc_UT3ywkvxck-UX8Pvh6GT8w_2_2"></a><a id="Tc_nRreEP1eVUO-xDDQlhAkfA_2_5"></a><a id="Tc_MYa77axlMUKQvlq0oKEr6A_3_0"></a><a id="Tc_T0hxAEyhbkSa-3YCpfQM4w_4_0"></a><a id="Tc_SrM0eNvgeUu2_R_K5TJsEg_4_2"></a><a id="Tc_-qR_yZmock-BZgGmFkSw3w_4_5"></a><a id="Tc_AMQrCqsT-UK2BdtErwBwlw_5_0"></a><a id="Tc_B_P0PJCIPUC_L4E8x-gqBA_6_0"></a><a id="Tc_RDn24cBUQ0-hskfMver2BQ_7_0"></a><a id="Tc_9An3vgdcy0Cjzy--agr07A_8_0"></a><a id="Tc_rFbBOEQJb0KtRQiYCHK3bQ_9_0"></a><a id="Tc_aovI-DNtekCSYxkHx4zDOQ_10_0"></a><a id="Tc_wnEPGKMOaEuatZlgzl3-SA_10_6"></a><a id="Tc_6FwtaY1wZ0KVMs13lbDwtw_11_0"></a><a id="Tc_KTUxcHc-_E6yLtSxibSZRg_12_0"></a><a id="Tc_ZT2TkLeygE-A2T47wYdJKg_13_0"></a><a id="Tc_sHOLUi020UGUdeHGNxsFEA_14_0"></a><a id="Tc_8edtSt9U30aFDBGqU88EPQ_15_0"></a><a id="Tc_W7uZ03fGcke1mkpB8G955w_15_6"></a><a id="Tc_MdAL8HDNtU6CrtTPxe7Ubg_16_0"></a><a id="Tc_tApCpw29lkOnw2G9QXBYCQ_17_0"></a><a id="Tc_wiAedkT1Z0mCUK2JfReHhQ_18_0"></a><a id="Tc_YzqLCANMEkCUnm1tZtREjA_19_0"></a><a id="Tc_BqwW-R7WmUmNbXvHbrLZAA_20_0"></a><a id="Tc_e0l5VBTuiESvdRnXbx98hA_21_0"></a><a id="Tc_r0qgTlD5G0CfazxR-dIsvw_23_0"></a><a id="Tc_SzpdOrPzaEmoBmaQAI3Dtw_24_0"></a><a id="Tc_uB3DX9GrqkmvGNvdkJeAbQ_24_6"></a><a id="Tc_PpP5QbGHJ0e2F_B5LzBMUA_25_0"></a><a id="Tc_7B_Mur_OQ0ywyEAQ9a-L5Q_25_3"></a><a id="Tc_u8O8Uz-kxEqSDIKDP6Xm2Q_26_0"></a><a id="Tc_UkXW7jO7wEieqoR9SpegUg_28_0"></a><a id="Tc_zEY0JzPuhUWevmyqBhTUCQ_29_0"></a><a id="Tc_yZE3f5tNCk-HqdGKFofEJg_30_0"></a><a id="Tc_l34f-3VLKE-8PmMu5i9BOg_31_0"></a><a id="Tc_Z9VMXGC7aUqVmItbuJorVQ_31_3"></a><a id="Tc_5O5StCEDrEGOcPe9i4PtCQ_32_0"></a><a id="Tc_dNwp3Ad9CEeMmsLWcIlu4w_33_0"></a><a id="Tc_CrnuGDZ7HUuR0Jo8eA7roA_33_6"></a><a id="Tc_dQOi9MbdXUe4NyAYviR_BQ_34_0"></a><a id="Tc_N30m9JSBJUes5b4qYR4vYg_35_0"></a><a id="Tc_BGeuK6LgC0a7n2D_KH_GOg_35_6"></a><a id="Tc_pHA_L786RUylMjp_4DABZA_36_0"></a><a id="Tc_RTGsKddqd02R9vamRmi0bQ_37_0"></a><a id="Tc_n21pv01ChU-QwIyZPtTYLg_39_0"></a><a id="Tc_Bm872ZCJ0EyzF3xItfyfNw_40_0"></a><a id="Tc_8FJkWlmNvk2XciHyR0kwCQ_41_0"></a><a id="Tc_cP8QlFyyTkaw9LIG6Z0U5w_41_2"></a><a id="Tc_5AWkGswG3EyCT6rEY_DwzQ_41_5"></a><a id="Tc_S6VbNqVLo02xlGnhF7pH6A_43_0"></a><a id="Tc_ss2yXjldQU2ZFCG31DchEw_44_0"></a><a id="Tc_Wecyhj9w0UizWRKcT4oUEA_44_2"></a><a id="Tc_zZ4mlRsfB0SHblKBpj9xGA_44_5"></a><a id="Tc_2ksk6zCZY0SIVAk0ALalxw_45_0"></a><a id="Tc_-WmbGqWfw0uL5Dmeby8Zvg_46_0"></a><a id="Tc_wGsuhEOi202ppqGvlfGUug_46_2"></a><a id="Tc_dggwSH3IAU2fKV-AAUvnfg_46_5"></a><a id="Tc_WHY7x4rlF0KH1U-UwAk_4w_47_0"></a><a id="Tc_4tvWBzw5V0yxD-hVpNhqtQ_47_2"></a><a id="Tc_GqAEWylfrUa547fnJn8UPg_47_3"></a><a id="Tc_NIoZPe52O0y_5W5CSLzjKg_47_5"></a><a id="Tc_nkiCQdNjPUyUS3b0jPoHRQ_48_0"></a><a id="Tc_d_NoDO6X9ky0gbq9aTM3nA_48_2"></a><a id="Tc_gmuQXl3Ny0SGpe7aedRHXQ_48_3"></a><a id="Tc_zp9jqImK0Ee1CMs1C7jF9w_48_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_bpmckFK9vUWp65ZBu97cGA_4_3">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_Nrg_tUjExkWZN-_fqDxfFQ_4_6">2,339</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Du_imwo1cEOzU2mGE_On1A_6_3">3,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_7zPjl_L0FUy4LnDeSDZSSg_6_6">4,233</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Common stock contribution to 401(k)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_KBx4g3-qTEC1bPyQ0TH4sw_7_3">88</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_l24nSDPou0GpfnKcNz9hnQ_7_6">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_DhhFlaoYF0Ww5aidfIWQPQ_8_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="Tc_Y_khy6nRAUWqXmQOn081nQ_8_6">19</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of debt issuance costs, debt discount and final payment on debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_lSIh1yba-0ehKG1ZiSQFCQ_9_3">546</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_4g5UlDtYZkWNyS4iO9lRCQ_9_6">390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Provision for bad debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_yZagoO1YWE6xvF26IB9LWQ_10_3">1,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash lease expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_kNJq5q4Sekyi14nqAhRSRQ_11_3">112</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_FAzxM4rkiE24nwm-L1Qb9Q_11_6">1,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="Tc_HNIRbcF_vkybbymGg-zJ4Q_12_3">1,891</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="Tc_BFo7e08TPE2R92aEYENr5g_12_6">481</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Trade and other receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_0MV0E62WEE6AP_Xk3eM6dA_14_3">1,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_zuO6a7YN9UO7orHbXGO-GQ_14_6">2,358</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Income tax receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="Tc_qwGgBKiI70OVGKNW0RF0TA_15_3">1,526</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_zMcnXtoGVkejHUS58tETFw_16_3">319</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_otu9TEX8UkyhMxrbsgLUPQ_16_6">265</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_mVDysY8jqUqdkga1rBOR_w_17_3">464</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_TZV5oRbDrEmf7bGb4qztPA_17_6">232</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Unearned revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_0SRNjyb-IUO9_lIh6KwphA_18_3">1,052</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_cdvV__5VpEexCgvg_Fs7gw_18_6">772</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="3" id="Tc_QPaWhKy-MEKQGfLm0veRjg_19_3">120</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="3" id="Tc_9z9KrF5-xU2TVWuLcDALOg_19_6">1,634</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_VL8crhopT0CTHlW2siGjEA_20_3">409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_-1QmGvjgy0CMmQxskifHmQ_20_6">594</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_qFTESsmzIUKklwfCBvGNMw_21_3">7,586</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_laSzzVNGb0SvPGc7ErF5iw_21_6">3,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_uJ0kDup-l0a5QogmJciMGQ_24_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payments related to purchase of royalty rights</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRights" scale="3" id="Tc_TsL3frbONU2MLxRI436Qeg_25_6">19,300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_pcMQ2bJ8VEamN2aqu3liWw_26_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_t-V4sRfoOEWjv83gYWsTGw_26_6">19,300</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_D7ujkbc6zEmxw-k8G7HYEQ_29_3">26</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Er2V77bXhE-MDagLFubLyw_29_6">17</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_lgKPnI73cUSf7SkIdP6miA_30_3">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_NViqDYSpO0SepzTa_A26KA_30_6">776</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="Tc_NHJaJhYuAUqjZtth_PUgmQ_31_6">9,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of stock issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_WO_VFWkQsECXMPHiqrYXBQ_32_3">231</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_6U4RYbdSO0WXB08-iXNcUA_32_6">377</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Principal payments &#8211; debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_dAR0j22Zn02uOFGJr6gZQw_33_3">3,188</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Principal payments &#8211; finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_dY-ZJJ1ONU6VLdsIIv-Ntg_34_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_r15u8tq0UkuI-tz1eXSlPQ_34_6">11</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from disgorgement of stockholder&#39;s short-swing profits </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ProceedsFromRepaymentsForDisgorgement" scale="3" id="Tc_dk1tssji30qdiXpUDjzZ1w_35_3">13</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_CW89ELkPcEuKDIyCzTBClQ_36_3">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_VGk1PgMRF0meAMX58gftLg_36_6">504</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_jXzBjSZ-m0Sr1bkJdt2Hvw_37_3">3,368</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_QV1RodtYN0mNP26eOFhN1A_37_6">9,401</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net decrease in cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_ILGUVNYCTE2R_YCgIMyuuA_39_3">10,963</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_S-cEqUj9RkuSPqB9shctMg_39_6">6,036</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_jxQ_OwhDgkyfoTAMZRR2Uw_40_3">56,688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_5KlPfBxxEU-_bNTGapq-rA_40_6">45,780</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash at the end of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Up-KA-vurkO2pbphY0kN5Q_41_3">45,725</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_bkIX8S28b0-qwGXvztHpQA_41_6">39,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental Cash Flow Information:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_oogv9pwDJUih-Dn0CgAk-g_44_3">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_yO8zCoJntEuXk0jVoPQyRg_44_6">357</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-cash investing and financing activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest added to principal balance on long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:InterestAddedPrincipalBalancesLongTermDebt" scale="3" id="Tc_ovpeKTw1Y022-Jnl99IkoA_46_3">317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:InterestAddedPrincipalBalancesLongTermDebt" scale="3" id="Tc_p6x4dfHLd0u0mxJ5wqowVg_46_6">376</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock warrant under SVB loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" id="Tc_Sj2Gx1xWO06vdGTNpVCqfg_47_6">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Estimated fair value of contingent consideration under the royalty<br />purchase agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="xoma:EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="3" id="Tc_hmnAbj2aq0W0HTriIw_7UA_48_6">75</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_d65573f5_d928_466c_a1c4_f98acde7190a"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">XOMA CORPORATION</p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:NatureOfOperations" id="Tb_mTE6SzoeeU2c9vdoCecZTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA Corporation (referred to as &#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with acquisitions of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had cash of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_VkYsNhKEO0iYzpFZZJy26w">45.7</ix:nonFraction> million. Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one&#160;year following the date that these condensed consolidated financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="_Hlk54250568"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_fMNXp5cK1kyx8WdGJT437A" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_sNzHH1AY7UmFid33T_z0NQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;10, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:UseOfEstimates" id="Tb_1wOnqa6zXkK3bEh-z5uAFw" continuedAt="Tb_1wOnqa6zXkK3bEh-z5uAFw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, operating lease right-of-use assets and liabilities, legal contingencies, contingent considerations under royalty purchase agreements, stock-based compensation and income taxes. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk54341413"></a><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont1" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont2"><ix:continuation id="Tb_1wOnqa6zXkK3bEh-z5uAFw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts and amortization of the payments received from HealthCare Royalty Partners II,&#160;L.P. (&#8220;HCRP&#8221;). Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company billed using NIH&#8217;s provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company&#8217;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The worldwide spread of the COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company&#8217;s royalty purchase agreements. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_Cffn1Zxt5kSn3OtOjsjRag" continuedAt="Tb_Cffn1Zxt5kSn3OtOjsjRag_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(&quot;ASC 606&quot;), except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont2" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont3"><ix:continuation id="Tb_Cffn1Zxt5kSn3OtOjsjRag_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock" id="Tb_RB2rCPp-202hTpUCQjDSXQ" continuedAt="Tb_RB2rCPp-202hTpUCQjDSXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont3" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont4"><ix:continuation id="Tb_RB2rCPp-202hTpUCQjDSXQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_ThP9cLmgW0W4mzBAkKMeUA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the &#8220;Black-Scholes Model&#8221;). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:EquitySecuritiesPolicy" id="Tb_bOcxpWYUcESndH9Rf5SZjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company received shares of common stock from Rezolute, Inc. (&#8220;Rezolute&#8221;) (Note&#160;4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive (loss) income in the period of sale.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" id="Tb_LdJruigYwEClgsytonWVSw" continuedAt="Tb_LdJruigYwEClgsytonWVSw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase of Rights to Future Milestones and Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note&#160;5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If freestanding instruments, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value is recorded in the condensed consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews any impairment indicators and changes in expected recoverability of the long-term royalty receivable asset at least quarterly. If expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_a_1MJOJuW0qWykr8or9ehg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_HUFMmZpyxUmnf6MQcbwsUQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_ickPsZbmdUKtTgvEpP8OBg">no</ix:nonFraction></ix:nonFraction> impairment was recorded as of September 30, 2020 and December&#160;31, 2019.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk54341642"></a><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont4" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont5"><ix:continuation id="Tb_LdJruigYwEClgsytonWVSw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_M4VxzMgny0WsQlPVu_cInw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement for its corporate headquarters in Emeryville, California and under its legacy business held leases for office and laboratory facilities in Berkeley, California. In connection with a series of restructuring events in 2017 and 2018, the Company completely vacated its leased facilities in Berkeley, California and subleased the space in the vacated buildings. In December 2019, the Company terminated its legacy operating leases in Berkeley, California and was fully released from any further payment obligations. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company continues to lease its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an operating lease were to reflect impairment, the Company will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:Reclassifications" id="Tb_vZLq1t2yb0mT-vttvObK5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Prior Period Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the condensed consolidated statement of cash flows, the Company separately presented the non-cash lease expense and changes in operating lease liabilities for the prior period to conform with current period presentation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_ST0Z3nm2sUm7xVBLVamLDQ" continuedAt="Tb_ST0Z3nm2sUm7xVBLVamLDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net (Loss) Income per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net (loss) income per share attributable to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net (loss) income attributable to common stockholders consists of net (loss) income, as adjusted for any convertible preferred stock deemed dividends related to beneficial conversion features on this instrument at issuance. During periods of income, the Company allocates participating securities a proportional share of net income, after deduction of any deemed dividends on preferred stock, determined by dividing total weighted average participating securities by the sum of the total weighted average number of common stock and participating securities (the &#8220;two-class method&#8221;). The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. For the three and nine months ended September 30, 2020 and 2019, the Company did <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Dividends" scale="6" id="Narr_Cp79NqYtSk6lekU83BgnxA"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Dividends" scale="6" id="Narr_Hj5euNgeXkODl_XVI93khg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Dividends" scale="6" id="Narr_jRPsz9jy6EuLFQOBflLIlQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Dividends" scale="6" id="Narr_rrimceA8LESLFyEIFGsjjw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t declare any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk54341747"></a><a id="_4b8408e8_df5c_4d26_a8a7_9a214419f6c4"></a><a id="Tc_ANX6zTEpSUCuKQK1h52YhA_1_2"></a><a id="Tc_b7spZruu3kmTAe7oM9Nu4g_2_0"></a><a id="Tc_yKZyYwvwdUyw_JuIR8uLAQ_2_2"></a><a id="Tc_c5osKo0dC06vc7OqvX5vkA_2_3"></a><a id="Tc_rLPNA0OArESFGk3ynkR6sg_3_0"></a><a id="Tc_AVpKv8vHLUSBKaeLc9FqMg_4_0"></a><a id="Tc_fhxEx3dTgkWEuUBVZumqUg_4_2"></a><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont5" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont6"><ix:continuation id="Tb_ST0Z3nm2sUm7xVBLVamLDQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="Tb__rshELCcXkeJDJrhzZiIPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Trade and other receivables, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade and other receivables, net consist mainly of credit extended to the Company&#39;s customers in the normal course of business and are reported net of an allowance for doubtful accounts. <span style="background-color:#ffffff;">Trade and other receivables are recorded upon triggering events specified in the agreement. Trade receivables under ASC 606 are recorded separately from contract assets when only the passage of time is required before consideration is due. </span>The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. Any increases to allowance for doubtful accounts are charged to operating expenses. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="6" id="Narr_iNnuSYWX4EWboYO5dcEhSg">1.4</ix:nonFraction> million in allowance for doubtful accounts for the three months ended March 31, 2020 related to Rezolute&#8217;s license agreement (Note 4). The Company evaluated the&#160;accounts&#160;receivable and determined there was <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="3" id="Narr_YKiboqU3dkWTdw91CybnNg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" scale="3" id="Narr_iZs95FiFKEajp84-_LIcbQ">no</ix:nonFraction></ix:nonFraction> further activity in allowance for doubtful accounts for the second and third quarters in 2020. The previously reserved accounts receivable from Rezolute was accelerated and collected in October 2020, as discussed in Note 14, Subsequent Events.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="Tb_AoTXmWCvOUm7uc94ARlGLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br />September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charged to operating expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="Tc_KV6-xOBeGUC7maadjwLQDA_3_3">1,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="Tc_4eiJcrwy5USP5VjgYOkW3w_4_3">1,409</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb__KIAnlVGqUeLoiGLeDaxWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three&#160;months ended September 30, 2020, <ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NwHPINtT2E27syT0FERCZg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_G7zvQNDjGEurrt-xJTft4g">two</ix:nonFraction> partners represented&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Vh-yAeDCzEam1o4LJU3R9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_02Ho40PHgUaazuODm8ukVA">64</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wW3g01I-CEqS98TMD6LhAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_9H69jQ04eEasnGljM9NcAg">36</ix:nonFraction>% of total revenues. For the nine&#160;months ended September 30, 2020, <ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DqK_86Lt2kGOZ5tETJSWVg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_UIySspdtlk-S0jXkmJmLfw">three</ix:nonFraction> partners represented&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_w6FnUVgyxk-uu6eq_pVLjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_6h5_IzGSDkmHrkxJ_CnyDA">58</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v9GiP1Qyk0qx9_F2-bs0WQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_BKqwtEQ71ESXNGJFGFNT9A">28</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wOjQWoE-yEyfuioBK5aSsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_PXg-EIxSiEuyGhNbZYgUFg">11</ix:nonFraction>% of total revenues. For the three&#160;months ended September 30, 2019, <ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_whotwsqlPUWlIpHCjIDEwA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_MXl7u68DIECV4KhwKRm25w">two</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NREQuj8uA0eP9aMHPRFc1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_5y7JZ4MzGUeYIENZZr6vYg">68</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4EvFxExj10OrmYqKm4c1sg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_J9e7Ky9nEEGjrbewmKWiQg">28</ix:nonFraction>% of total revenues. For the nine&#160;months ended September 30, 2019, <ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_tcvB75A62UqaD7Gz2Fyu6w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_4jWosvHgm0eNODAbjASQfw">two</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OT29fxEd0kmg6WxFKFQGSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_kY-89LPPokeQQEopxCY7LQ">78</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RVLPSZwwQEyCcFoXmWjm_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_LE0KYnQIwkqVCZdhDb-Npw">14</ix:nonFraction>% of total revenues. As of September 30, 2020 and as of December&#160;31, 2019, <ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_GZ0ur5U0GU2JqBoEJSMTdQ"><ix:nonFraction unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_Fh-Zmvn8rUS77a6HsG-OTw">one</ix:nonFraction></ix:nonFraction> partner represented <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_re_aZCHLUUe-rHoHYuQn-Q">100</ix:nonFraction>% of the trade receivables, net balance.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_UUjJwGsYC0eIrHWzmGvX2Q" continuedAt="Tb_UUjJwGsYC0eIrHWzmGvX2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont6" continuedAt="Tb_fMNXp5cK1kyx8WdGJT437A_cont7"><ix:continuation id="Tb_UUjJwGsYC0eIrHWzmGvX2Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_G9F9AWbgX06Siht8HvzVMg" continuedAt="Tb_G9F9AWbgX06Siht8HvzVMg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-13,&#160;<i style="font-style:italic;">Fair Value Measurement (Topic 820) (&#8220;ASU 2018-13&#8221;)</i>, which modifies, removes and adds certain disclosure requirements on fair value measurements based on the FASB&#160;<i style="font-style:italic;">Concepts Statement, Conceptual Framework for Financial Reporting&#8212;Chapter&#160;8: Notes&#160;to Financial Statements</i>. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the&#160;year ending December&#160;31, 2020, and all annual and interim reporting period thereafter. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal&#160;year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company <ix:nonNumeric contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" id="Narr_h0cLTJ2e90ik9ZJGi1lZsA">early</ix:nonNumeric> <ix:nonNumeric contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="Narr_RpHkCMY6S0KFW2x7DE4NZQ">adopted</ix:nonNumeric> the guidance related to removal of disclosures upon issuance of this ASU and adopted the deferred provisions as permitted under the ASU in the first quarter of 2020. The adoption of ASU 2018-13 did not have a material impact<span style="color:#212529;">&#160;</span>on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) &#8220;Clarifying the Interaction between Topic 808 and Topic 606,&#8221; which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service that is a distinct unit of account. The new standard also precludes an entity from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the year ending December 31, 2020, and all annual and interim reporting period thereafter. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. This ASU requires retrospective adoption to the date the Company adopted ASC 606, January 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company may elect to apply the ASU retrospectively either to all contracts or only to contracts that are not completed at the date it initially applied ASC 606. The Company <ix:nonNumeric contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201818Member_mlMnqtv8RUS5hgexXcSDqA" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="Narr_ImZfKiTkuEG2T25Cg7eEAg">adopted</ix:nonNumeric> ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13 and related updates&#160;as of January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued&#160;ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </i>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021 with early adoption permitted. The Company is evaluating the impact <span style="color:#212529;">of adopting this new accounting guidance </span>on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March&#160;2020, the FASB issued&#160;ASU&#160;2020-04,&#160;<i style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The&#160;ASU&#160;provides optional expedients and exceptions for </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fMNXp5cK1kyx8WdGJT437A_cont7"><ix:continuation id="Tb_G9F9AWbgX06Siht8HvzVMg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12,&#160;2020&#160;through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12,&#160;2020. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p></ix:continuation></ix:continuation><a id="_70efb590_d0c1_40c0_b7c5_c6a5ca3c471b"></a><a id="Tc_677Li2RgSUCsjcaJmoBIGQ_1_2"></a><a id="Tc_-ZE2Xx_Zq0uCwq3tKm6XuA_1_5"></a><a id="Tc_T2g7zdL9bESArS2YoUp1Mg_2_2"></a><a id="Tc_v5nhdFtzQE6FyIbw36sE0w_2_5"></a><a id="Tc_xZyNZNv3PUy9NZsBcv9aug_3_0"></a><a id="Tc_b7cy8HxPhEi2pMCH1ktCZA_3_2"></a><a id="Tc_n2eWZx-kBU6bXyi8_mB3NQ_3_5"></a><a id="Tc_MukjX_-LREi3Vdj-7v763A_4_0"></a><a id="Tc_XGxrSZj_mkuSmKJYnj2jCQ_5_0"></a><a id="Tc_K2BNXdrkB0azJRbkPFE39w_6_0"></a><a id="Tc_K9dogNVxfE23FJjpOLj0gg_7_0"></a><a id="Tc_lPXlImZ2rkafl1qRZ7qWtw_8_0"></a><a id="Tc_SUsIgliMIkSWAO3izZL70Q_8_2"></a><a id="Tc_4a81rjzyAU-gC8bnJjwZgA_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_u3GsQTWiFUmJAu68jM6aaw" continuedAt="Tb_u3GsQTWiFUmJAu68jM6aaw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Condensed Consolidated Financial Statements Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, equity securities consisted of an investment in Rezolute&#8217;s common stock of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_QJfyk6LBB0y8TAEOtRhUbg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EquitySecuritiesFvNiNonCurrent" scale="6" id="Narr_Ceeb7Uk520OKAR1xQVEgsg">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_WyJEPykhS0yKbLZyNfLarQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EquitySecuritiesFvNiNonCurrent" scale="6" id="Narr_BxYe0hqpDkq5RLwyb895cQ">0.7</ix:nonFraction> million, respectively (Note&#160;4). For the three and nine months ended September 30, 2020 the Company recognized gains of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_1WJzW9HoPEib8xgIXL4tQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="Narr_SpqtxK6ZwUWXJDyQTpI8hA">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_eFRO3EsZIkmFH2cQ0wM35w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="Narr_I4lOfzQTw0enkIQQD7rJ3g">1.9</ix:nonFraction> million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. The Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ZXd3cmpR10SClHLRFX8RSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_foLLXtDTTE69WcPOEhxiOQ">0.3</ix:nonFraction> million and a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_as3Q7AGP7kiK9uKgqvnZSQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="Narr_GuhcJ-n9P0yUYsGNP43LLw">0.5</ix:nonFraction> million for the three and nine months ended September 30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_E8wxHc_G4UCK3OYeLMNGbg" continuedAt="Tb_E8wxHc_G4UCK3OYeLMNGbg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_G50yhbacT0OKR1BpNe1J3A_3_3">202</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_CJba-Ye-9kSaHMP6ywRb5g_3_6">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_s5Jm0_SG4kqsqlYC6q95CA_4_3">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="Tc_SVIhrhD54kie7YZMIJU24Q_4_6">231</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_SXv6hXdVokue_ivYL58RRQ_5_3">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_WwM_A_Vykk2w_9gsneZTTA_5_6">69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_dn8miy3DE0K3yfs6lJ5pjQ_6_3">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_K3AoBasdDUOoKjfjXqFwIA_6_6">332</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_0SBsQD-RMEmOOZfdAGKGLA_7_3">33</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc__nuBcEtn7Ee3_Pr1rDgUuQ_7_6">57</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_bwSRUxHUE0GKYSk-7U7Smw_8_3">466</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_aKJpiVcTyUmna0kVh-FHxg_8_6">945</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bfe996eb_faf6_43e0_9b6d_4212ac7f8fc1"></a><a id="Tc_C7gFNVm0JEO9_NflppKHaw_1_2"></a><a id="Tc_BGc_nR6S50udu3sy58aiDg_1_8"></a><a id="Tc_KD87-kd8o0WI_5GBPLlT4Q_2_2"></a><a id="Tc_az5-a3oWU0mCfrGYZino4w_2_5"></a><a id="Tc_9ODjmlmB9kWLyZRRQ-s4Yw_2_8"></a><a id="Tc_oXXsT-2gFUGH3Jze3LROIg_2_11"></a><a id="Tc_BIwzaYSur0-8NvV40rK6ag_3_0"></a><a id="Tc__5tPhk_h5UKT4bcpdqT_gw_4_0"></a><a id="Tc_pziZfRDE8Uiy1tBOz0n9tg_4_2"></a><a id="Tc_1IJ2YTELN0Skd-vQCzYtiw_4_5"></a><a id="Tc_byX-jaVLEkSVMZMqFUrf8w_4_8"></a><a id="Tc_WGdMNEhsPEuMIDVnqtO_fQ_4_11"></a><a id="Tc_b5S1igP-SU6eD2KpQ_dpag_5_0"></a><a id="Tc_Zyq0npCh70GgZKcBZ48bZA_5_3"></a><a id="Tc_0xlTJgu1JUW_hVgdo-j9TQ_5_9"></a><a id="Tc_sIyRE99OlECR1KUYtJEO_g_6_0"></a><a id="Tc_nb58gdxErUeC9tgzusVGgw_7_0"></a><a id="Tc_9veslLjz4E-UXoZD1o5tlQ_7_3"></a><a id="Tc_u1uZo83ZdEm8G03gOUCpig_7_9"></a><a id="Tc_ETrl4zvX_UGJRMhpLZOVgA_8_0"></a><a id="Tc_ZBqwqmuF2UmQqbigvZY_KQ_8_2"></a><a id="Tc_RsQoLjs0okG1MjIJGB-piA_8_5"></a><a id="Tc_r_FLWGIzfkG26Nfz8jyg4Q_8_8"></a><a id="Tc_oBibNFm8HkyDOilVMOozdQ_8_11"></a><a id="Tc_4kBgLmIVzkyLVajXQGzjig_10_0"></a><a id="Tc_k4Do-rvmD0GfuPgtHYYNNQ_11_0"></a><a id="Tc_BKxkEOcV0EGmqbtq2O0TeA_12_0"></a><a id="Tc_7Q9wYspdYkupvELYFH6K-Q_12_3"></a><a id="Tc_jVQg9stdqUuGZcMfMrktRA_12_9"></a><a id="Tc_E73kqwyWH0SnCb-KldnHOA_13_0"></a><a id="Tc_vxpsMHhff0qxNG2kee-juQ_13_3"></a><a id="Tc_ojVpc_r2TkSyhxsjvsBlLA_13_9"></a><a id="Tc_dr6y7Z4-wkawN8fkL8GUOg_14_0"></a><a id="Tc_hAvELxQl7UGqfTH6I4nrmQ_15_0"></a><a id="Tc_5GkTO_KGZ0e_BD4N0BWD6g_15_2"></a><a id="Tc_I5ki6pnPJkumrgT2lKMPzQ_15_5"></a><a id="Tc_hl-tD4-nI0-9_lA829nayg_15_8"></a><a id="Tc_dv6CD2WnyUORqx_85gr3vw_15_11"></a><a id="Tc_2z9iKqmOSE20v7vz899tyQ_16_0"></a><a id="Tc_dQEJsJqvQ02W7je8gjgymw_16_2"></a><a id="Tc_wClGT9QJq0uyWiU5L4gxJA_16_5"></a><a id="Tc_5mDSQtluxka90PppMKqStQ_16_8"></a><a id="Tc_Du5Dm9qOMkC7t5rNlR5hdw_16_11"></a><a id="_27796615_b073_4bda_be69_0ae22386d9ec"></a><a id="Tc_E2-9tG3xA0Ss8XB1VjrC1Q_1_2"></a><a id="Tc_GTFtnITj6Ue2_xO474QEkQ_1_6"></a><a id="Tc_3kDyZCu03kif4T2Bl_tQgQ_2_2"></a><a id="Tc_AKMPh01Cl0ORAajsnkpYjg_2_4"></a><a id="Tc_nA9NivIqoEaqFjuGS-ycfw_2_6"></a><a id="Tc_6lWFgIEMX0SDf9_dO_L37Q_2_8"></a><a id="Tc_QHZrwp9wXkmGtqZi7h2Yxg_3_0"></a><a id="Tc_0VnMhmHwJUaIvecWder0Xg_3_4"></a><a id="Tc_bSGDrfP7pECqFWFKK0HMng_3_8"></a><a id="Tc_eKW9JsNlU0Wq_57Hu300-w_4_0"></a><a id="Tc_TXhlSaeHqU-Nt-KFwiU7bQ_5_0"></a><a id="Tc_eJJ5DNM9n0ilvRxTHSbcaQ_6_0"></a><ix:continuation id="Tb_u3GsQTWiFUmJAu68jM6aaw_cont1"><ix:continuation id="Tb_E8wxHc_G4UCK3OYeLMNGbg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net (Loss) Income Per Share Attributable to Common Stockholders</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_fHqMmCpXW0idTJU_MrDOcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss or income) and the denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net (loss) income  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4gyOZt09OEyhdc0acZjvwA_4_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_E8iCTiTvsUWCQO0dS-FxWg_4_6">3,178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5rIn3vumFEixWjoKKmN5Dg_4_9">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_0nrxAhtojkOlMv3CFIeZPg_4_12">2,339</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="Tc_IvpAwnurtECQzolbFk7rUg_5_6">1,327</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="Tc_8ieNHjsByUmrGcesB4hrzw_5_12">977</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_8tCtzwqKZUSPqkhY6ZsagQ_6_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_sL8FmFbSLEqZZ5EWm_EOsg_6_6">1,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_GmpNXqTH5UeledpBGixQKQ_6_9">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_IANffz5PfUKKjtENDNmXeQ_6_12">1,362</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" sign="-" scale="3" id="Tc_3hznQ1fJ70CVpJPzOtfEFQ_7_6">60</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" sign="-" scale="3" id="Tc_cQJr_6ZgbUGLbeigNVS5Lg_7_12">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_vuXLOLl4bEW7HKT08r_OTg_8_3">1,077</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_nyvMC_9Y10y-HLKmEV-j0A_8_6">1,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_5E-sgqXxckaXHUiJj2pOpg_8_9">9,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_IVhChZ7pR06KvQwY-BUHTg_8_12">1,403</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_LE3aaVDGGk2yxJxTgsP9AQ_11_3">11,019</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_jsOivbDKwkGc7nalBR-HGw_11_6">8,731</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_vGM9xIOXxEGZriPXLdgh_g_11_9">10,537</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_UXd_bG9-7EqEu4_AnRVVvg_11_12">8,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Tc_H-mOnEJGbESd-VyEnIPcOg_12_6">708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Tc_amyxav2VkUisvqBzyALEjA_12_12">657</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="Tc_dj1X88Ol5EmauPPxavLtsQ_13_6">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="Tc_otUf27diSUigRLKiEKfAZA_13_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_-SUjSZxVoEW5Zix5LeKpuw_14_3">11,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_YfmJAKIeb0msj8nYoaVs8A_14_6">9,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_-f-D15magkOFjkf-4pqw_g_14_9">10,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_6MVNoBcQb0KXl-7Mwz_CwA_14_12">9,379</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_pLA213zYIUSRcZV-7R857g_15_3">0.10</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_2V2lV_S_AUip148l2kXHXQ_15_6">0.21</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Ui5AXfjqi0qwjFLyPWijsQ_15_9">0.89</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_4b1Cxl0hTku_NprjLNFDLg_15_12">0.16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_YwodJZ509k6__SDSV-IrAw_16_3">0.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc__Tx1aToFuUW-KWVWZI0b5Q_16_6">0.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc__cW6r4KPz0iIroG5W8nV6Q_16_9">0.89</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_ua0sKyHfgUusObv3TlkO5w_16_12">0.15</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share available to common stockholders if their inclusion is anti-dilutive. </p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_5ruLEFqIrUm0YnfTDfZrLA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_HmB3foWGM0Wj8z_XGGsBhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_9ZQRIvpnvkCWE-ZsTCrTkg_3_2">5,003</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_0Cv-gufQXUiXoT0EaH7Cqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_k0qo_3LUEUScDEShf3G3pQ_3_6">5,483</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3CadpqFg8UOOttt6X8zQ0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_VDmuUOFDYEWzBAgPTq5vdg_4_2">931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_cB3ANTnBg0OCmZf8uEBeTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_XIePhiH6D0eXlJdYENhbMg_4_4">893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aQmUj8E-FUqSQDzVNxRfcw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Ca6BFesjGkKoQiaPSuAo8A_4_6">611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_UVoSolrPv0qV5x4CzEronQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_gFDEHB7T-ESQvFKojGHjfQ_4_8">926</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BzIKlySpD0yINoAWGMbaLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_qFI2_g7-iUWrHgaGAigtOg_5_2">19</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_uJR98_x7FUu-h9HgcgHodQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_IlWu-JBT2kSr0Gm0qnGDOQ_5_4">15</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_mkImYFxDL0WhSR47srlVEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_9J8tcHqX2UeaMiWw1UQ-DA_5_6">21</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_i4aGeX3zlkORauSmBIjKjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_z5d3YG47y06Sks8WQVOCRA_5_8">15</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_jOdu64zHskKWJvq_RiAlPQ_6_2">5,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_8fn2cJ8YsE2peyQV6HiFJQ_6_4">908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_1uRSkeQKE0-m_MbIDY0DYg_6_6">6,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_IDdhcUgIx0iVHN59rkG1Uw_6_8">941</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk53438281"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:LicensingAndOtherArrangementsTextBlock" id="Tb_1SzP3pOKPkCB0DdyoxrPzw" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis&#160;&#8211; Gevokizumab (VPM087) and IL-1 Beta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis Pharma AG (&#8220;Novartis&#8221;) entered into a license agreement (the &#8220;XOMA-052 License Agreement&#8221;) under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents (altogether, the &#8220;XOMA IP&#8221;). Under the terms of the XOMA-052 License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont1" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the XOMA-052 License Agreement, the Company received total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_awdxxvYqtEqIr8fX7s0row">30.0</ix:nonFraction> million for the license and rights granted to Novartis. Of the total consideration, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_OxeATdjP_068bR1JMNM2Ig">15.7</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_uScDoi0aGEi-gENFEud-Cg">14.3</ix:nonFraction> million (equal to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_rMXTIUZ4Q0GOaNm0YP-bKA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_nFkGpYLF5UOKLAJkY-ZTxw">12.0</ix:nonFraction> million) was paid by Novartis Institutes for BioMedical Research,&#160;Inc. (&#8220;NIBR&#8221;), on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, NIBR extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_UU3bZfxH-ESxQUGwTlQaOw">5.0</ix:nonFraction> million cash related to the sale of <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_h876bxgD4E6G4nwewYSkPw">539,131</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_3QGlIijL3UaaKs9duSDnWA">9.2742</ix:nonFraction> per share. The fair market value of the common stock issued to Novartis was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw" decimals="-5" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock" scale="6" id="Narr_gowUNwQp_UenLBctRIMp6g">4.8</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_IqJOsUQwxkKfQIGjxuH6jg">8.93</ix:nonFraction> per share on August&#160;24, 2017, resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_o-7v8FV91E-0N0JxWotIhA">0.2</ix:nonFraction> million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_3J3eYrJwe0CGhF_QaAhlkg">438.0</ix:nonFraction> million in development, regulatory and commercial milestones under the XOMA-052 License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_JlCyW65-O0OyudJIFvxeLA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_x42Y0ZmcD0upuJe_cSQvTA">10.0</ix:nonFraction> million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the XOMA-052 License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The <ix:nonFraction unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreements" scale="0" id="Narr_KjeEa--nOkSVuZiO5dcRoA">two</ix:nonFraction> agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the XOMA-052 License Agreement on a product-by-product and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_jDEe-gi0N02EIywvWQ4-0Q">six months</ix:nonNumeric>&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The XOMA-052 License Agreement and IL-1 Target License Agreement were accounted for as <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ArrangementsNumber" scale="0" id="Narr_TJtR6L0w_UeMxphchO5mow">one</ix:nonFraction> arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_SaGltyEaSEmo4iILDYE7-w">two</ix:nonFraction> distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_spNgKpVzV0SFHWEoUU3GIw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_ySm_Y4b3IUuwwP7YT_OL7A">no</ix:nonFraction> further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementTransactionPrice" scale="6" id="Narr_JW_5qHPFG0-DblEa377E7g">40.2</ix:nonFraction> million, which consisted of the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_nD4JjVHh_USA9EJyYzkKNg">25.7</ix:nonFraction> million upfront cash payments, the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_GFzXIp7W7ES6UdRMUmLz6g">14.3</ix:nonFraction> million Servier Loan payoff and the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_TuMrtVjBM0WZKj5h92pwUw">0.2</ix:nonFraction> million premium on the sale of the common stock. The transaction price was allocated to the <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_E7_ZDdmGUkaD2kHpvS6fbA">two</ix:nonFraction> performance obligations based on their standalone selling prices. The Company determined that the nature of the <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_8fYlQmmk90izZhFLDogumg">two</ix:nonFraction> performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_D1p_zcUBUkyNi8tT3yY_hg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_-pAe7vetzEWsBgskI2NXcg">40.2</ix:nonFraction> million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_699a6118_0dde_4d4e_9961_717c751d2c98"></a><a id="_699a6118_0dde_4d4e_9961_717c751d2c98_2"></a><a id="_699a6118_0dde_4d4e_9961_717c751d2c98_3"></a><a id="_Hlk54693411"></a><a id="_Hlk54694054"></a><a id="_Hlk54693824"></a><a id="_63781933_2bb2_4490_aeac_6f6355b00f29"></a><a id="_63781933_2bb2_4490_aeac_6f6355b00f29_2"></a><a id="_63781933_2bb2_4490_aeac_6f6355b00f29_3"></a><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont2" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_WqbFT2s5x0OgH0Xz3z1YLQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_iMNEGpBSukqoPuvHo3AJ_w">no</ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="3" id="Narr_MPDQYL7HnkSroUtT-oiO9w"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="3" id="Narr_1b_ZRS3ZLkW-n7ceNTPWaw">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_2tva6vIdREy4CHVmhj6hXA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_z18UUwQGeU2wf5TMtx_9MQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_BU0vF3ofNkq6-z8Hkgq8qQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_iZlLcj5W7kCdmFpYuiXaog"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_icqncM0pU0-kgas-GLplCw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_lNZ4l_qPVkaO5YJvbQxDvQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_qDUv8TEmVUiCki1cFKC_pw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_GkQdg9hBJUe9--tpiUBWeA">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized for the three and nine months ended September 30, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis International&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis International Pharmaceutical&#160;Ltd. (&#8220;Novartis International&#8221;) entered into a license agreement (the &#8220;License Agreement&#8221;) under which the Company granted Novartis International an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the License Agreement, Novartis International has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis International&#8217;s royalty obligations end. The License Agreement contains customary termination rights relating to material breach by either party. Novartis International also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_99jw6K1F2kyML9Mfsv6AMg">one hundred eighty days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there are multiple promised goods and services under the License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_swTNoatAnUW9jRjgeDXMDg">one</ix:nonFraction> combined performance obligation. The Company recognized the entire upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_p6M7bhFzkEityaF4ZSk6kQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_ExhvMTq2eUmqOi_bmk0HLg">37.0</ix:nonFraction> million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2017, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and as a result, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GtNAno1Ke0iBcXqeK0kWoQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_AyGTwnkRc0O-0fTN4rra8Q">10.0</ix:nonFraction> million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income. The Company is eligible to receive up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_EjqWqEleVUOU6Au4EhcrjQ">470.0</ix:nonFraction> million in development, regulatory and commercial milestones under the anti-TGFB antibody agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each quarter, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit&#160;percentage rate to up to a low double-digit&#160;percentage rate. Novartis International&#8217;s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_FLY13KMXSEq8LcrO0Y4QQA">ten years</ix:nonNumeric> from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_ZxH1RhYs4UKPlXKjBw13Wg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_CEEe4rDG7kmHUqYP1EVBZA">no</ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_5eOuxCyy5UOIXFzAMFCMSQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_p8gU-fHJrEmDcTWOLHmeJw">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0nldtO9DMkyHVBM2GSo1qQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_9KC11w0IuEqi_D3LhYSvXg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eIy62rKGB0arkcYOhjzDlQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_UBF5sf2aR0WDZgXQik-n9w"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_vFwBpj0KSki9O3qvws6NOg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lg0H9jEOVUWKuKkJPri6jw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_AFXBlq8OQEGuY49gfdDBXw">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized for the three and nine months ended September 30, 2020 and 2019.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont3" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_0aGr4ChytEKCRq8zp2tvNw">25.0</ix:nonFraction> million milestone payment as a result, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_VfcmGJWzGEixJ-L14J-IZg">232.0</ix:nonFraction> million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_b_RyZ7QntEO9dpBtwTKfSg">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, the Company is eligible to receive a low single digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_mQ-Twe7RO0Gh68dOSmYzIg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_DlmDJ-S34keeJt3NnJ15uQ">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country (the &#8220;Royalty Term&#8221;), provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country. Rezolute&#8217;s future royalty obligations will be reduced by <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfDecreaseInFutureRoyaltyObligations" scale="-2" id="Narr_TsIjHEE0nUSiPAHKt92q2w">20</ix:nonFraction>% at any time during the Royalty Term that a valid XOMA patent claim is not outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Rezolute had an option through June&#160;1, 2019 to obtain an exclusive license for their choice of one of the Company&#8217;s preclinical monoclonal antibody fragments, including X129 (the &#8220;Additional Product Option&#8221;), in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontOptionPayment" scale="6" id="Narr_osKBaroxqE6eUhIRmRM-iw">1.0</ix:nonFraction> million upfront option fee and additional clinical, regulatory and commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_PZN-7MHacE-qVvQd1CwpjA">237.0</ix:nonFraction> million in the aggregate based on the achievement of pre-specified criteria as well as royalties ranging from the high single digits to the mid-teens based on annual net sales. On June 1, 2019, Rezolute&#8217;s right to the Additional Product Option expired unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_7SBSxR3Tw0evPp1O4-zeZw">ninety days</ix:nonNumeric>&#8217; notice at any time. The Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the license agreement and common stock purchase agreement, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_16EF_ONIAkOJV7AD6i1Wng">no</ix:nonFraction> consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities and the amounts to be paid to be based on the timing of those activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- First Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March&#160;2018, the Company and Rezolute amended the license agreement and common stock purchase agreement. Pursuant to the as-amended terms of the license agreement and common stock purchase agreement, the Company was eligible to receive $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleToReceiveInCash" scale="6" id="Narr_xNXQko35HEqf-0nL2umRJQ">6.0</ix:nonFraction> million in cash, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities" scale="6" id="Narr_bjSB-ByqZkSlHH8B-oUbhQ">8.5</ix:nonFraction> million of Rezolute&#8217;s common stock, and <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:CommonStockSharesReceivable" scale="0" id="Narr_4YPhbbbq0UavHt5GJ5PI_A">7,000,000</ix:nonFraction> shares of Rezolute&#8217;s common stock, contingent on the completion of Rezolute&#8217;s financing activities. Further, in the event that </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont4" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rezolute did not complete a financing that raised at least $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:GrossProceedsFromQualifiedFinancing" scale="6" id="Narr_b-8rUjd3QUSC5hJcgFiY4w">20.0</ix:nonFraction> million in aggregate gross proceeds (&#8220;Qualified Financing&#8221;) by March&#160;31, 2019 (the &#8220;2019 Closing&#8221;), the Company would have received an additional number of shares of Rezolute&#8217;s common stock equal to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:AdditionalCommonStockReceiveForQualifiedFinancing" scale="6" id="Narr_eYbxdzmrhkGP0tqprm4X9w">8.5</ix:nonFraction> million divided by the weighted average of the closing bid and ask prices or the average closing prices of Rezolute&#8217;s common stock on the <ix:nonNumeric contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ" format="ixt-sec:durwordsen" name="xoma:CommonStockThresholdTradingDays" id="Narr_27vvtjJEd0ef_DqYE4DOHw">ten-day</ix:nonNumeric> trading period prior to March&#160;31, 2019. Finally, in the event that Rezolute was unable to complete a Qualified Financing by March&#160;31, 2020, the Company would have been eligible to receive $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2019_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nxvD1pY7ckS0UoRcs7ScvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleToReceiveInOrderToMaintainLicenseAgreement" scale="6" id="Narr_xAiUJN58YkK95FTMmHLPxQ">15.0</ix:nonFraction> million in cash in order for Rezolute to maintain the license. Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A" decimals="INF" format="ixt:numdotdecimal" name="xoma:NumberOfSharesRightAndOptionToSell" scale="0" id="Narr_t6XemsMsQEuvbHG0D9AOow">5,000,000</ix:nonFraction> shares of common stock or (ii)&#160;<span style="-sec-ix-hidden:Hidden_5JMn34DvnkG2-h_9uI7tlA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one third</span></span> of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2018, the Company completed the delivery of the license and related materials, product data/filing, process and know-how to Rezolute. However, the Company determined that it was not probable that the Company would collect substantially all of the consideration to which it was entitled in exchange for the goods and services transferred to Rezolute. Therefore, the Company determined no contract existed as of March&#160;31, 2018 and <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_gPaYGyy2xkaDpvkBVLS-vA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="Narr_67ikfwrQ80KmvFVqhTibIw">no</ix:nonFraction> revenue was recognized during the three&#160;months ended March&#160;31, 2018 under the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute completed the Interim Financing Closing and the Initial Closing financing activities, as defined in the common stock purchase agreement, during the first and second quarter of 2018, respectively. As a result, XOMA received <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g" decimals="INF" format="ixt:numdotdecimal" name="xoma:SharesReceived" scale="0" id="Narr_mGxk5ODCqUKowLXEhNJm7g">8,093,010</ix:nonFraction> shares of Rezolute&#8217;s common stock and cash of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashReceived" scale="6" id="Narr_AmGrmeZ8hESQINLaX4eRPg">0.5</ix:nonFraction> million in April&#160;2018. Under the license agreement, XOMA was also entitled to receive $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_90hIlWqbgUaomWenCQwomg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReimbursableTechnologyTransferExpensesReceived" scale="6" id="Narr_-zpaw-1XpUmSwfHXGjKGYw">0.3</ix:nonFraction> million of reimbursable technology transfer expenses from Rezolute. The Company concluded that the payment associated with the Initial Closing represented substantially all consideration for the delivered license and technology to Rezolute. Therefore, the Company determined that a contract existed between Rezolute and XOMA under ASC 606 on April&#160;3, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement and common stock purchase agreement were accounted for as <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ArrangementsNumber" scale="0" id="Narr_Cdrc2ECGlkyRSnufEDp7ow">one</ix:nonFraction> arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there were multiple promised goods and services under the combined arrangement, including the license to RZ358, the transfer of RZ358 materials and product data/filing, and the transfer of process and know-how related to RZ358, which were determined to represent one combined performance obligation. The Company determined that the Additional Product Option was not an option with material right because there was <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="-5" format="ixt-sec:numwordsen" name="xoma:UpfrontConsiderationToIncrementalDiscountForFuturePayment" scale="6" id="Narr_MVmTCVPVP0qUy0n8dG7Qbw">no</ix:nonFraction> upfront consideration to the Company that would result to an incremental discount for the future opt in payments. Therefore, the Company concluded that the Additional Product Option was not a performance obligation. On June&#160;1, 2019, Rezolute&#8217;s right to the Additional Product Option expired unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;3, 2018, the Company determined that the transaction price under the arrangement was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementTransactionPrice" scale="6" id="Narr_sAO8MnvNIk6MhwJ9bUlN8g">1.8</ix:nonFraction> million, which consisted of the <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="INF" format="ixt:numdotdecimal" name="xoma:SharesReceived" scale="0" id="Narr_SxhFRfFX_k68dgBei_MkDw">8,093,010</ix:nonFraction> shares of Rezolute&#8217;s common stock valued at $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:SharesReceivedValue" scale="6" id="Narr_6wv4CT07Zkmf5Pm3QUBOgA">1.0</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashReceived" scale="6" id="Narr_KesWoQweQkiBCP0tt6Tomg">0.5</ix:nonFraction> million in cash, and reimbursable technology transfer expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReimbursableTechnologyTransferExpensesReceived" scale="6" id="Narr_KiqQ0h2P0kiFH2gLOSYnRQ">0.3</ix:nonFraction> million. During the&#160;year ended December&#160;31, 2018, the Company recognized the entire transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_iK5dxlDC5kGuHLYJAFQjtQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_257R2w7bQ0-J9tWUTePFBQ">1.8</ix:nonFraction> million as revenue upon completion of the delivery of the licenses and related materials, product data/filing, process and know-how. The change in fair value of Rezolute&#8217;s common stock after the contract inception date was due to the form of the consideration and therefore, not included in the transaction price pursuant to the accounting guidance. The Company accounts for the change in the fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of the inception of the arrangement. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether the estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont5" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- Second Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;7, 2019, the Company and Rezolute further amended the license agreement and common stock purchase agreement. The parties agreed to replace the issuance of common stock valued at $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities" scale="6" id="Narr_HHjVG8rqQkegaalx6kuZ_w">8.5</ix:nonFraction> million to XOMA upon closing of a Qualified Financing with a requirement that Rezolute make <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" scale="0" id="Narr_w5VMONdkD0q6h3JSwWvydg">five</ix:nonFraction> future cash payments to XOMA totaling $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing" scale="6" id="Narr_8ZVx-hAeUkinKPqGmRcF9g">8.5</ix:nonFraction> million through September&#160;2020 (the &#8220;Future Cash Payments&#8221;). The amendment also provides for early payment of the Future Cash Payments (only until the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_eVulBzUmCkKYuR7HDbiMhg" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsOfRevenueRecognized" scale="6" id="Narr_lXIxOrSmCUyD7HSMiyir9g">8.5</ix:nonFraction> million is reached) by making cash payments to XOMA equal to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" scale="-2" id="Narr_KTjtUQgF8UueB8UXmmJudA">15</ix:nonFraction>% of the net proceeds of each future financing following the closing of the Qualified Financing, with such payments to be credited against any remaining unpaid Future Cash Payments in reverse order of their future payment date. In addition, the license agreement amendment revised the amount Rezolute is required to expend on development of RZ358 and related licensed products, revised provisions with respect to Rezolute&#8217;s diligence efforts in conducting clinical studies and eliminated XOMA&#8217;s right to appoint a member to Rezolute&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The common stock purchase agreement was amended to remove certain provisions related to the issuance of equity to XOMA in accordance with the new provisions regarding the Future Cash Payments in the license agreement. Lastly, the common stock purchase agreement was amended to provide the Company the right and option to sell up to <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg" decimals="INF" format="ixt:numdotdecimal" name="xoma:NumberOfSharesRightAndOptionToSell" scale="0" id="Narr__HhSCjvHNkCwspRG-jkFog">5,000,000</ix:nonFraction> shares of Rezolute&#8217;s common stock currently held by XOMA back to Rezolute upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2019. As of December 31, 2019, Rezolute failed to list its shares of common stock on the Nasdaq Stock Market or a similar exchange. Up to <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_qj2q9750f0eTH2ZT8YKEfQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:NumberOfSharesRightAndOptionToSell" scale="0" id="Narr_Ka7QkRM--kaxVpDJ2jvuUA">2,500,000</ix:nonFraction> shares may be sold back to Rezolute during calendar&#160;year 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;30, 2019, Rezolute closed a preferred stock financing for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg" decimals="-5" format="ixt:numdotdecimal" name="xoma:QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_dm5r69D8GkWX_w6Uhndb2A">25.0</ix:nonFraction> million, which triggered the Qualified Financing event defined under the amended common stock purchase agreement resulting in cash consideration due to XOMA of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ConsiderationPaidUponQualifiedFinancingEvent" scale="6" id="Narr_jmT0hhqxYkK5apWU0mkGQg">5.5</ix:nonFraction> million. In addition, the Company received from Rezolute a reimbursable technology transfer expense of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReimbursableTechnologyTransferExpensesReceived" scale="6" id="Narr_qRL01lXUuEqe_sog6rKo5A">0.3</ix:nonFraction> million. The cash consideration and technology reimbursement were received in February&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2019, Rezolute completed all financing activities, as defined in the license agreement and common stock purchase agreement, and the Company is eligible to receive $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_QGXGPdezx06vh-Y7VCyZzA" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing" scale="6" id="Narr_DRqYQpgxFUGQOaXo2CbiSg">8.5</ix:nonFraction> million in Future Cash Payments through September&#160;2020 (in addition to any clinical, regulatory and annual net sales milestone payments and royalties). The Company concluded that the Future Cash Payments are dependent on Rezolute&#8217;s ability to raise additional capital through future financing activities. The Company applied the variable consideration constraint to the Future Cash Payments and determined that it was probable that a significant revenue reversal would not occur in future periods for only $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_D0iNeUKX6UmzP9knxvEqaQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:DoubtfulRevenueReversalOfFutureCashPayments" scale="6" id="Narr_5LIqZYiYz0yOv_tvRRKjTA">2.5</ix:nonFraction> million of the total amount as of March&#160;31, 2019 and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_89o9tNvIJ0KB_EHx37NNug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Ut4SO6_UfESw-9dxZ1U9-Q">2.5</ix:nonFraction> million revenue in that quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;and August&#160;2019, Rezolute received additional cash through <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementNumberOfCommonStockFinancingEvents" scale="0" id="Narr_O-c_vsGZZUCQXXHeEArGuQ">two</ix:nonFraction> common stock financing events, which triggered early payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog" decimals="-5" format="ixt:numdotdecimal" name="xoma:EarlyPaymentOfUnrecognizedFutureCashPayments" scale="6" id="Narr_YrYKichY0UOGwrGjQP-Lhw">3.4</ix:nonFraction> million of the unrecognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_6_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Lk396fUAR0mQ7Bxv2PCf3w" decimals="-5" format="ixt:numdotdecimal" name="xoma:UnrecognizedFutureCashPayments" scale="6" id="Narr_ia4B1TV7rE62sCZ44oFZEw">6.0</ix:nonFraction> million of total Future Cash Payments. In addition, the Company received the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_30_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_J64v0Y9UbkWCwMWpG5hjQw" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_0GOMQSbwsk-HbWrfP7NDcw">1.5</ix:nonFraction> million payment due September&#160;30, 2019, resulting in a total of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_SfwG94ZdSEWQ0GJsnkRkJg">4.9</ix:nonFraction> million cash received from Rezolute in the third quarter of 2019. The Company re-assessed the outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_5lBpdkZpkEOX6-ywF04jcQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:DoubtfulRevenueReversalOfFutureCashPayments" scale="6" id="Narr_drRbnq2-_kGPmfxrAiUeZQ">3.6</ix:nonFraction> million of Future Cash Payments and determined that a significant revenue reversal was not probable due to Rezolute&#8217;s recent common stock financing events. Therefore, in the third quarter of 2019, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_cV6Jlmd_CUuNLMEhfiT3ug">6.0</ix:nonFraction> million as revenue related to the remaining Future Cash Payments. In the fourth quarter of 2019, the Company received the scheduled $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_RYA4JA0yrUCgyI6USQlccg" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_u7UXltNrAU2DnEaJofxw5w">1.0</ix:nonFraction> million Future Cash Payment from Rezolute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- Third Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 31, 2020, the Company and Rezolute further amended the license agreement to extend the payment schedule for the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsOfRevenueRecognized" scale="6" id="Narr_4xshLfgauEKdbuwE-E_zIA">2.6</ix:nonFraction> million in Future Cash Payments. The amendment to the payment terms was in response to Rezolute&#8217;s need to preserve cash as a result of the COVID-19 pandemic and w<span style="color:#231f20;">as agreed to by the Company. </span>The extended payment schedule did not impact the total amount due, but instead, spread the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsOfRevenueRecognized" scale="6" id="Narr_i3PIJNY5r0a3Jg8Jvucbpg">2.6</ix:nonFraction> million into <ix:nonFraction unitRef="Unit_Standard_installment_7zKUzhL-x069Du3GTyKbRQ" contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfQuarterlyPayments" scale="0" id="Narr_SeRBt3rCtUWPKfHpMRFZXQ">seven</ix:nonFraction> quarterly payments to be paid through September 30, 2021. The amended license agreement requires<span style="color:#231f20;"> that in the event Rezolute completes a Qualified Financing at any time between March 31, 2020 and the date of the final payment, Rezolute shall pay all amounts outstanding within </span><ix:nonNumeric contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w" format="ixt-sec:durwordsen" name="xoma:PaymentPeriodFollowingClosingOfQualifiedFinancing" id="Narr_eFvZMBJGmUGPEP6EySZhAQ"><span style="color:#231f20;">fifteen days</span></ix:nonNumeric><span style="color:#231f20;"> following the closing of the Qualified Financing. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ada47d3f_7bbe_44a0_b44f_daed78b01465"></a><a id="_ada47d3f_7bbe_44a0_b44f_daed78b01465_2"></a><a id="_ada47d3f_7bbe_44a0_b44f_daed78b01465_3"></a><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont6" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the first quarter of 2020, the Company received the scheduled $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nFBHFZRpIkK4eK-sS_dY2w" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_axxAAc9JAE2A1e8LA2nzmg">0.4</ix:nonFraction> million Future Cash Payment from Rezolute. The Company evaluated Rezolute&#8217;s cash position as of March 31, 2020, including the estimated impact of the COVID-19 pandemic, and determined payments scheduled beyond September 30, 2020 were unlikely to be collected unless Rezolute is able to obtain additional funding, which had not occurred as of March 31, 2020. Therefore, for the three months ended March 31, 2020, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FWdasQOebUi4BvD0XzdauQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="Narr_sqf9GD5kHUGf6mR6fL6d1g">1.4</ix:nonFraction> million in bad debt expense related to the Future Cash Payments. The Company received the scheduled $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bl4vMQZQ1UG2x7-nwv1Wxw" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_iQ58UBL5ukKBycNvDmw1MQ">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_St9i97mas0e22erorbJ1jA" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_0PhcWeK3HUq4etWm_irnTg">0.4</ix:nonFraction> million Future Cash Payments from Rezolute in the second and third quarters of 2020, respectively. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ovP2h0yP-E6tctRS1ZBHeQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="Narr_GXvSdURpekad9zvT3-BCYw">1.4</ix:nonFraction> million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. On October 9, 2020, Rezolute completed a Qualified Financing, which resulted in acceleration of the remaining receivables balance and the Company received the entire $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_s5WyiWEK0EODw10JAUC9lA">1.4</ix:nonFraction> million in October 2020, as discussed in Note 14, Subsequent Events. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_r6uPcWkw0EGKekDR39QOfA"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_JkYJGcnVg0KxedUqRaZpDg">no</ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_XGsfDc5af02XQtLN-BEh_w"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_EQX6bphJYkWSaQxlFSCEyA">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_aDDtU1Gqbk2yENmRPLeZEA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_uipsTpfxYUSs55v_uBh4NA"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IT6QiO78xka2AQOOc1LOTw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Narr_UntnigL5hEaG9ZvjSAmGdQ">No</ix:nonFraction></ix:nonFraction> revenue was recognized for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of September 30, 2020 and December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and Janssen Biotech,&#160;Inc. (&#8220;Janssen&#8221;) were parties to a license agreement which was terminated in 2017. In August&#160;2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA" decimals="-5" format="ixt:numdotdecimal" name="xoma:OneTimePayment" scale="6" id="Narr_2jG8mh1Ykk2D9MX2HpF3Xw">2.5</ix:nonFraction> million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" scale="6" id="Narr_CaNkHswdG0Of8Oo7o5iWEQ">3.0</ix:nonFraction> million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Upon commercialization, the Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA" decimals="4" format="ixt:numdotdecimal" name="xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization" scale="-2" id="Narr_ddxcv-idI0-TWp69P1rh6Q">0.75</ix:nonFraction>% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year and sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27iut_LRX06eiWjddrdvbA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_9bw978Bb3U6b5LmksyFgeg">2.5</ix:nonFraction> million as revenue in the consolidated statement of comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_PFvCXqI130O-wJDpuyfyqQ">no</ix:nonFraction> contract assets or contract <span style="-sec-ix-hidden:Hidden_IvzhjoQ1qkKnonNbFMwDHw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_qQiNs5xUGkO0e48Hs-HEZA">None</ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. Revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Ly6c31YnNUudvyfVl4nIcQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_cWH6euorlUOHBfZfUmS8IQ">0.2</ix:nonFraction> million was recognized for the three and nine months ended September 30, 2020.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont7" continuedAt="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Zydus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 3, 2020, the Company and Cadila Healthcare Limited (&#8220;Zydus&#8221;) entered into a license agreement (the &#8220;Zydus Agreement&#8221;) under which the Company granted Zydus an exclusive royalty-bearing license to the Company&#8217;s anti-interleukin-2 (&#8220;IL-2&#8221;) monoclonal antibody, including mAb19, for Zydus to develop and commercialize drug candidates in India, Brazil, Mexico and certain other emerging markets. The Company retains rights in all other territories, subject to a Zydus right of first negotiation. Under the terms of the Zydus Agreement, Zydus is responsible for the development and commercialization of IL-2 based immune-oncology drug candidates. XOMA is entitled to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" scale="6" id="Narr_wkS3O97diUqSmr4nGUGgEQ">0.5</ix:nonFraction> million development and regulatory milestone payments, up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" scale="6" id="Narr_6rZAkvZTzkCFfAS9NcspbQ">23.5</ix:nonFraction> million commercial milestone payments, and mid-single digit to low teens royalties from Zydus. The Company is also eligible to share out-licensing revenue received by Zydus should Zydus (sub)license to third parties, which are tiered based on clinical trial stage and range from a low to mid double-digit&#160;percentage rate. Unless terminated earlier, the License Agreement will remain in effect, on a product-by-product basis, until all payment obligations end. The Zydus Agreement contains customary termination rights relating to material breach by either party. Zydus also has a unilateral right to terminate the agreement upon required written notice in advance if certain conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there is <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_-dFSbnp1aU6GgNJd4OywVw">one</ix:nonFraction> performance obligation, and it had not completed its performance obligation. The development and regulatory milestone payments are solely dependent on Zydus&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Zydus and therefore, have also been excluded from the transaction price. Out-licensing revenue sharing will be recognized if and when Zydus receives or earns its out-licensing revenue. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_TkpDrOY-10GeeZRx6YaGDQ">no</ix:nonFraction> contract assets or contract <span style="-sec-ix-hidden:Hidden_6KcCQ2KmOUSERG_vOJUbuA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_-YDUHvsI20GviZeHZLZmag">None</ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UyMAk0h1pkWFrzI4SV59gQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_p1ew4G_1JkiVtq-5lvkjOg"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WNBaxopPiUiO0lekbTR3QA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_0aclRq365kGBwh-kLje9_w">No</ix:nonFraction></ix:nonFraction> revenue was recognized for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">NIAID</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the sale of the Company&#8217;s biodefense business, the Company performed services under a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumRevenueFromContract" scale="6" id="Narr_LhfLnLWgY0e_W_Vyd8Gg0Q">64.8</ix:nonFraction> million multiple-year contract funded with federal funds from NIAID (Contract No.&#160;HHSN272200800028C), for development of anti-botulinum antibody product candidates. The contract work was being performed on a cost-plus fixed fee basis over a <ix:nonNumeric contextRef="Duration_9_1_2008_To_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_QfxCyr376USWRtXD17lOFQ" format="ixt-sec:durwordsen" name="xoma:ContractualTerm" id="Narr_EFyhKraXhU-GzQ_h0i57Mg">three-year</ix:nonNumeric> period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company&#8217;s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2014, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID&#8217;s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="6" id="Narr_pkqqZGHlVkCcArD5t6dlbA">0.4</ix:nonFraction> million receivable and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_itvN6N30v0CRWDhJRlPOJg">0.8</ix:nonFraction> million deferred revenue balances. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company&#8217;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. As of December&#160;31, 2017, the Company wrote off the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_82L3K22qB0OdI0xUjjPm3A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContractsRevenueWroteOff" scale="6" id="Narr_FW6l7jJP_UGl-Vcq_hCO3w">0.4</ix:nonFraction> million receivable from NIAID as the likelihood of collection was remote. The Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_RE1e6CumO0O-2KGTFiCqsA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_T9qaVkFc8EK63hvxbxvwGA"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_UmYPv4uBU0-L1_gmyTWzwQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_fjQoQAzhwUCv8JxrhLgDhg">0.8</ix:nonFraction></ix:nonFraction> million as contract liabilities on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;21, 2016, the Company entered into <ix:nonFraction unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_IY-oiCHtZk6_-I42xb79UQ">two</ix:nonFraction> Royalty Interest Acquisition Agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer,&#160;Inc. (&#8220;Pfizer&#8221;)) for an upfront cash </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1SzP3pOKPkCB0DdyoxrPzw_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_uYjlieKTNEqKshJwUd9daQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_cIEhSn5dOEy6LdLvdaTu3w">6.5</ix:nonFraction> million, plus potential additional payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" scale="6" id="Narr_KbSM20fMYEWZvw1p0GMoqw">4.0</ix:nonFraction> million in the event <ix:nonFraction unitRef="Unit_Standard_period_AqtsOpMfTku-KpzgyKR7UQ" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:MilestonePeriodsNumber" scale="0" id="Narr_qtfCZLVYE0uhZ5zaRx6Ohw">three</ix:nonFraction> specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_bcq3GNUerEmVGRoYfGrnYw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_8lP0e8y3eU-PBWAkIJFj5g">11.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="Narr_wp9lPlT0EkCvroa4sIDo4g">18.0</ix:nonFraction> million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the <ix:nonFraction unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_0uPI2yU0iUS8hyjvd1t3XA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_sAiRxykmz0Gg96zYpZBRAw">two</ix:nonFraction> Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the &quot;units-of-revenue&quot; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_bsRXsMH6rEOZqpfaU8z-Yw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_NUZ2Wm4-3EijALJNE7gYHg">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_HlFFyZp90EKVNXtLD7WtKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_3rzcLnsUVEW8Hew79TLCqQ">1.1</ix:nonFraction> million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2020, respectively. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_hayCoIN1Nki93_kbNGtPnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_s0HGiwDMdEWSyaztwphrfw">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_9DVd9snmb02Tp8DZcf-2Yw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_bcvuuhs8kkiM1HizsvB4aw">0.8</ix:nonFraction> million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_yrRJWPYy9UuUh_ZhOeCDhA">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_UOIt_bYNM0q18Pp3V1cvbg">14.0</ix:nonFraction> million as current and non-current unearned revenue recognized under units-of-revenue method, respectively. As of December&#160;31, 2019, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_FV5DviRRfkOZTE8uAkP80A">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_ZDor1JHBAkGzdXUcaNZHZA">15.3</ix:nonFraction> million, respectively.</p></ix:continuation><a id="_Hlk53438055"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:RoyaltyPurchaseAgreementTextBlock" id="Tb_QsV4olzarEi4hFDXtHk4Jw" continuedAt="Tb_QsV4olzarEi4hFDXtHk4Jw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Agenus,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;20, 2018, the Company entered into a Royalty Purchase Agreement (the &#8220;Agenus Royalty Purchase Agreement&#8221;) with Agenus,&#160;Inc., and certain affiliates (collectively, &#8220;Agenus&#8221;). Under the Agenus Royalty Purchase Agreement, the Company purchased from Agenus the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_BGb-iMqfnkC7PsBVD921Og">33</ix:nonFraction>% of the future royalties on <ix:nonFraction unitRef="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ryahLRb460WZ_uEMdm-Gdg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" scale="0" id="Narr_sjRxMdJGv0KwinxOp5ArIQ">six</ix:nonFraction> Incyte immuno-oncology assets, currently in development, due to Agenus from Incyte Europe Sarl (&#8220;Incyte&#8221;) (net of certain royalties payable by Agenus to a third party) and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_EcZeyG2sRUiroMriJFedIQ">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low-single to mid-teen digit&#160;percentage of applicable net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company purchased from Agenus the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_4jH5Ny-cVUOL7Mkyoe8Zqg">33</ix:nonFraction>% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck Sharp&#160;&amp; Dohme Corp. (&#8220;Merck&#8221;) and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_wAQJtXvaTU-XYegX4LpDvA">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single digit&#160;percentage of applicable net sales. Pursuant to the Agenus Royalty Purchase Agreement, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pyJIa2rRckSbu4tMGZ7OQQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_k5DWSUfUdUm4tvr-SqD0UQ">59.5</ix:nonFraction> million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QsV4olzarEi4hFDXtHk4Jw_cont1" continuedAt="Tb_QsV4olzarEi4hFDXtHk4Jw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Royalty Purchase Agreement, the Company paid Agenus $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gkqI07hkKE2Ouf8ac3CdpQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRights" scale="6" id="Narr_X8eRQdDC2EmCvb4dK51MDQ">15.0</ix:nonFraction> million. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7r0aHlZReUi3PqLdTuvGMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_NTORXbhBgEyPhqT21TEqFg">7.5</ix:nonFraction> million of the purchase price with a term loan under its Loan and Security Agreement with Silicon Valley Bank (&#8220;SVB&#8221;) (Note&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sQZl0NJ6VEitMJ9UCcOjeg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="6" id="Narr_j3i8NvNJ9kyGOjRST9nJMQ">15.0</ix:nonFraction> million as long-term royalty receivables in the condensed consolidated balance sheets. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected.&#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_y28H4G623kys0zqGl3uk7w" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="3" id="Narr_RDnEYpMWKUuRMl_SvjnhHg">no</ix:nonFraction> impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Bioasis Technologies,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;25, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Bioasis Royalty Purchase Agreement&#8221;) with Bioasis Technologies,&#160;Inc. and certain affiliates (collectively &#8220;Bioasis&#8221;). Under the Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q" decimals="INF" format="ixt:numdotdecimal" name="xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" scale="-2" id="Narr_Hr4qg9_FykCqLkK1uW9AvA">1</ix:nonFraction>% royalty right on the next <ix:nonFraction unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreementsFutureLicenseAgreements" scale="0" id="Narr_Bz9I7eEpE026cXbOjo9Y-w">two</ix:nonFraction> license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" scale="6" id="Narr_tAPP-1Mcb0mRijy20mqU6A">0.3</ix:nonFraction> million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" scale="6" id="Narr_ZCIuJ_PSW0Gjd05ShkvReQ">0.4</ix:nonFraction> million per licensed product. The Company exercised its option under the Bioasis Royalty Purchase Agreement and entered into a second royalty purchase agreement with Bioasis on November 2, 2020, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis Royalty Purchase Agreement, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRights" scale="6" id="Narr_MYC8Q5Ee0EWCquO4_QUgTA">0.3</ix:nonFraction> million and will make contingent future cash payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XaAWLwY770yBqnJd66HkrA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr_o_gN8QwiwUSihGDh7gHyog">0.2</ix:nonFraction> million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="6" id="Narr_YWdbGIzcvEmWXqAP43Lc9A">0.4</ix:nonFraction> million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="6" id="Narr_QTl6cug1CEmvMTBc7Twvqg">0.1</ix:nonFraction> million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income. As of September 30, 2020, there was <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="3" id="Narr_M48lvclytkyWBoec9fnaiw">no</ix:nonFraction> change in the fair value of the contingent consideration from its initial value and <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt-sec:numwordsen" name="xoma:PaymentsOfContingentConsideration" scale="3" id="Narr_e004-KpvmUOHItxIk0xYTA"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt-sec:numwordsen" name="xoma:PaymentsOfContingentConsideration" scale="3" id="Narr_UIMGBcGDik68agKfOHxJZQ">no</ix:nonFraction></ix:nonFraction> amounts were paid during the three and nine months ended September 30, 2020. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vF4M7itcq0qmDA1FQGsWbQ" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="3" id="Narr_EwV3jwrFU0Gg2tPa67J8Fw">no</ix:nonFraction> impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Aronora,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;7, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Aronora Royalty Purchase Agreement&#8221;) with Aronora,&#160;Inc. (&#8220;Aronora&#8221;), which closed on June&#160;26, 2019. Under the Aronora Royalty Purchase Agreement, the Company purchased from Aronora the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_Kcay_nvAKUWvcRjnEQJI7A">five</ix:nonFraction> anti-thrombotic hematology drug candidates. <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_D1gC2lhfx0qVXmRcFhR-zw">Three</ix:nonFraction> candidates are subject to Aronora&#8217;s collaboration with Bayer Pharma AG (&#8220;Bayer&#8221;) (the &#8220;Bayer Products&#8221;), including <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber" scale="0" id="Narr_TsTwUUcnEEycMhv3te8Jfw">one</ix:nonFraction> which is subject to an exclusive license option by Bayer. The Company will receive <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_3Yx7Q2hwQ0K-9RdbtcVLtg">100</ix:nonFraction>% of future royalties and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_es0odPiiU02lGlh1BE5XEw">10</ix:nonFraction>% of future Non-Royalties from these Bayer Products. The other <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_-WKfBKxzcka-ic8QaaBjIA">two</ix:nonFraction> candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low-single digit&#160;percentage of net sales and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_cHvz_PuoaUeoaKjRtK5Q_w">10</ix:nonFraction>% of Non-Royalties. The future payment&#160;percentage for Non-Royalties will be reduced from <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_iLde9wOT4UqpV5L6mHipXQ">10</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" scale="-2" id="Narr_I8HRKy3QhEGLBRBfm3h6rQ">5</ix:nonFraction>% upon the Company&#8217;s receipt of <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementPaymentPercentageFactor" scale="0" id="Narr_lGDLcw4IvkWqeS7ucrLoOg">two</ix:nonFraction> times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QsV4olzarEi4hFDXtHk4Jw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora Royalty Purchase Agreement, the Company paid Aronora a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_3CJVa3OdmEey0x0Hv-fjFA">6.0</ix:nonFraction> million upfront payment at the close of the transaction. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VvqL6IhpekWtsweye5jZRQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_X5CiLeJ7QkySpU83gTfc4w">3.0</ix:nonFraction> million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8). The Company was required to make a contingent future cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VjJ154auA0SD0BIHuZfOvg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPaymentsPerProduct" scale="6" id="Narr_5J_qAJJ4G0KqUAFK-z5Xmw">1.0</ix:nonFraction> million for each of the <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_UimzKnANrUeP02FaPPAZsw">three</ix:nonFraction> Bayer Products that were active on September&#160;1, 2019 (up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr_R7OhBSKDi0Gk_mrTQIlZLg">3.0</ix:nonFraction> million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora Royalty Purchase Agreement, if the Company receives $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_DkVcYwI3W0yua5UY2yqJAA">250.0</ix:nonFraction> million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesPaymentsToAggregateAmountOfPerProduct" scale="6" id="Narr_SqKzSQBnUE6VWzb6n82D5Q">85.0</ix:nonFraction> million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_xO376R2SK0-XJ1FOLuSHuA">250.0</ix:nonFraction> million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_ccAIvMKei0GwfchdcFVSDA">250.0</ix:nonFraction> million are retained by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="6" id="Narr_iY3EYtQNHEKvPZS03Rr3hQ">9.0</ix:nonFraction> million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="6" id="Narr_d5o9JspLMUmC1rFBVUkoqQ">3.0</ix:nonFraction> million. In September&#160;2019, the Company paid the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_WQB1V7-nwkm5651laM-Szg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsOfContingentConsideration" scale="6" id="Narr_WzWsAqmdl0epVWXAYDHERg">3.0</ix:nonFraction> million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="3" id="Narr_N9khy0o2k0a5BtGmnFEpfA">no</ix:nonFraction> impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Palobiofarma, S.L.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;26, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Palo Royalty Purchase Agreement&#8221;) with Palobiofarma, S.L. (&#8220;Palo&#8221;), a company organized and existing under the laws of Spain. Pursuant to the Palo Royalty Purchase Agreement, the Company acquired the rights to potential royalty payments in low single digit&#160;percentages of aggregate Net Sales (as defined in the Palo Royalty Purchase Agreement) associated with <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_hDAQbLRLn0uft3SKdpWdyA">six</ix:nonFraction> drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis (the &#8220;Licensee&#8221;) is a development partner on NIR178, one of the Palo Licensed Products, and such NIR178 is being developed pursuant to a license agreement between Palo and the Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo Royalty Purchase Agreement, the Company paid Palo a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_O7QrlKu98UGAIfv-vA1UQA" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRights" scale="6" id="Narr_Al44A92RbUW_tEV1m0r0zA">10.0</ix:nonFraction> million payment at the close of the transaction which occurred simultaneously upon parties&#8217; entrance in the Palo Royalty Purchase Agreement on September&#160;26, 2019. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_JkbgTe29GU66NJfrMM3fWw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_AFd45TTPUU6wsWgOcIf7Og">5.0</ix:nonFraction> million of the payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRoyaltyReceivableNonCurrent" scale="6" id="Narr_eCM8TQzKbkCAjtWnLVha4g">10.0</ix:nonFraction> million as long-term royalty receivables in its condensed consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_9qNUOmhml0CM6tQxIvq-zQ" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="3" id="Narr_tN3cwMXBBkqNw0Sd09vZHA">no</ix:nonFraction> impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" scale="6" id="Narr_VrCh6VQtBkWy0o6UodR7kw">no</ix:nonFraction> change in the acquired royalty rights during the nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb__0U_gpDk-kCCdOIs2NnBxg" continuedAt="Tb__0U_gpDk-kCCdOIs2NnBxg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0b25052d_36fe_448d_8787_82a4d4872653"></a><a id="Tc_d7ZDWrVKl0el7eFygzmCiA_1_2"></a><a id="Tc_ALpc7M3IUUGseW5p4ZJoGw_2_2"></a><a id="Tc_6Hev16bQnUOAwHrZKzADHA_2_5"></a><a id="Tc_BZUB0INQRk2ZQgvV1bxoNw_2_8"></a><a id="Tc_wDvllfwavEydYBZYzuQnPQ_3_2"></a><a id="Tc_g_ZBKCdWy0GWQ93dfj_dVA_3_5"></a><a id="Tc_EmuPVmJ8NU6d4XRMCrWmUQ_3_8"></a><a id="Tc_6soMpjJCKEy2OsjYkUTvwg_4_2"></a><a id="Tc_bpu0GLjcUU6RHbQueLexqg_4_5"></a><a id="Tc_HLKQTSF4QkmbwHnReFqddw_4_8"></a><a id="Tc_0-psXoWCIUu93P9r_cxhlQ_5_2"></a><a id="Tc_ojQpjScUxkmPHQ1HKcyYjA_5_5"></a><a id="Tc_vpUECEpFiUmIji3EmLSmGA_5_8"></a><a id="Tc_kDTFlsACfUWSwKnK3wmXBA_5_11"></a><a id="Tc_Ti4x21e4w0G28g8_s0spkA_6_0"></a><a id="Tc_lbrmAL6pEUaqj1G3HJznjA_7_0"></a><a id="Tc_nDonZlZGk0OJaYbQNP_WWQ_7_2"></a><a id="Tc_vkVWqx_DREKBxnAqm-dHWg_7_3"></a><a id="Tc_HJNNmLi98E6N4UIIMe_bzw_7_5"></a><a id="Tc_YUyLIWgc30qcgDTs3UieXQ_7_6"></a><a id="Tc_b6R_Pn4QK0K9RIYM-FlVXw_7_8"></a><a id="Tc_3PBvwIhY7kiC29T_56iQSw_7_11"></a><a id="Tc_mLdsGKB9SU6W9I8s8ehONg_8_0"></a><a id="Tc_crYi9hi8dEy5KZ0hmp9iZQ_9_0"></a><a id="Tc_LDyms2JDskOZYnQqD75KZA_9_2"></a><a id="Tc_69m90hpGOUC3dfklYukj8w_9_3"></a><a id="Tc_iHWVP7curkSkSBGYNl-Zvg_9_5"></a><a id="Tc_nnc_8crYqka87n9rG0Bb_A_9_6"></a><a id="Tc_z1bwUlkCl0iFkG84Y7MMeQ_9_8"></a><a id="Tc_PgqrFDz6TkmW9wlG2JyQZQ_9_11"></a><a id="_3631cff9_6004_47eb_90e2_631f288033b0"></a><a id="Tc_QFjO_JjkakWri4v1ysmv9g_1_2"></a><a id="Tc_7pZ1fcM-EUKRp9YqCFLrYA_2_2"></a><a id="Tc_SuXovf3xPEmLrSf_vFdxfA_2_5"></a><a id="Tc_LGQu8fmPrUiukc2TX5ck3w_2_8"></a><a id="Tc_cBUEZ3-ayUmn_bWxlyK9ig_3_2"></a><a id="Tc_-VSy_O6yyU-j76tjAmsWRA_3_5"></a><a id="Tc_UJFMABKzEkiMwBvCrdi2SQ_3_8"></a><a id="Tc_9U0VGHcrok63WJJ5zZfLiQ_4_2"></a><a id="Tc_f61UP1gFEUGr3pzPvWSoEQ_4_5"></a><a id="Tc_FxzDGdRNbUS6ItmgE9F00A_4_8"></a><a id="Tc_lHjLxRiEK0W-7mKr6CvrgQ_5_2"></a><a id="Tc_TaMKwLV06E-PZwEcCaakBw_5_5"></a><a id="Tc_e2DZzYQAlEitDvUzVwoDvw_5_8"></a><a id="Tc_elrqVDy7xEeUyuAxvXdCDA_5_11"></a><a id="Tc_hn72GMURJE6ol5s-r8VF_A_6_0"></a><a id="Tc_wXvQWSCzd0uQerl-y3RJpA_7_0"></a><a id="Tc_SMSVT7-8SU-EX6m6oCDt6A_7_2"></a><a id="Tc_8ACmBOc1zkuhWW1zZ8ew2A_7_5"></a><a id="Tc_hLpeJpqSGEeC_P8UTVx6Mw_7_8"></a><a id="Tc_IQcKgyAU0EKGONbsNLIGsg_7_11"></a><a id="Tc_vIeU036MX0yguFqPCVem7w_8_0"></a><a id="Tc_5-M4DWF7c02WDKuFh4jEew_9_0"></a><a id="Tc_NEY0iDmSsEWd5SJ2T0HjQg_9_2"></a><a id="Tc__ihMKKKbnUerlEWLXGHSoQ_9_3"></a><a id="Tc_Ah9Xi1X5tkCzB6QW3tLPXg_9_5"></a><a id="Tc_woPxL4Vh9EydVBhLEHD-CQ_9_6"></a><a id="Tc_9ijLYR4TiU-9uL0jebn9IQ_9_8"></a><a id="Tc_JzxT2YKwOU6XyZFMTOnLgQ_9_11"></a><a id="_a5984d82_4339_4b73_8623_00271e60a842"></a><a id="_a5984d82_4339_4b73_8623_00271e60a842_2"></a><a id="_a5984d82_4339_4b73_8623_00271e60a842_3"></a><a id="_49950a95_0790_4f28_b2af_c66270237f19"></a><a id="_49950a95_0790_4f28_b2af_c66270237f19_2"></a><a id="_49950a95_0790_4f28_b2af_c66270237f19_3"></a><a id="_157bf9c7_e569_48e0_819c_2fd44b9c6b7d"></a><a id="_157bf9c7_e569_48e0_819c_2fd44b9c6b7d_2"></a><a id="_157bf9c7_e569_48e0_819c_2fd44b9c6b7d_3"></a><ix:continuation id="Tb__0U_gpDk-kCCdOIs2NnBxg_cont1" continuedAt="Tb__0U_gpDk-kCCdOIs2NnBxg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 1&#160;&#8211; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_TynZyC4v9kSj4afMOWDDdQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;September&#160;30,&#160;2020 Using </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_7vluZRyn3EG19YRqZujFCA_7_9">2,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_NZ76NBaB_0y2MjpU9Q0l7A_7_12">2,572</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_Ih1tCg_XVka7xnO8X-0CDg_9_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_g4eH-tzgyU2c-Eh87vqJbA_9_12">75</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_CbIjab0kOEaLSa_vn1zUkg_7_9">681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_m1dgDmpsKE6LJj1m-wthpA_7_12">681</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_Uf7LL-0djUiRPVIZwsOEcQ_9_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_0j1yPMQpV02qxb1MdLflxA_9_12">75</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="6" id="Narr_qXXV3-xptE2HBIbw0WFQ2w"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" scale="6" id="Narr_iD37CMA98UWPaz3IhsTeUw">no</ix:nonFraction></ix:nonFraction> transfers between Level 1, Level 2, or Level 3 assets reported at fair value on a recurring basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_4M3yFOkjVkebbww0pQytcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides a summary of changes in the estimated fair value of the Company&#8217;s Level 3 financial assets for the nine&#160;months ended September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br />September 30, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 681</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,572</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified as long-term assets on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019. The equity </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5f3626a5_bec7_4253_8c66_526a8e51876e"></a><a id="Tc_DqZzNxlPDEi-SEuKFd0xeg_1_3"></a><a id="Tc_N87XyItmQESkPovyKdcCXw_1_6"></a><a id="Tc_w0Wcxxgs7UyYHp22eHvG4w_2_3"></a><a id="Tc_gl3HgmSff0O5_LlCTg6Ffg_2_6"></a><a id="Tc_XKQGxqnw9kK3UxncczOQNw_3_0"></a><a id="Tc_ag8Vqv6UikWFtBb4ByN49g_3_2"></a><a id="Tc_i5t9x9yVf0uuLnGxdFWf6Q_3_5"></a><a id="Tc_oY0fK_Kcek-eNVkUp4u20w_5_0"></a><a id="Tc_uB__QhEdMUmkm95exyLwrw_6_0"></a><a id="Tc_dKiW46T_fUq-regwKzAv9g_6_4"></a><a id="Tc_EfAPCRzSPUOx-GjRFcj5rg_6_7"></a><a id="Tc_vdOuzwFpfkeDelDjudASjg_7_0"></a><a id="Tc_ttABxhrJ7EqZ6RP-yAsmIA_7_3"></a><a id="Tc_bVa0aeKCq0-B_xJaeivzhg_7_6"></a><a id="Tc_sj9do9-ggEWW12GizWks-Q_9_0"></a><a id="Tc_zdr_dgN36k2H3nIrJw9HGA_10_0"></a><a id="Tc_gLyambCIwkSse4GczSvexg_10_4"></a><a id="Tc_-QQr_NBMBkWDGSPSB73nYQ_10_7"></a><a id="Tc_nrS3yuvFo0uT32lJDjmwpQ_11_0"></a><a id="Tc_KJiiEatRgUKc6xi7Qjv_qA_11_3"></a><a id="Tc_cDYlZvXWlUCpsbARdgfpPQ_11_6"></a><a id="Tc_qM_JBMp9y0qUax6w_0QK7Q_1_2"></a><a id="Tc_oledTrymQEic4HCBYd0DYg_1_8"></a><a id="Tc_Av3o1j_i5ES-GY2GjxCgsA_2_2"></a><a id="Tc_ONMLha6oK0C2ylD_5uyUUA_2_5"></a><a id="Tc_vnUOlA0TK0KgXEzw_nQogw_2_8"></a><a id="Tc_uJaWF8strkSALbl8joL8Jw_2_11"></a><a id="Tc__DjWBe_7B0uXFiYdRXu6Kw_3_0"></a><a id="Tc_gyGrEHctBEKWDsTqc_go9g_3_2"></a><a id="Tc_JFJJCw92eEijJawsIHWpjA_3_5"></a><a id="Tc_3QdFSXvhXUKLA3b8V1aJgw_3_8"></a><a id="Tc_hVYfNLYvhUm17kh-frKXdQ_3_11"></a><a id="Tc_dxofGPjkxU-hoXIA_awZqg_4_0"></a><a id="Tc_rN2Unccx10qbYXyA6MplTA_5_0"></a><a id="Tc_r61Ns6F8bESE_tdUH4IAhg_5_2"></a><a id="Tc_sTpL8UAhk0CxLSsYmch8JA_5_5"></a><a id="Tc_nEU77GuvfUyDbOqH-moJEQ_5_8"></a><a id="Tc_6lcg5G-vDkWXSocFDtaPMQ_5_11"></a><ix:continuation id="Tb__0U_gpDk-kCCdOIs2NnBxg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company and its valuation specialist valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the over-the-counter exchange and adjusted for an illiquidity discount. The inputs used to calculate the illiquidity discount are based on observable and unobservable estimates and judgments and therefore is classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg" decimals="INF" format="ixt:numdotdecimal" name="xoma:NumberOfSharesRightAndOptionToSell" scale="0" id="Narr_BE2UCK4WpkGnKdBDnh4ZJA">5,000,000</ix:nonFraction> shares of Rezolute&#8217;s common stock back to Rezolute after December&#160;31, 2019 (Note&#160;4), the fair value of the equity securities was determined by dividing the total shares of Rezolute&#8217;s common stock held by the Company into <ix:nonFraction unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_1Myp4OOGqEKp2h3UVxadrQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:EquitySecuritiesNumberOfTranches" scale="0" id="Narr_Wqz5Y-sAME6m3n6zE8FxTQ">two</ix:nonFraction> tranches based on the estimated time to a potential liquidity event.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Group_6bDbIXWziE-m5RxTKdwmTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated fair value of the equity securities was calculated based on the following assumptions as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing common stock price on the Over-the-counter (OTC) exchange</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_9_30_2020_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_T9kkdRE5TU2GA0x-StB7yA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Tc_0XO3ukYHD0WRtSJidqik6g_3_3">0.43</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2019_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_QbXdq24V_UuHONHKjjaZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Tc_qqoaEWc220iX_1UxZH_Prg_3_6">0.12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 1:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_myPVpetgYkKI3zoBMnb_yQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="Tc_6KxVWGfS6kCBdBL0BCBL5g_6_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_0OemnNunTEaN1i6wIdopTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="Tc_BMTKv24W2ESwJIDLlz5rYw_6_6">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw" contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2SoVfK-psE-uIiixwmUMVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_8IJ2JhOUtECp37HidZQ0GQ">0.25</ix:nonFraction> year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-CVgtfFe3U6W6zb4Ddth-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_C4lBYWC0_kmUmSqW5bvQ2g">0.25</ix:nonFraction> year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 2:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_v4syz3rvHkSx0GCd0zfa9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Tc_YOyq2Xl9EU-AcYg1QGptyw_10_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_mI7JO_tljkCY56R1erZxTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="Tc_uAZNJoUw90O3pNuaqWLGqw_10_6">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw" contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qrgth34a6EattwAKv19FyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_B-cc9sjV3k2AYIiRE1ZpCA">1.25</ix:nonFraction> year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw" contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RyfA1p37m0mqf8zUp_nppA" decimals="1" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_AUcHeS3060mMsvnq6Mw3cg">1.5</ix:nonFraction> years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Bioasis Royalty Purchase Agreement represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income until settlement. As of September 30, 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="Narr_R4AZEdhEpEGxZIZMc6Uo8Q">no</ix:nonFraction> changes in the estimated fair value of the contingent consideration from its initial value of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="6" id="Narr_1Or-vK8pAk-kXLbZm6VxCA">0.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated fair value of the Company&#8217;s outstanding debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="Group_oDlb99GiY0yR03iQ16KnCA" continuedAt="Group_oDlb99GiY0yR03iQ16KnCA_2" escape="true">The carrying amount and the estimated fair value of the Company&#8217;s outstanding long-term debt at September 30, 2020 and December&#160;31, 2019, are as follows (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_oDlb99GiY0yR03iQ16KnCA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-qZT9POIkCNrG3Grph7dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_Zn2LP-dJd0-0TbaJozOGTA_3_3">16,220</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_fc2DGhmLsU-P9b9i3fCa3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_6IeORmpBxUyReQ1kW3QhSA_3_6">16,217</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_j3P1UZ7onkKj9MeRA1L4Pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_9M8kT46BAUG7zogpnOkIew_3_9">15,903</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_WZsCIx7v_0eJCosFrT_7PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_3tnQIXcfxE-vz-7wRI49PQ_3_12">15,713</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ROF4dELbnEKrkSBAq5Id-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_D568Fgr_u0CRPvg6BlYr_A_4_3">13,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BvERxoSpn02VGxEAbYiLDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_Z7zk9OjKH0KkNfjbn9dbsA_4_6">13,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_K5wO4sN8QkaBiKw6ZJuixQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_s3roxe4yPUqG5XitFy5c4A_4_9">16,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a30zLf3tz0OUKijReg49Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_sJIoNlXyMkSZEOjURnwfsw_4_12">16,048</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_IGuFXYX0RUWck1rS6sTCig_5_3">29,952</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_o9TKgo2PdkaRxCnPv5UwzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_ner7uawVnkO6xIEFSfPIKA_5_6">29,939</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-_VDIVr4EyNvxmIlDGnMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_zW28y0bK-Eezgwbisw2vpw_5_9">32,277</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qRuzS7PxN0mhOpigbZVLcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="3" id="Tc_lKTHW5BR0Eub8dxNVUHVmw_5_12">31,761</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk53482118"></a><a id="_069b87a5_6e6e_417a_a357_433384f1499c"></a><a id="Tc_I9-PWj8m1Ey8X78T5HdRuA_1_2"></a><a id="Tc_UcGhapGG30y4mNN0HHl0Iw_2_0"></a><a id="Tc_aIg_-Xdw4EeVnt8uU7lhgA_2_2"></a><a id="Tc_WHsX0wsb3UWS9Wld0xF1Cw_3_0"></a><a id="Tc_EdTT6bEg0E2eS8S0Pgc8Ag_3_2"></a><a id="Tc_uOCnIT5RnEOyW2NYWRcOjg_4_0"></a><a id="Tc_21-jTjLdNk6bClAXkzyvng_5_0"></a><a id="Tc_AAhR-YC5DEu9geqsMKCFLA_6_0"></a><a id="Tc_WkIzhxQcREeKF-fhVAb5Vw_7_0"></a><a id="Tc_MQ0tTbKnakiHw9ITfB3SWQ_7_3"></a><a id="Tc_0LgCz55rgUalggKNn2Pdaw_8_0"></a><a id="Tc_R4_hVzfFrU23bCZiPQmbJw_9_0"></a><a id="Tc_WxHIl2Qxzk-w55nkClt61g_10_0"></a><a id="Tc_XE_R0wxy3k-_vnc-nTcOPQ_10_2"></a><a id="_5df92fe9_6863_49cd_8738_20d83a95915a"></a><a id="Tc_ixFlElS_pESlg0Crc-e-zg_1_1"></a><a id="Tc_4DHK4a7t5kS2x2xm54T4xw_1_7"></a><a id="Tc_F1fmoGV8qE2zlQ7C6ln_nA_2_1"></a><a id="Tc_Z_JRxSr_cUGdwyrykZDjEA_2_4"></a><a id="Tc_MxWbMuwHrUmI3OhrazDi2w_2_7"></a><a id="Tc_AxMROKldWE2081bJrLsjPA_2_10"></a><a id="Tc_1NOW5BbNtk2c3vtfSEJrJQ_3_0"></a><a id="Tc_kxcskmZB60m6C4-6pNNFdg_4_0"></a><a id="Tc_ckpabXIJwEqEqJJEvMCkIA_4_1"></a><a id="Tc_uQyxOCUMfkudh7J-IQQsaA_4_4"></a><a id="Tc_9TxRB0vHY023Ef4dh2ZITw_4_7"></a><a id="Tc_iLGEb92x-ECWoI9K90zcLg_4_10"></a><a id="Tc_jZ18DlGy8EipaZO78Fa_3g_5_0"></a><a id="Tc_8H2cigOnV020TresiiksiQ_6_0"></a><a id="Tc_QG4GOWpHAEuRuuTmeh-6PQ_6_1"></a><a id="Tc_KmnVkVIgUkCXsKOh2qSSwA_6_4"></a><a id="Tc_gBAbYLC2NEOA3OdZCCy8hQ_6_7"></a><a id="Tc_M87AsLE97UmxkcYVYt1wiA_6_10"></a><a id="_750dccd0_a946_4ae5_8ba6_dd75831c90ff"></a><a id="Tc_duKYFuDAikmKRbFVZwCTCw_1_1"></a><a id="Tc_pMkE_hwPrkmR3Az8pKTgmA_2_1"></a><a id="Tc_YT_MScke4EO75KxsC--jYg_2_4"></a><a id="Tc_PElhZ_cSR0Gbora8RdvLDQ_3_0"></a><a id="Tc_tSvon-9_xkmumBCL86qf7A_4_0"></a><a id="Tc_0PBoXyS8jE-2HODhhNe2PQ_4_1"></a><a id="Tc_YAfEh6vHi0-ZUJKVIzjRlw_4_4"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:LeaseDisclosureTextBlock" id="Tb_i-0v0ZRrwUiJ4g8U77ccfw" continuedAt="Tb_i-0v0ZRrwUiJ4g8U77ccfw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"> 7. Lease Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company leases <ix:nonFraction unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_H1Cj_SIgjkCN0aYFMFbweg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesNumberOfLeasedFacilities" scale="0" id="Narr_OU9_TNPcMUWClfC3otJ64Q">one</ix:nonFraction> facility in Emeryville, California under an operating lease that expires in February&#160;2023. The Emeryville lease contains an option to early terminate the lease by notifying the landlord on or before February 1, 2020, which expired unexercised. The lease also contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company also previously leased <ix:nonFraction unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw" contextRef="Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesNumberOfLeasedFacilities" scale="0" id="Narr_xTMVYVgezk-AWRzpvnwu3A">two</ix:nonFraction> facilities in Berkeley, California under operating leases that had remaining lease terms until 2021 and 2023. On December 18, 2019, the Company entered into a Lease Termination Agreement (&#8220;the Lease Termination&#8221;) with each of the 7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street Properties II (&#8220;7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street LP&#8221;) and 7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street Property General Partnership (&#8220;7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street GP&#8221;) to early terminate the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw" contextRef="As_Of_12_18_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_mi0xAnsFn0qDd9-F2V5_PQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" scale="0" id="Narr_sat_l18ek0ubWgvy9wI-vA">two</ix:nonFraction> operating leases in Berkeley, California. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company agreed to pay an early termination fee of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:OperatingLeaseEarlyTerminationFee" scale="6" id="Narr_7o5k6u-p00iyxYez8AHiPw">1.6</ix:nonFraction> million in total and recognized a loss on lease termination of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" sign="-" scale="6" id="Narr_IYIaZi3hc0mdnIEjAUsY6Q">0.4</ix:nonFraction> million for the year ended December 31, 2019, which was included in other income (expense), net in the consolidated statements of operations and comprehensive loss.</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_AphBERHUkU6DnOUyFSq1Kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table summarizes maturity of the Company&#8217;s operating lease liabilities as of September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_aEQb2LbdWUOlF43ksjnvoQ_3_3">47</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_TdoFJHiDDU68jjzGVrCC_w_4_3">196</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_WBe0DgEQgkmBE_CP9p2Q-w_5_3">202</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_kgl_oMUwXUCFVsF8KuTRMA_6_3">35</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_rOvCZqqGE0CK0CoFzSmqUg_8_3">480</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_A8z_7FSMCEu7H45iF-2hqw_9_3">30</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_4cKWI1oFuEyCfWDDOq4dMA_10_3">450</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:LeaseCostTableTextBlock" id="Tb_QamgyfoH-kS-BWNAksuCRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the three and nine months ended September 30, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_hx2a6SyEwk-v27C4-3GjaA_4_2">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_exuRdGYirEKPg95aa5YXJA_4_5">595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_-HPsGuimB0yH8uy34wKUdw_4_8">133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_OzAxwcDyEESQLsLDC705HA_4_11">1,805</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_4r3v9Ww9akGoFx2nxB7mUA_5_2">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_WUGKymQWc0GM_yIcZFI6eg_5_5">375</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_OR4hlE5W20a6a8obo3ds2A_5_8">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_pfGEm6BvdEeZdosSx1OwDA_5_11">1,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_TFd8n6kZzUqBC6MIPgDF1g_6_2">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_no8pCXzR80a6M9esssixig_6_5">970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_tbdbk3BkUkCsxfkv3SBm-A_6_8">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_BevrCP0ZQkqMZPBT7GV06A_6_11">3,151</ix:nonFraction></p></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb__WXPmIonRE6IPU0b8iKtaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_qJAx2Pj7iUeUH7NnOEfr7g_4_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_gU-7GsrwWkShxxnvygB_cA_4_5">1,975</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_6R3SUKUP60C-TQsg_-CzEg_1_2"></a><a id="Tc_AjTf4IL3TEuBr-FAt6Sc1w_1_5"></a><a id="Tc_4BBigB69e0GqcjuHRok-fQ_2_2"></a><a id="Tc_w5KYm8bsLEuGfUQxX4vv-g_2_5"></a><a id="Tc_8IxZV8hD_0udSiFqcaVe9A_3_0"></a><a id="Tc_841DKWDXvUSInO6WKDiMxQ_4_0"></a><a id="Tc_FxUX7FQ_oEejpUz2IJ8xxg_4_2"></a><a id="Tc_X-x2zAbZSE6dZSt0WK-nqg_4_5"></a><a id="Tc_eU9uOlstTUao_vnO7_R5Hg_5_0"></a><a id="Tc_T4-D1SVc7EKGnlEIqgfj8A_6_0"></a><a id="Tc_uGhdGQZYmkWy1YPoZRlrHA_6_3"></a><a id="Tc_C6f1DXus6Uyi0RsQ1d3xYw_6_6"></a><ix:continuation id="Tb_i-0v0ZRrwUiJ4g8U77ccfw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The present value assumptions used in calculating the present value of the lease payments as of September 30, 2020 and December 31, 2019 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="Tb_gEkSe5--IkOfTIIGrjXseA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr__xPsCPGfl0yoNGwaZLNEcA">2.42</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_8WoJnWA4pEqaplU6J9Zq9A">3.17</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_-0K2aATdQES_frCsP6UxKg_6_2">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Ox5uK-NXrEqNwuzNaGmmnA_6_5">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sublease Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Company&#8217;s rights and obligations under its sublease arrangements transferred to 7th Street LP and 7th Street GP, and the Company was released from all financial obligations under its sublease agreements. Upon termination, the Company recognized a loss on lease termination of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainLossOnTerminationOfLease" sign="-" scale="6" id="Narr_2LwO7PhoPUGF73szT62DNg">0.4</ix:nonFraction> million in other income (expense).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_2CZITBcVHU-Wgwh02jgIcw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SubleaseIncome" scale="6" id="Narr_yDKNwGDQ80uxHaWqnNYQuQ"><ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_ym6GLGOCy0yMN7HEESO78g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SubleaseIncome" scale="6" id="Narr_KSlPkjeNpE2FeuT7zHAAbA">No</ix:nonFraction></ix:nonFraction> sublease income was recognized for the three and nine months ended September 30, 2020 due to the termination of the sublease agreements in 2019. For the three and nine months ended September 30, 2019, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_MLU4k6KwO0e9m_Pf_os80w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="Narr_UzPTwYIouUiqZmVjsPJD4w">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_HrZIHs7O0UmWnhE2ICmFRg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="6" id="Narr_OAEpYxTMBUG6YJGiUPXDcw">2.4</ix:nonFraction> million of sublease income under these sublease agreements in other income (expense). </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:LongTermDebtTextBlock" id="Tb_dQ7HISmhAESIQch4GZlAjQ" continuedAt="Tb_dQ7HISmhAESIQch4GZlAjQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Long-Term Debt and Other Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Silicon Valley Bank Loan Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;7, 2018 (the &#8220;Effective Date&#8221;), the Company executed a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with SVB. Under the Loan Agreement, upon the Company&#8217;s request, SVB may make advances (each, a &#8220;Term Loan Advance&#8221;) available to the Company up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_cr4vpSt4XkKcf4EHIC3d8Q">20.0</ix:nonFraction> million (the &#8220;Term Loan&#8221;). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March&#160;31, 2019 or an event of default (the &#8220;Draw Period&#8221;). In March 2019, the Draw Period was extended from March&#160;31, 2019 to March&#160;31, 2020. As of March 31, 2020, the Loan Agreement has not been amended to extend the Draw Period further. In the event of a default related to the Note&#160;Agreement with Novartis, SVB&#8217;s obligation to make any credit extensions to the Company under the Loan Agreement will immediately terminate. The interest rate will be calculated at a rate equal to the greater of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_5_7_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Jd47lV9m20mVoxI2mVnXeA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_pQKCnjwXo0mPu2KgoZTz5g">4.75</ix:nonFraction>%, or (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_AdKOII3dC0-c3gz97adv_A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_ChctoHKZWEakMNQT0gcvJw">0.25</ix:nonFraction>% plus the prime rate as reported from time to time in The Wall Street Journal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal&#160;monthly payments of principal and interest over <ix:nonNumeric contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA" format="ixt-sec:durwordsen" name="xoma:PeriodOfMonthlyPaymentsOfPrincipalAndInterest" id="Narr_zyyPv8_esEe1y0imXnoIxA">24 months</ix:nonNumeric>. Each Term Loan Advance will mature at the earlier of (i)&#160;the <ix:nonNumeric contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA" format="ixt-sec:durwordsen" name="xoma:DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" id="Narr_tRZtxA9IXECXImlv_4LU4Q">23 months</ix:nonNumeric> following the applicable term loan amortization date for each such Term Loan Advance (ii)&#160;March&#160;1, 2023, or (iii)&#160;<ix:nonNumeric contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA" format="ixt-sec:durwordsen" name="xoma:DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" id="Narr_jM7BfB5uQUmAXpSoa5vx1Q">30 days</ix:nonNumeric> prior to the earliest maturity of any portion of the Company&#8217;s loan with Novartis (the &#8220;Loan Maturity Date&#8221;). After repayment, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:DebtInstrumentAmountToBeReborrowed" scale="6" id="Narr_IGwGUSTMd0uC6AYCIoa5WQ">no</ix:nonFraction> Term Loan Advance (or any portion thereof) may be reborrowed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The entire principal balance, including a final payment fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ" decimals="3" format="ixt:numdotdecimal" name="xoma:DebtInstrumentFinalPaymentFeePercentage" scale="-2" id="Narr_eIEP9Fed3k2KAzZlMjRN1Q">8.5</ix:nonFraction>% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_m--qxWG3306IlcAtWJRFYw" decimals="4" format="ixt:numdotdecimal" name="xoma:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_Gr9ahyEiAEiqE0NAAjAWnQ">3.00</ix:nonFraction>% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_j9t6d3XVyEWVqb-VBqtwnA" decimals="4" format="ixt:numdotdecimal" name="xoma:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_AfRnJ8cn6ECDuq2LRbRFwA">2.00</ix:nonFraction>% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_hAurvrTCL0uLGiyoscfcDg" decimals="4" format="ixt:numdotdecimal" name="xoma:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="Narr_cMmBNOWmqkC97it3M7jBbg">1.00</ix:nonFraction>% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. In the event of a default, a default interest rate of an additional <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA" decimals="4" format="ixt:numdotdecimal" name="xoma:PercentageOfAdditionalInterestRateOfOutstandingLoan" scale="-2" id="Narr_Eob8GY5Ab0WFsx29vlk_Fw">4</ix:nonFraction>% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dQ7HISmhAESIQch4GZlAjQ_cont1" continuedAt="Tb_dQ7HISmhAESIQch4GZlAjQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_nIZ1HP6LzUilxk_SPHUPzA">6,332</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_CD13h9Kim0mvqN2DNjcz3A">23.69</ix:nonFraction> per share (the &#8220;Warrant&#8221;). The Warrant may be exercised on a cashless basis and is exercisable within <ix:nonNumeric contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_7DchDq9txkuakRpZQxN2Hg" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_eg1Kt-AFEEixaxaX8K7Blg">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_c3doTGjBBEa46QQnn-tYMw">0.1</ix:nonFraction> million. In addition, the Company incurred debt issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="Narr_rxRiIu4bGEeQ6aTT1Q0FpA">0.2</ix:nonFraction> million in connection with the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2019, the Loan Agreement was amended to extend the Draw Period from March&#160;31, 2019 to March&#160;31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Ohtb001sm0yrKosRKth-bg">4,845</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_TNgeIsQaT0K-VFF9INPRfA">14.71</ix:nonFraction> per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_bWwIAdcn5kKsPEkIcoJgmg">0.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, both warrants are outstanding. In addition, both warrants may be exercised on a cashless basis and are exercisable within <ix:nonNumeric contextRef="Duration_3_4_2019_To_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_5-XsEkqIb0O1_ILDeS9Gbw" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_a4DQUWHFk0q0YeURVVxpHw">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2018, the Company borrowed advances of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_9_1_2018_To_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_1sIgH-TDmESIxi03ZCZdFA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_-ENVLFGXr02zsvN8zjIJRg">7.5</ix:nonFraction> million under the Loan Agreement in connection with the Agenus Royalty Purchase Agreement (Note&#160;5). The Company recorded a discount of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_QpM51obSbEy_0dOTKgw2QA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="Narr_6E3kl2AcJkC1rf_TbeTntQ">0.3</ix:nonFraction> million against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company borrowed advances totaling $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_xb_L_CetzU-uTJy5lWyAAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_xaKeQZwVZ063dK1dQIS9mg">9.5</ix:nonFraction> million under the Loan Agreement in connection with the Aronora Royalty Purchase Agreement, Palo Royalty Purchase Agreement and payment of the Aronora Contingent Consideration (Note&#160;5). The Company recorded a discount of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_U_gsaxcdB0WA9FXj8HId5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" id="Narr_KIDGoYvIXEGLM0EeD876dw">45,000</ix:nonFraction> against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_qYEUuDrUSEe1znuorrq_sw">0.2</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_CiwH3PD_BkChjiWzLIxKbA">0.5</ix:nonFraction> million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three&#160;and nine months ended September 30, 2020, respectively. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_uwK22XvCxEeGdDNSoOUqww">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="Narr_xO2w3U6NYEif0LcfpSbCWA">0.4</ix:nonFraction> million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three and nine months ended&#160;September 30,&#160;2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the carrying value of the debt under the Loan Agreement was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_2QzPjjR6Q0O22wReH9Lqew">13.8</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="Narr_7g-oMTkrVE2QK1XWNaNtew">9.0</ix:nonFraction> million is classified as current portion of long-term debt and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="Narr_Jf3mswKE-0ynDTnT0-p1bA">4.8</ix:nonFraction> million is classified as long-term debt on the condensed consolidated balance sheet. As of December&#160;31, 2019, the carrying value of the debt under the Loan Agreement was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_atMtRudGrECMQ16jkGMylQ">16.4</ix:nonFraction> million. Of this amount, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="Narr_skDxibkbpUmvPExuydp-jw">5.2</ix:nonFraction> million was classified as current portion of long-term debt and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="Narr_irgcrPO5qUOJDWZOPgQMeA">11.2</ix:nonFraction> million was classified as long-term debt on the condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2005, the Company executed a secured note agreement (the &#8220;Note&#160;Agreement&#8221;) with Novartis, which was due and payable in full in June&#160;2015. Under the Note&#160;Agreement, the Company borrowed semi-annually to fund up to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_Aq-O5Rvu_EG2xp_gxz4Gog" decimals="2" format="ixt:numdotdecimal" name="xoma:CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" scale="-2" id="Narr_bphwUr1njEGhaa3f-gufKg">75</ix:nonFraction>% of the Company&#8217;s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_astWOgd6Lk2y1kqmJE5bcQ">50.0</ix:nonFraction> million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Laye7qFdbkaWNAv5Y8KxEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_LnaB-LgD3E6hCe8XNYoFkw">2</ix:nonFraction>%, which was equal to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="Narr_lwDNkubjMkOn4mQZt2eE_A">2.41</ix:nonFraction>% at September 30, 2020, and the interest rate resets in June and December annually. Accrued interest is payable semi-annually in June&#160;and December&#160;of each&#160;year or, at the Company&#8217;s election, the semi-annual interest payments may be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_kEZN8m5Lw0er3JciQxpbxw">50.0</ix:nonFraction> million. The Company has made this election for all interest payments. Loans under the Note&#160;Agreement are secured by the Company&#8217;s interest in its collaboration with Novartis, including any payments owed to it thereunder.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bffac380_6be7_40f4_83fe_abc96d70d795"></a><a id="Tc_ueW4pr1c2k6yjFOxzgmb5Q_1_3"></a><a id="Tc_Kb8pqu7GJUSQVOMfSCChRA_2_3"></a><a id="Tc_1tPVQVw08Ee1qzHDpkup3g_3_0"></a><a id="Tc_NepWa7p-WkCO_BqfKi-qkA_3_2"></a><a id="Tc_1wCtGn_NJkmsbEXz5dwAuw_4_0"></a><a id="Tc_Gs_hHaXObESCIqw_WrYwTQ_5_0"></a><a id="Tc_1IOL6jrzN0K5GjdTlcxucA_6_0"></a><a id="Tc_3ShgR6Cbvk2p69k2Mr0Zkg_6_3"></a><a id="Tc_eE7LJ7x8vEKBNYDgxlqP6g_7_0"></a><a id="Tc_Ou7SI0bKzEGC7yCu29QeFA_8_0"></a><a id="Tc_0AjzzsscW06tICl2-TfKUA_9_0"></a><a id="Tc_Y3-OJmel-EeRZWtdyAhZGA_10_0"></a><a id="Tc_uPE7k0C640-CTueDaY0qRg_11_0"></a><a id="Tc_GqI1y0STMEG5YfxjB0tKIA_11_2"></a><a id="_e7a7c237_9ac7_4910_8410_c581334ac4a7"></a><a id="Tc_WmWyF19n-kqNJQr9jWrzkQ_1_2"></a><a id="Tc__yvTynddBE6dlrhMZUPN0w_1_8"></a><a id="Tc_G3RSOJuG-0-2BwPfthaZCA_2_2"></a><a id="Tc_zsnImAhBfEm1zQ4vravFJQ_2_5"></a><a id="Tc_kK977AXWl0-B0rMYHDva2Q_2_8"></a><a id="Tc_W5hvMh8BL0edrGlLVWoITA_2_11"></a><a id="Tc_VHaUoBWtZ0Sxr7RQYbK0Nw_3_0"></a><a id="Tc_uJBqFcSyzkSbIkkKwtechQ_3_2"></a><a id="Tc_IWbUYwfzTUGKNPGk7BKGOQ_3_5"></a><a id="Tc_K2QkOMXbGkKzOcIyHkrRJQ_3_8"></a><a id="Tc_QWpwCoYhZUCVYSHs2hCYSQ_3_11"></a><a id="Tc_PoF_MeVEOEKJp2jJQWlMgw_4_0"></a><a id="Tc_PE2hpbe4K0y8LdBeUwne9A_5_0"></a><a id="Tc_yK7ih9dfdEyVOJgS35r9Qg_5_3"></a><a id="Tc_GVfHBDrxbEWsskkraKFcyQ_6_0"></a><a id="Tc_wAEGfF1IOUm7H9zsgZGqPg_6_2"></a><a id="Tc_NEoVDWczJk-T-1kaaoQ90g_6_5"></a><a id="Tc_ugz4Tf4vakW6ZX2Q8kDGuA_6_8"></a><a id="Tc_67-U-Zv6u0SB7mmfX27YOw_6_11"></a><ix:continuation id="Tb_dQ7HISmhAESIQch4GZlAjQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2015, concurrent with the execution of a license agreement with Novartis International as discussed in Note 4, XOMA and NIBR, who assumed the rights to the note from Novartis Vaccines Diagnostics,&#160;Inc. executed an amendment to the Note&#160;Agreement (the &#8220;Secured Note&#160;Amendment&#8221;) under which the parties extended the maturity date of the note from September&#160;30, 2015 to September&#160;30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note will be reduced by $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_EG_Q04r1k0GkBf-7UuDNjg" decimals="-5" format="ixt:numdotdecimal" name="xoma:DebtInstrumentDecreaseUponAchievementOfMilestones" scale="6" id="Narr_wY-uTCigCU-X6XrW0GMC_Q">7.3</ix:nonFraction> million rather than the Company receiving such amount as a cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;22, 2017, in connection with the XOMA-052 License Agreement with Novartis, the Company and NIBR executed an amendment to the Secured Note&#160;Amendment under which the parties further extended the maturity date of the Secured Note&#160;Amendment from September&#160;30, 2020 to September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December 31, 2019, the outstanding principal balance under the Secured Note Amendment was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_xzRcVK7tMki7Rg6me1lmqQ">16.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_NHx7oG_kKE65ICx_DXfo0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_pT_IGDGdpEWWua-EfO7z3A">15.9</ix:nonFraction> million, respectively, and was included in long-term debt in the accompanying condensed consolidated balance sheets. On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_xKKDc2PicUatz6ssVpqH_Q">25.0</ix:nonFraction> million milestone payment as a result, of which $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" sign="-" scale="6" id="Narr_vh4fca-1PEKjI3DujsVSSQ">7.3</ix:nonFraction> million will be recognized as a reduction to the debt obligation to Novartis, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Payments of Long-Term Debt</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_2Upxespyw0Wvelq-FNt7DQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aggregate future principal, final payment fees and discounts of the Company&#8217;s long-term debt as of September 30, 2020, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="Tc_b8FAZaXWm0OFgo5arPx9EQ_3_3">2,270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="Tc_cm5_STKMYUCx6LdDQsIh3w_4_3">8,534</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="Tc_pZWV1YdQwkK5dSe_6uL2pA_5_3">21,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermDebtFuturePrincipalInterestAndFinalFeePayments" scale="3" id="Tc_-51AC2MJSEuVF_CXIAAUyQ_7_3">32,004</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: interest, final payment fees, discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="Tc_0N8OpjlEtUm8LkOqx0L69w_8_3">2,052</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments, net of interest, final payment fees, discount and issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="Tc_J-Fx_ZvQHEugvXjyorVqFg_9_3">29,952</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="Tc_8wayyoaBWkeo6rFIF0gdpA_10_3">8,962</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="Tc_aZjQKjzoJUGx4RgS9gRjEg_11_3">20,990</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" id="Tb_iBFGzwfLA0mlRsssXHxzTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB loans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_rlYOP8oEKkW7r8CqrYeKPw_3_3">334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_n7VGeLJ_ok6KvEsfC8H-NQ_3_6">314</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_R9WL-SOVQkqWnI0H_NYE6g_3_9">1,073</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_f0-9Ale2qEK9qOBNgpKofQ_3_12">791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_uWG4bPOtsk2Nwyko1KBEuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_byTc-z9MmkmPL9yn13trjg_4_3">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_9TjQxVDWVkKyIj9TiaRkjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_48lvNXgGTU6AFudb_eEcyA_4_6">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_MNkxvd6px0Shg6qQPgSkhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_beFBnIarrk6D3GpRIHGt9A_4_9">409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_o7vjlCxW1UuogpVKDCyxSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_gj9dchXFZ0uYCCJxCrOmjQ_4_12">540</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_78opXNQ0QUCrlHhRR1n9Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_W3An4JUwQkiUOBJ8ySfhYg_5_6">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_hzEj56jCBEaI-AttEMG2SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_lPSKNqPQzk6f1hmtFMC3TA_5_9">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_pEtQLs5d2E-SAflZCpXZxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_LFbcZayab0eA5NW7vB_GNg_5_12">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_5rU0zgqtkU2I079OarzFfA_6_3">434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_mFQbjMzf3EiKBRA8QhSkbQ_6_6">484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_512QZrQMj06wEAyn4qrmUQ_6_9">1,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_ksasKlccm0e78TNfARDDNg_6_12">1,336</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_qdGUCj2etkOa66n6kNyjCQ_1_6"></a><a id="Tc_WE8iz2iZAEGTqQn7oI6eqw_1_9"></a><a id="Tc_C-XS9r_i8k6LHDHAtBsaYA_1_11"></a><a id="Tc_jroTsuAWx0yOPyp3SC1rTg_2_0"></a><a id="Tc_nMRF716sc02cfIGubgQekw_2_2"></a><a id="Tc_DFYcMzmqcEaMTyMHcHO4BQ_2_4"></a><a id="Tc_nssWW9BqKE2T8NmP729svw_2_6"></a><a id="Tc_mcyDcIEWm0GEv10jaSzEMw_2_9"></a><a id="Tc_wNBKrTPv9EigLPF7kQDVdQ_2_11"></a><a id="Tc_QYdVeTax0keVt5KfnXNdqA_3_0"></a><a id="Tc_9yPS_Lb6BESP6UrObr2zQw_3_2"></a><a id="Tc_IiNgoRbA50eOjxVVempJbQ_3_4"></a><a id="Tc_pm6Cx9vHOEeNL22XUuBZOA_3_6"></a><a id="Tc_uZ2EjDw_wUmbJTiOPfiqaw_3_9"></a><a id="Tc_56HCvnu9dE6fIq9_fHRo2Q_4_0"></a><a id="Tc_1oa5DEwfMUmEJwi_dPS41w_4_2"></a><a id="Tc_U5h9QC1tlEeLp2-iigscDg_4_4"></a><a id="Tc_uHgxWa_PfEil2kr8nKd8wg_4_6"></a><a id="Tc_2Efy0W4Ps06TRgcgHIGasg_5_0"></a><a id="Tc_FySvL0qThUOLKfjvSWyznw_5_2"></a><a id="Tc_SzgXNl-76UWvg2UoY6LQvw_5_4"></a><a id="Tc_EVUOFD2-zUunL-U59_JeTQ_5_6"></a><a id="Tc_636eXiu730i3DL4xnqM6bg_6_0"></a><a id="Tc_tieBvQ1cr0qH8DouE6fCBA_6_2"></a><a id="Tc_WZjgPJvrY0OweoP3-bUpqA_6_4"></a><a id="Tc__QM5fLZGDUeCqAt02xOFBw_6_6"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="xoma:CommonStockWarrantDisclosureTextBlock" id="Tb_TaDOuYFRzUWyelRWLezxLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of September 30, 2020 and December&#160;31, 2019, the following common stock warrants were outstanding:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_YM_RSXtfUU-v0Vjgjg8GHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_HmP8LjFabkGA9yqC580zKg_3_7">66.20</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc__AjQVVwKI0qVPeOZtiQAew_3_11">9,063</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_7E5MF0uFRESn_-Sd-JA-yg_4_7">15.40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_fj6WqWOwPEywU7lSKFu88w_4_9">8,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_Q6mklGoZ5UG2IWUzUTvntA_4_11">8,249</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_pHMUrN3-KEuGrOaUq9_e2w_5_7">23.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_nTmjwvTRr0CF02DT5LF4og_5_9">6,332</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_AUiV2GiTdky7d9VUPGKxMw_5_11">6,332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_Jbh6VHm-UU2nn8FGKrFmoQ_6_7">14.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_RKxFTPvUkk2zuulcjHxOpQ_6_9">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_Fvb9HkkQ-Ea4g-bDRsDYlA_6_11">4,845</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_mfgZSeKa0UWooGC1nEYnpA_7_9">19,426</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Tc_B9haxyOQok-r36kofi09Jw_7_11">28,489</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Narr_jAhXuuYgVEGbnm3HI5RB6Q"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_v1pkMkEpFUW2M_6v3GWKKQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContractualObligationEstimatedMilestonePayments" scale="6" id="Narr_HQUl4914MEOAwqIWezizwg">7.6</ix:nonFraction> million (assuming <ix:nonFraction unitRef="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" scale="0" id="Narr_KpcTMvlPTEO06Rx39QZI_A">one</ix:nonFraction> product per contract meets all milestones events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Company&#8217;s royalty purchase agreement with Bioasis the Company has committed to pay the Bioasis Contingent Consideration. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements" scale="6" id="Narr_2KMFmAUEWkKYTyDl_sTEkQ">0.1</ix:nonFraction> million for the Bioasis Contingent Consideration which represents the estimated fair value of these potential future payments at the inception of the agreements. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of September 30, 2020, there were <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="Narr_BK4peYJPx0SBLl8fLVtz0A">no</ix:nonFraction> changes in the estimated fair value of the contingent consideration from its initial value. The liability for future Aronora Royalty Milestones will be recorded when the amounts by product are estimable and probable. As of September 30, 2020, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_U6qdZrT-gUyphLqQMtHQng" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" scale="6" id="Narr_Y_t0axZOvUOV-pTan4JP_Q">none</ix:nonFraction> of these Aronora Royalty Milestones were assessed to be probable and as such, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_rxCwxf0QfUC9qk9Y_rh-eg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContractualObligationMilestonePayments" scale="6" id="Narr_wppxbqOD60qeCsSthWZ2Ww">no</ix:nonFraction> liability was recorded on the condensed consolidated balance sheet.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_rxFW4bzBa0OhmjsKZzomDQ" continuedAt="Tb_rxFW4bzBa0OhmjsKZzomDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, RSUs, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that allows employees to purchase Company shares at a purchase price equal to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_VwDWmwiaLEyWLERyG1-_UQ">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options generally vest&#160;monthly over <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QywYLWDewkuT4ebzmi68Mg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_JYz0Mr77TUqbirYt8nXLbg">three years</ix:nonNumeric> for employees and <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZtQmYwfNU6UL1F3kzpYtQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uWppOs8wM0KWXGDIM-iqBQ">one year</ix:nonNumeric> for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="Narr_c76HzEGOtUGLtFUpZhihqg">55 years</ix:nonNumeric> of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="Narr_bTxoE-vf50i1Zt9v0OxHUA">70 years</ix:nonNumeric>) vest on the earlier of scheduled vest date or the date of retirement.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_H4fyqvp7-EqsDzhpHbw4Qw_1_2"></a><a id="Tc_rWZtDF9PgU-nhvum10vfVg_1_7"></a><a id="Tc_aTP36Z8VikicUtL505nADg_2_2"></a><a id="Tc_t6EHN6T7PkKiG_3HWYv5mQ_2_4"></a><a id="Tc_7H6akETAC0-8bV0F9Mmgvw_2_7"></a><a id="Tc_s2y8rnwg40CfJi-Xi5JswA_2_9"></a><a id="Tc_YTWT_TGgMEOBpfelAB_gNw_3_0"></a><a id="Tc_xMPVpcQ_bESkIEgNRv2XYA_3_2"></a><a id="Tc_mmWYlBJz30q7u-P3fSUQ4g_3_5"></a><a id="Tc_qdwKa6DF-k2uzCdPqUCGdw_3_8"></a><a id="Tc_Mq3No9p7qE6H16kmI0-QpQ_3_10"></a><a id="Tc_7ABXc8hIX0CqBlfBPA3d2g_4_0"></a><a id="Tc_Ta88_3Am00eFsxz_IHhz0w_4_2"></a><a id="Tc_F9gpzd3Yn0OvE--eKBdk4g_4_5"></a><a id="Tc_YqGun0kolkeDta4Pn-XiPg_4_8"></a><a id="Tc_HrR4mTL_zkCENWL7v1U6GQ_4_10"></a><a id="Tc_3pEcgfyFgke1fqKX0K3ZnA_5_0"></a><a id="Tc_OPx7GCtm3EWNKjlhzY_BYQ_5_2"></a><a id="Tc_Ima41z1ZCUahP9Hvr3UA4g_5_5"></a><a id="Tc_Nyw1OctiCECMGLsq-UhGBA_5_8"></a><a id="Tc_fPjJVgsy-ECaF-kZIj9gTg_5_10"></a><a id="Tc_vwqnUFxxJE-T6DQBTbiMFw_6_0"></a><a id="Tc_pnsq1XYhgUm-Anq4uvPZLQ_6_2"></a><a id="Tc_Y65ss9gIGUCFXBLsbNUdlA_6_4"></a><a id="Tc_EVsmTd6xGEO2a8Wg15Tx2Q_6_7"></a><a id="Tc_NzyTrcg-kU60CS3oEQKqSQ_6_9"></a><a id="_c6f313fc_138f_434b_8cd1_37c30dac0d9a"></a><a id="Tc_xhecdJ6nwEKueQTvzwl6LA_1_4"></a><a id="Tc_jNo1L-sFsUeOotQatOF5sg_1_7"></a><a id="Tc_iUbjaPNvTE2tdER3P56Ukg_1_9"></a><a id="Tc_fXUau6ypTUSVEniCGfv50w_2_4"></a><a id="Tc_uEcEq_NFrkWpHxLIAWG-EQ_2_7"></a><a id="Tc_74ZNlbXwiEiY7pfvJbINiA_2_9"></a><a id="Tc_SNUKPBw-cEO-XUVwHLJkpw_3_4"></a><a id="Tc_bxxPgm4UWUqtET4eXiqpzA_3_7"></a><a id="Tc_ol4n8AdPoEO4iEmgPKDw6A_3_9"></a><a id="Tc_rOzaJ5WRh0OPEdJIhnhIvg_4_2"></a><a id="Tc_PrasRhCSqES_QKM3zPZ9pQ_4_4"></a><a id="Tc_970jamKbQkGbG4sExF66IA_4_7"></a><a id="Tc__obbWJp9Yk6XjSeNrlkS1g_4_9"></a><a id="Tc_A0hCS-fElUe9Lp99fqUQ_w_5_2"></a><a id="Tc_lwhtl7ne9ka6FmCr1lBqPA_5_4"></a><a id="Tc_42N-zrcYX02uq5U00O30Rw_5_7"></a><a id="Tc_MdA3XlFNZ0ed40v4-YR22w_5_9"></a><a id="Tc_8O1K9qbSJ0mARVIKL6CpoQ_6_0"></a><a id="Tc_f8lPjY-380W-Zn1hcgMeSw_6_4"></a><a id="Tc_lBoQyPBfLUi0FUxdZeVUew_6_9"></a><a id="Tc_hhWpaMH1EUyk_tKpV4uRBw_7_0"></a><a id="Tc_7xJPI29UOEamLflIyG4giw_8_0"></a><a id="Tc_wNgqU1HCN0O0KVYkfv9Y0w_9_0"></a><a id="Tc_iKycXdLYM02r7wYgzt3SXg_10_0"></a><a id="Tc_MAALFCNWJ0azhuwxd_dlfw_10_4"></a><a id="Tc_8pESgFSaQE63IlvmPCXxhg_10_9"></a><a id="Tc_prEdyP2DhU-Dj-SSBjPXRw_11_0"></a><a id="Tc_Ouy6JnlP0E2bt21z34dDZg_11_4"></a><a id="Tc_x19YRKcJNUa1yH7QBdBP4g_11_9"></a><ix:continuation id="Tb_rxFW4bzBa0OhmjsKZzomDQ_cont1" continuedAt="Tb_rxFW4bzBa0OhmjsKZzomDQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_EnsqSGPdvkeL_xzHhGrPPQ">no</ix:nonFraction> stock options granted during the three months ended September 30, 2020. The fair value of the stock options granted during the three months ended September 30, 2019 and nine months ended September 30, 2020 and 2019, was estimated based on the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_ZCrhZLou0kuzbEj0ySxGLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_DA-an6oIpkG72VDS2hV03g_3_4">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc__y7sWf-ZyUyIZnOkjq5cnQ_3_7">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_KaXxogng5EugeFQ7wPbong_3_9">0</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_SwLkolK60Euz43eFmxHKbA_4_4">101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ASaOVbuBIEejzBPM2y3_ZQ_4_7">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_frHYkrYa3kauyIO0M-ogew_4_9">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_4dUMFBeOJUGRcpG3BZZqkw_5_4">1.71</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_9Q3mDQl-YkOi7hjWQzjwsQ_5_7">0.77</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_-ynV4XOWjEGxRxr0a61L9g_5_9">2.49</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_zcmQ1ErEsUueIP8Xoybw4A">5.47</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_jIX8iFS0FUOqd6HmNPkMyQ">5.66</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_kPpHqVQXJEqrNxkrdkkM8w">5.60</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ewrpz9OZI0u25ggAFMx3mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock option activity for the nine&#160;months ended September 30, 2020, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_85bWwanQDEK4QKDx6QA_JQ_6_2">1,839,623</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_927HTHd4iUqk0i2Ra0Zndw_6_5">20.42</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RUC_5NPG6ka8TvuxEM93Jg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc__jyomjIiEkyx2ZjBSeBSYA_6_7"> 6.88</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_2-iGf5O02kiWA5JFCBUDNA_6_10">26,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_sTVjqn24DEuJIoNmQFK2eA_7_2">187,811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_qk_3lbrVW0i6xLZWMqsOVg_7_5">21.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_M5GPRXIPRkeSiEmZ4gQE7Q_8_2">6,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_O3uecqmUb0GUDIM2t9DcrA_8_5">4.28</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_B_6F9WJpX0WLPdTxuqeyKw_9_2">18,655</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_lNNn9gsqhESJypUeFIk7lw_9_5">141.47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_rEKYMG3AyEKg0BNtip0oCg_10_2">2,002,779</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_JwX-1FxBjkWl8Y_3w0LsYQ_10_5">19.41</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_xE9SjCYWhUyWHwyC0yOExA_10_7"> 6.50</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_iRmSCAYJ3EGbE-VAb862Xw_10_10">14,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_XhD-3o9EpUiEhXyQOOsd8w_11_2">1,659,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_jmmOJ37ewkKnn2SbQtSZ_A_11_5">19.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_q0JF2Ous5Ei1hKu_TcDb9Q_11_7"> 6.02</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_1lLz3d0qcUix2nMMpPOGsg_11_10">14,167</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the nine&#160;months ended September 30, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_PJXY6tOsYku48L9ffeWQyg">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_eDYYTI_O-0KTNghC-fVZEg">0.6</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted during the nine&#160;months ended September 30, 2020 and 2019 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_v8_CYsf750uL0fI7mOB5mQ">16.22</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Cz4EuoxyCUmpyrZnVplEnA">11.45</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_D-X7NhKJa0eSVMRi0bEdqg">3.3</ix:nonFraction> million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_BDJwniVXaUCMNzEixtpPuA">1.59</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Performance-Based Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense associated with the corporate performance-based stock options is recognized if the performance condition is considered probable of achievement using management&#8217;s best estimates. In 2017, the Company granted performance-based stock options with vesting criteria related to performance in 2017, 2018, and 2019. In 2019, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_Eae-KfdUT0qVbtF0Uws_Ag">41,250</ix:nonFraction> shares remaining related to outstanding performance-based stock options with a grant date fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w" decimals="-5" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" scale="6" id="Narr_su6BC-xso0qDQy2uO_P-Hw">0.2</ix:nonFraction> million that had vesting criteria based solely on the achievement of fiscal year 2019 corporate goals as set by the Compensation Committee of the Company&#8217;s Board of Directors. For the year ended December 31, 2019, the Company determined that all remaining performance criteria were achieved and therefore the related expense of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_ql4aVy4WmEur4m9MMRr5Dw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_hGsA7wrlo0-h7xpvurzjKQ">0.2</ix:nonFraction> million was recognized for the year ended December 31, 2019. After December 31, 2019, <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_a0mdTKTnhUax0jEq-iRUcw">no</ix:nonFraction> performance-based stock options were outstanding and there was <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_MBD6OuLEE0Gv5kACCmvulg">no</ix:nonFraction> unrecognized compensation cost related to performance-based stock options. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_233dbe07_3134_4da9_9d4e_027f718ec0b2"></a><a id="Tc_IOkas8MstkCV1DSxnR0suA_1_2"></a><a id="Tc_C7gLDGXDXUu0LYdt0-N45A_1_8"></a><a id="Tc_VZWkwT8Y2k2saId9d4cE6w_2_2"></a><a id="Tc_bU7VDXoOG0OZkvHhBn657A_2_5"></a><a id="Tc__BoESE8vL0KK7ClLeAlPtg_2_8"></a><a id="Tc_ApfJX2o0VUGI79SbALkh-g_2_11"></a><a id="Tc_ofykGoPZs0SjEt-mOrHaJw_3_0"></a><a id="Tc_Nc6p1VAYzE6s5n2U3u6d2Q_3_2"></a><a id="Tc_DWfYiY2mkESlCtNszab_sw_3_3"></a><a id="Tc_9UH2RzAcR0q4U3vq7pikQA_3_5"></a><a id="Tc_xLdGAwthcUG7BUgAJ_gLKA_3_8"></a><a id="Tc_HXPLY-M3ukKAcFqFq-Q8vw_3_9"></a><a id="Tc_thmLbCTD7kyhXwm97r_LkQ_3_11"></a><a id="Tc_cTrHV3r540SkyORw9DS5nw_4_0"></a><a id="Tc_IbAnRjdav02Tct8Nz-iFBQ_5_0"></a><a id="Tc_KpBuSizVb0qmZ1i8enIFqQ_5_2"></a><a id="Tc_j27hL5uCH0ePOYQA8q4Yzg_5_5"></a><a id="Tc_8LIvvLbO4ES4rq6HOUxGEA_5_8"></a><a id="Tc_JaRnI2AxXUK6vqHYQjfBeQ_5_11"></a><ix:continuation id="Tb_rxFW4bzBa0OhmjsKZzomDQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-based Compensation Expense</i></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_fOFw8xlXB0yMobr0ltMt_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0x8EMKzDr0a9bWPJF31vLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_a2eNy7Lho0m_O7wocjDg5g_3_6">66</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_p7ZWEJ2xMU2VC0KWzZIypg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_IqE4tF-ZsEaqkW0WmJincA_3_12">174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NZcEoPXaI0iAyxKBC5cgCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_9clkeYqF70OxkUibXAxpLw_4_3">708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_HsRG2H4itkerF2L9Qw8I9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_j1OR7cs_rEyydbj3dQyQrg_4_6">1,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_m0TV8U2aI0CDgV82mWs52g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bo4ubl5d_0qCF1Y_4EnhRQ_4_9">3,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1VjeaxaG8UOf7PR7WpN3Ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_AzWvxAOxO0KBAVPZ4G_xWQ_4_12">4,059</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vog4xD6sZ0WW5EMuf2YIOA_5_3">708</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__lzByOWjt0uDrCW-YElooA_5_6">1,494</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_T5jlNW0xEkmdJu8i53fBiQ_5_9">3,269</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_OcwOfOcK0Ey_VB8E7jEPVw_5_12">4,233</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_qQjoVPnmhkS4mKVtcSsErg" continuedAt="Tb_qQjoVPnmhkS4mKVtcSsErg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 12.25pt;"><span style="font-style:italic;font-weight:bold;">Rights Offering 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">On December 2, 2019, the Company commenced a rights offering to raise up to $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_2_2019_To_12_2_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_IZ5MZsXg_0uvXBtAPFu7OQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" scale="6" id="Narr_y9HXFb3UoEutv178v_MPuQ">22.0</ix:nonFraction> million through the distribution of subscription rights to holders of its common stock, Series X preferred stock and Series Y preferred stock (the &#8220;2019 Rights Offering&#8221;).<i style="font-style:italic;"> </i>In December 2019, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_aD3k4_xk0EmzKHYfKIHIkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_expAe34IQUO69vfvdDsQ-Q">1,000,000</ix:nonFraction> shares of common stock under the 2019 Rights Offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g" decimals="-5" format="ixt:numdotdecimal" name="xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" scale="6" id="Narr_mPeSTRH7K0WRyopA3bYTKg">22.0</ix:nonFraction> million. Total offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_q260gs1VWEe7pj3eH09uzw">0.2</ix:nonFraction> million were offset against the proceeds from the sale of common stock, for total net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_jkrDcysOMk617IPr0WyPHQ">21.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The 2019 Rights Offering was fully backstopped by Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;) </span><span style="font-style:normal;font-weight:normal;">pursuant to the terms of an Investment Agreement between the Company and BVF (the &#8220;Investment Agreement&#8221;)</span><span style="font-style:normal;font-weight:normal;">. In total, BVF purchased </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_XDDor7baIkKyVKi2CJALuw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_3hhqFUQRVEKOciLB8DKk1A">845,463</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock and the Company will pay approximately </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_SqIlV2-rakKVcalxYbzoAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LegalFees" scale="0" id="Narr_2A30t8pHE0uaSHDw4W_2KA">18,000</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> for BVF&#8217;s reasonable legal fees and expenses in connection with the </span><span style="font-style:normal;font-weight:normal;">Investment Agreement and </span><span style="font-style:normal;font-weight:normal;">the 2019 Rights Offering. One of the Company&#8217;s Directors, Matthew Perry, is the President of BVF. Each share of common stock has a stated value of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_RJ9Qlzbmi0O4zgEGElxXYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_NTPTD6qwhEmVQPjovQ4GoQ">22.00</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_2_29_2020_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_xoma_SeriesYConvertiblePreferredStockMember_Nj6TY6mgREyFvS2FQnthTQ" decimals="2" format="ixt:numdotdecimal" name="xoma:BeneficialOwnershipLimitation" scale="-2" id="Narr_6Maaiado20iRsY-ACfMlGQ">50</ix:nonFraction>%</span><span style="font-style:normal;font-weight:normal;">, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of their shares of Series Y preferred stock into common stock. As of September 30, 2020, BVF owned approximately </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_fV3hcalY7k-YWzODKiVqMg">37.9</ix:nonFraction>%</span><span style="font-style:normal;font-weight:normal;"> of the Company&#8217;s total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA" decimals="3" format="ixt:numdotdecimal" name="xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" scale="-2" id="Narr_AflWBeLKgE6Uz5ioRQwFwA">57.3</ix:nonFraction>%</span><span style="font-style:normal;font-weight:normal;"> of the Company&#8217;s total outstanding shares of common stock. </span><span style="font-style:normal;font-weight:normal;">Due to its significant equity ownership, BVF is considered a related party of the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_R6x4VB5rkUSXD6oQWozXow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_c6hUn3MGL0a-qKn72WgC1Q">5,003</ix:nonFraction> shares of Series X convertible preferred stock in 2017 and <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TyS4yAARRkOfhp3ZxgbyUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wS-yV9Ir2U6a4sVa_ik0OA">1,252.772</ix:nonFraction> shares of Series Y preferred stock in 2018. There were <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_z49RnI3stEODl-bB_4KFnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_FHZBP25v8U6yVi09at-ZCg">5,003</ix:nonFraction> shares of Series X convertible preferred stock and <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_6hHu9AeYSUi8Kjb-gsHXKg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_0qTlShmSdkWxOaYHZrPS6Q">no</ix:nonFraction> shares of Series Y convertible preferred stock outstanding as of September 30, 2020, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. The Series&#160;X and Series&#160;Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series&#160;Y is convertible into <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_MnJGbUR0Q0arUfSSoF2XOA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_pTLRxmVYsEa69MbAh5ri6w">1,000</ix:nonFraction> shares of registered common stock based on a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_hVBra_ri2UOdlaAWOeBi1Q" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_yoNNPYPibkSAth9qCV8bkQ">4.03</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TOYjkQxmGUCjZkjeSJlhUg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_2xC4QHk85EOHchXfDKyz4w">13.00</ix:nonFraction> per share of common stock, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qQjoVPnmhkS4mKVtcSsErg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Beneficial Conversion Feature&#8212; </i>The fair value of the common stock into which the Series&#160;X convertible preferred stock is convertible exceeded the allocated purchase price of the Series&#160;X convertible preferred stock by $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_2_1_2017_To_2_28_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_zbfdDVr-vEikYw024muE5g" decimals="-5" format="ixt:numdotdecimal" name="xoma:FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" scale="6" id="Narr_MBQYSHK-l0yT-C4PzskknQ">5.6</ix:nonFraction> million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series&#160;X convertible preferred stock sold on February&#160;16, 2017 multiplied by the difference between the fair value of the common stock and the Series&#160;X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series&#160;X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series&#160;Y convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;18, 2018, the Company entered into an At The Market Issuance Sales Agreement (the &#8220;2018 ATM Agreement&#8221;) with H.C. Wainwright&#160;&amp; Co., LLC (&#8220;HCW&#8221;), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfCommonStockToBeIssued" scale="6" id="Narr_ZaHVDHFYgk252dsbDCfCYg">30.0</ix:nonFraction> million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule&#160;415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ" contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_PlBfqshTSkaD5A1hfHjWOw" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" scale="-2" id="Narr__V1xjZtxN0iWhh2nb1UDJg">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the 2018 ATM Agreement. <ix:nonFraction unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg" contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_44Jv_9l0yEu1_bEJhWroxg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_77oXLJEN-keBI5eegfIuGA">No</ix:nonFraction> shares have been sold under the 2018 ATM Agreement since the agreement was executed.</p></ix:continuation><a id="_Hlk37628211"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_I4G9jLoa006vjQE2JHWzog" continuedAt="Tb_I4G9jLoa006vjQE2JHWzog_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law. The CARES Act includes a number of income tax changes, including, but not limited to (1) permitting NOL carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (2) accelerating AMT tax refunds, (3) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (4) providing a technical correction for depreciation as relates to qualified improvement property.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="6" id="Narr_PwO1xHXRoUuIuIoTZ3Dvfg">1.5</ix:nonFraction> million for the nine months ended September 30, 2020 as a result of the CARES Act, which was enacted on March 27, 2020. The CARES Act permits the Company to carry back losses from 2018 to offset its income in 2017 resulting in an income tax receivable. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a total of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_TaJiWjt-E0-zwp5QGcv6Lg">5.5</ix:nonFraction> million of gross unrecognized tax benefits, <ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_-tY-9xjCt0S97vow8as1VQ">none</ix:nonFraction> of which would affect the effective tax rate upon realization. The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_I4G9jLoa006vjQE2JHWzog_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through September 30, 2020, the Company has not accrued interest or penalties related to uncertain tax positions.</p></ix:continuation><a id="_Hlk54692977"></a><a id="_Hlk54711673"></a><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_3CxqWPq51U6E6TRiS6AQGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 9, 2020, Rezolute completed a private placement of its equity securities with gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_9_2020_To_10_9_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Wdtq6HhGbkyK1Ip4HHUIVw" decimals="-5" format="ixt:numdotdecimal" name="xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" scale="6" id="Narr_8cOA9I9U8EahIubo42D72g">41.0</ix:nonFraction> million, which is considered a Qualified Financing event under the Third Amendment. The Qualified Financing resulted in acceleration of the remaining receivables of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg" decimals="-5" format="ixt:numdotdecimal" name="xoma:FutureCashPaymentsReceived" scale="6" id="Narr_6HqUQoaO9kukgy6d6-M3jg">1.4</ix:nonFraction> million due from Rezolute, and the Company received the entire amount in October 2020. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="Narr_mRTayHOf5UOIyvXj2qwh6A">1.4</ix:nonFraction> million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. The Company will recognize the $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2020_To_12_31_2020_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_X8Vp97mKY0uNE717S6FXRA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" sign="-" scale="6" id="Narr_3GBV3U29_UaskN-Urf-Wvw">1.4</ix:nonFraction> million as a reversal of bad debt expense in the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, NIS793, an anti-TGF&#946; monoclonal antibody, licensed from the Company to Novartis International under the License Agreement, advanced to the Phase 2 development stage. &#160;As a result of the advancement, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_EVgArh411UutMgiPziAIxQ">25.0</ix:nonFraction> million milestone payment. As specified under the terms the License Agreement, the Company will receive $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="As_Of_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_x1Y6PfrxfE2TlMaI8OC3hA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGrossCurrent" scale="6" id="Narr_ltt5eY061UGvHVz2CRLC_A">17.7</ix:nonFraction> million in cash and the remaining balance of $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" sign="-" scale="6" id="Narr_XOEH8hy8KE6Ay2FTBQp_Ag">7.3</ix:nonFraction> million will be recognized as a reduction to the Company&#8217;s debt obligation to Novartis. The Company will record $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_SXy_rcf1HE-sOiNkx-qqfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_9YQ2bncO1EuERJoANoZAHg">25.0</ix:nonFraction> million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income (loss) in the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company exercised its option previously granted under the Bioasis Royalty Purchase Agreement and entered into another Royalty Purchase Agreement (the &#8220;Second Bioasis Royalty Purchase Agreement&#8221;) with Bioasis. Under the Second Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a Research Collaboration and License Agreement between Bioasis and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). The Company paid Bioasis $<ix:nonFraction unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyPurchaseAgreementMember_tYew2cGdwUWvjZAtJPwK7w" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRights" scale="6" id="Narr_9EktHPKBW0WorxPWrS2_YA">1.2</ix:nonFraction> million upon closing of the Second Bioasis Royalty Purchase Agreement for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_92b88e1f_e51b_484a_be3d_af571eb49561"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, which are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, extent to which our issued and pending patents may protect our products and technology, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments&#160;under license and collaboration agreements and the timing of receipt of those payments, and the impact of the recent and evolving COVID-19 pandemic. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: our product candidates subject to our out-license agreements are still being developed, and our licensees&#8217; may require substantial funds to continue development which may not be available; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties; and certain of our technologies are in-licensed from third parties, so our capabilities using them are restricted and subject to additional risks. These and other risks, including those related to current economic and financial market conditions, are contained principally in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q and our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form&#160;10-Q. You should read this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from those we expect. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">We are a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Our portfolio was built through licensing our proprietary products and platforms from our legacy discovery and development business, combined with acquisitions of rights to future milestones and royalties that we have made since our royalty aggregator business model was implemented in 2017. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Business Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, NIS793, an anti-TGF&#946; monoclonal antibody, that we licensed to Novartis International Pharmaceutical Ltd. (&#8220;Novartis International&#8221;) under the September, 2015 License Agreement (the &#8220;License Agreement&#8221;), advanced to the Phase 2 development stage. As a result of the advancement, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and we earned a $25.0 million milestone payment. As specified under the terms the License Agreement, we will receive $17.7 million in cash and the remaining balance of $7.3 million will be recognized as a reduction to our debt obligation to Novartis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2017, we entered into a license and common stock purchase agreement with Rezolute, which was amended on March&#160;30, 2018 and further amended on January&#160;7, 2019. The license agreement was amended to eliminate the requirement that equity securities be issued to us upon the closing of the Qualified Financing (as defined in the license agreement) and to replace it with a requirement that Rezolute: (1)&#160;make five cash payments to us totaling $8.5 million following the closing of a Qualified Financing on or before specified staggered future dates through September&#160;2020 (the &#8220;Future Cash Payments&#8221;); and (2)&#160;provide for early payment of the Future Cash Payments (only until $8.5 million is reached) by making cash payments to us equal to 15% of the net proceeds of each future financing following the closing of the Qualified Financing, with such payments to be credited against any remaining unpaid Future Cash Payments in reverse order of their future payment date. The common stock purchase agreement was amended to remove certain provisions related to the issuance of equity to us in accordance with the new provisions regarding the Future Cash Payments in the license agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 31, 2020, we and Rezolute further amended the license agreement to extend the payment schedule for the remaining $2.6 million in Future Cash Payments. The amendment to the payment terms was in response to Rezolute&#8217;s need to preserve cash as a result of the COVID-19 pandemic and w<span style="color:#231f20;">as agreed to by us. </span>The revised payment schedule did not impact the total amount due, but instead, spread the $2.6 million into seven quarterly payments to be paid through September 30, 2021. The amended license agreement requires<span style="color:#231f20;"> that in the event Rezolute completes a Qualified Financing at any time between March 31, 2020 and the date of the final payment, Rezolute shall pay all amounts outstanding within fifteen days following the closing of the Qualified Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>In the first quarter of 2020, we received the scheduled $0.4 million Future Cash Payment from Rezolute. We evaluated Rezolute&#8217;s cash position as of March 31, 2020, including the estimated impact of the COVID-19 pandemic, and determined payments scheduled beyond September 30, 2020 were unlikely to be collected unless Rezolute is able to obtain additional funding, which had not occurred as of March 31, 2020. Therefore, for the three months ended March 31, 2020, we recorded $1.4 million in bad debt expense related to the Future Cash Payments. We received the scheduled $0.4 million and $0.4 million Future Cash Payments from Rezolute in the second and third quarters of 2020, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">On &#160;October 9, 2020, Rezolute completed a private placement of its equity securities with gross proceeds of $41.0 million, which is considered a Qualified Financing event under the Third Amendment. The Qualified Financing resulted in acceleration of the remaining receivables of $1.4 million due from Rezolute, and we received the entire amount in October 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Bioasis </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, we exercised our option previously granted under the Bioasis Royalty Purchase Agreement and entered into another Royalty Purchase Agreement (the &#8220;Second Bioasis Royalty Purchase Agreement&#8221;) with Bioasis. Under the Second Bioasis Royalty Purchase Agreement, we purchased potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a Research Collaboration and License Agreement between Bioasis and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). We paid Bioasis $1.2 million upon closing of the Second Bioasis Royalty Purchase Agreement for the purchased rights.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Zydus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">In March 2020, we entered into a license agreement (the &#8220;Zydus Agreement&#8221;) with Cadila Healthcare Limited (&#8220;Zydus&#8221;) under which we granted Zydus an exclusive royalty-bearing license to our anti-interleukin-2 (&#8220;IL-2&#8221;) monoclonal antibody, including mAb19, for Zydus to develop and commercialize drug candidates in India, Brazil, Mexico and certain other emerging markets. We retain rights in all other territories, subject to a Zydus right of first negotiation. Under the terms of the Zydus Agreement, Zydus is responsible for the development and commercialization of IL-2 based immune-oncology drug candidates. XOMA is entitled to receive up to $0.5 million in development and regulatory milestone payments, up to $23.5 million in commercial milestone payments, and mid-single digit to low teens royalties from Zydus. We are also eligible to share out-licensing revenue received by Zydus should Zydus (sub)license to third parties, which are tiered based on clinical trial stage and range from a low to mid double-digit&#160;percentage rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 0pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The worldwide spread of the COVID-19 pandemic continues to pose risks to our business as clinical trials industry-wide have slowed. Our business is dependent on the continued development and commercialization efforts of our licensees and our royalty agreement counterparties. We have been monitoring and continue to monitor our portfolio programs for potential delays in underlying research programs and elections of our partners to continue or cease development. Delays in clinical trials and underlying research programs may lead to delayed revenue from milestones from our licensees or, if certain research programs are discontinued, we may recognize impairment charges for our royalty receivables. COVID-19 may impact our underlying programs in a variety of ways which are unknown in length and scope at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies</p><a id="_Hlk54343202"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Critical accounting policies are those that require significant judgment and/or estimates by management at the time that the financial statements are prepared such that materially different results might have been reported if other assumptions had been made. We consider certain accounting policies including those related to revenue recognition, stock-based compensation, the sale of future royalty streams, the purchase of rights to future milestones and royalties and leases to be critical policies. There have been no significant changes in our critical accounting policies during the nine&#160;months ended September 30, 2020, as compared with those previously disclosed in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the SEC on March&#160;10, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are included in &#8220;Part I - Item 1 &#8211; Condensed Consolidated Financial Statements - Note 2 &#8211; Basis of Presentation and Significant Accounting Policies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total revenues for the three&#160;and nine months ended September 30, 2020 and 2019, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue from contracts with customers</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 200</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,525</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,325)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 753</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,176</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,423)</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 330</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,051</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 772</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 557</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,855</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,298)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,804</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,948</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,144)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue from contracts with customers includes upfront fees, milestone payments and royalties related to the out-licensing of our product candidates and technologies. The decrease for the three months ended September 30, 2020, as compared to the same period in 2019, was primarily due to $6.0 million recognized under the Rezolute agreement and $2.5 million recognized under the Janssen license agreement in the third quarter of 2019. The decrease for the nine months ended September 30, 2020, as compared to the same period in 2019, was primarily due to $8.0 million and $6.0 million of license fee revenue recognized under our license agreement with Rezolute in the first and third quarters of 2019, respectively, and $2.5 million of revenue recognized under our license agreement with Janssen in the third quarter of 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Due to the anticipated impact of COVID-19 on clinical trial activities of our licensees, potential milestone payments may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Revenue recognized under units-of-revenue method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues recognized under the units-of-revenue method include the amortization of unearned revenue from the sale of royalty interests to HealthCare Royalty Partners II,&#160;L.P (&#8220;HCRP&#8221;) in 2016. The increase in revenues for the three and nine months ended September 30, 2020, as compared to the same periods in 2019, was primarily due to the increase in sales of products underlying the agreements with HCRP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development (&#8220;R&amp;D&#8221;) expenses were $34,000 and $0.1 million for the three and nine months ended September 30, 2020, respectively, compared with $0.1 million and $1.1 million for the same periods in 2019. The decrease of $0.1 million for the three&#160;months ended September 30, 2020, compared to the same period of 2019, was due to a $0.1 million decrease in salary and related expenses as a result of the recategorization of employees to department codes mapped to general and administrative expenses. The decrease of $1.0 million for the nine&#160;months ended September 30, 2020, compared to the same period of 2019, was primarily due to a $0.5 million decrease in license fee expenses and a $0.4 million decrease in salary and related expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our R&amp;D spending during the remainder of 2020 to be lower than 2019 levels due to the focus on our royalty aggregator business model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses include salaries and related personnel costs, professional fees, and facilities costs. G&amp;A expenses were $3.2 million and $13.1 million for the three and nine months ended September 30, 2020, respectively, compared with $5.8 million and $16.7 million for the same periods in 2019. The decrease of $2.6 million for the three&#160;months ended September 30, 2020, as compared to the same periods of 2019, was primarily due to a $1.3 million decrease in salary and related expenses and a $0.9 million decrease in facilities costs. The decrease of $3.6 million for the nine&#160;months ended September 30, 2020, as compared to the same period of 2019, was primarily due to a $3.0 million decrease in facilities costs and a $1.6 million decrease in salary and related expenses, partially offset by a $1.4 million increase in bad debt expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We expect to continue recognizing savings in facilities costs related to our legacy leases throughout the remainder of 2020, and in light of recent developments of COVID-19, we are evaluating the reduction of certain discretionary costs for the remainder of 2020. We do not anticipate any reduction to headcount, but we do expect to recognize a slight decrease in salaries and related personnel costs due to the termination of our Chief Business Officer in August of 2019. Finally, we expect to continue to actively evaluate potential acquisitions of milestone and royalty rights, which may result in an increase in related professional fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense is shown below for the three and nine months ended September 30, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB loans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 334</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 314</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,073</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 791</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 282</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 168</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 409</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (131)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 434</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,336</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 148</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk54344110"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increase in interest expense for the nine months ended September 30, 2020 as compared with the same period of 2019 is primarily due to the increase in the outstanding loan balance with SVB. If market interest rates increase in the near term, or if we elect to obtain additional financing, our interest expense may increase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the activity in other income (expense), net for the three and nine months ended September 30, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,041</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (265)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 481</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,410</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Sublease income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 827</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (827)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,354</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,354)</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 209</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (204)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 155</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (569)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:30.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,046</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 771</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,275</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,046</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,559</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,513)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of the early termination of our legacy leases in December 2019, we are no longer party to any subleases, resulting in a decrease in sublease income for the three and nine months ended September 30, 2020 as compared with the same periods of 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We own equity securities consisting of shares of Rezolute&#8217;s common stock which are remeasured at fair value at each reporting period. During the nine months ended&#160;September 30, 2020 and 2019 we remeasured the fair value of the equity securities and recognized gains of $1.9 million and $0.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provision for Income Taxes</p><a id="_Hlk37628054"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded an income tax benefit of $1.5 million for the nine months ended September 30, 2020 as a result of the CARES Act, which was enacted on March 27, 2020. The CARES Act permits us to carry back losses from 2018 to offset income in 2017 resulting in an income tax receivable. We continue to maintain a full valuation allowance against our remaining net deferred tax assets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our cash, working capital and cash flow activities for each of the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,725</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,688</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,963)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,098</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,289)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,586)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,863</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,449)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,300)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,291</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,368)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,401</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,769)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,963)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,036)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,927)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash (Used in) Provided by Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the nine&#160;months ended September 30, 2020 of $7.6 million was primarily due to the $9.4 million net loss incurred, partially offset by stock-based compensation expense of $3.3 million. The net cash provided by operating activities in 2019 of $3.9 million was primarily due to the $5.5 million cash receipts under the license and common stock purchase agreement with Rezolute in January 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cash Used in Investing Activities</p><a id="_Hlk53658901"></a><a id="_Hlk53658770"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background-color:#ffffff;">Net cash used in investing activities for the nine months ended September 30, 2020 of $9,000 was due to the purchase of property and equipment. </span>Net cash used in investing activities for the nine months ended September 30, 2019 was due to the purchases of milestone and royalty rights of $19.3 million in connection with the Bioasis Royalty Purchase Agreement, the Aronora Royalty Purchase Agreement, and the Palo Royalty Purchase Agreement executed in 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Cash (Used in) Provided by Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities for the nine&#160;months ended September 30, 2020 of $3.4 million was primarily related to principal payments of debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 4.5pt;">Net cash provided by financing activities for the nine months ended September 30, 2019 of $9.4 million was primarily related to proceeds received under the SVB Loan Agreement of $9.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.3pt;text-align:justify;text-indent:-21.3pt;margin:6pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Silicon Valley Bank Loan Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.7pt;margin:12pt 0pt 12pt 0pt;">Under our Loan Agreement with SVB, upon our request, SVB may make advances available to us up to $20.0 million. In March 2019, we and SVB amended the Loan Agreement to extend the draw period from March 31, 2019 to March 31, 2020. Our draw period lapsed on March 31, 2020 with no further extension. In connection with the amendment in March 2019, we issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of XOMA. As of September 30, 2020, we had an outstanding principal balance of $14.3 million under the Loan Agreement, and a net carrying value of $13.8 million, $9.0 million of which was classified as current portion of long-term debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">2018 ATM Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;18, 2018, we entered into an At The Market Issuance Sales Agreement (the &#8220;2018 ATM Agreement&#8221;) with H.C. Wainwright&#160;&amp; Co., LLC (&#8220;HCW&#8221;), under which we may offer and sell from time to time at our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">sole discretion shares of our common stock through HCW as our sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule&#160;415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. We are required to pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 ATM Agreement. We have not sold any shares of common stock under the 2018 ATM Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:31.5pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:40.5pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:center;">*</span></span>*<span style="display:inline-block;width:31pt;"></span>*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses since our inception and have an accumulated deficit of $1.2 billion as of September 30, 2020. As of September 30, 2020, we had $45.7 million in cash, which we anticipate will enable us to maintain our operations for a period of at least 12&#160;months following the filing date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have taken and continue to take steps to manage our resources by reducing and/or deferring certain discretionary expenditures to mitigate the adverse impact of the COVID-19 pandemic. Future impacts of COVID-19 may require further actions to improve our cash position, which may include reducing or delaying acquisitions of additional royalty and milestone rights or obtaining additional funds through debt arrangements, under the 2018 ATM Agreement, or other equity issuances. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. In addition, our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commitments and contingencies were reported in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, as filed with the SEC. There have been no material changes from the commitment and contingencies previously disclosed in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.</p><a id="_876b8873_9caf_41d1_8c04_9497479f4570"></a><a id="ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><a id="_e5c2e838_9f8a_48c4_99ef_84303138f2b0"></a><a id="ITEM4CONTROLSANDPROCEDURES_732379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have established disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act. Our Chief Executive Officer and our Chief Financial Officer have concluded, based on the evaluation of the effectiveness of our disclosure controls and procedures by our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, as of the end of the period covered by this report, that our disclosure controls and procedures were effective at the reasonable assurance level.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control</p><a id="_Hlk54358175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:2pt 0pt 2pt 0pt;">There have been no changes in our internal controls over financial reporting as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. While COVID-19 has resulted in our staff operating remotely, our established internal control structure is not impacted. As we continue to monitor and adapt to the changing environment due to COVID-19 and the related possibility of a cybersecurity impact, including a security breach or cyber-attack, we will continue to evaluate our internal controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><a id="_8b5d2f43_6cee_41d2_b244_f0ffb835249e"></a><a id="PARTIIOTHERINFORMATION_840286"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">PART&#160;II&#160;&#8211;&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dcd4e306_63b1_4acb_b128_89a203995301"></a><a id="ITEM1LEGALPROCEEDINGS_81705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1.&#160;LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_17e06825_2461_40b3_8249_e49cb0cc16fd"></a><a id="ITEM1ARISKFACTORS_925437"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ITEM&#160;1A.&#160;RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including our revenues, expenses, operating results, cash flows, net (loss) income and (loss) income per share. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider these risk factors, together with all of the other information included in this Quarterly Report on Form 10-Q as well as our other publicly available filings with the U.S. Securities and Exchange Commission, or SEC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:27.8pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2019.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Royalty Aggregator Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2020, COVID-19, the disease caused by a novel strain of coronavirus, was declared a pandemic by the World Health Organization. The pandemic has severely affected global economic activity and resulted in the implementation of significant governmental measures, including lockdowns, closures, quarantines and travel bans, intended to control the spread of the virus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties, which could cause delays, suspensions or cancellations of their drug development efforts including, without limitation, their clinical trials which would correspondingly delay, suspend or negate the timing of our potential receipts of milestones and royalties under our out-licensing or royalty acquisition agreements. The disruptions to our licensees or royalty purchase agreement counterparties could include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in recruiting and enrolling new patients in their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as their clinical trial sites and hospital staff supporting the conduct of their clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">limitations in employee resources that would otherwise be focused on the conduct of their clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">interruption in global shipping that may affect the transport of clinical trial supplies and materials, such as the investigational drug product used in their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in receiving approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;) and other U.S. and foreign federal, state and local regulatory authorities to initiate their planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in FDA, state and local regulation (and those of their foreign counterparts if applicable) as part of a response to the COVID-19 pandemic which may change the ways in which clinical trials are conducted or discontinue clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">delay in the timing of other interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention to approval of other therapeutics or other activities related to COVID-19; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States or of foreign regulatory authorities to accept data from clinical trials in affected areas outside their applicable countries.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which the COVID-19 pandemic continues to impact our business and prospects and the overall economies of the United States and other countries will depend on numerous evolving factors, which are highly uncertain and cannot be predicted with confidence, such as the duration and scope of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic continues to pose risks to our business, including at our headquarters in Emeryville, California, which has in the past been subject to local and statewide &#8220;stay-at-home&#8221; orders issued by Alameda County and the Governor of the State of California, as well as the business or operations of our partners and other third parties with whom we conduct business.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has resulted in extended travel and other continued restrictions in order to reduce the spread of the disease, including a California executive order, San Francisco Bay Area orders and several other state and local orders across the country, which, among other things, direct individuals to continue to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. The evolving effects of the COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as significant reductions in business related activities have occurred, supply chains have been disrupted, and manufacturing and clinical development activities have been curtailed or suspended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In response to these public health directives and orders, we previously implemented a work-from-home policy for all employees. We have been able to maintain our operations and productivity thus far; however, prolonged working remotely may negatively impact productivity, disrupt our business and delay our timelines, the magnitude of which will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, quarantines, stay-at-home, executive and similar government orders, shutdowns or other restrictions on the conduct of business operations continue to impact personnel at third-party clinical testing sites, manufacturing facilities, or the availability or cost of materials, which could disrupt our licensees&#8217; and royalty purchase agreement counterparties&#8217; supply chains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the evolving economic impacts brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has already significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p><a id="_Hlk54344586"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The evolving effects of the COVID-19 pandemic have already resulted in significant disruption of global financial markets. While several of our partners have experienced delays due to the COVID-19 pandemic, we do not yet know the full extent of potential delays or impacts on our business, clinical trials, healthcare systems or the global economy as a whole. However, the effects could continue to have an impact on our operations and could have a material adverse effect on our business, financial condition, results of operations and prospects in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;under the applicable license agreement(s)&#160;covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are engaged in a continual review of opportunities to acquire future royalties, milestones and other payments related to drug development and sales as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. Generally, at any time, we seek to have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, timing and amount of potential future royalty and milestone payments as well as the viability of the underlying technology and intellectual property. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of these acquisitions may expose us to credit risk in the event of a default by or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;that are parties to the applicable license agreement(s)&#160;covering the potential milestone and royalty streams being acquired. In addition, the impact of COVID-19 on the capital markets may limit our licensees&#8217; or royalty-agreement counterparties&#8217; ability to access additional funding. While we generally try to structure our receipt of potential milestone and royalty payments to minimize the risk associated with such a default or bankruptcy, there can be no assurance that any such default or bankruptcy will not adversely affect our ability to receive future potential royalty and/or milestone payments. To mitigate this risk, on occasion, we may obtain a security interest as collateral in such royalty, milestone and other payments. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices sufficient to recover the full amount we are due pursuant to the terms of the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">As part of our royalty aggregator strategy, we may continue to purchase future potential milestone and royalty streams associated with drug products which are in clinical development and have not yet received marketing approval by any regulatory authority or been commercialized. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. To the extent that any such drug products are not successfully developed and subsequently commercialized, the value of our acquired potential milestone and royalty streams will be negatively affected. The ultimate success of our royalty aggregator strategy will depend on our ability to properly identify and acquire high quality products and the ability of the applicable counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so would negatively affect our ability to receive royalty and/or milestone payments. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as protection of a patent estate, adequate reporting and other protections, and their failure to do so would presumably negatively impact our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;"> </span>If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalty, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 0pt 0pt;">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">We intend to continue, and may increase, this strategy of acquiring development-stage product candidates. While we believe that we can readily evaluate and gain conviction about the likelihood of a development-stage product candidate&#8217;s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to sales risks.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, loss of patent protection, the impact of the COVID-19 global pandemic or other factors and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals or declining sales. As a result, payments of our future potential milestones and/or royalties may be reduced or cease. In addition, these potential payments may be delayed, causing our near-term financial performance to be weaker than expected. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to substantial competition.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a royalty, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our royalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:24.5pt;margin:6pt 0pt 6pt 0pt;"><span style="font-size:10pt;">Competitive factors affecting the market position and success of each product include:</span>&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">effectiveness; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">safety and side effect profile; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">price, including third-party insurance reimbursement policies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">timing and introduction of the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">effectiveness of marketing strategy and execution; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">governmental regulation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">availability of lower-cost generics and/or biosimilars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">treatment innovations that eliminate or minimize the need for a product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical products that have the potential to generate future milestones and royalties for us may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. These developments could have a material adverse effect on the sales of the biopharmaceutical products that have potential to generate our milestones and royalties, and consequently could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from the audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalty and milestone payments we may receive are dependent on our licensees&#8217; achievement of regulatory and developmental milestones and product sales. Each licensee&#8217;s calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee and/or a licensee may fail to report the achievement of royalties or milestones in whole or in part. Our license and royalty agreements typically provide us the primary or back-up right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many&#160;months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on the part of the Company. Further, our licensees and royalty-agreement counterparties may be uncooperative or have insufficient records, which may complicate and delay the audit process.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we intend to regularly exercise our royalty audit rights as necessary and to the extent available, we rely in the first instance on our licensees and royalty-agreement counterparties to accurately report the achievement of milestones and royalty sales and calculate and pay applicable milestones and royalties and, upon exercise of such royalty and other audit rights, we rely on licensees&#8217; and royalty-agreement counterparties&#8217; cooperation in performing such audits. In the absence of such cooperation, we may be forced to incur expenses to exercise legal remedies, if available, to enforce our agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally acquire milestone and royalty rights that have limited secondary resale markets and may be subject to transfer restrictions. The illiquidity of most of our milestone and royalty receivable assets may make it difficult for us to dispose of them at a favorable price if at all and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a forced liquidation or otherwise. In addition, if we liquidate all or a portion of our potential future milestone and/or purchased royalty stream interests quickly or relating to a forced liquidation, we may realize significantly less than the value at which we had previously recorded these interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rules&#160;and interpretations of the SEC and the courts, relating to the definition of &quot;investment company&quot; are very complex. While we currently intend to conduct our operations so that we will not be an investment company under applicable SEC interpretations, we can provide no assurance that the SEC would not take the position that the Company would be required to register under the Investment Company Act of 1940 (the &#8220;&#8216;40 Act&#8221;) and comply with the &#8216;40 Act&#8217;s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. We monitor our assets and income for compliance under the &#8216;40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of &#8220;investment company&#8221; or qualify under one of the exemptions or exclusions provided by the &#8216;40 Act and corresponding SEC regulations. If we were to become an &#8220;investment company&#8221; and be subject to the restrictions of the &#8216;40 Act, those restrictions would likely require significant changes in the way we do business and add significant administrative burdens to our operations. To ensure that we do not fall within the &#8216;40 Act, we may need to take various actions which we might otherwise not pursue. These actions may include restructuring the Company and/or modifying our mixture of assets and income or a liquidation of certain of our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Financial Results and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception. We had net losses of $2.0 million and $13.3 million for the&#160;years ended December 31, 2019 and December&#160;31, 2018, respectively. As of September 30, 2020, we had an accumulated deficit of $1.2 billion. We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of equity securities and debt and royalty interests, and payments received under our collaboration and licensing arrangements. The size of our future net losses will depend, in part, on the rate of our future expenditures and our and our partners&#8217; ability to generate revenues. If our partners&#8217; product candidates are not successfully developed or commercialized by our licensees, or if revenues are insufficient following regulatory approval, we will not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our and our licensees&#8217; ability to license product candidates, and the success of our licensees&#8217; development programs, both of which are uncertain. Our success is also dependent on our licensees obtaining regulatory approval to market product candidates which may not materialize or prove to be successful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require us to raise additional funds to acquire<span style="font-style:normal;font-weight:normal;"> </span>milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may need to commit substantial funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, if at all. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders, including pursuant to our 2018 ATM Agreement. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If adequate funds are not available on a timely basis, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">reduce or eliminate royalty aggregation efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">further reduce our capital or operating expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">curtail our spending on protecting our intellectual property; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">take other actions which may adversely affect our financial condition or results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>Changes in the potential royalty acquisition market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire potential royalties, fewer potential royalties (or potential royalties of significant scale) being available, or increased competition for potential royalties. Even if we continue to acquire potential royalties and they become actual royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to acquire potential milestones and royalties as we have in the past, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have significantly restructured our business and revised our business plan and there are no assurances that we will be able to successfully implement our revised business plan or successfully operate as a royalty aggregator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have historically been focused on discovering and developing innovative therapeutics derived from our unique platform of antibody technologies. We have now become a royalty aggregator where we focus on expanding our pipeline of fully-funded programs by out-licensing our internally developed product candidates and acquiring potential milestone and royalty revenue streams on additional third-party drug product candidates. Our strategy is based on a number of factors and assumptions, some of which are not within our control, such as the actions of third parties. There can be no assurance that we will be able to successfully execute all or any elements of our strategy, or that our ability to successfully execute our strategy will be unaffected by external factors. If we are unsuccessful in acquiring potential milestone and royalty revenue streams on additional drug product candidates, or those acquisitions do not perform to our expectations, our financial performance and balance sheet could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not fully realize the expected benefits of our cost-saving initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Maintaining a low corporate cost structure is a key element of our current business strategy. If we experience unanticipated inefficiencies caused by our reduced headcount, we may be unable to fully execute our new strategy. In addition, we may incur expenses in excess of what we anticipate. Any of these outcomes could prevent us from meeting our strategic objectives and could adversely impact our results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We use leverage in connection with our capital deployment, which magnifies the potential for loss if the potential royalties acquired or generated through out-licensing agreements do not generate sufficient income to us.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We use borrowed funds to finance a portion of our deployed capital. The use of leverage creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by the future potential income from our assets. In addition, leverage may inhibit our operating flexibility and reduce cash flow available for dividends to our shareholders (if ever contemplated). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The level of our indebtedness could limit our ability to respond to changing business conditions. The various agreements relating to our borrowings may impose operating and financial restrictions on us which could affect the number and size of the potential milestones and royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional risks related to our leverage include: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our potential future milestones and royalties are used as collateral for our borrowings; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">in the event of a default under any of our secured borrowings, one or more of our creditors or their assignees could obtain control of our future potential milestones and royalties and, in the event of a distressed sale, these creditors could dispose of these royalties for significantly less value than we could realize for them; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we may have to comply with various financial covenants in future agreements that govern our debt, including requirements to maintain certain leverage ratios and coverage ratios, which may affect our ability to achieve our business objectives; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our ability to pay dividends to our shareholders (if ever contemplated) may be restricted; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">to the extent that interest rates at which we borrow increase, our borrowing costs will increase, and our leveraging strategy will become more costly, which could lead to diminished net profits; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">because our debt utilizes LIBOR as a factor in determining the applicable interest rate, the expected discontinuation and transition away from LIBOR may increase the cost of servicing our debt, lead to higher borrowing costs and have an adverse effect on our results of operations and cash flows. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may have limited information concerning the products generating the future potential royalties we are evaluating for acquisition. Often, the information we have regarding products following our acquisition of a potential royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products of others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual potential cash flow from a potential royalty may be significantly lower than our estimates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.*</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business model is based on multiple-year internal and external forecasts regarding potential product sales and numerous product-specific assumptions in connection with each potential milestone and royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding potential product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us potential royalties may also prove to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate our projected returns or in the time periods we expect. This could negatively impact our results of operation for a given period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reductions or declines in income from potential milestones and royalties, or significant reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect our financial condition and results of operations.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as patent expiration dates, regulatory exclusivity, years from first commercial sale of the patent-protected product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, claims of patent misuse, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing for the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. If an unexpected shortening of a potential royalty term were to occur, it could result in a reduction in a decline in potential income from milestones and royalties, a significant reduction in potential milestones and royalty payments compared to expectations, or a permanent impairment of such potential milestones and royalty payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation.* </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our asset portfolio may not be fully diversified by product, geographic region or other criteria. Any significant deterioration in the amount or likelihood of receipt of potential cash flows from the top products in our asset portfolio could have a material adverse effect on our business, financial condition and results of operations. In addition, should the payor of any future potential milestones or royalties decline to pay such potential milestones and royalties for any reason, such failure may result in a material adverse effect on our financial condition and results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">License or collaboration agreements relating to the products generating our future milestones and royalties and other payment rights may be terminated, which may adversely affect sales of such products and therefore the potential payments we may receive. For example, under certain license or collaboration agreements, marketers may retain the right to unilaterally terminate the agreements. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate the applicable license or collaboration agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor (which may be us in the case of our out-licensed products) or collaborator may no longer receive all of the payments it expected to receive from the applicable licensee or collaborator and may also be unable to find </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">another company to continue developing and commercializing the product on the same or similar terms as those under the license or collaboration agreement that has been terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, license or collaboration agreements may fail to provide significant protection for the applicable licensor (which may be us in the case of our out-licensed products) or collaborator in case of the applicable licensee&#8217;s or collaborator&#8217;s failure to perform or in the event of disputes. License and collaboration agreements which relate to the products underlying our potential future milestones, royalties and other payment rights, are complex and certain provisions in such agreements may be susceptible to multiple interpretations. Disputes may arise regarding intellectual property, royalty terms, payment rights or other contractual terms subject to a license or collaboration agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the scope or duration of rights granted under the license or collaboration agreement and other interpretative issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the amounts of royalties, milestones or other payments due under the license or collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the sublicensing of patent or other rights under our license or collaboration relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the diligence obligations under the license or collaboration </span><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">agreement and what activities satisfy such diligence obligations:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us or our partners; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The resolution of any contract interpretation disagreement that may arise could narrow what the licensor (which may be us in the case of our out-licensed products) or collaborator believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee&#8217;s or collaborator&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our potential royalties, milestones and other payments and have a material adverse effect on our business, financial condition, results of operations and prospects. If a marketer were to default on its obligations under a license or collaboration agreement, the licensor&#8217;s or collaborator&#8217;s remedy may be limited either to terminating certain licenses or collaborations related to certain countries or to generally terminate the license or collaboration agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor or collaborator (if not us) and we may be required to rely on the resources and willingness of the licensor or collaborator (if not us) to enforce its rights against the applicable licensee or collaborator. In any of these situations, if the expected upfront, milestone, royalty or other payments under the license or collaboration agreements do not materialize, this could result in a significant loss to us and materially adversely affect our business, financial condition and results of operations. At any given time, the Company may be engaged in discussions with its licensees or collaborators regarding the interpretation of the payment and other provisions relating to products as to which we have milestones and potential royalty or other payment rights. Should any such discussions result in a disagreement regarding a particular product that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product should it successfully progress through clinical development and be approved for commercialization. Should our milestone and future potential royalty or other payment interests be reduced or eliminated as result of any such disagreement, it could have an adverse effect on our business, financial condition, results of operation and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. Generally, our current collaborative partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all or failing to engage in commercially reasonable efforts to develop products if required), our product development under these agreements will be delayed or terminated. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our licensees rely on third parties to provide services in connection with our product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our licensees&#8217; product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties provide services in connection with preclinical and clinical development programs, including <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which we or our licensees have contracted, or cease to continue operations, and we are not able to find a replacement provider quickly or we lose information or items associated with our drug product candidates, our or our licensees&#8217; development programs and receipt of any potential resulting income may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with other third parties, many of which are significant to our business, expose us to numerous risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not know whether we or our licensees will successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under our contract with NIAID, a part of the National Institute of Health (&#8220;NIH&#8221;), we invoiced using NIH provisional rates, and these are subject to future audits at the discretion of NIAID&#8217;s contracting office.&#160;In October of 2019, NIH notified us that it engaged KPMG LLP (&#8220;KPMG&#8221;) to perform an audit of our Incurred Cost Submissions for 2013, 2014 and 2015 and the audit is still in progress. This audit may result in an adjustment to revenue previously reported, which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure of our licensees&#8217; product candidates to meet current Good Manufacturing Practices standards may subject our licensees to delays in regulatory approval and penalties for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our licensees may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under current Good Manufacturing Practices (&#8220;cGMP&#8221;) to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our and our licensees&#8217; drug product candidates on the schedule required for our clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our licensees or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our licensees&#8217; product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and standards. Any difficulties or delays in contractors&#8217; manufacturing and supply of our licensees&#8217; product candidates or any failure of our licensees&#8217; contractors to maintain compliance with the applicable regulations and standards could increase costs, reduce revenue, make our licensees postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our licensees&#8217; product candidates, or cause any of our licensees&#8217; product candidates that may be approved for commercial sale to be recalled or withdrawn.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, so our and our licensees&#8217; capabilities using them are restricted and subject to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees&#8217; use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license, which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our and our licensees&#8217; ability to commercialize our technologies, products or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to an Investment in Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our share price may be volatile, and there may not be an active trading market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the market price of our common stock will not decline below its present market price or that there will be an active trading market for our common stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our common stock price. We have experienced significant volatility in the price of our common stock. From January&#160;1, 2020, through November 2, 2020, the share price of our common stock has ranged from a high of $28.78 to a low of $14.14. Additionally, we have one significant holder of our stock that could affect the liquidity of our stock and have a significant negative impact on our stock price if the holder were to quickly sell their ownership position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future contribute to, increased volatility and diminished expectations for the economy and the markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may issue additional equity securities and thereby materially and adversely affect the price of our common stock. In addition, under certain circumstances each share of outstanding preferred stock could be converted into 1,000 shares of common stock which could cause a substantial dilution to our earnings per share and a change in the majority voting control of our Company, if enough of such preferred shares are converted to common shares.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in such a manner as we determine from time to time, including pursuant to our 2018 ATM Agreement. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">gain rights superior to our existing stockholders. If we issue additional equity securities, the price of our common stock may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:12pt 0pt 12pt 0pt;">We are authorized to issue, without stockholder approval, 1,000,000 shares of preferred stock, of which 5,003 shares of Series&#160;X preferred stock were issued and outstanding as of September 30, 2020. Each share of Series&#160;X preferred stock is convertible into 1,000 shares of registered common stock. The total number of shares of common stock issuable upon conversion of all issued Series&#160;X preferred stock would be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which was initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. A holder of Series X preferred shares may elect to increase or decrease the conversion blocker above or below 19.99% on 61 days&#8217; notice, provided the conversion blocker does not exceed the limits under Nasdaq Marketplace Rule 5635(b), to the extent then applicable. If holders of our Series X convertible preferred stock elect to convert their preferred shares into common stock such conversion would dilute our currently outstanding common stock both in number and in earnings per share. BVF (and its affiliates), as current holders of all shares of our Series X preferred stock, would, if they converted all such shares to common stock, obtain majority voting control of the Company. In February 2020, Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;), the holders of Series Y convertible preferred shares, elected to increase the beneficial ownership limitation to 50% and on April 15, 2020, BVF converted all of their shares of Series Y preferred stock into 1,252,772 shares of common stock. As of September 30, 2020, BVF owned approximately 37.9% of our total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own 57.3% of our total outstanding shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to raise additional funds to support our operations, we may sell additional equity or convertible debt securities, which would result in dilution to our stockholders and/or debt securities which may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in the issuance of additional shares of our capital stock and dilution to all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected and we may not be able to meet our debt service obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and by-laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies that file reports with the SEC, including us, are subject to the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;). Section&#160;404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form&#160;10-K filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We incur significant costs as a result of operating as a public company, which may adversely affect our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, we incur significant accounting, legal and other expenses, including costs associated with our public company reporting requirements. We also anticipate that we will continue to incur costs associated with corporate governance requirements, including requirements and rules&#160;under SOX and the Dodd-Frank Wall Street Reform and Consumer Protection Act (&quot;Dodd-Frank&quot;) among other rules&#160;and regulations implemented by the SEC, as well as listing requirements of Nasdaq. Furthermore, these laws and regulations could make it difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board Committees or as executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of SOX and Dodd-Frank and rules&#160;adopted by the SEC and Nasdaq, will likely result in increased costs to us as we respond to their requirements. We continue to invest resources to comply with evolving laws and regulations, and this investment may result in increased general and administrative expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carry-forwards and other tax attributes will be substantially limited by Section&#160;382 of the U.S. Internal Revenue Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the federal income tax law, federal net operating losses incurred in 2020 and in future&#160;years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the federal tax law. In addition, Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;ownership change&#8221; to utilize its net operating loss carry-forwards (&#8220;NOLs&#8221;) and certain other tax attributes against any taxable income in taxable periods after the ownership change. The amount of taxable income in each taxable&#160;year after the ownership change that may be offset by pre-change NOLs and certain other pre-change tax attributes is generally equal to the product of (a)&#160;the fair market value of the corporation&#8217;s outstanding shares (or, in the case of a foreign corporation, the fair market value of items treated as connected with the conduct of a trade or business in the United States) immediately prior to the ownership change and (b)&#160;the long-term tax exempt rate (i.e., a rate of interest established by the U.S. Internal Revenue Service that fluctuates from&#160;month to&#160;month). In general, an &#8220;ownership change&#8221; occurs whenever the&#160;percentage of the shares of a corporation owned, directly or indirectly, by &#8220;5-percent shareholders&#8221; (within the meaning of Section&#160;382 of the Internal Revenue Code) increases by more than 50&#160;percentage points over the lowest&#160;percentage of the shares of such corporation owned, directly or indirectly, by such &#8220;5-percent shareholders&#8221; at any time over the preceding three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to an annual limitation), we experienced ownership changes in 2009 and 2012, which substantially limit the future use of our pre-change NOLs and certain other pre-change tax attributes per&#160;year. In February&#160;16, 2017, we completed an equity financing for net proceeds of $24.8 million which triggered an additional ownership change under Section&#160;382 that significantly impacted the availability of our tax attributes against future income. Further, due to the existence of a net unrealized built-in loss at the ownership change date, Section&#160;382 further limits our ability to fully utilize the tax deductions associated with certain of our assets, including depreciation and amortization deductions recognized during the 60-month period following the ownership change ending in 2022. Although these deductions will occur in the post-change period, Section&#160;382 treats the deductions as pre-change losses subject to the annual 382 limitation. As of September 30, 2020, we have excluded the NOLs and research and development credits that will expire as a result of the annual limitations. To the extent that we do not utilize our carry-forwards within the applicable statutory carry-forward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Development and Commercialization of our Current and Future Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to successfully identify and acquire and/or in-license other products, product candidates, programs or companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these licenses or acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire and/or in-license potential milestone and royalty streams or companies. Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in entering into out-license agreements for our product candidates, which may adversely affect our liquidity and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to pursue a strategy to out-license all of our product candidates in order to provide for potential payments, funding and/or royalties on future product sales. The out-license agreements may be structured to share in the proceeds received by a licensee as a result of further development or commercialization of the product candidates. We may not be successful in entering into out-licensing agreements with favorable terms as a result of factors, many of which are outside of our control. These factors include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">research and spending priorities of potential licensing partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">willingness of, and the resources available to, pharmaceutical and biotechnology companies to in-license product candidates to fill their clinical pipelines; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our inability to generate proof-of-concept data and to agree with a potential partner on the value of our product candidates, or on the related terms.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to enter into out-licensing agreements for our product candidates and realize license<span style="font-style:italic;font-weight:bold;">, </span>milestone and/or royalty fees when anticipated, it may adversely affect our liquidity, which in turn may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our licensees&#8217; therapeutic product candidates do not receive regulatory approval, our licensees will be unable to market them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our licensees&#8217; product candidates cannot be manufactured and marketed in the United States or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">clinical development and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">record keeping;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">promotion and marketing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">importing and exporting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">controls of the product before administration to the patients participating in the clinical trials. This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a New Drug Application (&#8220;NDA&#8221;) for a drug, and in the form of a Biologic License Application (&#8220;BLA&#8221;) for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several&#160;years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our licensees ultimately may not be able to obtain approval in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or cause them to repeat or perform additional preclinical, clinical or manufacturing-related studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees&#8217; submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our licensees&#8217; interpretation or understanding of the FDA&#8217;s or other regulatory agencies&#8217; requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our licensees and potential milestone and royalty providers face uncertain results of clinical trials of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development has inherent risk, and our licensees and potential milestone and royalty providers are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible we or our licensees may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our licensees&#8217; product candidates require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of&#160;years. As clinical results frequently are susceptible to varying interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our licensees&#8217; future filings will be delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our licensees&#8217; preclinical studies will be successful;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our licensees will be successful in generating viable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our licensees will be able to provide necessary data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">results of future clinical trials by our licensees will justify further development; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">our licensees ultimately will achieve regulatory approval for our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing of the commencement, continuation and completion of clinical trials by our licensees may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, inability to engage contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we license our product candidates to others to fund and conduct clinical trials, we have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our licensees may conduct clinical trials in foreign countries, which may subject them to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose us and our licensees to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New products and technologies of other companies may render some or all of our licensees&#8217; product candidates noncompetitive or obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New developments by others may render our licensees&#8217; product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing continuously and substantially. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. Many of these competitors may be able to develop products and processes competitive with or superior to our and our licensees for many reasons, including that they may have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">significantly greater financial resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">larger research and development staffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">extensive experience in preclinical testing and human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">These factors may enable others to develop products and processes competitive with or superior to our own or those of our licensees. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our licensees may not be able to track development of competitive products, particularly at the early stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our licensed product will fail, our licensees may halt development of our licensed product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our licensees may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products, which would prevent our licensees&#8217; products from becoming profitable and negatively affect the royalties we may receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our third-party licensees succeed in bringing our product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow our licensees to sell the products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Significant uncertainty exists as to the coverage and reimbursement status of any products for which our licensees may obtain regulatory approval. Even if coverage is available, the associated reimbursement rate may not be adequate for us and our licensees to cover related costs. Additionally, coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. Therefore, the process of obtaining coverage and reimbursement is often time-consuming and costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our or our licensees&#8217; businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, our licensees may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over our product). Consequently, we do not know if physicians or patients will adopt or use our products for their approved indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are exposed to an increased risk of product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability. In the past, we were party to product liability claims filed against Genentech&#160;Inc. and, even though Genentech agreed to indemnify us in connection with these matters and these matters have been settled, there can be no assurance other product liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities. In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage. A significant product liability claim for which we were not covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse effect on our business and the value of our common stock. To the extent we have sufficient insurance coverage, such a claim would presumably result in higher subsequent insurance rates. In addition, product liability claims can have various other ramifications, including loss of future sales opportunities, increased costs associated with replacing products, a negative impact on our goodwill and reputation, and divert our management&#8217;s attention from our business, each of which could also adversely affect our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we and our partners are unable to protect our intellectual property, in particular our patent protection for our principal products, product candidates and processes, and prevent the use of the covered subject matter by third parties, our licensees&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates. However, these means may afford only limited protection and may not:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">prevent our competitors from duplicating our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">prevent our competitors from gaining access to our proprietary information and technology; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">permit us to gain or maintain a competitive advantage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the length of time and the expense associated with bringing new products to the marketplace, we and our partners hold and are in the process of applying for a number of patents in the United States and abroad to protect our product candidates and important processes and also have obtained or have the right to obtain exclusive licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Federal Courts, the U.S. Patent&#160;&amp; Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us or our licensees may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our intellectual property rights are not protected adequately, our licensees may not be able to commercialize our technologies or products, and our competitors could commercialize our technologies or products, which could result in a decrease in our licensees&#8217; sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate or available in the future. Accordingly, there is uncertainty as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">whether any pending or future patent applications held by us or our partners will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">whether competitors will be able to design around our or our partners&#8217; patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">the extent to which our or our partners&#8217; product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, and prevent our licensees from using our technology or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our licensees may require licenses from others to develop and commercialize certain potential products incorporating our technology or we may become involved in litigation to determine the proprietary rights of others. These licenses, if required, may not be available on acceptable terms, and any such litigation will presumably be costly and may have other adverse effects on our business, such as inhibiting our licensees&#8217; ability to compete in the marketplace and absorbing significant management time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our licensees&#8217; ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be required to engage in litigation or other proceedings to protect our intellectual property and/or enforce our contractual rights against former or current licensees or third parties, including third-party collaborators of such licensees. The cost to us of this litigation, even if resolved in our favor, could be substantial and parties to such litigation may be able to sustain the cost of such litigation and proceedings more effectively than we can if they have substantially greater resources than us. Such litigation and any negotiations leading up to it also could divert management&#8217;s attention and resources. If this litigation is resolved against us, we may lose the value associated with contract rights contained in our arrangements with licensees and third parties, our patents may be declared invalid, and we could be held liable for significant damages. While it is our current plan to pursue, on a selective basis, potential material contractual breaches against licensees and third-parties (including third-party collaborators of licensees) and/or infringement of our intellectual property rights or technology, there can be no assurance that any such enforcement actions will be successful, or if successful, the timing of such success or that we will have sufficient capital to prosecute any such actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be subject to claims that we, or our licensees, are infringing other parties&#8217; patents. If such claims are resolved against us, we or our licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party. Such license may not be available on reasonable terms or at all, thus preventing us, or our licensees, from using these products, processes or services and adversely affecting our potential future revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Uncertainties resulting from our participation in intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. There could also be public announcements of the results of hearings, motions or interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the perceived value of the drug product candidates as to which we hold future potential milestone or royalty interests, or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could have a material adverse effect of our business, financial condition and results of operation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employees, Location, Data Integrity, and Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The loss or COVID-19 related absence of any of our personnel, including our Chief Executive Officer or Chief Financial Officer, could delay or prevent achieving our objectives.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business efforts could be adversely affected by the loss or COVID-19 related absence of one or more key members of our staff, including our executive officers: James R. Neal, our Chief Executive Officer and Thomas Burns, our Senior Vice President, Finance and Chief Financial Officer. We currently do not have key person insurance on any of our employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we are a small biopharmaceutical focused company with limited resources, we may not be able to attract and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had 11 employees as of November 2, 2020. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. There is intense competition for the services of these personnel, especially in California. Moreover, we expect that the high cost of living in the San Francisco Bay Area, where our headquarters is located, may impair our ability to attract and retain employees in the future. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer, and we may be unable to implement our current initiatives or grow effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">Due to our small number of employees, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain of our functions as a public company. We may have limited control over these third parties, and we cannot guarantee that they will perform their obligations in an effective and timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Calamities, power shortages or power interruptions at our Emeryville headquarters could disrupt our business and adversely affect our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters is located in Emeryville, California. This location is in an area of seismic activity near active earthquake faults. Any earthquake, tsunami, terrorist attack, fire, power shortage or other calamity affecting our facilities may disrupt our business and could have material adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of system failures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and any future licensees, suppliers, contractors and consultants are vulnerable to damage from cyberattacks, computer viruses, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We could experience failures in our information systems and computer servers, which could be the result of a cyberattacks and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs and other business operations. The loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Similarly, we rely on third parties to manufacture our product candidates, and conduct clinical trials of our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of any of our product candidates could be delayed or otherwise adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Data breaches and cyberattacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we maintain sensitive data on our networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our customers and business partners. The secure maintenance of this information is critical to our business and reputation. We believe companies have been increasingly subject to a wide variety of security incidents, cyberattacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, all ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyberattacks have become more prevalent and much harder to detect and defend against. Our network and storage applications may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others which could expose us to liability under federal or state privacy laws. Cyberattacks can result in the theft of proprietary information which could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. and international authorities have been warning businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. Moreover, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures that are intended to protect our data security and information technology systems, such measures may not prevent such events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant disruptions of information technology systems, including cloud-based systems, or breaches of data security could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. Our computer systems, and those of our partners and contractors, are potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, our data security and information technology systems, as well as those of our partners and contractors, are potentially vulnerable to data security breaches, whether by employees or others, that may expose sensitive data or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">personal information to unauthorized persons. Effective May&#160;25, 2018, the European Union (&#8220;EU&#8221;) implemented the General Data Protection Regulation (&#8220;GDPR&#8221;) a broad data protection framework that expands the scope of current EU data protection law to non-European Union entities that process, or control the processing of, the personal information of EU subjects, including clinical trial data. The GDPR allows for the imposition of fines and/or corrective action on entities that improperly use or disclose the personal information of EU subjects, including through a data security breach. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also, in June&#160;2018, the State of California enacted the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which became effective in January 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and private rights of action. The CCPA requires covered companies to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. It remains unclear how the CCPA will be interpreted, but as currently written, it will likely impact our business activities and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data. As we expand our operations, the CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States. Other states are beginning to pass similar laws. Accordingly, data security breaches experienced by us, our partners or contractors could lead to significant fines, required corrective action, the loss of trade secrets or other intellectual property, public disclosure of sensitive clinical or commercial data, and the exposure of personally identifiable information (including sensitive personal information) of our employees, partners, and others. A data security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">harm to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">fines imposed on us by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">additional compliance obligations under federal, state or foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">requirements for mandatory corrective action to be taken by us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to prevent such data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. We expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, such as the CCPA, which has been characterized as the first &#8220;GDPR-like&#8221; privacy statute enacted in the United States because it mirrors a number of the key provisions in the GDPR. We cannot presently determine the impact such laws, regulations and standards will have on our business. In any event, it is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare or privacy laws, including the GDPR, in light of the lack of applicable precedent and regulations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shareholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities-related class action and shareholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is uncertain. We could be forced to expend significant resources in the defense of these suits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn, or it may be removed voluntarily from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our licensees receive regulatory approval for our product candidates, our licensees will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the EMA, or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials or obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for our products are subject to extensive regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such product may be withdrawn voluntarily by our partners based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The United States and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our licensees&#8217; ability to sell our products and any products as to which we own milestone and royalty interests, if approved, profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">initiatives. For example, in March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, which substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the United States pharmaceutical industry. There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently eliminates, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. In addition, the ACA has also been subject to judicial challenge. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well.<span style="color:#ff0000;"> </span>On March 2, 2020, the Supreme Court of the United States granted the petitions for writ of certiorari to review this case. Pending review, the ACA remains in effect, but is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our and our licensees&#8217; businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An expansion in the government&#8217;s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers, and reduced product utilization, any of which could adversely affect our business and results of operations. Moreover, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. We cannot know what form any such new legislation may take or the market&#8217;s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our licensees from being able to generate revenue, attain profitability, develop, or commercialize our current product candidates and those for which we may receive regulatory approval in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We and our licensees are subject to various state and federal healthcare-related laws and regulations that may impact the commercialization of our product candidates or third-party product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing or arranging for the purchase, lease, or order of a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The ACA modified the federal Anti-Kickback Statute&#8217;s intent requirement so that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it to have committed a violation. In addition, several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, persons and entities from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Certain suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individual, commonly known as a &#8220;whistleblower,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend and/or settle a False Claims Act action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including a private payor, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information by entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only federal healthcare programs, such as the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government. Additionally, certain state and local laws require the registration of pharmaceutical sales representatives, restrict payments that may be made to healthcare providers and other potential referral sources, and require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers. Further, some states have laws governing the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA and differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws, and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our or our licensees&#8217; business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our licensees are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we or our licensees may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, reputational harm, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our or our licensees&#8217; operations, any of which could have a material adverse effect on our business and results of operations. In addition, we and our licensees may be subject to certain analogous foreign laws and violations of such laws could result in significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As we or our licensees do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We or our licensees may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities will be a significant part of future business activities and when and if we or our licensees are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States. Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">competitive disadvantage or make it uneconomical to proceed with a product or product candidate&#8217;s development. International sales may be limited or disrupted by many factors, including without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">imposition of government controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">export license requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">political or economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">trade restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">changes in tariffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">restrictions on repatriating profits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">exchange rate fluctuations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">withholding and other taxation.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><a id="_63ba4be8_0ab9_4c7c_88e7_79ea80bd2f77"></a><a id="ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_93d9ba46_d226_4365_a0e0_00f8d83fa94b"></a><a id="ITEM3DEFAULTSUPONSENIORSECURITIES_154961"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;DEFAULTS UPON SENIOR SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_3d8ad9f8_bfd6_4f01_955d_de0c8edfe5de"></a><a id="ITEM4MINESAFETYDISCLOSURES_257142"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.<b style="font-size:12pt;font-weight:bold;">&#160;</b>MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_10ea2760_812f_4d89_83f2_e4b86af82104"></a><a id="ITEM5OTHERINFORMATION_588036"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5.&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e731603a_3bdf_4ac9_8a8a_812509c6c844"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ITEM6EXHIBITS_976152"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;6.&#160;EXHIBITS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></th><th colspan="6" style="font-weight:normal;text-align:left;vertical-align:bottom;width:31.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">SEC File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.2%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.19%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Filing Date</b></p></th></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:0.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:0.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:9.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:0.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">01/03/2012</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.2</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">05/31/2012</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:17.55pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.3</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">05/28/2014</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.4</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10/18/2016</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.5</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;X Convertible Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">02/16/2017</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.6</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000119312518348826/d677241dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;Y Convertible Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">12/13/2018</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.7</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">By-laws of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">3.2</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">01/03/2012</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.1</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.2</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Specimen of Common Stock Certificate</span></a> </p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">8-K</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.1</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">01/03/2012</p></td></tr><tr style="height:8.65pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:8.65pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.3</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459016017643/xoma-ex49_237.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form&#160;of Warrant (February&#160;2016 Warrant)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10-Q</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.9</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">05/04/2016</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.4</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018019989/xoma-ex46_73.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form&#160;of Warrant (May&#160;2018 Warrant)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10-Q</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.6</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">08/07/2018</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.5</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019016040/xoma-ex47_58.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form&#160;of Warrant (March&#160;2019 Warrant)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10-Q</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">000-14710</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">4.7</p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">05/06/2019</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+#</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 (this exhibit was previously filed under confidential treatment request as Exhibit 10.2 to Form 10-Q filed November 6, 2015)</span></a><span style="font-family:'Arial','Helvetica','sans-serif';"> </span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">10.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+#</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="tmb-20200930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Amended and Restated Research, Development and Commercialization Agreement, between the Company and Novartis Vaccine and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Diagnostics, Inc., dated September 30, 2015 (this exhibit was previously filed under confidential treatment request as Exhibit 10.4 to Form 10-Q filed November 6, 2015)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">31.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="tmb-20200930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer, as required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.43%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr style="height:1pt;"><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></th><th colspan="6" style="font-weight:normal;text-align:left;vertical-align:bottom;width:31.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:52.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">SEC File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.06%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:4.2%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.19%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Filing Date</b></p></th></tr><tr style="height:19.8pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">31.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="tmb-20200930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer, as required by Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)</span></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:6.3pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:38.5pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">32.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;" href="tmb-20200930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule&#160;13a-14(b)&#160;or Rule&#160;15d-14(b)&#160;and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:justify;top:0pt;vertical-align:top;">(1)</sup></a></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:9pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.INS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">XBRL Instance Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.SCH<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.CAL<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.DEF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.LAB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">XBRL Taxonomy Extension Labels Linkbase Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;margin:0pt 0pt 4pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">101.PRE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:9.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;">104</p></td><td style="vertical-align:top;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:52.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 4pt 0pt;"><span style="background-color:#ffffff;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Portions of this exhibit (indicated by asterisks) have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted information would likely cause competitive harm to the Registrant if publicly disclosed.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">This certification accompanies the Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8cd8a275_ae08_4ac2_9117_02f0352fc9fa"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_103825"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA Corporation</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;November 5, 2020</p></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ JAMES R. NEAL</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">James R. Neal</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer) and Director</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 5, 2020</p></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ THOMAS BURNS</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas Burns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal financial and principal accounting officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tmb-20200930xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 11/5/2020 12:41:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Execution Version</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#212121;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#212121;font-weight:bold;">CERTAIN&#160;</b><b style="color:#252525;font-weight:bold;">CONFIDENTIAL</b><b style="color:#212121;font-weight:bold;">&#160;</b><b style="color:#252525;font-weight:bold;">PORTIONS</b><b style="color:#212121;font-weight:bold;">&#160;OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;[***]&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I)&#160;NOT MATERIAL AND (II)&#160;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">by and between</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">XOMA (US) LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 48pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><b style="font-weight:bold;text-transform:uppercase;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 0pt 2.9pt 0pt;"><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">DEFINITIONS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">1</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">1.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Additional Definitions</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">9</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">DEVELOPMENT AND COMMERCIALIZATION</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">11</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">2.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Development and Commercialization</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">11</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">2.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Regulatory; Manufacturing</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">11</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">2.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Reporting</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">2.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Subcontracting</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">2.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Transfer of Materials, Process and Know-How</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">12</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">LICENSE GRANTS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">13</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">3.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">License Grants; [*]</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">13</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">3.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Rights Retained by the Parties</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">13</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">3.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Rights in Bankruptcy</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">3.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">FINANCIAL TERMS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Upfront Fee</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">14</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Development and Regulatory Milestone Payments</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">15</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product Royalties</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">16</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Reports; Royalty Payments</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">18</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sales Milestone Payment</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">18</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Methods of Payments</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">19</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.7</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Accounting</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">19</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.8</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Currency</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.9</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Late Payments</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.10</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Taxes</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">20</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.11</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">No Guarantee</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.12</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Costs</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">4.13</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:0pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">i</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><b style="font-weight:bold;text-transform:uppercase;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 0pt 2.9pt 0pt;"><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Ownership</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">21</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Prosecution and Maintenance of Patents</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">22</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Patent Costs</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">23</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Defense of Claims Brought by Third Parties</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">23</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Enforcement</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">23</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Recovery</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">24</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.7</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Patent Term Extensions</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">24</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">5.8</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Trademarks</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">25</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">CONFIDENTIALITY</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">25</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Confidentiality; Exceptions</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">25</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Authorized Disclosure</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">26</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Disclosure of Agreement</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">27</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Remedies</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">27</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Publications</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">6.6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Clinical Trial Register</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 7</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">REPRESENTATIONS; WARRANTIES; COVENANTS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Representations and Warranties of Both Parties</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">28</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Representations and Warranties of XOMA</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">29</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Representations and Warranties of Novartis</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Covenants of XOMA</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Covenants of Novartis</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">7.6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Disclaimer</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 8</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">INDEMNIFICATION</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">8.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indemnification by Novartis</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">31</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">8.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indemnification by XOMA</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">32</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">8.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Procedure</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">32</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">8.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SPECIAL, INDIRECT AND OTHER LOSSES</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">33</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">8.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">No Exclusion</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">ii</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><b style="font-weight:bold;text-transform:uppercase;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.9pt 0pt 2.9pt 0pt;"><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 9</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">TERM AND TERMINATION</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">9.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Term; Expiration</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">9.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Termination for Cause</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">9.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Termination by Novartis</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">9.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Effects of Expiration or Termination</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">34</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">9.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Effects of Termination for Novartis Termination due to XOMA Breach</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">37</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 10</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">ACCRUED RIGHTS; SURVIVING PROVISIONS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">37</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ARTICLE 11</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:12pt;">MISCELLANEOUS</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">38</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.1</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Dispute Resolution</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">38</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.2</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Governing Law</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">38</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.3</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Assignment</font></p></td><td style="vertical-align:top;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">38</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.4</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Force Majeure</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">39</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.5</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Notices</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">39</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.6</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Export Clause</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">40</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.7</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Waiver</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">40</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.8</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Severability</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">40</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.9</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Certain Amendments</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">41</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.10</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Entire Agreement</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">41</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.11</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Independent Contractors</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">41</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.12</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Headings; Construction; Interpretation</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">41</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.13</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Further Actions</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">42</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.14</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Parties in Interest; No Third Party Beneficiary Rights</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">42</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.15</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Performance by Affiliates</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">42</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.16</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Extension to Affiliates</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">42</font></p></td></tr><tr><td style="vertical-align:bottom;width:13.34%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">11.17</font></p></td><td style="vertical-align:bottom;width:80.48%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Counterparts</font></p></td><td style="vertical-align:bottom;width:6.17%;margin:0pt;padding:1.45pt 0pt 2.9pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;">42</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">iii</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;text-transform:uppercase;">Table of Contents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">List of Exhibits and Schedules</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A-1</b><font style="font-size:12pt;"> &#8211; [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A-2</b><font style="font-size:12pt;"> &#8211; XOMA Core Patents</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT B</b><font style="font-size:12pt;"> &#8211; Form of Novartis Invoice</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT C</b><font style="font-size:12pt;"> &#8211; Inventory</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT D</b><font style="font-size:12pt;"> &#8211; XOMA Third Party Agreements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT E</b><font style="font-size:12pt;"> &#8211; [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:76.5pt;text-indent:-76.5pt;margin:0pt 0pt 12pt 36pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT F</b><font style="font-size:12pt;"> &#8211; Form of Amendment to the Note</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:76.5pt;text-indent:-76.5pt;margin:0pt 0pt 12pt 36pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT G</b><font style="font-size:12pt;"> &#8211; Form of Amendment to the Security Agreement</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:76.5pt;text-indent:-76.5pt;margin:0pt 0pt 12pt 36pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT H </b><font style="font-size:12pt;">&#8211; Form of Amendment to the Amended and Restated Research, Development and Commercialization Agreement</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SCHEDULE 1 &#8211; </b><font style="font-size:12pt;">Exceptions to Representations and Warranties</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Execution Version</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#212121;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">LICENSE AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This LICENSE AGREEMENT (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:12pt;">&#8221;) is entered into and made effective as of the 30th day of September, 2015 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effective Date</u><font style="font-size:12pt;">&#8221;) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh Street, Berkeley, California (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA</u><font style="font-size:12pt;">&#8221;), and Novartis International Pharmaceutical Ltd., a company organized under the laws of Bermuda having offices at 131 Front Street, Hamilton, HM 12, Bermuda (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis</u><font style="font-size:12pt;">&#8221;). &#160;XOMA and Novartis are each referred to herein by name or as a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Party</u><font style="font-size:12pt;">&#8221; or, collectively, as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Parties</u><font style="font-size:12pt;">.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">RECITALS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, XOMA possesses proprietary technology and intellectual property, development and supply rights with respect to various Licensed Antibodies and Products (as defined below); and XOMA has been pursuing the research and development of various Licensed Antibodies and Products;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, Novartis possesses expertise in the manufacture, development and commercialization of human therapeutic products; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">WHEREAS, the Parties desire that XOMA grant Novartis exclusive rights and that Novartis be solely responsible for the further Development and Commercialization of Licensed Antibodies and Products in the Field in the Territory (each, as defined below), in exchange for certain milestones and royalties to be paid to XOMA, all on the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">As used in this Agreement, the following terms will have the meanings set forth in this Article 1 unless context dictates otherwise:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accounting Standards</u><font style="font-size:12pt;">&#8221; means, with respect to XOMA, U.S. GAAP, and means, with respect to Novartis, IFRS, in each case, as generally and consistently applied throughout the Party&#8217;s organization. Each Party shall promptly notify the other in the event that it changes the Accounting Standards pursuant to which its records are maintained, provided, however, that each Party may only use internationally recognized accounting principles (e.g. IFRS, U.S. GAAP, etc).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Acquiror IP</u><font style="font-size:12pt;">&#8221; means, in connection with a Change of Control of XOMA, any Patents and/or Know-How owned or controlled by a Third-Party acquiror of XOMA immediately prior to the date of the Change of Control or thereafter other than the XOMA IP existing immediately prior to such date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Affiliate</u><font style="font-size:12pt;">&#8221; means any Person that directly or indirectly controls or is controlled by or is under common control with a Party. &#160;For the purpose of this definition, &#8220;control,&#8221; &#8220;controls&#8221; or &#8220;controlled&#8221; means ownership (directly or through one or more Affiliates) of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors (in the case of a corporation) or fifty percent (50%) or more of the equity interests (in the case of any other type of legal entity), status as a general partner in any partnership, any other arrangement whereby a Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity or the ability to cause the direction of the management or policies of a corporation or other entity. &#160;The Parties acknowledge that in the case of certain entities organized under the Laws of certain countries, the maximum percentage ownership permitted by Law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that such foreign investor has the power to direct the management and policies of such entity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">AIA Proceedings</u><font style="font-size:12pt;">&#8221; means post-issuance patent challenges and other proceedings under the U.S. Leahy-Smith America Invents Act (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">AIA</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Antibody</u><font style="font-size:12pt;">&#8221; means a polypeptide that (a) is an antibody or is a part of an antibody, modified or unmodified, having at least one complementarity determining region (CDR) and which retains the ability to specifically bind antigen and can include an antigen-binding heavy chain, light chain, heavy chain-light chain dimer, Fab fragment, F(ab&#39;)2 fragment, dAb, or an Fv fragment, including a single chain Fv (scFv), and (b) binds to the Target with an in vitro affinity [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Biosimilar</u><font style="font-size:12pt;">&#8221; means any product for which Regulatory Approval is sought under (a) the U.S. Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) referencing a Product, or (b) any certification under a similar statutory or regulatory requirement in any non-United States country in the Territory, in each case where the applicant for such Regulatory Approval claims that a XOMA Patent Covering any Product is invalid or that infringement will not arise from the development, manufacture or commercialization of such product by a Third Party. A product shall not be considered to be a Biosimilar if (i) Novartis or any of its Affiliates or sublicensees was involved in the Development of such product, or (ii) such product is commercialized by any sublicensee of Novartis or any of its Affiliates or by any Person who obtained such product in a chain of distribution that included Novartis or any of its Affiliates or sublicensees).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">BLA</u><font style="font-size:12pt;">&#8221; means a Biologics License Application filed with the FDA in the United States with respect to a Product, as defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et. seq., or a comparable filing for Regulatory Approval in a jurisdiction other than the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Business Day</u><font style="font-size:12pt;">&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks are authorized or required to be closed, as the case may be, at the location where the respective activity is to be performed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Calendar Quarter</u><font style="font-size:12pt;">&#8221; means a period of three (3) consecutive months ending on the last day of March, June, September, or December, respectively.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">2</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Calendar Year</u><font style="font-size:12pt;">&#8221; means a period of twelve (12) consecutive months beginning on January 1 and ending on December 31.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">cGCP</u><font style="font-size:12pt;">&#8221; means current Good Clinical Practices as defined in U.S. Regulations 21 CFR &#167; 50, 54, 56, 312 and 314, and applicable ICH standards as each may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">cGLP</u><font style="font-size:12pt;">&#8221; means current Good Laboratory Practices as defined in U.S. Regulations 21 CFR &#167; 58 and applicable FDA then-current laboratory review and inspection requirements, as each may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">cGMP</u><font style="font-size:12pt;">&#8221; means current Good Manufacturing Practices pursuant to U.S. Regulations 21 C.F.R. &#167;211, et seq., and applicable ICH standards as each may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change of Control</u><font style="font-size:12pt;">&#8221; means, with respect to a Party: (a) completion of a merger, reorganization, amalgamation, arrangement, share exchange, consolidation, tender or exchange offer, private purchase, business combination, recapitalization or other transaction involving a Party as a result of which the stockholders of such Party immediately preceding such transaction hold less than fifty percent (50%) of the outstanding shares, or less than fifty percent (50%) of the outstanding voting power, respectively, of the ultimate company or entity resulting from such transaction immediately after consummation thereof (including a company or entity which as a result of such transaction owns the then-outstanding securities of a Party or all or substantially all of a Party&#39;s assets, either directly or through one or more subsidiaries); (b) the adoption of a plan relating to the liquidation or dissolution of a Party, other than in connection with a corporate reorganization (without limitation of clause (a), above); (c) the sale or disposition to a Third Party of all or substantially all the assets of a Party (determined on a consolidated basis); or (d) the sale or disposition to a Third Party of assets or businesses that constitute fifty percent (50%) or more of the total revenue or assets of a Party (determined on a consolidated basis). &#160;The entity(ies) gaining control of such Party pursuant to a transaction described in the preceding sentence are referred to herein as the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Acquiror</u><font style="font-size:12pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Combination Product</u><font style="font-size:12pt;">&#8221; means any pharmaceutical product (in any formulation) containing one or more active pharmaceutical ingredients in addition to a Licensed Antibody.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Commercialization</u><font style="font-size:12pt;">&#8221; and &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Commercialize</u><font style="font-size:12pt;">&#8221; means all activities undertaken relating to the marketing, promotion (including advertising, detailing, sponsored product or continuing medical education), use, offering for sale, importing for sale, exporting for sale, distribution and sale of a Product and the commercial manufacturing of a Product, as well as, in each case, maintaining Regulatory Approvals necessary or useful to undertake such activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Commercially Reasonable Efforts</u><font style="font-size:12pt;">&#8221; means the expenditure of those efforts and resources used consistent with the usual practice of Novartis in reasonably and diligently pursuing Development or Commercialization of other similar pharmaceutical products proprietary to Novartis with similar market and economic potential and at a similar stage in Development or product life, taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval given the regulatory structure involved, [*], and all other</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">3</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Commercially Relevant Factors. &#160;It is anticipated that the level of effort may change over time, reflecting changes in the status of a Licensed Antibody or Product, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Commercially Relevant Factors</u><font style="font-size:12pt;">&#8221; means, with respect to a Licensed Antibody or Product, all relevant factors that may affect the Development, Regulatory Approval or Commercialization of such Licensed Antibody or Product, including (as applicable): safety, efficacy, quality or stability; product profile (including product modality, category and mechanism of action); stage of Development or life cycle status; Development, Regulatory Approval, manufacturing, and Commercialization costs and risk; feasibility and cost of manufacture; the likelihood of obtaining Regulatory Approvals (including satisfactory price approvals) and the timing of such approvals; the current guidance and requirements for Regulatory Approval and the current and projected regulatory status, including expectations for post-approval commitments; labeling or anticipated labeling; the then-current competitive environment and the likely competitive environment at the time of projected entry into the market; past performance; present and future market potential; existing or projected pricing, sales, reimbursement and profitability; pricing or reimbursement changes in relevant countries; proprietary position, strength and duration of patent protection and anticipated exclusivity; and such Party&#8217;s [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;"> </font><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Control</u><font style="font-size:12pt;">&#8221;, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Controls</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Controlled</u><font style="font-size:12pt;">&#8221; means, with respect to any Know-How, Patents, proprietary information or trade secrets, or other intellectual property rights (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Rights</u><font style="font-size:12pt;">&#8221;), the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or a sublicense of or under such Rights to the other Party, or to otherwise disclose such proprietary information or trade secrets to the other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary information or trade secrets of a Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cover</u><font style="font-size:12pt;">&#8221;, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Covering</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Covered</u><font style="font-size:12pt;">&#8221; means, with respect to a product, composition, technology, process or method, that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or composition, or the practice of such technology, process or method, would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue as then being prosecuted in good faith).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Deliver</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Delivery</u><font style="font-size:12pt;">&#8221; means the dispatch of the Inventory by XOMA pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Develop</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Development</u><font style="font-size:12pt;">&#8221; means all research, discovery, pre-clinical development, clinical development, and regulatory activities with respect to Licensed Antibodies and Products, including optimization, non-clinical testing, pharmacology studies, toxicology studies, formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like), manufacturing process development and scale-up (including with respect to active pharmaceutical ingredient and drug product production), quality assurance and quality control, technical support, pharmacokinetic studies, clinical studies, regulatory affairs activities, and manufacturing, use and importation in support of such activities, in each case to the extent required</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">4</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">or useful to obtain any Regulatory Approvals from the FDA or any other applicable Regulatory Authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Dollars</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">$</u><font style="font-size:12pt;">&#8221; means the legal tender of the U.S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">EMA</u><font style="font-size:12pt;">&#8221; means the European Medicines Agency, and any successor entity thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Executive Officers</u><font style="font-size:12pt;">&#8221; means XOMA&#8217;s Chief Executive Officer (or his designee) and the President of Novartis Institutes for Biomedical Research, Inc. (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">NIBR</u><font style="font-size:12pt;">&#8221;), an Affiliate of Novartis, (or his designee).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">FDA</u><font style="font-size:12pt;">&#8221; means the U.S. Food and Drug Administration, and any successor entity thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Field</u><font style="font-size:12pt;">&#8221; means [*] indications and uses, including [*] indications and therapeutic uses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">First Commercial Sale</u><font style="font-size:12pt;">&#8221; means, with respect to a Product, the first arm&#8217;s length sale to a Third Party for use or consumption of any such Product in a country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">GAAP</u><font style="font-size:12pt;">&#8221; means United States generally accepted accounting principles consistently applied by the applicable Person.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">ICH</u><font style="font-size:12pt;">&#8221; means the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indication</u><font style="font-size:12pt;">&#8221; means the specific human disease or condition for which a Product has received Regulatory Approval, the approved label claim of which identifies such Indication; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that during the Development of a Licensed Antibody or Product (prior to Regulatory Approval), the Indication(s) for such Licensed Antibody or Product shall be the Indication(s) that are targeted by such Development efforts, as reflected in the applicable development plan and clinical trial protocols.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">IND</u><font style="font-size:12pt;">&#8221; means (a) an Investigational New Drug Application as defined in the U.S. Food, Drug &amp; Cosmetics Act and applicable regulations promulgated thereunder by the FDA; (b) a Clinical Trial Authorization filed with EU member states; or (c) the equivalent application to the equivalent Regulatory Authority in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of an investigational new drug in humans in such jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">IFRS</u><font style="font-size:12pt;">&#8221; means International Financial Reporting Standards, as amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Know-How</u><font style="font-size:12pt;">&#8221; means all technical or proprietary information, know-how and data, including inventions (whether patentable or not), discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to compounds, formulations, compositions, products or to their manufacture, development, registration, use or commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">5</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information, regulatory filings and copies thereof, relevant to the development, manufacture, use or commercialization of and/or which may be useful in studying, testing, development, production or formulation of products, or intermediates for the synthesis thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Law</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Laws</u><font style="font-size:12pt;">&#8221; means all laws, statutes, rules, regulations, orders, judgments, or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Licensed Antibody</u><font style="font-size:12pt;">&#8221; means (a) any Antibody [*], or (b) any Antibody for which Novartis&#8217; Development, manufacture or Commercialization would infringe any XOMA IP but for the license granted to Novartis under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;[*]&#8221; means, with respect to any [*], the following has occurred: &#160;[*] or [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;[*]&#8221; means [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Net Sales</u><font style="font-size:12pt;">&#8221; means the net sales on behalf of Novartis and any of its Affiliates or sublicensees (each, a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Selling Party</u><font style="font-size:12pt;">&#8221;) for any Product sold to Third Parties other than sublicensees in bona fide, arms-length transactions, [*]. &#160;The deductions booked on an accrual basis [*] to calculate the recorded net sales from gross sales include[*]:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;normal trade and cash discounts;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;amounts repaid or credited by reasons of defects, rejections, recalls or returns;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;rebates and chargebacks to customers and Third Parties (including Medicare, Medicaid, Managed Healthcare and similar types of rebates);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any amounts recorded in gross revenue associated with goods provided to customers for free;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;amounts provided or credited to customers through coupons and other discount programs;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;delayed ship order credits, discounts or payments related to the impact of price increases between purchase and shipping dates;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*]; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the case of any sale or other disposal of a Product between or among Novartis and its Affiliates or sublicensees, for resale, Net Sales shall be calculated only on the value charged or invoiced on the first arm&#8217;s-length sale thereafter to a Third Party. &#160;In the case of any sale which is not invoiced or is delivered before invoice, Net Sales shall be calculated at the time [*]. &#160;In the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">6</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">case of any sale or other disposal for value, such as barter or counter-trade, of any Product, or part thereof, other than in an arm&#8217;s length transaction exclusively for money, Net Sales shall be calculated on the value of the non-cash consideration received or the fair market price (if higher) of a Product in the country of sale or disposal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In the event a Product is sold as a Combination Product, the Net Sales of a Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in a particular country of a Product containing the Licensed Antibody as the sole active ingredient when sold separately in finished form and B is the weighted average sale price in that country of the product(s) containing the other component(s) as the sole active ingredient(s) when sold separately in finished form. &#160;Regarding prices comprised in the weighted average price when sold separately referred to above, if these are available for different dosages from the dosages of Licensed Antibody and other active ingredient components that are included in the Combination Product, then [*] in calculating the royalty-bearing Net Sales of the Combination Product. In the event that such weighted average sale price cannot be determined for both a Product and the other product(s) in combination, the calculation of Net Sales for purposes of determining royalty payments shall be [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">For the avoidance of doubt, sales between Novartis, its Affiliates, sublicensees and designees shall not be considered Net Sales (unless such Person is the end user of a Product), which shall be calculated on Net Sales of Novartis, its Affiliates, sublicensees and designees to independent Third Party customers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Patent</u><font style="font-size:12pt;">&#8221; means (a) all patents and patent applications in any country or supranational jurisdiction in the Territory, (b) any substitutions, divisionals, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications, and (c) foreign counterparts of any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Person</u><font style="font-size:12pt;">&#8221; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Phase I Clinical Trial</u><font style="font-size:12pt;">&#8221; means a clinical study of an investigational product in human subjects with the primary objective of characterizing its safety, tolerability, and pharmacokinetics for future studies. &#160;The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and shall be deemed commenced when the first patient in such study has received his or her initial dose of a product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Phase II Clinical Trial</u><font style="font-size:12pt;">&#8221; means a clinical study of an investigational product in patients with the primary objective of characterizing efficacy as well as generating more detailed safety, tolerability, and pharmacokinetics information. &#160;The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and shall be deemed commenced when the first patient in such study has received his or her initial dose of a product. &#160;Any clinical study conducted under a protocol which identifies such study as a &#8220;Phase</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">7</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">II&#8221; study (but excluding any study identified as a &#8220;Phase I/II&#8221; study unless such study otherwise satisfies the criteria in the first sentence of this definition) shall be deemed to be a Phase II Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Phase III Clinical Trial</u><font style="font-size:12pt;">&#8221; means a clinical study of an investigational product in patients with the primary objective of confirming with statistical significance the efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. &#160;The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and shall be deemed commenced when the first patient in such study has received his or her initial dose of a product. &#160;Any clinical study conducted under a protocol which identifies such study as a &#8220;Phase III&#8221; or &#8220;pivotal&#8221; study shall be deemed to be a Phase III Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Product</u><font style="font-size:12pt;">&#8221; means any pharmaceutical product containing a Licensed Antibody (alone or with other active ingredients), in all forms, presentations, formulations, methods of administration and dosage forms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Prosecution and Maintenance</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Prosecute and Maintain</u><font style="font-size:12pt;">&#8221; means, with regard to a Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues, appeals, and requests for patent term adjustments and patent term extensions with respect to such Patent, together with the initiation or defense of interferences, the initiation or defense of oppositions and other similar proceedings with respect to the particular Patent, and any appeals therefrom, and any AIA Proceedings. &#160;For clarification, &#8220;Prosecution and Maintenance&#8221; or &#8220;Prosecute and Maintain&#8221; shall not include any other enforcement actions taken with respect to a Patent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Approval</u><font style="font-size:12pt;">&#8221; means, with respect to a Product in any country or jurisdiction, any approval (including where required, pricing and reimbursement approvals), registration, license or authorization from a Regulatory Authority in a country or other jurisdiction that is necessary to market and sell such Product in such country or jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Authority</u><font style="font-size:12pt;">&#8221; means any governmental agency or authority responsible for granting Regulatory Approvals for Products, including the FDA, EMA and any corresponding national or regional regulatory authorities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Materials</u><font style="font-size:12pt;">&#8221; means regulatory applications, notifications, and registrations for Regulatory Approvals or other submissions made to or with a Regulatory Authority, together with all related correspondence to or from such Regulatory Authority, that are necessary or reasonably desirable in order to Develop or Commercialize a Product in a particular country, territory or possession in the Territory. &#160;Regulatory Materials include INDs, and BLAs, and amendments and supplements to any of the foregoing, and applications for pricing approvals.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Target</u><font style="font-size:12pt;">&#8221; means transforming growth factor beta 1 (TGF&#946;1), [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Territory</u><font style="font-size:12pt;">&#8221; means all countries of the world.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">8</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Third Party</u><font style="font-size:12pt;">&#8221; means any Person other than XOMA or Novartis that is not an Affiliate of XOMA or of Novartis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">United States</u><font style="font-size:12pt;">&#8221; or &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">U.S.</u><font style="font-size:12pt;">&#8221; means the United States of America and all of its territories and possessions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;[*]&#8221; means (a) [*], and (b) [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;[*]&#8221; means the [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Valid Claim</u><font style="font-size:12pt;">&#8221; means a claim of (a) an issued Patent or (b) pending application for a Patent, in each case, that has not expired, lapsed, been cancelled or abandoned, or been dedicated to the public, disclaimed, or held unenforceable, invalid, or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has been or can be taken, including through opposition, reexamination, reissue or disclaimer. &#160;An unissued claim in a pending Patent application shall only be deemed a Valid Claim to the extent such claim has not been pending for more than [*], provided that if such a claim ceases to be a Valid Claim by reason of the foregoing, then such claim shall again be deemed a Valid Claim in the event such claim subsequently issues within such Patent application.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Background Patents</u><font style="font-size:12pt;">&#8221; means any Patents, other than the XOMA Core Patents and any Patents that are part of any Acquiror IP, that are Controlled by XOMA or its Affiliates [*]. [*] included in the XOMA Background Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Core Patents</u><font style="font-size:12pt;">&#8221; means the Patents listed in </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT A-2</b><font style="font-size:12pt;"> and all Patents claiming priority thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA IP</u><font style="font-size:12pt;">&#8221; means XOMA Know-How and XOMA Patents, but excluding all Acquiror IP.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Know-How</u><font style="font-size:12pt;">&#8221; means Know-How that is Controlled by XOMA or its Affiliates [*] for the Development, manufacture or Commercialization of Antibodies, Licensed Antibodies and/or Products, but excluding any Know-How that is part of any Acquiror IP.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Patents</u><font style="font-size:12pt;">&#8221; means the XOMA Core Patents and XOMA Background Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Regulatory Materials</u><font style="font-size:12pt;">&#8221; means all Regulatory Materials and Regulatory Approvals owned or Controlled by XOMA or its Affiliates relating to Licensed Antibodies or Products in the Territory, whether as of the Effective Date or during the Term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Additional Definitions</u><font style="font-size:12pt;">. &#160;Each of the following definitions is set forth in the section of this Agreement indicated below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Definition:</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section</b><font style="font-size:12pt;">:</font></p></th></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Abandonment</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.2.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Act</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.7.1</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">9</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Definition:</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section</b><font style="font-size:12pt;">:</font></p></th></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Agreement</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Auditor</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.7.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bankruptcy Code</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">3.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BPCIA</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.7.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Claims</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Competing Infringing Activities</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.5</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">3.1.3(b)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Confidential Information</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">6.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Development and Regulatory Milestone</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Development and Regulatory Milestone Payment</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Disclosing Party</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">6.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">3.1.3(b)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Effective Date</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Enforcing Party</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.5</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Existing Confidentiality Agreement</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">6.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Future IP</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.1.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indemnified Party</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Indemnifying Party</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.3.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Inventory</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">7.2(l)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Loans</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2.4</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Losses</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">NIBR</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Definition of &#8220;Executive Officers&#8221; in Article 1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Note</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2.4</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Note Holder</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2.4</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Indemnitees</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Patents</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.1.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Products </font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.1.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Product IP</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.4.4(c)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Product-Related IP</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.4.4(d)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">NVDI</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.2.4</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Party or Parties</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Payment Breach</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.2.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Process</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">2.5.2</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product Marks</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.8</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5.2.1(b)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.4.11</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Receiving Party</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">6.1</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.3.2(e)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Royalty Term</font></p></td><td colspan="2" style="vertical-align:top;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.3.2(a)</font></p></td></tr><tr><td style="vertical-align:top;width:61.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Sales &amp; Royalty Report</font></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.4.2</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">10</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Definition:</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Section</b><font style="font-size:12pt;">:</font></p></th></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Selling Party</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Definition of &#8220;Net Sales&#8221; in Article 1</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.4.11</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Term</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9.1</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Trade Control Laws</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11.6</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">XOMA</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Preamble</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">XOMA Indemnitees</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">8.1</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.3.2(d)</font></p></td></tr><tr><td style="vertical-align:top;width:51.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:48.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4.3.2(d)</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">DEVELOPMENT AND COMMERCIALIZATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Development and Commercialization</u><font style="font-size:12pt;">. &#160;Novartis shall, at its own costs and expense, undertake the following itself, or through its Affiliates or sublicensees:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.1.1&#160;&#160;&#160;&#160;Use Commercially Reasonable Efforts to Develop [*], including [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.1.2&#160;&#160;&#160;&#160;Where such Development efforts are successful, use Commercially Reasonable Efforts to seek to obtain Regulatory Approval [*] for such Products in such Indications; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.1.3&#160;&#160;&#160;&#160;If Regulatory Approval is obtained, use Commercially Reasonable Efforts to (a) launch each such Product, and (b) further Commercialize each such Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Subject to compliance with the foregoing in Sections 2.1.1, 2.1.2 and 2.1.3, the Development and Commercialization of Licensed Antibodies and/or Products (as applicable) [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory; Manufacturing</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.2.1&#160;&#160;&#160;&#160;Novartis shall (a) determine the regulatory plans and strategies for the Licensed Antibodies and Products, (b) (either itself or through its Affiliates or sublicensees) make all Regulatory Filings with respect to the Products, and (c) be responsible for obtaining and maintaining Regulatory Approvals throughout the Territory in the name of Novartis or its Affiliates or sublicensees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.2.2&#160;&#160;&#160;&#160;XOMA shall reasonably cooperate with and provide assistance to Novartis in connection with filings to any Regulatory Authority relating to the Licensed Antibodies and Products, including by executing any required documents, providing reasonable access to personnel and providing Novartis with copies of all reasonably required documentation. &#160;[*] associated with such cooperation and assistance to the extent such activities are conducted during the ninety (90) days following the Effective Date [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.2.3&#160;&#160;&#160;&#160;Novartis or its designated sublicensee(s) will be solely responsible for the manufacture and supply of the Licensed Antibodies and Products being Developed or Commercialized under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">11</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Reporting</u><font style="font-size:12pt;">. &#160;Commencing in January 2016 and annually thereafter, Novartis shall provide XOMA with written reports detailing the activities of Novartis, its Affiliates and sublicensees with respect to the Development of (and, if applicable, pre-commercial launch activities for) Products in the Field in the Territory, both as to activities conducted during the prior Calendar Year and planned activities, in sufficient depth to enable XOMA to reasonably assess Novartis&#8217; compliance with Section 2.1. &#160;Novartis shall discuss with XOMA such report in a time and manner as mutually agreed by the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Subcontracting</u><font style="font-size:12pt;">. &#160;Novartis shall have the right to engage Affiliates or Third Party subcontractors to perform certain of its obligations under this Agreement, subject to ensuring such Affiliates&#8217; and subcontractors&#8217; compliance with the Agreement. &#160;Novartis shall remain directly liable for any breach of this Agreement attributable to any act or omission of any Novartis Affiliate, subcontractor or sublicensee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Transfer of Materials, Process and Know-How</u><font style="font-size:12pt;">. &#160;Within ninety (90) days after the Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5.1&#160;&#160;&#160;&#160;XOMA shall, [*], transfer to Novartis the entire Inventory. &#160;[*] such Inventory under this Agreement [*]. &#160;XOMA shall transfer, and shall cause its contractors to transfer, the Inventory in accordance with all applicable Laws. &#160;The Inventory shall be provided &#8220;AS-IS&#8221;, and XOMA expressly disclaims all representations and warranties with respect thereto, excepting only as to title and the right to transfer the Inventory to Novartis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5.2&#160;&#160;&#160;&#160;XOMA shall cooperate reasonably in good faith with Novartis to bring about and complete a smooth and orderly transition of the manufacture of each Licensed Antibody and Product existing as the Effective Date, including the Process for such Licensed Antibody and Product, to Novartis or to one Third Party or Affiliate of Novartis designated by Novartis. &#160;&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Process</u><font style="font-size:12pt;">&#8221; means, with respect to a Licensed Antibody or Product, [*], and [*], and [*], which [*] and [*] for the manufacture of such Licensed Antibody or Product. &#160;In support of the foregoing, upon request of Novartis, XOMA shall provide such technology transfer support services as described below to Novartis or to one Third Party or Affiliate of Novartis, as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During such ninety (90)-day period, XOMA shall use commercially reasonable efforts to ensure that Novartis has access to [*] and [*], including [*] and [*] the Process.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During such ninety (90)-day period, Novartis and the [*] shall [*], [*] and [*] the Process.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party shall [*] in connection with the transfer of the Process, and in the case of [*], for clarity, [*] and [*] or [*]. &#160;Notwithstanding the foregoing, to the extent [*] with respect to [*] such ninety (90)-day period, [*] in connection therewith.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5.3&#160;&#160;&#160;&#160;Without limiting the foregoing in Sections 2.5.1 and 2.5.2, or being limited thereby, XOMA shall use commercially reasonable efforts during such ninety (90) day period, to [*] and [*] or [*], including [*] that include [*] and [*] and [*], and [*] and [*] as described herein. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">12</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">XOMA shall also use commercially reasonable efforts to [*] and [*] and [*] in connection with this Agreement, including in relation to any of the foregoing [*] as contemplated hereunder. &#160;Such activities shall be [*] to the extent performed during such ninety (90)-day period, and [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5.4&#160;&#160;&#160;&#160;Notwithstanding any other provision of this Section 2.5, XOMA [*], or (b) [*] or [*], in each case in connection with [*] or [*]. &#160;XOMA shall use commercially reasonable efforts to [*] and provided that [*]. &#160;Such [*] during such ninety (90)-day period and [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.5.5&#160;&#160;&#160;&#160;All Know-How and documentation to be transferred to Novartis hereunder shall be provided in electronic form.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">LICENSE GRANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">License Grants; [*]</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.1.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">License Grants</u><font style="font-size:12pt;">. &#160;XOMA hereby grants to Novartis and its Affiliates an exclusive (even as to XOMA and its Affiliates) license, under the XOMA IP and XOMA Regulatory Materials to Develop, manufacture and Commercialize the Licensed Antibodies and Products for the Field in the Territory, including to conduct any and all medical affairs activities with respect thereto. &#160;The foregoing license set forth in this Section 3.1.1 shall bear royalties as set forth in Section 4.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.1.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sublicensing</u><font style="font-size:12pt;">. &#160;The license grant in Section 3.1.1 includes the right to grant and authorize sublicenses in multiple tiers, provided that: &#160;(a) Novartis shall require that each sublicensee comply with all applicable provisions of this Agreement; (b) Novartis shall remain directly responsible for each sublicensee&#8217;s performance in connection with this Agreement; and (c) Novartis shall, [*] such sublicensee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.1.3&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">[*]</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*] agrees that, during the Term of the Agreement, [*] or [*] (including [*]) with respect to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If [*] and if [*], then [*] shall [*] or [*] in connection with [*], and [*] will either (i) [*], provided that [*] or [*] in connection with [*] (and [*] shall be maintained and updated from time to time to [*]), or (ii) [*]. &#160;[*] during [*] shall [*] set forth in subsection (a). &#160;[*], as used in this subsection (b), means the [*] without [*] or [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Rights Retained by the Parties</u><font style="font-size:12pt;">. &#160;For purposes of clarity, each Party retains all rights under the Know-How and Patents Controlled by such Party not expressly granted to the other Party pursuant to this Agreement; further, XOMA retains a non-exclusive, limited right under the XOMA IP solely in order to perform its obligations under this Agreement for the benefit of Novartis. &#160;Novartis shall not, and shall not permit any of its Affiliates or sublicensees to, practice or use any of the XOMA Patents or XOMA Know-How outside of the scope of the license granted under Section 3.1.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">13</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Rights in Bankruptcy</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.3.1&#160;&#160;&#160;&#160;The Parties agree that this Agreement constitutes an executory contract under Section 365 of the United States Bankruptcy Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Bankruptcy Code</u><font style="font-size:12pt;">&#8221;) for the license of &#8220;intellectual property&#8221; as defined under Section 101 of the Bankruptcy Code and constitutes a license of &#8220;intellectual property&#8221; for purposes of any similar laws in any other country in the Territory. &#160;The Parties further agree that Novartis, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Bankruptcy Code, including, but not limited to, Section 365 (n) of the Bankruptcy Code, and any similar laws in any other country in the Territory. &#160;The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against XOMA under the Bankruptcy Code and any similar laws in any other country in the Territory, Novartis will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless XOMA elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (i) above, following the rejection of this Agreement by or on behalf of XOMA upon written request therefor by Novartis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.3.2&#160;&#160;&#160;&#160;All rights, powers and remedies of Novartis provided for in this Section 3.3 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including under the Bankruptcy Code and any similar laws in any other country in the Territory). &#160;Novartis, in addition to the rights, power and remedies expressly provided herein, shall be entitled to exercise all other such rights and powers and resort to all other such remedies as may now or hereafter exist at law or in equity (including under the Bankruptcy Code). &#160;The Parties agree that they intend the following Novartis rights to extend to the maximum extent permitted by law, including for purposes of the Bankruptcy Code: &#160;(a) the right of access to any XOMA IP (including all embodiments thereof), or any Third Party with whom XOMA contracts to perform an obligation of XOMA under this Agreement which is necessary for the Development, registration, manufacture and/or Commercialization of Products in the Territory; (b) the right to contract directly with any Third Party described in (a) to complete the contracted work; and (c) the right to cure any breach of or default under any such agreement with a Third Party and set off the costs thereof against amounts payable to XOMA under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">[*]</u><font style="font-size:12pt;">. &#160;If requested by Novartis, XOMA shall cooperate reasonably with Novartis [*] to [*]. &#160;[*] associated with such [*] shall [*] and shall [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FINANCIAL TERMS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Upfront Fee</u><font style="font-size:12pt;">. &#160;In partial consideration for the licenses granted to Novartis hereunder, Novartis shall pay XOMA a non-refundable, non-creditable payment of Thirty-Seven Million Dollars (US$37,000,000) within thirty (30) days after receipt of invoice in the form of </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT B</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">14</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Development and Regulatory Milestone Payments</u><font style="font-size:12pt;">. &#160;In further consideration of the licenses granted to Novartis hereunder, upon achievement of each of the milestone events relating to the Development or Regulatory Approval of a Licensed Antibody or Product, as applicable, set forth in the table immediately below (each, a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Development and Regulatory Milestone</u><font style="font-size:12pt;">&#8221;), Novartis shall pay the corresponding [*] milestone payment (each, a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Development and Regulatory Milestone Payment</u><font style="font-size:12pt;">&#8221;) to XOMA as set forth in the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-0.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="background-color:#d9d9d9;font-weight:normal;text-align:left;vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone<br>Number</b></p></th><th style="background-color:#d9d9d9;font-weight:normal;text-align:left;vertical-align:bottom;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Development and Regulatory Milestone</b></p></th><th style="background-color:#d9d9d9;font-weight:normal;text-align:left;vertical-align:bottom;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Development and Regulatory Milestone Payment(s)</b></p></th></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">1</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">2</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]*</font></p></td></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">3</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">4</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">5</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:12.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">6</font></p></td><td style="vertical-align:top;width:48.71%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]</font></p></td><td style="vertical-align:top;width:38.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">[*]:</font></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">US$[*]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:12pt;">* [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.2.1&#160;&#160;&#160;&#160;For clarity: (a) the aggregate of all Development and Regulatory Milestone Payments made under this Agreement shall not exceed [*]; (b) [*] Development and Regulatory Milestone Payment shall be [*] for the [*] Development and Regulatory Milestone; (c) Development and Regulatory Milestones may be achieved [*] or [*] that [*] Development and Regulatory Milestone; and (d) [*] refers to [*] (for clarity, [*] would be considered [*], but [*] would not be considered [*]).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.2.2&#160;&#160;&#160;&#160;If </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 1 is not achieved, then, effective upon achievement of the first of any of </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> numbers 2, 3, 4 and 5, </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 1 shall also be considered achieved. &#160;If </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 2 is not achieved, then, effective upon achievement of the first of any of </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> numbers 3, 4 and 5, </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 2 shall also be considered achieved. &#160;If </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 3 is not achieved, then, effective upon the achievement of the first of any of </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> numbers 4 and 5, </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> number 3 shall also be considered achieved.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.2.3&#160;&#160;&#160;&#160;Within [*] following</font><font style="font-size:12pt;"> the achievement of a Development and Regulatory Milestone (including where a Development and Regulatory Milestone is considered achieved pursuant to Section 4.2.2)</font><font style="font-size:12pt;">, Novartis shall </font><font style="font-size:12pt;">send a notice of such achievement in writing to XOMA. &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">15</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Upon</font><font style="font-size:12pt;"> receipt of a notice of achievement of such Development and Regulatory Milestone</font><font style="font-size:12pt;">, [*] with respect to the corresponding </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> Payment. &#160;Novartis shall pay to XOMA such </font><font style="font-size:12pt;">Development and Regulatory Milestone</font><font style="font-size:12pt;"> Payment within [*] after [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.2.4&#160;&#160;&#160;&#160;Upon delivery by Novartis to XOMA of written notice of achievement of Development and Regulatory Milestone Number 2, the amount of the Loans (as defined in the Note (as hereafter defined)) then outstanding under that certain Secured Note Agreement, dated May 26, 2005, as amended (as amended, restated, superseded or otherwise modified from time to time, the &#8220;Note&#8221;), between XOMA and Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation) (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">NVDI</u><font style="font-size:12pt;">&#8221;), which was assigned by NVDI to NIBR with XOMA&#8217;s consent immediately prior to the execution of this Agreement, shall be reduced by US$7,300,000 and Novartis shall cause the then-current Note holder (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Note Holder</u><font style="font-size:12pt;">&#8221;) to record such reduction of the Note in its records. &#160;In the event that the outstanding principal amount of the Note, together with all accrued and unpaid interest thereon, is less than $7,300,000 upon the date of delivery by Novartis &#160;to XOMA of written notice of achievement of Development and Regulatory Milestone Number 2, then the Development and Regulatory Milestone Number 2 payment shall be increased in an amount equal to the difference between (x) US$7,300,000 and (y) the then-outstanding principal amount of the Note, together with all accrued and unpaid interest thereon.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Product Royalties</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">4.3.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Product Royalties</u><font style="font-size:12pt;">. &#160;On a Product-by-Product basis, Novartis shall pay royalties on the Net Sales of each Product in the Territory, in all Indications in the Field, at the following rates, during the Royalty Term:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;" align="center"><tr><th style="background-color:#f2f2f2;font-weight:normal;text-align:left;vertical-align:bottom;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Aggregate Net Sales of a Product in any Calendar Year during the Royalty Term</b></p></th><th style="background-color:#f2f2f2;font-weight:normal;text-align:left;vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Royalty Rate</b></p></th></tr><tr><td style="vertical-align:top;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Portion of Net Sales of such Product up to US$[*]<br></font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]%</font></p></td></tr><tr><td style="vertical-align:top;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Portion of Net Sales of such Product above US$[*] and up to and including US$[*]</font></p></td><td style="vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]%</font></p></td></tr><tr><td style="vertical-align:top;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Portion of Net Sales of such Product above US$[*] and up to and including US$[*]</font></p></td><td style="vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]%</font></p></td></tr><tr><td style="vertical-align:top;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Portion of Net Sales of such Product above US$[*] and up to and including US$[*]</font></p></td><td style="vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]%</font></p></td></tr><tr><td style="vertical-align:top;width:80.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Portion of Net Sales of such Product above US$[*]<br></font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:19.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">[*]%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.3.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Royalty Term and Adjustments</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis&#8217; royalty obligations to XOMA under this Section 4.3 shall commence on a Product-by-Product and country-by-country basis on the date of First Commercial Sale of such Product by Novartis, its Affiliates or sublicensees to a Third Party in the relevant </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">16</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">country and shall expire on a Product-by-Product and country-by-country basis upon the later of the following (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Royalty Term</u><font style="font-size:12pt;">&#8221;), as applicable:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the expiration in such country of the last-to-expire Valid Claim in the XOMA Core Patents Covering such Product; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;ten (10) years after First Commercial Sale of such Product in the relevant country in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, and [*] provided for under this Agreement, for Net Sales of a Product in any country in which [*] such Product, during the Royalty Term the associated royalties pursuant to Section 4.3.1 shall be [*] from what otherwise would be payable by Novartis to XOMA under this Agreement. &#160;Further, [*] for a Product in a country in the Territory, [*] under this Agreement with respect to such Product in such country shall [*], which shall [*] this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If an event of [*] for a Product in any country has occurred, then so long as either (i) [*] such Product in such country, or (ii) [*] such Product in such country, then the Royalty Rate applicable to Net Sales of such Product in such country in accordance with in Section 4.3.1 shall be [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, [*] responsible for the payment of [*] and other payment obligations, if any, [*] in connection with (i) any [*] which [*] and [*] under this Agreement, or (ii) which relate to [*] relating to any [*], (collectively, the &#8220;[*]&#8221;). &#160;All such payments in respect of [*] shall be made promptly [*] in accordance with [*] (collectively, [*] after each such payment has been made. &#160;For clarity, any payment obligations that may arise pursuant to Section [*] with respect to the [*] shall not be deemed to be a [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that [*] or [*] or [*] or [*], including [*] (collectively, &#8220;[*]&#8221;), [*] and [*] or otherwise and [*] with respect to [*] (including [*]) by [*]; </font><i style="font-size:12pt;font-style:italic;">provided that</i><font style="font-size:12pt;"> to the extent (if at all) [*] provides [*] having [*] any [*] under this Agreement, [*] hereunder shall be [*] as reasonably [*] under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that [*] or [*] in connection with the [*] under this Agreement, [*] and [*] or otherwise and [*] with respect to [*] (including [*]) by [*]; </font><i style="font-size:12pt;font-style:italic;">provided that </i><font style="font-size:12pt;">to the extent (if at all) [*] provides [*] having [*] any [*] under this Agreement, [*] hereunder shall be [*] as reasonably [*] under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to, and without prejudice to, [*], in no event shall [*] such that the royalty payments due to XOMA from Novartis under Section 4.3 [*]. &#160;[*] with respect to a particular Product in a particular country [*] shall be [*] royalty payment amounts due to XOMA [*] that [*], provided further that [*] for such Product in such country, [*] with respect to any [*] any [*] hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">17</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Reports; Royalty Payments</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.4.1&#160;&#160;&#160;&#160;Until the expiration of Novartis&#8217; royalty payment obligations under this Article 4, Novartis agrees to make written reports to XOMA within [*] after the end of each Calendar Quarter covering sales of Product on a country-by-country basis in the Territory by Novartis, its Affiliates and sublicensees during such Calendar Quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.4.2&#160;&#160;&#160;&#160;Each such written report (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sales &amp; Royalty Report</u><font style="font-size:12pt;">&#8221;) shall, with respect to each country, provide:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;number of units sold for the Products;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Net Sales for the Products; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the calculation of the royalty payment due on such Net Sales in the Territory pursuant to this Article 4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.4.3&#160;&#160;&#160;&#160;Following receipt of each such Sales &amp; Royalty Report, [*], Novartis shall make the royalty payment due to be paid to XOMA under Article 4 for the Calendar Quarter covered by such report.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sales Milestone Payment</u><font style="font-size:12pt;">. &#160;In addition to the payments referenced in Sections 4.1 through 4.4 above, Novartis shall pay XOMA the following sales milestone payments following the first respective Calendar Quarter in which the total Net Sales of all Products in the Territory first reach or exceed the thresholds specified in the table below for the Calendar Year in which such Calendar Quarter occurs. &#160;Following XOMA&#8217;s receipt of a Sales &amp; Royalty Report for a Calendar Quarter of a Calendar Year, if a sales milestone payment has been achieved, [*] &#160;Novartis shall pay XOMA the associated milestone payment within [*]. &#160;In the interest of clarity, (a) XOMA may earn more than one payment pursuant to this Section 4.5. in a given year (e.g., if total Net Sales of all Products in the Territory are US$[*] in a Calendar Year, and no previous sales milestone had been achieved under this Section 4.5, then all four (4) sales milestones would be achieved, and all four (4) associated milestone payments would be earned, in such Calendar Year), and (b) the aggregate of all payments made pursuant to this Section 4.5 shall not exceed US$[*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;" align="center"><tr><td style="background-color:#f2f2f2;vertical-align:bottom;width:48.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Sales milestone</b></p></td><td style="background-color:#f2f2f2;vertical-align:bottom;width:51.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Associated milestone payment</b></p></td></tr><tr><td style="vertical-align:top;width:48.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Annual Net Sales first reach US$[*]</font></p></td><td style="vertical-align:top;width:51.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:48.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Annual Net Sales first reach US$[*]</font></p></td><td style="vertical-align:top;width:51.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:48.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Annual Net Sales first reach US$[*]</font></p></td><td style="vertical-align:top;width:51.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr><tr><td style="vertical-align:top;width:48.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">Annual Net Sales first reach US$[*]</font></p></td><td style="vertical-align:top;width:51.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;">US$[*]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">18</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Methods of Payments</u><font style="font-size:12pt;">. &#160;All payments due from Novartis to XOMA under this Agreement shall be paid in Dollars by Novartis via wire transfer to a bank designated in writing in advance by XOMA. &#160;Any payment which falls due on a date which is not a Business Day in the location from which the payment will be made may be made on the next succeeding Business Day in such location.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Accounting</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.1&#160;&#160;&#160;&#160;Novartis shall keep complete, true and accurate books and records in accordance with its Accounting Standards in relation to this Agreement, including, in relation to Net Sales and royalties. &#160;Novartis shall keep such books and records for at least [*] years following the Calendar Quarter to which they pertain.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.2&#160;&#160;&#160;&#160;XOMA may, upon written notice to Novartis, appoint an internationally-recognized independent accounting firm (which firm is reasonably acceptable to Novartis, such acceptance not to be unreasonably delayed or conditioned) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Auditor</u><font style="font-size:12pt;">&#8221;) to inspect the relevant reports, statements, records or books of accounts (as applicable) of Novartis and/or its Affiliates to verify the accuracy of any Sales &amp; Royalty Report. &#160;Before beginning its audit, the Auditor shall execute an undertaking reasonably acceptable to Novartis on customary terms by which the Auditor shall keep confidential all information reviewed during such audit. &#160;The Auditor shall have the right to disclose to XOMA its conclusions regarding any payments owed under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.3&#160;&#160;&#160;&#160;Novartis and its Affiliates shall make their records available for inspection by such Auditor during regular business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from XOMA. &#160;The records shall be reviewed solely to verify the accuracy of the Sales &amp; Royalty Reports. &#160;[*]. &#160;In addition, XOMA shall only be entitled to audit the relevant books and records of Novartis relating to a Sales &amp; Royalty Report for a period of [*] calendar years after receipt of the applicable Sales &amp; Royalty Report. &#160;XOMA agrees to hold in strict confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.4&#160;&#160;&#160;&#160;The Auditor shall provide its audit report and basis for any determination to Novartis at the time such report is provided to XOMA, before it is considered final. Novartis shall have the right to request a further determination by such Auditor as to matters which Novartis disputes within [*] following receipt of such report. Novartis will provide XOMA and the Auditor with a reasonably detailed statement of the grounds upon which it disputes any findings in the audit report and the Auditor shall undertake to complete such further determination within [*] after the dispute notice is provided, which determination shall be limited to the disputed matters. Any matter that remains unresolved shall be resolved in accordance with the dispute resolution procedures contained in Section 11.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.5&#160;&#160;&#160;&#160;In the event that the final result of the inspection reveals an undisputed underpayment or overpayment by Novartis, the underpaid or overpaid amount shall be settled promptly.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">19</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.7.6&#160;&#160;&#160;&#160;XOMA shall pay for such audits, as well as its own expenses associated with enforcing its rights with respect to any payments hereunder, except that in the event there is any upward adjustment in aggregate amounts payable for any year shown by such audit of more than [*] of the amount paid, Novartis shall pay for such audit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Currency</u><font style="font-size:12pt;">. &#160;All payments under this Agreement shall be payable in US Dollars. &#160;When conversion of payments from any foreign currency is required to be undertaken by Novartis, the US Dollar equivalent shall be calculated using Novartis&#8217; then-current standard exchange rate methodology as applied in its external reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Late Payments</u><font style="font-size:12pt;">. &#160;Any undisputed amount owed by Novartis to XOMA under this Agreement that is not paid on or before [*] the date such payment is due shall bear interest at a rate per annum equal to the lesser of (a) the thirty (30)-day United States dollar LIBOR rate in effect on the date that payment was due, as published by The Financial Times after such payment is due, plus [*], or (b) the highest rate permitted by applicable Law, in either case calculated on the number of days such payments are paid after such payments are due and compounded monthly; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that the foregoing shall not accrue on undisputed amounts that were paid after the due date as a result of mistaken XOMA actions (e.g., if a payment is late as a result of XOMA providing an incorrect account for receipt of payment).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.10&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Taxes</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.10.1&#160;&#160;Except as otherwise provided in this Section 4.10, each Party shall be responsible for any tax obligations of its own due to this Agreement, including but not limited to income tax and capital gains tax, and neither Party shall have any obligation towards the other Party in the event that the other Party fails to fully comply with its tax obligations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.10.2&#160;&#160;All transfer, VAT, GST, documentary, sales, use, stamp, registration and other such taxes, and any conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in connection with consummation of the transactions contemplated hereby, if any, shall be [*]. &#160;Novartis shall prepare and timely file all tax returns required to be filed in respect of any such taxes. &#160;The Parties shall reasonably cooperate in accordance with Applicable Laws to minimize any such transfer taxes payable in connection with this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.10.3&#160;&#160;Subject to Section 4.10.4, if any taxes are required to be withheld by Novartis, Novartis will: (a) deduct such taxes from the payment made to XOMA; (b) timely pay the taxes to the proper taxing authority; (c) promptly send proof of payment to XOMA; and (d) reasonably assist XOMA in its efforts to obtain a credit for such tax payment. &#160;Each Party agrees to reasonably assist the other Party in lawfully claiming exemptions from and/or minimizing such deductions or withholdings under double taxation laws or similar circumstances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:12pt;">4.10.4&#160;&#160;Notwithstanding anything to the contrary in this Agreement, if Novartis assigns or transfers some or all of its rights and obligations to any Person &#160;and if, as a result of such action, the withholding or deduction of tax required by applicable Law with respect to payments under this Agreement is increased, then any amount payable under this Agreement shall be </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">20</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">increased to take into account such withheld taxes as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts), XOMA receives an amount equal to the sum it would have received had no such increased withholding been made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.10.5&#160;&#160;For all tax purposes, both Parties agree to report the transactions contemplated by this Agreement in a manner consistent with its terms and to not take any position inconsistent therewith in any tax return, refund claim, litigation, or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.11&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Guarantee</u><font style="font-size:12pt;">. &#160;XOMA and Novartis acknowledge and agree that nothing in this Agreement shall be construed as representing an estimate or projection of anticipated sales of any Product, and that the milestones and Net Sales levels set forth in this Agreement or that have otherwise been discussed by the Parties are merely intended to define the milestone payments and royalty obligations to XOMA in the event such milestones or Net Sales levels are achieved. &#160;Neither Party provides any representation, warranty or guarantee that the Development of any Product will be successful, that Regulatory Approval for any Product will be obtained, or that any other particular results will be achieved with respect to the Commercialization of any Product hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.12&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Costs</u><font style="font-size:12pt;">. &#160;In addition to the specific costs to be assumed by each of XOMA and Novartis as described herein, each Party will be responsible for all costs that it incurs in exercising its rights and meeting its obligations under this Agreement, except as expressly set forth otherwise in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.13&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Set-off</u><font style="font-size:12pt;">. &#160;If an Event of Default (as defined in the Note) shall have occurred and be continuing, and all amounts thereunder have become due and payable in accordance with Section 5(b) of the Note, Novartis may elect to deduct from any upfront fees, milestone payments and royalty payments to be made by it to XOMA under this Agreement and pay to Note Holder any amounts then due and payable by XOMA to Note Holder under the Note. &#160;Any such election shall be confirmed by prompt written notice to XOMA delivered in accordance with Section 11.5, which notice shall describe (a) the Event of Default that has occurred and is continuing and (b) provide an accounting for any and all amounts being deducted. &#160;Novartis acknowledges that XOMA has granted a security interest to Note Holder in XOMA&#8217;s interest in all upfront fees, milestone payments, and royalty payments that may become due to XOMA pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Ownership</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.1.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Pre-Existing Patents and Know-How</u><font style="font-size:12pt;">. &#160;XOMA shall retain all of its right, title and interest in, to and under the XOMA IP, and Novartis shall retain all of its rights, title and interest in, to and under the Patents and Know-How owned by it, except in each case to the extent that any such rights or licenses are expressly granted by one Party to the other Party under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">21</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.1.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property Arising Under This Agreement</u><font style="font-size:12pt;">. &#160;Ownership of all data, Patents and Know-How generated, discovered, developed, invented, conceived or reduced to practice by or on behalf of Novartis, its sublicensees, XOMA (if any), or Affiliates of the Parties, whether solely by any such party or jointly by one or more such parties, in connection with the Development, manufacture and/or Commercialization of the Licensed Antibodies and Products under this Agreement, and all intellectual property rights therein, will be determined in accordance with the U.S. laws of inventorship (collectively, all such data, Patents and Know-How, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Future IP</u><font style="font-size:12pt;">&#8221;, and all Patents included in or claiming priority to the foregoing set forth in this Section 5.1.2, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis Patents</u><font style="font-size:12pt;">&#8221;). &#160;All Regulatory Approvals for the Licensed Antibodies and Products hereunder shall be made in the name of and owned by Novartis or its Affiliates or sublicensees. &#160;The Parties acknowledge and agree that XOMA&#8217;s interest in the Future IP shall be part of the XOMA IP and subject to the exclusive license granted in Section 3.1.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.1.3&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Invention Assignment Agreements.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA hereby covenants to Novartis that all contractors and employees of XOMA and its Affiliates will be under the obligation to assign all right, title and interest in and to such Novartis Patents and their inventions and discoveries relating thereto, whether or not patentable, to XOMA as the sole owner thereof. &#160;XOMA shall assign such right, title and interest in the Novartis Patents to Novartis in accordance with Section 5.1.2. &#160;For clarity, [*] shall not be deemed to be contractors of XOMA or its Affiliates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis hereby covenants to XOMA that all contractors and employees of Novartis and its Affiliates and sublicensees will be under the obligation to assign all right, title and interest in and to such Novartis Patents and their inventions and discoveries relating thereto, whether or not patentable, to Novartis as the sole owner thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Prosecution and Maintenance of Patents</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.2.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">[*] Patents</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to Section&#160;5.2.2, as between the Parties, [*] shall have the first right (but not the obligation) to Prosecute and Maintain the [*] Patents using outside counsel reasonably acceptable to [*]. &#160;[*] shall keep [*] informed as to material developments with respect to the Prosecution and Maintenance of such Patents, including by timely providing copies of all substantive office actions or any other substantive documents that [*] receives from or submits to any patent office, including notice of all interferences, reissues, re-examinations, oppositions or, subject to Section 5.7, requests for patent term extensions and providing [*] a reasonable opportunity to review and comment on all substantive filings and communications with any patent agency regarding any [*] Patent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to Section&#160;5.2.2, as between the Parties, [*] shall have the first right (but not the obligation) to Prosecute and Maintain the [*] Patents. &#160;[*] shall keep [*] informed as to material developments with respect to the Prosecution and Maintenance of the [*] Patents [*], including by providing copies of all substantive office actions or any other substantive documents that such Party receives from or submits to any patent office, including notice of all </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">22</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">interferences, reissues, re-examinations, AIA Proceedings, oppositions or, subject to Section 5.7, requests for patent term extensions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party shall designate appropriate patent counsel who shall be responsible for communicating and consulting with the other Party&#8217;s appropriate patent counsel to determine from time to time which [*] Patents should be [*]. &#160;Such counsel shall confer within ninety (90) days of the Effective Date to [*] as to which [*] Patents shall be [*] and to determine the timing and process for [*] Patents going forward.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.2.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Filing Decision or Prosecution Lapse</u><font style="font-size:12pt;">. &#160;If, during the Term, the Party, in exercising its right pursuant to Section 5.2.1 to Prosecute and Maintain a [*] Patent in any country, decides not to file such Patent or intends to allow such Patent to lapse or become abandoned without having first filed a substitute Patent (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Abandonment</u><font style="font-size:12pt;">&#8221;), such prosecuting Party shall notify in writing and consult with the other Party regarding such decision or intention at least sixty (60) days prior to the date upon which the subject matter of such Patent shall become unpatentable or such Patent shall lapse or become abandoned, and such other Party shall thereupon have the right (but not the obligation) to assume the Prosecution and Maintenance thereof at its own expense with counsel of its own choice. &#160;If [*] assumes the Prosecution and Maintenance of any [*] Patent pursuant to this Section 5.2.2, then such [*] Patent shall thereafter [*] and [*] under this Agreement. and for the avoidance of doubt, where such [*] Patent had been a [*] Patent, then from that time forward it shall [*]. &#160;For clarity, (a) [*] shall not be obligated to [*] under this Section 5.2.2 and [*] shall not have the rights set forth in this Section 5.2.2 with respect to [*], and (b) [*] shall not have the rights set forth in this Section 5.2.2 with respect to [*], unless [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Patent Costs</u><font style="font-size:12pt;">. &#160;[*] costs and expenses associated with [*] Prosecution and Maintenance activities under Section 5.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Defense of Claims Brought by Third Parties</u><font style="font-size:12pt;">. &#160;If a Party becomes aware of, or as of the Effective Date is aware of, any claim that the Development or Commercialization of a Licensed Antibody or Product in or for the Territory infringes or misappropriates the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. &#160;In any such instance, the Parties shall as soon as practicable thereafter discuss in good faith regarding the best response to such notice, subject to Article 8, and Novartis shall have the first right (but not the obligation) to defend such claim, at Novartis&#8217; cost and expense (subject to any other provision of this Agreement [*], or [*]). &#160;If Novartis does not undertake such defense within ninety (90) days of receiving notice of such infringement or misappropriation, then XOMA shall have the right to assume such defense. &#160;The Party undertaking such defense, shall keep the other Party reasonably informed of the progress of any such defense, and such other Party shall have the right to participate with counsel of its own choice at its own expense.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Enforcement</u><font style="font-size:12pt;">. &#160;Each Party shall promptly notify the other Party in writing if it reasonably believes that any [*] Patent is infringed by a Third Party with respect to the manufacture, sale, offer for sale, use or importation of a Licensed Antibody or Product in the Territory (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Competing Infringing Activities</u><font style="font-size:12pt;">&#8221;). &#160;[*] shall have the sole right, but not the obligation, to enforce [*] Patents with respect to Competing Infringing Activity, or to defend any declaratory judgment action with respect thereto. &#160;[*] shall have the sole right, but not </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">23</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the obligation, to enforce [*] Patents with respect to Competing Infringing Activity, or to defend any declaratory judgment action with respect thereto. &#160;The Party initiating or defending any such action under this Section 5.5 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Enforcing Party</u><font style="font-size:12pt;">&#8221;) shall keep the other Party reasonably informed of the progress of any such action, and such other Party shall have the right to participate with counsel of its own choice at its own expense. &#160;In any event, the other Party shall reasonably cooperate with the Enforcing Party, including providing information and materials, at the Enforcing Party&#8217;s request and expense, and joining as a plaintiff to such action to the extent necessary for standing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Recovery</u><font style="font-size:12pt;">. &#160;Any recovery received as a result of any action under Section 5.4 or 5.5 shall be used first to reimburse the Parties for the costs and expenses (including attorneys&#8217; and professional fees) incurred in connection with such Action (and not previously reimbursed), and the remainder of the recovery shall be [*], provided that any such remaining portion of recoveries [*] (including [*] included in such recoveries) shall be [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Patent Term Extensions</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.7.1&#160;&#160;&#160;&#160;Novartis shall be responsible for determining the strategy for applying for the extension of the term of any patents for which it has responsibility to prosecute, maintain and defend under this Article 5, such as under the &#8220;U.S. Drug Price Competition and Patent Term Restoration Act of 1984&#8221; (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Act</u><font style="font-size:12pt;">&#8221;), the Supplementary Certificate of Protection of the Member States of the European Union and other similar measures in any other country. &#160;If requested by Novartis, and at Novartis&#8217; cost, XOMA shall apply for and use its reasonable efforts to obtain such an extension or, should the law require Novartis (or one of its respective Affiliates, subcontractors or sublicensees hereunder) to so apply, XOMA hereby gives permission to Novartis to do so (in which case XOMA agrees to cooperate with Novartis in the exercise of such authorization and shall execute such documents and take such additional action as Novartis may reasonably request in connection therewith). &#160;Novartis and XOMA agree to cooperate with one another in obtaining any patent extension hereunder as directed by Novartis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.7.2&#160;&#160;&#160;&#160;Novartis shall be responsible for determining the strategy with respect to certifications, notices and patent enforcement procedures regarding patents for which it has responsibility to prosecute, maintain and defend under this Article 5 under the Act and the Biologics Price Competition and Innovation Act of 2009 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">BPCIA</u><font style="font-size:12pt;">&#8221;). &#160;XOMA shall cooperate, as reasonably requested by Novartis, in a manner consistent with this Section 5.7. &#160;XOMA hereby authorizes Novartis to: (a) provide in any BLA or in connection with the BPCIA, a list of patents (that may include XOMA Patents as required under the BPCIA; (b) except as otherwise provided in this Agreement, exercise any rights exercisable by Novartis as patent owner under the Act or the BPCIA; and (c) exercise any rights that may be exercisable by Novartis as reference product sponsor under the BPCIA, including (1) engaging in the patent resolution provisions of the BPCIA with regard to patents for which it has responsibility to prosecute, maintain and defend under this Article 5; and (2) determining which patents will be the subject of immediate patent infringement action under &#167; 351(l)(6) of the BPCIA; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that with respect to Novartis&#8217; exercise of rights under the BPCIA, Novartis shall consult with a representative of XOMA designated by XOMA in writing and qualified to receive confidential information pursuant to &#167; 365(l) of the BPCIA with respect to Novartis&#8217; exercise of any rights exercisable as reference product sponsor, including providing such representative with timely copies of material correspondence relating to such </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">24</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">matters, providing such representative the opportunity, reasonably in advance of any related Novartis action, to comment thereon and to consult with and consider in good faith the requests and suggestions of XOMA with respect to such matters.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.7.3&#160;&#160;&#160;&#160;In the event that Novartis desires to apply for an extension of any patents for which XOMA has responsibility to prosecute, maintain and defend under this Article 5 under the Act, the Supplementary Certificate of Protection of the Member States of the European Union or any other similar measures in any other country; or utilize any such patent for purposes of engaging in the patent resolution provisions or bringing a patent infringement action under the BPCIA; the Parties shall meet in good faith to discuss strategy for such activity, provided that XOMA shall not be obligated to agree to the use of any such patent for any such activity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Trademarks</u><font style="font-size:12pt;">. &#160;Novartis shall have the right to brand the Products using Novartis related trademarks and any other trademarks and trade names it determines appropriate for the Product, which may vary by country or within a country (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Product Marks</u><font style="font-size:12pt;">&#8221;). &#160;Novartis shall own all rights in the Product Marks and register and maintain the Product Marks in the countries and regions it determines reasonably necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 6</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality; Exceptions</u><font style="font-size:12pt;">. &#160;Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that a Party and its Affiliates and representatives (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Receiving Party</u><font style="font-size:12pt;">&#8221;) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Know-How or other confidential and proprietary information and materials, patentable or otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise) which is disclosed to it by the other Party or its Affiliates or representatives (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disclosing Party</u><font style="font-size:12pt;">&#8221;), including trade secrets, Know-How, inventions or discoveries, proprietary information, formulae, processes, techniques and information relating to a Party&#8217;s past, present and future marketing, financial and Development activities of any product or potential product or useful technology of the Disclosing Party and the pricing thereof (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Confidential Information</u><font style="font-size:12pt;">&#8221;), except to the extent that it can be established by the Receiving Party that such Confidential Information:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;was otherwise developed independently by the Receiving Party without use of or reference to the Disclosing Party&#8217;s Confidential Information, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">25</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party hereunder other than through any act or omission of the Receiving Party in breach of this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">All XOMA Know-How that is specific to the Development and/or manufacture of any Licensed Antibody and the XOMA Regulatory Materials shall be considered Confidential Information of both XOMA and Novartis (it being understood that both XOMA and Novartis will be deemed to be the Disclosing Party with respect thereto and the exceptions in Sections 6.1(a) and (e) shall not apply to XOMA with respect to such XOMA Know-How and the XOMA Regulatory Materials). &#160;Subject to and without prejudice to the foregoing, any Confidential Information disclosed by either Party (or their Affiliates) prior to the Effective Date pursuant to the Confidentiality Agreement between XOMA (US) LLC and Novartis Pharmaceuticals Corporation dated June 17, 2015 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Existing Confidentiality Agreement</u><font style="font-size:12pt;">&#8221;) shall be Confidential Information of such Party for all purposes under this Agreement, it being understood and agreed that this Agreement supersedes and replaces the Existing Confidentiality Agreement with respect to such Confidential Information and the rights and obligations of the Parties with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Authorized Disclosure</u><font style="font-size:12pt;">. &#160;Except as expressly provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;under appropriate confidentiality provisions at least as protective of such Confidential Information as those in this Agreement, as reasonably necessary for performance of its obligations or exercise of rights granted in this Agreement (including the rights to Develop and Commercialize Licensed Antibodies and Products) including in filing or prosecuting patent applications in accordance with Section 5.2, prosecuting or defending litigation, complying with applicable Law (subject to clause (b) below), seeking and obtaining Regulatory Approval, conducting non-clinical activities or clinical trials, preparing and submitting INDs to Regulatory Authorities, and marketing Products, in each case in accordance with this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent disclosure is required by Law; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party&#8217;s Confidential Information it will, where legally permitted and practicable, give reasonable advance notice to the Disclosing Party of such disclosure requirement, afford the Disclosing Party an opportunity to secure, and, if requested by the Disclosing Party, reasonably cooperate with the Disclosing Party to, secure confidential treatment of such Confidential Information required to be disclosed, and disclose only that portion of the Confidential Information that the Receiving Party is legally required to disclose as advised by the Receiving Party&#8217;s legal counsel;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in communication with actual or potential investors, lenders, acquirers, merger partners, consultants, professional advisors, collaborators, donors, or funding sources as reasonably necessary, and (with respect to XOMA) with its licensors as necessary to </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">26</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">satisfy its reporting obligations with respect to a Licensed Antibody or Product, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent mutually agreed to in writing by the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure of Agreement</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.3.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure of Agreement Terms</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except to the extent required by Law or any securities exchange or governmental authority or any tax authority to which any Party is subject or submits or as otherwise permitted in accordance with this Section&#160;6.3, neither Party shall make any public announcements concerning the terms of this Agreement or otherwise disclose the terms of this Agreement to any Third Party without the prior written consent of the other, which shall not be unreasonably withheld, conditioned or delayed. &#160;Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter hereof, as practicable under the circumstances, reasonably prior to its scheduled release. &#160;Each Party shall have the right to expeditiously review and recommend changes to any such announcement by the other Party, and, except as otherwise required by securities exchange listing requirements or applicable Law, approve such announcement and the Party whose announcement has been reviewed shall remove any Confidential Information of the reviewing Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, to the extent information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the consent of the other Party. &#160;Each Party shall also be permitted to disclose the terms of this Agreement, in each case on a need to know basis under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to its actual or potential investors, lenders, acquirers, merger partners, consultants, professional advisors, donors, or funding sources. &#160;Novartis may, in the ordinary course of business without XOMA&#8217;s consent, inform its customers, suppliers and business contacts that Novartis has obtained the right under this Agreement to sell Products in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party shall give the other Party a reasonable opportunity to review those portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the U.S.) describing the terms of this Agreement (including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which confidential treatment should be sought.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Remedies</u><font style="font-size:12pt;">. &#160;Each Party shall be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary injunction or other injunctive relief, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of this Article 6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">27</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Publications</u><font style="font-size:12pt;">. &#160;XOMA shall not make any public disclosure (whether written, electronic, oral or otherwise) relating to any Licensed Antibody or Product without the prior written consent of Novartis; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that the foregoing shall not apply to information which is in the public domain or any public disclosure required by law or governmental regulation or by the rules of any recognized stock exchange. &#160;For the avoidance of doubt, Novartis, any of its Affiliates or sublicensees may, without any required consents from XOMA, (a) issue press releases, disclosures, and other public statements as it deems appropriate in connection with the Development and Commercialization of Licensed Antibodies or Products under or in connection with this Agreement, and (b) publish or have published information about clinical trials related to the Licensed Antibodies or Products, including the results of such clinical trials; </font><i style="font-size:12pt;font-style:italic;">provided however</i><font style="font-size:12pt;"> if Novartis plans to issue a press release that in its judgment contains material adverse information regarding this Agreement in its entirety or a Product or Licensed Antibody under this Agreement, then Novartis shall use commercially reasonable efforts to provide XOMA with reasonable prior notice of such press release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Clinical Trial Register</u><font style="font-size:12pt;">. &#160;Each Party agrees that each clinical study and each nonclinical study with respect to a Licensed Antibody or Product that is required to be posted pursuant to applicable Law or applicable industry codes, including the PhRMA Code or the equivalent industry code of practice, on clinicaltrials.gov or any other similar registry shall be so posted. &#160;Unless otherwise agreed upon by the Parties (and as permitted by applicable Law or applicable industry codes), Novartis shall be responsible for such posting</font><font style="font-size:12pt;"> for the </font><font style="font-size:12pt;">Licensed Antibodies and Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 7</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">REPRESENTATIONS; WARRANTIES; COVENANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties of Both Parties</u><font style="font-size:12pt;">. &#160;Each Party hereby represents and warrants to the other Party, as of the Effective Date, that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Such Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction over such Party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">28</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements except as may be required to conduct clinical trials or to seek or obtain Regulatory Approvals of the Products; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;It is not debarred or excluded from reimbursement by the FDA (or subject to a similar sanction of EMA or any other Regulatory Authority) or subject of an FDA debarment or exclusion investigation or proceeding (or similar proceeding of EMA or other Regulatory Authority). &#160;To its knowledge, it has not (i) employed and has not used a contractor or consultant that has employed, any individual or entity debarred or excluded from reimbursement by the FDA (or subject to a similar sanction of EMA or any other Regulatory Authority), or, (ii) employed any individual who or entity that is the subject of an FDA debarment or exclusion investigation or proceeding (or similar proceeding of EMA or other Regulatory Authority), in each case in the conduct of any Development of the Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties of XOMA</u><font style="font-size:12pt;">. &#160;XOMA hereby represents and warrants to Novartis that (except as set forth in the schedules of disclosures attached hereto as </font><b style="font-size:12pt;font-weight:bold;">SCHEDULE 1</b><font style="font-size:12pt;">) as of the Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Patents listed in </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT A</b><font style="font-size:12pt;"> comprise a complete and accurate list of all Patents existing as of the Effective Date Controlled by XOMA that [*] exists as of the Effective Date, and with respect to which [*] (provided that [*] with respect to [*] solely to the extent of [*]</font><b style="font-size:12pt;font-weight:bold;">)</b><font style="font-size:12pt;">;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA has the right to use and disclose and to enable Novartis to use and disclose (in each case under conditions of confidentiality consistent with Section 6.2) the XOMA Know-How and XOMA Regulatory Materials, and XOMA has the right to grant all rights and licenses it purports to grant to Novartis with respect to the XOMA IP, the XOMA Regulatory Materials and the Licensed Antibodies and Products under this Agreement, free and clear of all liens, claims, security interests or encumbrances of any kind;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA has not granted any right or license to any Third Party that conflicts or interferes with or limits the scope of any of the rights or licenses granted to Novartis hereunder, [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Neither XOMA nor its Affiliates has received any written notice of any claim that any Patent or Know-How owned or controlled by a Third Party would be or is infringed or misappropriated by the manufacture, use, sale, offer for sale or importation of the Licensed Antibodies or Products in the form that they exist as of the Effective Date and, (ii) to the knowledge of XOMA, the manufacture, use, sale, offer for sale or importation of the Licensed Antibodies and Products in the form that they exist as of the Effective Date and without combination with any other product would not and does not infringe or misappropriate any Patent or Know-How owned or controlled by a Third Party [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">29</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of XOMA, the issued patents in the XOMA Patents are valid and enforceable without any claims, challenges, oppositions, nullity actions, interferences, inter-partes reexaminations, AIA Proceedings, derivation proceedings, or other proceedings pending or threatened and XOMA has filed and prosecuted patent applications within the XOMA Patents in good faith and complied with all duties of disclosure with respect thereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the knowledge of XOMA, XOMA has not committed any act, or omitted to commit any act, that may cause the XOMA Patents to expire prematurely or be declared invalid or unenforceable;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no Patents or Know-How Controlled by XOMA or its Affiliates as of to the Effective Date that, to XOMA&#8217;s knowledge, are necessary for the manufacture, Development or Commercialization of the Licensed Antibodies and Products as contemplated hereunder, other than the XOMA IP licensed to Novartis hereunder;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no contracts or other agreements between XOMA (or its Affiliate) and any Third Parties that relate to the Development, manufacture or Commercialization of the Licensed Antibodies or Products as contemplated hereunder, other than the contracts listed on </font><b style="font-size:12pt;font-weight:bold;">SCHEDULE 1</b><font style="font-size:12pt;"> and designated as responsive to Section 7.2(h), and such contracts are in full force and effect, and XOMA has not received or provided any notice of breach or termination with respect to any such contract;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA has not, nor to its knowledge, has any Third Party acting under authority of XOMA, [*] with respect to any Licensed Antibody or Product, or [*] with respect to any Licensed Antibody or Product. &#160;XOMA has, and to its knowledge such Third Parties have, [*] with respect to the Licensed Antibodies and Products and [*]. &#160;All [*] in compliance with all applicable Law, including, if and as applicable, cGMP, cGCP and cGLP, and all Regulatory Materials submitted to any Regulatory Authority [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To XOMA&#8217;s knowledge as of the Effective Date, [*] concerning the Licensed Antibodies or Products or active pharmaceutical ingredients therein that [*] and [*];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA has not entered into a government funding relationship that would result in rights to any Licensed Antibodies or Product residing in the US Government, National Institutes of Health, National Institute for Drug Abuse or other agency, and the licenses granted hereunder are not subject to overriding obligations to the US Government as set forth in Public Law 96 517 (35 U.S.C. 200 204), as amended, or any similar obligations under the laws of any other country;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached as </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT C</b><font style="font-size:12pt;"> is a detailed list of, to XOMA&#8217;s knowledge, any and all quantities and forms of Licensed Antibodies, Products, and all cell banks, bioassay materials, cell lines, Antibodies, sequences and constructs for the expression and production of such Licensed Antibodies, (collectively, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Inventory</u><font style="font-size:12pt;">&#8221;) existing as of the Effective Date owned by XOMA, whether in XOMA&#8217;s possession or in the possession of Third Parties. &#160;To the extent that, following the Effective Date, XOMA discovers any omissions with respect to </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT C</b><font style="font-size:12pt;">, XOMA shall promptly provide Novartis with an updated </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT C</b><font style="font-size:12pt;">, and XOMA </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">30</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shall not be deemed to be in breach of this subsection (l) if such update pertains to additional materials being added to </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT C</b><font style="font-size:12pt;"> or removal of not significant quantities of previously listed materials, and in each case such update is provided to Novartis within sixty (60) days of the Effective Date (and in any event within thirty (30) days of such discovery); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to the Effective Date, XOMA has disclosed to Novartis and provided [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties of Novartis</u><font style="font-size:12pt;">. &#160;Novartis hereby represents and warrants to XOMA that as of the Effective Date, neither Novartis nor any of its Affiliates is [*] that, as [*] for [*], and where [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Covenants of XOMA</u><font style="font-size:12pt;">. &#160;XOMA hereby covenants to Novartis that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.4.1&#160;&#160;&#160;&#160;XOMA will maintain all XOMA Third Party Agreements, including the XOMA Third Party Agreements set forth on </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT D</b><font style="font-size:12pt;">, in full force and effect during the Term, and will not (a) terminate any XOMA Third Party Agreement, nor (b) amend any XOMA Third Party Agreement, in each case in any manner that adversely effects the rights of Novartis under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.4.2&#160;&#160;&#160;&#160;XOMA will not grant during the Term, any right or license to any Third Party that conflicts or interferes with or limits the scope of any of the rights or licenses granted to Novartis hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Covenants of Novartis</u><font style="font-size:12pt;">. &#160;Novartis hereby covenants to XOMA that its and its Affiliates&#8217;, sublicensees&#8217; and representatives&#8217; performance in connection with this Agreement shall comply with all applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disclaimer</u><font style="font-size:12pt;">. &#160;EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INDEMNIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification by Novartis</u><font style="font-size:12pt;">. &#160;Novartis shall indemnify, defend and hold harmless XOMA and its Affiliates, and its or their respective directors, officers, employees and agents (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XOMA Indemnitees</u><font style="font-size:12pt;">&#8221;), from and against any and all liabilities, damages, losses, costs and expenses, including the reasonable fees of attorneys and other professional Third Parties (collectively, &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Losses</u><font style="font-size:12pt;">&#8221;), arising out of or resulting from any and all Third Party suits, claims, actions, proceedings or demands (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Claims</u><font style="font-size:12pt;">&#8221;) brought against any XOMA Indemnitee based upon:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">31</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The negligence, recklessness or wrongful intentional acts or omissions of Novartis or its Affiliates and its or their respective directors, officers, employees and agents, in connection with Novartis&#8217; performance of its obligations or exercise of its rights under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any breach of any representation or warranty or express covenant made by Novartis under Article 7 or any other provision under this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Development of the Products that is conducted by or under the authority of Novartis [*], the handling and storage by or on behalf of Novartis of any chemical agents or other molecules for the purpose of conducting such Development by or on behalf of Novartis, and the manufacture, marketing, Commercialization and sale by Novartis, its Affiliates or sublicensees of the Products, including&#160;any product liability, personal injury, property damage or other damage, in each case resulting from any of the foregoing activities described in this Section&#160;8.1(c);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">in each case, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided that</u><font style="font-size:12pt;">, such indemnity shall not apply to the extent such Losses arise from a cause or event described in clause (a), (b) or (c) of Section 8.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification by XOMA</u><font style="font-size:12pt;">. &#160;XOMA shall indemnify, defend and hold harmless Novartis and its Affiliates, and its or their respective directors, officers, employees and agents (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis Indemnitees</u><font style="font-size:12pt;">&#8221;), from and against any and all Losses, arising out of or resulting from any and all Claims against any Novartis Indemnitee based upon:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the negligence, recklessness or wrongful intentional acts or omissions of XOMA or its Affiliates or its or their respective directors, officers, employees and agents, in connection with XOMA&#8217;s performance of its obligations or exercise of its rights under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any breach of any representation or warranty or express covenant made by XOMA under Article 7 or any other provision under this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[*] and [*] or [*], including&#160;(i) any [*] damage or other damage, and (ii)&#160;[*], in each case resulting from any of the foregoing activities described in this Section&#160;8.2(c);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">in each case, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided that</u><font style="font-size:12pt;">, such indemnity shall not apply to the extent such Losses arise from a cause or event described in clause (a), (b) or (c) of Section 8.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Procedure</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.3.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Claim</u><font style="font-size:12pt;">. &#160;A Person entitled to indemnification under this Article 8 (an &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnified Party</u><font style="font-size:12pt;">&#8221;) shall give prompt written notification to the Party from whom indemnification is sought (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnifying Party</u><font style="font-size:12pt;">&#8221;) of the commencement of any action, suit or proceeding relating to a Claim for which indemnification is being sought or, if earlier, upon the assertion of any such Claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Claim as provided in this Section 8.3 shall not relieve the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">32</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of such failure to give notice).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.3.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assumption of Defense; Participation</u><font style="font-size:12pt;">. &#160;Within twenty (20) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of the defense of such Claim with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense and, without limiting the Indemnifying Party&#8217;s indemnification obligations, the Indemnifying Party shall reimburse the Indemnified Party for all costs and expenses, including reasonable attorney fees, incurred by the Indemnified Party in defending itself within thirty (30) days after receipt of any invoice therefor from the Indemnified Party. &#160;The Party not controlling such defense may participate therein at its own expense; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided,</u><font style="font-size:12pt;"> that if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such Claim, the Indemnifying Party shall be responsible for the reasonable fees and expenses of counsel to the Indemnified Party in connection therewith. &#160;The Party controlling such defense shall keep the other Party advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.3.3&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Settlements</u><font style="font-size:12pt;">. &#160;The Indemnified Party shall not agree to any settlement of such Claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. &#160;The Indemnifying Party shall not agree to any settlement of such Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party without the prior written consent of the Indemnified Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.3.4&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Mitigation of Loss</u><font style="font-size:12pt;">. &#160;Each Indemnified Party will take and will procure that its Affiliates take all such reasonable steps and actions as are necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 8. &#160;Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">SPECIAL, INDIRECT AND OTHER LOSSES</u><font style="font-size:12pt;">. &#160;EXCEPT FOR A BREACH OF ARTICLE 6 OR FOR CLAIMS OF A THIRD PARTY THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 8, NEITHER NOVARTIS NOR XOMA, NOR ANY OF THEIR RESPECTIVE AFFILIATES OR SUBLICENSEES, WILL BE LIABLE TO THE OTHER PARTY TO THIS AGREEMENT, ITS AFFILIATES OR ANY OF THEIR SUBLICENSEES FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR ROYALTIES, LOST DATA OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">33</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Exclusion</u><font style="font-size:12pt;">. &#160;Neither Party excludes any liability for death or personal injury caused by its negligence or that of its employees, agents or sub-contractors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 9</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">TERM AND TERMINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Term; Expiration</u><font style="font-size:12pt;">. &#160;This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 9, shall remain in effect until the expiration of the Royalty Term throughout the Territory (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Term</u><font style="font-size:12pt;">&#8221;). &#160;Upon expiration of the Term, all rights and licenses granted to Novartis pursuant to Section 3.1 shall survive, and shall become fully paid-up, perpetual and irrevocable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination for Cause</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.2.1&#160;&#160;&#160;&#160;If either Novartis or XOMA is in material breach of any material obligation hereunder, the non-breaching Party may give written notice to the breaching Party specifying the claimed particulars of such breach, and in the event such material breach is not cured within [*] after such notice (or, if such material breach relates to non-payment of monies due (a &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Payment Breach</u><font style="font-size:12pt;">&#8221;), then [*] after such notice), the non-breaching Party shall have the right thereafter to terminate this Agreement immediately by giving written notice to the breaching Party to such effect; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that, except with respect to [*], if [*] and [*] in accordance with [*] and [*], [*]. &#160;In the event that arbitration is commenced with respect to any alleged breach hereunder, no purported termination of this Agreement pursuant to this Section 9.2.1 shall take effect until the resolution of such arbitration. &#160;Any termination by any Party under this Section and the effects of termination provided herein shall be without prejudice to any damages or other legal or equitable remedies to which it may be entitled.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination by Novartis</u><font style="font-size:12pt;">. &#160;Novartis may terminate this Agreement without cause at any time after the Effective Date in its entirety or on a Licensed Antibody-by-Licensed Antibody or country-by-country basis at any time on one hundred eighty (180) days prior written notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effects of Expiration or Termination</u><font style="font-size:12pt;">. &#160;Upon any early termination (but not expiration) of this Agreement in its entirety or termination with respect to a country in the Territory other than any termination by Novartis under Section 9.2.1 due to XOMA&#8217;s breach:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.1&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Program Continuity</u><font style="font-size:12pt;">. The Parties intend that upon any termination of this Agreement, in whole or in part, the transfer from Novartis to XOMA of rights, materials, data and documentation related to the Licensed Antibodies and Products that are the subject of such termination as described below be conducted as expeditiously as is reasonably practicable, with the goal of ensuring an uninterrupted supply of Products to patients (including to patients enrolled in any clinical trials that are in progress as of the date of such termination), and in keeping with sound scientific, clinical and manufacturing practices and all applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">34</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.2&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">License Termination; Cessation of Development and Commercialization by Novartis</u><font style="font-size:12pt;">. &#160;All rights and licenses granted to Novartis under this Agreement shall be terminated and of no further force and effect, provided that if such termination is only with respect to a particular Licensed Antibody or country, then such termination shall apply only to such Licensed Antibody and Products containing such Licensed Antibody or with respect to the terminated countries, as applicable. &#160;Novartis shall cease its Development (except as set forth in Section 9.4.5) and Commercialization of such Licensed Antibodies and Products and in such countries as applicable, or, in the event of termination of this Agreement in its entirety, throughout the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.3&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Return of Confidential Information and Materials</u><font style="font-size:12pt;">. &#160;If this Agreement is terminated in its entirety, Novartis shall promptly return to XOMA all Know-How, data, materials and other Confidential Information made available to Novartis by XOMA under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.4&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Licenses</u><font style="font-size:12pt;">. &#160;Upon termination of this Agreement in whole or in part, except where Novartis has terminated this Agreement pursuant to Section 9.2, effective upon the date effective date of such termination:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis hereby grants XOMA [*] license under the Novartis Product IP (as defined below) solely to Develop, import, use, make, have made, offer for sale and sell, effective upon termination of this Agreement: (i) if this Agreement is terminated with respect to a particular Licensed Antibody, such Licensed Antibodies and Products containing such Licensed Antibody; (ii) if this Agreement is terminated with respect to a particular country, Licensed Antibodies and Products in such countries; and (iii) if this Agreement is terminated in full, Licensed Antibodies and Products throughout the Territory, subject to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Novartis hereby grants XOMA [*] license under the Novartis Product-Related IP (as defined below) solely in connection with XOMA&#8217;s practice of its license granted under subsection (a) above, subject to [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis Product IP</u><font style="font-size:12pt;">&#8221; means (i) all Novartis Patents that [*] of a Licensed Antibody or Product, and (ii) all Know-How [*] in connection with this Agreement that [*] any Licensed Antibody or Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis Product-Related IP</u><font style="font-size:12pt;">&#8221; means (i) all Novartis Patents, other than the Novartis Patents included in the Novartis Product IP, that [*] any Licensed Antibody or Product, and (ii) all Know-How [*] in connection with this Agreement, other than the Know-How included in the Novartis Product IP, that [*] any Licensed Antibody or Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;XOMA may decline to accept at any time either or both of the licenses set forth in subsections (a) and (b) above upon written notice to Novartis. Novartis shall [*] for any [*] to the extent arising from [*] set forth in [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.5&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Clinical Development Activities</u><font style="font-size:12pt;">. &#160;With respect to any clinical Development activities of Novartis directed to the Products with respect to the terminated countries that are in progress at the time of notice of termination, at XOMA&#8217;s election prior to the effective date of termination, Novartis shall to the extent not prohibited by applicable Law or any Regulatory </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">35</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Authority transfer to XOMA any such clinical Development activities, including responsibility for payment of all fees, costs and expenses associated with such clinical Development activities, and forward all interim and final reports and underlying data from such activities to XOMA to enable such clinical Development activities to be transferred to XOMA without interruption. &#160;Such transfer shall [*] in accordance with Section [*], unless [*] in accordance with Section [*], in which case [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.6&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Filings</u><font style="font-size:12pt;">. &#160;To the extent permitted by applicable Law, and within thirty (30) days of XOMA&#8217;s request, Novartis will promptly assign to XOMA all Regulatory Approvals and Regulatory Materials submitted and Controlled by Novartis for the Products solely with respect to the terminated countries and/or Products (as applicable). &#160;If Novartis is restricted under applicable Law from transferring ownership of any of the foregoing items to XOMA (including in order to continue to conduct any transition activities as contemplated in this Section 9.4, including the conduct of clinical Development activities, if applicable, pursuant to Section 9.4.5 above), Novartis shall grant XOMA (or its designee) an exclusive right of reference or use to such item. &#160;Novartis shall, [*], take actions reasonably necessary to effect such transfer or grant of right of reference or use to XOMA, including by making such filings as may be required with Regulatory Authorities and other governmental authorities in the Territory that may be necessary to record such assignment or effect such transfer. &#160; &#160;Such transfer shall [*] in accordance with Section [*], unless [*] in accordance with Section [*], in which case [*]. &#160;All such Regulatory Approval and Regulatory Materials shall be deemed to be XOMA&#8217;s Confidential Information as of the effective date of such termination and the exceptions in Sections 6.1(a) and (e) shall not apply to Novartis with respect to such Regulatory Approval and Regulatory Filings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.7&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Data</u><font style="font-size:12pt;">. &#160;Within thirty (30) days of the effective date of such termination, Novartis shall transfer and assign to XOMA, &#160;all data from preclinical, non-clinical and clinical studies conducted by or on behalf of Novartis, its Affiliates or sublicensees relating to any Licensed Antibodies or Products and all pharmacovigilance data (including all adverse event databases) relating to any Licensed Antibodies or Products, which data shall be deemed to be XOMA&#8217;s Confidential Information as of the effective date of such termination and the exceptions in Sections 6.1(a) and (e) shall not apply to Novartis with respect to such data. &#160;At XOMA&#8217;s request, Novartis shall provide XOMA with assistance with any inquiries and correspondence with Regulatory Authorities relating to any Licensed Antibody or Product for a period of twelve (12) months after such termination. &#160;Such transfer shall [*] in accordance with Section [*], unless [*] in accordance with Section [*], in which case [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.8&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Inventory Transfer</u><font style="font-size:12pt;">. &#160;As requested by XOMA, Novartis shall transfer to XOMA or its designee any and all inventory of Licensed Antibodies and Products (including all research materials, final product, bulk drug substance, intermediates, work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of Novartis, its Affiliates or sublicensees. &#160;Such activities shall [*] in accordance with Section [*], unless [*] in accordance with Section [*], in which case [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.9&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Patent Prosecution and Enforcement</u><font style="font-size:12pt;">. &#160;After the effective date of termination, Novartis shall promptly transfer to XOMA, and XOMA shall thereafter be solely </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">36</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">responsible for, the prosecution and maintenance of the XOMA Patents. &#160;Such transfer shall [*] in accordance with Section [*], unless [*] in accordance with Section [*], in which case [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.10&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination Press Releases</u><font style="font-size:12pt;">. &#160;In the event of termination of this Agreement for any reason and subject to the provisions of Section 6.3.1, the Parties shall cooperate in good faith to coordinate public disclosure of such termination and the reasons therefor, and shall not, except to the extent required by applicable Law, disclose such information without the prior approval of the other Party. &#160;The principles to be observed in such disclosures shall be accuracy, compliance with applicable Law and regulatory guidance documents, and reasonable sensitivity to potential negative investor reaction to such news.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.4.11&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">[*] Additional Transition Assistance, and Other Matters</u><font style="font-size:12pt;">. &#160;The Parties shall timely [*] that are [*] as well as any additional transition assistance that may be reasonably requested by XOMA (to be undertaken [*] to the extent [*]). &#160;[*] may also include [*] relating to the terminated Licensed Products; however, [*]. &#160;In the event that, [*] (or such [*] as the Parties may agree), [*] as to any [*] in connection therewith, [*] notice to the other Party [*] pursuant to this Section 9.4.11. &#160;Notwithstanding the foregoing, [*], by providing [*] with written notice [*] (or [*] pursuant to the preceding sentence), [*], it being understood that, in such event, [*]; provided that if [*] that are [*], then upon such notice being provided, [*] and shall [*] unless and until [*] that are [*]. &#160;Following such notice, the Parties shall [*] and [*], which [*] and [*] and [*], and shall [*]. &#160;If the Parties [*], then each Party shall [*] and [*], provided that [*], and [*] under this Section 9.4.11. &#160;[*] (or [*], as the case may be), each Party will [*] and [*] for the [*] and [*], [*]. &#160;The Parties will also [*] this Agreement, as may be amended at such time. &#160;[*], each Party [*]. &#160;Neither Party may [*] other than for the sole purpose of [*] or as expressly permitted in this Section 9.4.11; provided that [*] if [*] and [*], in which event [*]. &#160;[*] (or, if [*], then [*]), [*] provided [*] consistent with [*] this Agreement. &#160;[*]. &#160;[*], and [*] or [*]. &#160;The Parties shall [*], however, each Party shall [*] under this Section 9.4.11.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Effects of Termination for Novartis Termination due to XOMA Breach</u><font style="font-size:12pt;">. &#160;Upon any early termination of this Agreement in its entirety by Novartis under Section 9.2.1 due to XOMA&#8217;s breach, then in addition to any other right or remedy Novartis may have, at Law or in equity, then the following Sections shall survive such termination [*].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">ARTICLE 10  </b><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ACCRUED RIGHTS; SURVIVING PROVISIONS</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">10.1.1&#160;&#160;Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or expiration, including the payment obligations under Article 4 hereof, and any and all damages or remedies arising from any breach hereunder. &#160;Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">10.1.2&#160;&#160;In addition to any other provisions of this Agreement that are elsewhere expressly stated to survive, the provisions of [*] shall survive the termination of this Agreement in its entirety or expiration of this Agreement for any reason, in accordance with their respective terms and conditions, and for the duration stated, and where no duration is stated, shall survive </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">37</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">indefinitely. &#160;In addition: (a) [*] shall survive for a period of [*] years after the effective date of termination or expiration of this Agreement, and (b) Section [*] shall survive for a period of [*] years after the effective date of termination or expiration of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ARTICLE 11</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.1&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Dispute Resolution</u><font style="font-size:12pt;">. &#160;If a dispute between the Parties arises under this Agreement, either Party shall have the right to refer such dispute in writing to the respective Executive Officers, and such Executive Officers shall attempt in good faith to resolve such dispute. &#160;If the Parties are unable to resolve a given dispute pursuant to the preceding sentence within thirty (30) days after referring such dispute to the Executive Officers, either Party may have the given dispute settled in court pursuant to the remainder of this Section&#160;11.1. &#160;Each Party irrevocably submits to the exclusive jurisdiction of the United States District Court for the Southern District of New York for the purposes of any suit, action or other proceeding arising out of this Agreement. &#160;Each Party agrees to commence any such action, suit or proceeding in the United States District Court for the Southern District of New York or if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County. &#160;Each Party irrevocably and unconditionally waives any objection to the laying of venue of any such action, suit or proceeding arising out of this Agreement in the United States District Court for the Southern District of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. &#160;Notwithstanding anything in this Agreement to the contrary, a Party may seek a temporary restraining order or a preliminary injunction from any court of competent jurisdiction, at any time, in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the resolution of any dispute hereunder, including under this Section 11.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.2&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:12pt;">. &#160;This Agreement and any dispute arising from the performance or breach hereof shall be governed by and interpreted in accordance with the laws of the State of New York, without giving effect to any choice of law rules. &#160;The provisions of the United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement or any subject matter hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.3&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assignment</u><font style="font-size:12pt;">. &#160;Neither Party may assign this Agreement, in any manner including by operation of law, without the consent of the other Party, except as otherwise provided in this Section 11.3. &#160;Either Party may assign this Agreement in whole or in part to any Affiliate without the consent of the other Party. &#160;Either Party may also assign this Agreement, without the consent of the other Party, to any successor or Third Party that acquires all or substantially all of the business or assets of the assigning Party to which this Agreement relates, whether by sale, transfer, merger, reorganization, operation of law or otherwise, and Novartis may assign this Agreement to any Third Party in connection with any divestiture undertaken to satisfy an applicable governmental authority or agency; </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:12pt;">, that in each case such assigning Party provides the other Party with written notice of such assignment and the assignee agrees in writing to assume performance of all assigned obligations. &#160;The terms of this Agreement shall be binding upon and </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">38</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shall inure to the benefit of the successors, heirs, administrators and permitted assigns of the Parties. &#160;Any purported assignment in violation of this Section&#160;11.3 shall be null and void.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.4&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Force Majeure</u><font style="font-size:12pt;">. &#160;No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying. &#160;For purposes of this Agreement, force majeure is defined as causes beyond the reasonable control of the Party, including acts of God; material changes in Law; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public utilities or common carriers. &#160;In such event XOMA or Novartis, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. &#160;The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up to a maximum of ninety (90) days, after which time XOMA and Novartis shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by the Agreement. &#160;To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.5&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:12pt;">. &#160;Any notice or request required or permitted to be given under or in connection with this Agreement shall be given in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If to XOMA:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">XOMA (US) LLC<br>2910 Seventh Street <br>Berkeley, California 94710<br></font><font style="font-size:12pt;white-space:pre-wrap;">Attention:  Legal Department<br></font><font style="font-size:12pt;white-space:pre-wrap;">Fax:  510-644-2011</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">With a required copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">Cooley LLP<br>3175 Hanover Street<br></font><font style="font-size:12pt;white-space:pre-wrap;">Palo Alto, CA  94304-1130<br></font><font style="font-size:12pt;white-space:pre-wrap;">Attention:   Barbara A. Kosacz<br>Fax: +1 650 849 7400</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If to Novartis:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Novartis International Pharmaceutical Ltd. <br>131 Front Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">39</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Hamilton HM 12 Bermuda<br></font><font style="font-size:12pt;white-space:pre-wrap;">Attn:  General Counsel<br></font><font style="font-size:12pt;white-space:pre-wrap;">Fax:  (441) 296-5083</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">with a required copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 108pt;"><font style="font-size:12pt;">Novartis Institutes for BioMedical Research, Inc.<br>220 Massachusetts Avenue<br>Cambridge, Massachusetts 02139<br></font><font style="font-size:12pt;white-space:pre-wrap;">Attn:  General Counsel<br></font><font style="font-size:12pt;white-space:pre-wrap;">Fax:  (617) 871-3354</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">or to such other address for such Party as it shall have specified by like notice to the other Parties, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">provided that</u><font style="font-size:12pt;"> notices of a change of address shall be effective only upon receipt thereof. &#160;If delivered personally or by facsimile transmission, the date of delivery shall be deemed to be the date on which such notice or request was given. &#160;If sent by overnight express courier service, the date of delivery shall be deemed to be the next Business Day after such notice or request was deposited with such service. &#160;If sent by certified mail, the date of delivery shall be deemed to be the third (3rd) Business Day after such notice or request was deposited with the U.S. Postal Service.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.6&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Export Clause</u><font style="font-size:12pt;">. &#160;Each Party acknowledges that the Laws of the United States restrict the export and re-export of certain commodities and technical data of United States origin. &#160;Each Party agrees that it will not export or re-export restricted commodities or the technical data of the other Party in any form without the appropriate United States and foreign government licenses. &#160;Novartis shall not be required by the terms of this Agreement to be directly or indirectly involved in the provision of goods, services or technical data that may be prohibited by applicable export control, economic sanctions laws and anti-boycott regulations of the United States and other governments (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Trade Control Laws</u><font style="font-size:12pt;">&#8221;) if performed by Novartis. &#160;It shall be in the sole discretion of Novartis to refrain from being directly or indirectly involved in the provision of goods, services or technical data that may be prohibited by applicable Trade Control Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.7&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Waiver</u><font style="font-size:12pt;">. &#160;Neither Party may waive or release any of its rights or interests in this Agreement except in writing. &#160;The failure of either Party to assert a right hereunder or to insist upon compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. &#160;No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.8&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Severability</u><font style="font-size:12pt;">. &#160;If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. &#160;Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">40</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.9&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Certain Amendments</u><font style="font-size:12pt;">. &#160;Simultaneously with the execution of this Agreement, the Parties shall, or shall cause their Affiliates (as may be applicable), to execute (a) an amendment in the form of </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT F</b><font style="font-size:12pt;"> to the Note, (b) an amendment in the form of </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT G</b><font style="font-size:12pt;"> to the Security &#160;Agreement dated May 26, 2005, as amended, between XOMA and NVDI, which was assigned by NVDI to NIBR immediately prior to the execution of this Agreement, and (c) an amendment in the form of </font><b style="font-size:12pt;font-weight:bold;">EXHIBIT H</b><font style="font-size:12pt;"> to the Amended and Restated Research, Development and Commercialization Agreement, dated July 1, 2008, as amended, between XOMA and NVDI.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.10&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement</u><font style="font-size:12pt;">. &#160;This Agreement, together with the Schedules and Exhibits hereto, set forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties and supersede and terminate all prior agreements and understanding between the Parties with respect to the subject matter of this Agreement. &#160;In particular, and without limitation, this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date. &#160;There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties with respect to the subject matter of this Agreement other than as set forth herein and therein. &#160;No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.11&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Independent Contractors</u><font style="font-size:12pt;">. &#160;Nothing herein shall be construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. &#160;Each Party is an independent contractor. &#160;Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. &#160;Neither Party shall have the authority to bind or obligate the other Party and neither Party shall represent that it has such authority.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.12&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Headings; Construction; Interpretation</u><font style="font-size:12pt;">. &#160;Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement. &#160;The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. &#160;Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. &#160;Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. &#160;Except where the context otherwise requires, (a) any reference to any Law refers to such Law as from time to time enacted, repealed or amended or any replacement thereof, (b) the words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder,&#8221; and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof,&#160;(c) the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including,&#8221; shall be deemed to be followed by the phrase &#8220;but not limited to,&#8221; &#8220;without limitation&#8221; or words of similar import, (d) the&#160;word &#8220;or&#8221; is used in the </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">41</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">inclusive sense (and/or), (e) provisions that refer to Persons acting &#8220;under the authority of Novartis&#8221; shall include Novartis&#8217; Affiliates or sublicensees and those Persons acting &#8220;under the authority of XOMA&#8221; shall include XOMA&#8217;s Affiliates or licensees (other than Novartis); conversely, those Persons acting &#8220;under the authority of Novartis&#8221; shall exclude XOMA, its Affiliates and licensees and those Persons acting &#8220;under the authority of XOMA&#8221; shall exclude Novartis, its Affiliates and sublicensees; (f) the word &#8220;notice&#8221; shall require notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (g) words of any gender include the other gender; (h) words using the singular or plural number also include the plural or singular number, respectively; and (i) provisions that require that a Party or the Parties &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.13&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Further Actions</u><font style="font-size:12pt;">. &#160;Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.14&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Parties in Interest; No Third Party Beneficiary Rights</u><font style="font-size:12pt;">. &#160;All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit of and be enforceable by the Parties hereto and their respective successors, heirs, administrators and permitted assigns. &#160;The provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights to any Third Party (including any third party beneficiary rights).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.15&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Performance by Affiliates</u><font style="font-size:12pt;">. &#160;To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.16&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Extension to Affiliates</u><font style="font-size:12pt;">. &#160;Novartis shall have the right to extend the rights and obligations granted in this Agreement to one or more of its Affiliates. &#160;All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to Novartis. &#160;Novartis shall remain directly liable for any acts or omissions of its Affiliates, and Novartis hereby expressly waives any requirement that XOMA exhaust any right, power or remedy, or proceed directly against such Affiliate, for any obligation or performance hereunder prior to proceeding directly against Novartis.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">11.17&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:12pt;">. &#160;This Agreement may be signed in counterparts, each and every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. &#160;Facsimile signatures and signatures transmitted via PDF shall be treated as original signatures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[</b><i style="font-size:12pt;font-style:italic;">Signature page to follow</i><b style="font-size:12pt;font-weight:bold;">]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">-</font><font style="font-size:12pt;">42</font><font style="font-size:12pt;">-</font></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Execution Version</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[</font><i style="font-size:12pt;font-style:italic;">Signature page to License Agreement</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">XOMA (US) LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Jim R. Neal</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Jim R. Neal  </font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VP Business Development</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ H.S. Zivi</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: </font></p></td><td style="vertical-align:bottom;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">H.S. Zivi</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: </font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Director</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Michael Jones</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: </font></p></td><td style="vertical-align:bottom;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Michael Jones</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: </font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Director</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A-1 &#8211; [*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">[*</font><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A-2 - XOMA Core Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT B &#8211; Form of Novartis Invoice</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:42.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Sender&#39;s Logo</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">INVOICE</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">INVOICE DATE:</b></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Street</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">__ ________ 20__</b></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Town, Country</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Phone and Fax Nr.</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">INVOICE No.: XXXX</b></p></td></tr><tr style="height:8.6pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Bill To:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.72%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">For:</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[Product X Royalties 1st Quarter 20</font><b style="font-size:12pt;font-weight:bold;">__]</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[(or Milestone for event Y)]</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">P.O. Box HM 2899</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Hamilton, HM LX, Bermuda</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Attn: Simon Zivi/Laurieann Chaikowsky</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">And via fax to no. +1 441 296 5083</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:20.1pt;"><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:79.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">DESCRIPTION [</b><i style="font-size:12pt;font-style:italic;">Please specify the event for which the invoice is due]</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">AMOUNT (USD)</b></p></td></tr><tr style="height:38.25pt;"><td colspan="3" style="vertical-align:middle;width:79.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Product X [royalties] [January &#8211; March 20__] calculated based on Novartis provided [sales &amp; royalty report] (see attached worksheet)</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;"> US$ 000&#39;000.00 </font></p></td></tr><tr style="height:20.1pt;"><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:79.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[(Or milestone payment for event Y, according to paragraph XY of agreement ZZZZ dated &#8230;&#8230;)]</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:14.6pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:20.1pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Novartis Contract Code</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:17.3pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:20.1pt;"><td colspan="3" style="vertical-align:middle;width:79.38%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Please remit by wire transfer within [[___] days] to:</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Receiving Bank - &#8230;&#8230;..</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Swift Code - &#8230;&#8230;..&#160;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">ABA Number - &#8230;&#8230;..</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Credit Account - &#8230;&#8230;..</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:12pt;">Beneficiary - &#8230;&#8230;..</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:20.1pt;"><td style="vertical-align:middle;white-space:nowrap;width:59.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;white-space:pre-wrap;">TOTAL  </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;"> 000&#39;000,00 </font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:79.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">If you have any questions concerning this invoice, contact &#8230;&#8230;&#8230;&#8230;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">or e-mail to &#8230;&#8230;..</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VAT -Reg. No. Xxxxxxxxxx (if applicable)</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT C &#8211; Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">[*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT D &#8211; XOMA Third Party Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">[*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT E</b><font style="font-size:12pt;"> &#8211; [*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT F</b><font style="font-size:12pt;"> &#8211; </font><b style="font-size:12pt;font-weight:bold;">Form of Amendment to the Note</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">{Filed as Exhibit 10.3 to the Quarterly Report}</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT G</b><font style="font-size:12pt;"> &#8211; </font><b style="font-size:12pt;font-weight:bold;">Form of Amendment to the Security Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">AMENDMENT TO SECURITY AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">THIS AMENDMENT TO SECURITY AGREEMENT (this &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendment</u><font style="font-size:12pt;">&#8221;), dated as of September 30, 2015, is entered into between XOMA (US) LLC, a Delaware limited liability company (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;) and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">NIBR</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">RECITALS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and NIBR are parties to that certain Security Agreement dated as of May 26, 2005, as amended (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Security Agreement</u><font style="font-size:12pt;">&#8221;), and that certain Secured Note Agreement, dated May 26, 2005, as amended (as amended, restated, supplemented or otherwise amended from time to time, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Note</u><font style="font-size:12pt;">&#8221;), which in each case were assigned from Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation) to NIBR immediately prior to the execution of this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and NIBR are concurrently herewith entering into an amendment to the Note to, among other things, extend the maturity date of the Note.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and Novartis International Pharmaceutical Ltd., a corporation organized under the laws of Bermuda (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Novartis</u><font style="font-size:12pt;">&#8221;) are concurrently herewith entering into that certain License Agreement dated the date hereof (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">License</u><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and NIBR desire to amend the Security Agreement on the terms set forth in this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Definitions</u><font style="font-size:12pt;white-space:pre-wrap;">.  Capitalized terms used herein but not otherwise defined shall have the meaning given to such terms in the Security Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Amendments to Security Agreement</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Recital A of the Security Agreement is hereby amended and restated in its entirety as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;In accordance with that certain Secured Note Agreement, dated as of May 26, 2005, between the Company and the Lender (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Note</u><font style="font-size:12pt;">&#8221;) and that certain Research, Development and Commercialization Agreement dated as of May 26, 2005 between the Company and Novartis Vaccines and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Diagnostics, Inc. (f/k/a Chiron Corporation) (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Collaboration Agreement</u><font style="font-size:12pt;">&#8221;), the Lender has agreed to make loans to the Company;&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 4.5pt;"><font style="font-size:12pt;">2.2&#160;&#160;&#160;&#160;&#160;&#160;Section 2 of the Security Agreement is hereby amended and restated in its entirety as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">&#8220;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Collateral</u><font style="font-size:12pt;white-space:pre-wrap;">.  The Collateral shall consist of all right, title and interest of the Company in and to the following, whether now existing or hereafter acquired:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company&#8217;s interest in the Collaboration and its share of Pre-tax Profits from Collaboration Products (as each such term is defined in the Collaboration Agreement), payable to the Company pursuant to Section 6.2 of the Collaboration Agreement as well as the Company&#8217;s interest in all milestone payments, royalty-style payments or option payments that may become due to Company pursuant to the Amended and Restated Research, Development and Commercialization Agreement, effective as of July 1, 2008 by and between Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation) and the Company, as amended; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company&#8217;s interest in all upfront fees, milestone payments, and royalty payments that may become due to Company pursuant to the License; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all proceeds of the foregoing Collateral.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Limitation of Amendments</u><font style="font-size:12pt;">. &#160;Except as expressly provided herein and modified hereby, the Security Agreement shall remain unmodified and in full force and effect. &#160;This Amendment shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of the Security Agreement or any of the instruments or agreements referenced therein, or (b) otherwise prejudice any right or remedy which NIBR may now have or may have in the future under or in connection with the Security Agreement or any of the instruments or agreements referenced therein. &#160;This Amendment shall be construed in connection with and as part of the Security Agreement and all terms, conditions, representations, warranties, covenants and agreements set forth in the Security Agreement, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties; No Default</u><font style="font-size:12pt;">: By its execution hereof, the Company hereby certifies to NIBR as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties of the Company set forth in the Security Agreement are true and correct as of the date hereof; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;No default has occurred and is continuing which with the giving of notice or the passage of time would become an Event of Default, and no Event of Default has occurred and is continuing or will arise immediately after giving effect to or as a result of this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Assignment</u><font style="font-size:12pt;">. &#160;The parties acknowledge and agree that NIBR may assign or transfer its rights and obligations in the Security Agreement to any permitted transferee of the Note without the prior written consent of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Further Assurances</u><font style="font-size:12pt;">. &#160;The Company shall execute and deliver such other documents, and take such other actions, as may be requested by NIBR from time to time to give effect to the provisions of this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:12pt;">. &#160;This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement</u><font style="font-size:12pt;">. &#160;This Amendment, together with the Security Agreement and &#160;the Note constitute and contain the entire agreement of NIBR and the Company with respect to their respective subject matters, and supersede any and all prior agreements and understandings relating to the subject matter thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[</font><i style="font-size:12pt;font-style:italic;">signature pages follow</i><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">XOMA (US) LLC</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Jim R. Neal</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Jim R. Neal  </font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VP Business Development</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Christian Klee</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: </font></p></td><td style="vertical-align:bottom;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Christian Klee</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: </font></p></td><td style="vertical-align:bottom;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VP + CFO</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT H</b><font style="font-size:12pt;"> &#8211; </font><b style="font-size:12pt;font-weight:bold;">Form of Amendment to the Amended and Restated Research, Development and Commercialization Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">{Filed as Exhibit 10.4 to the Quarterly Report}</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SCHEDULE 1 &#8211; Exceptions to Representations and Warranties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">[*]</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Certain confidential portions of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i) not material and (ii) would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tmb-20200930xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 11/5/2020 12:41:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;text-transform:uppercase;margin:0pt;"><font style="color:#212121;font-size:10pt;margin-bottom:3pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-transform:uppercase;margin:0pt;"><b style="color:#212121;font-weight:bold;">CERTAIN&#160;</b><b style="color:#252525;font-weight:bold;">CONFIDENTIAL</b><b style="color:#212121;font-weight:bold;">&#160;</b><b style="color:#252525;font-weight:bold;">PORTIONS</b><b style="color:#212121;font-weight:bold;">&#160;OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#8220;[***]&#8221;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I)&#160;NOT MATERIAL AND (II)&#160;WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">NOVARTIS VACCINES AND DIAGNOSTICS, INC.<br>5300 Chiron Way<br><font style="white-space:pre-wrap;">Emeryville, California  94608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>September 30, 2015</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>XOMA (US) LLC<br>2910 Seventh Street<br><font style="white-space:pre-wrap;">Berkeley, California  94710</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Attention:  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">Re:  CD40 Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Ladies and Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Reference is made to (i) that certain Amended and Restated Research, Development and Commercialization Agreement, dated July 1, 2008, as amended (the &#8220;CD40 Agreement&#8221;), between XOMA (US) LLC, a Delaware limited liability company (&#8220;XOMA&#8221;), and Novartis Vaccines and Diagnostics, Inc. (f/k/a Chiron Corporation), a Delaware corporation (&#8220;NVDI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">XOMA and NVDI hereby agree to the terms of this letter agreement as an amendment to the CD40 Agreement. &#160;Capitalized terms used but not otherwise defined herein shall have the respective meanings assigned to them in the CD40 Agreement, unless the context requires otherwise. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Section 1.41 of the CD40 Agreement is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">1.41</b> &#160;<b style="font-weight:bold;">Royalty-Style Payment Period&#8221; </b>means, with respect to any Collaboration Product, Resumed Product, NVDI Ongoing Product, XOMA Ongoing Product or Reactivated Product, the longer of (i) the period during which such Product is covered by a Valid Claim of Related XOMA Patent Rights or Related NVDI Patent Rights as the case may be or (ii) ten (10) years from the launch of such Product on a country-by-country basis.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">The Parties acknowledge and agree that the milestone set forth in Section 3.3(a) of the CD40 Agreement has been paid in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Section 3.6(a) of the CD40 Agreement is hereby amended and restated in its entirety as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">(a) &#160;</b>Subject to the adjustment provisions of Section 3.6(g), NVDI shall pay to XOMA royalty-style payments on Net Sales of each Collaboration Product [*] at the following rates during the applicable Royalty-Style Payment Period:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font>[*] of the portion of the aggregate Net Sales for such Collaboration Product in each calendar year that is equal to or less than [*];</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font>[*] of the portion of the aggregate Net Sales for such Collaboration Product in each calendar year that is greater than [*] and equal to or less than [*]; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-weight:bold;">(iii)</b><font style="display:inline-block;width:18pt;"></font>[*] of the portion of the aggregate Net Sales for such Collaboration Product in each calendar year that is greater than [*].&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Except as expressly stated herein, all provisions of the CD40 Agreement remain in full force and effect. &#160;[*].</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">This letter agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;">Please confirm that the foregoing is in accordance with your understanding by acknowledging your agreement in the space provided below. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;width:180pt;"></font>Very truly yours,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 180pt;">NOVARTIS VACCINES AND DIAGNOSTICS, INC.<img src="tmb-20200930xex10d2001.jpg" alt="Graphic" style="display:inline-block;height:82.61pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:275.7pt;"><br><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">XOMA (US) LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">   /s/ Jim R. Neal</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:27.67pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name:<font style="display:inline-block;width:4.01pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">    Jim R. Neal</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:3.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Title:<font style="display:inline-block;width:10.01pt;"></font><u style="text-decoration:underline;text-decoration-color:#000000;white-space:pre-wrap;">    VP Business Development</u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:3.34pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration:underline;text-decoration-color:#000000;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;width:224pt;"></font>- 2 -</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-transform:uppercase;margin:0pt;"><font style="color:#212121;font-weight:normal;text-transform:none;">Certain&#160;</font><font style="color:#252525;font-weight:normal;text-transform:none;">confidential</font><font style="color:#212121;font-weight:normal;text-transform:none;">&#160;</font><font style="color:#252525;font-weight:normal;text-transform:none;">portions</font><font style="color:#212121;font-weight:normal;text-transform:none;">&#160;of this exhibit have been omitted and replaced with &#8220;[***]&#8221;. such identified information has been excluded from this exhibit because it is (i)&#160;not material and (ii)&#160;would likely cause competitive harm to the company if disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tmb-20200930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 11/5/2020 12:41:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, James R. Neal, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: November 5, 2020</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ JAMES R. NEAL</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">James R. Neal</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tmb-20200930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 11/5/2020 12:41:29 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Thomas Burns, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: November 5, 2020</font></p></td><td style="vertical-align:top;width:57.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer </font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tmb-20200930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 11/5/2020 12:41:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), James R. Neal, Chief Executive Officer of XOMA Corporation (the &#8220;Company&#8221;), and Thomas Burns, Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The Company&#8217;s Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">The information contained in Exhibit 32.1 fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 5</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;day of November, 2020</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;width:54.61%;"><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ JAMES R. NEAL</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">James R. Neal</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.28;text-align:justify;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></td></tr></table><div style="margin-top:8pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tmb-20200930xex10d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20200930xex10d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "G BT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8PSGFJ][/%:VSSRN!
M&@RWO5D]:XW7+B;6?%%GH=NX%O /M%VP_A_N#\:NG%SG9[;LB<N75;G+ZKJG
MB>74M)U.2<V=M<WBI%9(<L8_]JO5P20#WK@_%4@D\9>&K(<?OF?\A72Z_KD6
MA:--J$F&VC$:?WF/05T8KWX4E%:N^QC2NIRYF;0HKSG0?&6L_P#"26FF>(+&
M.!=0C,UJZGD'^Z:]%4Y%<U:C*FTI=3>,^8>.E% Z45)04444 %%%% !1110
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M9<NAF2>#=9FN+74EUW9J:+MD=HOE(/85)>^ Y]4TZ6*_\07DT\@QN^ZH_P"
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M_@6/\* .KHKE/^$.G_Z&?Q#_ .!0_P *7_A$)O\ H9?$'_@4/\* .JHKE/\
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M*[>FGD:0G=M)6L:[/M4N[;5 R35/3]8LM5$QLYA*(7*/CL:\\T>\U&\T*_\
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MM#S"6^\.WL4RZEJ7B"\>8$$M;S(B_P"Z@3:/QS6UIGBGP]I.GQ65K'J BC&
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MF_\ B:ZK ]*3:/04 8>D^)+#6IG@M#<"2( L)+=X_P"=;M(% .0!2T %%%%
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MT&=(_P# )_\ XNNJHH Y3[%XW_Z#.D?^ 3__ !5+_9_C,_\ ,8TC_P  6_\
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M76T4 <G_ &-XR_Z&JU_\%P_^*H_L;QE_T-5K_P""X?\ Q5=910!R?]C>,O\
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>tmb-20200930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2020 12:41:57 PM-->
<!--Modified on: 11/5/2020 12:41:57 PM-->
<schema xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.xoma.com/20200930" xmlns:xoma="http://www.xoma.com/20200930">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited) (calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails">
        <link:definition>40302 - Disclosure - Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails">
        <link:definition>40303 - Disclosure - Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" id="DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails">
        <link:definition>40702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" id="DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>40702 - Disclosure - Leases - Maturity of lease liabilities (Details) (calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" id="DisclosureLeaseAgreementsLeaseCostsDetails">
        <link:definition>40703 - Disclosure - Lease Agreements - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2" id="DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2">
        <link:definition>40803 - Disclosure - Long-Term Debt - Payments of Long-Term Debt (Details) (calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" id="DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails">
        <link:definition>40803 - Disclosure - Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" id="DisclosureLeaseAgreementsTables">
        <link:definition>30703 - Disclosure - Lease Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails">
        <link:definition>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails">
        <link:definition>40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails">
        <link:definition>40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails">
        <link:definition>40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails">
        <link:definition>40301 - Disclosure - Consolidated Financial Statements Detail - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails">
        <link:definition>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails" id="DisclosureLicensingAndOtherArrangementsNovartisDetails">
        <link:definition>40401 - Disclosure - Licensing and Other Arrangements - Novartis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" id="DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails">
        <link:definition>40402 - Disclosure - Licensing and Other Arrangements - Novartis International (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteDetails">
        <link:definition>40403 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails">
        <link:definition>40404 - Disclosure - Licensing and Other Arrangements - Rezolute - First Amendment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails">
        <link:definition>40405 - Disclosure - Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" id="DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails">
        <link:definition>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails" id="DisclosureLicensingAndOtherArrangementsZydusDetails">
        <link:definition>40407 - Disclosure - Licensing and Other Arrangements - Zydus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" id="DisclosureLicensingAndOtherArrangementsNiaidDetails">
        <link:definition>40408 - Disclosure - Licensing and Other Arrangements - NIAID (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" id="DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails">
        <link:definition>40409 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails" id="DisclosureRoyaltyPurchaseAgreementsAgenusDetails">
        <link:definition>40501 - Disclosure - Royalty Purchase Agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails" id="DisclosureRoyaltyPurchaseAgreementsBioasisDetails">
        <link:definition>40502 - Disclosure - Royalty Purchase Agreements - Bioasis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails" id="DisclosureRoyaltyPurchaseAgreementsAronoraDetails">
        <link:definition>40503 - Disclosure - Royalty Purchase Agreements - Aronora (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" id="DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails">
        <link:definition>40504 - Disclosure - Royalty Purchase Agreements - Palobiofarma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" id="DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails">
        <link:definition>40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" id="DisclosureFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails" id="DisclosureFairValueMeasurementsDebtDetails">
        <link:definition>40605 - Disclosure - Fair Value Measurements - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" id="DisclosureLeaseAgreementsLeasedFacilitiesDetails">
        <link:definition>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" id="DisclosureLeaseAgreementsAdditionalInformationDetails">
        <link:definition>40704 - Disclosure - Lease Agreements - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails" id="DisclosureLeaseAgreementsSubleaseAgreementsDetails">
        <link:definition>40705 - Disclosure - Lease Agreements - Sublease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" id="DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails">
        <link:definition>40801 - Disclosure - Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" id="DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails">
        <link:definition>40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" id="DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails">
        <link:definition>40804 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" id="DisclosureCommonStockWarrantsDetails">
        <link:definition>40901 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" id="DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" id="DisclosureCommitmentsAndContingenciesContingentConsiderationDetails">
        <link:definition>41002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" id="DisclosureStockBasedCompensationEsppDetails">
        <link:definition>41101 - Disclosure - Stock-based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>41102 - Disclosure - Stock-based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" id="DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>41103 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41104 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" id="DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails">
        <link:definition>41105 - Disclosure - Stock-based Compensation - Performance-based stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>41106 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details" id="DisclosureCapitalStockRightsOffering2019Details">
        <link:definition>41201 - Disclosure - Capital Stock - Rights Offering 2019 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails" id="DisclosureCapitalStockPreferredStockDetails">
        <link:definition>41202 - Disclosure - Capital Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" id="DisclosureCapitalStockAtmAgreementsDetails">
        <link:definition>41203 - Disclosure - Capital Stock - ATM Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41301 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEventDetails" id="DisclosureSubsequentEventDetails">
        <link:definition>41401 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetails">
        <link:definition>10301 - Disclosure - Condensed Consolidated Financial Statements Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" id="DisclosureLicensingAndOtherArrangements">
        <link:definition>10401 - Disclosure - Licensing and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements" id="DisclosureRoyaltyPurchaseAgreements">
        <link:definition>10501 - Disclosure - Royalty Purchase Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10601 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" id="DisclosureLeaseAgreements">
        <link:definition>10701 - Disclosure - Lease Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings" id="DisclosureLongTermDebtAndOtherFinancings">
        <link:definition>10801 - Disclosure - Long-Term Debt and Other Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrants" id="DisclosureCommonStockWarrants">
        <link:definition>10901 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11101 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStock" id="DisclosureCapitalStock">
        <link:definition>11201 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables" id="DisclosureCondensedConsolidatedFinancialStatementsDetailTables">
        <link:definition>30303 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30603 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables" id="DisclosureLongTermDebtAndOtherFinancingsTables">
        <link:definition>30803 - Disclosure - Long-Term Debt and Other Financings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" id="DisclosureCommonStockWarrantsTables">
        <link:definition>30903 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31103 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails" id="DisclosureDescriptionOfBusinessDetails">
        <link:definition>40101 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tmb-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tmb-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tmb-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tmb-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
    </appinfo>
  </annotation>
  <element id="xoma_LongTermRoyaltyReceivableNonCurrent" name="LongTermRoyaltyReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_EquitySecuritiesFvNiNonCurrent" name="EquitySecuritiesFvNiNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_AccruedAndOtherLiabilitiesCurrent" name="AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="xoma_SharesReleasedOfRestrictedStockUnits" name="SharesReleasedOfRestrictedStockUnits" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_ReleaseOfRestrictedStockUnits" name="ReleaseOfRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" name="DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_InterestAddedPrincipalBalancesLongTermDebt" name="InterestAddedPrincipalBalancesLongTermDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="xoma_ConsolidatedFinancialStatementDetailAbstract" name="ConsolidatedFinancialStatementDetailAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_LicensingAndOtherArrangementsTextBlock" name="LicensingAndOtherArrangementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_LicensingAndOtherArrangementsAbstract" name="LicensingAndOtherArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_RoyaltyPurchaseAgreementTextBlock" name="RoyaltyPurchaseAgreementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_RoyaltyPurchaseAgreementAbstract" name="RoyaltyPurchaseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" name="RevenueRecognitionDeferredRevenuePolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_EquitySecuritiesPolicy" name="EquitySecuritiesPolicy" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" name="FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" name="InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_ImpairmentOfLongTermRoyaltyReceivable" name="ImpairmentOfLongTermRoyaltyReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_RezoluteIncMember" name="RezoluteIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_LicenseAgreementConsiderationReceived" name="LicenseAgreementConsiderationReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_ProceedsFromUpfrontPayment" name="ProceedsFromUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_CommonStockPremium" name="CommonStockPremium" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" name="EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_NovartisPharmaAGMember" name="NovartisPharmaAGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_XOMA052LicenseAgreementMember" name="XOMA052LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_IL1TargetLicenseAgreementMember" name="IL1TargetLicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_NovartisInternationalPharmaceuticalLtdMember" name="NovartisInternationalPharmaceuticalLtdMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_NumberOfLicenseAgreements" name="NumberOfLicenseAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_AgreementTerminationPriorWrittenNoticePeriod" name="AgreementTerminationPriorWrittenNoticePeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_NumberOfPerformanceObligations" name="NumberOfPerformanceObligations" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_LicenseAgreementTransactionPrice" name="LicenseAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_UpfrontOptionPayment" name="UpfrontOptionPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_CommonStockPurchaseAgreementMember" name="CommonStockPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_EligibleToReceiveInCash" name="EligibleToReceiveInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" name="EligibleToReceiveCommonStockRelatedToFinancingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_GrossProceedsFromQualifiedFinancing" name="GrossProceedsFromQualifiedFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_AdditionalCommonStockReceiveForQualifiedFinancing" name="AdditionalCommonStockReceiveForQualifiedFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_CommonStockThresholdTradingDays" name="CommonStockThresholdTradingDays" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" name="EligibleToReceiveInOrderToMaintainLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_CommonStockSharesReceivable" name="CommonStockSharesReceivable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_SharesReceived" name="SharesReceived" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_CashReceived" name="CashReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_ReimbursableTechnologyTransferExpensesReceived" name="ReimbursableTechnologyTransferExpensesReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" name="UpfrontConsiderationToIncrementalDiscountForFuturePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_SharesReceivedValue" name="SharesReceivedValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_MaximumRevenueFromContract" name="MaximumRevenueFromContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_ContractualTerm" name="ContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_ContractsRevenueWroteOff" name="ContractsRevenueWroteOff" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_DeferredRevenueArrangementNameOfParty2Member" name="DeferredRevenueArrangementNameOfParty2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" name="NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" name="EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" name="NumberOfRoyaltyInterestAcquisitionAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" name="PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="xoma_PurchasedPercentageOfMilestones" name="PurchasedPercentageOfMilestones" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" name="NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" name="PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_RoyaltyPurchaseAgreementMember" name="RoyaltyPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_AgenusIncMember" name="AgenusIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_SiliconValleyBankMember" name="SiliconValleyBankMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_NovartisNoteMember" name="NovartisNoteMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" name="PeriodOfMonthlyPaymentsOfPrincipalAndInterest" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" name="PercentageOfAdditionalInterestRateOfOutstandingLoan" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_ExercisablePeriodOfWarrants" name="ExercisablePeriodOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" name="CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_OtherFinancingsMember" name="OtherFinancingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" name="TwoThousandFifteenEmployeeStockPurchasePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="xoma_SeriesYConvertiblePreferredStockMember" name="SeriesYConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" name="SeriesXAndSeriesYConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_BiotechnologyValueFundLPMember" name="BiotechnologyValueFundLPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="xoma_SeriesXConvertiblePreferredStockMember" name="SeriesXConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" name="FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" name="PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="xoma_TwoThousandEighteenAtMarketAgreementMember" name="TwoThousandEighteenAtMarketAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_FiveYearWarrantsIssuedFirstRangeMember" name="FiveYearWarrantsIssuedFirstRangeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_FiveYearWarrantsIssuedSecondRangeMember" name="FiveYearWarrantsIssuedSecondRangeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_TenYearWarrantsIssuedThirdRangeMember" name="TenYearWarrantsIssuedThirdRangeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_ContractualObligationEstimatedMilestonePayments" name="ContractualObligationEstimatedMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_OperatingLeasesNumberOfLeasedFacilities" name="OperatingLeasesNumberOfLeasedFacilities" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_Partner1Member" name="Partner1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_Partner2Member" name="Partner2Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_Partner3Member" name="Partner3Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_NumberOfMajorPartners" name="NumberOfMajorPartners" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_BioasisTechnologiesIncMember" name="BioasisTechnologiesIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" name="NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" name="FutureCashPaymentsUponClosingOfQualifiedFinancing" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" name="PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" name="PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" name="LicenseAgreementAndCommonStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" name="ContingentConsiderationUnderRoyaltyPurchaseAgreements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_OperatingLeasePaymentsNonCash" name="OperatingLeasePaymentsNonCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" name="PaymentsRelatedToPurchaseOfRoyaltyRights" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" name="EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract" name="CondensedConsolidatedFinancialStatementsDetailAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_CommonStockWarrantDisclosureTextBlock" name="CommonStockWarrantDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" name="PercentageOfDecreaseInFutureRoyaltyObligations" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_DoubtfulRevenueReversalOfFutureCashPayments" name="DoubtfulRevenueReversalOfFutureCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" name="EarlyPaymentOfUnrecognizedFutureCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_UnrecognizedFutureCashPayments" name="UnrecognizedFutureCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="xoma_FutureCashPaymentsReceived" name="FutureCashPaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_ConsiderationPaidUponQualifiedFinancingEvent" name="ConsiderationPaidUponQualifiedFinancingEvent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_FutureCashPaymentsOfRevenueRecognized" name="FutureCashPaymentsOfRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_OneTimePayment" name="OneTimePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" name="MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" name="PercentageOfRoyaltyOnNetSalesUponCommercialization" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_AronoraIncMember" name="AronoraIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_PalobiofarmaSLMember" name="PalobiofarmaSLMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_BayerProductsMember" name="BayerProductsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_NonBayerProductsMember" name="NonBayerProductsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_ContingentFutureCashPayments" name="ContingentFutureCashPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" name="ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_ChangesInEstimatedFairValueOfContingentConsideration" name="ChangesInEstimatedFairValueOfContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_PaymentsOfContingentConsideration" name="PaymentsOfContingentConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_UpfrontPayment" name="UpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" name="MilestonesPaymentsToAggregateAmountOfPerProduct" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_ContingentConsiderationFairValueDisclosure" name="ContingentConsiderationFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_EquitySecuritiesTrancheOneMember" name="EquitySecuritiesTrancheOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_EquitySecuritiesTrancheTwoMember" name="EquitySecuritiesTrancheTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_FirstTermLoanMember" name="FirstTermLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_SecondTermLoanMember" name="SecondTermLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" name="LongTermDebtFuturePrincipalInterestAndFinalFeePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" name="PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" name="LicenseAgreementConsiderationReceivedDebtRepayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" name="StockIssuedDuringPeriodValueNewIssuesCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" name="Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_ArrangementsNumber" name="ArrangementsNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_RoyaltiesPeriodMinimum" name="RoyaltiesPeriodMinimum" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_LicenseAgreementRz358Member" name="LicenseAgreementRz358Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_LicenseAgreementX129Member" name="LicenseAgreementX129Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_RoyaltyInterestAcquisitionAgreementsMember" name="RoyaltyInterestAcquisitionAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" name="FirstRoyaltyInterestAcquisitionAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" name="SecondRoyaltyInterestAcquisitionAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" name="HealthCareRoyaltyPartnersTwoLimitedPartnersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_MilestonePeriodsNumber" name="MilestonePeriodsNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" name="NumberOfLicenseAgreementsFutureLicenseAgreements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_IncyteImmunoOncologyAssetsMember" name="IncyteImmunoOncologyAssetsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_MerckImmunoOncologyProductMember" name="MerckImmunoOncologyProductMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" name="PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" name="PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_AgreementDrugCandidatesNumber" name="AgreementDrugCandidatesNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" name="CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" name="LeasedFacilitiesBerkeleyCaliforniaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_StockOptionsVestingBasedOnPerformanceMember" name="StockOptionsVestingBasedOnPerformanceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_EmployeeMember" name="EmployeeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" name="LeasedFacilitiesEmeryvilleCaliforniaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_OperatingLeaseEarlyTerminationFee" name="OperatingLeaseEarlyTerminationFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" name="DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" name="DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_DebtInstrumentAmountToBeReborrowed" name="DebtInstrumentAmountToBeReborrowed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_DebtInstrumentFinalPaymentFeePercentage" name="DebtInstrumentFinalPaymentFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_DebtInstrumentPrepaymentFeePercentage" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_CommonStockWarrantExercisePrice14.71Member" name="CommonStockWarrantExercisePrice14.71Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" name="DebtInstrumentDecreaseUponAchievementOfMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="xoma_RightsOffering2019Member" name="RightsOffering2019Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_MaximumValueOfCommonStockToBeIssued" name="MaximumValueOfCommonStockToBeIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_XomaCorporationMember" name="XomaCorporationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" name="NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_ContractualObligationMilestonePayments" name="ContractualObligationMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" name="ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_JanssenBiotechInc.Member" name="JanssenBiotechInc.Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_NumberOfSharesRightAndOptionToSell" name="NumberOfSharesRightAndOptionToSell" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" name="PercentageOfAggregateSharesHeldRightAndOptionToSell" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_AgreementNumberOfCommonStockFinancingEvents" name="AgreementNumberOfCommonStockFinancingEvents" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" name="AgreementDrugCandidatesExclusiveLicenseOptionNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_ContingentFutureCashPaymentsPerProduct" name="ContingentFutureCashPaymentsPerProduct" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_AgreementPaymentPercentageFactor" name="AgreementPaymentPercentageFactor" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_EquitySecuritiesNumberOfTranches" name="EquitySecuritiesNumberOfTranches" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" name="GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" name="LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" name="LesseeOperatingLeaseSupplementalInformationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" name="OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" name="QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_ZydusMember" name="ZydusMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" name="MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_LicenseAgreementNonRz358ProductsMember" name="LicenseAgreementNonRz358ProductsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" name="AdjustmentsToAdditionalPaidInCapitalDisgorgement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="xoma_ProceedsFromRepaymentsForDisgorgement" name="ProceedsFromRepaymentsForDisgorgement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" name="LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" name="PaymentPeriodFollowingClosingOfQualifiedFinancing" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_NumberOfQuarterlyPayments" name="NumberOfQuarterlyPayments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="xoma_BeneficialOwnershipLimitation" name="BeneficialOwnershipLimitation" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="xoma_SecondRoyaltyPurchaseAgreementMember" name="SecondRoyaltyPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>tmb-20200930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2020 12:41:57 PM-->
<!--Modified on: 11/5/2020 12:41:57 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" />
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637141762064875610" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="us-gaap_AssetsCurrent_637401769132767433" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637401769132767433" xlink:to="us-gaap_Cash_637401769132767433" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637401769132767433" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_637401769132767433" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637401769132767433" xlink:to="us-gaap_IncomeTaxesReceivable_637401769132767433" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637401769132767433" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637401769132767433" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637401769132767433" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637401769132767433" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637401769132767433" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769132777408" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesFvNiNonCurrent" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="xoma_EquitySecuritiesFvNiNonCurrent_637401769132777408" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637141762064875610" xlink:to="us-gaap_OtherAssetsNoncurrent_637401769132777408" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637141762064945772" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637141762064945772" xlink:to="us-gaap_Liabilities_637401769132777408" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637401769132777408" xlink:to="us-gaap_LiabilitiesCurrent_637401769132777408" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="us-gaap_AccountsPayableCurrent_637401769132777408" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_637401769132777408" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_637401769132777408" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769132787416" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637401769132787416" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="us-gaap_DeferredIncomeCurrent_637401769132787416" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637401769132787416" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637401769132777408" xlink:to="us-gaap_LongTermDebtCurrent_637401769132787416" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637401769132777408" xlink:to="us-gaap_DeferredIncomeNoncurrent_637401769132787416" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637401769132777408" xlink:to="us-gaap_LongTermDebtNoncurrent_637401769132787416" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637401769132787416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637401769132777408" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637401769132787416" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637401769132777408" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637401769132797429" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637141762064945772" xlink:to="us-gaap_CommitmentsAndContingencies_637401769132797429" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637141762064945772" xlink:to="us-gaap_StockholdersEquity_637401769132797429" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637401769132797429" xlink:to="us-gaap_PreferredStockValue_637401769132797429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637401769132797429" xlink:to="us-gaap_CommonStockValue_637401769132797429" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637401769132797429" xlink:to="us-gaap_AdditionalPaidInCapital_637401769132797429" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637401769132797429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637401769132797429" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637401769132797429" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132807429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132807429" xlink:to="us-gaap_OperatingIncomeLoss_637401769132807429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637401769132807429" xlink:to="us-gaap_Revenues_637401769132807429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637401769132807429" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769132807429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_637401769132807429" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637401769132807429" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637401769132807429" xlink:to="us-gaap_OperatingExpenses_637401769132807429" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637401769132807429" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637401769132807429" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637401769132807429" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637401769132807429" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637401769132807429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132807429" xlink:to="us-gaap_InterestExpenseDebt_637401769132807429" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132807429" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637401769132817397" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637401769132817397" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited) (calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637303147477177745" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637303147477177745" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769132817397" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637303147477177745" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637401769132817397" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637141762065908353" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637141762065908353" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_ProfitLoss_637401769132817397" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_ShareBasedCompensation_637401769132817397" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_637401769132817397" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_637401769132817397" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_DepreciationAndAmortization_637401769132827393" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637401769132827393" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637401769132827393" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="xoma_OperatingLeasePaymentsNonCash_637401769132827393" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769132827393" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637401769132827393" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637401769132827393" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637401769132827393" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637401769132827393" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637401769132827393" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769132837425" order="13" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_637401769132837425" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769132817397" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637401769132837425" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637141762065908353" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769132837425" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769132837425" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637401769132837425" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769132837425" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769132837425" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637141762065908353" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769132847416" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637401769132847416" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769132847416" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637401769132847416" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637401769132847416" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637401769132847416" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromRepaymentsForDisgorgement" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement_637401769132847416" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="xoma_ProceedsFromRepaymentsForDisgorgement_637401769132847416" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769132837425" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_637401769132857411" order="8" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637401769132857411" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent_637401769132857411" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637401769132857411" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637401769132857411" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637401769132857411" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637384328105223791" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769132857411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637384328105223791" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769132857411" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769132857411" xlink:to="us-gaap_NetIncomeLoss_637401769132867427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769132857411" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_637401769132867427" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637384328105223791" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_637401769132867427" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769132867427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637401769132867427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_637401769132867427" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637401769132867427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637401769132867427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637401769132867427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637401769132877422" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637401769132877422" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturity of lease liabilities (Details) (calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637147784189673667" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637147784189673667" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637401769132877422" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637147784189673667" xlink:to="us-gaap_OperatingLeaseLiability_637401769132877422" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreements - Lease costs (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637401769132877422" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637401769132877422" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt - Payments of Long-Term Debt (Details) (calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637141762072807084" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_637141762072807084" xlink:to="us-gaap_LongTermDebtCurrent_637401769132877422" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637401769132877422" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_637141762072807084" xlink:to="us-gaap_LongTermDebtNoncurrent_637401769132877422" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769132887424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769132887424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_637401769132887424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769132887424" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_637401769132887424" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637401769132887424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769132887424" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637401769132887424" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637401769132887424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769132887424" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637401769132887424" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637401769132887424" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637401769132887424" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>tmb-20200930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2020 12:41:57 PM-->
<!--Modified on: 11/5/2020 12:41:58 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNovartisDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsZydusDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNiaidDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsDebtDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsSubleaseAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockRightsOffering2019Details" roleURI="http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureSubsequentEventDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventDetails" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769132897430" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637401769132897430" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReleaseOfRestrictedStockUnits" xlink:label="xoma_ReleaseOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="xoma_ReleaseOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReleasedOfRestrictedStockUnits" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_ReleaseOfRestrictedStockUnits" xlink:to="xoma_SharesReleasedOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637401769132927417" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637401769132927417" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637401769132938948" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637401769132938948" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_637401769132947444" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain_637401769132947444" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637401769132947444" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_637401769132947444" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xoma_NumberOfMajorPartners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637401769132957437" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637401769132957437" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Detail - Equity Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637401769132967444" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_637401769132967444" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesFvNiNonCurrent" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="xoma_EquitySecuritiesFvNiNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637401769132977438" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637401769132977438" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - Novartis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769132987446" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769132987446" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisPharmaAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769132987446" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769132987446" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ArrangementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis International (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637401769133047401" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637401769133047401" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementRz358Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementX129Member" xlink:label="xoma_LicenseAgreementX129Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementX129Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontOptionPayment" xlink:label="xoma_UpfrontOptionPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontOptionPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Rezolute - First Amendment (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_CommonStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637401769133217462" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_637401769133217462" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInCash" xlink:label="xoma_EligibleToReceiveInCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleToReceiveInCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockSharesReceivable" xlink:label="xoma_CommonStockSharesReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockSharesReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromQualifiedFinancing" xlink:label="xoma_GrossProceedsFromQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_GrossProceedsFromQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdditionalCommonStockReceiveForQualifiedFinancing" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AdditionalCommonStockReceiveForQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockThresholdTradingDays" xlink:label="xoma_CommonStockThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfSharesRightAndOptionToSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceived" xlink:label="xoma_SharesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_SharesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CashReceived" xlink:label="xoma_CashReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CashReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ArrangementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceivedValue" xlink:label="xoma_SharesReceivedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_SharesReceivedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReimbursableTechnologyTransferExpensesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_CommonStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637401769133277418" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637401769133277418" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfSharesRightAndOptionToSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsiderationPaidUponQualifiedFinancingEvent" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ConsiderationPaidUponQualifiedFinancingEvent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReimbursableTechnologyTransferExpensesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DoubtfulRevenueReversalOfFutureCashPayments" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_DoubtfulRevenueReversalOfFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementNumberOfCommonStockFinancingEvents" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementNumberOfCommonStockFinancingEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UnrecognizedFutureCashPayments" xlink:label="xoma_UnrecognizedFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UnrecognizedFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsReceived" xlink:label="xoma_FutureCashPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_FutureCashPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsOfRevenueRecognized" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_FutureCashPaymentsOfRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfQuarterlyPayments" xlink:label="xoma_NumberOfQuarterlyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfQuarterlyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_JanssenBiotechInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OneTimePayment" xlink:label="xoma_OneTimePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_OneTimePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Zydus (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ZydusMember" xlink:label="xoma_ZydusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ZydusMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - NIAID (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DeferredRevenueArrangementNameOfParty2Member" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_DeferredRevenueArrangementNameOfParty2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumRevenueFromContract" xlink:label="xoma_MaximumRevenueFromContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumRevenueFromContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualTerm" xlink:label="xoma_ContractualTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContractualTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractsRevenueWroteOff" xlink:label="xoma_ContractsRevenueWroteOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContractsRevenueWroteOff" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePeriodsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty Purchase Agreements - Agenus (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637401769133447464" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637401769133447464" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_IncyteImmunoOncologyAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MerckImmunoOncologyProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769133447464" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769133447464" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty Purchase Agreements - Bioasis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty Purchase Agreements - Aronora (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_BayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_NonBayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementPaymentPercentageFactor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty Purchase Agreements - Palobiofarma (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637401769133597432" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637401769133597432" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637401769133607427" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637401769133607427" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="xoma_ContingentConsiderationFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637401769133627430" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637401769133627430" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_CommonStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769133647427" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769133647427" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheOneMember" xlink:label="xoma_EquitySecuritiesTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="xoma_EquitySecuritiesTrancheOneMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheTwoMember" xlink:label="xoma_EquitySecuritiesTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="xoma_EquitySecuritiesTrancheTwoMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="dei_EntityListingsExchangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain_637401769133647427" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain_637401769133647427" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_OTCM" xlink:label="exch_OTCM" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_ExchangeDomain" xlink:to="exch_OTCM" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="xoma_NumberOfSharesRightAndOptionToSell" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesNumberOfTranches" xlink:label="xoma_EquitySecuritiesNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="xoma_EquitySecuritiesNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Fair Value Measurements - Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769133757474" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769133757474" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769133777455" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769133777455" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeaseEarlyTerminationFee" xlink:label="xoma_OperatingLeaseEarlyTerminationFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeaseEarlyTerminationFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Lease Agreements - Sublease Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SubleaseIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstTermLoanMember" xlink:label="xoma_FirstTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_FirstTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondTermLoanMember" xlink:label="xoma_SecondTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_SecondTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769133807446" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769133807446" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637401769133817441" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_637401769133817441" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637401769133817441" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637401769133817441" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentAmountToBeReborrowed" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentAmountToBeReborrowed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentFinalPaymentFeePercentage" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentFinalPaymentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentPrepaymentFeePercentage" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentPrepaymentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_ExercisablePeriodOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OtherFinancingsMember" xlink:label="xoma_OtherFinancingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_OtherFinancingsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseAbstract" xlink:label="us-gaap_InterestExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InterestExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedFirstRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_FiveYearWarrantsIssuedFirstRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedSecondRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_FiveYearWarrantsIssuedSecondRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationMilestonePayments" xlink:label="xoma_ContractualObligationMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContractualObligationMilestonePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-based Compensation - ESPP (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637401769133967456" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637401769133967456" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-based Compensation - Stock Options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769133977493" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769133977493" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769133977493" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769133977493" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stock-based Compensation - Performance-based stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockOptionsVestingBasedOnPerformanceMember" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_StockOptionsVestingBasedOnPerformanceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637401769134047451" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637401769134047451" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details" xlink:type="extended" xlink:title="41201 - Disclosure - Capital Stock - Rights Offering 2019 (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637401769134057451" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637401769134057451" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_BiotechnologyValueFundLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637401769134057451" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637401769134057451" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RightsOffering2019Member" xlink:label="xoma_RightsOffering2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_RightsOffering2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="xoma_SeriesYConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BiotechnologyValueFundLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637401769134067452" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_637401769134067452" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="xoma_XomaCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_LegalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BeneficialOwnershipLimitation" xlink:label="xoma_BeneficialOwnershipLimitation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_BeneficialOwnershipLimitation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Capital Stock - Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637401769134097451" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637401769134097451" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesXConvertiblePreferredStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesYConvertiblePreferredStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockConversionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Capital Stock - ATM Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Event (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_SecondRoyaltyPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsReceived" xlink:label="xoma_FutureCashPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_FutureCashPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>tmb-20200930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2020 12:41:57 PM-->
<!--Modified on: 11/5/2020 12:41:57 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security12b Title</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Income Taxes Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Income tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRoyaltyReceivableNonCurrent" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_lbl" xml:lang="en-US">Long-term royalty receivable non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_lbl" xml:lang="en-US">Long Term Royalty Receivable Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_lbl" xml:lang="en-US">Long-term royalty receivables</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesFvNiNonCurrent" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesFvNiNonCurrent" xlink:to="xoma_EquitySecuritiesFvNiNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_lbl" xml:lang="en-US">Equity securities FvNi non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_lbl" xml:lang="en-US">Equity Securities Fv Ni Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_lbl" xml:lang="en-US">Equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued And Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Contingent consideration under royalty purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Contingent Consideration Under Royalty Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Contingent consideration under royalty purchase agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Unearned revenue recognized under units-of-revenue method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Unearned revenue recognized under units-of-revenue method, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract With Customer Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Long Term Debt Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Less: current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US">Current portion of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred Income, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Unearned revenue recognized under units-of-revenue method - long-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Unearned revenue recognized under units-of-revenue method, noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long Term Debt Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease Liability Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities - long-term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 10)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 and 6,256 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,022,143 and 9,758,583 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, stated value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement Of Income And Comprehensive Income [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue From Contract With Customer Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue from contracts with customers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US">Revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">(Loss) income from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense), net:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">(Loss) income before income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Net comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net (loss) income available to common stockholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net (loss) income and comprehensive (loss) income available to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net (loss) income available to common stockholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net (loss) income and comprehensive (loss) income available to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (loss) income per share of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (loss) income per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net (loss) income per share of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net (loss) income per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase Decrease In Stockholders Equity Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period Value Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock related to 401(k) contribution</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock Issued During Period Shares Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock related to 401(k) contribution (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Issuance of common stock related to ESPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Issuance of common stock related to ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock related to Series Y preferred stock conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock related to Series Y preferred stock conversion (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReleaseOfRestrictedStockUnits" xlink:label="xoma_ReleaseOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReleaseOfRestrictedStockUnits" xlink:to="xoma_ReleaseOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReleaseOfRestrictedStockUnits_lbl" xml:lang="en-US">This element represents the amount of recognized equity-based compensation related to restricted stock units released during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReleaseOfRestrictedStockUnits_lbl" xml:lang="en-US">Release Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReleaseOfRestrictedStockUnits_lbl" xml:lang="en-US">Vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReleasedOfRestrictedStockUnits" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SharesReleasedOfRestrictedStockUnits" xlink:to="xoma_SharesReleasedOfRestrictedStockUnits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits_lbl" xml:lang="en-US">Refers to release of restricted stock units (RSUs) in shares during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits_lbl" xml:lang="en-US">Shares Released Of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits_lbl" xml:lang="en-US">Vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" xlink:to="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_lbl" xml:lang="en-US">Amount of increase (decrease) in additional paid in capital (APIC) resulting from disgorgement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Disgorgement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_lbl" xml:lang="en-US">Disgorgement of stockholder's short-swing profits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Total number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of stock, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US">Defined contribution plan issuance of Common stock for services or claims.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US">Defined Contribution Plan Issuance Of Common Stock For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US">Common stock contribution to 401(k)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization Of Financing Costs And Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs, debt discount and final payment on debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for bad debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Charged to operating expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasePaymentsNonCash" xlink:to="xoma_OperatingLeasePaymentsNonCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US">Operating lease payments, non cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US">Operating Lease Payments Non Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Change in fair value of equity securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Gain (loss) recognized due to change in fair value of investment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Income tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Unearned revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of lease liabilities that result from activities that generate operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase Decrease In Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_lbl" xml:lang="en-US">Payments related to purchase of royalty rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_lbl" xml:lang="en-US">Payments Related To Purchase Of Royalty Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_lbl" xml:lang="en-US">Payments related to purchase of royalty rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_lbl" xml:lang="en-US">Payments to acquire milestones and royalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds From Issuance Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments Of Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Principal payments - debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Principal payments - finance lease</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromRepaymentsForDisgorgement" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromRepaymentsForDisgorgement" xlink:to="xoma_ProceedsFromRepaymentsForDisgorgement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement_lbl" xml:lang="en-US">Amount of cash inflow (outflow) from disgorgement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement_lbl" xml:lang="en-US">Proceeds from (Repayments for) Disgorgement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement_lbl" xml:lang="en-US">Proceeds from disgorgement of stockholder's short-swing profits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_InterestAddedPrincipalBalancesLongTermDebt" xlink:label="xoma_InterestAddedPrincipalBalancesLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_InterestAddedPrincipalBalancesLongTermDebt" xlink:to="xoma_InterestAddedPrincipalBalancesLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_InterestAddedPrincipalBalancesLongTermDebt_lbl" xml:lang="en-US">Unpaid interest added to the outstanding principal amount on long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_InterestAddedPrincipalBalancesLongTermDebt_lbl" xml:lang="en-US">Interest Added Principal Balances Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_InterestAddedPrincipalBalancesLongTermDebt_lbl" xml:lang="en-US">Interest added to principal balance on long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of common stock warrant under SVB loan</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Estimated fair value of contingent consideration under royalty purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Estimated Fair Value Of Contingent Consideration Under Royalty Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_lbl" xml:lang="en-US">Estimated fair value of contingent consideration under the royalty purchase agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US">Consolidated financial statement detail.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US">Condensed Consolidated Financial Statements Details</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Condensed Consolidated Financial Statements Details</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsTextBlock" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US">Licensing And Other Arrangements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract" xlink:to="xoma_RoyaltyPurchaseAgreementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_lbl" xml:lang="en-US">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_lbl" xml:lang="en-US">Royalty Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTextBlock" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US">Royalty Purchase Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US">Royalty Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeaseDisclosureTextBlock" xlink:to="xoma_LeaseDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Long-Term Debt and Other Financings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-Term Debt and Other Financings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantDisclosureTextBlock" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantDisclosureTextBlock" xlink:to="xoma_CommonStockWarrantDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US">Common stock warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrant Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue From Contract With Customer Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for sale of future revenue streams.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition Deferred Revenue Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US">Sale of Future Revenue Streams</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesPolicy" xlink:to="xoma_EquitySecuritiesPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US">Disclosure of accounting policy for equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US">Equity Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" xlink:to="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Future milestones and royalties purchase rights policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Future Milestones And Royalties Purchase Rights Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Purchase of Rights to Future Milestones and Royalties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee Leases Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassifications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Prior Period Reclassifications</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net (Loss) Income per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive (Loss) Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Summary of activity in allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CondensedConsolidatedFinancialStatementsDetailAbstract" xlink:label="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract" xlink:to="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_lbl" xml:lang="en-US">Condensed consolidated financial statements detail.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_lbl" xml:lang="en-US">Condensed Consolidated Financial Statements Detail [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Accrued and Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Outstanding Securities Considered Anti-Dilutive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Summary of Changes in Estimated Fair Value of Level 3 Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Equity Securities Assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xml:lang="en-US">Outstanding Long Term Debt Carrying Amount and Estimated Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee Operating Lease Liability Maturity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturity of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of cost components of operating leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of supplemental cash flows information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Summary of supplemental cash flow information related to operating leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Supplemental Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of present value assumptions used in calculating the present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule Of Maturities Of Long Term Debt Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" xlink:label="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" xlink:to="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of aggregate amount of interest expense and the amortization of debt issuance costs and discounts on all borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_lbl" xml:lang="en-US">Interest Expense And Amortization Of Debt Issuance Costs And Discounts Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_lbl" xml:lang="en-US">Interest Expense and Amortization of Debt Issuance Costs and Discounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Common Stock Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted Average Assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Licensing and other arrangements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:to="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US">Purchase of Rights to Future Milestones and Royalties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US">Purchase of Rights to Future Milestones and Royalties</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US">The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US">Impairment Of Long Term Royalty Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US">Impairment of long-term royalty receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Bad debt allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfMajorPartners" xlink:to="xoma_NumberOfMajorPartners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US">Number of major partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US">Number Of Major Partners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US">Number of major partners</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">Adopted Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Early Adoption</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US">Debt and Equity Securities, FV-NI [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued Liabilities And Other Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued Salaries Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll and other benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued incentive compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US">Net Income Loss Available To Common Stockholders Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US">Numerator</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US">Undistributed Earnings Loss Allocated To Participating Securities Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US">Less: Allocation of undistributed earnings to participating securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xml:lang="en-US">Undistributed Earnings Loss Allocated To Participating Securities Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xml:lang="en-US">Add: Adjustments to undistributed earnings allocated to participating securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Effect of dilutive stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Effect of dilutive warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceived" xlink:to="xoma_LicenseAgreementConsiderationReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US">License agreement consideration received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US">License Agreement Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US">License agreement consideration received</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromUpfrontPayment" xlink:to="xoma_ProceedsFromUpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US">Cash proceeds from upfront payment received as consideration in transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US">Proceeds From Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US">Initial payment received</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US">Amount of license agreement consideration received as repayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US">License Agreement Consideration Received, Debt Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US">License agreement consideration received, repayment of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US">Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US">Issuance of common stock, fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Closing stock price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockPremium" xlink:to="xoma_CommonStockPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US">Common stock premium received on sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US">Common Stock Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US">Common stock premium</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US">Number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US">Number of license agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US">Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US">Agreement Termination Prior Written Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US">Agreement termination prior written notice period</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArrangementsNumber" xlink:to="xoma_ArrangementsNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US">Number of arrangements the agreements are accounted for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US">Arrangements, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US">Number of arrangements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPerformanceObligations" xlink:to="xoma_NumberOfPerformanceObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US">Number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US">Number Of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Remaining performance obligations</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementTransactionPrice" xlink:to="xoma_LicenseAgreementTransactionPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US">License agreement transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US">License Agreement Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US">Transaction price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Contract With Customer Asset Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US">Contract assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract With Customer Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue/Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Capitalized Contract Cost Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Capitalized contract costs</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimum" xlink:to="xoma_RoyaltiesPeriodMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US">Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US">Royalties, Period, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US">Royalty payment period</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontOptionPayment" xlink:label="xoma_UpfrontOptionPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UpfrontOptionPayment" xlink:to="xoma_UpfrontOptionPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UpfrontOptionPayment_lbl" xml:lang="en-US">Upfront payment  to be received from counterparty, if counterparty  elects option to obtain exclusive license for one of entity's products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UpfrontOptionPayment_lbl" xml:lang="en-US">Upfront Option Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UpfrontOptionPayment_lbl" xml:lang="en-US">Upfront option fee</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US">Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US">Percentage Of Decrease In Future Royalty Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US">Percentage of decrease in future royalty obligations</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInCash" xlink:label="xoma_EligibleToReceiveInCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleToReceiveInCash" xlink:to="xoma_EligibleToReceiveInCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleToReceiveInCash_lbl" xml:lang="en-US">Eligible to receive in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleToReceiveInCash_lbl" xml:lang="en-US">Eligible To Receive In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleToReceiveInCash_lbl" xml:lang="en-US">Amount of cash eligible to receive</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:to="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_lbl" xml:lang="en-US">Amount of counterparty's common stock entity is eligible to receive under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_lbl" xml:lang="en-US">Eligible To Receive Common Stock Related To Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_lbl" xml:lang="en-US">Amount of Rezolute's common stock eligible to receive</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockSharesReceivable" xlink:label="xoma_CommonStockSharesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockSharesReceivable" xlink:to="xoma_CommonStockSharesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockSharesReceivable_lbl" xml:lang="en-US">The number of counterparty's common stock company may receive under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockSharesReceivable_lbl" xml:lang="en-US">Common Stock Shares Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockSharesReceivable_lbl" xml:lang="en-US">Number of Rezolute's common stock eligible to receive contingent on completion of financing activities</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromQualifiedFinancing" xlink:label="xoma_GrossProceedsFromQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_GrossProceedsFromQualifiedFinancing" xlink:to="xoma_GrossProceedsFromQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_GrossProceedsFromQualifiedFinancing_lbl" xml:lang="en-US">Minimum gross proceeds required to be raised by counterparty for qualified financing under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_GrossProceedsFromQualifiedFinancing_lbl" xml:lang="en-US">Gross Proceeds From Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_GrossProceedsFromQualifiedFinancing_lbl" xml:lang="en-US">Gross proceeds to be raised for qualified financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdditionalCommonStockReceiveForQualifiedFinancing" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AdditionalCommonStockReceiveForQualifiedFinancing" xlink:to="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_lbl" xml:lang="en-US">Additional amount of counterparty's common stock entity was eligible to receive if counterparty did not complete specified financing under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_lbl" xml:lang="en-US">Additional Common Stock Receive For Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_lbl" xml:lang="en-US">Additional common stock to be received if Rezolute did not complete financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockThresholdTradingDays" xlink:label="xoma_CommonStockThresholdTradingDays" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockThresholdTradingDays" xlink:to="xoma_CommonStockThresholdTradingDays_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockThresholdTradingDays_lbl" xml:lang="en-US">Trading period used in number of shares calculation under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockThresholdTradingDays_lbl" xml:lang="en-US">Common Stock Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockThresholdTradingDays_lbl" xml:lang="en-US">Common stock trading period</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" xlink:to="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_lbl" xml:lang="en-US">Additional amount of cash entity is eligible to receive if counterparty does not complete qualified financing by specified date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_lbl" xml:lang="en-US">Eligible To Receive In Order To Maintain License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_lbl" xml:lang="en-US">Eligible to receive, in order to maintain license agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfSharesRightAndOptionToSell" xlink:to="xoma_NumberOfSharesRightAndOptionToSell_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_lbl" xml:lang="en-US">Number of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_lbl" xml:lang="en-US">Number Of Shares, Right and Option To Sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_lbl" xml:lang="en-US">Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" xlink:to="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_lbl" xml:lang="en-US">Percent of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_lbl" xml:lang="en-US">Percentage Of Aggregate Shares Held, Right and Option To Sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_lbl" xml:lang="en-US">Percent of Rezolute's shares held Company has right and option to sell if Rezolute does not list common stock shares on national exchange</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceived" xlink:label="xoma_SharesReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SharesReceived" xlink:to="xoma_SharesReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SharesReceived_lbl" xml:lang="en-US">Consideration received in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SharesReceived_lbl" xml:lang="en-US">Shares Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SharesReceived_lbl" xml:lang="en-US">Transaction price, Shares received (in shares)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CashReceived" xlink:label="xoma_CashReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashReceived" xlink:to="xoma_CashReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashReceived_lbl" xml:lang="en-US">Amount of cash consideration received by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashReceived_lbl" xml:lang="en-US">Cash Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashReceived_lbl" xml:lang="en-US">Transaction price, cash consideration</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceivedValue" xlink:label="xoma_SharesReceivedValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SharesReceivedValue" xlink:to="xoma_SharesReceivedValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SharesReceivedValue_lbl" xml:lang="en-US">Value of shares received for consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SharesReceivedValue_lbl" xml:lang="en-US">Shares Received Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SharesReceivedValue_lbl" xml:lang="en-US">Transaction price, Value of common stock received</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:to="xoma_ReimbursableTechnologyTransferExpensesReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived_lbl" xml:lang="en-US">Reimbursable technology transfer expenses received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived_lbl" xml:lang="en-US">Reimbursable Technology Transfer Expenses Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived_lbl" xml:lang="en-US">Reimbursable technology transfer expense received</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:to="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_lbl" xml:lang="en-US">Upfront consideration to incremental discount for future payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_lbl" xml:lang="en-US">Upfront Consideration To Incremental Discount For Future Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_lbl" xml:lang="en-US">Upfront consideration to incremental discount for future payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:to="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Number of future cash payments upon closing of qualified financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Number Of Future Cash Payments Upon Closing Of Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Number of future cash payments upon closing of the qualified financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:to="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Future cash payments upon closing of qualified financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Future Cash Payments Upon Closing Of Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Future cash payments upon closing of the qualified financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" xlink:to="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_lbl" xml:lang="en-US">Percentage of net proceeds of each future financing upon closing of the qualified financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_lbl" xml:lang="en-US">Percentage Of Net Proceeds Of Each Future Financing Upon Closing Of The Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_lbl" xml:lang="en-US">Percentage of net proceeds of each future financing upon closing of the qualified financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Amount of proceeds third party received from issuance of capital stock which triggered a Qualified Financing event under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Qualified Financing Event Trigger, Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Gross proceeds received by third party from preferred stock financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsiderationPaidUponQualifiedFinancingEvent" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConsiderationPaidUponQualifiedFinancingEvent" xlink:to="xoma_ConsiderationPaidUponQualifiedFinancingEvent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent_lbl" xml:lang="en-US">Cash consideration received from counterparty following qualified financing event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent_lbl" xml:lang="en-US">Consideration Paid Upon Qualified Financing Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent_lbl" xml:lang="en-US">Consideration received following qualified financing event</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DoubtfulRevenueReversalOfFutureCashPayments" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DoubtfulRevenueReversalOfFutureCashPayments" xlink:to="xoma_DoubtfulRevenueReversalOfFutureCashPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments_lbl" xml:lang="en-US">Doubtful revenue reversal of future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments_lbl" xml:lang="en-US">Doubtful Revenue Reversal Of Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments_lbl" xml:lang="en-US">Doubtful revenue reversal of future cash payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementNumberOfCommonStockFinancingEvents" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementNumberOfCommonStockFinancingEvents" xlink:to="xoma_AgreementNumberOfCommonStockFinancingEvents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents_lbl" xml:lang="en-US">Number of common stock financing events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents_lbl" xml:lang="en-US">Agreement, Number of Common Stock Financing Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents_lbl" xml:lang="en-US">Number of common stock financing events</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" xlink:to="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Early payment of unrecognized future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Early Payment Of Unrecognized Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Early payment of unrecognized future cash payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UnrecognizedFutureCashPayments" xlink:label="xoma_UnrecognizedFutureCashPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UnrecognizedFutureCashPayments" xlink:to="xoma_UnrecognizedFutureCashPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Unrecognized future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Unrecognized Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UnrecognizedFutureCashPayments_lbl" xml:lang="en-US">Unrecognized future cash payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsReceived" xlink:label="xoma_FutureCashPaymentsReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureCashPaymentsReceived" xlink:to="xoma_FutureCashPaymentsReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureCashPaymentsReceived_lbl" xml:lang="en-US">Future cash payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureCashPaymentsReceived_lbl" xml:lang="en-US">Future Cash Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureCashPaymentsReceived_lbl" xml:lang="en-US">Future cash payments received</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsOfRevenueRecognized" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureCashPaymentsOfRevenueRecognized" xlink:to="xoma_FutureCashPaymentsOfRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized_lbl" xml:lang="en-US">Future cash payments of revenue recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized_lbl" xml:lang="en-US">Future Cash Payments Of Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized_lbl" xml:lang="en-US">Future cash payments of revenue recognized</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfQuarterlyPayments" xlink:label="xoma_NumberOfQuarterlyPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfQuarterlyPayments" xlink:to="xoma_NumberOfQuarterlyPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfQuarterlyPayments_lbl" xml:lang="en-US">Number of quarterly payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfQuarterlyPayments_lbl" xml:lang="en-US">Number of Quarterly Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfQuarterlyPayments_lbl" xml:lang="en-US">Number of quarterly payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" xlink:to="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Payment period within which counterparty will pay outstanding amounts following closing of Qualified Financing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Payment Period, Following Closing of Qualified Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_lbl" xml:lang="en-US">Payment period following closing of Qualified Financing</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OneTimePayment" xlink:label="xoma_OneTimePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OneTimePayment" xlink:to="xoma_OneTimePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OneTimePayment_lbl" xml:lang="en-US">One-time payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OneTimePayment_lbl" xml:lang="en-US">One Time Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OneTimePayment_lbl" xml:lang="en-US">One-time payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US">Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US">Percentage of royalty on net sales upon commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US">Percentage Of Royalty On Net Sales Upon Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US">Percentage of royalty on worldwide net sales of each product upon commercialization</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_lbl" xml:lang="en-US">Maximum eligible milestone payments receivable upon achievement of commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_lbl" xml:lang="en-US">Maximum Amount Receivable Milestone Payments Upon Achievement Of Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_lbl" xml:lang="en-US">Maximum amount receivable upon achievement of commercial milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DeferredRevenueArrangementNameOfParty2Member" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DeferredRevenueArrangementNameOfParty2Member" xlink:to="xoma_DeferredRevenueArrangementNameOfParty2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member_lbl" xml:lang="en-US">Describes the name of the party related to a deferred revenue arrangement. The party named is the other party that participates in a deferred revenue transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member_lbl" xml:lang="en-US">Deferred Revenue Arrangement Name Of Party2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member_lbl" xml:lang="en-US">NIAID</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" xlink:to="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_lbl" xml:lang="en-US">Category of deferred revenue arrangement wherein certain rights are granted under a license agreement with a governmental agency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_lbl" xml:lang="en-US">Nonsoftware License Arrangement With Governmental Agency2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_lbl" xml:lang="en-US">Arrangement with Governmental Agency</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumRevenueFromContract" xlink:label="xoma_MaximumRevenueFromContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumRevenueFromContract" xlink:to="xoma_MaximumRevenueFromContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumRevenueFromContract_lbl" xml:lang="en-US">Maximum revenue from contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumRevenueFromContract_lbl" xml:lang="en-US">Maximum Revenue From Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumRevenueFromContract_lbl" xml:lang="en-US">Total contract amount awarded</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualTerm" xlink:label="xoma_ContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualTerm" xlink:to="xoma_ContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualTerm_lbl" xml:lang="en-US">Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualTerm_lbl" xml:lang="en-US">Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualTerm_lbl" xml:lang="en-US">Contractual term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts Receivable Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractsRevenueWroteOff" xlink:label="xoma_ContractsRevenueWroteOff" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractsRevenueWroteOff" xlink:to="xoma_ContractsRevenueWroteOff_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractsRevenueWroteOff_lbl" xml:lang="en-US">Decrease in accounts receivable due to contracts revenue written off during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractsRevenueWroteOff_lbl" xml:lang="en-US">Contracts Revenue Wrote Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractsRevenueWroteOff_lbl" xml:lang="en-US">Accounts receivable written off</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US">Number of royalty interest acquisition agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US">Number Of Royalty Interest Acquisition Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US">Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US">Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePeriodsNumber" xlink:to="xoma_MilestonePeriodsNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US">Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US">Milestone Periods, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US">Number of milestone periods</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:to="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Purchased percentage of royalties on net sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Purchased Percentage Of Royalties On Net Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Royalties on net sales of products (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US">Number of licensed products related to milestones and royalties purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US">Number Of Licensed Products Related To Milestones And Royalties Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US">Number of licensed products related to milestone and royalties</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfMilestones" xlink:to="xoma_PurchasedPercentageOfMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US">Purchased percentage of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US">Purchased Percentage Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US">Purchased percentage of milestones</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US">Changes in estimated fair value of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US">Changes In Estimated Fair Value Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US">Changes in estimated fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US">Percentage of royalty rights entity has option to  purchase in future license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US">Percentage Of Optional Royalty Rights Purchase On Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US">Percentage of option to purchase royalty right on future license agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US">Number of future license agreements under optional purchase right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US">Number Of License Agreements, Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US">Number of future license agreements under optional purchase right</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US">Payments To Be Made Upon Exercise Of Option, Second License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US">Obligation upon exercise of options per licensed product, second agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US">Payments To Be Made Upon Exercise Of Option, Third License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US">Obligation upon exercise of options per licensed product, third agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPayments" xlink:to="xoma_ContingentFutureCashPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US">Contingent future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US">Contingent Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US">Potential future cash payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsOfContingentConsideration" xlink:to="xoma_PaymentsOfContingentConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US">Payments of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US">Payments Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US">Payments of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesNumber" xlink:to="xoma_AgreementDrugCandidatesNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US">Number of drug candidates under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US">Agreement, Drug Candidates, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US">Number of drug candidates</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US">Number of drug candidates subject to exclusive license option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US">Agreement, Drug Candidates, Exclusive License Option, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US">Number of drug candidates subject to exclusive license option</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Purchased percentage of non-royalties on net sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Purchased Percentage Of Non Royalties On Net Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US">Non-royalties to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US">Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US">Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US">Future non-royalty payments to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementPaymentPercentageFactor" xlink:to="xoma_AgreementPaymentPercentageFactor_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US">Multiplier used in determining change in payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US">Agreement, Payment Percentage, Factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US">Multiplier for cumulative amount of consideration paid</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UpfrontPayment" xlink:to="xoma_UpfrontPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US">Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPaymentsPerProduct" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US">Amount of contingent future cash payment for each product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US">Contingent Future Cash Payments, Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US">Contingent future cash payment for each product</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US">Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US">Cumulative Royalties On Net Sales Per Product, Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US">Threshold amount of cumulative royalties on net sales per product</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US">Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US">Milestones Payments To Aggregate Amount Of Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US">Aggregate milestones payments per product</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" xlink:to="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) of long-term royalty receivable, noncurrent, during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_lbl" xml:lang="en-US">Long Term Royalty Receivable NonCurrent, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) of long-term royalty receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Fair Value, Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Investments Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US">Equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationFairValueDisclosure" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US">Contingent consideration, fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US">Contingent Consideration Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US">Contingent consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" xml:lang="en-US">Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_lbl" xml:lang="en-US">Transfers between Levels</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US">Level 1 to Level 2 transfers, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US">Level 2 to Level 1 transfers, Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US">Level 1 to Level 2 transfers, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US">Level 2 to Level 1 transfers, Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesNumberOfTranches" xlink:label="xoma_EquitySecuritiesNumberOfTranches" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesNumberOfTranches" xlink:to="xoma_EquitySecuritiesNumberOfTranches_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesNumberOfTranches_lbl" xml:lang="en-US">Number of equity securities tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesNumberOfTranches_lbl" xml:lang="en-US">Equity Securities, Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesNumberOfTranches_lbl" xml:lang="en-US">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US">Equity Securities Fv Ni Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US">Valuation assumptions, measurement input</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value By Balance Sheet Grouping [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US">Fair Value By Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US">Fair Value By Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US">Portion At Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US">Fair Value Disclosure Item Amounts [Default]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US">Carrying Reported Amount Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US">Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US">Estimate Of Fair Value Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisNoteMember" xlink:to="xoma_NovartisNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US">Secured note agreement and subsequent amendments with Novartis referred to as the "Note Agreement".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US">Novartis Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US">Novartis Note</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_SiliconValleyBankMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank Loans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Long Term Debt Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US">Operating leases, number of leased facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US">Operating Leases Number Of Leased Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US">Operating leases, number of leased facilities</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" xlink:to="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_lbl" xml:lang="en-US">Number of leases for which the entity terminated the lease early.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_lbl" xml:lang="en-US">Operating Leases, Early Termination, Number of Leased Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_lbl" xml:lang="en-US">Number of operating leases terminated early</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeaseEarlyTerminationFee" xlink:label="xoma_OperatingLeaseEarlyTerminationFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeaseEarlyTerminationFee" xlink:to="xoma_OperatingLeaseEarlyTerminationFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeaseEarlyTerminationFee_lbl" xml:lang="en-US">Amount of fee for early termination of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeaseEarlyTerminationFee_lbl" xml:lang="en-US">Operating Lease, Early Termination Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeaseEarlyTerminationFee_lbl" xml:lang="en-US">Early termination fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain (Loss) on Termination of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Lease termination loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (excluding nine months ended September 30, 2020)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee Operating Lease Liability Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Present value adjustment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease Weighted Average Remaining Lease Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term, Operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease Weighted Average Discount Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate, Operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Debt Instrument [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum borrowing capacity under loan agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument Basis Spread On Variable Rate1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Basis spread on variable rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" xlink:to="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_lbl" xml:lang="en-US">Period of monthly payments of principal and interest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_lbl" xml:lang="en-US">Period Of Monthly Payments Of Principal And Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_lbl" xml:lang="en-US">Period of monthly payments of principal and interest</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" xlink:to="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_lbl" xml:lang="en-US">Maximum period following loan amortization date for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_lbl" xml:lang="en-US">Debt Instrument, Term, Maximum Period Following Loan Amortization Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_lbl" xml:lang="en-US">Maximum period following loan amortization date for which loan will mature</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" xlink:to="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_lbl" xml:lang="en-US">Maximum period prior to loan maturity date of specified loan for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_lbl" xml:lang="en-US">Debt Instrument, Term, Maximum Period Prior to Loan Maturity Date of Specified Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_lbl" xml:lang="en-US">Maximum period prior to loan maturity date of Novartis loan for which loan will mature</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentAmountToBeReborrowed" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentAmountToBeReborrowed" xlink:to="xoma_DebtInstrumentAmountToBeReborrowed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed_lbl" xml:lang="en-US">Amount of loan that may be reborrowed after repayment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed_lbl" xml:lang="en-US">Debt Instrument, Amount to Be Reborrowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed_lbl" xml:lang="en-US">Amount of loan that may be reborrowed after repayment</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentFinalPaymentFeePercentage" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentFinalPaymentFeePercentage" xlink:to="xoma_DebtInstrumentFinalPaymentFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US">Final payment fee as a percent of principal.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US">Debt Instrument, Final Payment Fee, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage_lbl" xml:lang="en-US">Final payment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentPrepaymentFeePercentage" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentPrepaymentFeePercentage" xlink:to="xoma_DebtInstrumentPrepaymentFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee as a percent of amount prepaid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage_lbl" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" xlink:to="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_lbl" xml:lang="en-US">Additional interest rate in the event of default (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_lbl" xml:lang="en-US">Percentage Of Additional Interest Rate Of Outstanding Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_lbl" xml:lang="en-US">Additional interest rate in the event of default (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Aggregate number of unregistered shares of common stock called by warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Aggregate number of shares of common stock called by warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ExercisablePeriodOfWarrants" xlink:to="xoma_ExercisablePeriodOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US">Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US">Exercisable Period Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US">Exercisable period of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Warrants Not Settleable In Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Fair value of warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt Issuance Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xml:lang="en-US">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument Unamortized Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Unamortized discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Non-cash interest expense resulting from amortization of discount and accretion of final payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Debt amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total payments, net of interest, final payment fees, discount and issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US">Variable Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">London Interbank Offered Rate L I B O R [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">Six-month LIBOR</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" xlink:to="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_lbl" xml:lang="en-US">The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_lbl" xml:lang="en-US">Collaborative Arrangement Research And Development Expense Funded Through Debt Instrument Percentage Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_lbl" xml:lang="en-US">Research and development expenses funded through loan facility, maximum (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument Interest Rate Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate at period end (as a percent)</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" xlink:to="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_lbl" xml:lang="en-US">The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_lbl" xml:lang="en-US">Debt Instrument, Decrease Upon Achievement of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_lbl" xml:lang="en-US">Amount by which note will be reduced upon achievement of specified milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Reduction in debt obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">2020 (excluding nine months ended September 30, 2020)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Long Term Debt Maturities Repayments Of Principal In Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" xlink:to="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_lbl" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and interest. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_lbl" xml:lang="en-US">Long Term Debt Future Principal Interest And Final Fee Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_lbl" xml:lang="en-US">Total payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less: interest, final payment fees, discount and issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseAbstract" xlink:label="us-gaap_InterestExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseAbstract" xlink:to="us-gaap_InterestExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseAbstract_lbl" xml:lang="en-US">Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseAbstract_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class Of Warrant Or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedFirstRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FiveYearWarrantsIssuedFirstRangeMember" xlink:to="xoma_FiveYearWarrantsIssuedFirstRangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember_lbl" xml:lang="en-US">Common stock warrant with exercise price of $66.20 per share. Issued in February 2015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember_lbl" xml:lang="en-US">Five Year Warrants Issued First Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember_lbl" xml:lang="en-US">Common stock warrant, Exercise price $66.20 per share, Issued February 2015</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedSecondRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FiveYearWarrantsIssuedSecondRangeMember" xlink:to="xoma_FiveYearWarrantsIssuedSecondRangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember_lbl" xml:lang="en-US">Common stock warrant with exercise price of $15.40 per share. Issued in February 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember_lbl" xml:lang="en-US">Five Year Warrants Issued Second Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember_lbl" xml:lang="en-US">Common stock warrant, Exercise Price $15.40 per share, Issued February 2016</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US">Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US">Ten Year Warrants Issued Third Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US">Common stock warrant, Exercise price $23.69 per share, Issued May 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="xoma_CommitmentsAndContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePayments" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US">Potential estimated obligations that due and payable upon achievement of certain criteria categorized as developmental, regulatory, or commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US">Contractual Obligation Estimated Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US">Estimate of milestone payments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US">Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US">Contractual Obligation, Estimated Milestone Payments, Number Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US">Assumed number of products per contract</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" xlink:to="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_lbl" xml:lang="en-US">Contractual obligation estimated fair value of contingent consideration liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_lbl" xml:lang="en-US">Contractual Obligation Estimated Fair Value Of Contingent Consideration Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_lbl" xml:lang="en-US">Estimated fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationMilestonePayments" xlink:label="xoma_ContractualObligationMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationMilestonePayments" xlink:to="xoma_ContractualObligationMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationMilestonePayments_lbl" xml:lang="en-US">Contractual obligations due to achievement of developmental, regulatory, or commercial milestones recorded as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationMilestonePayments_lbl" xml:lang="en-US">Contractual Obligation, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationMilestonePayments_lbl" xml:lang="en-US">Milestone liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage related to employees to purchase shares at the lower fair market value at offering period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title Of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US">Employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US">Employees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Directors</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US">Minimum age required for employees to qualify for immediate vesting of award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US">Minimum age required for employees to qualify for immediate vesting of award</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US">Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US">Threshold years required for retirement age</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Contractual Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Contractual Term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options exercised, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to stock options (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period of unrecognized compensation expense expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of options outstanding, non-vested options</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award options grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Sale of stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:to="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock and preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_lbl" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock And Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_lbl" xml:lang="en-US">Aggregate gross proceeds from issuance of common stock and preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_lbl" xml:lang="en-US">Aggregate gross proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds From Issuance Or Sale Of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from issuance of stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees and expenses</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BeneficialOwnershipLimitation" xlink:label="xoma_BeneficialOwnershipLimitation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BeneficialOwnershipLimitation" xlink:to="xoma_BeneficialOwnershipLimitation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BeneficialOwnershipLimitation_lbl" xml:lang="en-US">Represents the beneficial ownership limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BeneficialOwnershipLimitation_lbl" xml:lang="en-US">Beneficial Ownership Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BeneficialOwnershipLimitation_lbl" xml:lang="en-US">Beneficial ownership limitation (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Minority Interest Ownership Percentage By Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Ownership percentage on outstanding shares</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US">The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US">Ownership interest, if shares are converted (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Number of shares issued for each share of convertible preferred stock that is converted</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockConversionPricePerShare" xlink:to="xoma_PreferredStockConversionPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred stock conversion price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred stock conversion price per share</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" xlink:to="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Fair value of common stock amount exceeded allocated purchase price of convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Fair Value Of Common Stock Amount Exceeded Allocated Purchase Price Of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Fair value of common stock amount exceeded purchase price of convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumValueOfCommonStockToBeIssued" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US">Maximum value of common stock to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US">Maximum Value Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US">Maximum amount of shares to be issued</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US">Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US">Sales commission paid per transaction (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Cash receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xml:lang="en-US">Trade Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xml:lang="en-US">Trade Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner1Member" xlink:to="xoma_Partner1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US">Name or description of a single external partner 1 that accounts for 10 percent or more of the entity's revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US">Partner1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US">Partner 1</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner2Member" xlink:to="xoma_Partner2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US">Name or description of a single external partner 2 that accounts for 10 percent or more of the entity's revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US">Partner2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US">Partner 2</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner3Member" xlink:to="xoma_Partner3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US">Name or description of a single external partner 3 that accounts for 10 percent or more of the entity's revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US">Partner3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US">Partner 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type of Adoption</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xml:lang="en-US">Accounting Standards Update201813 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xml:lang="en-US">ASU 2018-13</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xml:lang="en-US">Accounting Standards Update201818 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xml:lang="en-US">ASU 2018-18</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Equity Method Investee Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RezoluteIncMember" xlink:to="xoma_RezoluteIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US">Rezolute, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US">Rezolute Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US">Rezolute</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible preferred stock.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants for common stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisPharmaAGMember" xlink:to="xoma_NovartisPharmaAGMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US">Novartis Pharma AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US">Novartis Pharma A G [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US">Novartis Pharma AG</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">XOMA-052 license agreement and IL1 target license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">Xoma052 License Agreement And I L1 Target License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">XOMA-052 License Agreement and I L1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XOMA052LicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US">XOMA-052 license agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US">X O M A052 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US">XOMA-052 License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">IL-1 target license agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">I L1 Target License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US">IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US">Novartis International Pharmaceutical Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US">Novartis International Pharmaceutical Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US">Novartis International</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US">License agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">License agreement and common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">License Agreement And Common Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">License Agreement and Common Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementRz358Member" xlink:to="xoma_LicenseAgreementRz358Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US">License agreement related to activities associated with RZ358.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US">License Agreement Rz358 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US">License Agreement, RZ358</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementNonRz358ProductsMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US">License agreement related to activities associated with non-RZ358 products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US">License Agreement Non Rz358 Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US">License Agreement, Non-RZ358 products</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementX129Member" xlink:label="xoma_LicenseAgreementX129Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementX129Member" xlink:to="xoma_LicenseAgreementX129Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementX129Member_lbl" xml:lang="en-US">License agreement related to activities associated with monoclonal antibody fragments , including X129.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementX129Member_lbl" xml:lang="en-US">License Agreement X129 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementX129Member_lbl" xml:lang="en-US">License Agreement, X129</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockPurchaseAgreementMember" xlink:to="xoma_CommonStockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">Common stock purchase agreement in which entity receives stock from counterparty.  Includes subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">Common Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US">Common Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Scenario Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_JanssenBiotechInc.Member" xlink:to="xoma_JanssenBiotechInc.Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US">Janssen Biotech, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US">Janssen Biotech Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US">Janssen Biotech Inc.</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ZydusMember" xlink:label="xoma_ZydusMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ZydusMember" xlink:to="xoma_ZydusMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ZydusMember_lbl" xml:lang="en-US">Cadila Healthcare Limited ("Zydus").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ZydusMember_lbl" xml:lang="en-US">Zydus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ZydusMember_lbl" xml:lang="en-US">Zydus</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US">Health Care Royalty Partners Two Limited Partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US">Health Care Royalty Partners Two Limited Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US">Health Care Royalty Partners Two Limited Partners</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US">Royalty Interest Acquisition Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US">Royalty Interest Acquisition Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US">Royalty Interest Acquisition Agreements</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">First Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">First Royalty Interest Acquisition Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">First Royalty Interest Acquisition Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">Second Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">Second Royalty Interest Acquisition Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US">Second Royalty Interest Acquisition Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Royalty Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgenusIncMember" xlink:to="xoma_AgenusIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US">Agenus Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US">Agenus Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US">Agenus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncyteImmunoOncologyAssetsMember" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US">Incyte immuno-oncology assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US">Incyte Immuno Oncology Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US">Incyte Immuno-Oncology Assets</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MerckImmunoOncologyProductMember" xlink:to="xoma_MerckImmunoOncologyProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US">Merck immuno-oncology product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US">Merck Immuno Oncology Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US">Merck Immuno-Oncology Product</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BioasisTechnologiesIncMember" xlink:to="xoma_BioasisTechnologiesIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US">Bioasis Technologies Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US">Bioasis Technologies Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US">Bioasis Technologies Inc</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraIncMember" xlink:to="xoma_AronoraIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US">Aronora, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US">Aronora Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US">Aronora</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BayerProductsMember" xlink:to="xoma_BayerProductsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US">Bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US">Bayer Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US">Bayer Products</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NonBayerProductsMember" xlink:to="xoma_NonBayerProductsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US">Non-bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US">Non Bayer Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US">Non-Bayer Products</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PalobiofarmaSLMember" xlink:to="xoma_PalobiofarmaSLMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US">Palobiofarma, S.L.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US">Palobiofarma S L [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US">Palobiofarma, S.L.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Closing common stock price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US">Measurement Input Discount For Lack Of Marketability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US">Discount for lack of marketability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Estimated time to liquidity of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheOneMember" xlink:label="xoma_EquitySecuritiesTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesTrancheOneMember" xlink:to="xoma_EquitySecuritiesTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesTrancheOneMember_lbl" xml:lang="en-US">Equity securities tranche one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesTrancheOneMember_lbl" xml:lang="en-US">Equity Securities Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesTrancheOneMember_lbl" xml:lang="en-US">Tranche 1</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheTwoMember" xlink:label="xoma_EquitySecuritiesTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesTrancheTwoMember" xlink:to="xoma_EquitySecuritiesTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesTrancheTwoMember_lbl" xml:lang="en-US">Equity securities tranche two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesTrancheTwoMember_lbl" xml:lang="en-US">Equity Securities Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesTrancheTwoMember_lbl" xml:lang="en-US">Tranche 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_EntityListingsExchangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsExchangeAxis_lbl" xml:lang="en-US">Entity Listings, Exchange [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ExchangeDomain" xlink:to="dei_ExchangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ExchangeDomain_lbl" xml:lang="en-US">Exchange [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ExchangeDomain_lbl" xml:lang="en-US">Exchange</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_OTCM" xlink:label="exch_OTCM" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_OTCM" xlink:to="exch_OTCM_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="exch_OTCM_lbl" xml:lang="en-US">O T C [M]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="exch_OTCM_lbl" xml:lang="en-US">OTC exchange</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:to="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_lbl" xml:lang="en-US">Leased facilities in Berkeley, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_lbl" xml:lang="en-US">Leased Facilities Berkeley California [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_lbl" xml:lang="en-US">Leased facilities, Berkeley, California</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US">Leased facilities in Emeryville, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US">Leased Facilities Emeryville California [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US">Leased facilities, Emeryville, California</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstTermLoanMember" xlink:label="xoma_FirstTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FirstTermLoanMember" xlink:to="xoma_FirstTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FirstTermLoanMember_lbl" xml:lang="en-US">First term loan from Silicon Valley Bank credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FirstTermLoanMember_lbl" xml:lang="en-US">First Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FirstTermLoanMember_lbl" xml:lang="en-US">Silicon Valley Bank, First Term Loan</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondTermLoanMember" xlink:label="xoma_SecondTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondTermLoanMember" xlink:to="xoma_SecondTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondTermLoanMember_lbl" xml:lang="en-US">Second term loan from Silicon Valley Bank credit facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondTermLoanMember_lbl" xml:lang="en-US">Second Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SecondTermLoanMember_lbl" xml:lang="en-US">Silicon Valley Bank, Second Term Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument Redemption Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument Redemption Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US">Debt Instrument Redemption Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US">On or before first anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US">Debt Instrument Redemption Period Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US">Following first anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US">Debt Instrument Redemption Period Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US">Following second anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantExercisePrice14.71Member" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US">Common stock warrant with exercise price of $14.71 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US">Common Stock Warrant Exercise Price14.71 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OtherFinancingsMember" xlink:label="xoma_OtherFinancingsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OtherFinancingsMember" xlink:to="xoma_OtherFinancingsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OtherFinancingsMember_lbl" xml:lang="en-US">Other debt obligations not specifically mentioned in the taxonomy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OtherFinancingsMember_lbl" xml:lang="en-US">Other Financings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OtherFinancingsMember_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2015 Employee Stock Purchase Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Two Thousand Fifteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2015 ESPP</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockOptionsVestingBasedOnPerformanceMember" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionsVestingBasedOnPerformanceMember" xlink:to="xoma_StockOptionsVestingBasedOnPerformanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US">Represents a stock option award with vesting based on achievement of performance conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US">Stock Options Vesting Based On Performance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember_lbl" xml:lang="en-US">Stock Options Vesting Based On Performance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BiotechnologyValueFundLPMember" xlink:to="xoma_BiotechnologyValueFundLPMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US">Biotechnology Value Fund, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US">Biotechnology Value Fund L P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US">BVF</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RightsOffering2019Member" xlink:label="xoma_RightsOffering2019Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RightsOffering2019Member" xlink:to="xoma_RightsOffering2019Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RightsOffering2019Member_lbl" xml:lang="en-US">2019 Rights Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RightsOffering2019Member_lbl" xml:lang="en-US">Rights Offering2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RightsOffering2019Member_lbl" xml:lang="en-US">2019 Rights Offering</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Y Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Y Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XomaCorporationMember" xlink:to="xoma_XomaCorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US">Xoma Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US">Xoma Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US">Xoma Corporation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Statement Class Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X and series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X And Series Y Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X and Series Y Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXConvertiblePreferredStockMember" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series X Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US">Two thousand eighteen at the market agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US">Two Thousand Eighteen At Market Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US">2018 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondRoyaltyPurchaseAgreementMember" xlink:to="xoma_SecondRoyaltyPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Second royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Second Royalty Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US">Second Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>tmb-20200930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2020 12:41:57 PM-->
<!--Modified on: 11/5/2020 12:41:57 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureDescriptionOfBusiness" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangements" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreements" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreements" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancings" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommonStockWarrants" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrants" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStock" roleURI="http://www.xoma.com/role/DisclosureCapitalStock" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureIncomeTaxes" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureSubsequentEvents" roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailTables" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsTables" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommonStockWarrantsTables" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureDescriptionOfBusinessDetails" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNovartisDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsZydusDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsNiaidDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureFairValueMeasurementsDebtDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsAdditionalInformationDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLeaseAgreementsSubleaseAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockRightsOffering2019Details" roleURI="http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="tmb-20200930.xsd#DisclosureSubsequentEventDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventDetails" />
  <presentationLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637401769134257501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637401769134257501" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637401769134257501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637401769134257501" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637401769134257501" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637401769134257501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637401769134257501" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637401769134257501" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637401769134257501" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637401769134257501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637401769134257501" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637401769134267479" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637401769134267479" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637401769134267479" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637401769134267479" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637401769134267479" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637401769134267479" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637401769134267479" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637401769134267479" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637401769134267479" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637401769134267479" order="20" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637401769134267479" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637401769134267479" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637401769134267479" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637401769134277504" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637401769134277504" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637401769134277504" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637401769134277504" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637401769134277504" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637401769134277504" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637401769134277504" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637401769134277504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637401769134277504" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637141762064750287" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637141762064750287" xlink:to="us-gaap_AssetsAbstract_637401769134287505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="us-gaap_AssetsCurrentAbstract_637401769134287505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637401769134287505" xlink:to="us-gaap_Cash_637401769134287505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637401769134287505" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_637401769134287505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637401769134287505" xlink:to="us-gaap_IncomeTaxesReceivable_637401769134287505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637401769134287505" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637401769134287505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637401769134287505" xlink:to="us-gaap_AssetsCurrent_637401769134287505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637401769134287505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637401769134287505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134287505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesFvNiNonCurrent" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="xoma_EquitySecuritiesFvNiNonCurrent_637401769134287505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637401769134287505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="us-gaap_OtherAssetsNoncurrent_637401769134287505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637401769134287505" xlink:to="us-gaap_Assets_637401769134297482" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637141762064750287" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_AccountsPayableCurrent_637401769134297482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_637401769134297482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134297482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637401769134297482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_DeferredIncomeCurrent_637401769134297482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637401769134297482" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_LongTermDebtCurrent_637401769134297482" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637401769134297482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637401769134297482" xlink:to="us-gaap_LiabilitiesCurrent_637401769134297482" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_DeferredIncomeNoncurrent_637401769134307471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_LongTermDebtNoncurrent_637401769134307471" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637401769134307471" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637401769134307471" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_Liabilities_637401769134307471" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_CommitmentsAndContingencies_637401769134307471" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637401769134297482" xlink:to="us-gaap_StockholdersEquityAbstract_637401769134307471" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637401769134307471" xlink:to="us-gaap_PreferredStockValue_637401769134307471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637401769134307471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637401769134307471" xlink:to="us-gaap_CommonStockValue_637401769134307471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637401769134317518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637401769134307471" xlink:to="us-gaap_AdditionalPaidInCapital_637401769134317518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637401769134317518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637401769134307471" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637401769134317518" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637401769134317518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637401769134307471" xlink:to="us-gaap_StockholdersEquity_637401769134317518" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637401769134317518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637141762064750287" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637401769134317518" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637401769134317518" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637401769134317518" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637401769134327510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637401769134327510" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637401769134327510" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637401769134327510" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637401769134327510" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637401769134327510" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637401769134327510" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenuesAbstract_637401769134327510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134327510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637401769134327510" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134327510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637401769134339447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637401769134327510" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637401769134339447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637401769134339447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637401769134327510" xlink:to="us-gaap_Revenues_637401769134339447" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637401769134347491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637401769134347491" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637401769134347491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637401769134347491" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637401769134347491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637401769134347491" xlink:to="us-gaap_OperatingExpenses_637401769134347491" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637401769134347491" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637401769134347491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637401769134347491" xlink:to="us-gaap_InterestExpenseDebt_637401769134347491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637401769134347491" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637401769134347491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637401769134347491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637401769134347491" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_637401769134347491" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637401769134347491" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769134347491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769134347491" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637401769134357510" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637401769134357510" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637401769134357510" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769134357510" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637401769134357510" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637401769134357510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637401769134357510" xlink:to="us-gaap_StatementEquityComponentsAxis_637401769134357510" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134357510" xlink:to="us-gaap_PreferredStockMember_637401769134357510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134357510" xlink:to="us-gaap_CommonStockMember_637401769134357510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637401769134357510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134357510" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637401769134357510" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134357510" xlink:to="us-gaap_RetainedEarningsMember_637401769134367508" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134357510" xlink:to="us-gaap_EquityComponentDomain_637401769134367508" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637401769134357510" xlink:to="us-gaap_StatementLineItems_637401769134367508" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637401769134367508" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockholdersEquity_637401769134367508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_SharesOutstanding_637401769134367508" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637401769134367508" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637401769134367508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637401769134367508" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637401769134367508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637401769134367508" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637401769134367508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637401769134367508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637401769134367508" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637401769134377513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReleaseOfRestrictedStockUnits" xlink:label="xoma_ReleaseOfRestrictedStockUnits_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="xoma_ReleaseOfRestrictedStockUnits_637401769134377513" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReleasedOfRestrictedStockUnits" xlink:label="xoma_SharesReleasedOfRestrictedStockUnits_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ReleaseOfRestrictedStockUnits_637401769134377513" xlink:to="xoma_SharesReleasedOfRestrictedStockUnits_637401769134377513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637401769134377513" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement" xlink:label="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement_637401769134377513" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637401769134377513" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637401769134377513" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769134377513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_NetIncomeLoss_637401769134377513" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637401769134377513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_StockholdersEquity_637401769134377513" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637401769134367508" xlink:to="us-gaap_SharesOutstanding_637401769134387487" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_ProfitLoss_637401769134387487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_ShareBasedCompensation_637401769134387487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_637401769134387487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_DepreciationAndAmortization_637401769134387487" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637401769134387487" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637401769134387487" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="xoma_OperatingLeasePaymentsNonCash_637401769134387487" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769134387487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769134387487" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637401769134397477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_637401769134397477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637401769134397477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637401769134397477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769134397477" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="xoma_IncreaseDecreaseInOperatingLeaseLiabilities_637401769134397477" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637401769134397477" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637401769134397477" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637401769134387487" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637401769134397477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637401769134397477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637401769134397477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637401769134397477" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637401769134397477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637401769134397477" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134407507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637401769134397477" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637401769134407507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769134407507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637401769134407507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134407507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637401769134407507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637401769134407507" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_637401769134407507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_FinanceLeasePrincipalPayments_637401769134407507" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromRepaymentsForDisgorgement" xlink:label="xoma_ProceedsFromRepaymentsForDisgorgement_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="xoma_ProceedsFromRepaymentsForDisgorgement_637401769134417516" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_637401769134417516" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637401769134407507" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637401769134417516" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637401769134417516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637401769134417516" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6374017691344175161" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6374017691344175161" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637401769134417516" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637401769134417516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637401769134417516" xlink:to="us-gaap_InterestPaidNet_637401769134417516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637401769134427511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637401769134427511" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_InterestAddedPrincipalBalancesLongTermDebt" xlink:label="xoma_InterestAddedPrincipalBalancesLongTermDebt_637401769134427511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637401769134427511" xlink:to="xoma_InterestAddedPrincipalBalancesLongTermDebt_637401769134427511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637401769134427511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637401769134427511" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_637401769134427511" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134427511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637401769134427511" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134427511" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637401769134437509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637401769134437509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation and Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637401769134437509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637401769134437509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" xlink:type="extended" xlink:title="10301 - Disclosure - Condensed Consolidated Financial Statements Details">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_637401769134437509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_637401769134437509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xlink:type="extended" xlink:title="10401 - Disclosure - Licensing and Other Arrangements">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_637401769134437509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_637401769134437509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements" xlink:type="extended" xlink:title="10501 - Disclosure - Royalty Purchase Agreements">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_637401769134447514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_637401769134447514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10601 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637401769134447514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637401769134447514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreements" xlink:type="extended" xlink:title="10701 - Disclosure - Lease Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock_637401769134447514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="xoma_LeaseDisclosureTextBlock_637401769134447514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings" xlink:type="extended" xlink:title="10801 - Disclosure - Long-Term Debt and Other Financings">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_637401769134457484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock_637401769134457484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrants" xlink:type="extended" xlink:title="10901 - Disclosure - Common Stock Warrants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637141762065998616" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantDisclosureTextBlock" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_637401769134457484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637141762065998616" xlink:to="xoma_CommonStockWarrantDisclosureTextBlock_637401769134457484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637401769134457484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637401769134457484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11101 - Disclosure - Stock-based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637401769134457484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637401769134457484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStock" xlink:type="extended" xlink:title="11201 - Disclosure - Capital Stock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637401769134467506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637401769134467506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637401769134467506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637401769134467506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637401769134467506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637401769134467506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637401769134477489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637401769134477489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637401769134477489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_637401769134477489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637401769134477489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xoma_EquitySecuritiesPolicy_637401769134477489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock_637401769134477489" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637401769134477489" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Reclassifications_637401769134477489" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637401769134477489" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_637401769134477489" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637401769134477489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637401769134477489" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637401769134487484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637401769134487484" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637401769134487484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637401769134487484" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_637401769134487484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_637401769134487484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables" xlink:type="extended" xlink:title="30303 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CondensedConsolidatedFinancialStatementsDetailAbstract" xlink:label="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_637141762066048730" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637401769134487484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_637141762066048730" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637401769134487484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637401769134487484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_637141762066048730" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637401769134487484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CondensedConsolidatedFinancialStatementsDetailAbstract_637141762066048730" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637401769134497498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637401769134497498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637401769134497498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637401769134497498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_637401769134497498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Lease Agreements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637401769134497498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637401769134497498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_637401769134497498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_637401769134497498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_637401769134497498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Long-Term Debt and Other Financings (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637401769134507487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_637401769134507487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock" xlink:label="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_637401769134507487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock_637401769134507487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Common Stock Warrants (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637141762066078795" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637401769134507487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_637141762066078795" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637401769134507487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31103 - Disclosure - Stock-based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637401769134507487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637401769134507487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637401769134517485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637401769134517485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_Cash_637401769134517485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_637401769134517485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_637401769134517485" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134517485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - EPS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends_637401769134517485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Dividends_637401769134517485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769134527493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637401769134527493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_6374017691345274931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_6374017691345274931" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637141762066108880" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637141762066108880" xlink:to="us-gaap_ConcentrationRiskTable_637401769134527493" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637401769134527493" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637401769134527493" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637401769134527493" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637401769134527493" xlink:to="us-gaap_CustomerConcentrationRiskMember_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637401769134527493" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637401769134527493" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637401769134527493" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637401769134527493" xlink:to="us-gaap_SalesRevenueNetMember_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637401769134527493" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_637401769134527493" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_637401769134527493" xlink:to="us-gaap_ReceivableTypeDomain_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember_637401769134527493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_637401769134527493" xlink:to="us-gaap_TradeAccountsReceivableMember_637401769134527493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637401769134527493" xlink:to="srt_MajorCustomersAxis_637401769134537480" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637401769134537480" xlink:to="srt_NameOfMajorCustomerDomain_637401769134537480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637401769134537480" xlink:to="xoma_Partner1Member_637401769134537480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637401769134537480" xlink:to="xoma_Partner2Member_637401769134537480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637401769134537480" xlink:to="xoma_Partner3Member_637401769134537480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637401769134527493" xlink:to="us-gaap_ConcentrationRiskLineItems_637401769134537480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637401769134537480" xlink:to="xoma_NumberOfMajorPartners_637401769134537480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637401769134537480" xlink:to="us-gaap_ConcentrationRiskPercentage1_637401769134537480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637306481064453483" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637306481064453483" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637401769134537480" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637401769134537480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637401769134537480" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637401769134537480" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637401769134537480" xlink:to="us-gaap_TypeOfAdoptionMember_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637401769134547485" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637401769134547485" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_637401769134547485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637401769134537480" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637401769134547485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637401769134547485" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637401769134547485" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_637401769134547485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Detail - Equity Securities (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_637401769134547485" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_637401769134547485" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637401769134547485" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_637401769134547485" xlink:to="srt_EquityMethodInvesteeNameDomain_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_637401769134547485" xlink:to="xoma_RezoluteIncMember_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_637401769134547485" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_637401769134547485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesFvNiNonCurrent" xlink:label="xoma_EquitySecuritiesFvNiNonCurrent_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_637401769134547485" xlink:to="xoma_EquitySecuritiesFvNiNonCurrent_637401769134547485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769134547485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_637401769134547485" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_637401769134547485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637401769134557480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="us-gaap_AccruedSalariesCurrent_637401769134557480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="us-gaap_InterestPayableCurrent_637401769134557480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="us-gaap_AccruedBonusesCurrent_637401769134557480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637401769134557480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637401769134557480" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_637401769134557480" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637141762066464809" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637141762066464809" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" xlink:to="us-gaap_NetIncomeLoss_637401769134557480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_637401769134557480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769134557480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637401769134557480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_637401769134567480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637401769134557480" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_637401769134567480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637141762066464809" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637401769134567480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_637401769134567480" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_637401769134567480" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637401769134567480" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_EarningsPerShareBasic_637401769134567480" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637401769134567480" xlink:to="us-gaap_EarningsPerShareDiluted_637401769134567480" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637141762066494898" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637141762066494898" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637401769134567480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637401769134567480" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637401769134567480" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637401769134567480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637401769134567480" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637401769134567480" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637401769134567480" xlink:to="us-gaap_ConvertiblePreferredStockMember_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637401769134567480" xlink:to="us-gaap_EmployeeStockOptionMember_637401769134577483" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637401769134567480" xlink:to="us-gaap_WarrantMember_637401769134577483" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637401769134567480" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637401769134577483" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637401769134577483" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - Novartis (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" xlink:to="srt_CounterpartyNameAxis_637401769134577483" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134577483" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134577483" xlink:to="xoma_NovartisPharmaAGMember_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134577483" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134577483" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134577483" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember_637401769134577483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_637401769134577483" xlink:to="xoma_XOMA052LicenseAgreementMember_637401769134577483" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_637401769134577483" xlink:to="xoma_IL1TargetLicenseAgreementMember_637401769134587486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" xlink:to="us-gaap_StatementEquityComponentsAxis_637401769134587486" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769134587486" xlink:to="us-gaap_EquityComponentDomain_637401769134587486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637401769134587486" xlink:to="us-gaap_CommonStockMember_637401769134587486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134577483" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_LicenseAgreementConsiderationReceived_637401769134587486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_ProceedsFromUpfrontPayment_637401769134587486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_637401769134587486" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637401769134587486" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769134587486" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637401769134587486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_SharesIssuedPricePerShare_637401769134587486" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_637401769134597480" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_SharePrice_637401769134597480" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_CommonStockPremium_637401769134597480" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134597480" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_NumberOfLicenseAgreements_637401769134597480" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134597480" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_ArrangementsNumber_637401769134597480" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_NumberOfPerformanceObligations_637401769134597480" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637401769134597480" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637401769134597480" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="xoma_LicenseAgreementTransactionPrice_637401769134607482" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134607482" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_ContractWithCustomerAssetNet_637401769134607482" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134607482" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134587486" xlink:to="us-gaap_CapitalizedContractCostNet_637401769134607482" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis International (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_637145863395208503" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract_637145863395208503" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" xlink:to="srt_CounterpartyNameAxis_637401769134617485" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134617485" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134617485" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134617485" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134617485" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134617485" xlink:to="xoma_LicenseAgreementMember_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" xlink:to="us-gaap_SubsequentEventTypeAxis_637401769134617485" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637401769134617485" xlink:to="us-gaap_SubsequentEventTypeDomain_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637401769134617485" xlink:to="us-gaap_SubsequentEventMember_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134607482" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134617485" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="xoma_NumberOfPerformanceObligations_637401769134617485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="xoma_ProceedsFromUpfrontPayment_637401769134617485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134617485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134617485" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134627482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="xoma_RoyaltiesPeriodMinimum_637401769134627482" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="us-gaap_ContractWithCustomerAssetNet_637401769134627482" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134627482" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134617485" xlink:to="us-gaap_CapitalizedContractCostNet_637401769134627482" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134627482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134627482" xlink:to="srt_CounterpartyNameAxis_637401769134627482" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134627482" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134627482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769134627482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134627482" xlink:to="xoma_RezoluteIncMember_637401769134627482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134627482" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134637482" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134637482" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134637482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134637482" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134637482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134637482" xlink:to="xoma_LicenseAgreementMember_637401769134637482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_637401769134637482" xlink:to="xoma_LicenseAgreementRz358Member_637401769134637482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_637401769134637482" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_637401769134637482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementX129Member" xlink:label="xoma_LicenseAgreementX129Member_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_637401769134637482" xlink:to="xoma_LicenseAgreementX129Member_637401769134637482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134627482" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontOptionPayment" xlink:label="xoma_UpfrontOptionPayment_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_UpfrontOptionPayment_637401769134637482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_637401769134637482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_RoyaltiesPeriodMinimum_637401769134637482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_637401769134637482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134637482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_637401769134637482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134637482" xlink:to="xoma_LicenseAgreementConsiderationReceived_637401769134647487" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Rezolute - First Amendment (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_637152027015443215" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract_637152027015443215" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" xlink:to="srt_CounterpartyNameAxis_637401769134647487" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134647487" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134647487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134647487" xlink:to="xoma_RezoluteIncMember_637401769134647487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134647487" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134647487" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134647487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134647487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134647487" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134647487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134647487" xlink:to="xoma_LicenseAgreementMember_637401769134657506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134647487" xlink:to="xoma_CommonStockPurchaseAgreementMember_637401769134657506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" xlink:to="srt_StatementScenarioAxis_637401769134657506" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637401769134657506" xlink:to="srt_ScenarioUnspecifiedDomain_637401769134657506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637401769134657506" xlink:to="srt_ScenarioForecastMember_637401769134657506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134647487" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInCash" xlink:label="xoma_EligibleToReceiveInCash_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_EligibleToReceiveInCash_637401769134657506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_637401769134657506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockSharesReceivable" xlink:label="xoma_CommonStockSharesReceivable_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_CommonStockSharesReceivable_637401769134657506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromQualifiedFinancing" xlink:label="xoma_GrossProceedsFromQualifiedFinancing_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_GrossProceedsFromQualifiedFinancing_637401769134657506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AdditionalCommonStockReceiveForQualifiedFinancing" xlink:label="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_637401769134657506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_AdditionalCommonStockReceiveForQualifiedFinancing_637401769134657506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockThresholdTradingDays" xlink:label="xoma_CommonStockThresholdTradingDays_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_CommonStockThresholdTradingDays_637401769134667490" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement" xlink:label="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement_637401769134667490" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_NumberOfSharesRightAndOptionToSell_637401769134667490" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell" xlink:label="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell_637401769134667490" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="us-gaap_Revenues_637401769134667490" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceived" xlink:label="xoma_SharesReceived_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_SharesReceived_637401769134667490" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CashReceived" xlink:label="xoma_CashReceived_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_CashReceived_637401769134667490" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber_637401769134667490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_ArrangementsNumber_637401769134667490" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_LicenseAgreementTransactionPrice_637401769134677487" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SharesReceivedValue" xlink:label="xoma_SharesReceivedValue_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_SharesReceivedValue_637401769134677487" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_ReimbursableTechnologyTransferExpensesReceived_637401769134677487" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_NumberOfPerformanceObligations_637401769134677487" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_637401769134677487" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134677487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134657506" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134677487" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_637152027508728378" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract_637152027508728378" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="srt_CounterpartyNameAxis_637401769134747491" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134747491" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134747491" xlink:to="xoma_RezoluteIncMember_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134747491" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134747491" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134747491" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134747491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134747491" xlink:to="xoma_LicenseAgreementMember_637401769134747491" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134747491" xlink:to="xoma_CommonStockPurchaseAgreementMember_637401769134757490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="us-gaap_SubsequentEventTypeAxis_637401769134757490" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637401769134757490" xlink:to="us-gaap_SubsequentEventTypeDomain_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637401769134757490" xlink:to="us-gaap_SubsequentEventMember_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="srt_StatementScenarioAxis_637401769134757490" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637401769134757490" xlink:to="srt_ScenarioUnspecifiedDomain_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637401769134757490" xlink:to="srt_ScenarioForecastMember_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="srt_RangeAxis_637401769134757490" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637401769134757490" xlink:to="srt_RangeMember_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637401769134757490" xlink:to="srt_MaximumMember_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134747491" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities" xlink:label="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_637401769134757490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities_637401769134757490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing_637401769134767491" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing" xlink:label="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing_637401769134767491" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing" xlink:label="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing_637401769134767491" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_NumberOfSharesRightAndOptionToSell_637401769134767491" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock_637401769134767491" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ConsiderationPaidUponQualifiedFinancingEvent" xlink:label="xoma_ConsiderationPaidUponQualifiedFinancingEvent_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_ConsiderationPaidUponQualifiedFinancingEvent_637401769134767491" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ReimbursableTechnologyTransferExpensesReceived" xlink:label="xoma_ReimbursableTechnologyTransferExpensesReceived_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_ReimbursableTechnologyTransferExpensesReceived_637401769134767491" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134767491" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DoubtfulRevenueReversalOfFutureCashPayments" xlink:label="xoma_DoubtfulRevenueReversalOfFutureCashPayments_637401769134767491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_DoubtfulRevenueReversalOfFutureCashPayments_637401769134767491" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementNumberOfCommonStockFinancingEvents" xlink:label="xoma_AgreementNumberOfCommonStockFinancingEvents_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_AgreementNumberOfCommonStockFinancingEvents_637401769134777486" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EarlyPaymentOfUnrecognizedFutureCashPayments" xlink:label="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_EarlyPaymentOfUnrecognizedFutureCashPayments_637401769134777486" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UnrecognizedFutureCashPayments" xlink:label="xoma_UnrecognizedFutureCashPayments_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_UnrecognizedFutureCashPayments_637401769134777486" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsReceived" xlink:label="xoma_FutureCashPaymentsReceived_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_FutureCashPaymentsReceived_637401769134777486" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_NumberOfPerformanceObligations_637401769134777486" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment" xlink:label="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment_637401769134777486" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637401769134777486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637401769134777486" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsOfRevenueRecognized" xlink:label="xoma_FutureCashPaymentsOfRevenueRecognized_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_FutureCashPaymentsOfRevenueRecognized_637401769134787495" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfQuarterlyPayments" xlink:label="xoma_NumberOfQuarterlyPayments_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_NumberOfQuarterlyPayments_637401769134787495" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing" xlink:label="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing_637401769134787495" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637401769134787495" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769134787495" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_ContractWithCustomerAssetNet_637401769134787495" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134787495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134787495" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134757490" xlink:to="us-gaap_CapitalizedContractCostNet_637401769134797499" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134797499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134797499" xlink:to="srt_CounterpartyNameAxis_637401769134797499" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134797499" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134797499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134797499" xlink:to="xoma_JanssenBiotechInc.Member_637401769134797499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134797499" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134797499" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134797499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134797499" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134797499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134797499" xlink:to="xoma_LicenseAgreementMember_637401769134807492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134797499" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="xoma_ProceedsFromUpfrontPayment_637401769134807492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OneTimePayment" xlink:label="xoma_OneTimePayment_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="xoma_OneTimePayment_637401769134807492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_637401769134807492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_637401769134807492" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134807492" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="us-gaap_ContractWithCustomerAssetNet_637401769134807492" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134807492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134807492" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134807492" xlink:to="us-gaap_CapitalizedContractCostNet_637401769134817514" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Zydus (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_637212589039047632" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract_637212589039047632" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134817514" xlink:to="srt_CounterpartyNameAxis_637401769134817514" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134817514" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ZydusMember" xlink:label="xoma_ZydusMember_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134817514" xlink:to="xoma_ZydusMember_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134817514" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134817514" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134817514" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134817514" xlink:to="xoma_LicenseAgreementMember_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134817514" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_637401769134817514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_637401769134817514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones_637401769134817514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="xoma_NumberOfPerformanceObligations_637401769134827496" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="us-gaap_ContractWithCustomerAssetNet_637401769134827496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134827496" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="us-gaap_CapitalizedContractCostNet_637401769134827496" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134817514" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769134827496" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - NIAID (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134827496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134827496" xlink:to="srt_CounterpartyNameAxis_637401769134827496" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134827496" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134827496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DeferredRevenueArrangementNameOfParty2Member" xlink:label="xoma_DeferredRevenueArrangementNameOfParty2Member_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134827496" xlink:to="xoma_DeferredRevenueArrangementNameOfParty2Member_637401769134827496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134827496" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134827496" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134827496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134827496" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134827496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member" xlink:label="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134827496" xlink:to="xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_637401769134837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134827496" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumRevenueFromContract" xlink:label="xoma_MaximumRevenueFromContract_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" xlink:to="xoma_MaximumRevenueFromContract_637401769134837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualTerm" xlink:label="xoma_ContractualTerm_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" xlink:to="xoma_ContractualTerm_637401769134837495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" xlink:to="us-gaap_AccountsReceivableNet_637401769134837495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" xlink:to="us-gaap_ContractWithCustomerLiability_637401769134837495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractsRevenueWroteOff" xlink:label="xoma_ContractsRevenueWroteOff_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134837495" xlink:to="xoma_ContractsRevenueWroteOff_637401769134837495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134837495" xlink:to="srt_CounterpartyNameAxis_637401769134837495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134837495" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_637401769134837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134837495" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_637401769134837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134837495" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134847493" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134847493" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134847493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134847493" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_637401769134847493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_637401769134847493" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_637401769134847493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_637401769134847493" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_637401769134847493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134837495" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_637401769134847493" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="xoma_ProceedsFromUpfrontPayment_637401769134847493" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_637401769134847493" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="xoma_MilestonePeriodsNumber_637401769134847493" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_637401769134847493" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_637401769134847493" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_637401769134847493" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="us-gaap_DeferredIncomeCurrent_637401769134857495" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134847493" xlink:to="us-gaap_DeferredIncomeNoncurrent_637401769134857495" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty Purchase Agreements - Agenus (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_637141762068369874" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract_637141762068369874" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134857495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134857495" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134857495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134857495" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769134857495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" xlink:to="srt_CounterpartyNameAxis_637401769134857495" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134857495" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134857495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134857495" xlink:to="xoma_AgenusIncMember_637401769134857495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" xlink:to="srt_ProductOrServiceAxis_637401769134857495" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637401769134857495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637401769134857495" xlink:to="srt_ProductsAndServicesDomain_637401769134857495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637401769134857495" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_637401769134867495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637401769134857495" xlink:to="xoma_MerckImmunoOncologyProductMember_637401769134867495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" xlink:to="us-gaap_DebtInstrumentAxis_637401769134867495" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769134867495" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769134867495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769134867495" xlink:to="xoma_SiliconValleyBankMember_637401769134867495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134857495" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_637401769134867495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_637401769134867495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_PurchasedPercentageOfMilestones_637401769134867495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_637401769134867495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134867495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134867495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134877497" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134877497" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134877497" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134867495" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134877497" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty Purchase Agreements - Bioasis (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_637146080140498167" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract_637146080140498167" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" xlink:to="srt_CounterpartyNameAxis_637401769134877497" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134877497" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134877497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134877497" xlink:to="xoma_BioasisTechnologiesIncMember_637401769134877497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134877497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134877497" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134877497" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134887496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134887496" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769134887496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" xlink:to="srt_RangeAxis_637401769134887496" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637401769134887496" xlink:to="srt_RangeMember_637401769134887496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637401769134887496" xlink:to="srt_MaximumMember_637401769134887496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134877497" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_637401769134887496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_637401769134887496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_637401769134887496" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_637401769134887496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134887496" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134887496" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_637401769134887496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_ContingentFutureCashPayments_637401769134887496" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134897497" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134897497" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_PaymentsOfContingentConsideration_637401769134897497" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134887496" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134897497" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty Purchase Agreements - Aronora (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_637146079631938167" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract_637146079631938167" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134897497" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134897497" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134897497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769134897497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134897497" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769134897497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="srt_CounterpartyNameAxis_637401769134907499" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134907499" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134907499" xlink:to="xoma_AronoraIncMember_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="srt_ProductOrServiceAxis_637401769134907499" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637401769134907499" xlink:to="srt_ProductsAndServicesDomain_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637401769134907499" xlink:to="xoma_BayerProductsMember_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637401769134907499" xlink:to="xoma_NonBayerProductsMember_637401769134907499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="us-gaap_DebtInstrumentAxis_637401769134907499" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769134907499" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769134907499" xlink:to="xoma_SiliconValleyBankMember_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="srt_RangeAxis_637401769134907499" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637401769134907499" xlink:to="srt_RangeMember_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637401769134907499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637401769134907499" xlink:to="srt_MaximumMember_637401769134907499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134897497" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_AgreementDrugCandidatesNumber_637401769134917498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_637401769134917498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts_637401769134917498" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_637401769134917498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_637401769134917498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_AgreementPaymentPercentageFactor_637401769134917498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_UpfrontPayment_637401769134917498" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_637401769134917498" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_637401769134917498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_ContingentFutureCashPayments_637401769134917498" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_637401769134927503" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134927503" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769134927503" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PaymentsOfContingentConsideration_637401769134927503" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769134927503" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134927503" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_637401769134927503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_637401769134927503" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PurchasedPercentageOfMilestones_637401769134937501" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_637401769134937501" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_637401769134937501" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134937501" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134937501" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_637401769134937501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134917498" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_637401769134937501" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty Purchase Agreements - Palobiofarma (Details)">
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementAbstract" xlink:label="xoma_RoyaltyPurchaseAgreementAbstract_637146080664088167" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAbstract_637146080664088167" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134947498" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134947498" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134947498" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" xlink:to="srt_CounterpartyNameAxis_637401769134947498" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134947498" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134947498" xlink:to="xoma_PalobiofarmaSLMember_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" xlink:to="us-gaap_DebtInstrumentAxis_637401769134947498" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769134947498" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769134947498" xlink:to="xoma_SiliconValleyBankMember_637401769134947498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637401769134947498" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="xoma_AgreementDrugCandidatesNumber_637401769134957501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769134957501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769134957501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNonCurrent" xlink:label="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="xoma_LongTermRoyaltyReceivableNonCurrent_637401769134957501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_637401769134957501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease" xlink:label="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_637401769134957501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637401769134947498" xlink:to="xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease_637401769134957501" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637401769134970857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637401769134970857" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637401769134970857" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637401769134970857" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637401769134970857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637401769134970857" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637401769134970857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637401769134970857" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637401769134970857" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637401769134970857" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637401769134970857" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637401769134970857" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637401769134970857" xlink:to="us-gaap_FairValueInputsLevel3Member_637401769134977512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637401769134970857" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769134977512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769134977512" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637401769134977512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637401769134977512" xlink:to="us-gaap_InvestmentsFairValueDisclosure_637401769134977512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769134977512" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_637401769134977512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_637401769134977512" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_637401769134977512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract" xlink:label="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769134977512" xlink:to="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637401769134977512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637401769134977512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637401769134977512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637401769134977512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract_637401769134977512" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637401769134977512" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637141762069272272" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637141762069272272" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="us-gaap_MeasurementInputTypeAxis_637401769134987508" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637401769134987508" xlink:to="us-gaap_MeasurementInputTypeDomain_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637401769134987508" xlink:to="us-gaap_MeasurementInputSharePriceMember_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637401769134987508" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_637401769134987508" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637401769134987508" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637401769134987508" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="us-gaap_TypeOfArrangementAxis_637401769134987508" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769134987508" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769134987508" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockPurchaseAgreementMember" xlink:label="xoma_CommonStockPurchaseAgreementMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_637401769134987508" xlink:to="xoma_CommonStockPurchaseAgreementMember_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="srt_CounterpartyNameAxis_637401769134987508" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769134987508" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769134987508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769134987508" xlink:to="xoma_RezoluteIncMember_637401769134987508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="us-gaap_FinancialInstrumentAxis_637401769134997502" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637401769134997502" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769134997502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheOneMember" xlink:label="xoma_EquitySecuritiesTrancheOneMember_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769134997502" xlink:to="xoma_EquitySecuritiesTrancheOneMember_637401769134997502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesTrancheTwoMember" xlink:label="xoma_EquitySecuritiesTrancheTwoMember_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637401769134997502" xlink:to="xoma_EquitySecuritiesTrancheTwoMember_637401769134997502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:label="dei_EntityListingsExchangeAxis_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="dei_EntityListingsExchangeAxis_637401769134997502" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_ExchangeDomain" xlink:label="dei_ExchangeDomain_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis_637401769134997502" xlink:to="dei_ExchangeDomain_637401769134997502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd#exch_OTCM" xlink:label="exch_OTCM_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain_637401769134997502" xlink:to="exch_OTCM_637401769134997502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769134987508" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637401769134997502" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NumberOfSharesRightAndOptionToSell" xlink:label="xoma_NumberOfSharesRightAndOptionToSell_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637401769134997502" xlink:to="xoma_NumberOfSharesRightAndOptionToSell_637401769134997502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EquitySecuritiesNumberOfTranches" xlink:label="xoma_EquitySecuritiesNumberOfTranches_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637401769134997502" xlink:to="xoma_EquitySecuritiesNumberOfTranches_637401769134997502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_637401769134997502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_637401769134997502" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_637401769134997502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637214217706003445" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637214217706003445" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769135007503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769135007503" xlink:to="us-gaap_TypeOfArrangementAxis_637401769135007503" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769135007503" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135007503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135007503" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769135007503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637401769135007503" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769135007503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769135007503" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_637401769135007503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769135007503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637401769135007503" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769135007503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Fair Value Measurements - Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637401769135017505" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637401769135017505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637401769135017505" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769135017505" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637401769135017505" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637401769135017505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637401769135017505" xlink:to="us-gaap_DebtInstrumentAxis_637401769135017505" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769135017505" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135017505" xlink:to="xoma_NovartisNoteMember_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135017505" xlink:to="xoma_SiliconValleyBankMember_637401769135017505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_637401769135017505" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637401769135017505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_637401769135017505" xlink:to="us-gaap_LongTermDebtFairValue_637401769135017505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637147759255374727" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147759255374727" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637401769135017505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135017505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637401769135017505" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135017505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135017505" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135027505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135027505" xlink:to="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_637401769135027505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135027505" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_637401769135027505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637401769135017505" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_637401769135027505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" xlink:to="xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities_637401769135027505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OperatingLeaseEarlyTerminationFee" xlink:label="xoma_OperatingLeaseEarlyTerminationFee_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" xlink:to="xoma_OperatingLeaseEarlyTerminationFee_637401769135027505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135027505" xlink:to="us-gaap_GainLossOnTerminationOfLease_637401769135027505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637147774608355631" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637401769135027505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637401769135027505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637401769135027505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637401769135027505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637401769135027505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637401769135027505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637401769135037507" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147774608355631" xlink:to="us-gaap_OperatingLeaseLiability_637401769135037507" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreements - Lease costs (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637147856255423040" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147856255423040" xlink:to="us-gaap_LeaseCostAbstract_637401769135037507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637401769135037507" xlink:to="us-gaap_OperatingLeaseCost_637401769135037507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637401769135037507" xlink:to="us-gaap_VariableLeaseCost_637401769135037507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637401769135037507" xlink:to="us-gaap_LeaseCost_637401769135037507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Lease Agreements - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637147856854192911" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147856854192911" xlink:to="us-gaap_OperatingLeasePayments_637401769135037507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147856854192911" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637401769135037507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637401769135037507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147856854192911" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637401769135037507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Lease Agreements - Sublease Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_637147857641961680" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_637147857641961680" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637401769135047533" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637401769135047533" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135047533" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637401769135047533" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LeasedFacilitiesBerkeleyCaliforniaMember" xlink:label="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637401769135047533" xlink:to="xoma_LeasedFacilitiesBerkeleyCaliforniaMember_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637401769135047533" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637401769135047533" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135047533" xlink:to="us-gaap_GainLossOnTerminationOfLease_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637401769135047533" xlink:to="us-gaap_SubleaseIncome_637401769135047533" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="us-gaap_DebtInstrumentAxis_637401769135047533" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769135047533" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769135047533" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135047533" xlink:to="xoma_SiliconValleyBankMember_637401769135047533" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FirstTermLoanMember" xlink:label="xoma_FirstTermLoanMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_SiliconValleyBankMember_637401769135047533" xlink:to="xoma_FirstTermLoanMember_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondTermLoanMember" xlink:label="xoma_SecondTermLoanMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_SiliconValleyBankMember_637401769135047533" xlink:to="xoma_SecondTermLoanMember_637401769135057512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_637401769135057512" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_637401769135057512" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769135057512" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769135057512" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_637401769135057512" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_637401769135057512" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_637401769135057512" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="us-gaap_VariableRateAxis_637401769135057512" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637401769135057512" xlink:to="us-gaap_VariableRateDomain_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637401769135057512" xlink:to="us-gaap_PrimeRateMember_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637401769135057512" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637401769135057512" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_637401769135057512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135057512" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_637401769135057512" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135057512" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_637401769135067516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="srt_RangeAxis_637401769135067516" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637401769135067516" xlink:to="srt_RangeMember_637401769135067516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637401769135067516" xlink:to="srt_MinimumMember_637401769135067516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135047533" xlink:to="us-gaap_DebtInstrumentLineItems_637401769135067516" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637401769135067516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637401769135067516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637401769135067516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest" xlink:label="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest_637401769135067516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate" xlink:label="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_637401769135067516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate_637401769135067516" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan" xlink:label="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan_637401769135077511" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentAmountToBeReborrowed" xlink:label="xoma_DebtInstrumentAmountToBeReborrowed_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_DebtInstrumentAmountToBeReborrowed_637401769135077511" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentFinalPaymentFeePercentage" xlink:label="xoma_DebtInstrumentFinalPaymentFeePercentage_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_DebtInstrumentFinalPaymentFeePercentage_637401769135077511" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentPrepaymentFeePercentage" xlink:label="xoma_DebtInstrumentPrepaymentFeePercentage_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_DebtInstrumentPrepaymentFeePercentage_637401769135077511" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan" xlink:label="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan_637401769135077511" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637401769135077511" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637401769135077511" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants_637401769135077511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="xoma_ExercisablePeriodOfWarrants_637401769135077511" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637401769135087510" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_DeferredFinanceCostsGross_637401769135087510" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637401769135087510" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_637401769135087510" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_637401769135087510" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_LongTermDebt_637401769135087510" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637401769135087510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_LongTermDebtCurrent_637401769135087510" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135067516" xlink:to="us-gaap_LongTermDebtNoncurrent_637401769135097517" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637401769135097517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="srt_CounterpartyNameAxis_637401769135097517" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769135097517" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135097517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135097517" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769135097517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="us-gaap_TypeOfArrangementAxis_637401769135097517" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135097517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769135097517" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135097517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135097517" xlink:to="xoma_LicenseAgreementMember_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="us-gaap_SubsequentEventTypeAxis_637401769135107520" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637401769135107520" xlink:to="us-gaap_SubsequentEventTypeDomain_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637401769135107520" xlink:to="us-gaap_SubsequentEventMember_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="us-gaap_DebtInstrumentAxis_637401769135107520" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769135107520" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135107520" xlink:to="xoma_NovartisNoteMember_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="us-gaap_VariableRateAxis_637401769135107520" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis_637401769135107520" xlink:to="us-gaap_VariableRateDomain_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain_637401769135107520" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135097517" xlink:to="us-gaap_DebtInstrumentLineItems_637401769135107520" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum" xlink:label="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum_637401769135107520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637401769135107520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_637401769135107520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_637401769135117509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_637401769135117509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_DebtInstrumentDecreaseUponAchievementOfMilestones" xlink:label="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="xoma_DebtInstrumentDecreaseUponAchievementOfMilestones_637401769135117509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_LongTermDebt_637401769135117509" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769135117509" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_637401769135117509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135107520" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_637401769135117509" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_637401769135127532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_637401769135127532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637401769135127532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments" xlink:label="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments_637401769135127532" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_637401769135127532" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_637401769135127532" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent_637401769135127532" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent_637401769135127532" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637401769135127532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135127532" xlink:to="us-gaap_DebtInstrumentAxis_637401769135127532" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769135127532" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769135127532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_637401769135127532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135127532" xlink:to="xoma_SiliconValleyBankMember_637401769135127532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135127532" xlink:to="xoma_NovartisNoteMember_637401769135137513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_OtherFinancingsMember" xlink:label="xoma_OtherFinancingsMember_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135127532" xlink:to="xoma_OtherFinancingsMember_637401769135137513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637401769135127532" xlink:to="us-gaap_DebtInstrumentLineItems_637401769135137513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseAbstract" xlink:label="us-gaap_InterestExpenseAbstract_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637401769135137513" xlink:to="us-gaap_InterestExpenseAbstract_637401769135137513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseAbstract_637401769135137513" xlink:to="us-gaap_InterestExpenseDebt_637401769135137513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Common Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637401769135137513" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637401769135137513" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637401769135137513" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637401769135137513" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedFirstRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedFirstRangeMember_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" xlink:to="xoma_FiveYearWarrantsIssuedFirstRangeMember_637401769135137513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FiveYearWarrantsIssuedSecondRangeMember" xlink:label="xoma_FiveYearWarrantsIssuedSecondRangeMember_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" xlink:to="xoma_FiveYearWarrantsIssuedSecondRangeMember_637401769135137513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_637401769135137513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_637401769135137513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637401769135137513" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_637401769135137513" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637401769135137513" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637401769135147521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637401769135147521" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637401769135147521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637401769135147521" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637401769135147521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637141762070891531" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637141762070891531" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_637401769135147521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637141762070891531" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_637401769135147521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637214419170039181" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637214419170039181" xlink:to="xoma_CommitmentsAndContingenciesTable_637401769135147521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_637401769135147521" xlink:to="us-gaap_TypeOfArrangementAxis_637401769135147521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769135147521" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135147521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_637401769135147521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135147521" xlink:to="xoma_RoyaltyPurchaseAgreementMember_637401769135147521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_637401769135147521" xlink:to="srt_CounterpartyNameAxis_637401769135157517" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769135157517" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135157517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135157517" xlink:to="xoma_BioasisTechnologiesIncMember_637401769135157517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135157517" xlink:to="xoma_AronoraIncMember_637401769135157517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_637401769135147521" xlink:to="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" xlink:to="xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements_637401769135157517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_637401769135157517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability" xlink:label="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" xlink:to="xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability_637401769135157517" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ContractualObligationMilestonePayments" xlink:label="xoma_ContractualObligationMilestonePayments_637401769135157517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_637401769135157517" xlink:to="xoma_ContractualObligationMilestonePayments_637401769135157517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Stock-based Compensation - ESPP (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637148629219688674" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637148629219688674" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" xlink:to="us-gaap_PlanNameAxis_637401769135167521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637401769135167521" xlink:to="us-gaap_PlanNameDomain_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637401769135167521" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135167521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135167521" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Stock-based Compensation - Stock Options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" xlink:to="us-gaap_AwardTypeAxis_637401769135167521" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637401769135167521" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135167521" xlink:to="us-gaap_EmployeeStockOptionMember_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" xlink:to="srt_TitleOfIndividualAxis_637401769135167521" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637401769135167521" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_637401769135167521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769135167521" xlink:to="xoma_EmployeeMember_637401769135167521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637401769135167521" xlink:to="srt_DirectorMember_637401769135177516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135167521" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637401769135177516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_637401769135177516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_637401769135177516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135177516" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637401769135177516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135177516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135177516" xlink:to="us-gaap_AwardTypeAxis_637401769135177516" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637401769135177516" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135177516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637401769135177516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135177516" xlink:to="us-gaap_EmployeeStockOptionMember_637401769135177516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135177516" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135187513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135187513" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637401769135187513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637401769135187513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637401769135187513" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637401769135187513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637401769135187513" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637401769135187513" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135247551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135247551" xlink:to="us-gaap_AwardTypeAxis_637401769135247551" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135247551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135247551" xlink:to="us-gaap_EmployeeStockOptionMember_637401769135247551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637401769135247551" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637401769135247551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637401769135247551" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637401769135257555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637401769135257555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637401769135257555" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637401769135257555" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637401769135257555" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637401769135257555" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637401769135257555" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637401769135257555" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6374017691352575551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6374017691352575551" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637401769135257555" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637401769135257555" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637401769135257555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637401769135257555" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637401769135267558" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637401769135267558" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637401769135267558" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637401769135267558" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637401769135267558" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637401769135267558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135247551" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637401769135267558" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Stock-based Compensation - Performance-based stock options (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637148682361152430" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637148682361152430" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135277826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135277826" xlink:to="us-gaap_AwardTypeAxis_637401769135277826" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637401769135277826" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135277826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135277826" xlink:to="us-gaap_EmployeeStockOptionMember_637401769135277826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_StockOptionsVestingBasedOnPerformanceMember" xlink:label="xoma_StockOptionsVestingBasedOnPerformanceMember_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637401769135277826" xlink:to="xoma_StockOptionsVestingBasedOnPerformanceMember_637401769135277826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637401769135277826" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637401769135277826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_637401769135277826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637401769135277826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637401769135277826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637401769135277826" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637401769135277826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637401769135287553" xlink:to="us-gaap_IncomeStatementLocationAxis_637401769135287553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637401769135287553" xlink:to="us-gaap_IncomeStatementLocationDomain_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637401769135287553" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637401769135287553" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637401769135287553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637401769135287553" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637401769135287553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637401769135287553" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details" xlink:type="extended" xlink:title="41201 - Disclosure - Capital Stock - Rights Offering 2019 (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637150197874698520" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637150197874698520" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="dei_LegalEntityAxis_637401769135287553" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637401769135287553" xlink:to="dei_EntityDomain_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637401769135287553" xlink:to="xoma_BiotechnologyValueFundLPMember_637401769135287553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637401769135287553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637401769135287553" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637401769135287553" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RightsOffering2019Member" xlink:label="xoma_RightsOffering2019Member_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135297553" xlink:to="xoma_RightsOffering2019Member_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="us-gaap_StatementEquityComponentsAxis_637401769135297553" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769135297553" xlink:to="us-gaap_EquityComponentDomain_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637401769135297553" xlink:to="us-gaap_CommonStockMember_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637401769135297553" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_637401769135297553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="srt_CounterpartyNameAxis_637401769135297553" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769135297553" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135297553" xlink:to="xoma_BiotechnologyValueFundLPMember_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="srt_OwnershipAxis_637401769135297553" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637401769135297553" xlink:to="srt_OwnershipDomain_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637401769135297553" xlink:to="xoma_XomaCorporationMember_637401769135297553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135287553" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_637401769135307557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135307557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637401769135307557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637401769135307557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_LegalFees_637401769135307557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_SharesIssuedPricePerShare_637401769135307557" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637401769135307557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BeneficialOwnershipLimitation" xlink:label="xoma_BeneficialOwnershipLimitation_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="xoma_BeneficialOwnershipLimitation_637401769135307557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637401769135307557" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_637401769135307557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135297553" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_637401769135307557" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Capital Stock - Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_637150161321631455" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_637150161321631455" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135317558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135317558" xlink:to="us-gaap_StatementEquityComponentsAxis_637401769135317558" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769135317558" xlink:to="us-gaap_EquityComponentDomain_637401769135317558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637401769135317558" xlink:to="us-gaap_CommonStockMember_637401769135317558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135317558" xlink:to="us-gaap_StatementClassOfStockAxis_637401769135317558" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637401769135317558" xlink:to="us-gaap_ClassOfStockDomain_637401769135317558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637401769135317558" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_637401769135317558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_637401769135317558" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_637401769135317558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_637401769135317558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_637401769135317558" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_637401769135317558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135317558" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135327527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" xlink:to="us-gaap_PreferredStockSharesOutstanding_637401769135327527" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637401769135327527" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" xlink:to="xoma_PreferredStockConversionPricePerShare_637401769135327527" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock" xlink:label="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135327527" xlink:to="xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock_637401769135327527" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Capital Stock - ATM Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135327527" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135327527" xlink:to="us-gaap_StatementEquityComponentsAxis_637401769135327527" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637401769135327527" xlink:to="us-gaap_EquityComponentDomain_637401769135327527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637401769135327527" xlink:to="us-gaap_CommonStockMember_637401769135327527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637401769135327527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135327527" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637401769135327527" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637401769135327527" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135337520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135337520" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_637401769135337520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637401769135327527" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637401769135337520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135337520" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued_637401769135337520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135337520" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_637401769135337520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637401769135337520" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637401769135337520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637401769135337520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_637401769135337520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_637401769135337520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_637401769135337520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Event (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="us-gaap_DebtInstrumentAxis_637401769135347520" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637401769135347520" xlink:to="us-gaap_DebtInstrumentNameDomain_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637401769135347520" xlink:to="xoma_NovartisNoteMember_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="us-gaap_SubsequentEventTypeAxis_637401769135347520" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637401769135347520" xlink:to="us-gaap_SubsequentEventTypeDomain_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637401769135347520" xlink:to="us-gaap_SubsequentEventMember_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="dei_LegalEntityAxis_637401769135347520" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637401769135347520" xlink:to="dei_EntityDomain_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637401769135347520" xlink:to="xoma_RezoluteIncMember_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="us-gaap_TypeOfArrangementAxis_637401769135347520" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637401769135347520" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135347520" xlink:to="xoma_LicenseAgreementMember_637401769135347520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_SecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_SecondRoyaltyPurchaseAgreementMember_637401769135347520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637401769135347520" xlink:to="xoma_SecondRoyaltyPurchaseAgreementMember_637401769135347520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="srt_CounterpartyNameAxis_637401769135357556" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637401769135357556" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135357556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135357556" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_637401769135357556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135357556" xlink:to="xoma_RezoluteIncMember_637401769135357556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637401769135357556" xlink:to="xoma_BioasisTechnologiesIncMember_637401769135357556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637401769135357556" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637401769135357556" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135357556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637401769135357556" xlink:to="us-gaap_PrivatePlacementMember_637401769135357556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="srt_StatementScenarioAxis_637401769135357556" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637401769135357556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637401769135357556" xlink:to="srt_ScenarioUnspecifiedDomain_637401769135357556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637401769135357556" xlink:to="srt_ScenarioForecastMember_637401769135367557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637401769135347520" xlink:to="us-gaap_SubsequentEventLineItems_637401769135367557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock" xlink:label="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock_637401769135367557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_FutureCashPaymentsReceived" xlink:label="xoma_FutureCashPaymentsReceived_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="xoma_FutureCashPaymentsReceived_637401769135367557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="tmb-20200930.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRights_637401769135367557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_637401769135367557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_637401769135367557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_6374017691353675571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_6374017691353675571" order="6" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769135367557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637401769135367557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent_637401769135377557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_AccountsReceivableGrossCurrent_637401769135377557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_637401769135377557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637401769135367557" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_637401769135377557" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>tmb-20200930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xoma="http://www.xoma.com/20200930"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tmb-20200930.xsd" xlink:type="simple"/>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VvqL6IhpekWtsweye5jZRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Lk396fUAR0mQ7Bxv2PCf3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_mQ-Twe7RO0Gh68dOSmYzIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_90hIlWqbgUaomWenCQwomg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pyJIa2rRckSbu4tMGZ7OQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_JlCyW65-O0OyudJIFvxeLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_bcq3GNUerEmVGRoYfGrnYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_uYjlieKTNEqKshJwUd9daQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TOYjkQxmGUCjZkjeSJlhUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_hVBra_ri2UOdlaAWOeBi1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_PlBfqshTSkaD5A1hfHjWOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyPurchaseAgreementMember_tYew2cGdwUWvjZAtJPwK7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_O7QrlKu98UGAIfv-vA1UQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gkqI07hkKE2Ouf8ac3CdpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_WQB1V7-nwkm5651laM-Szg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_H1Cj_SIgjkCN0aYFMFbweg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-17</endDate>
        </period>
    </context>
    <context id="As_Of_12_18_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_mi0xAnsFn0qDd9-F2V5_PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-18</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_qj2q9750f0eTH2ZT8YKEfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_0uPI2yU0iUS8hyjvd1t3XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NwHPINtT2E27syT0FERCZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DqK_86Lt2kGOZ5tETJSWVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_whotwsqlPUWlIpHCjIDEwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_tcvB75A62UqaD7Gz2Fyu6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ryahLRb460WZ_uEMdm-Gdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-09-30</instant>
        </period>
    </context>
    <context id="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-03</startDate>
            <endDate>2020-03-03</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sQZl0NJ6VEitMJ9UCcOjeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_9qNUOmhml0CM6tQxIvq-zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vF4M7itcq0qmDA1FQGsWbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_y28H4G623kys0zqGl3uk7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_HUFMmZpyxUmnf6MQcbwsUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_9_2020_To_10_9_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Wdtq6HhGbkyK1Ip4HHUIVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-09</startDate>
            <endDate>2020-10-09</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2019_To_12_2_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_IZ5MZsXg_0uvXBtAPFu7OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-02</startDate>
            <endDate>2019-12-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_QGXGPdezx06vh-Y7VCyZzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_St9i97mas0e22erorbJ1jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bl4vMQZQ1UG2x7-nwv1Wxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nFBHFZRpIkK4eK-sS_dY2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_RYA4JA0yrUCgyI6USQlccg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_J64v0Y9UbkWCwMWpG5hjQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_eVulBzUmCkKYuR7HDbiMhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-07</startDate>
            <endDate>2019-01-07</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2017_To_2_28_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_zbfdDVr-vEikYw024muE5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="Duration_3_4_2019_To_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_5-XsEkqIb0O1_ILDeS9Gbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-04</startDate>
            <endDate>2019-03-04</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2018_To_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_7DchDq9txkuakRpZQxN2Hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-07</startDate>
            <endDate>2018-05-07</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_1Myp4OOGqEKp2h3UVxadrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_QJfyk6LBB0y8TAEOtRhUbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_WyJEPykhS0yKbLZyNfLarQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nxvD1pY7ckS0UoRcs7ScvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-07</startDate>
            <endDate>2019-01-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-21</instant>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementX129Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2019-06-01</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_5lBpdkZpkEOX6-ywF04jcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_D0iNeUKX6UmzP9knxvEqaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-07</startDate>
            <endDate>2018-05-07</endDate>
        </period>
    </context>
    <context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_j9t6d3XVyEWVqb-VBqtwnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_hAurvrTCL0uLGiyoscfcDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_m--qxWG3306IlcAtWJRFYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_EG_Q04r1k0GkBf-7UuDNjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2008_To_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_QfxCyr376USWRtXD17lOFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-09-01</startDate>
            <endDate>2008-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_rxCwxf0QfUC9qk9Y_rh-eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_U6qdZrT-gUyphLqQMtHQng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_82L3K22qB0OdI0xUjjPm3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VjJ154auA0SD0BIHuZfOvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XaAWLwY770yBqnJd66HkrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-30</startDate>
            <endDate>2019-01-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_Aq-O5Rvu_EG2xp_gxz4Gog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-05-01</startDate>
            <endDate>2005-05-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_29_2020_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_xoma_SeriesYConvertiblePreferredStockMember_Nj6TY6mgREyFvS2FQnthTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-03</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-30</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_ym6GLGOCy0yMN7HEESO78g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_2CZITBcVHU-Wgwh02jgIcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_MLU4k6KwO0e9m_Pf_os80w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_HrZIHs7O0UmWnhE2ICmFRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WqMgA-6e6kKmzgZNkJ6D0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ccfeS0VvmEuzUI-eiCKILw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFqqIoJL6E-YhthBhWYj6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_XDDor7baIkKyVKi2CJALuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_aD3k4_xk0EmzKHYfKIHIkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_44Jv_9l0yEu1_bEJhWroxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TyS4yAARRkOfhp3ZxgbyUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_R6x4VB5rkUSXD6oQWozXow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BpbgFdtUnke6KePzNaAfHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gWy-6Gw0aE-cAVIs8qB1-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hVEOeh5aZEmR21X1cz8YBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hlXDqQFb7UiKkqmKiwmObQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4A9-6p_84UiD0W2C5Za79Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_A4Fy7zVmnE2bfYQP0JYuiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pjxiTZywc0Wh6ZS22OYjuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sxxar2wWpEO_tGxnLsLLNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_s8s2F801V0SAntrBz7QyGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4N7F13h40ei1PNANLYZSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rP3tRAF8okybPM5hXTuJcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cY_riJ8ogEyCIjKm-1Dt3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uJ6C1JclfEqlTJ-BWfyYmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8THgqDdF-UuNoobclQVfIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jjydCrSLg0mxBT8T-UT6lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_AzRfCDaAQUKUmbmpbfVREg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BQMMHQz-90SmMzcNZJyNuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_osmPZAaeXEeF1lGAcFKPOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_Gh1sLtuoUk-sktvmIjYABQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xpsU-mpF3kaxH7Ar8BNhJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1ACuNNCz302yJVI99Iw5Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ROSrvWU66Eihc8UxuVEfvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_5cJagsvRIUaSv_KPMcQ3kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ECWY-fNR0Um4xrsyO9bRHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_GyucTZFnFU2YNGHx9ZQbnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zP13eTII7UilJItaI_yfUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bny-C6Pdi0WV2-8Z_Y4imQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_86zFUJxWa0Sowa2Y2-Beuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_b2BCEiFHZkqKPcE1gO60xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_RJ9Qlzbmi0O4zgEGElxXYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RUC_5NPG6ka8TvuxEM93Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QywYLWDewkuT4ebzmi68Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZtQmYwfNU6UL1F3kzpYtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_gPaYGyy2xkaDpvkBVLS-vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_spNgKpVzV0SFHWEoUU3GIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_bsRXsMH6rEOZqpfaU8z-Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_HlFFyZp90EKVNXtLD7WtKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_hayCoIN1Nki93_kbNGtPnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_9DVd9snmb02Tp8DZcf-2Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-21</startDate>
            <endDate>2020-10-21</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_SXy_rcf1HE-sOiNkx-qqfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WNBaxopPiUiO0lekbTR3QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IT6QiO78xka2AQOOc1LOTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_qDUv8TEmVUiCki1cFKC_pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lg0H9jEOVUWKuKkJPri6jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UyMAk0h1pkWFrzI4SV59gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_aDDtU1Gqbk2yENmRPLeZEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_icqncM0pU0-kgas-GLplCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Ly6c31YnNUudvyfVl4nIcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_BU0vF3ofNkq6-z8Hkgq8qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eIy62rKGB0arkcYOhjzDlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_89o9tNvIJ0KB_EHx37NNug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27iut_LRX06eiWjddrdvbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_2tva6vIdREy4CHVmhj6hXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0nldtO9DMkyHVBM2GSo1qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_iK5dxlDC5kGuHLYJAFQjtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_D1p_zcUBUkyNi8tT3yY_hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GtNAno1Ke0iBcXqeK0kWoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_p6M7bhFzkEityaF4ZSk6kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_X8Vp97mKY0uNE717S6FXRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FWdasQOebUi4BvD0XzdauQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_JkbgTe29GU66NJfrMM3fWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_xb_L_CetzU-uTJy5lWyAAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SecondTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7r0aHlZReUi3PqLdTuvGMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_1sIgH-TDmESIxi03ZCZdFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:FirstTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_6hHu9AeYSUi8Kjb-gsHXKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_z49RnI3stEODl-bB_4KFnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I1_FVLXQ30-8Ii9Rp4UaBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VR-z9bAmAEORRoi_pcVyOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Es2aTH6mzkmx8JPow1Wk5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BfyNiRBteUaq65VmnaTxwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lTYMNfRN7UyqGN9s3-87hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_55yjxRlLR0OOL8PFIxgQ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BvERxoSpn02VGxEAbYiLDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ROF4dELbnEKrkSBAq5Id-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_fc2DGhmLsU-P9b9i3fCa3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-qZT9POIkCNrG3Grph7dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_o9TKgo2PdkaRxCnPv5UwzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a30zLf3tz0OUKijReg49Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_K5wO4sN8QkaBiKw6ZJuixQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_WZsCIx7v_0eJCosFrT_7PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_j3P1UZ7onkKj9MeRA1L4Pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qRuzS7PxN0mhOpigbZVLcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-_VDIVr4EyNvxmIlDGnMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_NHx7oG_kKE65ICx_DXfo0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_SqIlV2-rakKVcalxYbzoAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:RightsOffering2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_uWG4bPOtsk2Nwyko1KBEuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_hzEj56jCBEaI-AttEMG2SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_MNkxvd6px0Shg6qQPgSkhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_78opXNQ0QUCrlHhRR1n9Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_9TjQxVDWVkKyIj9TiaRkjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_pEtQLs5d2E-SAflZCpXZxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:OtherFinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_o7vjlCxW1UuogpVKDCyxSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesBerkeleyCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_1WJzW9HoPEib8xgIXL4tQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_eFRO3EsZIkmFH2cQ0wM35w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ZXd3cmpR10SClHLRFX8RSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_as3Q7AGP7kiK9uKgqvnZSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qrgth34a6EattwAKv19FyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_v4syz3rvHkSx0GCd0zfa9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2SoVfK-psE-uIiixwmUMVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_myPVpetgYkKI3zoBMnb_yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_T9kkdRE5TU2GA0x-StB7yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:OTCM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RyfA1p37m0mqf8zUp_nppA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_mI7JO_tljkCY56R1erZxTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-CVgtfFe3U6W6zb4Ddth-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_0OemnNunTEaN1i6wIdopTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">xoma:EquitySecuritiesTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_QbXdq24V_UuHONHKjjaZgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:OTCM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_U_gsaxcdB0WA9FXj8HId5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SecondTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_QpM51obSbEy_0dOTKgw2QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:FirstTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Jd47lV9m20mVoxI2mVnXeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-21</startDate>
            <endDate>2020-10-21</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_AdKOII3dC0-c3gz97adv_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-07</startDate>
            <endDate>2018-05-07</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Laye7qFdbkaWNAv5Y8KxEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-05-01</startDate>
            <endDate>2005-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_MnJGbUR0Q0arUfSSoF2XOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_RE1e6CumO0O-2KGTFiCqsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_UmYPv4uBU0-L1_gmyTWzwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wW3g01I-CEqS98TMD6LhAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Vh-yAeDCzEam1o4LJU3R9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wOjQWoE-yEyfuioBK5aSsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v9GiP1Qyk0qx9_F2-bs0WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_w6FnUVgyxk-uu6eq_pVLjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4EvFxExj10OrmYqKm4c1sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NREQuj8uA0eP9aMHPRFc1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RVLPSZwwQEyCcFoXmWjm_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OT29fxEd0kmg6WxFKFQGSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-04</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:FiveYearWarrantsIssuedSecondRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:FiveYearWarrantsIssuedFirstRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-02-28</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201818Member_mlMnqtv8RUS5hgexXcSDqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BzIKlySpD0yINoAWGMbaLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3CadpqFg8UOOttt6X8zQ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_HmB3foWGM0Wj8z_XGGsBhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_mkImYFxDL0WhSR47srlVEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aQmUj8E-FUqSQDzVNxRfcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_0Cv-gufQXUiXoT0EaH7Cqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_uJR98_x7FUu-h9HgcgHodQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_cB3ANTnBg0OCmZf8uEBeTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_i4aGeX3zlkORauSmBIjKjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_UVoSolrPv0qV5x4CzEronQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ovP2h0yP-E6tctRS1ZBHeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NZcEoPXaI0iAyxKBC5cgCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_m0TV8U2aI0CDgV82mWs52g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0x8EMKzDr0a9bWPJF31vLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_HsRG2H4itkerF2L9Qw8I9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_ql4aVy4WmEur4m9MMRr5Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:StockOptionsVestingBasedOnPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_p7ZWEJ2xMU2VC0KWzZIypg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1VjeaxaG8UOf7PR7WpN3Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:DeferredRevenueArrangementNameOfParty2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_x1Y6PfrxfE2TlMaI8OC3hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-21</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_2_2020_5kIZ95MFdkGBcfQ2IYo9lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ">
        <measure>xoma:agreement</measure>
    </unit>
    <unit id="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">
        <measure>xoma:customer</measure>
    </unit>
    <unit id="Unit_Standard_installment_7zKUzhL-x069Du3GTyKbRQ">
        <measure>xoma:installment</measure>
    </unit>
    <unit id="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw">
        <measure>xoma:facility</measure>
    </unit>
    <unit id="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw">
        <measure>xoma:Y</measure>
    </unit>
    <unit id="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">
        <measure>xoma:item</measure>
    </unit>
    <unit id="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg">
        <measure>xoma:product</measure>
    </unit>
    <unit id="Unit_Standard_EUR_rMXTIUZ4Q0GOaNm0YP-bKA">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_period_AqtsOpMfTku-KpzgyKR7UQ">
        <measure>xoma:period</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      id="Hidden_9fZV6tGInEm0Q_FtG97kvg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      id="Hidden_Y_CFql4RikqDJzDMsiLOyQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg"
      xsi:nil="true"/>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_VjJVgvPwDkec6c4_FaXVnw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_6rFBxsxSGUqWrzXyiyTPaQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig"
      decimals="-5"
      id="Hidden_qM6MJxl9CUKlygW0ppMF8g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A"
      decimals="-5"
      id="Hidden_Vt48BbUiq06CvSGayf-8QA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew"
      decimals="-5"
      id="Hidden_aSz0lyBNPk-MEGOiHfxTfg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg"
      decimals="-5"
      id="Hidden_eU6K4_Z_lk2aE4zqKPrSgw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow"
      decimals="-5"
      id="Hidden_BNB6kHviz0CsAKBxm_14mA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw"
      decimals="-5"
      id="Hidden_dBHKRSLA002JHAMa878AjA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_PCfTgI7zUU6RVWqBWo-Hlg_2_1">0000791908</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_5tUrkpsvjU2amZ1qdjVLwQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_5id4Yf-dpkuTgJ8dP_Ri_g_4_1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_zSQfT3WjbEmPtjRFfOqTlg_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_TmsJzZ2QoE67KOQXsJj-MQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_0v2GnvbuBUGnfiOITD1bGQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_HtFobGvaM0a2AGcx3GzdcQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_wmNk2xC8k0S5yzE_7UsZ3w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Hidden_s4qMH8rVcku8i1uqsZgWBg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Hidden_9jDFZSkITEmOQWDHpi9lVg"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6256</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Hidden_VlGnZTX-K0GzxN0CnUm8kQ"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      id="Hidden_pSbH5_Hu1UuaeDzOMSNqVg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      id="Hidden_P4u2-aylQkOppw-2vXNJkA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Hidden_MGA0NvMgU0KJy_aFX1818A"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9758583</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Hidden_wN9uB1ZuGk2FpHpwvpoRrA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11022143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Hidden_h9_CU4N9hUeGKrZXcAoQxQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Hidden_GqyhXSrR5ky5_NPVxRDXDg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Hidden_Xa8_bVITYUiniHoTQl_7aA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Hidden_v_w-0LV3PkSUVby9iBXvjg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2339000</us-gaap:ComprehensiveIncomeNetOfTax>
    <xoma:PercentageOfAggregateSharesHeldRightAndOptionToSell
      contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A"
      decimals="4"
      id="Hidden_5JMn34DvnkG2-h_9uI7tlA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.3333</xoma:PercentageOfAggregateSharesHeldRightAndOptionToSell>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ"
      decimals="-5"
      id="Hidden_IvzhjoQ1qkKnonNbFMwDHw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw"
      decimals="-5"
      id="Hidden_6KcCQ2KmOUSERG_vOJUbuA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerLiability>
    <dei:DocumentType
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_PjdEX2Z2cUeSme2L3Nxbeg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_VWFLRcn6OUK1wcNuxtOXAw_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_WaN98j5630-NT1Ug4LQ-NQ">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_hAk3C7AizEq-F0_oPcimBg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_q84vPGbCnkKsaDnndQepvA">0-14710</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_Q8nTZ5JC5UWgV7cjePBEYg">XOMA Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_d2vEn6RSqkeDgyRdLy0Rng_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_XwVT9O9yS0utGUl6Mcp2SA_1_2">52-2154066</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_KcLiusEReEmYxslDRf0fgQ">2200 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_q4yeoUKay0mXCKSUzEX6bA">Suite&#160;310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_s1AiYu8gS0G3BAyezsFLBQ">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_0OKKcgb0K0e4z6m3kMb6lw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_kiCSIju9d0GMNbylpSnK6A_6_2">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_gcEX9hLYlkCXHWt1-E_3Og">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_9BKmzQEZuEGfx_UBWHoIaA">204-7200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_np0WsH2gxEi0VzppZJw3eA">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_sgNkcz2BFUCJiAug52mYjg_2_1">XOMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_3C5MqUBAukWgQwMI-TyX2g_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_pwvdNW_smk-HEHzp3eCYrg">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr__htFWruhSEy4_k2zH-IpbQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_W6rr8l_h1kOoM0u84dYnmA_1_3">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_MN000lvHVU6JUaWm4QPgOg_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tc_6hWDl_EoQUie5q4GZf48TQ_3_1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Narr_MqbbgiFPVUuMy7DshUKVEg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_2_2020_5kIZ95MFdkGBcfQ2IYo9lw"
      decimals="INF"
      id="Narr_j3J_Rx8aZEqsjLxDp1DsQw"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11022143</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_N3PCQBUsUUOd7CtYnj45Xg_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">45725000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_2QusaOESx0ur2PFoam0Taw_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">56688000</us-gaap:Cash>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_HS65OOS-3kaWYR7H9uq5XQ_7_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">222000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_LBF1-NCEGUqoBLW6Sito6A_7_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2933000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_C0dfnV4xdkiIfMRelNgJwQ_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1526000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_i16S-heXYE6hv0Mgwm1I5Q_9_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">671000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">352000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_Vey0yC-yU06HdJh0_I_FYg_10_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">48144000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_D4UqmmRuG0O1At5TqCYp8w_10_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">59973000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_F52JZngr2UqXrc9hJPZx9w_11_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_vGy_7ECjK06v13AqRMdINQ_11_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">34000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_-JvaULAnME2BcDvH3UixCg_12_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">398000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_GeyTclnuQ0qNX78tFlSPTg_12_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">510000</us-gaap:OperatingLeaseRightOfUseAsset>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_mVhc9mj1skettGGDS3BYpA_13_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">34375000</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_v_kra4dIXUqGKGjoC1FCVA_13_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">34375000</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:EquitySecuritiesFvNiNonCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_MvmA2agzEkqx0AvgR8kGTQ_14_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2572000</xoma:EquitySecuritiesFvNiNonCurrent>
    <xoma:EquitySecuritiesFvNiNonCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">681000</xoma:EquitySecuritiesFvNiNonCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_kvA9DDCMKUuCMt5R-XoGhg_15_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">215000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">151000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_cf8UTROuP0Wj8h6DRqgtSQ_16_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">85728000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_v8RjykmcG06RZG0yBSfN8w_16_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">95724000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_1stLr7aVUUyjRTbDCiRbPQ_20_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">614000</us-gaap:AccountsPayableCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_gcCVlr-O5USkZ6kzzYmoaQ_21_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">466000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">945000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_4e6uCov1bE-ERumGzLSYTw_22_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_hp12ClTSyEyTwT8TcCjkdw_23_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">175000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_kuGUR7hnm0uhzcSQMsH34A_23_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">163000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_2_ODOdGkZUi-1uUO2KMpPA_24_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1409000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1096000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_sf7_rdnIDUK-Ep_nWVltTg_25_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">798000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_gNXHDdUGOUGblWIvgAVenw_25_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">798000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_-UTGHkHbH0a92-MaKVr11w_26_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8962000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_m2RJdozbC0W-6_yBYsrafA_26_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5184000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_7nkpZHp9eEeYgNRvxeZG8w_27_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">12335000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8875000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_rVntGiWrSky9GY67thNFJQ_28_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13952000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_WtNHDEvBt06od3wj_CVkow_28_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15317000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_ZGg83IryT0isZwvzXyFCTw_29_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">20990000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_GdgJoNAAc0KIhoRV97vELA_29_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">27093000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_Mn5AHFzwLEi_3-Vq1XGHyw_30_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">275000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_X6GCUHcXrUKlhPczPH8d_A_30_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">408000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_Nv6fjvsxPUGimh1k92vRzA_31_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">134000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">43000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_kG8cjDJ0qEGXS0y3fOzzng_32_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">47686000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_9fPqO3HUnkWpBDZekGHmNg_32_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">51736000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_AIyElOeG3Uenm-1WndONGg"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_jcr0GVhHyUaS3UPxB2WnxA"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_Wyr4uQHdk06jmDybyg2oMQ"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_dz_BRu6cmUef03R2QLHWOQ"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_a8Ksc08o0UqVNwspBBP77g"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_2vT89XmhE0q_mBhNmvfA5w"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6256</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_0PqcfniucE2o_pd2ZzCYFg"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_LFIWRWs-vUWMyZyQd7Jjqg"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_oimf3P2yqk6au8FP-JRT3g"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_3S9In2N8RkeqGZcpEZAalw"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_Lv7_42sqgkKEOcurH8fwRA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11022143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Narr_GmAoKruxxUGht20CNXJzNQ"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9758583</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_uuU1MbVxYEKkCOUfB73alA_38_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">83000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_M6ssgo2M90642RA-IF9OCg_38_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">73000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_eBzb24q93E62nsqRuJTyHw_39_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1241711000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1238299000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_ASGkU4h-XUmmHuVZ0Cjg9g_40_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1203752000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_5rG1U6AyMUinpVHKmveKig_40_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1194384000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_tSOOQ7dSFUOT7huE2fTLGg_41_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">38042000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">43988000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_89IQwm5q1EeC47wZQr817g_42_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">85728000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">95724000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc__bmQcLavmkiqIpMoe3QHmw_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_OKEV0VgxD0uxRYdlovwk5Q_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_7vQzuBmni0KFoeT80z3jDQ_4_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Pkq93CKuKESClXRivxS5xQ_4_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">17176000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_9D89koMId0mjfIQMaJYndw_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">357000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_DxzFEPWdZUSv66MySV0zFg_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">330000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_KuN7pgopqEWTK8Q8eY6eJA_5_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1051000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_xY0jB1L0HUWfYabHEaP00w_5_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">772000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc__eR8nf4iT0u3aKrXYTepDQ_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">557000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_0ENloJszI0Gl_AK07SLcqw_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8855000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_sH0FgrutH0ODkY9QbNHM_Q_6_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1804000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_ex-ffHADOUuuNH5HLGPUbQ_6_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">17948000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_hbx4rXo0YEq4GENxR6Rh2A_9_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">34000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_Uy2W223X1UiAUfyUlaln2A_9_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">143000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_ldNmc4SCEECnZ-9ESWL2_g_9_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">134000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_og8JuhsUok25urlOE08TnQ_9_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_d1s15ay210GjKUnqdXiw1g_10_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3212000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_5Wder3-v_ESm8VOX2Wh0BA_10_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5821000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_Q5DKwB5lwEu83UHv6pwxgg_10_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13126000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_iEYufruCukS2A9EC_WDQSA_10_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16709000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_Q9C47mnVH0CAfhc-zmb7iw_11_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3246000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_c4clvqkqLUKxg788gmqfhg_11_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5964000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_inrW3_bI9UyXPNU-iK7Tvg_11_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13260000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_sJo_OF55-Emk6r9YduJ7gg_11_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">17832000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_hxD76l-0ak-oDmd_uUxejA_13_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-2689000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_bX0XnGYf-0-YM1YmzRppIg_13_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2891000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_-VEX6F9jvUCd2tbl23jB4g_13_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-11456000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_AY8Yw1jJ7ke0_vmSXeYJEg_13_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">116000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_HoMQkdep50SPZVi4XYii_g_16_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">434000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_FTQClJdcnkGqC-E3N_xFpg_16_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">484000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_HfZpFg-jikWuYSDDOJLtBQ_16_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1484000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_JyT6iPDCCEi1vjwCOTt_JQ_16_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1336000</us-gaap:InterestExpenseDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_2wUscXXx5EW2_ZcQ2UXzPw_17_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2046000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_QO-zQjNoO0y-cj4oBryF5A_17_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">771000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_fxIBxKmpUkK5kghwi6tLMw_17_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2046000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_BVzDa4Fd-U-DXEpyQPwC7w_17_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3559000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_H9dftLV-n0uVFIxnpQRWXQ_18_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_qCTJQNvltku9FPoHH8xV0Q_18_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_F14Gc7n35EWwmrK671fbmA_18_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-10894000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_t1Gre71MfUK_QrCE3tOQtw_18_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_t10Lk5Y4rkiHCQIR0FkOlA_19_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1526000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_NxBWIzkE50u2HxuWM0yEBg_20_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_X8X5UTcUHk-0jDeqDfMang_20_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_jx0w0TIBO0eyLA7laEUBfw_20_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Ew8WNRB4v0OcJmcJ1WbKHw_20_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_hpeZHvWihECG0OcyuafySQ_21_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_6vhQHUSBbkG5Vjvy5kNNGQ_21_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_xFWn6SvquECCteXola9rAw_21_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_edtu8djfEE-kj3dy4nZhNg_21_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1362000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_ZZVT1NXFBUG91bv7f0VJMA_22_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_a6byQqzjDEKuF9lbj2hNrA_22_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1911000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_A-eSFcrxBkOhwYdOGXqIVg_22_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_qEoe_Q23bUGx6fjEBEMQQA_22_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1403000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="2"
      id="Tc_qiYNbIEgME26Ue77Nvyp9Q_23_3"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="2"
      id="Tc_EOD33HRdEU-sKqQHRUDdYw_23_6"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="2"
      id="Tc_67mhh2Y4Nke6BF8x4MzA9A_23_9"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="2"
      id="Tc_95kU8mBsPUqGPXS7_LdZJQ_23_12"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="2"
      id="Tc_GZf4Tf72tEOS-cyxe4peyA_24_3"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="2"
      id="Tc__gSd0SvnpU6J45Q00aWPmw_24_6"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="2"
      id="Tc_pAG8euVOI0-FVbE8K2-sJQ_24_9"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="2"
      id="Tc_xF5KuBAHSUWAke2yJTw4dg_24_12"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_kKyJzsfLsUeOFmPVryxN4Q_25_3"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11019000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_5OWq_GosEkuFwDCDeRKB6Q_25_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8731000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_rL1QhSY27kKkjVeBTN6ahQ_25_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">10537000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_LdSqR3jN0UyEbnC441B75A_25_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_zcefCODvZkOA1JkkNfGUWw_26_3"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11019000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_89pRMmmWX0eqEauHoMofsQ_26_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9441000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_mV5QCcpIMkSTlfp0zZ1hyQ_26_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">10537000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_kRonUj9tWkq8JooregCRIw_26_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9379000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_GyucTZFnFU2YNGHx9ZQbnA"
      decimals="-3"
      id="Tc_NQEboWyyt0mGOBGmwFItYQ_5_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA"
      decimals="-3"
      id="Tc_a5HsRJB3hUSUDPMrJoQJ2w_5_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9759000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_F1kzWvuMdUePw9azS5Y6nA"
      decimals="-3"
      id="Tc_rKfifFs_2USlxxP8zeoXuw_5_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rP3tRAF8okybPM5hXTuJcw"
      decimals="-3"
      id="Tc_3DkLqdVZMUyZZsYnjWaURQ_5_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1238299000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_U4N7F13h40ei1PNANLYZSw"
      decimals="-3"
      id="Tc_cvd8EcnRtU6s5YYKhBkV_g_5_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1194384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_N6thasIIak6VbTJ-nZO7YQ_5_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">43988000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cFqqIoJL6E-YhthBhWYj6w"
      decimals="-3"
      id="Tc_QsDpQ7SP3kOrAJZ1Ocn6aA_6_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">3000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg"
      decimals="-3"
      id="Tc_Cl_6oFxwT0qfAr7SpUmDaQ_6_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">88000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"
      decimals="-3"
      id="Tc_pelV70ndO0uwzryDcLAfVg_6_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">88000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg"
      decimals="-3"
      id="Tc_lbjdW0-Fu0Gr3PlCzO53Mw_7_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"
      decimals="-3"
      id="Tc_dLmq35yfoEy17J2VSmTRGQ_7_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1788000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9GklmPof5Uuh7fDmDXfWTg"
      decimals="-3"
      id="Tc_sa-YJpUzSU-yubyxfW0Sqg_8_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13000</xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement>
    <xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement
      contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"
      decimals="-3"
      id="Tc_HrHiVd7Im02FfF2_XEUk2w_8_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13000</xoma:AdjustmentsToAdditionalPaidInCapitalDisgorgement>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Es2aTH6mzkmx8JPow1Wk5Q"
      decimals="-3"
      id="Tc_qASed3bfAkKw1AZG-LVqYg_9_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-4758000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"
      decimals="-3"
      id="Tc_lnJ5sZRTw0et4EO50XWxqg_9_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-4758000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ECWY-fNR0Um4xrsyO9bRHg"
      decimals="-3"
      id="Tc_9GOcjakEWUu47pQGQmQlVQ_10_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA"
      decimals="-3"
      id="Tc_4uEPyzpxeU6KlWAJkHsGDg_10_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9762000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_syAymmqGiUiQWEom6TZjTA"
      decimals="-3"
      id="Tc_StDRkcVEsESVjGesVz-s2g_10_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sxxar2wWpEO_tGxnLsLLNA"
      decimals="-3"
      id="Tc_OiCZVrpMfUKFFnWQHafRKw_10_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1240188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pjxiTZywc0Wh6ZS22OYjuA"
      decimals="-3"
      id="Tc_DSyXln_Er0arQ8xTNLC2ww_10_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1199142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_s8s2F801V0SAntrBz7QyGA"
      decimals="-3"
      id="Tc_7c0T6bn0skGn9y6Im96JWA_10_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">41119000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw"
      decimals="-3"
      id="Tc_OnShDLVahEK-OxPPiNnV-g_11_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ"
      decimals="-3"
      id="Tc_fseiRmOvD0Cw3sPQJvZ6Ag_11_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"
      decimals="-3"
      id="Tc_1JOKGYaz10C1QFAmQu62ww_11_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw"
      decimals="-3"
      id="Tc_NXKR3UqCzU-l2Yr3avj-QA_12_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ"
      decimals="-3"
      id="Tc_EXUW4l-Nt0-M_Ap35wL-GA_12_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">26000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"
      decimals="-3"
      id="Tc_x_xvhsaZeUGOunfjRP-jhg_12_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">26000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BpbgFdtUnke6KePzNaAfHw"
      decimals="-3"
      id="Tc_6NBPimJvKEGNABYIYfmWqg_13_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">-1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw"
      decimals="-3"
      id="Tc_x5lEo3ZEO0y8wPOkpt3zrw_13_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1253000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ifj9CEabfkW2KjK3j0hoxw"
      decimals="-3"
      id="Tc_BydsyKrl-Ue-xcLb-zDCzQ_13_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ"
      decimals="-3"
      id="Tc_c9r70P7jEUOaNOqIp1Glbw_13_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__C0PS6un5UOgvayfLQNFgQ"
      decimals="-3"
      id="Tc_XreE1JByTk6waH54-XGsjw_14_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">773000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"
      decimals="-3"
      id="Tc_FW76vxZN4kOPZSpqOt3mkQ_14_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">773000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VR-z9bAmAEORRoi_pcVyOg"
      decimals="-3"
      id="Tc_FNVn10NSAUO0DvcZC-9CCQ_15_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-3533000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"
      decimals="-3"
      id="Tc_sTjPssxRZUCTqJPXGbQlxQ_15_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-3533000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_5cJagsvRIUaSv_KPMcQ3kw"
      decimals="-3"
      id="Tc_cu7vobWr20a5xs1OD4s2IA_16_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A"
      decimals="-3"
      id="Tc_MAu4Pz-VUkaUCmKsj2wflg_16_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11018000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hxfKJA_Av0mzZCsWie2e9A"
      decimals="-3"
      id="Tc_FKmEUpEwuEqG4w6nhimijg_16_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4A9-6p_84UiD0W2C5Za79Q"
      decimals="-3"
      id="Tc_HJjC3RICQkGyCeZ4xjjieQ_16_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1240987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hlXDqQFb7UiKkqmKiwmObQ"
      decimals="-3"
      id="Tc_GLgSIPfN-0OqspqVC79FOA_16_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1202675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_A4Fy7zVmnE2bfYQP0JYuiA"
      decimals="-3"
      id="Tc_uGibXeiKe0edlDrusBrxLg_16_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">38395000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WqMgA-6e6kKmzgZNkJ6D0g"
      decimals="-3"
      id="Tc_0EdfEAd0DUGlZ7ipcuwAvw_17_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ"
      decimals="-3"
      id="Tc_pqSuWyZNFEmrgh2dsHwv1Q_17_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_rzRAsA6V40uPcy8_jlLu-Q_17_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__-63iS5HiEONVfhqTqV1SQ"
      decimals="-3"
      id="Tc_-pqGp5gvU02dQUzNd_5eOw_18_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_r4VRrTj7CUGMqG0DIgx12A_18_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I1_FVLXQ30-8Ii9Rp4UaBg"
      decimals="-3"
      id="Tc_EOnmy3CDHUGNZMc1xwYATw_19_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_AbKRe6aTlUaM8AfKgtMX8g_19_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ROSrvWU66Eihc8UxuVEfvw"
      decimals="-3"
      id="Tc_La50Q-p-MEeKh0zxZouU9A_20_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA"
      decimals="-3"
      id="Tc_qSihX8-kEk-L2l9QW26BbQ_20_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11022000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HgwOY6R2UkqKYrX1FKVpSA"
      decimals="-3"
      id="Tc_20tbeRI_Vkm0cf_ogLsIXw_20_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hVEOeh5aZEmR21X1cz8YBg"
      decimals="-3"
      id="Tc_lSt28omn60i3zWbhTZWX9A_20_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1241711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gWy-6Gw0aE-cAVIs8qB1-w"
      decimals="-3"
      id="Tc_s_AYsrBsIEi4O3n60GpQtw_20_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1203752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_xAiViHSKW0yq3FSCNu0p_w_20_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">38042000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_b2BCEiFHZkqKPcE1gO60xw"
      decimals="-3"
      id="Tc_-OmNXZRqEkOqBfwe0VtWkg_5_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A"
      decimals="-3"
      id="Tc_9thb2HNCbkaFMCrJ84fOMw_5_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8691000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A"
      decimals="-3"
      id="Tc_SuOC0dqJfUSE8bObo4wcSA_5_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_1ACuNNCz302yJVI99Iw5Cw"
      decimals="-3"
      id="Tc_cCVCkJ8Jj0S1Jqq5HGGyAg_5_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1211122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_xpsU-mpF3kaxH7Ar8BNhJQ"
      decimals="-3"
      id="Tc_AZdF5qj_f0GnXQ05cyh6eQ_5_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1192402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg"
      decimals="-3"
      id="Tc_p5Ri9YTdOEOdh-jQlAoqEQ_5_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">18785000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q"
      decimals="-3"
      id="Tc_SpTGX14CIUSt-c7cR2pZFg_6_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">24000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA"
      decimals="-3"
      id="Tc_4R-71N3fCUuuo-5gn0JAgQ_6_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"
      decimals="-3"
      id="Tc_alT4RHBE5k2Sl3Ex49JXbw_6_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q"
      decimals="-3"
      id="Tc_dNR366h8P0yIQxweTH9rnA_7_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">7000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA"
      decimals="-3"
      id="Tc_zRS6GieSWkqzn8RJmgfkSw_7_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">102000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"
      decimals="-3"
      id="Tc_h_wCzu7Dx0WGYiLZI7lTPA_7_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">102000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <xoma:SharesReleasedOfRestrictedStockUnits
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_NSdSh7ktgUqhB1Ro7uaE2Q"
      decimals="-3"
      id="Tc_P2wfi3K7q06MX1xT7fkAMA_8_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2000</xoma:SharesReleasedOfRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA"
      decimals="-3"
      id="Tc_s8P0nrC3uke_6RRqZFxSPQ_9_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1728000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"
      decimals="-3"
      id="Tc_r4-wScUJRkyKrGOPhbt_EA_9_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1728000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA"
      decimals="-3"
      id="Tc_wwlCpJFNk02GrTti7hm75w_10_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">66000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"
      decimals="-3"
      id="Tc_fWX8a53x6EqTfX-wwzzjVg_10_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">66000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_55yjxRlLR0OOL8PFIxgQ3g"
      decimals="-3"
      id="Tc_h91QF0dHfEuNaIUUEBEtIA_11_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3233000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_mUvAmeynt0mIYS9_zpc3cg"
      decimals="-3"
      id="Tc_DM1VA_q0RU-OW9t2v7mI3g_11_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3233000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_86zFUJxWa0Sowa2Y2-Beuw"
      decimals="-3"
      id="Tc_w7MA-ikXdUCGbvNtMuk63A_12_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg"
      decimals="-3"
      id="Tc_CzNDPkeMcEC7r0qJPK05wg_12_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8724000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ve1XfnqFTE2vH5YdDvM0Pg"
      decimals="-3"
      id="Tc_fnCdIED_ZE--U4_aoj7hLQ_12_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_osmPZAaeXEeF1lGAcFKPOA"
      decimals="-3"
      id="Tc_zr_JRJiQNUOEbVy6T6GE6w_12_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1213133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BQMMHQz-90SmMzcNZJyNuw"
      decimals="-3"
      id="Tc_v4ydJ5FOQEq4Pp6sQOeXAw_12_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1189169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_Gh1sLtuoUk-sktvmIjYABQ"
      decimals="-3"
      id="Tc_ixW5ONZNqkOBoZQ3sSMrTA_12_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">24029000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ"
      decimals="-3"
      id="Tc_KsiZHViAXkW0uxgsXUgbIA_13_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg"
      decimals="-3"
      id="Tc_6NZxPQ_-BU26srzlcFPf4w_13_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA"
      decimals="-3"
      id="Tc_lsDKyFoa7kGnfUXoU1A6cg_13_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_a5vxbQE_e0eVOSiqDUxTeQ"
      decimals="-3"
      id="Tc_t6te9bW9dEKy5itsQWIIww_14_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg"
      decimals="-3"
      id="Tc_l-Fot0MZLUue1Ty3_LHdMA_14_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA"
      decimals="-3"
      id="Tc_M3Cl_9FhRU2D57KCaSz3kA_14_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eF4jh9x_dkmqbylYyPi3Sg"
      decimals="-3"
      id="Tc_JP7lLoQxPkGuWL_DtdH-uw_15_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA"
      decimals="-3"
      id="Tc_fjktyJpXRUyrK78Gf-2xtg_15_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1011000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lTYMNfRN7UyqGN9s3-87hA"
      decimals="-3"
      id="Tc_cFOxxciaTkOt37tbkjb_YQ_16_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-4072000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_6waGgOdmIU295YuYVUVcMA"
      decimals="-3"
      id="Tc_jqFJurnVfkyQT1pERXvclg_16_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-4072000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bny-C6Pdi0WV2-8Z_Y4imQ"
      decimals="-3"
      id="Tc_8pH-4wHdLkistGVeixdACQ_17_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A"
      decimals="-3"
      id="Tc_O0InrZ_Na0OXt1hnGmVxxQ_17_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8728000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mXZusyPgukiH6FdMApCM4A"
      decimals="-3"
      id="Tc_Z5rA90MXoUut8N1AavlNdw_17_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jjydCrSLg0mxBT8T-UT6lg"
      decimals="-3"
      id="Tc_ogyn6LvhjkKEPm_Nf5NR5w_17_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1214168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8THgqDdF-UuNoobclQVfIw"
      decimals="-3"
      id="Tc_YoSGFcm4L0W4kBuG9j5Rjg_17_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1193241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_AzRfCDaAQUKUmbmpbfVREg"
      decimals="-3"
      id="Tc_-ih9gI-zz0iDS3j_mrtCSA_17_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">20992000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ccfeS0VvmEuzUI-eiCKILw"
      decimals="-3"
      id="Tc_xpZqXLMIT0qMfQh7hKVoTA_18_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">24000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw"
      decimals="-3"
      id="Tc_VCA2_FzPUkKk7AMJc677mA_18_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">122000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_eDVzdOMRmUG_plSARS9KQg_18_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">122000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ashrG__KW0i61zBCbWmZJw"
      decimals="-3"
      id="Tc_DBTyj825DUinaW85RNQosQ_19_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1494000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_kJMuMvygj0qjYL-ZcCleiw_19_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1494000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BfyNiRBteUaq65VmnaTxwQ"
      decimals="-3"
      id="Tc_gxv0Pf162E6RSU8kW27YCQ_20_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_H6o16gCgx0WoGv0julspsg_20_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zP13eTII7UilJItaI_yfUg"
      decimals="-3"
      id="Tc_k97Jx1RYbkOQsnNsxKO9vQ_21_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ"
      decimals="-3"
      id="Tc_jjGtBPzgfUqY5fgQoD94gw_21_7"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8752000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__Mva2he3DEi2YsGH9DrzDQ"
      decimals="-3"
      id="Tc_oKmN-FdUZU-Genw5usvR2A_21_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uJ6C1JclfEqlTJ-BWfyYmw"
      decimals="-3"
      id="Tc_9K2sotVbokC_-1TzWX7-IQ_21_13"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1215784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cY_riJ8ogEyCIjKm-1Dt3Q"
      decimals="-3"
      id="Tc_LciqlLFCqUOerdJZvTbzSw_21_16"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1190063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg"
      decimals="-3"
      id="Tc_iM8dX_RcY0-I5ARf7vcOTw_21_19"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25786000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_bpmckFK9vUWp65ZBu97cGA_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Nrg_tUjExkWZN-_fqDxfFQ_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2339000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_Du_imwo1cEOzU2mGE_On1A_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3269000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_7zPjl_L0FUy4LnDeSDZSSg_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4233000</us-gaap:ShareBasedCompensation>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_KBx4g3-qTEC1bPyQ0TH4sw_7_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">88000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_l24nSDPou0GpfnKcNz9hnQ_7_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">102000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_DhhFlaoYF0Ww5aidfIWQPQ_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">19000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Y_khy6nRAUWqXmQOn081nQ_8_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">19000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_lSIh1yba-0ehKG1ZiSQFCQ_9_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">546000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_4g5UlDtYZkWNyS4iO9lRCQ_9_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">390000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_yZagoO1YWE6xvF26IB9LWQ_10_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1409000</us-gaap:ProvisionForDoubtfulAccounts>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_kNJq5q4Sekyi14nqAhRSRQ_11_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-112000</xoma:OperatingLeasePaymentsNonCash>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_FAzxM4rkiE24nwm-L1Qb9Q_11_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1464000</xoma:OperatingLeasePaymentsNonCash>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_HNIRbcF_vkybbymGg-zJ4Q_12_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1891000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_BFo7e08TPE2R92aEYENr5g_12_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">481000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_0MV0E62WEE6AP_Xk3eM6dA_14_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1302000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_zuO6a7YN9UO7orHbXGO-GQ_14_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2358000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_qwGgBKiI70OVGKNW0RF0TA_15_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1526000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_zMcnXtoGVkejHUS58tETFw_16_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">319000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_otu9TEX8UkyhMxrbsgLUPQ_16_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">265000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_mVDysY8jqUqdkga1rBOR_w_17_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-464000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_TZV5oRbDrEmf7bGb4qztPA_17_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">232000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_0SRNjyb-IUO9_lIh6KwphA_18_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1052000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_cdvV__5VpEexCgvg_Fs7gw_18_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-772000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_QPaWhKy-MEKQGfLm0veRjg_19_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-120000</xoma:IncreaseDecreaseInOperatingLeaseLiabilities>
    <xoma:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_9z9KrF5-xU2TVWuLcDALOg_19_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1634000</xoma:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_VL8crhopT0CTHlW2siGjEA_20_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">409000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_-1QmGvjgy0CMmQxskifHmQ_20_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">594000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_qFTESsmzIUKklwfCBvGNMw_21_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-7586000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_laSzzVNGb0SvPGc7ErF5iw_21_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3863000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_uJ0kDup-l0a5QogmJciMGQ_24_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRights
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_TsL3frbONU2MLxRI436Qeg_25_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">19300000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRights>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_pcMQ2bJ8VEamN2aqu3liWw_26_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_t-V4sRfoOEWjv83gYWsTGw_26_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-19300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_D7ujkbc6zEmxw-k8G7HYEQ_29_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">26000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Er2V77bXhE-MDagLFubLyw_29_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">17000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_lgKPnI73cUSf7SkIdP6miA_30_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">42000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_NViqDYSpO0SepzTa_A26KA_30_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">776000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_NHJaJhYuAUqjZtth_PUgmQ_31_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_WO_VFWkQsECXMPHiqrYXBQ_32_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">231000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_6U4RYbdSO0WXB08-iXNcUA_32_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">377000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_dAR0j22Zn02uOFGJr6gZQw_33_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3188000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_dY-ZJJ1ONU6VLdsIIv-Ntg_34_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_r15u8tq0UkuI-tz1eXSlPQ_34_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">11000</us-gaap:FinanceLeasePrincipalPayments>
    <xoma:ProceedsFromRepaymentsForDisgorgement
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_dk1tssji30qdiXpUDjzZ1w_35_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13000</xoma:ProceedsFromRepaymentsForDisgorgement>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_CW89ELkPcEuKDIyCzTBClQ_36_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_VGk1PgMRF0meAMX58gftLg_36_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">504000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_jXzBjSZ-m0Sr1bkJdt2Hvw_37_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-3368000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_QV1RodtYN0mNP26eOFhN1A_37_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9401000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_ILGUVNYCTE2R_YCgIMyuuA_39_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-10963000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_S-cEqUj9RkuSPqB9shctMg_39_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-6036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_jxQ_OwhDgkyfoTAMZRR2Uw_40_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">56688000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_i3CbPgIjZ0-5rxulkZQvRg"
      decimals="-3"
      id="Tc_5KlPfBxxEU-_bNTGapq-rA_40_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">45780000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_Up-KA-vurkO2pbphY0kN5Q_41_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">45725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2019_estrhLFddEuEK4AxvfElgg"
      decimals="-3"
      id="Tc_bkIX8S28b0-qwGXvztHpQA_41_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">39744000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_oogv9pwDJUih-Dn0CgAk-g_44_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">546000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_yO8zCoJntEuXk0jVoPQyRg_44_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">357000</us-gaap:InterestPaidNet>
    <xoma:InterestAddedPrincipalBalancesLongTermDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_ovpeKTw1Y022-Jnl99IkoA_46_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">317000</xoma:InterestAddedPrincipalBalancesLongTermDebt>
    <xoma:InterestAddedPrincipalBalancesLongTermDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_p6x4dfHLd0u0mxJ5wqowVg_46_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">376000</xoma:InterestAddedPrincipalBalancesLongTermDebt>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_Sj2Gx1xWO06vdGTNpVCqfg_47_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">66000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <xoma:EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_hmnAbj2aq0W0HTriIw_7UA_48_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_mTE6SzoeeU2c9vdoCecZTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;XOMA Corporation (referred to as &#x201c;XOMA&#x201d; or the &#x201c;Company&#x201d;), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company&#x2019;s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with acquisitions of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had cash of $45.7 million. Based on the Company&#x2019;s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one&#160;year following the date that these condensed consolidated financial statements are issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:Cash
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_VkYsNhKEO0iYzpFZZJy26w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">45700000</us-gaap:Cash>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_fMNXp5cK1kyx8WdGJT437A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of Presentation and Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;10, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;These financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, operating lease right-of-use assets and liabilities, legal contingencies, contingent considerations under royalty purchase agreements, stock-based compensation and income taxes. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s billing under government contracts and amortization of the payments received from HealthCare Royalty Partners II,&#160;L.P. (&#x201c;HCRP&#x201d;). Under the Company&#x2019;s contracts with the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID&#x201d;), a part of the National Institutes of Health (&#x201c;NIH&#x201d;), the Company billed using NIH&#x2019;s provisional rates and thus is subject to future audits at the discretion of NIAID&#x2019;s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company&#x2019;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The worldwide spread of the COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company&#x2019;s royalty purchase agreements. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;("ASC 606"), except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the &#x201c;Black-Scholes Model&#x201d;). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company received shares of common stock from Rezolute, Inc. (&#x201c;Rezolute&#x201d;) (Note&#160;4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive (loss) income in the period of sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Purchase of Rights to Future Milestones and Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note&#160;5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If freestanding instruments, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value is recorded in the condensed consolidated statement of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require Food and Drug Administration (&#x201c;FDA&#x201d;) or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews any impairment indicators and changes in expected recoverability of the long-term royalty receivable asset at least quarterly. If expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of September 30, 2020 and December&#160;31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a lease agreement for its corporate headquarters in Emeryville, California and under its legacy business held leases for office and laboratory facilities in Berkeley, California. In connection with a series of restructuring events in 2017 and 2018, the Company completely vacated its leased facilities in Berkeley, California and subleased the space in the vacated buildings. In December 2019, the Company terminated its legacy operating leases in Berkeley, California and was fully released from any further payment obligations. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company continues to lease its headquarters office space in Emeryville, California.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an operating lease were to reflect impairment, the Company will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prior Period Reclassifications&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Within the condensed consolidated statement of cash flows, the Company separately presented the non-cash lease expense and changes in operating lease liabilities for the prior period to conform with current period presentation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net (Loss) Income per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net (loss) income per share attributable to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net (loss) income attributable to common stockholders consists of net (loss) income, as adjusted for any convertible preferred stock deemed dividends related to beneficial conversion features on this instrument at issuance. During periods of income, the Company allocates participating securities a proportional share of net income, after deduction of any deemed dividends on preferred stock, determined by dividing total weighted average participating securities by the sum of the total weighted average number of common stock and participating securities (the &#x201c;two-class method&#x201d;). The Company&#x2019;s convertible preferred stock participates in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. For the three and nine months ended September 30, 2020 and 2019, the Company did not declare any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade and other receivables, net consist mainly of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. &lt;span style="background-color:#ffffff;"&gt;Trade and other receivables are recorded upon triggering events specified in the agreement. Trade receivables under ASC 606 are recorded separately from contract assets when only the passage of time is required before consideration is due. &lt;/span&gt;The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. Any increases to allowance for doubtful accounts are charged to operating expenses. The Company recorded $1.4 million in allowance for doubtful accounts for the three months ended March 31, 2020 related to Rezolute&#x2019;s license agreement (Note 4). The Company evaluated the&#160;accounts&#160;receivable and determined there was no further activity in allowance for doubtful accounts for the second and third quarters in 2020. The previously reserved accounts receivable from Rezolute was accelerated and collected in October 2020, as discussed in Note 14, Subsequent Events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Beginning balance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charged to operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three&#160;months ended September 30, 2020, two partners represented&#160;64% and 36% of total revenues. For the nine&#160;months ended September 30, 2020, three partners represented&#160;58%, 28% and 11% of total revenues. For the three&#160;months ended September 30, 2019, two partners represented 68% and 28% of total revenues. For the nine&#160;months ended September 30, 2019, two partners represented 78% and 14% of total revenues. As of September 30, 2020 and as of December&#160;31, 2019, one partner represented 100% of the trade receivables, net balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (Loss) Income &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-13,&#160;&lt;i style="font-style:italic;"&gt;Fair Value Measurement (Topic 820) (&#x201c;ASU 2018-13&#x201d;)&lt;/i&gt;, which modifies, removes and adds certain disclosure requirements on fair value measurements based on the FASB&#160;&lt;i style="font-style:italic;"&gt;Concepts Statement, Conceptual Framework for Financial Reporting&#x2014;Chapter&#160;8: Notes&#160;to Financial Statements&lt;/i&gt;. The ASU is effective for the Company&#x2019;s interim and annual reporting periods during the&#160;year ending December&#160;31, 2020, and all annual and interim reporting period thereafter. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal&#160;year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company early adopted the guidance related to removal of disclosures upon issuance of this ASU and adopted the deferred provisions as permitted under the ASU in the first quarter of 2020. The adoption of ASU 2018-13 did not have a material impact&lt;span style="color:#212529;"&gt;&#160;&lt;/span&gt;on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) &#x201c;Clarifying the Interaction between Topic 808 and Topic 606,&#x201d; which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service that is a distinct unit of account. The new standard also precludes an entity from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The ASU is effective for the Company&#x2019;s interim and annual reporting periods during the year ending December 31, 2020, and all annual and interim reporting period thereafter. Early adoption is permitted, but no earlier than an entity&#x2019;s adoption date of Topic 606. This ASU requires retrospective adoption to the date the Company adopted ASC 606, January 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company may elect to apply the ASU retrospectively either to all contracts or only to contracts that are not completed at the date it initially applied ASC 606. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13 and related updates&#160;as of January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued&#160;ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. &lt;/i&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021 with early adoption permitted. The Company is evaluating the impact &lt;span style="color:#212529;"&gt;of adopting this new accounting guidance &lt;/span&gt;on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In March&#160;2020, the FASB issued&#160;ASU&#160;2020-04,&#160;&lt;i style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/i&gt;. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The&#160;ASU&#160;provides optional expedients and exceptions for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12,&#160;2020&#160;through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12,&#160;2020. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_sNzHH1AY7UmFid33T_z0NQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles (&#x201c;GAAP&#x201d;) in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;10, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;These financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_1wOnqa6zXkK3bEh-z5uAFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, operating lease right-of-use assets and liabilities, legal contingencies, contingent considerations under royalty purchase agreements, stock-based compensation and income taxes. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s billing under government contracts and amortization of the payments received from HealthCare Royalty Partners II,&#160;L.P. (&#x201c;HCRP&#x201d;). Under the Company&#x2019;s contracts with the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID&#x201d;), a part of the National Institutes of Health (&#x201c;NIH&#x201d;), the Company billed using NIH&#x2019;s provisional rates and thus is subject to future audits at the discretion of NIAID&#x2019;s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company&#x2019;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The worldwide spread of the COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company&#x2019;s royalty purchase agreements. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_Cffn1Zxt5kSn3OtOjsjRag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/i&gt;("ASC 606"), except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_RB2rCPp-202hTpUCQjDSXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;</xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_ThP9cLmgW0W4mzBAkKMeUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the &#x201c;Black-Scholes Model&#x201d;). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <xoma:EquitySecuritiesPolicy
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_bOcxpWYUcESndH9Rf5SZjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company received shares of common stock from Rezolute, Inc. (&#x201c;Rezolute&#x201d;) (Note&#160;4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive (loss) income in the period of sale.&lt;/p&gt;</xoma:EquitySecuritiesPolicy>
    <xoma:FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_LdJruigYwEClgsytonWVSw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Purchase of Rights to Future Milestones and Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note&#160;5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If freestanding instruments, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value is recorded in the condensed consolidated statement of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require Food and Drug Administration (&#x201c;FDA&#x201d;) or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews any impairment indicators and changes in expected recoverability of the long-term royalty receivable asset at least quarterly. If expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of September 30, 2020 and December&#160;31, 2019.&lt;/p&gt;</xoma:FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-5"
      id="Narr_a_1MJOJuW0qWykr8or9ehg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019_HUFMmZpyxUmnf6MQcbwsUQ"
      decimals="-5"
      id="Narr_ickPsZbmdUKtTgvEpP8OBg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_M4VxzMgny0WsQlPVu_cInw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a lease agreement for its corporate headquarters in Emeryville, California and under its legacy business held leases for office and laboratory facilities in Berkeley, California. In connection with a series of restructuring events in 2017 and 2018, the Company completely vacated its leased facilities in Berkeley, California and subleased the space in the vacated buildings. In December 2019, the Company terminated its legacy operating leases in Berkeley, California and was fully released from any further payment obligations. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company continues to lease its headquarters office space in Emeryville, California.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If an operating lease were to reflect impairment, the Company will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:Reclassifications
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_vZLq1t2yb0mT-vttvObK5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Prior Period Reclassifications&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Within the condensed consolidated statement of cash flows, the Company separately presented the non-cash lease expense and changes in operating lease liabilities for the prior period to conform with current period presentation.&lt;/p&gt;</us-gaap:Reclassifications>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_ST0Z3nm2sUm7xVBLVamLDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net (Loss) Income per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net (loss) income per share attributable to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net (loss) income attributable to common stockholders consists of net (loss) income, as adjusted for any convertible preferred stock deemed dividends related to beneficial conversion features on this instrument at issuance. During periods of income, the Company allocates participating securities a proportional share of net income, after deduction of any deemed dividends on preferred stock, determined by dividing total weighted average participating securities by the sum of the total weighted average number of common stock and participating securities (the &#x201c;two-class method&#x201d;). The Company&#x2019;s convertible preferred stock participates in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. For the three and nine months ended September 30, 2020 and 2019, the Company did not declare any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:Dividends
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-5"
      id="Narr_Cp79NqYtSk6lekU83BgnxA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-5"
      id="Narr_Hj5euNgeXkODl_XVI93khg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-5"
      id="Narr_jRPsz9jy6EuLFQOBflLIlQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-5"
      id="Narr_rrimceA8LESLFyEIFGsjjw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:Dividends>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb__rshELCcXkeJDJrhzZiIPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Trade and other receivables, net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Trade and other receivables, net consist mainly of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. &lt;span style="background-color:#ffffff;"&gt;Trade and other receivables are recorded upon triggering events specified in the agreement. Trade receivables under ASC 606 are recorded separately from contract assets when only the passage of time is required before consideration is due. &lt;/span&gt;The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. Any increases to allowance for doubtful accounts are charged to operating expenses. The Company recorded $1.4 million in allowance for doubtful accounts for the three months ended March 31, 2020 related to Rezolute&#x2019;s license agreement (Note 4). The Company evaluated the&#160;accounts&#160;receivable and determined there was no further activity in allowance for doubtful accounts for the second and third quarters in 2020. The previously reserved accounts receivable from Rezolute was accelerated and collected in October 2020, as discussed in Note 14, Subsequent Events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Beginning balance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charged to operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="Duration_1_1_2020_To_3_31_2020_xDEgBpOe10icHB8LVt-Brg"
      decimals="-5"
      id="Narr_iNnuSYWX4EWboYO5dcEhSg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="Duration_4_1_2020_To_6_30_2020_MRUoidiki06o-LWcAwpBcQ"
      decimals="-3"
      id="Narr_YKiboqU3dkWTdw91CybnNg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Narr_iZs95FiFKEajp84-_LIcbQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_AoTXmWCvOUm7uc94ARlGLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Beginning balance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Charged to operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_KV6-xOBeGUC7maadjwLQDA_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1409000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_4eiJcrwy5USP5VjgYOkW3w_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1409000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb__KIAnlVGqUeLoiGLeDaxWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three&#160;months ended September 30, 2020, two partners represented&#160;64% and 36% of total revenues. For the nine&#160;months ended September 30, 2020, three partners represented&#160;58%, 28% and 11% of total revenues. For the three&#160;months ended September 30, 2019, two partners represented 68% and 28% of total revenues. For the nine&#160;months ended September 30, 2019, two partners represented 78% and 14% of total revenues. As of September 30, 2020 and as of December&#160;31, 2019, one partner represented 100% of the trade receivables, net balance.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NwHPINtT2E27syT0FERCZg"
      decimals="INF"
      id="Narr_G7zvQNDjGEurrt-xJTft4g"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Vh-yAeDCzEam1o4LJU3R9Q"
      decimals="2"
      id="Narr_02Ho40PHgUaazuODm8ukVA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.64</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wW3g01I-CEqS98TMD6LhAg"
      decimals="2"
      id="Narr_9H69jQ04eEasnGljM9NcAg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.36</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_DqK_86Lt2kGOZ5tETJSWVg"
      decimals="INF"
      id="Narr_UIySspdtlk-S0jXkmJmLfw"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">3</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_w6FnUVgyxk-uu6eq_pVLjA"
      decimals="2"
      id="Narr_6h5_IzGSDkmHrkxJ_CnyDA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v9GiP1Qyk0qx9_F2-bs0WQ"
      decimals="2"
      id="Narr_BKqwtEQ71ESXNGJFGFNT9A"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wOjQWoE-yEyfuioBK5aSsw"
      decimals="2"
      id="Narr_PXg-EIxSiEuyGhNbZYgUFg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.11</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_whotwsqlPUWlIpHCjIDEwA"
      decimals="INF"
      id="Narr_MXl7u68DIECV4KhwKRm25w"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_NREQuj8uA0eP9aMHPRFc1g"
      decimals="2"
      id="Narr_5y7JZ4MzGUeYIENZZr6vYg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_4EvFxExj10OrmYqKm4c1sg"
      decimals="2"
      id="Narr_J9e7Ky9nEEGjrbewmKWiQg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.28</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_tcvB75A62UqaD7Gz2Fyu6w"
      decimals="INF"
      id="Narr_4jWosvHgm0eNODAbjASQfw"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OT29fxEd0kmg6WxFKFQGSg"
      decimals="2"
      id="Narr_kY-89LPPokeQQEopxCY7LQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_RVLPSZwwQEyCcFoXmWjm_A"
      decimals="2"
      id="Narr_LE0KYnQIwkqVCZdhDb-Npw"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.14</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w"
      decimals="INF"
      id="Narr_GZ0ur5U0GU2JqBoEJSMTdQ"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">1</xoma:NumberOfMajorPartners>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA"
      decimals="INF"
      id="Narr_Fh-Zmvn8rUS77a6HsG-OTw"
      unitRef="Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A">1</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_iQ2poI2ceUKkaZ4LOxYyFA"
      decimals="2"
      id="Narr_re_aZCHLUUe-rHoHYuQn-Q"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_UUjJwGsYC0eIrHWzmGvX2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (Loss) Income &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_G9F9AWbgX06Siht8HvzVMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August&#160;2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2018-13,&#160;&lt;i style="font-style:italic;"&gt;Fair Value Measurement (Topic 820) (&#x201c;ASU 2018-13&#x201d;)&lt;/i&gt;, which modifies, removes and adds certain disclosure requirements on fair value measurements based on the FASB&#160;&lt;i style="font-style:italic;"&gt;Concepts Statement, Conceptual Framework for Financial Reporting&#x2014;Chapter&#160;8: Notes&#160;to Financial Statements&lt;/i&gt;. The ASU is effective for the Company&#x2019;s interim and annual reporting periods during the&#160;year ending December&#160;31, 2020, and all annual and interim reporting period thereafter. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal&#160;year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company early adopted the guidance related to removal of disclosures upon issuance of this ASU and adopted the deferred provisions as permitted under the ASU in the first quarter of 2020. The adoption of ASU 2018-13 did not have a material impact&lt;span style="color:#212529;"&gt;&#160;&lt;/span&gt;on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) &#x201c;Clarifying the Interaction between Topic 808 and Topic 606,&#x201d; which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service that is a distinct unit of account. The new standard also precludes an entity from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The ASU is effective for the Company&#x2019;s interim and annual reporting periods during the year ending December 31, 2020, and all annual and interim reporting period thereafter. Early adoption is permitted, but no earlier than an entity&#x2019;s adoption date of Topic 606. This ASU requires retrospective adoption to the date the Company adopted ASC 606, January 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company may elect to apply the ASU retrospectively either to all contracts or only to contracts that are not completed at the date it initially applied ASC 606. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt;. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13 and related updates&#160;as of January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued&#160;ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. &lt;/i&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021 with early adoption permitted. The Company is evaluating the impact &lt;span style="color:#212529;"&gt;of adopting this new accounting guidance &lt;/span&gt;on its condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In March&#160;2020, the FASB issued&#160;ASU&#160;2020-04,&#160;&lt;i style="font-style:italic;"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/i&gt;. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The&#160;ASU&#160;provides optional expedients and exceptions for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12,&#160;2020&#160;through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12,&#160;2020. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ"
      id="Narr_h0cLTJ2e90ik9ZJGi1lZsA">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ"
      id="Narr_RpHkCMY6S0KFW2x7DE4NZQ">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201818Member_mlMnqtv8RUS5hgexXcSDqA"
      id="Narr_ImZfKiTkuEG2T25Cg7eEAg">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_u3GsQTWiFUmJAu68jM6aaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;Condensed Consolidated Financial Statements Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020 and December&#160;31, 2019, equity securities consisted of an investment in Rezolute&#x2019;s common stock of $2.6 million and $0.7 million, respectively (Note&#160;4). For the three and nine months ended September 30, 2020 the Company recognized gains of $2.0 million and $1.9 million, respectively, due to the change in fair value of its investment in Rezolute&#x2019;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. The Company recognized a loss of $0.3 million and a gain of $0.5 million for the three and nine months ended September 30, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll and other benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net (Loss) Income Per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss or income) and the denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Net (loss) income  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Allocation of undistributed earnings to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,327)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (977)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income available to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add: Adjustments to undistributed earnings allocated to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income available to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic net (loss) income per share available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,731&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,537&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,721&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing diluted net (loss) income per share available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net (loss) income per share of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share available to common stockholders if their inclusion is anti-dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,483&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <xoma:EquitySecuritiesFvNiNonCurrent
      contextRef="As_Of_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_QJfyk6LBB0y8TAEOtRhUbg"
      decimals="-5"
      id="Narr_Ceeb7Uk520OKAR1xQVEgsg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2600000</xoma:EquitySecuritiesFvNiNonCurrent>
    <xoma:EquitySecuritiesFvNiNonCurrent
      contextRef="As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_WyJEPykhS0yKbLZyNfLarQ"
      decimals="-5"
      id="Narr_BxYe0hqpDkq5RLwyb895cQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">700000</xoma:EquitySecuritiesFvNiNonCurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_1WJzW9HoPEib8xgIXL4tQQ"
      decimals="-5"
      id="Narr_SpqtxK6ZwUWXJDyQTpI8hA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2000000.0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_eFRO3EsZIkmFH2cQ0wM35w"
      decimals="-5"
      id="Narr_I4lOfzQTw0enkIQQD7rJ3g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ZXd3cmpR10SClHLRFX8RSQ"
      decimals="-5"
      id="Narr_foLLXtDTTE69WcPOEhxiOQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_as3Q7AGP7kiK9uKgqvnZSQ"
      decimals="-5"
      id="Narr_GuhcJ-n9P0yUYsGNP43LLw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_E8wxHc_G4UCK3OYeLMNGbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll and other benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 945&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_G50yhbacT0OKR1BpNe1J3A_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">202000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_CJba-Ye-9kSaHMP6ywRb5g_3_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">256000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_s5Jm0_SG4kqsqlYC6q95CA_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">154000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_SVIhrhD54kie7YZMIJU24Q_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">231000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_SXv6hXdVokue_ivYL58RRQ_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">51000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_WwM_A_Vykk2w_9gsneZTTA_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">69000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_dn8miy3DE0K3yfs6lJ5pjQ_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">26000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_K3AoBasdDUOoKjfjXqFwIA_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">332000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_0SBsQD-RMEmOOZfdAGKGLA_7_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">33000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc__nuBcEtn7Ee3_Pr1rDgUuQ_7_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">57000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_bwSRUxHUE0GKYSk-7U7Smw_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">466000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-3"
      id="Tc_aKJpiVcTyUmna0kVh-FHxg_8_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">945000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_fHqMmCpXW0idTJU_MrDOcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss or income) and the denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Net (loss) income  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,339&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Allocation of undistributed earnings to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,327)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (977)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income available to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,362&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add: Adjustments to undistributed earnings allocated to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income available to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,077)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,368)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic net (loss) income per share available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,731&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,537&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,721&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing diluted net (loss) income per share available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,379&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net (loss) income per share of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share of common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.89)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_4gyOZt09OEyhdc0acZjvwA_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_E8iCTiTvsUWCQO0dS-FxWg_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3178000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_5rIn3vumFEixWjoKKmN5Dg_4_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_0nrxAhtojkOlMv3CFIeZPg_4_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2339000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_IvpAwnurtECQzolbFk7rUg_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1327000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_8ieNHjsByUmrGcesB4hrzw_5_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">977000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_8tCtzwqKZUSPqkhY6ZsagQ_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_sL8FmFbSLEqZZ5EWm_EOsg_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1851000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_GmpNXqTH5UeledpBGixQKQ_6_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_IANffz5PfUKKjtENDNmXeQ_6_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1362000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_3hznQ1fJ70CVpJPzOtfEFQ_7_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-60000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_cQJr_6ZgbUGLbeigNVS5Lg_7_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-41000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_vuXLOLl4bEW7HKT08r_OTg_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_nyvMC_9Y10y-HLKmEV-j0A_8_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1911000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_5E-sgqXxckaXHUiJj2pOpg_8_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-9368000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_IVhChZ7pR06KvQwY-BUHTg_8_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1403000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_LE3aaVDGGk2yxJxTgsP9AQ_11_3"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11019000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_jsOivbDKwkGc7nalBR-HGw_11_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8731000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_vGM9xIOXxEGZriPXLdgh_g_11_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">10537000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_UXd_bG9-7EqEu4_AnRVVvg_11_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8721000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_H-mOnEJGbESd-VyEnIPcOg_12_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">708000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_amyxav2VkUisvqBzyALEjA_12_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">657000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_dj1X88Ol5EmauPPxavLtsQ_13_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_otUf27diSUigRLKiEKfAZA_13_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_-SUjSZxVoEW5Zix5LeKpuw_14_3"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">11019000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_YfmJAKIeb0msj8nYoaVs8A_14_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9441000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_-f-D15magkOFjkf-4pqw_g_14_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">10537000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_6MVNoBcQb0KXl-7Mwz_CwA_14_12"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9379000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="2"
      id="Tc_pLA213zYIUSRcZV-7R857g_15_3"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="2"
      id="Tc_2V2lV_S_AUip148l2kXHXQ_15_6"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="2"
      id="Tc_Ui5AXfjqi0qwjFLyPWijsQ_15_9"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="2"
      id="Tc_4b1Cxl0hTku_NprjLNFDLg_15_12"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="2"
      id="Tc_YwodJZ509k6__SDSV-IrAw_16_3"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="2"
      id="Tc__Tx1aToFuUW-KWVWZI0b5Q_16_6"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="2"
      id="Tc__cW6r4KPz0iIroG5W8nV6Q_16_9"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="2"
      id="Tc_ua0sKyHfgUusObv3TlkO5w_16_12"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_5ruLEFqIrUm0YnfTDfZrLA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,483&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 893&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,115&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_HmB3foWGM0Wj8z_XGGsBhA"
      decimals="-3"
      id="Tc_9ZQRIvpnvkCWE-ZsTCrTkg_3_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_0Cv-gufQXUiXoT0EaH7Cqw"
      decimals="-3"
      id="Tc_k0qo_3LUEUScDEShf3G3pQ_3_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5483000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_3CadpqFg8UOOttt6X8zQ0w"
      decimals="-3"
      id="Tc_VDmuUOFDYEWzBAgPTq5vdg_4_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">931000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_cB3ANTnBg0OCmZf8uEBeTw"
      decimals="-3"
      id="Tc_XIePhiH6D0eXlJdYENhbMg_4_4"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">893000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aQmUj8E-FUqSQDzVNxRfcw"
      decimals="-3"
      id="Tc_Ca6BFesjGkKoQiaPSuAo8A_4_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">611000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_UVoSolrPv0qV5x4CzEronQ"
      decimals="-3"
      id="Tc_gFDEHB7T-ESQvFKojGHjfQ_4_8"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">926000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_BzIKlySpD0yINoAWGMbaLA"
      decimals="-3"
      id="Tc_qFI2_g7-iUWrHgaGAigtOg_5_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">19000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_uJR98_x7FUu-h9HgcgHodQ"
      decimals="-3"
      id="Tc_IlWu-JBT2kSr0Gm0qnGDOQ_5_4"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_mkImYFxDL0WhSR47srlVEQ"
      decimals="-3"
      id="Tc_9J8tcHqX2UeaMiWw1UQ-DA_5_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">21000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_i4aGeX3zlkORauSmBIjKjg"
      decimals="-3"
      id="Tc_z5d3YG47y06Sks8WQVOCRA_5_8"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">15000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_jOdu64zHskKWJvq_RiAlPQ_6_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5953000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_8fn2cJ8YsE2peyQV6HiFJQ_6_4"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">908000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_1uRSkeQKE0-m_MbIDY0DYg_6_6"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6115000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_IDdhcUgIx0iVHN59rkG1Uw_6_8"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">941000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <xoma:LicensingAndOtherArrangementsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_1SzP3pOKPkCB0DdyoxrPzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Licensing and Other Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Novartis&#160;&#x2013; Gevokizumab (VPM087) and IL-1 Beta&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, the Company and Novartis Pharma AG (&#x201c;Novartis&#x201d;) entered into a license agreement (the &#x201c;XOMA-052 License Agreement&#x201d;) under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#x201c;VPM087&#x201d;), a novel anti-Interleukin-1 (&#x201c;IL-1&#x201d;) beta allosteric monoclonal antibody and related know-how and patents (altogether, the &#x201c;XOMA IP&#x201d;). Under the terms of the XOMA-052 License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, pursuant to a separate agreement (the &#x201c;IL-1 Target License Agreement&#x201d;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#x201c;Exclusivity Option&#x201d;) to such intellectual property for the treatment and prevention of cardiovascular disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the XOMA-052 License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#x20ac;12.0 million) was paid by Novartis Institutes for BioMedical Research,&#160;Inc. (&#x201c;NIBR&#x201d;), on behalf of the Company, to settle the Company&#x2019;s outstanding debt with Les Laboratories Servier (&#x201c;Servier&#x201d;) (the &#x201c;Servier Loan&#x201d;). In addition, NIBR extended the maturity date on the Company&#x2019;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#x2019;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the XOMA-052 License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#x2019;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single digits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Unless terminated earlier, the XOMA-052 License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the XOMA-052 License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#x2019; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The XOMA-052 License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Novartis International&#160;&#x2013; Anti-TGF&#x3b2; Antibody (NIS793)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;30, 2015, the Company and Novartis International Pharmaceutical&#160;Ltd. (&#x201c;Novartis International&#x201d;) entered into a license agreement (the &#x201c;License Agreement&#x201d;) under which the Company granted Novartis International an exclusive, world-wide, royalty-bearing license to the Company&#x2019;s anti-transforming growth factor beta (&#x201c;TGF&#x3b2;&#x201d;) antibody program (now &#x201c;NIS793&#x201d;). Under the terms of the License Agreement, Novartis International has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis International&#x2019;s royalty obligations end. The License Agreement contains customary termination rights relating to material breach by either party. Novartis International also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that there are multiple promised goods and services under the License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;year ended December&#160;31, 2017, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income. The Company is eligible to receive up to a total of $470.0 million in development, regulatory and commercial milestones under the anti-TGFB antibody agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each quarter, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit&#160;percentage rate to up to a low double-digit&#160;percentage rate. Novartis International&#x2019;s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020 and 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $25.0 million milestone payment as a result, as discussed in Note 14, Subsequent Events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#x201c;RZ358&#x201d;) for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#x2019;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the license agreement, the Company is eligible to receive a low single digit royalty on sales of Rezolute&#x2019;s other non-RZ358 products from its current programs. Rezolute&#x2019;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country (the &#x201c;Royalty Term&#x201d;), provided that any such licensee royalty will terminate upon the termination of the licensee&#x2019;s obligation to make payments to Rezolute based on sales of such product in such country. Rezolute&#x2019;s future royalty obligations will be reduced by 20% at any time during the Royalty Term that a valid XOMA patent claim is not outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;"&gt;Rezolute had an option through June&#160;1, 2019 to obtain an exclusive license for their choice of one of the Company&#x2019;s preclinical monoclonal antibody fragments, including X129 (the &#x201c;Additional Product Option&#x201d;), in exchange for a $1.0 million upfront option fee and additional clinical, regulatory and commercial milestone payments to the Company of up to $237.0 million in the aggregate based on the achievement of pre-specified criteria as well as royalties ranging from the high single digits to the mid-teens based on annual net sales. On June 1, 2019, Rezolute&#x2019;s right to the Additional Product Option expired unexercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#x2019; notice at any time. The Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the license agreement and common stock purchase agreement, no consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#x2019;s financing activities and the amounts to be paid to be based on the timing of those activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Rezolute License Agreement&#160;- First Amendment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In March&#160;2018, the Company and Rezolute amended the license agreement and common stock purchase agreement. Pursuant to the as-amended terms of the license agreement and common stock purchase agreement, the Company was eligible to receive $6.0 million in cash, $8.5 million of Rezolute&#x2019;s common stock, and 7,000,000 shares of Rezolute&#x2019;s common stock, contingent on the completion of Rezolute&#x2019;s financing activities. Further, in the event that &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute did not complete a financing that raised at least $20.0 million in aggregate gross proceeds (&#x201c;Qualified Financing&#x201d;) by March&#160;31, 2019 (the &#x201c;2019 Closing&#x201d;), the Company would have received an additional number of shares of Rezolute&#x2019;s common stock equal to $8.5 million divided by the weighted average of the closing bid and ask prices or the average closing prices of Rezolute&#x2019;s common stock on the ten-day trading period prior to March&#160;31, 2019. Finally, in the event that Rezolute was unable to complete a Qualified Financing by March&#160;31, 2020, the Company would have been eligible to receive $15.0 million in cash in order for Rezolute to maintain the license. Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i)&#160;5,000,000 shares of common stock or (ii)&#160;&lt;span style="-sec-ix-hidden:Hidden_5JMn34DvnkG2-h_9uI7tlA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;one third&lt;/span&gt;&lt;/span&gt; of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three&#160;months ended March&#160;31, 2018, the Company completed the delivery of the license and related materials, product data/filing, process and know-how to Rezolute. However, the Company determined that it was not probable that the Company would collect substantially all of the consideration to which it was entitled in exchange for the goods and services transferred to Rezolute. Therefore, the Company determined no contract existed as of March&#160;31, 2018 and no revenue was recognized during the three&#160;months ended March&#160;31, 2018 under the arrangement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute completed the Interim Financing Closing and the Initial Closing financing activities, as defined in the common stock purchase agreement, during the first and second quarter of 2018, respectively. As a result, XOMA received 8,093,010 shares of Rezolute&#x2019;s common stock and cash of $0.5 million in April&#160;2018. Under the license agreement, XOMA was also entitled to receive $0.3 million of reimbursable technology transfer expenses from Rezolute. The Company concluded that the payment associated with the Initial Closing represented substantially all consideration for the delivered license and technology to Rezolute. Therefore, the Company determined that a contract existed between Rezolute and XOMA under ASC 606 on April&#160;3, 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement and common stock purchase agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there were multiple promised goods and services under the combined arrangement, including the license to RZ358, the transfer of RZ358 materials and product data/filing, and the transfer of process and know-how related to RZ358, which were determined to represent one combined performance obligation. The Company determined that the Additional Product Option was not an option with material right because there was no upfront consideration to the Company that would result to an incremental discount for the future opt in payments. Therefore, the Company concluded that the Additional Product Option was not a performance obligation. On June&#160;1, 2019, Rezolute&#x2019;s right to the Additional Product Option expired unexercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;3, 2018, the Company determined that the transaction price under the arrangement was $1.8 million, which consisted of the 8,093,010 shares of Rezolute&#x2019;s common stock valued at $1.0 million, $0.5 million in cash, and reimbursable technology transfer expenses of $0.3 million. During the&#160;year ended December&#160;31, 2018, the Company recognized the entire transaction price of $1.8 million as revenue upon completion of the delivery of the licenses and related materials, product data/filing, process and know-how. The change in fair value of Rezolute&#x2019;s common stock after the contract inception date was due to the form of the consideration and therefore, not included in the transaction price pursuant to the accounting guidance. The Company accounts for the change in the fair value of its investment in Rezolute&#x2019;s common stock in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#x2019;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of the inception of the arrangement. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether the estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Rezolute License Agreement&#160;- Second Amendment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;7, 2019, the Company and Rezolute further amended the license agreement and common stock purchase agreement. The parties agreed to replace the issuance of common stock valued at $8.5 million to XOMA upon closing of a Qualified Financing with a requirement that Rezolute make five future cash payments to XOMA totaling $8.5 million through September&#160;2020 (the &#x201c;Future Cash Payments&#x201d;). The amendment also provides for early payment of the Future Cash Payments (only until the $8.5 million is reached) by making cash payments to XOMA equal to 15% of the net proceeds of each future financing following the closing of the Qualified Financing, with such payments to be credited against any remaining unpaid Future Cash Payments in reverse order of their future payment date. In addition, the license agreement amendment revised the amount Rezolute is required to expend on development of RZ358 and related licensed products, revised provisions with respect to Rezolute&#x2019;s diligence efforts in conducting clinical studies and eliminated XOMA&#x2019;s right to appoint a member to Rezolute&#x2019;s board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The common stock purchase agreement was amended to remove certain provisions related to the issuance of equity to XOMA in accordance with the new provisions regarding the Future Cash Payments in the license agreement. Lastly, the common stock purchase agreement was amended to provide the Company the right and option to sell up to 5,000,000 shares of Rezolute&#x2019;s common stock currently held by XOMA back to Rezolute upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2019. As of December 31, 2019, Rezolute failed to list its shares of common stock on the Nasdaq Stock Market or a similar exchange. Up to 2,500,000 shares may be sold back to Rezolute during calendar&#160;year 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;30, 2019, Rezolute closed a preferred stock financing for gross proceeds of $25.0 million, which triggered the Qualified Financing event defined under the amended common stock purchase agreement resulting in cash consideration due to XOMA of $5.5 million. In addition, the Company received from Rezolute a reimbursable technology transfer expense of $0.3 million. The cash consideration and technology reimbursement were received in February&#160;2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of March&#160;31, 2019, Rezolute completed all financing activities, as defined in the license agreement and common stock purchase agreement, and the Company is eligible to receive $8.5 million in Future Cash Payments through September&#160;2020 (in addition to any clinical, regulatory and annual net sales milestone payments and royalties). The Company concluded that the Future Cash Payments are dependent on Rezolute&#x2019;s ability to raise additional capital through future financing activities. The Company applied the variable consideration constraint to the Future Cash Payments and determined that it was probable that a significant revenue reversal would not occur in future periods for only $2.5 million of the total amount as of March&#160;31, 2019 and recognized $2.5 million revenue in that quarter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July&#160;and August&#160;2019, Rezolute received additional cash through two common stock financing events, which triggered early payment of $3.4 million of the unrecognized $6.0 million of total Future Cash Payments. In addition, the Company received the $1.5 million payment due September&#160;30, 2019, resulting in a total of $4.9 million cash received from Rezolute in the third quarter of 2019. The Company re-assessed the outstanding $3.6 million of Future Cash Payments and determined that a significant revenue reversal was not probable due to Rezolute&#x2019;s recent common stock financing events. Therefore, in the third quarter of 2019, the Company recognized $6.0 million as revenue related to the remaining Future Cash Payments. In the fourth quarter of 2019, the Company received the scheduled $1.0 million Future Cash Payment from Rezolute.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;&lt;i style="text-decoration:underline;"&gt;Rezolute License Agreement&#160;- Third Amendment&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On March 31, 2020, the Company and Rezolute further amended the license agreement to extend the payment schedule for the remaining $2.6 million in Future Cash Payments. The amendment to the payment terms was in response to Rezolute&#x2019;s need to preserve cash as a result of the COVID-19 pandemic and w&lt;span style="color:#231f20;"&gt;as agreed to by the Company. &lt;/span&gt;The extended payment schedule did not impact the total amount due, but instead, spread the $2.6 million into seven quarterly payments to be paid through September 30, 2021. The amended license agreement requires&lt;span style="color:#231f20;"&gt; that in the event Rezolute completes a Qualified Financing at any time between March 31, 2020 and the date of the final payment, Rezolute shall pay all amounts outstanding within &lt;/span&gt;&lt;span style="color:#231f20;"&gt;fifteen days&lt;/span&gt;&lt;span style="color:#231f20;"&gt; following the closing of the Qualified Financing. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In the first quarter of 2020, the Company received the scheduled $0.4 million Future Cash Payment from Rezolute. The Company evaluated Rezolute&#x2019;s cash position as of March 31, 2020, including the estimated impact of the COVID-19 pandemic, and determined payments scheduled beyond September 30, 2020 were unlikely to be collected unless Rezolute is able to obtain additional funding, which had not occurred as of March 31, 2020. Therefore, for the three months ended March 31, 2020, the Company recorded $1.4 million in bad debt expense related to the Future Cash Payments. The Company received the scheduled $0.4 million and $0.4 million Future Cash Payments from Rezolute in the second and third quarters of 2020, respectively. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $1.4 million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. On October 9, 2020, Rezolute completed a Qualified Financing, which resulted in acceleration of the remaining receivables balance and the Company received the entire $1.4 million in October 2020, as discussed in Note 14, Subsequent Events. &lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of September 30, 2020 and December&#160;31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Janssen Biotech&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company and Janssen Biotech,&#160;Inc. (&#x201c;Janssen&#x201d;) were parties to a license agreement which was terminated in 2017. In August&#160;2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#x2019;s achievement of certain clinical development and regulatory approval events. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#x2019;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year and sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#x2019;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, there were no contract assets or contract &lt;span style="-sec-ix-hidden:Hidden_IvzhjoQ1qkKnonNbFMwDHw"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;liabilities&lt;/span&gt;&lt;/span&gt; related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Revenue of $0.2 million was recognized for the three and nine months ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Zydus&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 3, 2020, the Company and Cadila Healthcare Limited (&#x201c;Zydus&#x201d;) entered into a license agreement (the &#x201c;Zydus Agreement&#x201d;) under which the Company granted Zydus an exclusive royalty-bearing license to the Company&#x2019;s anti-interleukin-2 (&#x201c;IL-2&#x201d;) monoclonal antibody, including mAb19, for Zydus to develop and commercialize drug candidates in India, Brazil, Mexico and certain other emerging markets. The Company retains rights in all other territories, subject to a Zydus right of first negotiation. Under the terms of the Zydus Agreement, Zydus is responsible for the development and commercialization of IL-2 based immune-oncology drug candidates. XOMA is entitled to receive up to $0.5 million development and regulatory milestone payments, up to $23.5 million commercial milestone payments, and mid-single digit to low teens royalties from Zydus. The Company is also eligible to share out-licensing revenue received by Zydus should Zydus (sub)license to third parties, which are tiered based on clinical trial stage and range from a low to mid double-digit&#160;percentage rate. Unless terminated earlier, the License Agreement will remain in effect, on a product-by-product basis, until all payment obligations end. The Zydus Agreement contains customary termination rights relating to material breach by either party. Zydus also has a unilateral right to terminate the agreement upon required written notice in advance if certain conditions are met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that there is one performance obligation, and it had not completed its performance obligation. The development and regulatory milestone payments are solely dependent on Zydus&#x2019; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Zydus and therefore, have also been excluded from the transaction price. Out-licensing revenue sharing will be recognized if and when Zydus receives or earns its out-licensing revenue. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, there were no contract assets or contract &lt;span style="-sec-ix-hidden:Hidden_6KcCQ2KmOUSERG_vOJUbuA"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;liabilities&lt;/span&gt;&lt;/span&gt; related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;NIAID&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the sale of the Company&#x2019;s biodefense business, the Company performed services under a $64.8 million multiple-year contract funded with federal funds from NIAID (Contract No.&#160;HHSN272200800028C), for development of anti-botulinum antibody product candidates. The contract work was being performed on a cost-plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company&#x2019;s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2014, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID&#x2019;s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company&#x2019;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. As of December&#160;31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. The Company classified $0.8 million as contract liabilities on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On December&#160;21, 2016, the Company entered into two Royalty Interest Acquisition Agreements (together, the &#x201c;Royalty Sale Agreements&#x201d;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer,&#160;Inc. (&#x201c;Pfizer&#x201d;)) for an upfront cash &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company&#x2019;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#x2019;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#x2019;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $0.4 million and $1.1 million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2020, respectively. The Company recognized $0.3 million and $0.8 million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2019, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, the Company classified $1.4 million and $14.0 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively. As of December&#160;31, 2019, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.1 million and $15.3 million, respectively.&lt;/p&gt;</xoma:LicensingAndOtherArrangementsTextBlock>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_awdxxvYqtEqIr8fX7s0row"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">30000000.0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_OxeATdjP_068bR1JMNM2Ig"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_uScDoi0aGEi-gENFEud-Cg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_nFkGpYLF5UOKLAJkY-ZTxw"
      unitRef="Unit_Standard_EUR_rMXTIUZ4Q0GOaNm0YP-bKA">12000000.0</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_UU3bZfxH-ESxQUGwTlQaOw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw"
      decimals="INF"
      id="Narr_h876bxgD4E6G4nwewYSkPw"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">539131</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg"
      decimals="INF"
      id="Narr_3QGlIijL3UaaKs9duSDnWA"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">9.2742</us-gaap:SharesIssuedPricePerShare>
    <xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Heyb61JduUawQj0hXLZbFw"
      decimals="-5"
      id="Narr_gowUNwQp_UenLBctRIMp6g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4800000</xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_Mb12fns7lUqrFQ2w0el0zg"
      decimals="INF"
      id="Narr_IqJOsUQwxkKfQIGjxuH6jg"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">8.93</us-gaap:SharePrice>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_o-7v8FV91E-0N0JxWotIhA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</xoma:CommonStockPremium>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      decimals="-5"
      id="Narr_3J3eYrJwe0CGhF_QaAhlkg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">438000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_JlCyW65-O0OyudJIFvxeLA"
      decimals="-5"
      id="Narr_x42Y0ZmcD0upuJe_cSQvTA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:NumberOfLicenseAgreements
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="INF"
      id="Narr_KjeEa--nOkSVuZiO5dcRoA"
      unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ">2</xoma:NumberOfLicenseAgreements>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_te1GtzkSyU6fPjsUE5D3EQ"
      id="Narr_jDEe-gi0N02EIywvWQ4-0Q">P6M</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:ArrangementsNumber
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="INF"
      id="Narr_TJtR6L0w_UeMxphchO5mow"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">1</xoma:ArrangementsNumber>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="INF"
      id="Narr_SaGltyEaSEmo4iILDYE7-w"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_spNgKpVzV0SFHWEoUU3GIw"
      decimals="-5"
      id="Narr_ySm_Y4b3IUuwwP7YT_OL7A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueRemainingPerformanceObligation>
    <xoma:LicenseAgreementTransactionPrice
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="-5"
      id="Narr_JW_5qHPFG0-DblEa377E7g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">40200000</xoma:LicenseAgreementTransactionPrice>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="-5"
      id="Narr_nD4JjVHh_USA9EJyYzkKNg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="-5"
      id="Narr_GFzXIp7W7ES6UdRMUmLz6g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="-5"
      id="Narr_TuMrtVjBM0WZKj5h92pwUw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</xoma:CommonStockPremium>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="INF"
      id="Narr_E7_ZDdmGUkaD2kHpvS6fbA"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:NumberOfPerformanceObligations>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg"
      decimals="INF"
      id="Narr_8fYlQmmk90izZhFLDogumg"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_D1p_zcUBUkyNi8tT3yY_hg"
      decimals="-5"
      id="Narr_-pAe7vetzEWsBgskI2NXcg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew"
      decimals="-5"
      id="Narr_WqbFT2s5x0OgH0Xz3z1YLQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg"
      decimals="-5"
      id="Narr_iMNEGpBSukqoPuvHo3AJ_w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_bGsEf8mRqUuf7Nhf_MAGew"
      decimals="-3"
      id="Narr_MPDQYL7HnkSroUtT-oiO9w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_Rqy6fpEObUSufnOp96A9tg"
      decimals="-3"
      id="Narr_1b_ZRS3ZLkW-n7ceNTPWaw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_2tva6vIdREy4CHVmhj6hXA"
      decimals="-3"
      id="Narr_z18UUwQGeU2wf5TMtx_9MQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_BU0vF3ofNkq6-z8Hkgq8qQ"
      decimals="-3"
      id="Narr_iZlLcj5W7kCdmFpYuiXaog"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_icqncM0pU0-kgas-GLplCw"
      decimals="-3"
      id="Narr_lNZ4l_qPVkaO5YJvbQxDvQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_qDUv8TEmVUiCki1cFKC_pw"
      decimals="-3"
      id="Narr_GkQdg9hBJUe9--tpiUBWeA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw"
      id="Narr_99jw6K1F2kyML9Mfsv6AMg">P180D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw"
      decimals="INF"
      id="Narr_swTNoatAnUW9jRjgeDXMDg"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">1</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_p6M7bhFzkEityaF4ZSk6kQ"
      decimals="-5"
      id="Narr_ExhvMTq2eUmqOi_bmk0HLg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">37000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GtNAno1Ke0iBcXqeK0kWoQ"
      decimals="-5"
      id="Narr_AyGTwnkRc0O-0fTN4rra8Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA"
      decimals="-5"
      id="Narr_EjqWqEleVUOU6Au4EhcrjQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">470000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw"
      id="Narr_FLY13KMXSEq8LcrO0Y4QQA">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow"
      decimals="-5"
      id="Narr_ZxH1RhYs4UKPlXKjBw13Wg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw"
      decimals="-5"
      id="Narr_CEEe4rDG7kmHUqYP1EVBZA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_kX4rw22WT0aL9TFPn575Ow"
      decimals="-5"
      id="Narr_5eOuxCyy5UOIXFzAMFCMSQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9_aWBfHFLU6J058hw1EByw"
      decimals="-5"
      id="Narr_p8gU-fHJrEmDcTWOLHmeJw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0nldtO9DMkyHVBM2GSo1qQ"
      decimals="-5"
      id="Narr_9KC11w0IuEqi_D3LhYSvXg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eIy62rKGB0arkcYOhjzDlQ"
      decimals="-5"
      id="Narr_UBF5sf2aR0WDZgXQik-n9w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7CqgFZqUQ0Cn3ykxSaEBeA"
      decimals="-5"
      id="Narr_vFwBpj0KSki9O3qvws6NOg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_lg0H9jEOVUWKuKkJPri6jw"
      decimals="-5"
      id="Narr_AFXBlq8OQEGuY49gfdDBXw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ"
      decimals="-5"
      id="Narr_0aGr4ChytEKCRq8zp2tvNw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg"
      decimals="-5"
      id="Narr_VfcmGJWzGEixJ-L14J-IZg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">232000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_AZu-zPSD80yvRwAj2LQiNg"
      id="Narr_b_RyZ7QntEO9dpBtwTKfSg">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_mQ-Twe7RO0Gh68dOSmYzIg"
      id="Narr_DlmDJ-S34keeJt3NnJ15uQ">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:PercentageOfDecreaseInFutureRoyaltyObligations
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q"
      decimals="2"
      id="Narr_TsIjHEE0nUSiPAHKt92q2w"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.20</xoma:PercentageOfDecreaseInFutureRoyaltyObligations>
    <xoma:UpfrontOptionPayment
      contextRef="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg"
      decimals="-5"
      id="Narr_osKBaroxqE6eUhIRmRM-iw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1000000.0</xoma:UpfrontOptionPayment>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_12_6_2017_To_6_1_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementX129Member_9eCaFclrT0u2N0U8p8c5yg"
      decimals="-5"
      id="Narr_PZN-7MHacE-qVvQd1CwpjA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">237000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_OuL4NdWL0U6jI7VT_8oP8Q"
      id="Narr_7SBSxR3Tw0evPp1O4-zeZw">P90D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ"
      decimals="-5"
      id="Narr_16EF_ONIAkOJV7AD6i1Wng"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:EligibleToReceiveInCash
      contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ"
      decimals="-5"
      id="Narr_xNXQko35HEqf-0nL2umRJQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">6000000.0</xoma:EligibleToReceiveInCash>
    <xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities
      contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ"
      decimals="-5"
      id="Narr_bjSB-ByqZkSlHH8B-oUbhQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities>
    <xoma:CommonStockSharesReceivable
      contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_B3GGaL3OVUmjsH1Oh6oysQ"
      decimals="INF"
      id="Narr_4YPhbbbq0UavHt5GJ5PI_A"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">7000000</xoma:CommonStockSharesReceivable>
    <xoma:GrossProceedsFromQualifiedFinancing
      contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ"
      decimals="-5"
      id="Narr_b-8rUjd3QUSC5hJcgFiY4w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">20000000.0</xoma:GrossProceedsFromQualifiedFinancing>
    <xoma:AdditionalCommonStockReceiveForQualifiedFinancing
      contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ"
      decimals="-5"
      id="Narr_eYbxdzmrhkGP0tqprm4X9w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:AdditionalCommonStockReceiveForQualifiedFinancing>
    <xoma:CommonStockThresholdTradingDays
      contextRef="Duration_3_1_2018_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_13tEE3shWU20pfOONFEvvQ"
      id="Narr_27vvtjJEd0ef_DqYE4DOHw">P10D</xoma:CommonStockThresholdTradingDays>
    <xoma:EligibleToReceiveInOrderToMaintainLicenseAgreement
      contextRef="Duration_4_1_2019_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nxvD1pY7ckS0UoRcs7ScvQ"
      decimals="-5"
      id="Narr_xAiUJN58YkK95FTMmHLPxQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15000000.0</xoma:EligibleToReceiveInOrderToMaintainLicenseAgreement>
    <xoma:NumberOfSharesRightAndOptionToSell
      contextRef="Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A"
      decimals="INF"
      id="Narr_t6XemsMsQEuvbHG0D9AOow"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5000000</xoma:NumberOfSharesRightAndOptionToSell>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_gPaYGyy2xkaDpvkBVLS-vA"
      decimals="-5"
      id="Narr_67ikfwrQ80KmvFVqhTibIw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:Revenues>
    <xoma:SharesReceived
      contextRef="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g"
      decimals="INF"
      id="Narr_mGxk5ODCqUKowLXEhNJm7g"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8093010</xoma:SharesReceived>
    <xoma:CashReceived
      contextRef="Duration_4_1_2018_To_4_30_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_KCqY-xsm00GcuJ-WXweR6g"
      decimals="-5"
      id="Narr_AmGrmeZ8hESQINLaX4eRPg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">500000</xoma:CashReceived>
    <xoma:ReimbursableTechnologyTransferExpensesReceived
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_90hIlWqbgUaomWenCQwomg"
      decimals="-5"
      id="Narr_-zpaw-1XpUmSwfHXGjKGYw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</xoma:ReimbursableTechnologyTransferExpensesReceived>
    <xoma:ArrangementsNumber
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="INF"
      id="Narr_Cdrc2ECGlkyRSnufEDp7ow"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">1</xoma:ArrangementsNumber>
    <xoma:UpfrontConsiderationToIncrementalDiscountForFuturePayment
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="-5"
      id="Narr_MVmTCVPVP0qUy0n8dG7Qbw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:UpfrontConsiderationToIncrementalDiscountForFuturePayment>
    <xoma:LicenseAgreementTransactionPrice
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="-5"
      id="Narr_sAO8MnvNIk6MhwJ9bUlN8g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1800000</xoma:LicenseAgreementTransactionPrice>
    <xoma:SharesReceived
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="INF"
      id="Narr_SxhFRfFX_k68dgBei_MkDw"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8093010</xoma:SharesReceived>
    <xoma:SharesReceivedValue
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="-5"
      id="Narr_6wv4CT07Zkmf5Pm3QUBOgA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1000000.0</xoma:SharesReceivedValue>
    <xoma:CashReceived
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="-5"
      id="Narr_KesWoQweQkiBCP0tt6Tomg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">500000</xoma:CashReceived>
    <xoma:ReimbursableTechnologyTransferExpensesReceived
      contextRef="Duration_4_3_2018_To_4_3_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bRFx8429dEmnAKLSVzOn4w"
      decimals="-5"
      id="Narr_KiqQ0h2P0kiFH2gLOSYnRQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</xoma:ReimbursableTechnologyTransferExpensesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_iK5dxlDC5kGuHLYJAFQjtQ"
      decimals="-5"
      id="Narr_257R2w7bQ0-J9tWUTePFBQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw"
      decimals="-5"
      id="Narr_HHjVG8rqQkegaalx6kuZ_w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:EligibleToReceiveCommonStockRelatedToFinancingActivities>
    <xoma:NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw"
      decimals="INF"
      id="Narr_w5VMONdkD0q6h3JSwWvydg"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">5</xoma:NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing>
    <xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw"
      decimals="-5"
      id="Narr_8ZVx-hAeUkinKPqGmRcF9g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing>
    <xoma:FutureCashPaymentsOfRevenueRecognized
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_eVulBzUmCkKYuR7HDbiMhg"
      decimals="-5"
      id="Narr_lXIxOrSmCUyD7HSMiyir9g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:FutureCashPaymentsOfRevenueRecognized>
    <xoma:PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing
      contextRef="Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw"
      decimals="2"
      id="Narr_KTjtUQgF8UueB8UXmmJudA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.15</xoma:PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing>
    <xoma:NumberOfSharesRightAndOptionToSell
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg"
      decimals="INF"
      id="Narr__HhSCjvHNkCwspRG-jkFog"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5000000</xoma:NumberOfSharesRightAndOptionToSell>
    <xoma:NumberOfSharesRightAndOptionToSell
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_qj2q9750f0eTH2ZT8YKEfQ"
      decimals="INF"
      id="Narr_Ka7QkRM--kaxVpDJ2jvuUA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2500000</xoma:NumberOfSharesRightAndOptionToSell>
    <xoma:QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg"
      decimals="-5"
      id="Narr_dm5r69D8GkWX_w6Uhndb2A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25000000.0</xoma:QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <xoma:ConsiderationPaidUponQualifiedFinancingEvent
      contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg"
      decimals="-5"
      id="Narr_jmT0hhqxYkK5apWU0mkGQg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5500000</xoma:ConsiderationPaidUponQualifiedFinancingEvent>
    <xoma:ReimbursableTechnologyTransferExpensesReceived
      contextRef="Duration_1_30_2019_To_1_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Yeyux0-OIUeOfaR06vNzdg"
      decimals="-5"
      id="Narr_qRL01lXUuEqe_sog6rKo5A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</xoma:ReimbursableTechnologyTransferExpensesReceived>
    <xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing
      contextRef="Duration_1_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_QGXGPdezx06vh-Y7VCyZzA"
      decimals="-5"
      id="Narr_DRqYQpgxFUGQOaXo2CbiSg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8500000</xoma:FutureCashPaymentsUponClosingOfQualifiedFinancing>
    <xoma:DoubtfulRevenueReversalOfFutureCashPayments
      contextRef="As_Of_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_D0iNeUKX6UmzP9knxvEqaQ"
      decimals="-5"
      id="Narr_5LIqZYiYz0yOv_tvRRKjTA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2500000</xoma:DoubtfulRevenueReversalOfFutureCashPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_3_1_2019_To_3_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_89o9tNvIJ0KB_EHx37NNug"
      decimals="-5"
      id="Narr_Ut4SO6_UfESw-9dxZ1U9-Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:AgreementNumberOfCommonStockFinancingEvents
      contextRef="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog"
      decimals="INF"
      id="Narr_O-c_vsGZZUCQXXHeEArGuQ"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:AgreementNumberOfCommonStockFinancingEvents>
    <xoma:EarlyPaymentOfUnrecognizedFutureCashPayments
      contextRef="Duration_7_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bMICDsWm3kiGhS6NGG-Pog"
      decimals="-5"
      id="Narr_YrYKichY0UOGwrGjQP-Lhw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3400000</xoma:EarlyPaymentOfUnrecognizedFutureCashPayments>
    <xoma:UnrecognizedFutureCashPayments
      contextRef="As_Of_6_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_Lk396fUAR0mQ7Bxv2PCf3w"
      decimals="-5"
      id="Narr_ia4B1TV7rE62sCZ44oFZEw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">6000000.0</xoma:UnrecognizedFutureCashPayments>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_9_30_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_J64v0Y9UbkWCwMWpG5hjQw"
      decimals="-5"
      id="Narr_0GOMQSbwsk-HbWrfP7NDcw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1500000</xoma:FutureCashPaymentsReceived>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA"
      decimals="-5"
      id="Narr_SfwG94ZdSEWQ0GJsnkRkJg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4900000</xoma:FutureCashPaymentsReceived>
    <xoma:DoubtfulRevenueReversalOfFutureCashPayments
      contextRef="As_Of_8_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_5lBpdkZpkEOX6-ywF04jcQ"
      decimals="-5"
      id="Narr_drRbnq2-_kGPmfxrAiUeZQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3600000</xoma:DoubtfulRevenueReversalOfFutureCashPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_zXRAwI0jgkS-v0ATnS7xYA"
      decimals="-5"
      id="Narr_cV6Jlmd_CUuNLMEhfiT3ug"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">6000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_10_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_RYA4JA0yrUCgyI6USQlccg"
      decimals="-5"
      id="Narr_u7UXltNrAU2DnEaJofxw5w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1000000.0</xoma:FutureCashPaymentsReceived>
    <xoma:FutureCashPaymentsOfRevenueRecognized
      contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w"
      decimals="-5"
      id="Narr_4xshLfgauEKdbuwE-E_zIA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2600000</xoma:FutureCashPaymentsOfRevenueRecognized>
    <xoma:FutureCashPaymentsOfRevenueRecognized
      contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w"
      decimals="-5"
      id="Narr_i3PIJNY5r0a3Jg8Jvucbpg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2600000</xoma:FutureCashPaymentsOfRevenueRecognized>
    <xoma:NumberOfQuarterlyPayments
      contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w"
      decimals="INF"
      id="Narr_SeRBt3rCtUWPKfHpMRFZXQ"
      unitRef="Unit_Standard_installment_7zKUzhL-x069Du3GTyKbRQ">7</xoma:NumberOfQuarterlyPayments>
    <xoma:PaymentPeriodFollowingClosingOfQualifiedFinancing
      contextRef="Duration_3_31_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mnLZtiAS2ECyKd514W2H0w"
      id="Narr_eFvZMBJGmUGPEP6EySZhAQ">P15D</xoma:PaymentPeriodFollowingClosingOfQualifiedFinancing>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_nFBHFZRpIkK4eK-sS_dY2w"
      decimals="-5"
      id="Narr_axxAAc9JAE2A1e8LA2nzmg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:FutureCashPaymentsReceived>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2020_To_3_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FWdasQOebUi4BvD0XzdauQ"
      decimals="-5"
      id="Narr_sqf9GD5kHUGf6mR6fL6d1g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</us-gaap:ProvisionForDoubtfulAccounts>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_bl4vMQZQ1UG2x7-nwv1Wxw"
      decimals="-5"
      id="Narr_iQ58UBL5ukKBycNvDmw1MQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:FutureCashPaymentsReceived>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_St9i97mas0e22erorbJ1jA"
      decimals="-5"
      id="Narr_0PhcWeK3HUq4etWm_irnTg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:FutureCashPaymentsReceived>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_ovP2h0yP-E6tctRS1ZBHeQ"
      decimals="-5"
      id="Narr_GXvSdURpekad9zvT3-BCYw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg"
      decimals="-5"
      id="Narr_s5WyiWEK0EODw10JAUC9lA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</xoma:FutureCashPaymentsReceived>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig"
      decimals="-5"
      id="Narr_r6uPcWkw0EGKekDR39QOfA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A"
      decimals="-5"
      id="Narr_JkYJGcnVg0KxedUqRaZpDg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_4L7JtzWm0UWp_NB6vu6Xig"
      decimals="-5"
      id="Narr_XGsfDc5af02XQtLN-BEh_w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_ZtfpqPYQeUiRk5M7rJlm5A"
      decimals="-5"
      id="Narr_EQX6bphJYkWSaQxlFSCEyA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_aDDtU1Gqbk2yENmRPLeZEA"
      decimals="-3"
      id="Narr_uipsTpfxYUSs55v_uBh4NA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IT6QiO78xka2AQOOc1LOTw"
      decimals="-3"
      id="Narr_UntnigL5hEaG9ZvjSAmGdQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:OneTimePayment
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA"
      decimals="-5"
      id="Narr_2jG8mh1Ykk2D9MX2HpF3Xw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2500000</xoma:OneTimePayment>
    <xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA"
      decimals="-5"
      id="Narr_CaNkHswdG0Of8Oo7o5iWEQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3000000.0</xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents>
    <xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA"
      decimals="4"
      id="Narr_ddxcv-idI0-TWp69P1rh6Q"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0075</xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27iut_LRX06eiWjddrdvbA"
      decimals="-5"
      id="Narr_9bw978Bb3U6b5LmksyFgeg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ"
      decimals="-5"
      id="Narr_PFvCXqI130O-wJDpuyfyqQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KvFcz6P2OkW-L8T8GssCxQ"
      decimals="-5"
      id="Narr_qQiNs5xUGkO0e48Hs-HEZA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Ly6c31YnNUudvyfVl4nIcQ"
      decimals="-5"
      id="Narr_cWH6euorlUOHBfZfUmS8IQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents
      contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg"
      decimals="-5"
      id="Narr_wkS3O97diUqSmr4nGUGgEQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">500000</xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents>
    <xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones
      contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg"
      decimals="-5"
      id="Narr_6rZAkvZTzkCFfAS9NcspbQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">23500000</xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg"
      decimals="INF"
      id="Narr_-dFSbnp1aU6GgNJd4OywVw"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">1</xoma:NumberOfPerformanceObligations>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw"
      decimals="-5"
      id="Narr_TkpDrOY-10GeeZRx6YaGDQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IrwtAc8F2UC_We9byklKKw"
      decimals="-5"
      id="Narr_-YDUHvsI20GviZeHZLZmag"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UyMAk0h1pkWFrzI4SV59gQ"
      decimals="-5"
      id="Narr_p1ew4G_1JkiVtq-5lvkjOg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WNBaxopPiUiO0lekbTR3QA"
      decimals="-5"
      id="Narr_0aclRq365kGBwh-kLje9_w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:MaximumRevenueFromContract
      contextRef="As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ"
      decimals="-5"
      id="Narr_LhfLnLWgY0e_W_Vyd8Gg0Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">64800000</xoma:MaximumRevenueFromContract>
    <xoma:ContractualTerm
      contextRef="Duration_9_1_2008_To_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_QfxCyr376USWRtXD17lOFQ"
      id="Narr_EFyhKraXhU-GzQ_h0i57Mg">P3Y</xoma:ContractualTerm>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg"
      decimals="-5"
      id="Narr_pkqqZGHlVkCcArD5t6dlbA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2014_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_T6Au_IFIQUyyU7MJLdMyTg"
      decimals="-5"
      id="Narr_itvN6N30v0CRWDhJRlPOJg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">800000</us-gaap:ContractWithCustomerLiability>
    <xoma:ContractsRevenueWroteOff
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_82L3K22qB0OdI0xUjjPm3A"
      decimals="-5"
      id="Narr_FW6l7jJP_UGl-Vcq_hCO3w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:ContractsRevenueWroteOff>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_RE1e6CumO0O-2KGTFiCqsA"
      decimals="-5"
      id="Narr_T9qaVkFc8EK63hvxbxvwGA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_UmYPv4uBU0-L1_gmyTWzwQ"
      decimals="-5"
      id="Narr_fjQoQAzhwUCv8JxrhLgDhg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">800000</us-gaap:ContractWithCustomerLiability>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q"
      decimals="INF"
      id="Narr_IY-oiCHtZk6_-I42xb79UQ"
      unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_uYjlieKTNEqKshJwUd9daQ"
      decimals="-5"
      id="Narr_cIEhSn5dOEy6LdLvdaTu3w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">6500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA"
      decimals="-5"
      id="Narr_KbSM20fMYEWZvw1p0GMoqw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4000000.0</xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones>
    <xoma:MilestonePeriodsNumber
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ANxU18hqMU2r3_weP1C1OA"
      decimals="INF"
      id="Narr_qtfCZLVYE0uhZ5zaRx6Ohw"
      unitRef="Unit_Standard_period_AqtsOpMfTku-KpzgyKR7UQ">3</xoma:MilestonePeriodsNumber>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_bcq3GNUerEmVGRoYfGrnYw"
      decimals="-5"
      id="Narr_8lP0e8y3eU-PBWAkIJFj5g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">11500000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q"
      decimals="-5"
      id="Narr_wp9lPlT0EkCvroa4sIDo4g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">18000000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_0uPI2yU0iUS8hyjvd1t3XA"
      decimals="INF"
      id="Narr_sAiRxykmz0Gg96zYpZBRAw"
      unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_bsRXsMH6rEOZqpfaU8z-Yw"
      decimals="-5"
      id="Narr_NUZ2Wm4-3EijALJNE7gYHg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_HlFFyZp90EKVNXtLD7WtKQ"
      decimals="-5"
      id="Narr_3rzcLnsUVEW8Hew79TLCqQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_hayCoIN1Nki93_kbNGtPnQ"
      decimals="-5"
      id="Narr_s0HGiwDMdEWSyaztwphrfw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_9DVd9snmb02Tp8DZcf-2Yw"
      decimals="-5"
      id="Narr_bcvuuhs8kkiM1HizsvB4aw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">800000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ"
      decimals="-5"
      id="Narr_yrRJWPYy9UuUh_ZhOeCDhA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_Kpv22Rice0Ca3aBBFtC8VQ"
      decimals="-5"
      id="Narr_UOIt_bYNM0q18Pp3V1cvbg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14000000.0</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-5"
      id="Narr_FV5DviRRfkOZTE8uAkP80A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1100000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="-5"
      id="Narr_ZDor1JHBAkGzdXUcaNZHZA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15300000</us-gaap:DeferredIncomeNoncurrent>
    <xoma:RoyaltyPurchaseAgreementTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_QsV4olzarEi4hFDXtHk4Jw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Royalty Purchase Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Purchase Agreement with Agenus,&#160;Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;20, 2018, the Company entered into a Royalty Purchase Agreement (the &#x201c;Agenus Royalty Purchase Agreement&#x201d;) with Agenus,&#160;Inc., and certain affiliates (collectively, &#x201c;Agenus&#x201d;). Under the Agenus Royalty Purchase Agreement, the Company purchased from Agenus the right to receive 33% of the future royalties on six Incyte immuno-oncology assets, currently in development, due to Agenus from Incyte Europe Sarl (&#x201c;Incyte&#x201d;) (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low-single to mid-teen digit&#160;percentage of applicable net sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company purchased from Agenus the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck Sharp&#160;&amp;amp; Dohme Corp. (&#x201c;Merck&#x201d;) and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single digit&#160;percentage of applicable net sales. Pursuant to the Agenus Royalty Purchase Agreement, the Company&#x2019;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Royalty Purchase Agreement, the Company paid Agenus $15.0 million. The Company financed $7.5 million of the purchase price with a term loan under its Loan and Security Agreement with Silicon Valley Bank (&#x201c;SVB&#x201d;) (Note&#160;8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the condensed consolidated balance sheets. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected.&#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Purchase Agreement with Bioasis Technologies,&#160;Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;25, 2019, the Company entered into a Royalty Purchase Agreement (the &#x201c;Bioasis Royalty Purchase Agreement&#x201d;) with Bioasis Technologies,&#160;Inc. and certain affiliates (collectively &#x201c;Bioasis&#x201d;). Under the Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. The Company exercised its option under the Bioasis Royalty Purchase Agreement and entered into a second royalty purchase agreement with Bioasis on November 2, 2020, as discussed in Note 14, Subsequent Events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Bioasis Royalty Purchase Agreement, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#x201c;Bioasis Contingent Consideration&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income. As of September 30, 2020, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the three and nine months ended September 30, 2020. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Purchase Agreement with Aronora,&#160;Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April&#160;7, 2019, the Company entered into a Royalty Purchase Agreement (the &#x201c;Aronora Royalty Purchase Agreement&#x201d;) with Aronora,&#160;Inc. (&#x201c;Aronora&#x201d;), which closed on June&#160;26, 2019. Under the Aronora Royalty Purchase Agreement, the Company purchased from Aronora the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#x201c;Non-Royalties&#x201d;) related to five anti-thrombotic hematology drug candidates. Three candidates are subject to Aronora&#x2019;s collaboration with Bayer Pharma AG (&#x201c;Bayer&#x201d;) (the &#x201c;Bayer Products&#x201d;), including one which is subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties from these Bayer Products. The other two candidates are unpartnered (the &#x201c;non-Bayer Products&#x201d;) for which the Company will receive low-single digit&#160;percentage of net sales and 10% of Non-Royalties. The future payment&#160;percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#x2019;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Aronora Royalty Purchase Agreement, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September&#160;1, 2019 (up to a total of $3.0 million, the &#x201c;Aronora Contingent Consideration&#x201d;). Pursuant to the Aronora Royalty Purchase Agreement, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#x201c;Royalty Milestones&#x201d;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September&#160;2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Purchase Agreement with Palobiofarma, S.L.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;26, 2019, the Company entered into a Royalty Purchase Agreement (the &#x201c;Palo Royalty Purchase Agreement&#x201d;) with Palobiofarma, S.L. (&#x201c;Palo&#x201d;), a company organized and existing under the laws of Spain. Pursuant to the Palo Royalty Purchase Agreement, the Company acquired the rights to potential royalty payments in low single digit&#160;percentages of aggregate Net Sales (as defined in the Palo Royalty Purchase Agreement) associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#x2019;s lymphoma, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#x201c;Palo Licensed Products&#x201d;) that are being developed by Palo. Novartis (the &#x201c;Licensee&#x201d;) is a development partner on NIR178, one of the Palo Licensed Products, and such NIR178 is being developed pursuant to a license agreement between Palo and the Licensee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Palo Royalty Purchase Agreement, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties&#x2019; entrance in the Palo Royalty Purchase Agreement on September&#160;26, 2019. The Company financed $5.0 million of the payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its condensed consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There was no change in the acquired royalty rights during the nine months ended September 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:RoyaltyPurchaseAgreementTextBlock>
    <xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ"
      decimals="INF"
      id="Narr_BGb-iMqfnkC7PsBVD921Og"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.33</xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts>
    <xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ryahLRb460WZ_uEMdm-Gdg"
      decimals="INF"
      id="Narr_sjRxMdJGv0KwinxOp5ArIQ"
      unitRef="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg">6</xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_tleLtCkiSEeEKyMstiPemQ"
      decimals="INF"
      id="Narr_EcZeyG2sRUiroMriJFedIQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA"
      decimals="INF"
      id="Narr_4jH5Ny-cVUOL7Mkyoe8Zqg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.33</xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__WXCDIjxAEG8uTDk2KCBXA"
      decimals="INF"
      id="Narr_wAQJtXvaTU-XYegX4LpDvA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pyJIa2rRckSbu4tMGZ7OQQ"
      decimals="-5"
      id="Narr_k5DWSUfUdUm4tvr-SqD0UQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">59500000</xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRights
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gkqI07hkKE2Ouf8ac3CdpQ"
      decimals="-5"
      id="Narr_X8eRQdDC2EmCvb4dK51MDQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15000000.0</xoma:PaymentsRelatedToPurchaseOfRoyaltyRights>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7r0aHlZReUi3PqLdTuvGMA"
      decimals="-5"
      id="Narr_NTORXbhBgEyPhqT21TEqFg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">7500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sQZl0NJ6VEitMJ9UCcOjeg"
      decimals="-5"
      id="Narr_j3i8NvNJ9kyGOjRST9nJMQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15000000.0</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_y28H4G623kys0zqGl3uk7w"
      decimals="-3"
      id="Narr_RDnEYpMWKUuRMl_SvjnhHg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"
      decimals="INF"
      id="Narr_Hr4qg9_FykCqLkK1uW9AvA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.01</xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements>
    <xoma:NumberOfLicenseAgreementsFutureLicenseAgreements
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g"
      decimals="INF"
      id="Narr_Bz9I7eEpE026cXbOjo9Y-w"
      unitRef="Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ">2</xoma:NumberOfLicenseAgreementsFutureLicenseAgreements>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"
      decimals="-5"
      id="Narr_tAPP-1Mcb0mRijy20mqU6A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g"
      decimals="-5"
      id="Narr_ZCIuJ_PSW0Gjd05ShkvReQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRights
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_uI8bN9V-YES3I925tP9o4g"
      decimals="-5"
      id="Narr_MYC8Q5Ee0EWCquO4_QUgTA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRights>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XaAWLwY770yBqnJd66HkrA"
      decimals="-5"
      id="Narr_o_gN8QwiwUSihGDh7gHyog"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</xoma:ContingentFutureCashPayments>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"
      decimals="-5"
      id="Narr_YWdbGIzcvEmWXqAP43Lc9A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"
      decimals="-5"
      id="Narr_QTl6cug1CEmvMTBc7Twvqg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Narr_M48lvclytkyWBoec9fnaiw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Narr_e004-KpvmUOHItxIk0xYTA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:PaymentsOfContingentConsideration>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Narr_UIMGBcGDik68agKfOHxJZQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:PaymentsOfContingentConsideration>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vF4M7itcq0qmDA1FQGsWbQ"
      decimals="-3"
      id="Narr_EwV3jwrFU0Gg2tPa67J8Fw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="INF"
      id="Narr_Kcay_nvAKUWvcRjnEQJI7A"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">5</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="INF"
      id="Narr_D1gC2lhfx0qVXmRcFhR-zw"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="INF"
      id="Narr_TsTwUUcnEEycMhv3te8Jfw"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">1</xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber>
    <xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="INF"
      id="Narr_3Yx7Q2hwQ0K-9RdbtcVLtg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">1</xoma:PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="INF"
      id="Narr_es0odPiiU02lGlh1BE5XEw"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg"
      decimals="INF"
      id="Narr_-WKfBKxzcka-ic8QaaBjIA"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1Wh0W5D8kEaK_8zeU5dUtg"
      decimals="INF"
      id="Narr_cHvz_PuoaUeoaKjRtK5Q_w"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="INF"
      id="Narr_iLde9wOT4UqpV5L6mHipXQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="INF"
      id="Narr_I8HRKy3QhEGLBRBfm3h6rQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.05</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage>
    <xoma:AgreementPaymentPercentageFactor
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="INF"
      id="Narr_lGDLcw4IvkWqeS7ucrLoOg"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:AgreementPaymentPercentageFactor>
    <xoma:UpfrontPayment
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"
      decimals="-5"
      id="Narr_3CJVa3OdmEey0x0Hv-fjFA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">6000000.0</xoma:UpfrontPayment>
    <xoma:UpfrontPayment
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VvqL6IhpekWtsweye5jZRQ"
      decimals="-5"
      id="Narr_X5CiLeJ7QkySpU83gTfc4w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3000000.0</xoma:UpfrontPayment>
    <xoma:ContingentFutureCashPaymentsPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VjJ154auA0SD0BIHuZfOvg"
      decimals="-5"
      id="Narr_5J_qAJJ4G0KqUAFK-z5Xmw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1000000.0</xoma:ContingentFutureCashPaymentsPerProduct>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="INF"
      id="Narr_UimzKnANrUeP02FaPPAZsw"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rTRblFattEOEraVi0Jax4g"
      decimals="-5"
      id="Narr_R7OhBSKDi0Gk_mrTQIlZLg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3000000.0</xoma:ContingentFutureCashPayments>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"
      decimals="-5"
      id="Narr_DkVcYwI3W0yua5UY2yqJAA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:MilestonesPaymentsToAggregateAmountOfPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"
      decimals="-5"
      id="Narr_SqKzSQBnUE6VWzb6n82D5Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">85000000.0</xoma:MilestonesPaymentsToAggregateAmountOfPerProduct>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"
      decimals="-5"
      id="Narr_xO376R2SK0-XJ1FOLuSHuA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ypEe-DYs2kaWTOJFBNJzDg"
      decimals="-5"
      id="Narr_ccAIvMKei0GwfchdcFVSDA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="-5"
      id="Narr_iY3EYtQNHEKvPZS03Rr3hQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9000000.0</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg"
      decimals="-5"
      id="Narr_d5o9JspLMUmC1rFBVUkoqQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3000000.0</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_WQB1V7-nwkm5651laM-Szg"
      decimals="-5"
      id="Narr_WzWsAqmdl0epVWXAYDHERg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3000000.0</xoma:PaymentsOfContingentConsideration>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA"
      decimals="-3"
      id="Narr_N9khy0o2k0a5BtGmnFEpfA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q"
      decimals="INF"
      id="Narr_hDAQbLRLn0uft3SKdpWdyA"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">6</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRights
      contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_O7QrlKu98UGAIfv-vA1UQA"
      decimals="-5"
      id="Narr_Al44A92RbUW_tEV1m0r0zA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000000.0</xoma:PaymentsRelatedToPurchaseOfRoyaltyRights>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_JkbgTe29GU66NJfrMM3fWw"
      decimals="-5"
      id="Narr_AFd45TTPUU6wsWgOcIf7Og"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <xoma:LongTermRoyaltyReceivableNonCurrent
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ro0ml19sxUyaWEuCtjcR3Q"
      decimals="-5"
      id="Narr_eCM8TQzKbkCAjtWnLVha4g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">10000000.0</xoma:LongTermRoyaltyReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_9qNUOmhml0CM6tQxIvq-zQ"
      decimals="-3"
      id="Narr_tN3cwMXBBkqNw0Sd09vZHA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:LongTermRoyaltyReceivableNoncurrentIncreaseDecrease
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-5"
      id="Narr_VrCh6VQtBkWy0o6UodR7kw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:LongTermRoyaltyReceivableNoncurrentIncreaseDecrease>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb__0U_gpDk-kCCdOIs2NnBxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Level 1&#160;&#x2013; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Level 2&#160;&#x2013; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;September&#160;30,&#160;2020 Using &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the three and nine months ended September 30, 2020, there were no transfers between Level 1, Level 2, or Level 3 assets reported at fair value on a recurring basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table provides a summary of changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets for the nine&#160;months ended September 30, 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 2,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The equity securities consisted of an investment in Rezolute&#x2019;s common stock and are classified as long-term assets on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019. The equity &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, the Company and its valuation specialist valued the equity securities using the closing price for Rezolute&#x2019;s common stock traded on the over-the-counter exchange and adjusted for an illiquidity discount. The inputs used to calculate the illiquidity discount are based on observable and unobservable estimates and judgments and therefore is classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 5,000,000 shares of Rezolute&#x2019;s common stock back to Rezolute after December&#160;31, 2019 (Note&#160;4), the fair value of the equity securities was determined by dividing the total shares of Rezolute&#x2019;s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The estimated fair value of the equity securities was calculated based on the following assumptions as of September 30, 2020 and December 31, 2019:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Closing common stock price on the Over-the-counter (OTC) exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tranche 1:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount for lack of marketability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated time to liquidity of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tranche 2:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount for lack of marketability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated time to liquidity of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingent Consideration&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the contingent consideration liability at the inception of the Bioasis Royalty Purchase Agreement represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income until settlement. As of September 30, 2020, there were no changes in the estimated fair value of the contingent consideration from its initial value of $0.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The estimated fair value of the Company&#x2019;s outstanding debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company&#x2019;s outstanding long-term debt at September 30, 2020 and December&#160;31, 2019, are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Novartis note&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,220&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,217&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,903&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;SVB Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,952&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,939&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,277&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_TynZyC4v9kSj4afMOWDDdQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;September&#160;30,&#160;2020 Using &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019 Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 681&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA"
      decimals="-3"
      id="Tc_7vluZRyn3EG19YRqZujFCA_7_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2572000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g"
      decimals="-3"
      id="Tc_NZ76NBaB_0y2MjpU9Q0l7A_7_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2572000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7zZTMVOXzkSA4ABym2DaeA"
      decimals="-3"
      id="Tc_Ih1tCg_XVka7xnO8X-0CDg_9_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_48iwPG2OYk6uiZqDXGMI3g"
      decimals="-3"
      id="Tc_g4eH-tzgyU2c-Eh87vqJbA_9_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g"
      decimals="-3"
      id="Tc_CbIjab0kOEaLSa_vn1zUkg_7_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">681000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA"
      decimals="-3"
      id="Tc_m1dgDmpsKE6LJj1m-wthpA_7_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">681000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HqEC2Yk8j0GTPddlvVWM8g"
      decimals="-3"
      id="Tc_Uf7LL-0djUiRPVIZwsOEcQ_9_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_WCSBMxJFqEyOdqxJtZ65mA"
      decimals="-3"
      id="Tc_0j1yPMQpV02qxb1MdLflxA_9_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_qXXV3-xptE2HBIbw0WFQ2w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_iD37CMA98UWPaz3IhsTeUw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_4M3yFOkjVkebbww0pQytcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table provides a summary of changes in the estimated fair value of the Company&#x2019;s Level 3 financial assets for the nine&#160;months ended September 30, 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;br/&gt;September 30, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at September&#160;30,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 2,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <xoma:NumberOfSharesRightAndOptionToSell
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_6F-n32ayokuaGfQg16rBDg"
      decimals="INF"
      id="Narr_BE2UCK4WpkGnKdBDnh4ZJA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5000000</xoma:NumberOfSharesRightAndOptionToSell>
    <xoma:EquitySecuritiesNumberOfTranches
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_1Myp4OOGqEKp2h3UVxadrQ"
      decimals="INF"
      id="Narr_Wqz5Y-sAME6m3n6zE8FxTQ"
      unitRef="Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA">2</xoma:EquitySecuritiesNumberOfTranches>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Group_6bDbIXWziE-m5RxTKdwmTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The estimated fair value of the equity securities was calculated based on the following assumptions as of September 30, 2020 and December 31, 2019:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Closing common stock price on the Over-the-counter (OTC) exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.12&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tranche 1:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount for lack of marketability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated time to liquidity of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tranche 2:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount for lack of marketability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Estimated time to liquidity of shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.25 year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.5 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_9_30_2020_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_T9kkdRE5TU2GA0x-StB7yA"
      decimals="2"
      id="Tc_0XO3ukYHD0WRtSJidqik6g_3_3"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.43</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2019_dei_EntityListingsExchangeAxis_exch_OTCM_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_QbXdq24V_UuHONHKjjaZgA"
      decimals="2"
      id="Tc_qqoaEWc220iX_1UxZH_Prg_3_6"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">0.12</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_myPVpetgYkKI3zoBMnb_yQ"
      decimals="2"
      id="Tc_6KxVWGfS6kCBdBL0BCBL5g_6_3"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.12</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_0OemnNunTEaN1i6wIdopTg"
      decimals="2"
      id="Tc_BMTKv24W2ESwJIDLlz5rYw_6_6"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.13</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2SoVfK-psE-uIiixwmUMVw"
      decimals="2"
      id="Narr_8IJ2JhOUtECp37HidZQ0GQ"
      unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw">0.25</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheOneMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_-CVgtfFe3U6W6zb4Ddth-Q"
      decimals="2"
      id="Narr_C4lBYWC0_kmUmSqW5bvQ2g"
      unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw">0.25</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_v4syz3rvHkSx0GCd0zfa9g"
      decimals="0"
      id="Tc_YOyq2Xl9EU-AcYg1QGptyw_10_3"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">33</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_mI7JO_tljkCY56R1erZxTA"
      decimals="2"
      id="Tc_uAZNJoUw90O3pNuaqWLGqw_10_6"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.33</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_9_30_2020_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_qrgth34a6EattwAKv19FyA"
      decimals="2"
      id="Narr_B-cc9sjV3k2AYIiRE1ZpCA"
      unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw">1.25</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2019_us-gaap_FinancialInstrumentAxis_xoma_EquitySecuritiesTrancheTwoMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_RyfA1p37m0mqf8zUp_nppA"
      decimals="1"
      id="Narr_AUcHeS3060mMsvnq6Mw3cg"
      unitRef="Unit_Standard_Y_Qlk2ioNsbkaScAfCuMPQzw">1.5</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-5"
      id="Narr_R4AZEdhEpEGxZIZMc6Uo8Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_1Or-vK8pAk-kXLbZm6VxCA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Group_oDlb99GiY0yR03iQ16KnCA">The carrying amount and the estimated fair value of the Company&#x2019;s outstanding long-term debt at September 30, 2020 and December&#160;31, 2019, are as follows (in thousands):&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&#160;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Novartis note&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,220&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,217&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,903&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;SVB Loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,722&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,952&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,939&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,277&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-qZT9POIkCNrG3Grph7dg"
      decimals="-3"
      id="Tc_Zn2LP-dJd0-0TbaJozOGTA_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16220000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_fc2DGhmLsU-P9b9i3fCa3A"
      decimals="-3"
      id="Tc_6IeORmpBxUyReQ1kW3QhSA_3_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16217000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_j3P1UZ7onkKj9MeRA1L4Pw"
      decimals="-3"
      id="Tc_9M8kT46BAUG7zogpnOkIew_3_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15903000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_WZsCIx7v_0eJCosFrT_7PA"
      decimals="-3"
      id="Tc_3tnQIXcfxE-vz-7wRI49PQ_3_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15713000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ROF4dELbnEKrkSBAq5Id-w"
      decimals="-3"
      id="Tc_D568Fgr_u0CRPvg6BlYr_A_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13732000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_BvERxoSpn02VGxEAbYiLDw"
      decimals="-3"
      id="Tc_Z7zk9OjKH0KkNfjbn9dbsA_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13722000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_K5wO4sN8QkaBiKw6ZJuixQ"
      decimals="-3"
      id="Tc_s3roxe4yPUqG5XitFy5c4A_4_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16374000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_a30zLf3tz0OUKijReg49Jw"
      decimals="-3"
      id="Tc_sJIoNlXyMkSZEOjURnwfsw_4_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16048000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg"
      decimals="-3"
      id="Tc_IGuFXYX0RUWck1rS6sTCig_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">29952000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_o9TKgo2PdkaRxCnPv5UwzQ"
      decimals="-3"
      id="Tc_ner7uawVnkO6xIEFSfPIKA_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">29939000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_g-_VDIVr4EyNvxmIlDGnMQ"
      decimals="-3"
      id="Tc_zW28y0bK-Eezgwbisw2vpw_5_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">32277000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="As_Of_12_31_2019_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qRuzS7PxN0mhOpigbZVLcA"
      decimals="-3"
      id="Tc_lKTHW5BR0Eub8dxNVUHVmw_5_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">31761000</us-gaap:LongTermDebtFairValue>
    <xoma:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_i-0v0ZRrwUiJ4g8U77ccfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7. Lease Agreements &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases one facility in Emeryville, California under an operating lease that expires in February&#160;2023. The Emeryville lease contains an option to early terminate the lease by notifying the landlord on or before February 1, 2020, which expired unexercised. The lease also contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also previously leased two facilities in Berkeley, California under operating leases that had remaining lease terms until 2021 and 2023. On December 18, 2019, the Company entered into a Lease Termination Agreement (&#x201c;the Lease Termination&#x201d;) with each of the 7&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; Street Properties II (&#x201c;7&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; Street LP&#x201d;) and 7&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; Street Property General Partnership (&#x201c;7&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; Street GP&#x201d;) to early terminate the Company&#x2019;s two operating leases in Berkeley, California. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company agreed to pay an early termination fee of $1.6 million in total and recognized a loss on lease termination of $0.4 million for the year ended December 31, 2019, which was included in other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;The following table summarizes maturity of the Company&#x2019;s operating lease liabilities as of September 30, 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Undiscounted lease payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2020 (excluding nine months ended September 30, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total net lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating leases for the three and nine months ended September 30, 2020 and 2019 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The present value assumptions used in calculating the present value of the lease payments as of September 30, 2020 and December 31, 2019 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.42 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Sublease Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the Company&#x2019;s rights and obligations under its sublease arrangements transferred to 7th Street LP and 7th Street GP, and the Company was released from all financial obligations under its sublease agreements. Upon termination, the Company recognized a loss on lease termination of $0.4 million in other income (expense).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"&gt;No sublease income was recognized for the three and nine months ended September 30, 2020 due to the termination of the sublease agreements in 2019. For the three and nine months ended September 30, 2019, the Company recognized $0.8 million and $2.4 million of sublease income under these sublease agreements in other income (expense). &lt;/p&gt;</xoma:LeaseDisclosureTextBlock>
    <xoma:OperatingLeasesNumberOfLeasedFacilities
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_H1Cj_SIgjkCN0aYFMFbweg"
      decimals="INF"
      id="Narr_OU9_TNPcMUWClfC3otJ64Q"
      unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw">1</xoma:OperatingLeasesNumberOfLeasedFacilities>
    <xoma:OperatingLeasesNumberOfLeasedFacilities
      contextRef="Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ"
      decimals="INF"
      id="Narr_xTMVYVgezk-AWRzpvnwu3A"
      unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw">2</xoma:OperatingLeasesNumberOfLeasedFacilities>
    <xoma:OperatingLeasesEarlyTerminationNumberOfLeasedFacilities
      contextRef="As_Of_12_18_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_mi0xAnsFn0qDd9-F2V5_PQ"
      decimals="INF"
      id="Narr_sat_l18ek0ubWgvy9wI-vA"
      unitRef="Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw">2</xoma:OperatingLeasesEarlyTerminationNumberOfLeasedFacilities>
    <xoma:OperatingLeaseEarlyTerminationFee
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ"
      decimals="-5"
      id="Narr_7o5k6u-p00iyxYez8AHiPw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1600000</xoma:OperatingLeaseEarlyTerminationFee>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ"
      decimals="-5"
      id="Narr_IYIaZi3hc0mdnIEjAUsY6Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-400000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_AphBERHUkU6DnOUyFSq1Kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"&gt;The following table summarizes maturity of the Company&#x2019;s operating lease liabilities as of September 30, 2020 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Undiscounted lease payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2020 (excluding nine months ended September 30, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value adjustment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total net lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_aEQb2LbdWUOlF43ksjnvoQ_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">47000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_TdoFJHiDDU68jjzGVrCC_w_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">196000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_WBe0DgEQgkmBE_CP9p2Q-w_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">202000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_kgl_oMUwXUCFVsF8KuTRMA_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">35000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_rOvCZqqGE0CK0CoFzSmqUg_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_A8z_7FSMCEu7H45iF-2hqw_9_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">30000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_4cKWI1oFuEyCfWDDOq4dMA_10_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">450000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_QamgyfoH-kS-BWNAksuCRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating leases for the three and nine months ended September 30, 2020 and 2019 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 595&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 375&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,151&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_hx2a6SyEwk-v27C4-3GjaA_4_2"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">44000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_exuRdGYirEKPg95aa5YXJA_4_5"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">595000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_-HPsGuimB0yH8uy34wKUdw_4_8"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">133000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_OzAxwcDyEESQLsLDC705HA_4_11"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1805000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_4r3v9Ww9akGoFx2nxB7mUA_5_2"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_WUGKymQWc0GM_yIcZFI6eg_5_5"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">375000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_OR4hlE5W20a6a8obo3ds2A_5_8"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_pfGEm6BvdEeZdosSx1OwDA_5_11"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1346000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_TFd8n6kZzUqBC6MIPgDF1g_6_2"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">46000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_no8pCXzR80a6M9esssixig_6_5"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">970000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_tbdbk3BkUkCsxfkv3SBm-A_6_8"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">138000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_BevrCP0ZQkqMZPBT7GV06A_6_11"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3151000</us-gaap:LeaseCost>
    <xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb__WXPmIonRE6IPU0b8iKtaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_qJAx2Pj7iUeUH7NnOEfr7g_4_2"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">141000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_gU-7GsrwWkShxxnvygB_cA_4_5"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1975000</us-gaap:OperatingLeasePayments>
    <xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_gEkSe5--IkOfTIIGrjXseA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average remaining lease term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2.42 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted-average discount rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      id="Narr__xPsCPGfl0yoNGwaZLNEcA">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      id="Narr_8WoJnWA4pEqaplU6J9Zq9A">P3Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="4"
      id="Tc_-0K2aATdQES_frCsP6UxKg_6_2"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="4"
      id="Tc_Ox5uK-NXrEqNwuzNaGmmnA_6_5"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ"
      decimals="-5"
      id="Narr_2LwO7PhoPUGF73szT62DNg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-400000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_2CZITBcVHU-Wgwh02jgIcw"
      decimals="-5"
      id="Narr_yDKNwGDQ80uxHaWqnNYQuQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_ym6GLGOCy0yMN7HEESO78g"
      decimals="-5"
      id="Narr_KSlPkjeNpE2FeuT7zHAAbA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_MLU4k6KwO0e9m_Pf_os80w"
      decimals="-5"
      id="Narr_UzPTwYIouUiqZmVjsPJD4w"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">800000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_HrZIHs7O0UmWnhE2ICmFRg"
      decimals="-5"
      id="Narr_OAEpYxTMBUG6YJGiUPXDcw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2400000</us-gaap:SubleaseIncome>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_dQ7HISmhAESIQch4GZlAjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Long-Term Debt and Other Financings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;"&gt;Silicon Valley Bank Loan Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;7, 2018 (the &#x201c;Effective Date&#x201d;), the Company executed a Loan and Security Agreement (the &#x201c;Loan Agreement&#x201d;) with SVB. Under the Loan Agreement, upon the Company&#x2019;s request, SVB may make advances (each, a &#x201c;Term Loan Advance&#x201d;) available to the Company up to $20.0 million (the &#x201c;Term Loan&#x201d;). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March&#160;31, 2019 or an event of default (the &#x201c;Draw Period&#x201d;). In March 2019, the Draw Period was extended from March&#160;31, 2019 to March&#160;31, 2020. As of March 31, 2020, the Loan Agreement has not been amended to extend the Draw Period further. In the event of a default related to the Note&#160;Agreement with Novartis, SVB&#x2019;s obligation to make any credit extensions to the Company under the Loan Agreement will immediately terminate. The interest rate will be calculated at a rate equal to the greater of (i)&#160;4.75%, or (ii)&#160;0.25% plus the prime rate as reported from time to time in The Wall Street Journal.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal&#160;monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i)&#160;the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii)&#160;March&#160;1, 2023, or (iii)&#160;30 days prior to the earliest maturity of any portion of the Company&#x2019;s loan with Novartis (the &#x201c;Loan Maturity Date&#x201d;). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The entire principal balance, including a final payment fee equal to 8.5% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to 3.00% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, 2.00% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and 1.00% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. In the event of a default, a default interest rate of an additional 4% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the &#x201c;Warrant&#x201d;). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;4, 2019, the Loan Agreement was amended to extend the Draw Period from March&#160;31, 2019 to March&#160;31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, both warrants are outstanding. In addition, both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus Royalty Purchase Agreement (Note&#160;5). The Company recorded a discount of $0.3 million against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora Royalty Purchase Agreement, Palo Royalty Purchase Agreement and payment of the Aronora Contingent Consideration (Note&#160;5). The Company recorded a discount of $45,000 against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $0.2 and $0.5 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three&#160;and nine months ended September 30, 2020, respectively. The Company recorded $0.2 million and $0.4 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three and nine months ended&#160;September 30,&#160;2019, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, the carrying value of the debt under the Loan Agreement was $13.8 million. Of this amount, $9.0 million is classified as current portion of long-term debt and $4.8 million is classified as long-term debt on the condensed consolidated balance sheet. As of December&#160;31, 2019, the carrying value of the debt under the Loan Agreement was $16.4 million. Of this amount, $5.2 million was classified as current portion of long-term debt and $11.2 million was classified as long-term debt on the condensed consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Novartis Note&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2005, the Company executed a secured note agreement (the &#x201c;Note&#160;Agreement&#x201d;) with Novartis, which was due and payable in full in June&#160;2015. Under the Note&#160;Agreement, the Company borrowed semi-annually to fund up to 75% of the Company&#x2019;s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.41% at September 30, 2020, and the interest rate resets in June and December annually. Accrued interest is payable semi-annually in June&#160;and December&#160;of each&#160;year or, at the Company&#x2019;s election, the semi-annual interest payments may be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50.0 million. The Company has made this election for all interest payments. Loans under the Note&#160;Agreement are secured by the Company&#x2019;s interest in its collaboration with Novartis, including any payments owed to it thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2015, concurrent with the execution of a license agreement with Novartis International as discussed in Note 4, XOMA and NIBR, who assumed the rights to the note from Novartis Vaccines Diagnostics,&#160;Inc. executed an amendment to the Note&#160;Agreement (the &#x201c;Secured Note&#160;Amendment&#x201d;) under which the parties extended the maturity date of the note from September&#160;30, 2015 to September&#160;30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note will be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;22, 2017, in connection with the XOMA-052 License Agreement with Novartis, the Company and NIBR executed an amendment to the Secured Note&#160;Amendment under which the parties further extended the maturity date of the Secured Note&#160;Amendment from September&#160;30, 2020 to September 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020 and December 31, 2019, the outstanding principal balance under the Secured Note Amendment was $16.2 million and $15.9 million, respectively, and was included in long-term debt in the accompanying condensed consolidated balance sheets. On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $25.0 million milestone payment as a result, of which $7.3 million will be recognized as a reduction to the debt obligation to Novartis, as discussed in Note 14, Subsequent Events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;"&gt;Payments of Long-Term Debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Aggregate future principal, final payment fees and discounts of the Company&#x2019;s long-term debt as of September 30, 2020, are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2020 (excluding nine months ended September 30, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: interest, final payment fees, discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,052)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total payments, net of interest, final payment fees, discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Interest Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;SVB loans&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,073&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Novartis note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ"
      decimals="-5"
      id="Narr_cr4vpSt4XkKcf4EHIC3d8Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_7_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Jd47lV9m20mVoxI2mVnXeA"
      decimals="4"
      id="Narr_pQKCnjwXo0mPu2KgoZTz5g"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember_AdKOII3dC0-c3gz97adv_A"
      decimals="4"
      id="Narr_ChctoHKZWEakMNQT0gcvJw"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <xoma:PeriodOfMonthlyPaymentsOfPrincipalAndInterest
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA"
      id="Narr_zyyPv8_esEe1y0imXnoIxA">P24M</xoma:PeriodOfMonthlyPaymentsOfPrincipalAndInterest>
    <xoma:DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA"
      id="Narr_tRZtxA9IXECXImlv_4LU4Q">P23M</xoma:DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate>
    <xoma:DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA"
      id="Narr_jM7BfB5uQUmAXpSoa5vx1Q">P30D</xoma:DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan>
    <xoma:DebtInstrumentAmountToBeReborrowed
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ"
      decimals="-5"
      id="Narr_IGwGUSTMd0uC6AYCIoa5WQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:DebtInstrumentAmountToBeReborrowed>
    <xoma:DebtInstrumentFinalPaymentFeePercentage
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ"
      decimals="3"
      id="Narr_eIEP9Fed3k2KAzZlMjRN1Q"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.085</xoma:DebtInstrumentFinalPaymentFeePercentage>
    <xoma:DebtInstrumentPrepaymentFeePercentage
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_m--qxWG3306IlcAtWJRFYw"
      decimals="4"
      id="Narr_Gr9ahyEiAEiqE0NAAjAWnQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0300</xoma:DebtInstrumentPrepaymentFeePercentage>
    <xoma:DebtInstrumentPrepaymentFeePercentage
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_j9t6d3XVyEWVqb-VBqtwnA"
      decimals="4"
      id="Narr_AfRnJ8cn6ECDuq2LRbRFwA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0200</xoma:DebtInstrumentPrepaymentFeePercentage>
    <xoma:DebtInstrumentPrepaymentFeePercentage
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_hAurvrTCL0uLGiyoscfcDg"
      decimals="4"
      id="Narr_cMmBNOWmqkC97it3M7jBbg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0100</xoma:DebtInstrumentPrepaymentFeePercentage>
    <xoma:PercentageOfAdditionalInterestRateOfOutstandingLoan
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_yDT9c2wKTkiPPwlOB6ufNA"
      decimals="4"
      id="Narr_Eob8GY5Ab0WFsx29vlk_Fw"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.04</xoma:PercentageOfAdditionalInterestRateOfOutstandingLoan>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA"
      decimals="INF"
      id="Narr_nIZ1HP6LzUilxk_SPHUPzA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6332</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA"
      decimals="2"
      id="Narr_CD13h9Kim0mvqN2DNjcz3A"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_5_7_2018_To_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_7DchDq9txkuakRpZQxN2Hg"
      id="Narr_eg1Kt-AFEEixaxaX8K7Blg">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_5_7_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_hbAkAPPjM0CTbB10sTJxXA"
      decimals="-5"
      id="Narr_c3doTGjBBEa46QQnn-tYMw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ"
      decimals="-5"
      id="Narr_rxRiIu4bGEeQ6aTT1Q0FpA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA"
      decimals="INF"
      id="Narr_Ohtb001sm0yrKosRKth-bg"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">4845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA"
      decimals="2"
      id="Narr_TNgeIsQaT0K-VFF9INPRfA"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_jrjtAApn5EiAnVU9jqxXwA"
      decimals="-5"
      id="Narr_bWwIAdcn5kKsPEkIcoJgmg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_3_4_2019_To_3_4_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_5-XsEkqIb0O1_ILDeS9Gbw"
      id="Narr_a4DQUWHFk0q0YeURVVxpHw">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_9_1_2018_To_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_1sIgH-TDmESIxi03ZCZdFA"
      decimals="-5"
      id="Narr_-ENVLFGXr02zsvN8zjIJRg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">7500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_9_30_2018_us-gaap_DebtInstrumentAxis_xoma_FirstTermLoanMember_QpM51obSbEy_0dOTKgw2QA"
      decimals="-5"
      id="Narr_6E3kl2AcJkC1rf_TbeTntQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_xb_L_CetzU-uTJy5lWyAAg"
      decimals="-5"
      id="Narr_xaKeQZwVZ063dK1dQIS9mg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SecondTermLoanMember_U_gsaxcdB0WA9FXj8HId5Q"
      decimals="-3"
      id="Narr_KIDGoYvIXEGLM0EeD876dw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">45000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw"
      decimals="-5"
      id="Narr_qYEUuDrUSEe1znuorrq_sw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg"
      decimals="-5"
      id="Narr_CiwH3PD_BkChjiWzLIxKbA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">500000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q"
      decimals="-5"
      id="Narr_uwK22XvCxEeGdDNSoOUqww"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ"
      decimals="-5"
      id="Narr_xO2w3U6NYEif0LcfpSbCWA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">400000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg"
      decimals="-5"
      id="Narr_2QzPjjR6Q0O22wReH9Lqew"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">13800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg"
      decimals="-5"
      id="Narr_7g-oMTkrVE2QK1XWNaNtew"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">9000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_O7n7sRPfok2-X1D-1Svawg"
      decimals="-5"
      id="Narr_Jf3mswKE-0ynDTnT0-p1bA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw"
      decimals="-5"
      id="Narr_atMtRudGrECMQ16jkGMylQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw"
      decimals="-5"
      id="Narr_skDxibkbpUmvPExuydp-jw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_SeCQJeMyV068B59zJoIzVw"
      decimals="-5"
      id="Narr_irgcrPO5qUOJDWZOPgQMeA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">11200000</us-gaap:LongTermDebtNoncurrent>
    <xoma:CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum
      contextRef="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_Aq-O5Rvu_EG2xp_gxz4Gog"
      decimals="2"
      id="Narr_bphwUr1njEGhaa3f-gufKg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.75</xoma:CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ"
      decimals="-5"
      id="Narr_astWOgd6Lk2y1kqmJE5bcQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember_Laye7qFdbkaWNAv5Y8KxEg"
      decimals="INF"
      id="Narr_LnaB-LgD3E6hCe8XNYoFkw"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.02</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA"
      decimals="4"
      id="Narr_lwDNkubjMkOn4mQZt2eE_A"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0241</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_1WlE-jHZRUWalLk7j0J0EQ"
      decimals="-5"
      id="Narr_kEZN8m5Lw0er3JciQxpbxw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <xoma:DebtInstrumentDecreaseUponAchievementOfMilestones
      contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_EG_Q04r1k0GkBf-7UuDNjg"
      decimals="-5"
      id="Narr_wY-uTCigCU-X6XrW0GMC_Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">7300000</xoma:DebtInstrumentDecreaseUponAchievementOfMilestones>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_-DMRSBW5z0im0FAFQ0XJFA"
      decimals="-5"
      id="Narr_xzRcVK7tMki7Rg6me1lmqQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">16200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_NHx7oG_kKE65ICx_DXfo0g"
      decimals="-5"
      id="Narr_pT_IGDGdpEWWua-EfO7z3A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">15900000</us-gaap:LongTermDebt>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ"
      decimals="-5"
      id="Narr_xKKDc2PicUatz6ssVpqH_Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ"
      decimals="-5"
      id="Narr_vh4fca-1PEKjI3DujsVSSQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-7300000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_2Upxespyw0Wvelq-FNt7DQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Aggregate future principal, final payment fees and discounts of the Company&#x2019;s long-term debt as of September 30, 2020, are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2020 (excluding nine months ended September 30, 2020)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: interest, final payment fees, discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,052)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total payments, net of interest, final payment fees, discount and issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,952&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,962)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_b8FAZaXWm0OFgo5arPx9EQ_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2270000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_cm5_STKMYUCx6LdDQsIh3w_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8534000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_pZWV1YdQwkK5dSe_6uL2pA_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">21200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <xoma:LongTermDebtFuturePrincipalInterestAndFinalFeePayments
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_-51AC2MJSEuVF_CXIAAUyQ_7_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">32004000</xoma:LongTermDebtFuturePrincipalInterestAndFinalFeePayments>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_0N8OpjlEtUm8LkOqx0L69w_8_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2052000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_J-Fx_ZvQHEugvXjyorVqFg_9_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">29952000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_8wayyoaBWkeo6rFIF0gdpA_10_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">8962000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-3"
      id="Tc_aZjQKjzoJUGx4RgS9gRjEg_11_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">20990000</us-gaap:LongTermDebtNoncurrent>
    <xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_iBFGzwfLA0mlRsssXHxzTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;SVB loans&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,073&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Novartis note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 168&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 409&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw"
      decimals="-3"
      id="Tc_rlYOP8oEKkW7r8CqrYeKPw_3_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">334000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_h88WvUQcEU22fTOvcANI1Q"
      decimals="-3"
      id="Tc_n7VGeLJ_ok6KvEsfC8H-NQ_3_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">314000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_I5WoQSm0MUKY3m0JIdJwAg"
      decimals="-3"
      id="Tc_R9WL-SOVQkqWnI0H_NYE6g_3_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1073000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_CB-ehtplZESCtI4Y4nmBQQ"
      decimals="-3"
      id="Tc_f0-9Ale2qEK9qOBNgpKofQ_3_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">791000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_uWG4bPOtsk2Nwyko1KBEuA"
      decimals="-3"
      id="Tc_byTc-z9MmkmPL9yn13trjg_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_9TjQxVDWVkKyIj9TiaRkjg"
      decimals="-3"
      id="Tc_48lvNXgGTU6AFudb_eEcyA_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">168000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_MNkxvd6px0Shg6qQPgSkhw"
      decimals="-3"
      id="Tc_beFBnIarrk6D3GpRIHGt9A_4_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">409000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_o7vjlCxW1UuogpVKDCyxSg"
      decimals="-3"
      id="Tc_gj9dchXFZ0uYCCJxCrOmjQ_4_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">540000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_78opXNQ0QUCrlHhRR1n9Xw"
      decimals="-3"
      id="Tc_W3An4JUwQkiUOBJ8ySfhYg_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_hzEj56jCBEaI-AttEMG2SQ"
      decimals="-3"
      id="Tc_lPSKNqPQzk6f1hmtFMC3TA_5_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">2000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_xoma_OtherFinancingsMember_pEtQLs5d2E-SAflZCpXZxA"
      decimals="-3"
      id="Tc_LFbcZayab0eA5NW7vB_GNg_5_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_5rU0zgqtkU2I079OarzFfA_6_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">434000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc_mFQbjMzf3EiKBRA8QhSkbQ_6_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">484000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_512QZrQMj06wEAyn4qrmUQ_6_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1484000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_ksasKlccm0e78TNfARDDNg_6_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1336000</us-gaap:InterestExpenseDebt>
    <xoma:CommonStockWarrantDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_TaDOuYFRzUWyelRWLezxLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2020 and December&#160;31, 2019, the following common stock warrants were outstanding:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,063&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,426&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:CommonStockWarrantDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_YM_RSXtfUU-v0Vjgjg8GHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2015&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66.20&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,063&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;February&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,249&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,426&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ"
      decimals="INF"
      id="Tc_HmP8LjFabkGA9yqC580zKg_3_7"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">66.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ"
      decimals="INF"
      id="Tc__AjQVVwKI0qVPeOZtiQAew_3_11"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">9063</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw"
      decimals="INF"
      id="Tc_7E5MF0uFRESn_-Sd-JA-yg_4_7"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">15.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw"
      decimals="INF"
      id="Tc_fj6WqWOwPEywU7lSKFu88w_4_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8249</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_2_29_2016_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedSecondRangeMember_iSwsqRlm4UOdOFHQ15lyhw"
      decimals="INF"
      id="Tc_Q6mklGoZ5UG2IWUzUTvntA_4_11"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">8249</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ"
      decimals="INF"
      id="Tc_pHMUrN3-KEuGrOaUq9_e2w_5_7"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ"
      decimals="INF"
      id="Tc_nTmjwvTRr0CF02DT5LF4og_5_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6332</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_UouPlY0BQE6QjZrtluAFVQ"
      decimals="INF"
      id="Tc_AUiV2GiTdky7d9VUPGKxMw_5_11"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6332</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ"
      decimals="INF"
      id="Tc_Jbh6VHm-UU2nn8FGKrFmoQ_6_7"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ"
      decimals="INF"
      id="Tc_RKxFTPvUkk2zuulcjHxOpQ_6_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">4845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_DS4JLSxyREWuX37VuWCbzQ"
      decimals="INF"
      id="Tc_Fvb9HkkQ-Ea4g-bDRsDYlA_6_11"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">4845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Tc_mfgZSeKa0UWooGC1nEYnpA_7_9"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">19426</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g"
      decimals="INF"
      id="Tc_B9haxyOQok-r36kofi09Jw_7_11"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">28489</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_v1pkMkEpFUW2M_6v3GWKKQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Collaborative Agreements, Royalties and Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#x2019;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $7.6 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingent Consideration&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Pursuant to the Company&#x2019;s royalty purchase agreement with Bioasis the Company has committed to pay the Bioasis Contingent Consideration. The Company recorded $0.1 million for the Bioasis Contingent Consideration which represents the estimated fair value of these potential future payments at the inception of the agreements. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of September 30, 2020, there were no changes in the estimated fair value of the contingent consideration from its initial value. The liability for future Aronora Royalty Milestones will be recorded when the amounts by product are estimable and probable. As of September 30, 2020, none of these Aronora Royalty Milestones were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xoma:ContractualObligationEstimatedMilestonePayments
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_HQUl4914MEOAwqIWezizwg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">7600000</xoma:ContractualObligationEstimatedMilestonePayments>
    <xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="INF"
      id="Narr_KpcTMvlPTEO06Rx39QZI_A"
      unitRef="Unit_Standard_product_z1vsU2YAp0Wjckurq5wYdg">1</xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts>
    <xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q"
      decimals="-5"
      id="Narr_2KMFmAUEWkKYTyDl_sTEkQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-SKPQGWoK0-_rCbIVVkYEA"
      decimals="-5"
      id="Narr_BK4peYJPx0SBLl8fLVtz0A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <xoma:ContractualObligationEstimatedFairValueOfContingentConsiderationLiability
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_U6qdZrT-gUyphLqQMtHQng"
      decimals="-5"
      id="Narr_Y_t0axZOvUOV-pTan4JP_Q"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ContractualObligationEstimatedFairValueOfContingentConsiderationLiability>
    <xoma:ContractualObligationMilestonePayments
      contextRef="As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_AronoraIncMember_rxCwxf0QfUC9qk9Y_rh-eg"
      decimals="-5"
      id="Narr_wppxbqOD60qeCsSthWZ2Ww"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</xoma:ContractualObligationMilestonePayments>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_rxFW4bzBa0OhmjsKZzomDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Stock-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may grant qualified and non-qualified stock options, RSUs, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#x2019;s common stock on the date of grant. Additionally, the Company has an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options generally vest&#160;monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;There were no stock options granted during the three months ended September 30, 2020. The fair value of the stock options granted during the three months ended September 30, 2019 and nine months ended September 30, 2020 and 2019, was estimated based on the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.77&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.47 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.60 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Stock option activity for the nine&#160;months ended September 30, 2020, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,839,623&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.88&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187,811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.28&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,655)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 141.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,779&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.41&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,659,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options exercised during the nine&#160;months ended September 30, 2020 and 2019 was $0.1 million and $0.6 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of the options granted during the nine&#160;months ended September 30, 2020 and 2019 was $16.22 and $11.45, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2020, $3.3 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 1.59&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"&gt;Performance-Based Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense associated with the corporate performance-based stock options is recognized if the performance condition is considered probable of achievement using management&#x2019;s best estimates. In 2017, the Company granted performance-based stock options with vesting criteria related to performance in 2017, 2018, and 2019. In 2019, the Company had 41,250 shares remaining related to outstanding performance-based stock options with a grant date fair value of $0.2 million that had vesting criteria based solely on the achievement of fiscal year 2019 corporate goals as set by the Compensation Committee of the Company&#x2019;s Board of Directors. For the year ended December 31, 2019, the Company determined that all remaining performance criteria were achieved and therefore the related expense of $0.2 million was recognized for the year ended December 31, 2019. After December 31, 2019, no performance-based stock options were outstanding and there was no unrecognized compensation cost related to performance-based stock options. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-based Compensation Expense&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,269&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ"
      decimals="2"
      id="Narr_VwDWmwiaLEyWLERyG1-_UQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QywYLWDewkuT4ebzmi68Mg"
      id="Narr_JYz0Mr77TUqbirYt8nXLbg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cZtQmYwfNU6UL1F3kzpYtQ"
      id="Narr_uWppOs8wM0KWXGDIM-iqBQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Narr_c76HzEGOtUGLtFUpZhihqg">P55Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Narr_bTxoE-vf50i1Zt9v0OxHUA">P70Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="INF"
      id="Narr_EnsqSGPdvkeL_xzHhGrPPQ"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_ZCrhZLou0kuzbEj0ySxGLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.77&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.49&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.47 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.60 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w"
      decimals="2"
      id="Tc_DA-an6oIpkG72VDS2hV03g_3_4"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Tc__y7sWf-ZyUyIZnOkjq5cnQ_3_7"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      decimals="2"
      id="Tc_KaXxogng5EugeFQ7wPbong_3_9"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w"
      decimals="2"
      id="Tc_SwLkolK60Euz43eFmxHKbA_4_4"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Tc_ASaOVbuBIEejzBPM2y3_ZQ_4_7"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      decimals="2"
      id="Tc_frHYkrYa3kauyIO0M-ogew_4_9"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w"
      decimals="4"
      id="Tc_4dUMFBeOJUGRcpG3BZZqkw_5_4"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="4"
      id="Tc_9Q3mDQl-YkOi7hjWQzjwsQ_5_7"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      decimals="4"
      id="Tc_-ynV4XOWjEGxRxr0a61L9g_5_9"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.0249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w"
      id="Narr_zcmQ1ErEsUueIP8Xoybw4A">P5Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Narr_jIX8iFS0FUOqd6HmNPkMyQ">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      id="Narr_kPpHqVQXJEqrNxkrdkkM8w">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_ewrpz9OZI0u25ggAFMx3mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Stock option activity for the nine&#160;months ended September 30, 2020, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of&#160;year&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,839,623&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.88&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187,811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.28&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,655)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 141.47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,002,779&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.41&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,659,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA"
      decimals="INF"
      id="Tc_85bWwanQDEK4QKDx6QA_JQ_6_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1839623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA"
      decimals="2"
      id="Tc_927HTHd4iUqk0i2Ra0Zndw_6_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">20.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_RUC_5NPG6ka8TvuxEM93Jg"
      id="Tc__jyomjIiEkyx2ZjBSeBSYA_6_7">P6Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aQx_DIuAyEGuuys-70ZHPA"
      decimals="-3"
      id="Tc_2-iGf5O02kiWA5JFCBUDNA_6_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">26829000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="INF"
      id="Tc_sTVjqn24DEuJIoNmQFK2eA_7_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">187811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Tc_qk_3lbrVW0i6xLZWMqsOVg_7_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">21.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="INF"
      id="Tc_M5GPRXIPRkeSiEmZ4gQE7Q_8_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">6000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Tc_O3uecqmUb0GUDIM2t9DcrA_8_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">4.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="INF"
      id="Tc_B_6F9WJpX0WLPdTxuqeyKw_9_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">18655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Tc_lNNn9gsqhESJypUeFIk7lw_9_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">141.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="INF"
      id="Tc_rEKYMG3AyEKg0BNtip0oCg_10_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">2002779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="2"
      id="Tc_JwX-1FxBjkWl8Y_3w0LsYQ_10_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">19.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Tc_xE9SjCYWhUyWHwyC0yOExA_10_7">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="-3"
      id="Tc_iRmSCAYJ3EGbE-VAb862Xw_10_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14864000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="INF"
      id="Tc_XhD-3o9EpUiEhXyQOOsd8w_11_2"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1659679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="2"
      id="Tc_jmmOJ37ewkKnn2SbQtSZ_A_11_5"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">19.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Tc_q0JF2Ous5Ei1hKu_TcDb9Q_11_7">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="-3"
      id="Tc_1lLz3d0qcUix2nMMpPOGsg_11_10"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">14167000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="-5"
      id="Narr_PJXY6tOsYku48L9ffeWQyg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      decimals="-5"
      id="Narr_eDYYTI_O-0KTNghC-fVZEg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      decimals="2"
      id="Narr_v8_CYsf750uL0fI7mOB5mQ"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">16.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nc2_BeOYLUeF5x02QMdjQw"
      decimals="2"
      id="Narr_Cz4EuoxyCUmpyrZnVplEnA"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">11.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_UwknqO2cX0GFsXFv7t5Z-Q"
      decimals="-5"
      id="Narr_D-X7NhKJa0eSVMRi0bEdqg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA"
      id="Narr_BDJwniVXaUCMNzEixtpPuA">P1Y7M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w"
      decimals="INF"
      id="Narr_Eae-KfdUT0qVbtF0Uws_Ag"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">41250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w"
      decimals="-5"
      id="Narr_su6BC-xso0qDQy2uO_P-Hw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_ql4aVy4WmEur4m9MMRr5Dw"
      decimals="-5"
      id="Narr_hGsA7wrlo0-h7xpvurzjKQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA"
      decimals="INF"
      id="Narr_a0mdTKTnhUax0jEq-iRUcw"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2020_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_QVHe7Vx5b0uwGeGe1twwQA"
      decimals="-5"
      id="Narr_MBD6OuLEE0Gv5kACCmvulg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_fOFw8xlXB0yMobr0ltMt_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,269&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,059&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 708&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,269&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0x8EMKzDr0a9bWPJF31vLg"
      decimals="-3"
      id="Tc_a2eNy7Lho0m_O7wocjDg5g_3_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">66000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_p7ZWEJ2xMU2VC0KWzZIypg"
      decimals="-3"
      id="Tc_IqE4tF-ZsEaqkW0WmJincA_3_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_NZcEoPXaI0iAyxKBC5cgCQ"
      decimals="-3"
      id="Tc_9clkeYqF70OxkUibXAxpLw_4_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_HsRG2H4itkerF2L9Qw8I9g"
      decimals="-3"
      id="Tc_j1OR7cs_rEyydbj3dQyQrg_4_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_m0TV8U2aI0CDgV82mWs52g"
      decimals="-3"
      id="Tc_bo4ubl5d_0qCF1Y_4EnhRQ_4_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1VjeaxaG8UOf7PR7WpN3Ew"
      decimals="-3"
      id="Tc_AzWvxAOxO0KBAVPZ4G_xWQ_4_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4059000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg"
      decimals="-3"
      id="Tc_vog4xD6sZ0WW5EMuf2YIOA_5_3"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg"
      decimals="-3"
      id="Tc__lzByOWjt0uDrCW-YElooA_5_6"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-3"
      id="Tc_T5jlNW0xEkmdJu8i53fBiQ_5_9"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">3269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w"
      decimals="-3"
      id="Tc_OcwOfOcK0Ey_VB8E7jEPVw_5_12"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">4233000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_qQjoVPnmhkS4mKVtcSsErg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Capital Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 12.25pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Rights Offering 2019&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;On December 2, 2019, the Company commenced a rights offering to raise up to $22.0 million through the distribution of subscription rights to holders of its common stock, Series X preferred stock and Series Y preferred stock (the &#x201c;2019 Rights Offering&#x201d;).&lt;i style="font-style:italic;"&gt; &lt;/i&gt;In December 2019, the Company sold a total of 1,000,000 shares of common stock under the 2019 Rights Offering for aggregate gross proceeds of $22.0 million. Total offering costs of $0.2 million were offset against the proceeds from the sale of common stock, for total net proceeds of $21.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The 2019 Rights Offering was fully backstopped by Biotechnology Value Fund, L.P. (&#x201c;BVF&#x201d;) &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;pursuant to the terms of an Investment Agreement between the Company and BVF (the &#x201c;Investment Agreement&#x201d;)&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;. In total, BVF purchased &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;845,463&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock and the Company will pay approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$18,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; for BVF&#x2019;s reasonable legal fees and expenses in connection with the &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Investment Agreement and &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;the 2019 Rights Offering. One of the Company&#x2019;s Directors, Matthew Perry, is the President of BVF. Each share of common stock has a stated value of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$22.00&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; per share. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;50%&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of their shares of Series Y preferred stock into common stock. As of September 30, 2020, BVF owned approximately &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;37.9%&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; of the Company&#x2019;s total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;57.3%&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; of the Company&#x2019;s total outstanding shares of common stock. &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Due to its significant equity ownership, BVF is considered a related party of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y preferred stock in 2018. There were 5,003 shares of Series X convertible preferred stock and no shares of Series Y convertible preferred stock outstanding as of September 30, 2020, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. The Series&#160;X and Series&#160;Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&#x2014; &lt;/i&gt;Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Rights&#x2014; &lt;/i&gt;In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&#x2014; &lt;/i&gt;Each share of Series&#160;X and Series&#160;Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&#x2014; &lt;/i&gt;Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&#x2014; &lt;/i&gt;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#x2019;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Beneficial Conversion Feature&#x2014; &lt;/i&gt;The fair value of the common stock into which the Series&#160;X convertible preferred stock is convertible exceeded the allocated purchase price of the Series&#160;X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series&#160;X convertible preferred stock sold on February&#160;16, 2017 multiplied by the difference between the fair value of the common stock and the Series&#160;X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series&#160;X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series&#160;Y convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2018 ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;18, 2018, the Company entered into an At The Market Issuance Sales Agreement (the &#x201c;2018 ATM Agreement&#x201d;) with H.C. Wainwright&#160;&amp;amp; Co., LLC (&#x201c;HCW&#x201d;), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule&#160;415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 ATM Agreement. No shares have been sold under the 2018 ATM Agreement since the agreement was executed.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock
      contextRef="Duration_12_2_2019_To_12_2_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_IZ5MZsXg_0uvXBtAPFu7OQ"
      decimals="-5"
      id="Narr_y9HXFb3UoEutv178v_MPuQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">22000000.0</xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_aD3k4_xk0EmzKHYfKIHIkA"
      decimals="INF"
      id="Narr_expAe34IQUO69vfvdDsQ-Q"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g"
      decimals="-5"
      id="Narr_mPeSTRH7K0WRyopA3bYTKg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">22000000.0</xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g"
      decimals="-5"
      id="Narr_q260gs1VWEe7pj3eH09uzw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_zTiRtAbs506kDsIZvcoo3g"
      decimals="-5"
      id="Narr_jkrDcysOMk617IPr0WyPHQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">21800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_XDDor7baIkKyVKi2CJALuw"
      decimals="INF"
      id="Narr_3hhqFUQRVEKOciLB8DKk1A"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">845463</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LegalFees
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_SqIlV2-rakKVcalxYbzoAA"
      decimals="-3"
      id="Narr_2A30t8pHE0uaSHDw4W_2KA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">18000</us-gaap:LegalFees>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2019_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_RightsOffering2019Member_RJ9Qlzbmi0O4zgEGElxXYw"
      decimals="INF"
      id="Narr_NTPTD6qwhEmVQPjovQ4GoQ"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">22.00</us-gaap:SharesIssuedPricePerShare>
    <xoma:BeneficialOwnershipLimitation
      contextRef="As_Of_2_29_2020_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_xoma_SeriesYConvertiblePreferredStockMember_Nj6TY6mgREyFvS2FQnthTQ"
      decimals="2"
      id="Narr_6Maaiado20iRsY-ACfMlGQ"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.50</xoma:BeneficialOwnershipLimitation>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA"
      decimals="3"
      id="Narr_fV3hcalY7k-YWzODKiVqMg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.379</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted
      contextRef="As_Of_9_30_2020_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i6SoKJJNrESh5bXndNwOIA"
      decimals="3"
      id="Narr_AflWBeLKgE6Uz5ioRQwFwA"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.573</xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_R6x4VB5rkUSXD6oQWozXow"
      decimals="INF"
      id="Narr_c6hUn3MGL0a-qKn72WgC1Q"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TyS4yAARRkOfhp3ZxgbyUA"
      decimals="INF"
      id="Narr_wS-yV9Ir2U6a4sVa_ik0OA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1252.772</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_z49RnI3stEODl-bB_4KFnA"
      decimals="INF"
      id="Narr_FHZBP25v8U6yVi09at-ZCg"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_6hHu9AeYSUi8Kjb-gsHXKg"
      decimals="INF"
      id="Narr_0qTlShmSdkWxOaYHZrPS6Q"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_MnJGbUR0Q0arUfSSoF2XOA"
      decimals="INF"
      id="Narr_pTLRxmVYsEa69MbAh5ri6w"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_hVBra_ri2UOdlaAWOeBi1Q"
      decimals="INF"
      id="Narr_yoNNPYPibkSAth9qCV8bkQ"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">4.03</xoma:PreferredStockConversionPricePerShare>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_TOYjkQxmGUCjZkjeSJlhUg"
      decimals="INF"
      id="Narr_2xC4QHk85EOHchXfDKyz4w"
      unitRef="Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw">13.00</xoma:PreferredStockConversionPricePerShare>
    <xoma:FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock
      contextRef="Duration_2_1_2017_To_2_28_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_zbfdDVr-vEikYw024muE5g"
      decimals="-5"
      id="Narr_MBQYSHK-l0yT-C4PzskknQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5600000</xoma:FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock>
    <xoma:MaximumValueOfCommonStockToBeIssued
      contextRef="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw"
      decimals="-5"
      id="Narr_ZaHVDHFYgk252dsbDCfCYg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">30000000.0</xoma:MaximumValueOfCommonStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares
      contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_PlBfqshTSkaD5A1hfHjWOw"
      decimals="2"
      id="Narr__V1xjZtxN0iWhh2nb1UDJg"
      unitRef="Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_44Jv_9l0yEu1_bEJhWroxg"
      decimals="INF"
      id="Narr_77oXLJEN-keBI5eegfIuGA"
      unitRef="Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_I4G9jLoa006vjQE2JHWzog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act was enacted and signed into law. The CARES Act includes a number of income tax changes, including, but not limited to (1) permitting NOL carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (2) accelerating AMT tax refunds, (3) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (4) providing a technical correction for depreciation as relates to qualified improvement property.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded an income tax benefit of $1.5 million for the nine months ended September 30, 2020 as a result of the CARES Act, which was enacted on March 27, 2020. The CARES Act permits the Company to carry back losses from 2018 to offset its income in 2017 resulting in an income tax receivable. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a total of $5.5 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization. The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through September 30, 2020, the Company has not accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      decimals="-5"
      id="Narr_PwO1xHXRoUuIuIoTZ3Dvfg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_TaJiWjt-E0-zwp5QGcv6Lg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">5500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_-tY-9xjCt0S97vow8as1VQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ"
      id="Tb_3CxqWPq51U6E6TRiS6AQGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Subsequent Events &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 9, 2020, Rezolute completed a private placement of its equity securities with gross proceeds of $41.0 million, which is considered a Qualified Financing event under the Third Amendment. The Qualified Financing resulted in acceleration of the remaining receivables of $1.4 million due from Rezolute, and the Company received the entire amount in October 2020. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $1.4 million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. The Company will recognize the $1.4 million as a reversal of bad debt expense in the fourth quarter of 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 21, 2020, NIS793, an anti-TGF&#x3b2; monoclonal antibody, licensed from the Company to Novartis International under the License Agreement, advanced to the Phase 2 development stage. &#160;As a result of the advancement, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and the Company earned a $25.0 million milestone payment. As specified under the terms the License Agreement, the Company will receive $17.7 million in cash and the remaining balance of $7.3 million will be recognized as a reduction to the Company&#x2019;s debt obligation to Novartis. The Company will record $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income (loss) in the fourth quarter of 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2020, the Company exercised its option previously granted under the Bioasis Royalty Purchase Agreement and entered into another Royalty Purchase Agreement (the &#x201c;Second Bioasis Royalty Purchase Agreement&#x201d;) with Bioasis. Under the Second Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a Research Collaboration and License Agreement between Bioasis and Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;). The Company paid Bioasis $1.2 million upon closing of the Second Bioasis Royalty Purchase Agreement for the purchased rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock
      contextRef="Duration_10_9_2020_To_10_9_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Wdtq6HhGbkyK1Ip4HHUIVw"
      decimals="-5"
      id="Narr_8cOA9I9U8EahIubo42D72g"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">41000000.0</xoma:GrossProceedsFromIssuanceOfCommonStockAndPreferredStock>
    <xoma:FutureCashPaymentsReceived
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LeV2Lq8xKkabozDro2bYAg"
      decimals="-5"
      id="Narr_6HqUQoaO9kukgy6d6-M3jg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</xoma:FutureCashPaymentsReceived>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw"
      decimals="-5"
      id="Narr_mRTayHOf5UOIyvXj2qwh6A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1400000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_10_1_2020_To_12_31_2020_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_X8Vp97mKY0uNE717S6FXRA"
      decimals="-5"
      id="Narr_3GBV3U29_UaskN-Urf-Wvw"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-1400000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_21_2020_To_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__gk87KcQ7kitA8XDb5-UxQ"
      decimals="-5"
      id="Narr_EVgArh411UutMgiPziAIxQ"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="As_Of_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_x1Y6PfrxfE2TlMaI8OC3hA"
      decimals="-5"
      id="Narr_ltt5eY061UGvHVz2CRLC_A"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">17700000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="Duration_10_21_2020_To_10_21_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_OagLgBYKq0KNe-Bj4I80xQ"
      decimals="-5"
      id="Narr_XOEH8hy8KE6Ay2FTBQp_Ag"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">-7300000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2020_To_12_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_SXy_rcf1HE-sOiNkx-qqfA"
      decimals="-5"
      id="Narr_9YQ2bncO1EuERJoANoZAHg"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRights
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyPurchaseAgreementMember_tYew2cGdwUWvjZAtJPwK7w"
      decimals="-5"
      id="Narr_9EktHPKBW0WorxPWrS2_YA"
      unitRef="Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg">1200000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRights>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_LBF1-NCEGUqoBLW6Sito6A_7_6"
          xlink:label="Tc_LBF1-NCEGUqoBLW6Sito6A_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" xlink:label="_8c96f9cb_1ce3_410c_9bba_c419c0510c03" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</xhtml:i></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_LBF1-NCEGUqoBLW6Sito6A_7_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6"
          xlink:label="Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DJqUNY-I7Eqo5Lnp6sNHTA_20_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6"
          xlink:label="Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_hL2UiMcY4kqwX3o7d3rqCA_39_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_v8RjykmcG06RZG0yBSfN8w_16_6"
          xlink:label="Tc_v8RjykmcG06RZG0yBSfN8w_16_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_v8RjykmcG06RZG0yBSfN8w_16_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_D4UqmmRuG0O1At5TqCYp8w_10_6"
          xlink:label="Tc_D4UqmmRuG0O1At5TqCYp8w_10_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_D4UqmmRuG0O1At5TqCYp8w_10_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_2QusaOESx0ur2PFoam0Taw_6_6"
          xlink:label="Tc_2QusaOESx0ur2PFoam0Taw_6_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2QusaOESx0ur2PFoam0Taw_6_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_Y_CFql4RikqDJzDMsiLOyQ"
          xlink:label="Hidden_Y_CFql4RikqDJzDMsiLOyQ"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_Y_CFql4RikqDJzDMsiLOyQ"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_M6ssgo2M90642RA-IF9OCg_38_6"
          xlink:label="Tc_M6ssgo2M90642RA-IF9OCg_38_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_M6ssgo2M90642RA-IF9OCg_38_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gNXHDdUGOUGblWIvgAVenw_25_6"
          xlink:label="Tc_gNXHDdUGOUGblWIvgAVenw_25_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gNXHDdUGOUGblWIvgAVenw_25_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6"
          xlink:label="Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3cxs7tsPl0KO07OFF-CyLQ_24_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_WtNHDEvBt06od3wj_CVkow_28_6"
          xlink:label="Tc_WtNHDEvBt06od3wj_CVkow_28_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_WtNHDEvBt06od3wj_CVkow_28_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9fPqO3HUnkWpBDZekGHmNg_32_6"
          xlink:label="Tc_9fPqO3HUnkWpBDZekGHmNg_32_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9fPqO3HUnkWpBDZekGHmNg_32_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6"
          xlink:label="Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GG4Fwp3iXk25l29LY3YRPQ_42_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6"
          xlink:label="Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kkyjYznXsUCCAOEu-TIaYQ_27_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_m2RJdozbC0W-6_yBYsrafA_26_6"
          xlink:label="Tc_m2RJdozbC0W-6_yBYsrafA_26_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_m2RJdozbC0W-6_yBYsrafA_26_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GdgJoNAAc0KIhoRV97vELA_29_6"
          xlink:label="Tc_GdgJoNAAc0KIhoRV97vELA_29_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GdgJoNAAc0KIhoRV97vELA_29_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kuGUR7hnm0uhzcSQMsH34A_23_6"
          xlink:label="Tc_kuGUR7hnm0uhzcSQMsH34A_23_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kuGUR7hnm0uhzcSQMsH34A_23_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_X6GCUHcXrUKlhPczPH8d_A_30_6"
          xlink:label="Tc_X6GCUHcXrUKlhPczPH8d_A_30_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_X6GCUHcXrUKlhPczPH8d_A_30_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_GeyTclnuQ0qNX78tFlSPTg_12_6"
          xlink:label="Tc_GeyTclnuQ0qNX78tFlSPTg_12_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_GeyTclnuQ0qNX78tFlSPTg_12_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6"
          xlink:label="Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_wH7ciA5TT0iLMSIXbxkIQg_15_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6"
          xlink:label="Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_09KeyzZOtUuXN2ZZ14FuiA_31_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Hidden_P4u2-aylQkOppw-2vXNJkA"
          xlink:label="Hidden_P4u2-aylQkOppw-2vXNJkA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Hidden_P4u2-aylQkOppw-2vXNJkA"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6"
          xlink:label="Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_CSkNHJiLZUexA7G1GE4L2Q_9_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vGy_7ECjK06v13AqRMdINQ_11_6"
          xlink:label="Tc_vGy_7ECjK06v13AqRMdINQ_11_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vGy_7ECjK06v13AqRMdINQ_11_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5rG1U6AyMUinpVHKmveKig_40_6"
          xlink:label="Tc_5rG1U6AyMUinpVHKmveKig_40_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5rG1U6AyMUinpVHKmveKig_40_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6"
          xlink:label="Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_hVNu6CSW4kKYOUN5DPr55Q_41_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6"
          xlink:label="Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_beK2OBmRcEKn6Tmg3q3LVA_21_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6"
          xlink:label="Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3F8Uxn2XKkmkNWObEfaA4A_22_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6"
          xlink:label="Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Ugk4w_Qc3Ey_BqF3GBR6YQ_14_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_v_kra4dIXUqGKGjoC1FCVA_13_6"
          xlink:label="Tc_v_kra4dIXUqGKGjoC1FCVA_13_6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_v_kra4dIXUqGKGjoC1FCVA_13_6"
          xlink:to="_8c96f9cb_1ce3_410c_9bba_c419c0510c03"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307598391432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-14710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XOMA Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2154066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">2200 Powell Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line2</a></td>
<td class="text">Suite&#160;310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">204-7200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,022,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000791908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602014776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 45,725<span></span>
</td>
<td colspan="2" class="nump">$ 56,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">222<span></span>
</td>
<td colspan="2" class="nump">2,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">1,526<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">671<span></span>
</td>
<td colspan="2" class="nump">352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">48,144<span></span>
</td>
<td colspan="2" class="nump">59,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">24<span></span>
</td>
<td colspan="2" class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">398<span></span>
</td>
<td colspan="2" class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="nump">34,375<span></span>
</td>
<td colspan="2" class="nump">34,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EquitySecuritiesFvNiNonCurrent', window );">Equity securities</a></td>
<td class="nump">2,572<span></span>
</td>
<td colspan="2" class="nump">681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">215<span></span>
</td>
<td colspan="2" class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">85,728<span></span>
</td>
<td colspan="2" class="nump">95,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">450<span></span>
</td>
<td colspan="2" class="nump">614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">466<span></span>
</td>
<td colspan="2" class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="nump">75<span></span>
</td>
<td colspan="2" class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td colspan="2" class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">1,409<span></span>
</td>
<td colspan="2" class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">798<span></span>
</td>
<td colspan="2" class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">8,962<span></span>
</td>
<td colspan="2" class="nump">5,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,335<span></span>
</td>
<td colspan="2" class="nump">8,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method - long-term</a></td>
<td class="nump">13,952<span></span>
</td>
<td colspan="2" class="nump">15,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">20,990<span></span>
</td>
<td colspan="2" class="nump">27,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">275<span></span>
</td>
<td colspan="2" class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities - long-term</a></td>
<td class="nump">134<span></span>
</td>
<td colspan="2" class="nump">43<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">47,686<span></span>
</td>
<td colspan="2" class="nump">51,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 and 6,256 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,022,143 and 9,758,583 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">83<span></span>
</td>
<td colspan="2" class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,241,711<span></span>
</td>
<td colspan="2" class="nump">1,238,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,203,752)<span></span>
</td>
<td colspan="2" class="num">(1,194,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">38,042<span></span>
</td>
<td colspan="2" class="nump">43,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 85,728<span></span>
</td>
<td colspan="2" class="nump">$ 95,724<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesFvNiNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FvNi non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesFvNiNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty receivable non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594490680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0075<span></span>
</td>
<td class="nump">$ 0.0075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">277,333,332<span></span>
</td>
<td class="nump">277,333,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,022,143<span></span>
</td>
<td class="nump">9,758,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,022,143<span></span>
</td>
<td class="nump">9,758,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307595060584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">8,855<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">17,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="nump">5,821<span></span>
</td>
<td class="nump">13,126<span></span>
</td>
<td class="nump">16,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">5,964<span></span>
</td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">17,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(2,689)<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
<td class="num">(11,456)<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(434)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(1,484)<span></span>
</td>
<td class="num">(1,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="num">(10,894)<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive (loss) income</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income and comprehensive (loss) income available to common stockholders, basic</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income and comprehensive (loss) income available to common stockholders, diluted</a></td>
<td class="num">$ (1,077)<span></span>
</td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="num">$ (9,368)<span></span>
</td>
<td class="nump">$ 1,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share available to common stockholders</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share available to common stockholders</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="nump">8,731<span></span>
</td>
<td class="nump">10,537<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="nump">9,441<span></span>
</td>
<td class="nump">10,537<span></span>
</td>
<td class="nump">9,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594233816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 1,211,122<span></span>
</td>
<td class="num">$ (1,192,402)<span></span>
</td>
<td class="nump">$ 18,785<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_SharesReleasedOfRestrictedStockUnits', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,213,133<span></span>
</td>
<td class="num">(1,189,169)<span></span>
</td>
<td class="nump">24,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,211,122<span></span>
</td>
<td class="num">(1,192,402)<span></span>
</td>
<td class="nump">18,785<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,215,784<span></span>
</td>
<td class="num">(1,190,063)<span></span>
</td>
<td class="nump">25,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,213,133<span></span>
</td>
<td class="num">(1,189,169)<span></span>
</td>
<td class="nump">24,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,072)<span></span>
</td>
<td class="num">(4,072)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,214,168<span></span>
</td>
<td class="num">(1,193,241)<span></span>
</td>
<td class="nump">20,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,215,784<span></span>
</td>
<td class="num">(1,190,063)<span></span>
</td>
<td class="nump">25,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">1,238,299<span></span>
</td>
<td class="num">(1,194,384)<span></span>
</td>
<td class="nump">43,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement', window );">Disgorgement of stockholder's short-swing profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">1,240,188<span></span>
</td>
<td class="num">(1,199,142)<span></span>
</td>
<td class="nump">41,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">1,238,299<span></span>
</td>
<td class="num">(1,194,384)<span></span>
</td>
<td class="nump">43,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">1,241,711<span></span>
</td>
<td class="num">(1,203,752)<span></span>
</td>
<td class="nump">38,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">1,240,188<span></span>
</td>
<td class="num">(1,199,142)<span></span>
</td>
<td class="nump">41,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock related to Series Y preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock related to Series Y preferred stock conversion (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,533)<span></span>
</td>
<td class="num">(3,533)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">1,240,987<span></span>
</td>
<td class="num">(1,202,675)<span></span>
</td>
<td class="nump">38,395<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
<td class="num">(1,077)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 1,241,711<span></span>
</td>
<td class="num">$ (1,203,752)<span></span>
</td>
<td class="nump">$ 38,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">11,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from disgorgement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_SharesReleasedOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to release of restricted stock units (RSUs) in shares during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_SharesReleasedOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307601911192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (9,368)<span></span>
</td>
<td class="nump">$ 2,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,269<span></span>
</td>
<td class="nump">4,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims', window );">Common stock contribution to 401(k)</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs, debt discount and final payment on debt</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OperatingLeasePaymentsNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="num">(1,891)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables, net</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="num">(2,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(464)<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="num">(1,052)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(1,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(7,586)<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments related to purchase of royalty rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(19,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments - debt</a></td>
<td class="num">(3,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments - finance lease</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromRepaymentsForDisgorgement', window );">Proceeds from disgorgement of stockholder's short-swing profits</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(3,368)<span></span>
</td>
<td class="nump">9,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash</a></td>
<td class="num">(10,963)<span></span>
</td>
<td class="num">(6,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at the beginning of the period</a></td>
<td class="nump">56,688<span></span>
</td>
<td class="nump">45,780<span></span>
</td>
<td class="nump">$ 45,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at the end of the period</a></td>
<td class="nump">45,725<span></span>
</td>
<td class="nump">39,744<span></span>
</td>
<td class="nump">$ 56,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_InterestAddedPrincipalBalancesLongTermDebt', window );">Interest added to principal balance on long-term debt</a></td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock warrant under SVB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Estimated fair value of contingent consideration under the royalty purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan issuance of Common stock for services or claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of lease liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_InterestAddedPrincipalBalancesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid interest added to the outstanding principal amount on long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_InterestAddedPrincipalBalancesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasePaymentsNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments, non cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasePaymentsNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromRepaymentsForDisgorgement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from disgorgement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromRepaymentsForDisgorgement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591658952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA Corporation (referred to as &#8220;XOMA&#8221; or the &#8220;Company&#8221;), a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with acquisitions of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2020, the Company had cash of $45.7 million. Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one&#160;year following the date that these condensed consolidated financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590249112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;10, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, operating lease right-of-use assets and liabilities, legal contingencies, contingent considerations under royalty purchase agreements, stock-based compensation and income taxes. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts and amortization of the payments received from HealthCare Royalty Partners II,&#160;L.P. (&#8220;HCRP&#8221;). Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company billed using NIH&#8217;s provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company&#8217;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The worldwide spread of the COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company&#8217;s royalty purchase agreements. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>("ASC 606"), except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the &#8220;Black-Scholes Model&#8221;). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company received shares of common stock from Rezolute, Inc. (&#8220;Rezolute&#8221;) (Note&#160;4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive (loss) income in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase of Rights to Future Milestones and Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note&#160;5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If freestanding instruments, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value is recorded in the condensed consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews any impairment indicators and changes in expected recoverability of the long-term royalty receivable asset at least quarterly. If expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of September 30, 2020 and December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement for its corporate headquarters in Emeryville, California and under its legacy business held leases for office and laboratory facilities in Berkeley, California. In connection with a series of restructuring events in 2017 and 2018, the Company completely vacated its leased facilities in Berkeley, California and subleased the space in the vacated buildings. In December 2019, the Company terminated its legacy operating leases in Berkeley, California and was fully released from any further payment obligations. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company continues to lease its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an operating lease were to reflect impairment, the Company will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Prior Period Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the condensed consolidated statement of cash flows, the Company separately presented the non-cash lease expense and changes in operating lease liabilities for the prior period to conform with current period presentation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net (Loss) Income per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net (loss) income per share attributable to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net (loss) income attributable to common stockholders consists of net (loss) income, as adjusted for any convertible preferred stock deemed dividends related to beneficial conversion features on this instrument at issuance. During periods of income, the Company allocates participating securities a proportional share of net income, after deduction of any deemed dividends on preferred stock, determined by dividing total weighted average participating securities by the sum of the total weighted average number of common stock and participating securities (the &#8220;two-class method&#8221;). The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. For the three and nine months ended September 30, 2020 and 2019, the Company did not declare any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Trade and other receivables, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade and other receivables, net consist mainly of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. <span style="background-color:#ffffff;">Trade and other receivables are recorded upon triggering events specified in the agreement. Trade receivables under ASC 606 are recorded separately from contract assets when only the passage of time is required before consideration is due. </span>The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. Any increases to allowance for doubtful accounts are charged to operating expenses. The Company recorded $1.4 million in allowance for doubtful accounts for the three months ended March 31, 2020 related to Rezolute&#8217;s license agreement (Note 4). The Company evaluated the&#160;accounts&#160;receivable and determined there was no further activity in allowance for doubtful accounts for the second and third quarters in 2020. The previously reserved accounts receivable from Rezolute was accelerated and collected in October 2020, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br/>September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charged to operating expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three&#160;months ended September 30, 2020, two partners represented&#160;64% and 36% of total revenues. For the nine&#160;months ended September 30, 2020, three partners represented&#160;58%, 28% and 11% of total revenues. For the three&#160;months ended September 30, 2019, two partners represented 68% and 28% of total revenues. For the nine&#160;months ended September 30, 2019, two partners represented 78% and 14% of total revenues. As of September 30, 2020 and as of December&#160;31, 2019, one partner represented 100% of the trade receivables, net balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-13,&#160;<i style="font-style:italic;">Fair Value Measurement (Topic 820) (&#8220;ASU 2018-13&#8221;)</i>, which modifies, removes and adds certain disclosure requirements on fair value measurements based on the FASB&#160;<i style="font-style:italic;">Concepts Statement, Conceptual Framework for Financial Reporting&#8212;Chapter&#160;8: Notes&#160;to Financial Statements</i>. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the&#160;year ending December&#160;31, 2020, and all annual and interim reporting period thereafter. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal&#160;year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company early adopted the guidance related to removal of disclosures upon issuance of this ASU and adopted the deferred provisions as permitted under the ASU in the first quarter of 2020. The adoption of ASU 2018-13 did not have a material impact<span style="color:#212529;">&#160;</span>on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) &#8220;Clarifying the Interaction between Topic 808 and Topic 606,&#8221; which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service that is a distinct unit of account. The new standard also precludes an entity from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the year ending December 31, 2020, and all annual and interim reporting period thereafter. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. This ASU requires retrospective adoption to the date the Company adopted ASC 606, January 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company may elect to apply the ASU retrospectively either to all contracts or only to contracts that are not completed at the date it initially applied ASC 606. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13 and related updates&#160;as of January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued&#160;ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </i>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021 with early adoption permitted. The Company is evaluating the impact <span style="color:#212529;">of adopting this new accounting guidance </span>on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March&#160;2020, the FASB issued&#160;ASU&#160;2020-04,&#160;<i style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The&#160;ASU&#160;provides optional expedients and exceptions for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12,&#160;2020&#160;through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12,&#160;2020. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594182040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Condensed Consolidated Financial Statements Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Condensed Consolidated Financial Statements Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Condensed Consolidated Financial Statements Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, equity securities consisted of an investment in Rezolute&#8217;s common stock of $2.6 million and $0.7 million, respectively (Note&#160;4). For the three and nine months ended September 30, 2020 the Company recognized gains of $2.0 million and $1.9 million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. The Company recognized a loss of $0.3 million and a gain of $0.5 million for the three and nine months ended September 30, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 945</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net (Loss) Income Per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss or income) and the denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net (loss) income  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,339</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,327)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (977)</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,362</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,403</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,721</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 657</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,379</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.89)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.16</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.15</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share available to common stockholders if their inclusion is anti-dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,483</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 926</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 941</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592043608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsAbstract', window );"><strong>Licensing and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsTextBlock', window );">Licensing and Other Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis&#160;&#8211; Gevokizumab (VPM087) and IL-1 Beta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis Pharma AG (&#8220;Novartis&#8221;) entered into a license agreement (the &#8220;XOMA-052 License Agreement&#8221;) under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents (altogether, the &#8220;XOMA IP&#8221;). Under the terms of the XOMA-052 License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the XOMA-052 License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#8364;12.0 million) was paid by Novartis Institutes for BioMedical Research,&#160;Inc. (&#8220;NIBR&#8221;), on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, NIBR extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#8217;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the XOMA-052 License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the XOMA-052 License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the XOMA-052 License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The XOMA-052 License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis International&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis International Pharmaceutical&#160;Ltd. (&#8220;Novartis International&#8221;) entered into a license agreement (the &#8220;License Agreement&#8221;) under which the Company granted Novartis International an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the License Agreement, Novartis International has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis International&#8217;s royalty obligations end. The License Agreement contains customary termination rights relating to material breach by either party. Novartis International also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there are multiple promised goods and services under the License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;year ended December&#160;31, 2017, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of operations and comprehensive income. The Company is eligible to receive up to a total of $470.0 million in development, regulatory and commercial milestones under the anti-TGFB antibody agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each quarter, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit&#160;percentage rate to up to a low double-digit&#160;percentage rate. Novartis International&#8217;s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020 and 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $25.0 million milestone payment as a result, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, the Company is eligible to receive a low single digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country (the &#8220;Royalty Term&#8221;), provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country. Rezolute&#8217;s future royalty obligations will be reduced by 20% at any time during the Royalty Term that a valid XOMA patent claim is not outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:6pt 0pt 0pt 0pt;">Rezolute had an option through June&#160;1, 2019 to obtain an exclusive license for their choice of one of the Company&#8217;s preclinical monoclonal antibody fragments, including X129 (the &#8220;Additional Product Option&#8221;), in exchange for a $1.0 million upfront option fee and additional clinical, regulatory and commercial milestone payments to the Company of up to $237.0 million in the aggregate based on the achievement of pre-specified criteria as well as royalties ranging from the high single digits to the mid-teens based on annual net sales. On June 1, 2019, Rezolute&#8217;s right to the Additional Product Option expired unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#8217; notice at any time. The Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the license agreement and common stock purchase agreement, no consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities and the amounts to be paid to be based on the timing of those activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- First Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March&#160;2018, the Company and Rezolute amended the license agreement and common stock purchase agreement. Pursuant to the as-amended terms of the license agreement and common stock purchase agreement, the Company was eligible to receive $6.0 million in cash, $8.5 million of Rezolute&#8217;s common stock, and 7,000,000 shares of Rezolute&#8217;s common stock, contingent on the completion of Rezolute&#8217;s financing activities. Further, in the event that </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rezolute did not complete a financing that raised at least $20.0 million in aggregate gross proceeds (&#8220;Qualified Financing&#8221;) by March&#160;31, 2019 (the &#8220;2019 Closing&#8221;), the Company would have received an additional number of shares of Rezolute&#8217;s common stock equal to $8.5 million divided by the weighted average of the closing bid and ask prices or the average closing prices of Rezolute&#8217;s common stock on the ten-day trading period prior to March&#160;31, 2019. Finally, in the event that Rezolute was unable to complete a Qualified Financing by March&#160;31, 2020, the Company would have been eligible to receive $15.0 million in cash in order for Rezolute to maintain the license. Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i)&#160;5,000,000 shares of common stock or (ii)&#160;<span style="-sec-ix-hidden:Hidden_5JMn34DvnkG2-h_9uI7tlA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one third</span></span> of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three&#160;months ended March&#160;31, 2018, the Company completed the delivery of the license and related materials, product data/filing, process and know-how to Rezolute. However, the Company determined that it was not probable that the Company would collect substantially all of the consideration to which it was entitled in exchange for the goods and services transferred to Rezolute. Therefore, the Company determined no contract existed as of March&#160;31, 2018 and no revenue was recognized during the three&#160;months ended March&#160;31, 2018 under the arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute completed the Interim Financing Closing and the Initial Closing financing activities, as defined in the common stock purchase agreement, during the first and second quarter of 2018, respectively. As a result, XOMA received 8,093,010 shares of Rezolute&#8217;s common stock and cash of $0.5 million in April&#160;2018. Under the license agreement, XOMA was also entitled to receive $0.3 million of reimbursable technology transfer expenses from Rezolute. The Company concluded that the payment associated with the Initial Closing represented substantially all consideration for the delivered license and technology to Rezolute. Therefore, the Company determined that a contract existed between Rezolute and XOMA under ASC 606 on April&#160;3, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement and common stock purchase agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there were multiple promised goods and services under the combined arrangement, including the license to RZ358, the transfer of RZ358 materials and product data/filing, and the transfer of process and know-how related to RZ358, which were determined to represent one combined performance obligation. The Company determined that the Additional Product Option was not an option with material right because there was no upfront consideration to the Company that would result to an incremental discount for the future opt in payments. Therefore, the Company concluded that the Additional Product Option was not a performance obligation. On June&#160;1, 2019, Rezolute&#8217;s right to the Additional Product Option expired unexercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;3, 2018, the Company determined that the transaction price under the arrangement was $1.8 million, which consisted of the 8,093,010 shares of Rezolute&#8217;s common stock valued at $1.0 million, $0.5 million in cash, and reimbursable technology transfer expenses of $0.3 million. During the&#160;year ended December&#160;31, 2018, the Company recognized the entire transaction price of $1.8 million as revenue upon completion of the delivery of the licenses and related materials, product data/filing, process and know-how. The change in fair value of Rezolute&#8217;s common stock after the contract inception date was due to the form of the consideration and therefore, not included in the transaction price pursuant to the accounting guidance. The Company accounts for the change in the fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of the inception of the arrangement. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether the estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- Second Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;7, 2019, the Company and Rezolute further amended the license agreement and common stock purchase agreement. The parties agreed to replace the issuance of common stock valued at $8.5 million to XOMA upon closing of a Qualified Financing with a requirement that Rezolute make five future cash payments to XOMA totaling $8.5 million through September&#160;2020 (the &#8220;Future Cash Payments&#8221;). The amendment also provides for early payment of the Future Cash Payments (only until the $8.5 million is reached) by making cash payments to XOMA equal to 15% of the net proceeds of each future financing following the closing of the Qualified Financing, with such payments to be credited against any remaining unpaid Future Cash Payments in reverse order of their future payment date. In addition, the license agreement amendment revised the amount Rezolute is required to expend on development of RZ358 and related licensed products, revised provisions with respect to Rezolute&#8217;s diligence efforts in conducting clinical studies and eliminated XOMA&#8217;s right to appoint a member to Rezolute&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The common stock purchase agreement was amended to remove certain provisions related to the issuance of equity to XOMA in accordance with the new provisions regarding the Future Cash Payments in the license agreement. Lastly, the common stock purchase agreement was amended to provide the Company the right and option to sell up to 5,000,000 shares of Rezolute&#8217;s common stock currently held by XOMA back to Rezolute upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December&#160;31, 2019. As of December 31, 2019, Rezolute failed to list its shares of common stock on the Nasdaq Stock Market or a similar exchange. Up to 2,500,000 shares may be sold back to Rezolute during calendar&#160;year 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January&#160;30, 2019, Rezolute closed a preferred stock financing for gross proceeds of $25.0 million, which triggered the Qualified Financing event defined under the amended common stock purchase agreement resulting in cash consideration due to XOMA of $5.5 million. In addition, the Company received from Rezolute a reimbursable technology transfer expense of $0.3 million. The cash consideration and technology reimbursement were received in February&#160;2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2019, Rezolute completed all financing activities, as defined in the license agreement and common stock purchase agreement, and the Company is eligible to receive $8.5 million in Future Cash Payments through September&#160;2020 (in addition to any clinical, regulatory and annual net sales milestone payments and royalties). The Company concluded that the Future Cash Payments are dependent on Rezolute&#8217;s ability to raise additional capital through future financing activities. The Company applied the variable consideration constraint to the Future Cash Payments and determined that it was probable that a significant revenue reversal would not occur in future periods for only $2.5 million of the total amount as of March&#160;31, 2019 and recognized $2.5 million revenue in that quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July&#160;and August&#160;2019, Rezolute received additional cash through two common stock financing events, which triggered early payment of $3.4 million of the unrecognized $6.0 million of total Future Cash Payments. In addition, the Company received the $1.5 million payment due September&#160;30, 2019, resulting in a total of $4.9 million cash received from Rezolute in the third quarter of 2019. The Company re-assessed the outstanding $3.6 million of Future Cash Payments and determined that a significant revenue reversal was not probable due to Rezolute&#8217;s recent common stock financing events. Therefore, in the third quarter of 2019, the Company recognized $6.0 million as revenue related to the remaining Future Cash Payments. In the fourth quarter of 2019, the Company received the scheduled $1.0 million Future Cash Payment from Rezolute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;"><i style="text-decoration:underline;">Rezolute License Agreement&#160;- Third Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 31, 2020, the Company and Rezolute further amended the license agreement to extend the payment schedule for the remaining $2.6 million in Future Cash Payments. The amendment to the payment terms was in response to Rezolute&#8217;s need to preserve cash as a result of the COVID-19 pandemic and w<span style="color:#231f20;">as agreed to by the Company. </span>The extended payment schedule did not impact the total amount due, but instead, spread the $2.6 million into seven quarterly payments to be paid through September 30, 2021. The amended license agreement requires<span style="color:#231f20;"> that in the event Rezolute completes a Qualified Financing at any time between March 31, 2020 and the date of the final payment, Rezolute shall pay all amounts outstanding within </span><span style="color:#231f20;">fifteen days</span><span style="color:#231f20;"> following the closing of the Qualified Financing. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the first quarter of 2020, the Company received the scheduled $0.4 million Future Cash Payment from Rezolute. The Company evaluated Rezolute&#8217;s cash position as of March 31, 2020, including the estimated impact of the COVID-19 pandemic, and determined payments scheduled beyond September 30, 2020 were unlikely to be collected unless Rezolute is able to obtain additional funding, which had not occurred as of March 31, 2020. Therefore, for the three months ended March 31, 2020, the Company recorded $1.4 million in bad debt expense related to the Future Cash Payments. The Company received the scheduled $0.4 million and $0.4 million Future Cash Payments from Rezolute in the second and third quarters of 2020, respectively. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $1.4 million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. On October 9, 2020, Rezolute completed a Qualified Financing, which resulted in acceleration of the remaining receivables balance and the Company received the entire $1.4 million in October 2020, as discussed in Note 14, Subsequent Events. <span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of September 30, 2020 and December&#160;31, 2019, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reassessed the development and regulatory milestones and concluded that such variable consideration is fully constrained and excluded from the transaction price as of September 30, 2020 and December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and Janssen Biotech,&#160;Inc. (&#8220;Janssen&#8221;) were parties to a license agreement which was terminated in 2017. In August&#160;2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year and sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue in the consolidated statement of comprehensive loss for the year ended December 31, 2019 as it had completed its performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, there were no contract assets or contract <span style="-sec-ix-hidden:Hidden_IvzhjoQ1qkKnonNbFMwDHw"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. Revenue of $0.2 million was recognized for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Zydus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 3, 2020, the Company and Cadila Healthcare Limited (&#8220;Zydus&#8221;) entered into a license agreement (the &#8220;Zydus Agreement&#8221;) under which the Company granted Zydus an exclusive royalty-bearing license to the Company&#8217;s anti-interleukin-2 (&#8220;IL-2&#8221;) monoclonal antibody, including mAb19, for Zydus to develop and commercialize drug candidates in India, Brazil, Mexico and certain other emerging markets. The Company retains rights in all other territories, subject to a Zydus right of first negotiation. Under the terms of the Zydus Agreement, Zydus is responsible for the development and commercialization of IL-2 based immune-oncology drug candidates. XOMA is entitled to receive up to $0.5 million development and regulatory milestone payments, up to $23.5 million commercial milestone payments, and mid-single digit to low teens royalties from Zydus. The Company is also eligible to share out-licensing revenue received by Zydus should Zydus (sub)license to third parties, which are tiered based on clinical trial stage and range from a low to mid double-digit&#160;percentage rate. Unless terminated earlier, the License Agreement will remain in effect, on a product-by-product basis, until all payment obligations end. The Zydus Agreement contains customary termination rights relating to material breach by either party. Zydus also has a unilateral right to terminate the agreement upon required written notice in advance if certain conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there is one performance obligation, and it had not completed its performance obligation. The development and regulatory milestone payments are solely dependent on Zydus&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of September 30, 2020. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Zydus and therefore, have also been excluded from the transaction price. Out-licensing revenue sharing will be recognized if and when Zydus receives or earns its out-licensing revenue. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, there were no contract assets or contract <span style="-sec-ix-hidden:Hidden_6KcCQ2KmOUSERG_vOJUbuA"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">liabilities</span></span> related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized for the three and nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">NIAID</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the sale of the Company&#8217;s biodefense business, the Company performed services under a $64.8 million multiple-year contract funded with federal funds from NIAID (Contract No.&#160;HHSN272200800028C), for development of anti-botulinum antibody product candidates. The contract work was being performed on a cost-plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company&#8217;s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2014, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID&#8217;s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. In October of 2019, NIH, which includes NIAID, notified the Company that it engaged KPMG to perform an audit of the Company&#8217;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. As of December&#160;31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection was remote. The Company classified $0.8 million as contract liabilities on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December&#160;21, 2016, the Company entered into two Royalty Interest Acquisition Agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer,&#160;Inc. (&#8220;Pfizer&#8221;)) for an upfront cash </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $0.4 million and $1.1 million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2020, respectively. The Company recognized $0.3 million and $0.8 million as revenue under units-of-revenue method under these arrangements during the three and nine months ended September 30, 2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company classified $1.4 million and $14.0 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively. As of December&#160;31, 2019, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $1.1 million and $15.3 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591337688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RoyaltyPurchaseAgreementAbstract', window );"><strong>Royalty Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RoyaltyPurchaseAgreementTextBlock', window );">Royalty Purchase Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Agenus,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;20, 2018, the Company entered into a Royalty Purchase Agreement (the &#8220;Agenus Royalty Purchase Agreement&#8221;) with Agenus,&#160;Inc., and certain affiliates (collectively, &#8220;Agenus&#8221;). Under the Agenus Royalty Purchase Agreement, the Company purchased from Agenus the right to receive 33% of the future royalties on six Incyte immuno-oncology assets, currently in development, due to Agenus from Incyte Europe Sarl (&#8220;Incyte&#8221;) (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low-single to mid-teen digit&#160;percentage of applicable net sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company purchased from Agenus the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck Sharp&#160;&amp; Dohme Corp. (&#8220;Merck&#8221;) and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single digit&#160;percentage of applicable net sales. Pursuant to the Agenus Royalty Purchase Agreement, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Royalty Purchase Agreement, the Company paid Agenus $15.0 million. The Company financed $7.5 million of the purchase price with a term loan under its Loan and Security Agreement with Silicon Valley Bank (&#8220;SVB&#8221;) (Note&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the condensed consolidated balance sheets. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected.&#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Bioasis Technologies,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February&#160;25, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Bioasis Royalty Purchase Agreement&#8221;) with Bioasis Technologies,&#160;Inc. and certain affiliates (collectively &#8220;Bioasis&#8221;). Under the Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. The Company exercised its option under the Bioasis Royalty Purchase Agreement and entered into a second royalty purchase agreement with Bioasis on November 2, 2020, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis Royalty Purchase Agreement, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income. As of September 30, 2020, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the three and nine months ended September 30, 2020. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Aronora,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April&#160;7, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Aronora Royalty Purchase Agreement&#8221;) with Aronora,&#160;Inc. (&#8220;Aronora&#8221;), which closed on June&#160;26, 2019. Under the Aronora Royalty Purchase Agreement, the Company purchased from Aronora the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to five anti-thrombotic hematology drug candidates. Three candidates are subject to Aronora&#8217;s collaboration with Bayer Pharma AG (&#8220;Bayer&#8221;) (the &#8220;Bayer Products&#8221;), including one which is subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties from these Bayer Products. The other two candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low-single digit&#160;percentage of net sales and 10% of Non-Royalties. The future payment&#160;percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#8217;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora Royalty Purchase Agreement, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8). The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September&#160;1, 2019 (up to a total of $3.0 million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora Royalty Purchase Agreement, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its condensed consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September&#160;2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement with Palobiofarma, S.L.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;26, 2019, the Company entered into a Royalty Purchase Agreement (the &#8220;Palo Royalty Purchase Agreement&#8221;) with Palobiofarma, S.L. (&#8220;Palo&#8221;), a company organized and existing under the laws of Spain. Pursuant to the Palo Royalty Purchase Agreement, the Company acquired the rights to potential royalty payments in low single digit&#160;percentages of aggregate Net Sales (as defined in the Palo Royalty Purchase Agreement) associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis (the &#8220;Licensee&#8221;) is a development partner on NIR178, one of the Palo Licensed Products, and such NIR178 is being developed pursuant to a license agreement between Palo and the Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo Royalty Purchase Agreement, the Company paid Palo a $10.0 million payment at the close of the transaction which occurred simultaneously upon parties&#8217; entrance in the Palo Royalty Purchase Agreement on September&#160;26, 2019. The Company financed $5.0 million of the payment with a term loan under its Loan and Security Agreement with SVB (Note&#160;8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its condensed consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the investment has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There was no change in the acquired royalty rights during the nine months ended September 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307593948136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 1&#160;&#8211; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 24.5pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;September&#160;30,&#160;2020 Using </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,572</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 681</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the three and nine months ended September 30, 2020, there were no transfers between Level 1, Level 2, or Level 3 assets reported at fair value on a recurring basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides a summary of changes in the estimated fair value of the Company&#8217;s Level 3 financial assets for the nine&#160;months ended September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br/>September 30, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 681</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,572</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified as long-term assets on the condensed consolidated balance sheets as of September 30, 2020 and December&#160;31, 2019. The equity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the Company and its valuation specialist valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the over-the-counter exchange and adjusted for an illiquidity discount. The inputs used to calculate the illiquidity discount are based on observable and unobservable estimates and judgments and therefore is classified as a Level 3 fair value measurement. As the Company has the right and option to sell up to 5,000,000 shares of Rezolute&#8217;s common stock back to Rezolute after December&#160;31, 2019 (Note&#160;4), the fair value of the equity securities was determined by dividing the total shares of Rezolute&#8217;s common stock held by the Company into two tranches based on the estimated time to a potential liquidity event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated fair value of the equity securities was calculated based on the following assumptions as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing common stock price on the Over-the-counter (OTC) exchange</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 1:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 2:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in any of the assumptions related to the unobservable inputs identified above may change the fair value of the equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Bioasis Royalty Purchase Agreement represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive (loss) income until settlement. As of September 30, 2020, there were no changes in the estimated fair value of the contingent consideration from its initial value of $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated fair value of the Company&#8217;s outstanding debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company&#8217;s outstanding long-term debt at September 30, 2020 and December&#160;31, 2019, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,217</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,903</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,713</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,048</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,939</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,277</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,761</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590256232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LeaseDisclosureTextBlock', window );">Lease Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;"> 7. Lease Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company leases one facility in Emeryville, California under an operating lease that expires in February&#160;2023. The Emeryville lease contains an option to early terminate the lease by notifying the landlord on or before February 1, 2020, which expired unexercised. The lease also contains an option to extend the lease for an additional term, however, the Company is not reasonably certain to exercise this option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company also previously leased two facilities in Berkeley, California under operating leases that had remaining lease terms until 2021 and 2023. On December 18, 2019, the Company entered into a Lease Termination Agreement (&#8220;the Lease Termination&#8221;) with each of the 7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street Properties II (&#8220;7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street LP&#8221;) and 7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street Property General Partnership (&#8220;7<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Street GP&#8221;) to early terminate the Company&#8217;s two operating leases in Berkeley, California. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company agreed to pay an early termination fee of $1.6 million in total and recognized a loss on lease termination of $0.4 million for the year ended December 31, 2019, which was included in other income (expense), net in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table summarizes maturity of the Company&#8217;s operating lease liabilities as of September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 450</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the three and nine months ended September 30, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,805</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,346</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,151</p></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,975</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The present value assumptions used in calculating the present value of the lease payments as of September 30, 2020 and December 31, 2019 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.42 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sublease Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the Company&#8217;s rights and obligations under its sublease arrangements transferred to 7th Street LP and 7th Street GP, and the Company was released from all financial obligations under its sublease agreements. Upon termination, the Company recognized a loss on lease termination of $0.4 million in other income (expense).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">No sublease income was recognized for the three and nine months ended September 30, 2020 due to the termination of the sublease agreements in 2019. For the three and nine months ended September 30, 2019, the Company recognized $0.8 million and $2.4 million of sublease income under these sublease agreements in other income (expense). </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590254952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt and Other Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt and Other Financings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Long-Term Debt and Other Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Silicon Valley Bank Loan Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May&#160;7, 2018 (the &#8220;Effective Date&#8221;), the Company executed a Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with SVB. Under the Loan Agreement, upon the Company&#8217;s request, SVB may make advances (each, a &#8220;Term Loan Advance&#8221;) available to the Company up to $20.0 million (the &#8220;Term Loan&#8221;). The Company was allowed to borrow advances under the Term Loan from the Effective Date until the earlier of March&#160;31, 2019 or an event of default (the &#8220;Draw Period&#8221;). In March 2019, the Draw Period was extended from March&#160;31, 2019 to March&#160;31, 2020. As of March 31, 2020, the Loan Agreement has not been amended to extend the Draw Period further. In the event of a default related to the Note&#160;Agreement with Novartis, SVB&#8217;s obligation to make any credit extensions to the Company under the Loan Agreement will immediately terminate. The interest rate will be calculated at a rate equal to the greater of (i)&#160;4.75%, or (ii)&#160;0.25% plus the prime rate as reported from time to time in The Wall Street Journal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal&#160;monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i)&#160;the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii)&#160;March&#160;1, 2023, or (iii)&#160;30 days prior to the earliest maturity of any portion of the Company&#8217;s loan with Novartis (the &#8220;Loan Maturity Date&#8221;). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The entire principal balance, including a final payment fee equal to 8.5% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to 3.00% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, 2.00% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and 1.00% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. In the event of a default, a default interest rate of an additional 4% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the &#8220;Warrant&#8221;). The Warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the Warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. In addition, the Company incurred debt issuance costs of $0.2 million in connection with the Loan Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March&#160;4, 2019, the Loan Agreement was amended to extend the Draw Period from March&#160;31, 2019 to March&#160;31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, both warrants are outstanding. In addition, both warrants may be exercised on a cashless basis and are exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2018, the Company borrowed advances of $7.5 million under the Loan Agreement in connection with the Agenus Royalty Purchase Agreement (Note&#160;5). The Company recorded a discount of $0.3 million against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2019, the Company borrowed advances totaling $9.5 million under the Loan Agreement in connection with the Aronora Royalty Purchase Agreement, Palo Royalty Purchase Agreement and payment of the Aronora Contingent Consideration (Note&#160;5). The Company recorded a discount of $45,000 against the debt, which is being amortized to interest expense over the term of the Term Loan Advance using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $0.2 and $0.5 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three&#160;and nine months ended September 30, 2020, respectively. The Company recorded $0.2 million and $0.4 million of non-cash interest expense resulting from the amortization of the discount and accretion of the final payment for the three and nine months ended&#160;September 30,&#160;2019, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, the carrying value of the debt under the Loan Agreement was $13.8 million. Of this amount, $9.0 million is classified as current portion of long-term debt and $4.8 million is classified as long-term debt on the condensed consolidated balance sheet. As of December&#160;31, 2019, the carrying value of the debt under the Loan Agreement was $16.4 million. Of this amount, $5.2 million was classified as current portion of long-term debt and $11.2 million was classified as long-term debt on the condensed consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Novartis Note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2005, the Company executed a secured note agreement (the &#8220;Note&#160;Agreement&#8221;) with Novartis, which was due and payable in full in June&#160;2015. Under the Note&#160;Agreement, the Company borrowed semi-annually to fund up to 75% of the Company&#8217;s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrues at six-month LIBOR plus 2%, which was equal to 2.41% at September 30, 2020, and the interest rate resets in June and December annually. Accrued interest is payable semi-annually in June&#160;and December&#160;of each&#160;year or, at the Company&#8217;s election, the semi-annual interest payments may be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount does not exceed $50.0 million. The Company has made this election for all interest payments. Loans under the Note&#160;Agreement are secured by the Company&#8217;s interest in its collaboration with Novartis, including any payments owed to it thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2015, concurrent with the execution of a license agreement with Novartis International as discussed in Note 4, XOMA and NIBR, who assumed the rights to the note from Novartis Vaccines Diagnostics,&#160;Inc. executed an amendment to the Note&#160;Agreement (the &#8220;Secured Note&#160;Amendment&#8221;) under which the parties extended the maturity date of the note from September&#160;30, 2015 to September&#160;30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note will be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;22, 2017, in connection with the XOMA-052 License Agreement with Novartis, the Company and NIBR executed an amendment to the Secured Note&#160;Amendment under which the parties further extended the maturity date of the Secured Note&#160;Amendment from September&#160;30, 2020 to September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020 and December 31, 2019, the outstanding principal balance under the Secured Note Amendment was $16.2 million and $15.9 million, respectively, and was included in long-term debt in the accompanying condensed consolidated balance sheets. On October 21, 2020, Novartis International achieved a clinical development milestone pursuant to the License Agreement and the Company earned a $25.0 million milestone payment as a result, of which $7.3 million will be recognized as a reduction to the debt obligation to Novartis, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Payments of Long-Term Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aggregate future principal, final payment fees and discounts of the Company&#8217;s long-term debt as of September 30, 2020, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,270</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,534</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,200</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,004</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: interest, final payment fees, discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,052)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments, net of interest, final payment fees, discount and issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,952</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,962)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,990</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB loans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 314</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,073</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 540</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,336</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307593348280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommonStockWarrantDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of September 30, 2020 and December&#160;31, 2019, the following common stock warrants were outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,063</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,249</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,332</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,845</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,426</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,489</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockWarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockWarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591534984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $7.6 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the Company&#8217;s royalty purchase agreement with Bioasis the Company has committed to pay the Bioasis Contingent Consideration. The Company recorded $0.1 million for the Bioasis Contingent Consideration which represents the estimated fair value of these potential future payments at the inception of the agreements. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of September 30, 2020, there were no changes in the estimated fair value of the contingent consideration from its initial value. The liability for future Aronora Royalty Milestones will be recorded when the amounts by product are estimable and probable. As of September 30, 2020, none of these Aronora Royalty Milestones were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590210760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Stock-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, RSUs, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an Employee Stock Purchase Plan (&#8220;ESPP&#8221;) that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options generally vest&#160;monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There were no stock options granted during the three months ended September 30, 2020. The fair value of the stock options granted during the three months ended September 30, 2019 and nine months ended September 30, 2020 and 2019, was estimated based on the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.47 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.60 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock option activity for the nine&#160;months ended September 30, 2020, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,839,623</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.88</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,829</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,779</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,864</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,659,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,167</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the nine&#160;months ended September 30, 2020 and 2019 was $0.1 million and $0.6 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted during the nine&#160;months ended September 30, 2020 and 2019 was $16.22 and $11.45, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2020, $3.3 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 1.59&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Performance-Based Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense associated with the corporate performance-based stock options is recognized if the performance condition is considered probable of achievement using management&#8217;s best estimates. In 2017, the Company granted performance-based stock options with vesting criteria related to performance in 2017, 2018, and 2019. In 2019, the Company had 41,250 shares remaining related to outstanding performance-based stock options with a grant date fair value of $0.2 million that had vesting criteria based solely on the achievement of fiscal year 2019 corporate goals as set by the Compensation Committee of the Company&#8217;s Board of Directors. For the year ended December 31, 2019, the Company determined that all remaining performance criteria were achieved and therefore the related expense of $0.2 million was recognized for the year ended December 31, 2019. After December 31, 2019, no performance-based stock options were outstanding and there was no unrecognized compensation cost related to performance-based stock options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,059</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,269</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,233</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591265496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 12.25pt;"><span style="font-style:italic;font-weight:bold;">Rights Offering 2019</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">On December 2, 2019, the Company commenced a rights offering to raise up to $22.0 million through the distribution of subscription rights to holders of its common stock, Series X preferred stock and Series Y preferred stock (the &#8220;2019 Rights Offering&#8221;).<i style="font-style:italic;"> </i>In December 2019, the Company sold a total of 1,000,000 shares of common stock under the 2019 Rights Offering for aggregate gross proceeds of $22.0 million. Total offering costs of $0.2 million were offset against the proceeds from the sale of common stock, for total net proceeds of $21.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The 2019 Rights Offering was fully backstopped by Biotechnology Value Fund, L.P. (&#8220;BVF&#8221;) </span><span style="font-style:normal;font-weight:normal;">pursuant to the terms of an Investment Agreement between the Company and BVF (the &#8220;Investment Agreement&#8221;)</span><span style="font-style:normal;font-weight:normal;">. In total, BVF purchased </span><span style="font-style:normal;font-weight:normal;">845,463</span><span style="font-style:normal;font-weight:normal;"> shares of common stock and the Company will pay approximately </span><span style="font-style:normal;font-weight:normal;">$18,000</span><span style="font-style:normal;font-weight:normal;"> for BVF&#8217;s reasonable legal fees and expenses in connection with the </span><span style="font-style:normal;font-weight:normal;">Investment Agreement and </span><span style="font-style:normal;font-weight:normal;">the 2019 Rights Offering. One of the Company&#8217;s Directors, Matthew Perry, is the President of BVF. Each share of common stock has a stated value of </span><span style="font-style:normal;font-weight:normal;">$22.00</span><span style="font-style:normal;font-weight:normal;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In February 2020, BVF elected to increase the beneficial ownership limitation of the Series Y preferred stock to </span><span style="font-style:normal;font-weight:normal;">50%</span><span style="font-style:normal;font-weight:normal;">, which became effective on April 11, 2020. On April 15, 2020, BVF converted all of their shares of Series Y preferred stock into common stock. As of September 30, 2020, BVF owned approximately </span><span style="font-style:normal;font-weight:normal;">37.9%</span><span style="font-style:normal;font-weight:normal;"> of the Company&#8217;s total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own </span><span style="font-style:normal;font-weight:normal;">57.3%</span><span style="font-style:normal;font-weight:normal;"> of the Company&#8217;s total outstanding shares of common stock. </span><span style="font-style:normal;font-weight:normal;">Due to its significant equity ownership, BVF is considered a related party of the Company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 12.25pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y preferred stock in 2018. There were 5,003 shares of Series X convertible preferred stock and no shares of Series Y convertible preferred stock outstanding as of September 30, 2020, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. The Series&#160;X and Series&#160;Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series&#160;Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Beneficial Conversion Feature&#8212; </i>The fair value of the common stock into which the Series&#160;X convertible preferred stock is convertible exceeded the allocated purchase price of the Series&#160;X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series&#160;X convertible preferred stock sold on February&#160;16, 2017 multiplied by the difference between the fair value of the common stock and the Series&#160;X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series&#160;X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. There was no beneficial conversion feature associated with the issuance of Series&#160;Y convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;18, 2018, the Company entered into an At The Market Issuance Sales Agreement (the &#8220;2018 ATM Agreement&#8221;) with H.C. Wainwright&#160;&amp; Co., LLC (&#8220;HCW&#8221;), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule&#160;415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 ATM Agreement. No shares have been sold under the 2018 ATM Agreement since the agreement was executed.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590290328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law. The CARES Act includes a number of income tax changes, including, but not limited to (1) permitting NOL carrybacks to offset 100% of taxable income for taxable years beginning before 2021, (2) accelerating AMT tax refunds, (3) temporarily increasing the allowable business interest deduction from 30% to 50% of adjusted taxable income, and (4) providing a technical correction for depreciation as relates to qualified improvement property.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded an income tax benefit of $1.5 million for the nine months ended September 30, 2020 as a result of the CARES Act, which was enacted on March 27, 2020. The CARES Act permits the Company to carry back losses from 2018 to offset its income in 2017 resulting in an income tax receivable. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a total of $5.5 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization. The Company currently has a full valuation allowance against its U.S. net deferred tax assets, which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through September 30, 2020, the Company has not accrued interest or penalties related to uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307593474552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 9, 2020, Rezolute completed a private placement of its equity securities with gross proceeds of $41.0 million, which is considered a Qualified Financing event under the Third Amendment. The Qualified Financing resulted in acceleration of the remaining receivables of $1.4 million due from Rezolute, and the Company received the entire amount in October 2020. The Company reassessed the collectability of the outstanding receivables and determined that the bad debt allowance of $1.4 million remained appropriate as of September 30, 2020, as the Company assessed that the financing was not probable as of the balance sheet date and as such the Company continued to have an incurred loss with respect to the collection of the remaining receivable. The Company will recognize the $1.4 million as a reversal of bad debt expense in the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 21, 2020, NIS793, an anti-TGF&#946; monoclonal antibody, licensed from the Company to Novartis International under the License Agreement, advanced to the Phase 2 development stage. &#160;As a result of the advancement, Novartis International achieved a clinical development milestone pursuant to the License Agreement, and the Company earned a $25.0 million milestone payment. As specified under the terms the License Agreement, the Company will receive $17.7 million in cash and the remaining balance of $7.3 million will be recognized as a reduction to the Company&#8217;s debt obligation to Novartis. The Company will record $25.0 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive income (loss) in the fourth quarter of 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company exercised its option previously granted under the Bioasis Royalty Purchase Agreement and entered into another Royalty Purchase Agreement (the &#8220;Second Bioasis Royalty Purchase Agreement&#8221;) with Bioasis. Under the Second Bioasis Royalty Purchase Agreement, the Company purchased potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a Research Collaboration and License Agreement between Bioasis and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;). The Company paid Bioasis $1.2 million upon closing of the Second Bioasis Royalty Purchase Agreement for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307609481176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;10, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under units-of-revenue method, royalty receivables, equity securities, operating lease right-of-use assets and liabilities, legal contingencies, contingent considerations under royalty purchase agreements, stock-based compensation and income taxes. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s billing under government contracts and amortization of the payments received from HealthCare Royalty Partners II,&#160;L.P. (&#8220;HCRP&#8221;). Under the Company&#8217;s contracts with the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;), a part of the National Institutes of Health (&#8220;NIH&#8221;), the Company billed using NIH&#8217;s provisional rates and thus is subject to future audits at the discretion of NIAID&#8217;s contracting office. In October of 2019, NIH notified the Company that it engaged KPMG to perform an audit of the Company&#8217;s incurred cost submissions for 2013, 2014 and 2015. This audit is not complete and may result in an adjustment to revenue previously reported which potentially could be material. In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The worldwide spread of the COVID-19 pandemic has resulted in a global slowdown of economic activity which has led to delays and could result in further delays or terminations of some clinical trials underlying the Company&#8217;s royalty purchase agreements. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>("ASC 606"), except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock', window );">Sale of Future Revenue Streams</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the &#8220;Black-Scholes Model&#8221;). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EquitySecuritiesPolicy', window );">Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company received shares of common stock from Rezolute, Inc. (&#8220;Rezolute&#8221;) (Note&#160;4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive (loss) income in the period of sale.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock', window );">Purchase of Rights to Future Milestones and Royalties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase of Rights to Future Milestones and Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note&#160;5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If freestanding instruments, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value is recorded in the condensed consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent since no payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews any impairment indicators and changes in expected recoverability of the long-term royalty receivable asset at least quarterly. If expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of September 30, 2020 and December&#160;31, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement for its corporate headquarters in Emeryville, California and under its legacy business held leases for office and laboratory facilities in Berkeley, California. In connection with a series of restructuring events in 2017 and 2018, the Company completely vacated its leased facilities in Berkeley, California and subleased the space in the vacated buildings. In December 2019, the Company terminated its legacy operating leases in Berkeley, California and was fully released from any further payment obligations. As a result of the lease terminations the Company was also released from all financial obligations under its sublease agreements. The Company continues to lease its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for operating leases is recognized on a straight-line basis, unless the right-of-use asset has been impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If an operating lease were to reflect impairment, the Company will recognize the amortization of the right-of-use asset on a straight-line basis over the remaining lease term with rent expense still included in operating expenses in the condensed consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Prior Period Reclassifications</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Prior Period Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Within the condensed consolidated statement of cash flows, the Company separately presented the non-cash lease expense and changes in operating lease liabilities for the prior period to conform with current period presentation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net (Loss) Income per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net (loss) income per share attributable to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net (loss) income attributable to common stockholders consists of net (loss) income, as adjusted for any convertible preferred stock deemed dividends related to beneficial conversion features on this instrument at issuance. During periods of income, the Company allocates participating securities a proportional share of net income, after deduction of any deemed dividends on preferred stock, determined by dividing total weighted average participating securities by the sum of the total weighted average number of common stock and participating securities (the &#8220;two-class method&#8221;). The Company&#8217;s convertible preferred stock participates in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. For the three and nine months ended September 30, 2020 and 2019, the Company did not declare any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share attributable to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to loss per share attributable to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade and other receivables, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Trade and other receivables, net</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade and other receivables, net consist mainly of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. <span style="background-color:#ffffff;">Trade and other receivables are recorded upon triggering events specified in the agreement. Trade receivables under ASC 606 are recorded separately from contract assets when only the passage of time is required before consideration is due. </span>The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry, or specific customer conditions that may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts. Any increases to allowance for doubtful accounts are charged to operating expenses. The Company recorded $1.4 million in allowance for doubtful accounts for the three months ended March 31, 2020 related to Rezolute&#8217;s license agreement (Note 4). The Company evaluated the&#160;accounts&#160;receivable and determined there was no further activity in allowance for doubtful accounts for the second and third quarters in 2020. The previously reserved accounts receivable from Rezolute was accelerated and collected in October 2020, as discussed in Note 14, Subsequent Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br/>September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charged to operating expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three&#160;months ended September 30, 2020, two partners represented&#160;64% and 36% of total revenues. For the nine&#160;months ended September 30, 2020, three partners represented&#160;58%, 28% and 11% of total revenues. For the three&#160;months ended September 30, 2019, two partners represented 68% and 28% of total revenues. For the nine&#160;months ended September 30, 2019, two partners represented 78% and 14% of total revenues. As of September 30, 2020 and as of December&#160;31, 2019, one partner represented 100% of the trade receivables, net balance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (Loss) Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-13,&#160;<i style="font-style:italic;">Fair Value Measurement (Topic 820) (&#8220;ASU 2018-13&#8221;)</i>, which modifies, removes and adds certain disclosure requirements on fair value measurements based on the FASB&#160;<i style="font-style:italic;">Concepts Statement, Conceptual Framework for Financial Reporting&#8212;Chapter&#160;8: Notes&#160;to Financial Statements</i>. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the&#160;year ending December&#160;31, 2020, and all annual and interim reporting period thereafter. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal&#160;year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company early adopted the guidance related to removal of disclosures upon issuance of this ASU and adopted the deferred provisions as permitted under the ASU in the first quarter of 2020. The adoption of ASU 2018-13 did not have a material impact<span style="color:#212529;">&#160;</span>on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) &#8220;Clarifying the Interaction between Topic 808 and Topic 606,&#8221; which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service that is a distinct unit of account. The new standard also precludes an entity from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The ASU is effective for the Company&#8217;s interim and annual reporting periods during the year ending December 31, 2020, and all annual and interim reporting period thereafter. Early adoption is permitted, but no earlier than an entity&#8217;s adoption date of Topic 606. This ASU requires retrospective adoption to the date the Company adopted ASC 606, January 1, 2018, by recognizing a cumulative-effect adjustment to the opening balance of retained earnings of the earliest annual period presented. The Company may elect to apply the ASU retrospectively either to all contracts or only to contracts that are not completed at the date it initially applied ASC 606. The Company adopted ASU 2018-18 as of January 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for all entities except public companies that are not smaller reporting companies for fiscal&#160;years beginning after December&#160;15, 2022, including interim periods within those fiscal&#160;years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13 and related updates&#160;as of January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued&#160;ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </i>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning January 1, 2021 with early adoption permitted. The Company is evaluating the impact <span style="color:#212529;">of adopting this new accounting guidance </span>on its condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March&#160;2020, the FASB issued&#160;ASU&#160;2020-04,&#160;<i style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. These amendments provide temporary optional guidance to ease the potential burden in accounting for reference rate reform. The&#160;ASU&#160;provides optional expedients and exceptions for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. It is intended to help stakeholders during the global market-wide reference rate transition period. The guidance is effective for all entities as of March 12,&#160;2020&#160;through December 31, 2022 and can be adopted as of any date from the beginning of an interim period that includes or is subsequent to March 12,&#160;2020. The Company is evaluating the impact of adopting this new accounting guidance on its condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future milestones and royalties purchase rights policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sale of future revenue streams.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594318264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of activity in allowance for doubtful accounts</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table shows the activity in the allowance for doubtful accounts from continuing operations for the nine months ended September 30, 2020 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br/>September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Beginning balance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Charged to operating expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,409</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307598517672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CondensedConsolidatedFinancialStatementsDetailAbstract', window );"><strong>Condensed Consolidated Financial Statements Detail [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and Other Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 256</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 332</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 945</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss or income) and the denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Net (loss) income  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,339</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,327)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (977)</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,362</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,077)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,368)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,403</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,731</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,537</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,721</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 657</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,379</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.10)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.89)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.16</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.89)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.15</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Securities Considered Anti-Dilutive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,483</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 893</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 926</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,115</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 941</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CondensedConsolidatedFinancialStatementsDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Condensed consolidated financial statements detail.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CondensedConsolidatedFinancialStatementsDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591500632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;September&#160;30,&#160;2020 Using </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,572</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2019 Using</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 681</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Estimated Fair Value of Level 3 Financial Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides a summary of changes in the estimated fair value of the Company&#8217;s Level 3 financial assets for the nine&#160;months ended September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:15.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended <br/>September 30, 2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 681</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at September&#160;30,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,572</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Estimated Fair Value of Equity Securities Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The estimated fair value of the equity securities was calculated based on the following assumptions as of September 30, 2020 and December 31, 2019:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closing common stock price on the Over-the-counter (OTC) exchange</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.12</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 1:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tranche 2:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount for lack of marketability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated time to liquidity of shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.25 year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Outstanding Long Term Debt Carrying Amount and Estimated Fair Value</a></td>
<td class="text">The carrying amount and the estimated fair value of the Company&#8217;s outstanding long-term debt at September 30, 2020 and December&#160;31, 2019, are as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2019</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying&#160;Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,220</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,217</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,903</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,713</p></td></tr><tr><td style="vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB Loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,722</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,048</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,952</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,939</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,277</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,761</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592030120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity of operating lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">The following table summarizes maturity of the Company&#8217;s operating lease liabilities as of September 30, 2020 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Undiscounted lease payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Leases</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 480</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30)</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total net lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 450</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of cost components of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating leases for the three and nine months ended September 30, 2020 and 2019 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 133</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,805</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 375</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,346</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 970</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,151</p></td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock', window );">Summary of supplemental cash flow information related to operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,975</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock', window );">Schedule of present value assumptions used in calculating the present value of lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average remaining lease term</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2.42 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted-average discount rate</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591797816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt and Other Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Aggregate future principal, final payment fees and discounts of the Company&#8217;s long-term debt as of September 30, 2020, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2020 (excluding nine months ended September 30, 2020)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,270</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,534</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,200</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,004</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: interest, final payment fees, discount and issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,052)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total payments, net of interest, final payment fees, discount and issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,952</p></td></tr><tr><td style="vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,962)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:79.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,990</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock', window );">Interest Expense and Amortization of Debt Issuance Costs and Discounts</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SVB loans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 314</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,073</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 409</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 540</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:45.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,336</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of aggregate amount of interest expense and the amortization of debt issuance costs and discounts on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591540088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Common Stock Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2015</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66.20</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,063</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,249</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2018</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May&#160;2028</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,332</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,845</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,426</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,489</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307640543576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.77</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.49</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:41.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.47 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.60 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock option activity for the nine&#160;months ended September 30, 2020, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of&#160;year</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,839,623</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.88</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,829</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,000)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.28</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,655)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 141.47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at end of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,002,779</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.41</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,864</p></td></tr><tr><td style="vertical-align:bottom;width:59.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,659,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,167</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows total stock-based compensation expense for stock options and ESPP in the condensed consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174</p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,269</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,059</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 708</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,269</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,233</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594330696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 45,725<span></span>
</td>
<td class="nump">$ 56,688<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594161720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract', window );"><strong>Purchase of Rights to Future Milestones and Royalties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591578712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - EPS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594352792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Increase (decrease) in allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Charged to operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307595423080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details) - Customer Concentration Risk - customer<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Trade Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenues | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenues | Partner 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenues | Partner 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfMajorPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfMajorPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307605908760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)<br></strong></div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Adopted Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in Accounting Principle, Accounting Standards Update, Early Adoption</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">ASU 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Adopted Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520240&amp;loc=SL120174030-210619<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594568920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Detail - Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EquitySecuritiesFvNiNonCurrent', window );">Equity securities</a></td>
<td class="nump">$ 2,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">$ 481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EquitySecuritiesFvNiNonCurrent', window );">Equity securities</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesFvNiNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FvNi non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesFvNiNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592183048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued and other liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other benefits</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentive compensation</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 945<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307598478856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (1,077)<span></span>
</td>
<td class="num">$ (3,533)<span></span>
</td>
<td class="num">$ (4,758)<span></span>
</td>
<td class="nump">$ 3,178<span></span>
</td>
<td class="num">$ (4,072)<span></span>
</td>
<td class="nump">$ 3,233<span></span>
</td>
<td class="num">$ (9,368)<span></span>
</td>
<td class="nump">$ 2,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Allocation of undistributed earnings to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(977)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income available to common stockholders, basic</a></td>
<td class="num">(1,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,368)<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Add: Adjustments to undistributed earnings allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income available to common stockholders, diluted</a></td>
<td class="num">$ (1,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,368)<span></span>
</td>
<td class="nump">$ 1,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net (loss) income per share available to common stockholders</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,537<span></span>
</td>
<td class="nump">8,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Effect of dilutive warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net (loss) income per share available to common stockholders</a></td>
<td class="nump">11,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,537<span></span>
</td>
<td class="nump">9,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share of common stock</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share of common stock</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602052520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">611<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592722808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>USD ($) </div>
<div>item </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>EUR (&#8364;) </div>
<div>item </div>
<div>agreement </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | XOMA-052 License Agreement and I L1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreements', window );">Number of license agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ArrangementsNumber', window );">Number of arrangements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | XOMA-052 License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">&#8364; 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | XOMA-052 License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares) | shares</a></td>
<td class="nump">539,131<span></span>
</td>
<td class="nump">539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.2742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Issuance of common stock, fair value</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ArrangementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of arrangements the agreements are accounted for.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ArrangementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock premium received on sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of license agreement consideration received as repayment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds from upfront payment received as consideration in transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602453768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis International (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307604361080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute (Details) - Rezolute - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 06, 2017</div></th>
<th class="th"><div>Jun. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations', window );">Percentage of decrease in future royalty obligations</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">License Agreement, RZ358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 232.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">License Agreement, Non-RZ358 products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">License Agreement, X129</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UpfrontOptionPayment', window );">Upfront option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfDecreaseInFutureRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontOptionPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment  to be received from counterparty, if counterparty  elects option to obtain exclusive license for one of entity's products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontOptionPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementX129Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementX129Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307604221272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute - First Amendment (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 07, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2018 </div>
<div>USD ($) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 8,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,804<span></span>
</td>
<td class="nump">$ 17,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">8,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleToReceiveInCash', window );">Amount of cash eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities', window );">Amount of Rezolute's common stock eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommonStockSharesReceivable', window );">Number of Rezolute's common stock eligible to receive contingent on completion of financing activities | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_GrossProceedsFromQualifiedFinancing', window );">Gross proceeds to be raised for qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AdditionalCommonStockReceiveForQualifiedFinancing', window );">Additional common stock to be received if Rezolute did not complete financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommonStockThresholdTradingDays', window );">Common stock trading period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement', window );">Eligible to receive, in order to maintain license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_SharesReceived', window );">Transaction price, Shares received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,093,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,093,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CashReceived', window );">Transaction price, cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ArrangementsNumber', window );">Number of arrangements | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LicenseAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_SharesReceivedValue', window );">Transaction price, Value of common stock received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ReimbursableTechnologyTransferExpensesReceived', window );">Reimbursable technology transfer expense received</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment', window );">Upfront consideration to incremental discount for future payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ReimbursableTechnologyTransferExpensesReceived', window );">Reimbursable technology transfer expense received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfSharesRightAndOptionToSell', window );">Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell', window );">Percent of Rezolute's shares held Company has right and option to sell if Rezolute does not list common stock shares on national exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AdditionalCommonStockReceiveForQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional amount of counterparty's common stock entity was eligible to receive if counterparty did not complete specified financing under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AdditionalCommonStockReceiveForQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ArrangementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of arrangements the agreements are accounted for.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ArrangementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash consideration received by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockSharesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of counterparty's common stock company may receive under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockSharesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading period used in number of shares calculation under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of counterparty's common stock entity is eligible to receive under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleToReceiveInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible to receive in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleToReceiveInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional amount of cash entity is eligible to receive if counterparty does not complete qualified financing by specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_GrossProceedsFromQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum gross proceeds required to be raised by counterparty for qualified financing under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_GrossProceedsFromQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfSharesRightAndOptionToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfSharesRightAndOptionToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReimbursableTechnologyTransferExpensesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursable technology transfer expenses received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReimbursableTechnologyTransferExpensesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_SharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration received in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_SharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_SharesReceivedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares received for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_SharesReceivedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration to incremental discount for future payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307514730328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 07, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Apr. 03, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Bad debt allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities', window );">Amount of Rezolute's common stock eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing', window );">Number of future cash payments upon closing of the qualified financing | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing', window );">Future cash payments upon closing of the qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing', window );">Percentage of net proceeds of each future financing upon closing of the qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds received by third party from preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ConsiderationPaidUponQualifiedFinancingEvent', window );">Consideration received following qualified financing event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ReimbursableTechnologyTransferExpensesReceived', window );">Reimbursable technology transfer expense received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DoubtfulRevenueReversalOfFutureCashPayments', window );">Doubtful revenue reversal of future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementNumberOfCommonStockFinancingEvents', window );">Number of common stock financing events | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EarlyPaymentOfUnrecognizedFutureCashPayments', window );">Early payment of unrecognized future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UnrecognizedFutureCashPayments', window );">Unrecognized future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsReceived', window );">Future cash payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment', window );">Upfront consideration to incremental discount for future payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsOfRevenueRecognized', window );">Future cash payments of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ReimbursableTechnologyTransferExpensesReceived', window );">Reimbursable technology transfer expense received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsOfRevenueRecognized', window );">Future cash payments of revenue recognized</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfQuarterlyPayments', window );">Number of quarterly payments | installment</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing', window );">Payment period following closing of Qualified Financing</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Bad debt allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsReceived', window );">Future cash payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfSharesRightAndOptionToSell', window );">Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | Common Stock Purchase Agreement | Forecast | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfSharesRightAndOptionToSell', window );">Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementNumberOfCommonStockFinancingEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock financing events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementNumberOfCommonStockFinancingEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsiderationPaidUponQualifiedFinancingEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration received from counterparty following qualified financing event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsiderationPaidUponQualifiedFinancingEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DoubtfulRevenueReversalOfFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Doubtful revenue reversal of future cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DoubtfulRevenueReversalOfFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EarlyPaymentOfUnrecognizedFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early payment of unrecognized future cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EarlyPaymentOfUnrecognizedFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of counterparty's common stock entity is eligible to receive under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureCashPaymentsOfRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash payments of revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureCashPaymentsOfRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureCashPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureCashPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash payments upon closing of qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of future cash payments upon closing of qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfQuarterlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfQuarterlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfSharesRightAndOptionToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfSharesRightAndOptionToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment period within which counterparty will pay outstanding amounts following closing of Qualified Financing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net proceeds of each future financing upon closing of the qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds third party received from issuance of capital stock which triggered a Qualified Financing event under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReimbursableTechnologyTransferExpensesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursable technology transfer expenses received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReimbursableTechnologyTransferExpensesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UnrecognizedFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized future cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UnrecognizedFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration to incremental discount for future payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307598060264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen Biotech Inc. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OneTimePayment', window );">One-time payment</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents', window );">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization', window );">Percentage of royalty on worldwide net sales of each product upon commercialization</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OneTimePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One-time payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OneTimePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales upon commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602443880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Zydus (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 03, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ZydusMember', window );">Zydus | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents', window );">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones', window );">Maximum amount receivable upon achievement of commercial milestones</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68051541&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ZydusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ZydusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307608706952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - NIAID (Details) - NIAID - Arrangement with Governmental Agency - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2008</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MaximumRevenueFromContract', window );">Total contract amount awarded</a></td>
<td class="nump">$ 64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractualTerm', window );">Contractual term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue/Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractsRevenueWroteOff', window );">Accounts receivable written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractsRevenueWroteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in accounts receivable due to contracts revenue written off during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractsRevenueWroteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumRevenueFromContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum revenue from contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumRevenueFromContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_DeferredRevenueArrangementNameOfParty2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_DeferredRevenueArrangementNameOfParty2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307607893832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>period</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,052)<span></span>
</td>
<td class="num">$ (772)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 15,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">Health Care Royalty Partners Two Limited Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">Health Care Royalty Partners Two Limited Partners | Royalty Interest Acquisition Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">Health Care Royalty Partners Two Limited Partners | First Royalty Interest Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Initial payment received</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones', window );">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MilestonePeriodsNumber', window );">Number of milestone periods | period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">Health Care Royalty Partners Two Limited Partners | Second Royalty Interest Acquisition Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Initial payment received</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePeriodsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePeriodsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of royalty interest acquisition agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfRoyaltyInterestAcquisitionAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds from upfront payment received as consideration in transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602261432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Agreements - Agenus (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Agenus | Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Agenus | Incyte Immuno-Oncology Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts', window );">Royalties on net sales of products (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased', window );">Number of licensed products related to milestone and royalties | product</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Agenus | Merck Immuno-Oncology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts', window );">Royalties on net sales of products (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones', window );">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</a></td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty receivable non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products related to milestones and royalties purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307595606408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Agreements - Bioasis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,375<span></span>
</td>
<td class="nump">34,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis Technologies Inc | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements', window );">Percentage of option to purchase royalty right on future license agreements</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements', window );">Number of future license agreements under optional purchase right | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement', window );">Obligation upon exercise of options per licensed product, second agreement</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement', window );">Obligation upon exercise of options per licensed product, third agreement</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis Technologies Inc | Royalty Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty receivable non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of future license agreements under optional purchase right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreementsFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rights entity has option to  purchase in future license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307593298216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Agreements - Aronora (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 07, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Aronora</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage', window );">Future non-royalty payments to be received (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementPaymentPercentageFactor', window );">Multiplier for cumulative amount of consideration paid | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount', window );">Threshold amount of cumulative royalties on net sales per product</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct', window );">Aggregate milestones payments per product</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Aronora | Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Aronora | Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber', window );">Number of drug candidates subject to exclusive license option | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts', window );">Royalties on net sales of products (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentFutureCashPaymentsPerProduct', window );">Contingent future cash payment for each product</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Aronora | Non-Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates subject to exclusive license option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementPaymentPercentageFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Multiplier used in determining change in payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementPaymentPercentageFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent future cash payment for each product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty receivable non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesPaymentsToAggregateAmountOfPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of non-royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_BayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_BayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_NonBayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_NonBayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602076888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Purchase Agreements - Palobiofarma (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,375<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease', window );">Increase (decrease) of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Palobiofarma, S.L.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermRoyaltyReceivableNonCurrent', window );">Long-term royalty receivables</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Palobiofarma, S.L. | Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty receivable non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) of long-term royalty receivable, noncurrent, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594461560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract', window );"><strong>Transfers between Levels</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Level 1 to Level 2 transfers, Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Level 2 to Level 1 transfers, Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Level 1 to Level 2 transfers, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Level 2 to Level 1 transfers, Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">$ 681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602028424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>Y </div>
<div>item</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NumberOfSharesRightAndOptionToSell', window );">Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_EquitySecuritiesNumberOfTranches', window );">Number of tranches | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Closing common stock price | OTC exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
<td class="nump">0.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Discount for lack of marketability | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Discount for lack of marketability | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Estimated time to liquidity of shares | Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Estimated time to liquidity of shares | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity securities tranches.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfSharesRightAndOptionToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfSharesRightAndOptionToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_OTCM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_OTCM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=xoma_EquitySecuritiesTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=xoma_EquitySecuritiesTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=xoma_EquitySecuritiesTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=xoma_EquitySecuritiesTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590057144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="nump">$ 75<span></span>
</td>
<td colspan="2" class="nump">$ 75<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307595227192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">$ 29,952<span></span>
</td>
<td class="nump">$ 32,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">16,220<span></span>
</td>
<td class="nump">15,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">13,732<span></span>
</td>
<td class="nump">16,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">29,939<span></span>
</td>
<td class="nump">31,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">16,217<span></span>
</td>
<td class="nump">15,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt</a></td>
<td class="nump">$ 13,722<span></span>
</td>
<td class="nump">$ 16,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590279320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Leased facilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 17, 2019 </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 18, 2019 </div>
<div>facility</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesBerkeleyCaliforniaMember', window );">Leased facilities, Berkeley, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OperatingLeasesNumberOfLeasedFacilities', window );">Operating leases, number of leased facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities', window );">Number of operating leases terminated early</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OperatingLeaseEarlyTerminationFee', window );">Early termination fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Lease termination loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember', window );">Leased facilities, Emeryville, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_OperatingLeasesNumberOfLeasedFacilities', window );">Operating leases, number of leased facilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeaseEarlyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fee for early termination of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeaseEarlyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of leases for which the entity terminated the lease early.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasesNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases, number of leased facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasesNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesBerkeleyCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesBerkeleyCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307599166392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Agreements - Maturity of lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding nine months ended September 30, 2020)</a></td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591345880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 1,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 3,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591488632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602408984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Sublease Agreements (Details) - Leased facilities, Berkeley, California - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Lease termination loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesBerkeleyCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesBerkeleyCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307516658504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2019</div></th>
<th class="th"><div>May 07, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,489<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,184<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,093<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Common stock warrant, Exercise price $23.69 per share, Issued May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest', window );">Period of monthly payments of principal and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate', window );">Maximum period following loan amortization date for which loan will mature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan', window );">Maximum period prior to loan maturity date of Novartis loan for which loan will mature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentAmountToBeReborrowed', window );">Amount of loan that may be reborrowed after repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentFinalPaymentFeePercentage', window );">Final payment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan', window );">Additional interest rate in the event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense resulting from amortization of discount and accretion of final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Common stock warrant, Exercise price $23.69 per share, Issued May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of shares of common stock called by warrants</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of per share (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrant</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | On or before first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Following first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans | Following second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_FirstTermLoanMember', window );">Silicon Valley Bank, First Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SecondTermLoanMember', window );">Silicon Valley Bank, Second Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentAmountToBeReborrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loan that may be reborrowed after repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentAmountToBeReborrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final payment fee as a percent of principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee as a percent of amount prepaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period following loan amortization date for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum period prior to loan maturity date of specified loan for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ExercisablePeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ExercisablePeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional interest rate in the event of default (as a percent)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of monthly payments of principal and interest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_FirstTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_FirstTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SecondTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SecondTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307604327640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 21, 2020</div></th>
<th class="th"><div>May 31, 2005</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum', window );">Research and development expenses funded through loan facility, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate at period end (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_DebtInstrumentDecreaseUponAchievementOfMilestones', window );">Amount by which note will be reduced upon achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note | Six-month LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Reduction in debt obligation</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DebtInstrumentDecreaseUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DebtInstrumentDecreaseUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594322808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Debt and Other Financings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020 (excluding nine months ended September 30, 2020)</a></td>
<td class="nump">$ 2,270<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">8,534<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">21,200<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments', window );">Total payments</a></td>
<td class="nump">32,004<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: interest, final payment fees, discount and issuance costs</a></td>
<td class="num">(2,052)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total payments, net of interest, final payment fees, discount and issuance costs</a></td>
<td class="nump">29,952<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt</a></td>
<td class="num">(8,962)<span></span>
</td>
<td colspan="2" class="num">$ (5,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 20,990<span></span>
</td>
<td colspan="2" class="nump">$ 27,093<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and interest. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592957144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Other Financings - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 484<span></span>
</td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 1,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember', window );">Silicon Valley Bank Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_OtherFinancingsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_OtherFinancingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_OtherFinancingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602320104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Feb. 28, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">19,426<span></span>
</td>
<td class="nump">28,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedFirstRangeMember', window );">Common stock warrant, Exercise price $66.20 per share, Issued February 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedSecondRangeMember', window );">Common stock warrant, Exercise Price $15.40 per share, Issued February 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Common stock warrant, Exercise price $23.69 per share, Issued May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedFirstRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedFirstRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedSecondRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_FiveYearWarrantsIssuedSecondRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307590293288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePayments', window );">Estimate of milestone payments | $</a></td>
<td class="nump">$ 7.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts', window );">Assumed number of products per contract | product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential estimated obligations that due and payable upon achievement of certain criteria categorized as developmental, regulatory, or commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307607945448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Apr. 07, 2019</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="nump">$ 75<span></span>
</td>
<td colspan="2" class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractualObligationMilestonePayments', window );">Milestone liability</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Bioasis Technologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Aronora</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements', window );">Contingent consideration under royalty purchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><i style="font-style:italic;">The consolidated balance sheet as of December&#160;31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2019.</i></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration under royalty purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual obligation estimated fair value of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual obligations due to achievement of developmental, regulatory, or commercial milestones recorded as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591559672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage related to employees to purchase shares at the lower fair market value at offering period</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594705480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Options (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward', window );">Minimum age required for employees to qualify for immediate vesting of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">55 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge', window );">Threshold years required for retirement age</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum age required for employees to qualify for immediate vesting of award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307591396344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Weighted Average Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 5 months 19 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602543320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,839,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited, expired or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">2,002,779<span></span>
</td>
<td class="nump">2,002,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,839,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable at end of period</a></td>
<td class="nump">1,659,679<span></span>
</td>
<td class="nump">1,659,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at end of period</a></td>
<td class="nump">$ 19.41<span></span>
</td>
<td class="nump">19.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable at end of period</a></td>
<td class="nump">$ 19.64<span></span>
</td>
<td class="nump">$ 19.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 14,864<span></span>
</td>
<td class="nump">$ 14,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">14,167<span></span>
</td>
<td class="nump">14,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.22<span></span>
</td>
<td class="nump">$ 11.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation expense expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594138008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based stock options (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">$ 3,269<span></span>
</td>
<td class="nump">$ 4,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_StockOptionsVestingBasedOnPerformanceMember', window );">Stock Options Vesting Based On Performance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of options outstanding, non-vested options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_StockOptionsVestingBasedOnPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_StockOptionsVestingBasedOnPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307594399144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">$ 3,269<span></span>
</td>
<td class="nump">$ 4,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 708<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 3,269<span></span>
</td>
<td class="nump">$ 4,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307602224056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Rights Offering 2019 (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, stated value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=xoma_SeriesYConvertiblePreferredStockMember', window );">Series Y Preferred Stock | BVF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_BeneficialOwnershipLimitation', window );">Beneficial ownership limitation (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member', window );">2019 Rights Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock', window );">Aggregate gross proceeds from issuance of common stock and preferred stock</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member', window );">2019 Rights Offering | BVF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member', window );">2019 Rights Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Total number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member', window );">2019 Rights Offering | Common Stock | BVF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Total number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember', window );">BVF | Common Stock | Xoma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage on outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted', window );">Ownership interest, if shares are converted (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_BeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the beneficial ownership limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_BeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=xoma_SeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=xoma_SeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BiotechnologyValueFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BiotechnologyValueFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_RightsOffering2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=xoma_XomaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=xoma_XomaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307595622728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">6,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember', window );">Series X and Series Y Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock', window );">Fair value of common stock amount exceeded purchase price of convertible preferred stock</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember', window );">Series Y Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252.772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock amount exceeded allocated purchase price of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307592094568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - ATM Agreements (Details) - 2018 ATM Agreement<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 18, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_MaximumValueOfCommonStockToBeIssued', window );">Maximum amount of shares to be issued | $</a></td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares', window );">Sales commission paid per transaction (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumValueOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum value of common stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumValueOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307593469800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140307517321832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 21, 2020</div></th>
<th class="th"><div>Oct. 09, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Bad debt allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,525<span></span>
</td>
<td class="nump">753<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | Novartis International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Bad debt allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | License Agreement | Novartis International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Cash receivable</a></td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | License Agreement | Novartis International | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | License Agreement | Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_FutureCashPaymentsReceived', window );">Future cash payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Royalty Purchase Agreement | Bioasis Technologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights', window );">Payments to acquire milestones and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Rezolute | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock', window );">Aggregate gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Reduction in debt obligation</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureCashPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureCashPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MEWMV,*JC71?<F2> Y!=8$:_KW3<- F='H'6TBV8,*-]<3(EGEH'%AEIYM=S
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M1"WO5/'//#.;ZTD\(9E<BZ8P7]73KW(?4&#[2U51M[_)T][6FY"TJ8TJ]\Z
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M!O!\K6!KL+^Q+SC\(\+-?P%02P,$%     @ 5CUE4<4]M2T( P  "PH  !@
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MQH6L3A[51(N\_'A/A39'@7*8FM,:2&M@GL^$T"\3>QZHSW^]OU!+ P04
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MS X'*B/G=RTPR^YJH//A?_S;B[.ST^_^<G[^@?[YY+M'."!R[5-#A%WCO+X
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ME$7AL&<VEN4CPR#B%>FNYO<RJ8B%!;^(TZ]K\*TBC)GIHE0!>6NK<2GNEI\
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M XO\UQXP%M#T_*@U?LZ^)LQP&0.2DPO&]S\S.!&S_/3L.41L[_**5/XD_HK
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MF$'_Q$XNT^(#\#W^9HW^@1.$7TK[\9]02P,$%     @ 5CUE4=!$PHUE!@
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MO21(4W?GUMA[47#J9-V'$,\)/6\O0CQG[ :/XO*IOY>=(O1_97VU7S=XE]Y
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M ,80Q^["*.-S9!8;  A()B\(8/'B^BI-\ZZ7E#1"+RA*H*[4<@DL((^'*5!
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M_!99H89,WR5'%$X-948@D3M>,?6.V2&TFW-03E1QZMS >L3:P" WB?+0V8B
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MA"5=3N99GN:SM6W?@3""R\(4X'ABMZESP993_.1S:"U-DP\6LEO:U,:UCLV
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M+D25T-^D$V/QSYD8ZU!S_*$QRU8++0H:L@+.'Y;*F,?A.!AT"_QP=H3H5$^
M7KP&(L</$-O533(F^DY7;/VV@*5\<Q+0DPN='/@\F-(6\"F_DK10^;&CH+'C
M1KST-_K]*Z'?"ZUJI7D'>"_0!I;LZ=<#N^&$_2>?/8X.^U3BT@%;%I*R,\+0
M3R9^:^#<DR>>[][0\][S=X^5PO:-<Z4[LP R+P<FUC$1-@M0H2-:'_33W%#>
MVR!*-?96U4?O(LE6.8D_S^AL-\%#<*MJ"EB7,;J"LGYFE>MFGE0R\E?* 4EM
MHYA-8&6B73=J(5?G4]7F7$((? 6%7A=<5YQ=_-(:QOW>=?9I.?0[?&$UG>6Z
M2D--@K>C[*%<3L -BURFC; L:(R@&!'N!Z$K"]$JXY&?GFVTSKCWK*=J;W _
MGNTS[P_S%8:P_9HFFYJP<>V"(]5 #>J;M>!Z'R^ZW29&,CG=-&MK!VRI6#UY
M>I.^X&DI$>*AKX"NNH+;& %$&D8Y^P[.')J<]=&<8WGAJB:I!W5=>'QEE46Q
MRIJ*1G+.:]LY6K_ N:H%VZ;:Z!S3=6J_-<BJOJAZI0J?CFF=KP<!ZR?P.?#K
M 7[/%*'?0BV+T,]-_9:I'[H.AJ.6$(A6E<Q:W'C7LENA[X/SCYOIA4V</7J2
M#+I"-FF-&>:-+@O&\RS:5L/=1>ZV*>!)0C+L6J?\16/ #Y?)B*\7IJYH?6JD
M#H69L#R_!\T[/#E.6":_==@\2NRR6]\<WK2NH/K;;'*%KD".?9U@A[Y+X,%1
MZ:1$.=XP:W7L?G1_9]Z]AP?(V3KBIQQ@V*/)V2@1G>X>NF#JS:"[?$"M9G#J
MP=WTXL*[,P&UJ\FM$:C1@VZ(TU:H+AJ)"W*!.=BGMC<)ZM!TG:?3V82=7G:,
MZKAJT5FGPO?)$/PJ06\1W_H+"9>//G,M56/:#H@D,#3,AI>X4@U/H6+SA9J,
M4$KV?R8ZJ%4$C,EY^F<0NUI0^RC6D]L7](#/'CCY_A8]X'W!L!Y)+H&G%^OK
MV-)9E7[H):>M_5!:&B[,YM#1_;H>6:;LP7?$1]=,^ $!G\J2DASM"]EI@V?2
M4],@)T6_6*)3[-HB-YEQ^L2WOWNLOU:/=<U+-95J1M!YP&Z&OZ^_9O+DZW5;
M=-;>K=8&Q@X3.AUDYV[Z05PI/>=^[.)<^E8:"M!D3%GRI5<4M%C?K87W\-=7
M <]BG8K-EY_"MU<.[5@SQHG<>47M&.O*UEOD^1N7YP]IQ"EF+D^'R+F'T<=W
M7K6@=US6&B^B%<O3IE<&:-XTIZL<R_5<V)AX.;Q3&>F*KRV6?.4/Z,0.U^Q^
M-H4S7$)GMJG@X .'37]5^?RCK%N 7JZJ1:'(RMS8HN+'&1I'\,/4U%C=>(2T
M:,I*U739E0-&0URJ"+.25Y6_3I^JI2B39[E4Q""H=#MG<JJ5FY.73>UTD='+
M+0NCM&RO.< A+S-5@.T,.A @7PB0DC8LB+.\O)7RCH__'B>W=UJKK?='J,"T
M=4@C;KK+Z%,-!+M7AXB7GK5"D^>&Y&_>C9^>#UP'&TKB9JY\M^\J@]]#9/_L
MQ98[PO<M(AXEMC8>#PHU5W\]?8#M%,3LV6N$;E9E[D49B"P!KBRO!9R_7'FH
M%FZ0@E>Z%Y,<_-@OY/H(OAOU;.YQSN[V.%^_M_GSKR^,OA&(^[_$%G\E,/%^
M^WU!6P[7+M638?]^(WX*P-')\TWO\1XG[T=7 E6)W@(GUX/"_:O2[:_MB^87
M_OWJ;KE_2_T*14TB=9=BAJVCX=.S \]Q_&+5PKUM/576JLI]+ 2*GZ8%>#Y3
MB+/PA0YH7[]_]3]02P,$%     @ 5CUE48_%5.TD"@  ["0  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL[1II;]LX]J\0WME% J@^Y)QM&B!).Y@!
M>FW3=C_3$FUS2HDJ2<7U_/I][Y&2Z%AVTVF[6RSV0V+Q>GSW)5VLM/EHET(X
M]KE0I7TZ6#I7/1Z-;+84!;=#78D25N;:%-S!T"Q&MC*"YW2H4*-T/#X9%5R6
M@\L+FGMC+B]T[90LQ1O#;%T4W*ROA=*KIX/)H)EX*Q=+AQ.CRXN*+\2M<.^K
M-P9&HQ9*+@M16JE+9L3\Z>!J\OCZ"/?3A@]2K&STS)"2F=8?<?![_G0P1H2$
M$IE#"!Q^[L2-4 H! 1J? LQ!>R4>C)\;Z+\2[4#+C%MQH]6_9.Z63P=G Y:+
M.:^5>ZM7OXE SS'"R[2R])^M_-[T:,"RVCI=A,. 02%+_\L_!SY$!\[&.PZD
MX4!*>/N+",MGW/'+"Z-7S.!N@(8/1"J=!N1DB4*Y=096)9QSE[]R:=@'KFK!
M7@IN:R. X\Y>C!P QRVC+ "Z]H#2'8#.V4M=NJ5ES\M<Y)OG1X!4BUG:8':=
M[@5X*ZHAFXX3EH[3\1YXTY;2*<&;?@NE&Y"/6LA'!/GHVWFX']#)D.V Q=XM
M!;O11<7+-=A"IDUNF83YN2QYF4FN&+=6P 0O<Z8DGTDEG10P=FR.,.\0YI#@
M9-R8M2P7C!>Z1N!ZSC)A')@P/KKNJG_\[2R=G#Z)KY&E=:8FI!(89*K.$53&
M[3)ASO!<('Y"WO&9$K"E!,>"./$L\Y=5?(U+">-59?1G"98E\$[ L4.4Y?#G
M=)BW2VT<:+VK#1$5V.1W2HM6")R$.RPA+SYG2UXN!*N,S! V\&"E:Y6S68,<
M;)X;73!P#XHX47K^,6T 09G3W8:7=BX,XRU#UT Q[@7V"Z/6?@OW_F4FW$J(
M$M T'P%0Q8V3F00N.A("(E9T$F4YD.W%$3B#:"QJF0.?!0-O&W-#6 <\DV#F
M  LPYX5 9T?;/% \'1T@CL<32RD,-]ER[=D!G-'(RS^%9YDLJQKPK"TP!DC$
M,YRH<B);EO)3C4R_ARS@5.;<Y,!^FQDY\[CU78EN,V<(;6F$8$K<"45:YZ]-
M\'&UE-F2<)E+8X%?*\VX 675$ " VPA@9H4AO2+Z<*_BL+4NNY7$TU?P-0J;
MZ %1!L9'V"7A0KR"+M4*XA.0]9B]0/38A)'R3YZPU]VU#;ZVQJ.6?:JU@QM(
MSRSI!@69H .6Y /( [^RSD)A+C+08;@OW7>?D("C8;D$[76@=PBV;$; /EH%
MPLOO@='7D6=E(14WNT!M@6C.DIB0^Z5V#5PX[$D)ZMCNB20/>S*.U@::88R>
M:</Q@MDZWA1L$&R,>R3K&6JK P>&5HORKI4"Y39%X_'V"F?:"N=]I&M;:-JZ
MJL!3>70 @O/XEKI!B.A$-^+UMSDF%Z6<@T# +7B?%YO1/OR>X!*D,=J 0AOQ
MJ98F>#.4,-P#X'*D0%<4+?2JW[:]O["0F56X$FR]M0GFR)DS=)!PEUOVQX@^
MTR=]>TB<"B::;P8L=!H<?79MB#+P).#ON0VX678@T:OHV@(\>_B8Y#2>/OFO
M_>Z*WT 5)#1.%#-0[R:K8>\M$G4?QC^]S;QI;:99N(T4Y3492M_*0U&]\D;W
M,C+F9BER0<W4AN(_](K?6T]SY:7>+GC+V3'<]7L07/-A\Y2V3]-#]DZ[]J(?
MKPC/P=C P"RJIM?@9N47[RS2)WMGTN3X--T:O^@LXL>3<*,ID&,VTD19[QB^
MCI+3X_[!3VB"SR#Y\Q8X00N<G/_? G]>"_R2A<5[^V9.SB;W1O]+UO7,Y_P8
MB'U6C0&UA#*(%;X.%UB']P2=Q.<,;"4H^6K+'-M6,$'&29.9)IAU-(E0"-]&
MA$SGR^%ZV$CRMI-D3WH!.:*^ RYA%1%:1%284BE'1DBUG754,>8]*=+]A*1!
M>2OW0$/# P]AUW?+,%[A97&/A%US1<5>KV/:U-P;7] "*A'9S99)<G8^B:'U
M4+$K\* @Q):AD<):Y#*P%K))6=X!XZEN!13>BC^UJIUH&9WI K@(!:'./OI4
M$@LWJ,TL>$1?ERM=+AY1OMTDLEZ><!-X*"S3\$ZM9.[3^4 ,-;8HX0-$>LC"
MR[9X-]Q!%6)E!/$N9X)#C>.U&%6P$E 1YVP%A5:L<A&W?=?%U\>(>5.I /&"
M'8C/%9)QZ!L>V-B!M%>TU<4.,J$H<2$ZP49=!1?ALV, 7!FQQ 8H!(D#I:T]
M#/<-P<GV<R2)+8' 8/;=Y?RV$F@)(%P6&.%Z>57;QKMD<#%QB)HI:#K[Y4\]
MH+R1K[X3YA$\/**V 2#:-F=(3_(_:E(S!(MZIA34(S)'9')IZ8R79MR@@*(&
M EI6J] YZCU&TFX;#_=:!W''H'4IGNM_U/DBY N^Q^#+*VPS;6HT[_Q+IR11
MAX=D% MC&=I3!AO%!%U7O@[3U(=B=86/Q\EX/,8_4'Z@@>2\G^,SCFS7[2[&
MY\CI;9]R\ K2&G9TF.RH,;?58,6QNX9V2PVV&?(7G'0;>2C@/Q3/I5 $(F:*
M++'B7?DPE&%_*VH6Q>X>?JDCR%D%1% ISSJI@R0:3=D7(?H);)4IW[R\"U!1
M:?R5ONC'Y1F;&+1I08S KJ,;$:&;! VY"<:^(3=O^8$IK^\;],'K=S>'G5EW
M@68\/)IN#"?I=R/^G=<6-OGK_'W6. KT/0I-",3J^S1-L[<-L"G[>S>8PN#Y
MEEYVN@A@@D4T1\;#])BM!3=;2.Q>^5;.I/\1SC2_TVG$H>G7<ZAE[DY^3(9^
M8?O,31>NT:-T_;+69(WPUAV::W5/#\_W1+UOGVGJ<:Y#(O!09SF,4_Z;C93_
M2WXIVU4K="\>PBL$B/_"1XUP]%IJZHF]U6NN8-^;V@#:5K"K!50%E+)!E@.\
MIICF6Y^NCAKKH1>(S4AI8TSJ*I@\9$H2'"S!0M%A"D&<"JU%6BBD @IU*7QZ
MS3&=S^O,8;<VE]W;COY@B5>WOC?NAS8Q-HBIZ4QC+Q=?KC3ZA0F7C]AP[:SA
M&2:OA#NZM!W(PAY*!17X.$K0>O"^V:Q!MN77B0EIWRG-%20JX1W43Y-*,GR;
MH["UZU27M^S.+:/*\2M*LYTLH;=PF*+*4E),;X_] @$#!:5@VQ#BVLQ]T8SN
M%X :5 9?4GGQSTC+NO-=BHM\#B:R";#BZ_"FLTDK?<5+)1$$/P#&C,]"6_.A
MP@D 42D1^OX;FVWS[DEV263J%;SW_6S[LNNODM[57L2$_@*Q-WM)*(O^B=OM
M>RK=W27U3</?*\_?J&&X9^F5OL-7NA9?6,5ISN0D23<*;)R8G,83Q\GY>+HY
M<0IIQ.V':_9"\[(G#$Z3T^EVMH33:<_T23(]/>J;'A^=A:9<5/^?)^?'Z;V)
M:=QPF*9)>AH3 !P\/6F;:7U?3(RB+U *81;TG0V: S#1?XS2SK:?\ESY+UBZ
M[?X[H)?<+"3P1(DY'!T/3X\'OF1J!DY7]#W+3#NG"WI<"J@Y#6Z ];D& 84!
M7M!^X'3Y;U!+ P04    " !6/651HPH&@80&  !T$P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6RU6&UOVS80_BN$UPT)X,J69<?.*]"DS58@;8,F
M:3_3TMGB2HD:2<7Q?OWN2$F6[3CITA8P9(GB'9][>WC4R4+I;R8%L.PAD[DY
M[:36%D>]GHE3R+@)5 $YOIDIG7&+CWK>,X4&GCBA3/8&_?Y!+^,B[YR=N+%K
M?7:B2BM%#M>:F3++N%Z>@U2+TT[8J0<^BWEJ::!W=E+P.=R O2NN-3[U&BV)
MR" W0N5,P^RT\R8\.A_2?#?ABX"%:=TSLF2JU#=Z>)^<=OH$""3$EC1P_+N'
M"Y"2%"&,?RJ=G69)$FS?U]HOG>UHRY0;N%#RJTAL>MJ9=%@",UY*^UDM_H+*
MGA'IBY4T[LH6?FXX[K"X-%9EE3 BR$3N__E#Y8>6P*2_0V!0"0P<;K^00_F6
M6WYVHM6":9J-VNC&F>JD$9S(*2@W5N-;@7+V[ K0)/9FK@'0U=:<]"QJI7>]
MN-)P[C4,=F@X9!]4;E/#WN4)).OR/4330!K4D,X'3RJ\@2)@4;_+!OU!_PE]
M46-BY/1%+S)Q3>6P43ET*H<_X+4G-5"M'9F"QW#:P6(RH.^A<\;& =M4S6Y3
M8!<J*WB^9))>&J9R8#,>"RGLDHF<O<M +^^%E-!E%UP*K-5<<%9B0#3C.<,2
MUMR*?.X5,)MRR^"A$+@RR5_"5)=8DN3Q*' KKE16,C$&&6O<>'VNHJQBP+5<
M,@L:4Y-;TES/GRY9KJR8+6E9-\SS1"J=('JFL)0 4<)JZ=#'N\L6J8C3"EV"
M-L #Z%@82#PPKYU+HW9!>K"0)RTDN [-X$DB: Z7#F^7I6H!]Z"[;FKM86$(
M-M(--SAUBL;%H&D5K]I#00F<YY<,U@+D<&% [X4JC:P"AF 6J@Z8\"X_!_T-
MJ6GY2, VHF5\N%*>("JBV58<T0Z#4E9(<EZ(9B95##_E["W$D$U183@AWX:'
MZY9B<@%Y6.1H&:_R[K:*)/FRR4&V]\=OD\&@?TSB6_/<N_!X'XG+8MPX!D_-
MW$ICO*Y^Y*:9DK@+N(Q WT*U%8A_T4@DV%)3/E?"%4S2'HZ/S58.2\&GM3^Y
M(2GD#>L-KLF#[5'<4@P%.L;L'S'2UH^.__?_IV;QNSP1)E;H<W2=1U+PI:_4
M*Q\NOS(\Q+),2 0#!BSS' G$D8\@W6^6>L6&8Q_,>B0\/*"!03. #R[*S4 T
M(N]BSLXPI&O@P\$QNU46<[Y\ G@M,9STV36Q$<;\GLL2ZRSY&_<@EP3UI+T(
MT7J=.38-V]% "T;]9OHS8:=0Q\I8O&0%\AK!^;X,,*ZP::)-,5%=[G^/JZLB
M"0]_6G:\]/_6X6[OGAMPZXD?R:SOF.?,6SV@B6[$W5U5+&ZL^766?MHH4A=9
MS(=A*[U'AR.\AE%$U^ZD/V)?,!=<7K2$]L)]MLKX:#QJ[E=W83<:'E2IN!)U
M"7C06O!PW'<+3EIC43<<A6Z1.\>Y+HT<FU;)5VTSS3:\M4LXIL=:P:0U@L!3
M-M9[Q?VZ14VA.2;GN.W1'B-R8@C'P$YYAG-+[1EW#45=7,M@TU6-XDH7ZLU?
MUZYHZLF4R,G(D3B442.,1,%H(\%]DN<Q(@<PP4:ABMPW_+[W+CPID*JBD XB
M^IP(12K"W)2BL=@%U!;$W*1LA@H-JI"<B >WFJTR_MEE^/)JN2# !1>)[QDR
M8DOS7)RV"?#YZFAY9L>>CPD[#%L)&W8/6S5 L2K6B=H@J;J&!%4:#S;F,BZE
M5VNW)-92K$FDG5LIL6;3442A[RC8 G<=DO&)\PN8Y?'0K0'9'<^O[DP&R6N.
M?1X>,1]MH'Z4Y%;Q'@3# 5MB2[R= E$0CC=>;8&K]V>FJ9/^::A& 3+=[[L>
M;\JIW#QQO&_UCEM]8[,=:X)O7%ZHJ11S7B6?RV?AN*)2S;7F^;Q2;O'>S$!K
MSP9C[ SQ7$2?'ZZNG;+6R)_773?4IMX%=VSB^^J95ADRL60S050FD)2>P]*8
M&;"[@DX,JTYVG>,UQ&J>8Y.28'>,-$?'KE;:U%TR5LNK?C#$L[F4](QUIU"-
M)MI0&5 C6$!N8#]@']4*1_766],L],*.)L%R1E_6FU@+FN/D;=L))44V8)<O
M6''S)-$R %TQ:5Q!VEX-6KY!0)L.*.OMU^P$NLN=CYWC>ZTO(7B"G;OO/;3S
M85WYCR+-:/-)Z8W_DK*:[K]'?>!Z3H=+"3,4[0?C4<?G?/U@5>&^JTR5M2IS
MMREP-(<FX/N94K9^H 6:#VUG_P%02P,$%     @ 5CUE40D3:R7U#0  XBT
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ME!9@]G="Z,ZP!_3O[O(74$L#!!0    ( %8]95$*)GSOP 0  +T+   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U6VV[C-A#]%<)=%+N 83MV=I/N
M)@'BM$7[$"!(>GFFI+'$AB)5DHKCO^^9D2PKR,9=H'U))'GFS)DS%_)BZ\-C
MK(B2>JZMBY>3*J7F\WP>\XIJ'6>^(8=?-C[4.N$UE//8!-*%.-5VOEPL/LUK
M;=SDZD*^W86K"]\F:QS=!17;NM9AMR;KMY>3D\G^P[TIJ\0?YE<7C2[I@=+O
MS5W VWQ *4Q-+AKO5*#-Y>3ZY//ZE.W%X ]#VSAZ5IQ)YOTCO_Q:7$X63(@L
MY8D1-/X]T0U9RT"@\7>/.1E"LN/X>8_^L^2.7#(=Z<;;/TV1JLO)^405M-&M
M3?=^^POU^7QDO-S;*'_5MK-=+28J;V/R=>\,!K5QW7_]W.LP<CA_RV'9.RR%
M=Q=(6/ZHD[ZZ"'ZK EL#C1\D5?$&.>.X* \IX%<#OW1UX^O:)*B<HM*N4#?>
M)>-*<KFA>#%/",&&\[R'6W=PRS?@?E"W *BB^LD55+STGX/:P&^YY[=>'@5\
MH&:F5HNI6BZ6BR-XJR'?E>"M_GN^+_!/!_Q3P3_]O_0\#G>RF*FCD'BS5F<^
M:.YN=5T&(C&=JGN_TS:Q#7O=&DOH)D?J3N\ZL-\J8O!&NYVJ=%2Y!$I4J.31
M8X^D&I]@:;15FS:U@="!>Y1FC\+@EDJV(<2":ZI,*& 0NN!1'I7?*&MR'F=7
MBE-!3]@)#:.H)O@RZ#K.#NQ:=%  %D52>DA+902:I(J6! 0T=&9)>6=WJFTP
MY_# K%<&Z *-N#F%A/TTCJCM%#NE;*U./NP$BM.GD'.V0YJ(MQ/$7J?OOSM?
MGIQ]B7TJ2'BFUI3K%B1-4H9I[Z.9C<!N*W)]&B/8K;$6N>R9%E.LQ;P"AU%M
MI\@;B9>:/R$YUO;=V>P3XUA>:>]UQ#+E'Z4BP1=M#BTA&^,$;#Q58S&@!O9%
M3@@(*3^@Z&@9YQ.($*_8W =,K1I$S+ND.0  "TZ897+16U-H;I1,6XV$E2P@
M:#%N*1%#B@/>!24*H,HT*3=8R[M.&98(2O7MI'QF#2>,((<.&->_%^[0!+$7
M=^RIT:J\JR670\]V>4^_UB+;RD!^4(YM]A=.#.:L532E,QN3:QBYMLY ![;!
MQ,>N[X=B<Z?/#I.9^#$:T!="ZJX-L640F8[7W11D5'>J:4..21PEC'Q3I=;&
MZVCBV/?UQ$)",=@;O\7F996&JK];S$Z&SL)I_TU8O6Z!4-4H]6$OR&UJZ8^-
M-D$]:8M"0;BN4*^6RF&5)'$W4+41],YG5/Z.>WY@D[]@ Z8!ACH"MF"X47R\
MD>ZX^B 3A4$Q'I,G$D-W($8$'SL-ZN"S!Y7 Y+CUWM-SP_/P8:H<I9FZCDP6
MIU4B:9/]D27-AARW_,?Y<9A_4>KM+#?!U]@V#&)$1W'KI+%&9\8:]!*7L!?X
M.GB'$Z(_$7:'L^"PAX9$]^M*Z=JWLG!WPV;AL>H8\U3+^@T^XY=C C@>O:'Z
MQ[BP1EAI%&/7T1D- 22:CK(E&7*4Z%;'5[OK6];53/'\+59?OG;LST=7*IP*
MI5P<>>"@27>[&KX.=]/K[DIV,.\NMK<ZE 9+R=(&KHO9V<<)5HA<%KN7Y!NY
MH&4^X;HGCQ7NUQ38 +]O/":F?^$ PXW]ZA]02P,$%     @ 5CUE45;'6N$?
M"   %1@  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULQ5G9;N.V&GX5
MPB<]F *.+<G[9 &2F;1G+MH&R;2]9B3:(B*)*DG'<9_^?#^IU5F[H+V(S.W?
M5S*G.Z7O32J$98]Y5IBS06IM^7$\-G$J<FY&JA0%=M9*Y]QBJC=C4VK!$P>4
M9^,H".;CG,MB<'[JUJ[U^:G:VDP6XEHSL\USKO>7(E.[LT$XJ!=NY":UM# ^
M/RWY1MP*^W-YK3$;-U@2F8O"2%4P+=9G@XOPX^64SKL#OTBQ,YTQ(TGNE+JG
MR9?D;! 00R(3L24,'#\/XI/(,D($-GZK< X:D@38'=?8OW.R0Y8[;L0GE?TJ
M$YN>#98#EH@UWV;V1NW^)RIY9H0O5IEQ7[;S9Z/9@,5;8U5> 8.#7!;^ES]6
M>N@ +(,7 *(*(')\>T*.R\_<\O-3K79,TVE@HX$3U4&#.5F046ZMQJX$G#V_
MM2J^/R:Y$O9)Y;"UX:2NT[$%=CHSCBM,EQY3] *F%?M!%38U[*I(1-*''X.K
MAK6H9NTR>A7AK2A';!(,611$P2OX)HVH$X=O\I=$[:&>-JBG#O7T;]#BZYC"
M<,1>PL:^IL(M\&(/']BSC>:%9;]M>2;7$H=YD;!"%<?MBB%43)4$;H;LYO9G
M?&.5Y\#F]PA&V51H/Z_(\AW7B6%;F%*S!ZZEVAI69KPPS"J62(V@4AJXU'HM
M8T$CD9>9V@MA.BAED<@'F8 =4XE5\\*X%IY_HF:9>!0ZED:P4@.? 5Y(8EDF
M#"BFO,!'L#67&H+K>R2K!YYM!1VSK5+^^Y]E%"Y.3%]"Y8$3;MUY1W3$+I)$
M$B<\R_;#+A*6<A*!757R5'Q?;W6,'<&NH07V@4A%P<G5[?6U&X8GWQ*?E@&?
MVIF.-J"OLH:M29@4XAN2F[>;3G(FR'@$M)Q]4XL'C%!F-?E+2EA+;2RSFB>R
MV$ E^QH8=A2:UDK\*-A/UR 9!\3+)VN[_E39M6_EC2B$)A6S!P$T.64(3-0#
MY+&IAG;W@FO#4%T.':CP>VZK<;A#+TI%EK"[?0=VEZHJ(O8.5 L+8)01Z'HC
MV =D;(0<?*YG(V<Y>"2G'"OS;4[2SF85=Q@3++%%&C!^&T-8@C;*#-'1'%UO
ML^S8HG)5!!SMG;1IS\O$8RP$0FP1>,AOO88JI6,ED][F5(>3;0:6W0'OQKKG
MTJV,(\H1D&-'GT+UX[^)MV3K#$@HO!%RG[D%96Z&O&M%?@?J=?)U6+WC]3SN
M[\ >KGS:@E'>8L,=)(@AVY'Y#)3,B:+/6;6+*XI XF#G2C+9&N[F#&A@.L_M
M1T9Q$DQ._K'?KTX7W1IY(&)]\$=2Q3O..94X!;:CSY1NH3^VEQ09Q9@WQP/V
M3?-W]5@BGLBE5(;2DDF[[YT-@Q"GPB!PWPF^-]+<'Z]) @DC:_)$3=[7@QHM
M""P8+1;XB4;359<4H/+>\=EHNJBBIEV:SY\N!0=+]6\W%?CVCN185\'Q'H_R
MCL1-Y33_@E?\6OMH,[C8;+38D&[?@KVHW/JE^9?"(A*-C-_$=%57WWKA$_2F
MH5*J1?7:+R[T#T%_W#J-(B/4*]>NCC5N3V:O)Q]D\01!50L;:""[I:4>4)4B
MZR6;HA]!-L#23UMK+(84\$CB=V(CBX(FX,C5CW"XG*R&\VC20!_!]J-IQ.:C
MY9(F\^$R6K'OJ_05+A?#91BV81:.PNB)IA+V83X,@J#E:3J*ELT$-X:UD$"'
MONBQ1')V%37F18S[!P&'R^%\-FNAPVE(X5!/#Z2BB(8\56V.0#@:+A:KCD3A
M:C0-(=$LZ"Y.A\OYM.:9WV7B*;(0?$ ]A\@ -A\%41]9.&\YI(K &U>5C:LU
M!:)?'$2CMTYY^$-)WX7J43 *4:*SS(4\=K PKQ>&*(2&L@WN>=G>%ZVZ!AS7
M-<!5J6-7.3L%K:3^UWE=W>6\7-3^!-?A?!1%GE\T^-/9(:<7KG%X+C\=34:3
M1F#B35F$Y+9 /Z0VA?P=U./N%0'>AK$ _LR51GO8 TCCSL35YAT=;5"YOHP_
M+9QU4[A&CI^M?#2.*%3=JP"<^OC2E>!G6L'J0O$LDZC'*I:.SZ8_BI4NE2LM
M90>]1_)$D@[KTMNM P14A>_QZ2@F!J61(K'4ZLX% _5U<2K%@^\/MX9,#%B(
M3 M-)WU'Y:YN-R#XEX)LN^A?&VI/>8MM)RFU<D0LUD@26O*NO;HBR)H2OLMA
MXU4U"ZO#FTO"IN$P0A*HLBJZ0BY=.NP04)WD\BYN>773/(P:Z _Q%S7^Z=IH
M8N*)>!5JE0GJ_GVCUE4]M<W2Q'!ME[-=Y+2>L%&X0%*9-KCSH-NO96X<"I-<
M6BM>O M=*MQG:?-S>Y/XKFH4'$4?R)]%7 5@.'Q&OXF@)L9='^J[7D?#/=>K
M!7>->"5I4M\@M,!!X5#79JE#XE"EE#XZ7KY^!\]()VL0?TZ80KUM<&*XZR$-
MSXX78'@Y^<2*VL)G/?DY6J^\=%Q5ZOC::^BMBUJ3T@7;)T+S5HHAA?4%)'GH
MVDZQY1,.U%AX! 4\5":.?<AOG6^ZU*P@"F_AB906*;U-/N!.F2F#3D066!:N
M76G[DW^^H_Q7[ATWPL CX]1I)X&O9ZIT@=WV#RX6HY/."GK]U[;#Q91][]\/
M'%J>T-W<6#+$0]L>+H*V[0J'TTX3-AE&\[:MF0X#E*ZO[W.;EHLN^B,BL)IV
MYGT21R 239I&\[F'Q7'GJ387>N,>I*DZ;0OK7VV;U>;-^\(_];;'_8/Y#URC
MUS4L$VN XM8U&S#M'Z']Q*K2/?S>*6M5[H:IX*B!= #[:Z5L/2$"S7\"SO\/
M4$L#!!0    ( %8]95%O7\=XRP8  ,<0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;*58;6_;-A#^*P>O&S; D&TY7M(U"9 X*UJ@W8*F:[>/M$1;
M1"12(ZDX_O=[CI1D.4VRKOO26!+O[;F[YXX]W1I[ZPHI/=U7I79GH\+[^I?)
MQ&6%K(1+3"TUOJR-K83'H]U,7&VER(-054[2Z?3G2264'IV?AG?7]OS4-+Y4
M6EY;<DU5";N[E*79GHUFH^[%![4I/+^8G)_68B-OI/^COK9XFO1:<E5)[931
M9.7Z;'0Q^^7RB,^' Y^4W+K!;^)(5L;<\L/;_&PT98=D*3//&@3^W,FE+$M6
M!#?^;G6.>I,L./S=:7\=8D<L*^'DTI2?5>Z+L]')B'*Y%DWI/YCM&]G&LV!]
MF2E=^)>V\>SL:$19X[RI6F%X4"D=_XK[%H>!P,GT"8&T%4B#W]%0\/)*>'%^
M:LV6+)^&-OX10@W2<$YI3LJ-M_BJ(.?/EZ)67I1TXTUV>SKQ4,D?)EDK?AG%
MTR?$7])[HWWAZ%>=R_Q0?@)7>G_2SI_+]%F%-[).:#X=4SI-I\_HF_?QS8.^
M^7^/[T#?4:_O*.@[^E:\GA>?I0D=J*#0!HY^7Z^E57J#N&<OZ7=-5S*3U4I:
M2L?AW9A\(6EIJEKH'66F0F=D,B=!-FHPG09OR KE)#4U_WZ1ILD4I5.6W 6^
ML*;9%$%9KIRW:M6$]C!K-.;*95;5X;G5"@6%*7-IV0 IO&'3^.[8^S'=P*9T
M]">!$F#?PJ/PA83.NX]_??'Q1S;_PW<G:3I]%0)^@$+X-'OU4T(?<?"Q$[05
MCM9-6>[0E-DMU-8UU*]V=*F,EUFA36DV._HDRD;2ZT;G8WJ77"?T8VOV\M/K
MS@K5C76-T)ZC9<^\M%6(5VAZJ^^D\P#;T\7&2AE^K:3?2JD/4L(!0^E!;(\)
M]U83Z(9%E,(X",*+K #!Y'1RM!@?_3PG5P@K@R-#T(.EH>4M<DNU@ MU;<V]
M E=)X/)B=C*>3J<$YJ8VVMGQ*P<J%<YHL2HEE7*#0EQ+&&&E\AY<[_"@-"QJ
MW3+G5OE8,(]BT7GS6)825+)D_P?N]GY<*0L#QKHQO1<>)[9TC2+9C4FY('"-
MX%7.-J !$23TJ\B*B,H7H  Y](+SB#VGNY!U' G%/Z4:?13$ N:OY<HVF$"!
M8R+V84I $ 6@=,8(R>#"2FJY5ID"2F:KT06%JJE4%1JXZQH^]F2A0]]B^CV-
M:5LHN+Z2F:@D2< 3IA%!Q45M54FS6:0\1JQ[M1@//$0^[J1E'P6R'>TJ.RB1
M)WU0&EX,L4KHHI6H?>28CG"C*8XT?U!,\^/DY?=/93(4,6'D WZ=<W<^7KGC
M4"QJ/0AA3R!M@(KK<A!"5+252'D/071S:YHR9V=I<9S,_[=S"5VA9K@ 4,!.
M;;1"XID4Y-^-\KM]_J-UQ4RHN3YM9&%9AM*KA>7#![XD7,IM0)'U/P[:UX%?
MP<7<#  :#K#Z!5IW_F5VGX2IS31WX7% >39.%VER?)Q^78FPX$F@6P =T/XF
M#]BR-H^9?$YJF!SQ9&F*-7CYD5[X^L(?M-NB:[>/PQH\&%K/>5R(NT@0:U-B
MKV7'P=T6.R:DG5>9ZUJ>N<IAN08+@T4!]))U<FGYB-"5Y&+KZ216"L]VJ&CI
ME-UZUY,.YIXJX4E/RU<HO2W;N9&@+L_,QA R%:*HU1US:.Y"0Z2OH CUG$=[
M47_W91D"YG6[>_/)> [MP;%2.!<C&!R]W#/E7@^H5OC&RNX0%QE=?'P_&!_#
M50<#*QPYW'5P*O182"<F\H4/27LO["UP?>MX=&<(7I0 =*_XP8[QP&X_A0.*
M;Y)E0I]QA=F&M8=^$%7->"18&MXM^YWAS?)S)S<FK!1P.29YZ&XE=G$7"VG#
M_0,#UIJ*/.XR8<'@O\)'FC%E6,,X;0S7OF\>;EK]X@8?N$>"=(@85R?MQUQ9
MP$9L$. &B2=1F08H:!.V&GF?24#X8C[=[X))T,7N!B<YAM;^BK<91")]87(>
MGB@]'[<K5!HN/8 PS,J59*,M.HB)=50A+RU.^ZT4/N.RI'1()'UH$/C1;+&?
M EECE>?&N\A\G!-AK6DPB#LLI.7R D<.-AB,4C16R\7.<^)#1EE&\[4-@5D1
MF873$2"KN5$5.HQC>!A\W)KY10NAJV6&<I=Y<D#;_=85,A(<5,ZU71R5[(?2
MQAK'=@VGH5TM=T_M=V$@Q/)J%ZL'Q9O0;SW'!B9:\3+ZKV*8:MPH(;3^'>_1
M\A[P(\')8Q>DR>!RB11LPA6: 0<V\9[9O^UOZ1?Q<KH_'J_X:-F- G^5<@W1
M:7*\&,5[1O> +3Y<55?&X^(;?A92("(^@.]K@]V^?6 #_?]=G/\#4$L#!!0
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MDF 8LT0SLP+)4. &@+'4#GX_J/!^"=: A#?-LE9?*2CM087P)/979)W4;':
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M,Z51#1!E5IQ7%0S5ZF;AW_%CX<MMHVJG2$SA@XT%>F8K@Y68%GENIQM=Z,J
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M^@;.!,X4=C/DM@:U9V6 Y'1D;(2<K9', 0J *3?-HMN .,#L;I))/S#E;FU
M7Z-LT#>L=%$! ,/C>?S6E2O1I'/P_WA$U31[_!*932>\W3^C1","PZ&)1&VD
MMJCL84O+QFYDF\[">1"F7+0=*5A>(:JFTH!<P2,1H\,@]"[;XT!T., .-G/
M9,"B*EPT4V9E;W13;X1/ *LN9/D@L "X_@@:A;"!VC,-F(]11>+T/VM@I?4%
M[N]*V.J#:MH:4<SEY:3X9?9A%NSDSQ=7 37.0.?XXQFQ K*:8)+?TV* *I<
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MWRT@15![Y,0L/")%D6C@,R*/*DM1XHEBR#D-&91/-Q,!#P9X2G*)8%A;XDY
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MNA,:(NWC&*>I-\K&DVYT@'H31[W)0:[<$N!##MQHO 5*7-<ED5@+:;&Z(EQ
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MD0@C0+,Q5TI Q+AA#43HJ!\AS'$JF[-+KH5NLT WC$D,;"83C#=B8JPA&6)
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M+)ZU.+K?#_S=?$ADKX4\ZOO!41O9.3HN*^G&!7[2/QEZCPA^LV+PO;X7- 5
M#08CMRVD!HVGOA34W#YHXIU)RBM>_6IJ_69Z43P5;I87#Z[XZS(7J(L$9KC5
M.0RP!%3%(V8Q,')A'PZGTAB9VFX,'&MA6H#S,XF&*0=T0/V2?/XG4$L#!!0
M   ( %8]95&?IMQBJP0  '$/   9    >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;+57;6_;-A#^*X3W@@1P;;U8=IPX 9*TPP:L:]"D[6=:.EM<*5(CJ3C>
MK]^1DFDY=A6ORSY8)D_W\ASYW(F<K:3ZJG, 0YX*+O1E+S>F/!\.=9I#0?5
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M%Y%N'D!F3'6BUQ@WB2%=T[*E_:#E^JE1W]8VHF+94F:291W?G:F[_>:<\2<
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M@5\^( T#OE\*H?<;HZ#]EIK^"U!+ P04    " !6/6517*+PKKX"  "9!@
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M?(5.C]M@)KEVOV33YB:7'LD:;635@7$'%1/M/WWJ^K %& <' %$'B'8 87P
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M6]3.P=[G2M'1< 'Z^9W\ 5!+ P04    " !6/651##"KZ6("  ##!@  &0
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M]96^M?<%D27E"A@61BH8?#*F(5O+; ,M&N<):Z&-P[AE9;XR*&V".2^$T/O
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M,KJA,6$*W<4QWS-%V18M>4IC"A*]1S/.8@T1!49SK*A\1/_,01&:RK?&P@8
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M/0M!85E>Z)0#+3)SVG\26HO4/&XH@2U8",#[E1#Z=5 L4%^KS?X%4$L#!!0
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M)\6(.V_%CB]^A<]Z(-M;X,@FZY>4UYEUF9(EFJ:L:C29?6W<YV1-E4!;:?(
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M7%VC4-7<RYN.D96[>#Y*@]=8URSP6P:4#<#_<RG-OF,GZ+Z.%K\ 4$L#!!0
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M?9R299N>[_FG1I.R4>"W3VT>RC8XP$&WL#IQO5.XWJEUO>((^1?MP@[H;BG
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M73"#2YV'5:F!I0Y4B#".HE%8,"Z#Q<SMK?1BIFHCN(25)E5=%$P?/H)0^WE
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MLRD&JYI[8;,QLG+WF)4TJ,TM"[Q+@[(&^'XCI7G9V*M1=SM?_ -02P,$%
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M6@-,FRH.X&)@Y,8=&&MI\/AQMQE^LX"R!?@\D=(<!K9!]14T^0-02P,$%
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MR;$WG,"?UZXO&+Y@YQ< C9VH,<#&3MP8@&,G<@S0L1,[!O#8B1X#?.S$CZ$
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MMQ/&96LT]._N]&BH,BNXA#M-3)8D3*_'(-3JLD5;FQ?W?+ZP[D5[-$S9'![
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M3RKIUG)$7U7>XP*O=R21RGAI^ -E6( ?H3):N3=MMN\C=(:%!RXXNA+YRH2
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M9)K-IE(\$&EF(YJYL/FUUI@1GIE2O-,2GW*TT[-;L6&)WI";0H8QII1<K"4
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MK?/^)Q]8M<GJ]86R6/UGCVOL&4&[!?A^J91]'K@-RBYT_"]02P,$%     @
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MFMR5!OZ2!1:/\2&%U,>5G.*Z2D8)[["^@#1Z#4F41 -Z-N/P#'."QPX>OQN
M9^/P[_&/D1C2OC:I9TG_7VU&F"<]\\0S3\XP;TI&E36N:&@LI\\'"]@Y=_?>
MG=I!_KO\^</R#]6V=3;SSMP]<[^FE-\/Z)OV^J;C^LXXAX;:0X-61R;L$>I&
MYR5]],#V&H>2T\J;/I,WG_;ZVFX8/?(HA%GPQ##O8YJ/QO2L)UIQXZ#/)?H,
M*,$+7Z0M$TSF".U,8,:5BIH5JRWEY=2P0$F!+:*D&U#3M4JUU:H"2V2L*;CC
M>42ZXY)(.1-@+!G:&Z#EMB6SX$Y1K^2BH8_3-8UCVJBJ9O+XYQ]ODWC^WL"E
ME TQW&*MM 6JE;N7(8[>? *:3AYR1*8!W1?^7//%4%N'#RZV"O7>#PA#XAMI
MV\SWUGX&7?JK]XE]0[,I'K*GBRP=LD\6V63(/EUDTP'[Y6R1S0;L5_-N)H:_
MY;<#]9KI/9<&!.XHE.AB3BVHVR'5;JRJ_;6]59:&@%^6--=1NP/T?J>4/6V<
M@_Z?POI?4$L#!!0    ( %8]95'#ZB[Y! ,  (H+   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;*V6T6[:,!2&7\6*>M%*:Q,G)"$5(+6@:I/:J2IK
M=VW@ %83F]D.M-(>?G:2)@%"U YNP';.?WS.%_/CWH:+5[D$4.@MB9GL6TNE
M5M>V+:=+2(B\XBM@^LF<BX0H/14+6ZX$D%DF2F+;=9S 3@AEUJ"7K3V*08^G
M*J8,'@62:9(0\7X+,=_T+6Q]+#S1Q5*9!7O06Y$%C$$]KQZ%GMEEEAE-@$G*
M&1(P[ULW^'J((R/((EXH;&1MC$PK$\Y?S>3'K&\YIB*(8:I,"J*_UC"$.#:9
M=!U_BJ16N:<1UL<?V>^RYG4S$R)AR./?=*:6?:MKH1G,21JK)[[Y#D5#OLDW
MY;',/M$FCPT""TU3J7A2B'4%"67Y-WDK0-0$N'- X!8"][,"KQ!X6:-Y95E;
M(Z+(H"?X!@D3K;.90<8F4^MN*#.O<:R$?DJU3@WN"!7HA<0IH <@,A6@WY&2
MZ!*-8*+0^0@4H;&\T O/XQ$Z/[M 9X@R]&O)4TG83/9LI<LPR>QIL>5MOJ5[
M8,LQK*Z0YWQ#KN,Z#?)ANWP$4RW'1HZC;;FMFR\)N"4!-\O7.9!O2(1XIVR!
M;A*>,M62T2LS>EE&[VM,6S)WRLR=UEKO.5M<*A")/JD3U80^UP>9WOR$UP,W
MBGRW9Z_KA/>C/-<-PS)JJSB_+,[_"DCT%_WD:R(4E7J@H*7]H-PA.#'8L,P<
M'@DVU_LU9#APS?G= ML0Y4>.UPRV6Q;7_2+8,8WI5)N@9A'#.[HE[!7=<\+:
M4$3E;M&)(6.G,AOG2,Q%@BV"7NCM'N"FL, +.\V@<<T-<6N!5?-M_5;6@MU3
MLZQ,!GO'LO3V(&DS\*)=EOMA'@X#?(!EY56XW:QJS7_>"G#E-M@_-=O*9W!P
M+-N@R0]PN,NV(<P/\0%#P)5=X7:_VF+[/VZ *_/!W5-SKJP&1\=RCO;^JK0?
MN'M^T! 6.)WN#F>[=E$RM]0'(A:4213#7.N<JU"_*)%?_/*)XJOL[C3A2M_$
MLN%27Y9!F #]?,[U<2XFYCI67K\'_P!02P,$%     @ 5CUE489D.5GN @
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M[7=L] P,7R0R9;^P;6P]!Z)*:9$W8(H@YT7]9Z]-'O8 07@"$#2 X!W [Y\
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M%?2^8\"J:B'5Q,C2/7EK:? !=<,<NRXHZX#K&RG-86(%FCZ>O )02P,$%
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M H:4B$"##^M8M=D/W^O:]N>&@ 9E0(-&17>%0U,N-%(W%0APJMU5+V "$:L
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MYVTS_!86;1+U?/"3#';J^NB4?)T+ZF/VLCX:^+LU?[?D[Y[EK^LK.:FO DM
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M;@.^7RIE]POGH!Z9I_\"4$L#!!0    ( %8]95%(!*XK-@(  /@$   9
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M3/"# (0&X/,%YVHWT0:J3XSA/U!+ P04    " !6/6519:9*+N$"  #E"0
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 5CUE4>\<^YR6!0  Z3,   \
M  !X;"]W;W)K8F]O:RYX;6S%FUUSVC@4AO^*AJON19;@SR33=(8$NIN9?# A
MDUYVA"U 4W^PDDC:_OJ53=D])N&=O3GK*["L. ]'6(^.?/CX6IMOB[K^)KZ7
M164O!VOG-A?#H<W6JI3V]WJC*G]F69M2.G]H5D.[,4KF=JV4*XMA<'J:#$NI
MJ\&GC_MKS<R0'M1.94[7E6]L&IZU>K7_GF\.Q8NV>J$+[7Y<#MKWA1J(4E>Z
MU#]5?CDX'0B[KE__K(W^65=.%O/,U$5Q.1CM3CPKXW3VIGG>0#[)A6U;G%P\
M2@]R.4A._067VEC7]FBO+SWCB_*==T=;5W_6A5-F(IWZP]3;C:Y6S67\IQB2
MC]'&8?^Z"^*%^2]AK)=+G:E)G6U+5;E='(TJ&L#*KO7&#D0E2W4YV'<1LLK%
MM'(^2.*FVEW*]VT^J?_7-_GN4SN/2V)H+K0_86[R%IP/\OKA?C*]GT\GPK^;
M/]S>3,9/_N!J?#N^OYX* AD R*!'R*\!@0P!9-@+Y/S)O]Q-[PED!""C'B$[
MD8P!9-PG9$@@$P"9\$).E,V,WC3MHEZ*JZW5E;*6P*4 +N6%NY)6VP9K9I3U
M7=L>[3PTUZM*$\@S 'G&/,QUE:O*JESX=[8N=.XY<O%95[+*M"20YP#RG!?R
MUG>K_-"NVN@]N+4R8FR,K%:J^4LZB9^B6?R4%_.Q_B$+[Y?9UF1K:948KXQJ
M">DW<@1%PVR:SU(;\2R+K1)W2MJM>8N'%#-B=LRM.AXV9)41LU9NZVIU\J1,
M*29JX<BW<'>?4$SDE1&W6.JR]%/,W-79-_%%-G=(-X;()R-NH7@X[=IA;0/H
MYQOG;VGEIQG5@40^&3$+I0W=R4+N)L327\F^62<BI8R8G7(M-]HOX'=#3*&0
M0D;,#KFILKI4XDE^[PXD,L:(61GS[<*JO[;-RG_Z<C"5!$@2 ;,DX*J@L_@+
MD"@"9E%@3+K\"V!.PIV4H.5+-YK('P&S/XYH5WSP&7/1N6D"Y(^ V1^'^MWS
M_48!D4,"9H= #W>'&UDD8+;(NQY^-YC()0&S2XZY[A<HQ41V"9CM<B3'$Q\F
MRDE=4$PDG(!9.'C"C.CV"-)/V*M^8HJ)]!/VJI^$8B+]A,SZP9@IQ82;8LSZ
MP9AG%!/I)V1/7][9@6C6NK[!_RG%1!(*V1,9@-G="$42"MDEA)9&= 47(@N%
MW!D-Q.S,F\A"(;.%X!94=]"1A<(^=\HZ@QXA"T7,%L*8=- C9*&(V4(8D\HR
M0A:*N'?-(":5980L%'%OHD%,*LL(/ISA3H(@)I5EA"P4<:="$/.<8B(+1<P6
M0IA?V]WZ?S"1A2)F"X&M>W$BQA0362ABMA#&O**8R$(1LX4@9O<!)[)0W-_S
M&A_-&<5$%HK[>6;C$=M%$L5$%HJ9+70<<VJ=+BDFLE#<TU;<R>Z!!,5$%HJ9
M+70<L]WYHIBP2(#;0H<[AB>B;<K%4F:=S9D862CFMM!;S#OIMJ:I!O)I,<5$
M%HJ9+70LFB*KK3^BF,A",7<N]!9SG.>ZZ>?SX,XMA"P4<^=";S'G6X_PJY56
ML" +)=RY$-S3[A3:( LEW+D0Q*0I6X(LE'#G0A"3IFP)LE#29T%!)V5+D(62
M/@H*]COOG2<9";)0TF=I@3BAF+!8[7]X+'04L[,L3I"%DKZ>"_F5W'Q&E\4)
MLE#";"& V9RBF,A""7<APG',+TJO:*DBLE#*;"$8S<YW,T462IDM!#!GRBPI
M)K)0RFPA'$WJ]!19*.6NEJ;51)[M4:_6?FYZ6"Z5\1,3Q4062KDM=( Y,\H#
M&A_;PS*H%%DHY;;0 >;XZ8ZN/BDFLE#*;"%:K?6NRE-8,\TMGX.ZK?<)D7?2
MUCO#MK/]]#%72UVI_-Y?W?KV3!;9S(CFI:U1"Z*XJ5-;;HOBVK<]5+>US/>_
M5-G_RN;3WU!+ P04    " !6/651>@0#75P"   A+@  &@   'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(+CNJYQ6G%%/,FUE \@I
M/Q3;(*#5R>[;<@;V03WH2<09H0)Q^4>?4,'3KW)LQD-['O:';EA\G([G85WM
MQ['[4=?#9E].S?#0=N5\N;)M^U,S7I;]KNZ:S7NS*[4LEU'W]S.JYZ?[F8O7
MSZ[\S\1VNSULRL]V\_M4SN,_!M=_VOY]V)<R5HO7IM^5<5W5'\?;Z:&^'M+#
M97*U>'E;5_W+6ZKJN8,$@F3^((4@G3_((,CF#W((\OF# H)B_J ,07G^H!4$
MK>8/>H2@Q_F#TA)E7!(D3; FT#HAUXG ZX1@)P*Q$Y*=",Q.B'8B4#LAVXG
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MY^_4>Q@_CV6X]7RM\?G?2?5XN;?<'G]=?IU$"5=7G.O[BN'Y+U!+ P04
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M<' N>&UL4$L! A0#%     @ 5CUE40S]1@3O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 5CUE49E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !6/651<\]X<28%  #B%0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 5CUE45[7#=D0
M"   E"   !@              ("!:@T  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( %8]95'%/;4M" ,   L*   8              "
M@; 5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !6/651
M,0S<C_4%  #<&0  &               @('N&   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ 5CUE44)VO]'U"0  C#H  !@
M     ("!&1\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M %8]95%?2U)(#P@  .P?   8              " @40I  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " !6/651&6N"JW $  #7"0  &
M            @(&),0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ 5CUE43\MHT7#(0  -6T  !@              ("!+S8  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %8]95'01,*-908  .T4
M   8              " @2A8  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " !6/651;:/]$XL?  #"A@  &0              @('#7@
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %8]95'QPLMX
MM P  (HO   9              " @85^  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ 5CUE48_%5.TD"@  ["0  !D
M ("!<(L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !6
M/651HPH&@80&  !T$P  &0              @('+E0  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %8]95$)$VLE]0T  .(M   9
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M970Q."YX;6Q02P$"% ,4    " !6/651@6$.;- $  #J"@  &0
M    @($*P@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M %8]95%O;!?=E@4  (X-   9              " @1''  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ 5CUE4>.'U^ZS(@  BW0  !D
M             ("!WLP  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " !6/6515C>)+I$"   0!@  &0              @('([P  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %8]95$G7X0_F 4
M )@2   9              " @9#R  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ 5CUE4>[4 SEE!0  518  !D              ("!
M7_@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !6/651
MGZ;<8JL$  !Q#P  &0              @('[_0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( %8]95$N@G**_0,  " +   9
M      " @=T" 0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ 5CUE4<:.RT2Z @  ' <  !D              ("!$0<! 'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !6/651$3@5(8X$  !7#0
M&0              @($""@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( %8]95%<HO"NO@(  )D&   9              " @<<. 0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 5CUE44BM26-Q
M @  RP4  !D              ("!O!$! 'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " !6/651##"KZ6("  ##!@  &0
M@(%D% $ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %8]
M95$5\:_RVP(  $((   9              " @?T6 0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ 5CUE47J3NZAX P  ^0X  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( %8]95$8?WG(>@,  "D-   9
M  " @>HL 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M5CUE45UR.BH_!@  -AP  !D              ("!FS ! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " !6/651Q5&093$$  "F$   &0
M            @($1-P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( %8]95%/"UB,B@,  +,,   9              " @7D[ 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 5CUE4;E>50-3!@
M.!T  !D              ("!.C\! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " !6/651&N.-MS((  #R*@  &0              @('$
M10$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %8]95%0
MMJV/^@,  *@-   9              " @2U. 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ 5CUE48>G^<UV P  J0L  !D
M     ("!7E(! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %8]95&R9BDL6@8  !8<   9              "
M@?AI 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 5CUE
M43@((#DX!   D0X  !D              ("!B7 ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " !6/651I$M'/2D#  ##"@  &0
M        @('X= $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( %8]95'NJ_99^0,   (/   9              " @5AX 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 5CUE44#=]FXO P  -0@
M !D              ("!B'P! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " !6/651P^HN^00#  "*"P  &0              @('N?P$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %8]95&&9#E9
M[@(  '()   9              " @2F# 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ 5CUE44'M%X>) @  Q 8  !D
M ("!3H8! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !6
M/651B\DA**P"  !&"   &0              @($.B0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %8]95&&(AL[T@(  ,H'   9
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M970V,RYX;6Q02P$"% ,4    " !6/651C)21TQ0#   7"P  &0
M    @('[HP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M %8]95'!3:E6@P,  !T/   9              " @4:G 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ 5CUE4<]H\KXV @  O00  !D
M             ("! *L! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " !6/651EXZ!%#\$   ^#P  &0              @(%MK0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( %8]95%(!*XK-@(
M /@$   9              " @>.Q 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ 5CUE42]1#E+Y @  / H  !D              ("!
M4+0! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !6/651
M@H7A;\0"  !4"0  &0              @(& MP$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( %8]95&7U5E#+04  #@6   9
M      " @7NZ 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%
M  @ 5CUE42,/5,UE P  ;@P  !D              ("!W[\! 'AL+W=O<FMS
M:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " !6/6519:9*+N$"  #E"0
M&0              @(%[PP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+
M 0(4 Q0    ( %8]95%O:5M7;P0  )@1   9              " @9/& 0!X
M;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 5CUE47HI9#/
M P  #0X  !D              ("!.<L! 'AL+W=O<FMS:&5E=',O<VAE970W
M-2YX;6Q02P$"% ,4    " !6/651KY=Y7& "  #)!0  &0
M@($PSP$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( %8]
M95%L^N]6.P(  &(%   9              " @<?1 0!X;"]W;W)K<VAE971S
M+W-H965T-S<N>&UL4$L! A0#%     @ 5CUE4;"@#6]4!0  :1H  !D
M         ("!.=0! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
M    " !6/6511#>?&G@"   ^#@  #0              @ '$V0$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( %8]95&7BKL<P    !,"   +
M  "  6?< 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %8]95'O'/N<E@4  .DS
M   /              "  5#= 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !6/651>@0#75P"   A+@  &@              @ $3XP$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !6/651+B@*V!4"  #\+
M$P              @ &GY0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..5@!6 )$7  #MYP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>330</ContextCount>
  <ElementCount>445</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Condensed Consolidated Financial Statements Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Licensing and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</Role>
      <ShortName>Licensing and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Royalty Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements</Role>
      <ShortName>Royalty Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Lease Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreements</Role>
      <ShortName>Lease Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Long-Term Debt and Other Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings</Role>
      <ShortName>Long-Term Debt and Other Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables</Role>
      <ShortName>Condensed Consolidated Financial Statements Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Lease Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsTables</Role>
      <ShortName>Lease Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLeaseAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Long-Term Debt and Other Financings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables</Role>
      <ShortName>Long-Term Debt and Other Financings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCommonStockWarrants</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureDescriptionOfBusiness</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Consolidated Financial Statements Detail - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails</Role>
      <ShortName>Consolidated Financial Statements Detail - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Licensing and Other Arrangements - Novartis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails</Role>
      <ShortName>Licensing and Other Arrangements - Novartis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Licensing and Other Arrangements - Novartis International (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails</Role>
      <ShortName>Licensing and Other Arrangements - Novartis International (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Licensing and Other Arrangements - Rezolute - First Amendment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute - First Amendment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails</Role>
      <ShortName>Licensing and Other Arrangements - Janssen Biotech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Licensing and Other Arrangements - Zydus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails</Role>
      <ShortName>Licensing and Other Arrangements - Zydus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40408 - Disclosure - Licensing and Other Arrangements - NIAID (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails</Role>
      <ShortName>Licensing and Other Arrangements - NIAID (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40409 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails</Role>
      <ShortName>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Royalty Purchase Agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails</Role>
      <ShortName>Royalty Purchase Agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Royalty Purchase Agreements - Bioasis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails</Role>
      <ShortName>Royalty Purchase Agreements - Bioasis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Royalty Purchase Agreements - Aronora (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails</Role>
      <ShortName>Royalty Purchase Agreements - Aronora (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Royalty Purchase Agreements - Palobiofarma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails</Role>
      <ShortName>Royalty Purchase Agreements - Palobiofarma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40605 - Disclosure - Fair Value Measurements - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails</Role>
      <ShortName>Fair Value Measurements - Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails</Role>
      <ShortName>Lease Agreements - Leased facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>Lease Agreements - Maturity of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Lease Agreements - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails</Role>
      <ShortName>Lease Agreements - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Lease Agreements - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Lease Agreements - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Lease Agreements - Sublease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails</Role>
      <ShortName>Lease Agreements - Sublease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails</Role>
      <ShortName>Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails</Role>
      <ShortName>Long-Term Debt and Other Financings - Novartis Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails</Role>
      <ShortName>Long-Term Debt and Other Financings - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCommonStockWarrantsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Stock-based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails</Role>
      <ShortName>Stock-based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Stock-based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41105 - Disclosure - Stock-based Compensation - Performance-based stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41106 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Capital Stock - Rights Offering 2019 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details</Role>
      <ShortName>Capital Stock - Rights Offering 2019 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Capital Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails</Role>
      <ShortName>Capital Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Capital Stock - ATM Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails</Role>
      <ShortName>Capital Stock - ATM Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="tmb-20200930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="tmb-20200930x10q.htm">tmb-20200930x10q.htm</File>
    <File>tmb-20200930.xsd</File>
    <File>tmb-20200930_cal.xml</File>
    <File>tmb-20200930_def.xml</File>
    <File>tmb-20200930_lab.xml</File>
    <File>tmb-20200930_pre.xml</File>
    <File>tmb-20200930xex10d1.htm</File>
    <File>tmb-20200930xex10d2.htm</File>
    <File>tmb-20200930xex31d1.htm</File>
    <File>tmb-20200930xex31d2.htm</File>
    <File>tmb-20200930xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/exch/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tmb-20200930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 33,
   "contextCount": 330,
   "dts": {
    "calculationLink": {
     "local": [
      "tmb-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20200930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "tmb-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 617,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 26,
    "http://www.xoma.com/20200930": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 32
   },
   "keyCustom": 127,
   "keyStandard": 318,
   "memberCustom": 56,
   "memberStandard": 33,
   "nsprefix": "xoma",
   "nsuri": "http://www.xoma.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Licensing and Other Arrangements",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements",
     "shortName": "Licensing and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Royalty Purchase Agreements",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements",
     "shortName": "Royalty Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fair Value Measurements",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Lease Agreements",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreements",
     "shortName": "Lease Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Long-Term Debt and Other Financings",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings",
     "shortName": "Long-Term Debt and Other Financings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:CommonStockWarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Common Stock Warrants",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:CommonStockWarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Stock-based Compensation",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Capital Stock",
     "role": "http://www.xoma.com/role/DisclosureCapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Income Taxes",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Subsequent Events",
     "role": "http://www.xoma.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables)",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables",
     "shortName": "Condensed Consolidated Financial Statements Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Lease Agreements (Tables)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsTables",
     "shortName": "Lease Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Long-Term Debt and Other Financings (Tables)",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables",
     "shortName": "Long-Term Debt and Other Financings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Common Stock Warrants (Tables)",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Description of Business (Details)",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "xoma:FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ImpairmentOfLongTermRoyaltyReceivable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Use of Estimates and Purchase of Rights to Future Milestones and Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:Dividends",
       "us-gaap:Dividends",
       "us-gaap:Dividends",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Dividends",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - EPS (Details)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:Dividends",
       "us-gaap:Dividends",
       "us-gaap:Dividends",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Dividends",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
       "p",
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Trade and Other Receivables, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
       "p",
       "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfMajorPartners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ZUHP-cpch0KvEFXedV6y6w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfMajorPartners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_customer_G9VTsNlZikGrrkaYSv2_5A",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_1_1_2020_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201813Member_PwN1PHBQFESMbRjJkpTqhQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:EquitySecuritiesFvNiNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Consolidated Financial Statements Detail - Equity Securities (Details)",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails",
     "shortName": "Consolidated Financial Statements Detail - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_31_2019_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_WyJEPykhS0yKbLZyNfLarQ",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:EquitySecuritiesFvNiNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails",
     "shortName": "Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Net (Loss) Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_21rYFuDP606kenfTT2WCmg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Licensing and Other Arrangements - Novartis (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
     "shortName": "Licensing and Other Arrangements - Novartis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbtFnhkCZk2VVC8u9KiRIg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:ProceedsFromUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Licensing and Other Arrangements - Novartis International (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
     "shortName": "Licensing and Other Arrangements - Novartis International (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uFrV6BraS0Wpq_Qd2lRsbw",
      "decimals": null,
      "lang": "en-US",
      "name": "xoma:AgreementTerminationPriorWrittenNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:LicenseAgreementConsiderationReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
     "shortName": "Licensing and Other Arrangements - Rezolute (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_vXRH7WcHFEmH6TGIHL2XyQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:LicenseAgreementConsiderationReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Licensing and Other Arrangements - Rezolute - First Amendment (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
     "shortName": "Licensing and Other Arrangements - Rezolute - First Amendment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_gPaYGyy2xkaDpvkBVLS-vA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40405 - Disclosure - Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
     "shortName": "Licensing and Other Arrangements - Rezolute - Second and Third Amendments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_7_2019_To_1_7_2019_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_8nH_WG93-US2b2BaDsJMsw",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
     "shortName": "Licensing and Other Arrangements - Janssen Biotech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GlkTOkV4MkiZQT8mUW8hJA",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:OneTimePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40407 - Disclosure - Licensing and Other Arrangements - Zydus (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
     "shortName": "Licensing and Other Arrangements - Zydus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_3_3_2020_To_3_3_2020_srt_CounterpartyNameAxis_xoma_ZydusMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_INoSnd2jpka_c0W6_8_wfg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:MaximumRevenueFromContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40408 - Disclosure - Licensing and Other Arrangements - NIAID (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
     "shortName": "Licensing and Other Arrangements - NIAID (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2008_srt_CounterpartyNameAxis_xoma_DeferredRevenueArrangementNameOfParty2Member_us-gaap_TypeOfArrangementAxis_xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member_JC_mzQY1Z0mRiwPUs8L2hQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:MaximumRevenueFromContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40409 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
     "shortName": "Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_7v0gIkHng0WDoN5wFBc-5Q",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:NumberOfRoyaltyInterestAcquisitionAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_agreement_0c1nNawdwUWPJaykM7pyVQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Royalty Purchase Agreements - Agenus (Details)",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
     "shortName": "Royalty Purchase Agreements - Agenus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gkqI07hkKE2Ouf8ac3CdpQ",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Royalty Purchase Agreements - Bioasis (Details)",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
     "shortName": "Royalty Purchase Agreements - Bioasis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zjLoDyB6QEu4vTx1qJHz2Q",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGm-d7esGEuVgjxrtOHH6A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3WTfFsXjX0mgeXAL_8baAA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRoyaltyReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Royalty Purchase Agreements - Aronora (Details)",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
     "shortName": "Royalty Purchase Agreements - Aronora (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lixgnJlxqE-hSOfbe_E0Yg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40504 - Disclosure - Royalty Purchase Agreements - Palobiofarma (Details)",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
     "shortName": "Royalty Purchase Agreements - Palobiofarma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:LongTermRoyaltyReceivableNoncurrentIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_3_1_2018_To_3_31_2018_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_WP8S9rRbZUauqwVfAZlC-A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfSharesRightAndOptionToSell",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
     "shortName": "Fair Value Measurements - Estimated Fair Value of Equity Securities Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_CommonStockPurchaseAgreementMember_1Myp4OOGqEKp2h3UVxadrQ",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:EquitySecuritiesNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_-_gZH0sC_Uq42XlVkl3AZA",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ChangesInEstimatedFairValueOfContingentConsideration",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40605 - Disclosure - Fair Value Measurements - Debt (Details)",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails",
     "shortName": "Fair Value Measurements - Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b78nuSFILUO33fBKKL4hPg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Lease Agreements - Leased facilities (Details)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
     "shortName": "Lease Agreements - Leased facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_12_17_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_g--KOHjv2E24vfXn7lQBAQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_facility_lwk9lHasRUeWDiqnv7xbYw",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Lease Agreements - Maturity of lease liabilities (Details)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails",
     "shortName": "Lease Agreements - Maturity of lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Lease Agreements - Lease costs (Details)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails",
     "shortName": "Lease Agreements - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Lease Agreements - Additional information (Details)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails",
     "shortName": "Lease Agreements - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_e5A2no5OvU2r4wtyfVTlaQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnTerminationOfLease",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - Lease Agreements - Sublease Agreements (Details)",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails",
     "shortName": "Lease Agreements - Sublease Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SubleaseIncome",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesBerkeleyCaliforniaMember_ym6GLGOCy0yMN7HEESO78g",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:SubleaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
     "shortName": "Long-Term Debt and Other Financings - Silicon Valley Bank Loan Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_5_7_2018_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_Cdo6tH6YGEaFv2AMW8oHKQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Long-Term Debt and Other Financings - Novartis Note (Details)",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
     "shortName": "Long-Term Debt and Other Financings - Novartis Note (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_5_1_2005_To_5_31_2005_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_Aq-O5Rvu_EG2xp_gxz4Gog",
      "decimals": "2",
      "lang": null,
      "name": "xoma:CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails",
     "shortName": "Long-Term Debt and Other Financings - Payments of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Long-Term Debt and Other Financings - Interest Expense (Details)",
     "role": "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
     "shortName": "Long-Term Debt and Other Financings - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_MPyaCSVmkEayYSPLw6TpMw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Common Stock Warrants (Details)",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_2_28_2015_us-gaap_ClassOfWarrantOrRightAxis_xoma_FiveYearWarrantsIssuedFirstRangeMember_gm6Q8gPATEK2mCHGfutYMQ",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rNcZLe3wnEaN-TXAEvVGiw",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails",
     "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ContingentConsiderationUnderRoyaltyPurchaseAgreements",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
     "shortName": "Commitments and Contingencies - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Stock-based Compensation - ESPP (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
     "shortName": "Stock-based Compensation - ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_4bakuPc48Uanf04wFqIeUQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Stock-based Compensation - Stock Options (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA",
      "decimals": null,
      "lang": "en-US",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of Business",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Stock-based Compensation - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9bzrT4reckaFLH0Bbbnj5w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_nGtmBvgeekaWTMhsfQIrDA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - Stock-based Compensation - Performance-based stock options (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
     "shortName": "Stock-based Compensation - Performance-based stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_AwardTypeAxis_xoma_StockOptionsVestingBasedOnPerformanceMember_LaUrOudSE0W57k98RnKO9w",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_z8_luJzjB0eOTjD6EGGXJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41106 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0x8EMKzDr0a9bWPJF31vLg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Capital Stock - Rights Offering 2019 (Details)",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
     "shortName": "Capital Stock - Rights Offering 2019 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_2_29_2020_srt_CounterpartyNameAxis_xoma_BiotechnologyValueFundLPMember_us-gaap_StatementEquityComponentsAxis_xoma_SeriesYConvertiblePreferredStockMember_Nj6TY6mgREyFvS2FQnthTQ",
      "decimals": "2",
      "lang": null,
      "name": "xoma:BeneficialOwnershipLimitation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_gUjO8oETzEKp6ZQFYXWMRQ",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_31_2019_QWKgPzAnvECNjdoIhCgi-g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Capital Stock - Preferred Stock (Details)",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
     "shortName": "Capital Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_MnJGbUR0Q0arUfSSoF2XOA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_rShzL2wREk2t52CY4mWQdg",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:MaximumValueOfCommonStockToBeIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Capital Stock - ATM Agreements (Details)",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
     "shortName": "Capital Stock - ATM Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_wm0pWoJvy0-FNoqt8pI4Dw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:MaximumValueOfCommonStockToBeIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Income Taxes (Details)",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_9_30_2020_EQDriaGUhEmCI0od1WBZtw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_q7PiIfnhvEiLtQBRptY01w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentsRelatedToPurchaseOfRoyaltyRights",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.xoma.com/role/DisclosureSubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "As_Of_10_21_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_x1Y6PfrxfE2TlMaI8OC3hA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_m5QOU9XxIkmOiW5zmZZMyg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Condensed Consolidated Financial Statements Details",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails",
     "shortName": "Condensed Consolidated Financial Statements Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tmb-20200930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_4VxiFswkq0m3ARN0l669ZQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 94,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]",
        "terseLabel": "Exchange"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exch_OTCM": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "O T C [M]",
        "terseLabel": "OTC exchange"
       }
      }
     },
     "localname": "OTCM",
     "nsuri": "http://xbrl.sec.gov/exch/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investee Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r240",
      "r243",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r254",
      "r256",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r418",
      "r455",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r254",
      "r256",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r418",
      "r455",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r240",
      "r243",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r163",
      "r240",
      "r242",
      "r419",
      "r454",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r163",
      "r240",
      "r242",
      "r419",
      "r454",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r245",
      "r254",
      "r256",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r418",
      "r455",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r245",
      "r254",
      "r256",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r418",
      "r455",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r209",
      "r255",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r166",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title Of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update201813 [Member]",
        "terseLabel": "ASU 2018-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update201818 [Member]",
        "terseLabel": "ASU 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Cash receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r15",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued incentive compensation"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities [Abstract]",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued legal and accounting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries Current",
        "terseLabel": "Accrued payroll and other benefits"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Financial Statements Details"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r294"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r291",
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r310",
      "r311",
      "r420",
      "r421",
      "r422",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r257",
      "r259",
      "r297",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r259",
      "r283",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r169",
      "r187",
      "r189",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Bad debt allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
        "terseLabel": "Increase (decrease) in allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r58",
      "r72",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "verboseLabel": "Non-cash interest expense resulting from amortization of discount and accretion of final payment"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r72",
      "r364"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Amortization of debt issuance costs, debt discount and final payment on debt"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r82",
      "r152",
      "r155",
      "r161",
      "r176",
      "r323",
      "r327",
      "r352",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r42",
      "r82",
      "r176",
      "r323",
      "r327",
      "r352"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r261",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost Net",
        "terseLabel": "Capitalized contract costs"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Carrying Reported Amount Fair Value Disclosure [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r24",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r68",
      "r74",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at the end of the period",
        "periodStartLabel": "Cash at the beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r354"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r93",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r287",
      "r288",
      "r289",
      "r308",
      "r331",
      "r353",
      "r366",
      "r420",
      "r421",
      "r459",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r93",
      "r177",
      "r180",
      "r183",
      "r290",
      "r309",
      "r331",
      "r353",
      "r366",
      "r422",
      "r459",
      "r460",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Early Adoption"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r80",
      "r82",
      "r110",
      "r115",
      "r116",
      "r121",
      "r125",
      "r131",
      "r132",
      "r133",
      "r176",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r225",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "verboseLabel": "Exercise price of per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Aggregate number of unregistered shares of common stock called by warrants (in shares)",
        "verboseLabel": "Aggregate number of shares of common stock called by warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r225",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Agreements",
        "verboseLabel": "Licensing and other arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r208",
      "r429",
      "r446"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies.",
        "terseLabel": "Commitments and Contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,022,143 and 9,758,583 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r52",
      "r432",
      "r449"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r165",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r165",
      "r349",
      "r350",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r165",
      "r349",
      "r350",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r137",
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r142",
      "r143",
      "r165",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r349",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r142",
      "r143",
      "r165",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r227",
      "r229",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r227",
      "r228",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Contract liabilities",
        "verboseLabel": "Deferred revenue/Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r227",
      "r228",
      "r241"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock."
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r12",
      "r13",
      "r219",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r141",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Debt and Other Financings"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r425",
      "r426",
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument Basis Spread On Variable Rate1",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "negatedLabel": "Reduction in debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r33",
      "r215",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument Interest Rate Effective Percentage",
        "terseLabel": "Interest rate at period end (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period One [Member]",
        "terseLabel": "On or before first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Three [Member]",
        "terseLabel": "Following second anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Two [Member]",
        "terseLabel": "Following first anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r34",
      "r85",
      "r219",
      "r221",
      "r222",
      "r223",
      "r362",
      "r363",
      "r365",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r362",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument Unamortized Discount",
        "terseLabel": "Unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r213",
      "r364"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Less: interest, final payment fees, discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income, Current",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r72",
      "r201"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "verboseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r224",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r110",
      "r121",
      "r124",
      "r125",
      "r128",
      "r129",
      "r433",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "Basic net (loss) income per share of common stock",
        "verboseLabel": "Basic net (loss) income per share available to common stockholders"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r110",
      "r121",
      "r124",
      "r125",
      "r128",
      "r129",
      "r433",
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "Diluted net (loss) income per share of common stock",
        "verboseLabel": "Diluted net (loss) income per share available to common stockholders"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r126",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net (Loss) Income per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period of unrecognized compensation expense expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r95",
      "r104",
      "r106",
      "r130",
      "r184",
      "r218",
      "r224",
      "r291",
      "r292",
      "r293",
      "r310",
      "r311",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Measurement Input",
        "terseLabel": "Valuation assumptions, measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r174",
      "r451"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Gain (loss) recognized due to change in fair value of investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate Of Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Equity Securities Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Level 1 to Level 2 transfers, Assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Level 2 to Level 1 transfers, Assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r338",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Summary of Changes in Estimated Fair Value of Level 3 Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r332",
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value By Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r333",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r332",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Fair Value By Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r332",
      "r333",
      "r336",
      "r337",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r333",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Level 1 to Level 2 transfers, Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Level 2 to Level 1 transfers, Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r340",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]",
        "terseLabel": "Transfers between Levels"
       }
      }
     },
     "localname": "FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r370",
      "r377"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease Principal Payments",
        "negatedLabel": "Principal payments - finance lease"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Lease termination loss"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r152",
      "r154",
      "r157",
      "r160",
      "r162",
      "r423",
      "r430",
      "r434",
      "r452"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "(Loss) income before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r306",
      "r307",
      "r312",
      "r314",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r83",
      "r105",
      "r106",
      "r151",
      "r302",
      "r313",
      "r315",
      "r453"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnauditedCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r40",
      "r428",
      "r447"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase Decrease In Stockholders Equity Roll Forward",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r125"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Effect of dilutive warrants"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r111",
      "r112",
      "r114",
      "r125"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Interest Expense [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r58",
      "r216"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r66",
      "r69",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of common stock warrant under SVB loan"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r380",
      "r382"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of cost components of operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Agreements"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees and expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of maturity of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2020 (excluding nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r82",
      "r156",
      "r176",
      "r324",
      "r327",
      "r328",
      "r352"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r82",
      "r176",
      "r352",
      "r427",
      "r444"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r82",
      "r176",
      "r324",
      "r327",
      "r328",
      "r352"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity under loan agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate L I B O R [Member]",
        "terseLabel": "Six-month LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r214",
      "r426",
      "r442"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "terseLabel": "Debt amount",
        "totalLabel": "Total payments, net of interest, final payment fees, discount and issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Current",
        "negatedLabel": "Less: current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long Term Debt Fair Value",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r87",
      "r212"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r87",
      "r212"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year",
        "terseLabel": "2020 (excluding nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtPaymentsOfLongTermDebtDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt Noncurrent",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long Term Debt [Text Block]",
        "verboseLabel": "Long-Term Debt and Other Financings"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input Discount For Lack Of Marketability [Member]",
        "terseLabel": "Discount for lack of marketability"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Estimated time to liquidity of shares"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input Share Price [Member]",
        "terseLabel": "Closing common stock price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Minority Interest Ownership Percentage By Noncontrolling Owners",
        "terseLabel": "Ownership percentage on outstanding shares"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r134",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r51",
      "r73",
      "r82",
      "r94",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r118",
      "r152",
      "r154",
      "r157",
      "r160",
      "r162",
      "r176",
      "r352",
      "r431",
      "r448"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r102",
      "r107",
      "r108",
      "r120",
      "r125",
      "r152",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net (loss) income available to common stockholders, basic",
        "verboseLabel": "Net (loss) income and comprehensive (loss) income available to common stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r109",
      "r120",
      "r125"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Diluted",
        "totalLabel": "Net (loss) income available to common stockholders, diluted",
        "verboseLabel": "Net (loss) income and comprehensive (loss) income available to common stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "verboseLabel": "Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r128",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r310",
      "r311",
      "r420",
      "r421",
      "r422",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r152",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r374",
      "r382"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeasesMaturityOfLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsMaturityOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r371",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r379",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r378",
      "r382"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities - long-term"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "verboseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of stock issuance costs",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r261",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion At Fair Value Fair Value Disclosure [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, stated value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 and 6,256 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Net proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r286"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r44",
      "r46",
      "r67",
      "r82",
      "r94",
      "r105",
      "r106",
      "r152",
      "r154",
      "r157",
      "r160",
      "r162",
      "r176",
      "r322",
      "r325",
      "r326",
      "r329",
      "r330",
      "r352",
      "r434"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "verboseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r25",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r203",
      "r445"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r7",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r55",
      "r190"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debt",
        "verboseLabel": "Charged to operating expenses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTradeAndOtherReceivablesNetDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable Type [Domain]",
        "terseLabel": "Receivable"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r21",
      "r78",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Reclassifications": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.",
        "label": "Reclassifications",
        "terseLabel": "Prior Period Reclassifications"
       }
      }
     },
     "localname": "Reclassifications",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Principal payments - debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r300",
      "r475"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r224",
      "r294",
      "r443",
      "r465",
      "r470"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r95",
      "r104",
      "r106",
      "r184",
      "r291",
      "r292",
      "r293",
      "r310",
      "r311",
      "r461",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r149",
      "r150",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r165",
      "r239",
      "r240",
      "r419"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue from contracts with customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r49",
      "r82",
      "r149",
      "r150",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r165",
      "r176",
      "r352",
      "r434"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r142",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Outstanding Securities Considered Anti-Dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Outstanding Long Term Debt Carrying Amount and Estimated Fair Value"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r259",
      "r282",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r259",
      "r282",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r261",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r265",
      "r271",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r225",
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "periodEndLabel": "Number of shares, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of shares, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of shares, Granted",
        "verboseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r267",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r258",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing stock price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r277",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "terseLabel": "Number of options outstanding, non-vested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage related to employees to purchase shares at the lower fair market value at offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r80",
      "r82",
      "r110",
      "r115",
      "r116",
      "r121",
      "r125",
      "r131",
      "r132",
      "r133",
      "r176",
      "r218",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r89",
      "r90",
      "r91",
      "r95",
      "r104",
      "r106",
      "r130",
      "r184",
      "r218",
      "r224",
      "r291",
      "r292",
      "r293",
      "r310",
      "r311",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r130",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r218",
      "r219",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock related to Series Y preferred stock conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "positiveLabel": "Total number of shares issued",
        "terseLabel": "Issuance of stock, net (in shares)",
        "verboseLabel": "Sale of shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "verboseLabel": "Issuance of common stock related to 401(k) contribution (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224",
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r218",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock related to Series Y preferred stock conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r218",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r224",
      "r260",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "verboseLabel": "Issuance of common stock related to 401(k) contribution"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r218",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r82",
      "r171",
      "r176",
      "r352"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r224",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r376",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r361",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r361",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r361",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r361",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r384",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Sale of stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services  that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r308",
      "r309",
      "r310",
      "r311",
      "r420",
      "r421",
      "r422",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r119",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings Loss Allocated To Participating Securities Basic",
        "negatedLabel": "Less: Allocation of undistributed earnings to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r117",
      "r119",
      "r122",
      "r123"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings Loss Allocated To Participating Securities Diluted",
        "negatedLabel": "Add: Adjustments to undistributed earnings allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r301",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "verboseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r139",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r375",
      "r382"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants for common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "verboseLabel": "Fair value of warrant"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r125"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted average shares used in computing diluted net (loss) income per share available to common stockholders",
        "verboseLabel": "Weighted average shares used in computing diluted net (loss) income per share available to common stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r125"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "verboseLabel": "Weighted average shares used in computing basic net (loss) income per share available to common stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossIncomePerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncomeUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AdditionalCommonStockReceiveForQualifiedFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional amount of counterparty's common stock entity was eligible to receive if counterparty did not complete specified financing under terms of agreement.",
        "label": "Additional Common Stock Receive For Qualified Financing",
        "terseLabel": "Additional common stock to be received if Rezolute did not complete financing"
       }
      }
     },
     "localname": "AdditionalCommonStockReceiveForQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AdjustmentsToAdditionalPaidInCapitalDisgorgement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from disgorgement.",
        "label": "Adjustments to Additional Paid in Capital, Disgorgement",
        "terseLabel": "Disgorgement of stockholder's short-swing profits"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDisgorgement",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AgenusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agenus Inc.",
        "label": "Agenus Inc [Member]",
        "terseLabel": "Agenus"
       }
      }
     },
     "localname": "AgenusIncMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of drug candidates subject to exclusive license option.",
        "label": "Agreement, Drug Candidates, Exclusive License Option, Number",
        "terseLabel": "Number of drug candidates subject to exclusive license option"
       }
      }
     },
     "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementDrugCandidatesNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of drug candidates under the terms of the agreement.",
        "label": "Agreement, Drug Candidates, Number",
        "terseLabel": "Number of drug candidates"
       }
      }
     },
     "localname": "AgreementDrugCandidatesNumber",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementNumberOfCommonStockFinancingEvents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common stock financing events.",
        "label": "Agreement, Number of Common Stock Financing Events",
        "terseLabel": "Number of common stock financing events"
       }
      }
     },
     "localname": "AgreementNumberOfCommonStockFinancingEvents",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementPaymentPercentageFactor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiplier used in determining change in payment percentage.",
        "label": "Agreement, Payment Percentage, Factor",
        "terseLabel": "Multiplier for cumulative amount of consideration paid"
       }
      }
     },
     "localname": "AgreementPaymentPercentageFactor",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementTerminationPriorWrittenNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Agreement Termination Prior Written Notice Period",
        "terseLabel": "Agreement termination prior written notice period"
       }
      }
     },
     "localname": "AgreementTerminationPriorWrittenNoticePeriod",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_AronoraIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aronora, Inc.",
        "label": "Aronora Inc [Member]",
        "terseLabel": "Aronora"
       }
      }
     },
     "localname": "AronoraIncMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ArrangementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of arrangements the agreements are accounted for.",
        "label": "Arrangements, Number",
        "terseLabel": "Number of arrangements"
       }
      }
     },
     "localname": "ArrangementsNumber",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_BayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bayer products.",
        "label": "Bayer Products [Member]",
        "terseLabel": "Bayer Products"
       }
      }
     },
     "localname": "BayerProductsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BeneficialOwnershipLimitation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the beneficial ownership limitation.",
        "label": "Beneficial Ownership Limitation",
        "terseLabel": "Beneficial ownership limitation (as a percent)"
       }
      }
     },
     "localname": "BeneficialOwnershipLimitation",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_BioasisTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bioasis Technologies Inc.",
        "label": "Bioasis Technologies Inc [Member]",
        "terseLabel": "Bioasis Technologies Inc"
       }
      }
     },
     "localname": "BioasisTechnologiesIncMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BiotechnologyValueFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biotechnology Value Fund, L.P.",
        "label": "Biotechnology Value Fund L P [Member]",
        "terseLabel": "BVF"
       }
      }
     },
     "localname": "BiotechnologyValueFundLPMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash consideration received by the entity.",
        "label": "Cash Received",
        "terseLabel": "Transaction price, cash consideration"
       }
      }
     },
     "localname": "CashReceived",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ChangesInEstimatedFairValueOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Changes in estimated fair value of contingent consideration.",
        "label": "Changes In Estimated Fair Value Of Contingent Consideration",
        "terseLabel": "Changes in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangesInEstimatedFairValueOfContingentConsideration",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company.",
        "label": "Collaborative Arrangement Research And Development Expense Funded Through Debt Instrument Percentage Maximum",
        "terseLabel": "Research and development expenses funded through loan facility, maximum (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommonStockPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock premium received on sale of common stock.",
        "label": "Common Stock Premium",
        "terseLabel": "Common stock premium"
       }
      }
     },
     "localname": "CommonStockPremium",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock purchase agreement in which entity receives stock from counterparty.  Includes subsequent amendments.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CommonStockSharesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of counterparty's common stock company may receive under the terms of the agreement.",
        "label": "Common Stock Shares Receivable",
        "terseLabel": "Number of Rezolute's common stock eligible to receive contingent on completion of financing activities"
       }
      }
     },
     "localname": "CommonStockSharesReceivable",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_CommonStockThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading period used in number of shares calculation under the terms of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Common Stock Threshold Trading Days",
        "terseLabel": "Common stock trading period"
       }
      }
     },
     "localname": "CommonStockThresholdTradingDays",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_CommonStockWarrantDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrant.",
        "label": "Common Stock Warrant Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantDisclosureTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_CommonStockWarrantExercisePrice14.71Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $14.71 per share.",
        "label": "Common Stock Warrant Exercise Price14.71 [Member]",
        "terseLabel": "Common stock warrant, Exercise price $14.71 per share, Issued March 2019"
       }
      }
     },
     "localname": "CommonStockWarrantExercisePrice14.71Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CondensedConsolidatedFinancialStatementsDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Condensed consolidated financial statements detail.",
        "label": "Condensed Consolidated Financial Statements Detail [Abstract]"
       }
      }
     },
     "localname": "CondensedConsolidatedFinancialStatementsDetailAbstract",
     "nsuri": "http://www.xoma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "xoma_ConsiderationPaidUponQualifiedFinancingEvent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash consideration received from counterparty following qualified financing event.",
        "label": "Consideration Paid Upon Qualified Financing Event",
        "terseLabel": "Consideration received following qualified financing event"
       }
      }
     },
     "localname": "ConsiderationPaidUponQualifiedFinancingEvent",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ConsolidatedFinancialStatementDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated financial statement detail.",
        "label": "Condensed Consolidated Financial Statements Details"
       }
      }
     },
     "localname": "ConsolidatedFinancialStatementDetailAbstract",
     "nsuri": "http://www.xoma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "xoma_ContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent consideration, fair value disclosure.",
        "label": "Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent consideration under royalty purchase agreements.",
        "label": "Contingent Consideration Under Royalty Purchase Agreements",
        "terseLabel": "Contingent consideration under royalty purchase agreements"
       }
      }
     },
     "localname": "ContingentConsiderationUnderRoyaltyPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent future cash payments.",
        "label": "Contingent Future Cash Payments",
        "terseLabel": "Potential future cash payments"
       }
      }
     },
     "localname": "ContingentFutureCashPayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPaymentsPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contingent future cash payment for each product.",
        "label": "Contingent Future Cash Payments, Per Product",
        "terseLabel": "Contingent future cash payment for each product"
       }
      }
     },
     "localname": "ContingentFutureCashPaymentsPerProduct",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractsRevenueWroteOff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in accounts receivable due to contracts revenue written off during the period.",
        "label": "Contracts Revenue Wrote Off",
        "terseLabel": "Accounts receivable written off"
       }
      }
     },
     "localname": "ContractsRevenueWroteOff",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedFairValueOfContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual obligation estimated fair value of contingent consideration liability.",
        "label": "Contractual Obligation Estimated Fair Value Of Contingent Consideration Liability",
        "terseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "ContractualObligationEstimatedFairValueOfContingentConsiderationLiability",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential estimated obligations that due and payable upon achievement of certain criteria categorized as developmental, regulatory, or commercial milestones.",
        "label": "Contractual Obligation Estimated Milestone Payments",
        "terseLabel": "Estimate of milestone payments"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.",
        "label": "Contractual Obligation, Estimated Milestone Payments, Number Of Products",
        "terseLabel": "Assumed number of products per contract"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ContractualObligationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual obligations due to achievement of developmental, regulatory, or commercial milestones recorded as of the balance sheet date.",
        "label": "Contractual Obligation, Milestone Payments",
        "terseLabel": "Milestone liability"
       }
      }
     },
     "localname": "ContractualObligationMilestonePayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Contractual Term",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "ContractualTerm",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement",
        "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount",
        "terseLabel": "Threshold amount of cumulative royalties on net sales per product"
       }
      }
     },
     "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_DebtInstrumentAmountToBeReborrowed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loan that may be reborrowed after repayment.",
        "label": "Debt Instrument, Amount to Be Reborrowed",
        "terseLabel": "Amount of loan that may be reborrowed after repayment"
       }
      }
     },
     "localname": "DebtInstrumentAmountToBeReborrowed",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_DebtInstrumentDecreaseUponAchievementOfMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount by which the note will be reduced upon achievement of specified milestones rather than receiving cash payment under the terms of the agreement.",
        "label": "Debt Instrument, Decrease Upon Achievement of Milestones",
        "terseLabel": "Amount by which note will be reduced upon achievement of specified milestones"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseUponAchievementOfMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_DebtInstrumentFinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Final payment fee as a percent of principal.",
        "label": "Debt Instrument, Final Payment Fee, Percentage",
        "terseLabel": "Final payment fee (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentFinalPaymentFeePercentage",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepayment fee as a percent of amount prepaid.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment fee (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum period following loan amortization date for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term, Maximum Period Following Loan Amortization Date",
        "terseLabel": "Maximum period following loan amortization date for which loan will mature"
       }
      }
     },
     "localname": "DebtInstrumentTermMaximumPeriodFollowingLoanAmortizationDate",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum period prior to loan maturity date of specified loan for which loan will mature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term, Maximum Period Prior to Loan Maturity Date of Specified Loan",
        "terseLabel": "Maximum period prior to loan maturity date of Novartis loan for which loan will mature"
       }
      }
     },
     "localname": "DebtInstrumentTermMaximumPeriodPriorToLoanMaturityDateOfSpecifiedLoan",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_DeferredRevenueArrangementNameOfParty2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the name of the party related to a deferred revenue arrangement. The party named is the other party that participates in a deferred revenue transaction.",
        "label": "Deferred Revenue Arrangement Name Of Party2 [Member]",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "DeferredRevenueArrangementNameOfParty2Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined contribution plan issuance of Common stock for services or claims.",
        "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims",
        "terseLabel": "Common stock contribution to 401(k)"
       }
      }
     },
     "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_DoubtfulRevenueReversalOfFutureCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Doubtful revenue reversal of future cash payments.",
        "label": "Doubtful Revenue Reversal Of Future Cash Payments",
        "terseLabel": "Doubtful revenue reversal of future cash payments"
       }
      }
     },
     "localname": "DoubtfulRevenueReversalOfFutureCashPayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EarlyPaymentOfUnrecognizedFutureCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Early payment of unrecognized future cash payments.",
        "label": "Early Payment Of Unrecognized Future Cash Payments",
        "terseLabel": "Early payment of unrecognized future cash payments"
       }
      }
     },
     "localname": "EarlyPaymentOfUnrecognizedFutureCashPayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.",
        "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones",
        "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years"
       }
      }
     },
     "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleToReceiveCommonStockRelatedToFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of counterparty's common stock entity is eligible to receive under terms of agreement.",
        "label": "Eligible To Receive Common Stock Related To Financing Activities",
        "terseLabel": "Amount of Rezolute's common stock eligible to receive"
       }
      }
     },
     "localname": "EligibleToReceiveCommonStockRelatedToFinancingActivities",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleToReceiveInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible to receive in cash.",
        "label": "Eligible To Receive In Cash",
        "terseLabel": "Amount of cash eligible to receive"
       }
      }
     },
     "localname": "EligibleToReceiveInCash",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleToReceiveInOrderToMaintainLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional amount of cash entity is eligible to receive if counterparty does not complete qualified financing by specified date.",
        "label": "Eligible To Receive In Order To Maintain License Agreement",
        "terseLabel": "Eligible to receive, in order to maintain license agreement"
       }
      }
     },
     "localname": "EligibleToReceiveInOrderToMaintainLicenseAgreement",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee of entity.",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EquitySecuritiesFvNiNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities FvNi non current.",
        "label": "Equity Securities Fv Ni Non Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiNonCurrent",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EquitySecuritiesNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity securities tranches.",
        "label": "Equity Securities, Number of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "EquitySecuritiesNumberOfTranches",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_EquitySecuritiesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity securities.",
        "label": "Equity Securities Policy",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesPolicy",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_EquitySecuritiesTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities tranche one.",
        "label": "Equity Securities Tranche One [Member]",
        "terseLabel": "Tranche 1"
       }
      }
     },
     "localname": "EquitySecuritiesTrancheOneMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EquitySecuritiesTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities tranche two.",
        "label": "Equity Securities Tranche Two [Member]",
        "terseLabel": "Tranche 2"
       }
      }
     },
     "localname": "EquitySecuritiesTrancheTwoMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated fair value of contingent consideration under royalty purchase agreements.",
        "label": "Estimated Fair Value Of Contingent Consideration Under Royalty Purchase Agreements",
        "terseLabel": "Estimated fair value of contingent consideration under the royalty purchase agreements"
       }
      }
     },
     "localname": "EstimatedFairValueOfContingentConsiderationUnderRoyaltyPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ExercisablePeriodOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable Period Of Warrants",
        "terseLabel": "Exercisable period of warrants"
       }
      }
     },
     "localname": "ExercisablePeriodOfWarrants",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of common stock amount exceeded allocated purchase price of convertible preferred stock.",
        "label": "Fair Value Of Common Stock Amount Exceeded Allocated Purchase Price Of Convertible Preferred Stock",
        "terseLabel": "Fair value of common stock amount exceeded purchase price of convertible preferred stock"
       }
      }
     },
     "localname": "FairValueOfCommonStockAmountExceededAllocatedPurchasePriceOfConvertiblePreferredStock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First Royalty Interest Acquisition Agreement.",
        "label": "First Royalty Interest Acquisition Agreement [Member]",
        "terseLabel": "First Royalty Interest Acquisition Agreement"
       }
      }
     },
     "localname": "FirstRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FirstTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First term loan from Silicon Valley Bank credit facility.",
        "label": "First Term Loan [Member]",
        "terseLabel": "Silicon Valley Bank, First Term Loan"
       }
      }
     },
     "localname": "FirstTermLoanMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FiveYearWarrantsIssuedFirstRangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $66.20 per share. Issued in February 2015.",
        "label": "Five Year Warrants Issued First Range [Member]",
        "terseLabel": "Common stock warrant, Exercise price $66.20 per share, Issued February 2015"
       }
      }
     },
     "localname": "FiveYearWarrantsIssuedFirstRangeMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FiveYearWarrantsIssuedSecondRangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $15.40 per share. Issued in February 2016.",
        "label": "Five Year Warrants Issued Second Range [Member]",
        "terseLabel": "Common stock warrant, Exercise Price $15.40 per share, Issued February 2016"
       }
      }
     },
     "localname": "FiveYearWarrantsIssuedSecondRangeMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FutureCashPaymentsOfRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash payments of revenue recognized.",
        "label": "Future Cash Payments Of Revenue Recognized",
        "terseLabel": "Future cash payments of revenue recognized"
       }
      }
     },
     "localname": "FutureCashPaymentsOfRevenueRecognized",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FutureCashPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash payments received.",
        "label": "Future Cash Payments Received",
        "terseLabel": "Future cash payments received"
       }
      }
     },
     "localname": "FutureCashPaymentsReceived",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FutureCashPaymentsUponClosingOfQualifiedFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash payments upon closing of qualified financing.",
        "label": "Future Cash Payments Upon Closing Of Qualified Financing",
        "terseLabel": "Future cash payments upon closing of the qualified financing"
       }
      }
     },
     "localname": "FutureCashPaymentsUponClosingOfQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future milestones and royalties purchase rights policy.",
        "label": "Future Milestones And Royalties Purchase Rights Policy Policy [Text Block]",
        "terseLabel": "Purchase of Rights to Future Milestones and Royalties"
       }
      }
     },
     "localname": "FutureMilestonesAndRoyaltiesPurchaseRightsPolicyPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_GrossProceedsFromIssuanceOfCommonStockAndPreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock and preferred stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock And Preferred Stock",
        "terseLabel": "Aggregate gross proceeds from issuance of common stock and preferred stock",
        "verboseLabel": "Aggregate gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStockAndPreferredStock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_GrossProceedsFromQualifiedFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum gross proceeds required to be raised by counterparty for qualified financing under the terms of the agreement.",
        "label": "Gross Proceeds From Qualified Financing",
        "terseLabel": "Gross proceeds to be raised for qualified financing"
       }
      }
     },
     "localname": "GrossProceedsFromQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Care Royalty Partners Two Limited Partners.",
        "label": "Health Care Royalty Partners Two Limited Partners [Member]",
        "terseLabel": "Health Care Royalty Partners Two Limited Partners"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_IL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IL-1 target license agreement with Novartis.",
        "label": "I L1 Target License Agreement [Member]",
        "terseLabel": "IL-1 Target License Agreement"
       }
      }
     },
     "localname": "IL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ImpairmentOfLongTermRoyaltyReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.",
        "label": "Impairment Of Long Term Royalty Receivable",
        "terseLabel": "Impairment of long-term royalty receivable"
       }
      }
     },
     "localname": "ImpairmentOfLongTermRoyaltyReceivable",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of lease liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_IncyteImmunoOncologyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incyte immuno-oncology assets.",
        "label": "Incyte Immuno Oncology Assets [Member]",
        "terseLabel": "Incyte Immuno-Oncology Assets"
       }
      }
     },
     "localname": "IncyteImmunoOncologyAssetsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_InterestAddedPrincipalBalancesLongTermDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unpaid interest added to the outstanding principal amount on long-term debt.",
        "label": "Interest Added Principal Balances Long Term Debt",
        "terseLabel": "Interest added to principal balance on long-term debt"
       }
      }
     },
     "localname": "InterestAddedPrincipalBalancesLongTermDebt",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of aggregate amount of interest expense and the amortization of debt issuance costs and discounts on all borrowings.",
        "label": "Interest Expense And Amortization Of Debt Issuance Costs And Discounts Table [Text Block]",
        "terseLabel": "Interest Expense and Amortization of Debt Issuance Costs and Discounts"
       }
      }
     },
     "localname": "InterestExpenseAndAmortizationOfDebtIssuanceCostsAndDiscountsTableTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_JanssenBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen Biotech, Inc.",
        "label": "Janssen Biotech Inc. [Member]",
        "terseLabel": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechInc.Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseDisclosureTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LeasedFacilitiesBerkeleyCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leased facilities in Berkeley, California.",
        "label": "Leased Facilities Berkeley California [Member]",
        "terseLabel": "Leased facilities, Berkeley, California"
       }
      }
     },
     "localname": "LeasedFacilitiesBerkeleyCaliforniaMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureLeaseAgreementsSubleaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California.",
        "label": "Leased Facilities Emeryville California [Member]",
        "terseLabel": "Leased facilities, Emeryville, California"
       }
      }
     },
     "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Summary of supplemental cash flow information related to operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.",
        "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]",
        "terseLabel": "Schedule of present value assumptions used in calculating the present value of lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement and common stock purchase agreement.",
        "label": "License Agreement And Common Stock Purchase Agreement [Member]",
        "terseLabel": "License Agreement and Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement consideration received.",
        "label": "License Agreement Consideration Received",
        "terseLabel": "License agreement consideration received"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceived",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of license agreement consideration received as repayment of debt.",
        "label": "License Agreement Consideration Received, Debt Repayment",
        "terseLabel": "License agreement consideration received, repayment of debt"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceivedDebtRepayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementNonRz358ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement related to activities associated with non-RZ358 products.",
        "label": "License Agreement Non Rz358 Products [Member]",
        "terseLabel": "License Agreement, Non-RZ358 products"
       }
      }
     },
     "localname": "LicenseAgreementNonRz358ProductsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementRz358Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement related to activities associated with RZ358.",
        "label": "License Agreement Rz358 [Member]",
        "terseLabel": "License Agreement, RZ358"
       }
      }
     },
     "localname": "LicenseAgreementRz358Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement transaction price.",
        "label": "License Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "LicenseAgreementTransactionPrice",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementX129Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement related to activities associated with monoclonal antibody fragments , including X129.",
        "label": "License Agreement X129 [Member]",
        "terseLabel": "License Agreement, X129"
       }
      }
     },
     "localname": "LicenseAgreementX129Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicensingAndOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsAbstract",
     "nsuri": "http://www.xoma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "xoma_LicensingAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing And Other Arrangements [Text Block]",
        "terseLabel": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LongTermDebtFuturePrincipalInterestAndFinalFeePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt and interest. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long Term Debt Future Principal Interest And Final Fee Payments",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LongTermDebtFuturePrincipalInterestAndFinalFeePayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsPaymentsOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LongTermRoyaltyReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term royalty receivable non current.",
        "label": "Long Term Royalty Receivable Non Current",
        "terseLabel": "Long-term royalty receivables"
       }
      }
     },
     "localname": "LongTermRoyaltyReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LongTermRoyaltyReceivableNoncurrentIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) of long-term royalty receivable, noncurrent, during the period.",
        "label": "Long Term Royalty Receivable NonCurrent, Increase (Decrease)",
        "terseLabel": "Increase (decrease) of long-term royalty receivable"
       }
      }
     },
     "localname": "LongTermRoyaltyReceivableNoncurrentIncreaseDecrease",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.",
        "label": "Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events",
        "terseLabel": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events"
       }
      }
     },
     "localname": "MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of commercial milestones.",
        "label": "Maximum Amount Receivable Milestone Payments Upon Achievement Of Commercial Milestones",
        "terseLabel": "Maximum amount receivable upon achievement of commercial milestones"
       }
      }
     },
     "localname": "MaximumAmountReceivableMilestonePaymentsUponAchievementOfCommercialMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumRevenueFromContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum revenue from contract.",
        "label": "Maximum Revenue From Contract",
        "terseLabel": "Total contract amount awarded"
       }
      }
     },
     "localname": "MaximumRevenueFromContract",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumValueOfCommonStockToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum value of common stock to be issued.",
        "label": "Maximum Value Of Common Stock To Be Issued",
        "terseLabel": "Maximum amount of shares to be issued"
       }
      }
     },
     "localname": "MaximumValueOfCommonStockToBeIssued",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MerckImmunoOncologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck immuno-oncology product.",
        "label": "Merck Immuno Oncology Product [Member]",
        "terseLabel": "Merck Immuno-Oncology Product"
       }
      }
     },
     "localname": "MerckImmunoOncologyProductMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MilestonePeriodsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.",
        "label": "Milestone Periods, Number",
        "terseLabel": "Number of milestone periods"
       }
      }
     },
     "localname": "MilestonePeriodsNumber",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.",
        "label": "Milestones Payments To Aggregate Amount Of Per Product",
        "terseLabel": "Aggregate milestones payments per product"
       }
      }
     },
     "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_NonBayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-bayer products.",
        "label": "Non Bayer Products [Member]",
        "terseLabel": "Non-Bayer Products"
       }
      }
     },
     "localname": "NonBayerProductsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted",
        "terseLabel": "Ownership interest, if shares are converted (as a percent)"
       }
      }
     },
     "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Category of deferred revenue arrangement wherein certain rights are granted under a license agreement with a governmental agency.",
        "label": "Nonsoftware License Arrangement With Governmental Agency2 [Member]",
        "terseLabel": "Arrangement with Governmental Agency"
       }
      }
     },
     "localname": "NonsoftwareLicenseArrangementWithGovernmentalAgency2Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNiaidDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisInternationalPharmaceuticalLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd.",
        "label": "Novartis International Pharmaceutical Ltd [Member]",
        "terseLabel": "Novartis International"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalLtdMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Secured note agreement and subsequent amendments with Novartis referred to as the \"Note Agreement\".",
        "label": "Novartis Note [Member]",
        "terseLabel": "Novartis Note"
       }
      }
     },
     "localname": "NovartisNoteMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsNovartisNoteDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novartis Pharma AG.",
        "label": "Novartis Pharma A G [Member]",
        "terseLabel": "Novartis Pharma AG"
       }
      }
     },
     "localname": "NovartisPharmaAGMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of future cash payments upon closing of qualified financing.",
        "label": "Number Of Future Cash Payments Upon Closing Of Qualified Financing",
        "terseLabel": "Number of future cash payments upon closing of the qualified financing"
       }
      }
     },
     "localname": "NumberOfFutureCashPaymentsUponClosingOfQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of license agreements.",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreementsFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of future license agreements under optional purchase right.",
        "label": "Number Of License Agreements, Future License Agreements",
        "terseLabel": "Number of future license agreements under optional purchase right"
       }
      }
     },
     "localname": "NumberOfLicenseAgreementsFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of licensed products related to milestones and royalties purchased.",
        "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased",
        "terseLabel": "Number of licensed products related to milestone and royalties"
       }
      }
     },
     "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfMajorPartners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of major partners.",
        "label": "Number Of Major Partners",
        "terseLabel": "Number of major partners"
       }
      }
     },
     "localname": "NumberOfMajorPartners",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfQuarterlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of quarterly payments.",
        "label": "Number of Quarterly Payments",
        "terseLabel": "Number of quarterly payments"
       }
      }
     },
     "localname": "NumberOfQuarterlyPayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfRoyaltyInterestAcquisitionAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of royalty interest acquisition agreements.",
        "label": "Number Of Royalty Interest Acquisition Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfRoyaltyInterestAcquisitionAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfSharesRightAndOptionToSell": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.",
        "label": "Number Of Shares, Right and Option To Sell",
        "terseLabel": "Number of Rezolute's shares Company has right and option to sell if Rezolute does not list common stock shares on national exchange"
       }
      }
     },
     "localname": "NumberOfSharesRightAndOptionToSell",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_OneTimePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One-time payment.",
        "label": "One Time Payment",
        "terseLabel": "One-time payment"
       }
      }
     },
     "localname": "OneTimePayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLeaseEarlyTerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of fee for early termination of operating lease.",
        "label": "Operating Lease, Early Termination Fee",
        "terseLabel": "Early termination fee"
       }
      }
     },
     "localname": "OperatingLeaseEarlyTerminationFee",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLeasePaymentsNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating lease payments, non cash.",
        "label": "Operating Lease Payments Non Cash",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeasePaymentsNonCash",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLeasesEarlyTerminationNumberOfLeasedFacilities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of leases for which the entity terminated the lease early.",
        "label": "Operating Leases, Early Termination, Number of Leased Facilities",
        "terseLabel": "Number of operating leases terminated early"
       }
      }
     },
     "localname": "OperatingLeasesEarlyTerminationNumberOfLeasedFacilities",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_OperatingLeasesNumberOfLeasedFacilities": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating leases, number of leased facilities.",
        "label": "Operating Leases Number Of Leased Facilities",
        "terseLabel": "Operating leases, number of leased facilities"
       }
      }
     },
     "localname": "OperatingLeasesNumberOfLeasedFacilities",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_OtherFinancingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other debt obligations not specifically mentioned in the taxonomy.",
        "label": "Other Financings [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFinancingsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PalobiofarmaSLMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Palobiofarma, S.L.",
        "label": "Palobiofarma S L [Member]",
        "terseLabel": "Palobiofarma, S.L."
       }
      }
     },
     "localname": "PalobiofarmaSLMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name or description of a single external partner 1 that accounts for 10 percent or more of the entity's revenues.",
        "label": "Partner1 [Member]",
        "terseLabel": "Partner 1"
       }
      }
     },
     "localname": "Partner1Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name or description of a single external partner 2 that accounts for 10 percent or more of the entity's revenues.",
        "label": "Partner2 [Member]",
        "terseLabel": "Partner 2"
       }
      }
     },
     "localname": "Partner2Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name or description of a single external partner 3 that accounts for 10 percent or more of the entity's revenues.",
        "label": "Partner3 [Member]",
        "terseLabel": "Partner 3"
       }
      }
     },
     "localname": "Partner3Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PaymentPeriodFollowingClosingOfQualifiedFinancing": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment period within which counterparty will pay outstanding amounts following closing of Qualified Financing, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Payment Period, Following Closing of Qualified Financing",
        "terseLabel": "Payment period following closing of Qualified Financing"
       }
      }
     },
     "localname": "PaymentPeriodFollowingClosingOfQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_PaymentsOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments of contingent consideration.",
        "label": "Payments Of Contingent Consideration",
        "terseLabel": "Payments of contingent consideration"
       }
      }
     },
     "localname": "PaymentsOfContingentConsideration",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsRelatedToPurchaseOfRoyaltyRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments related to purchase of royalty rights.",
        "label": "Payments Related To Purchase Of Royalty Rights",
        "negatedLabel": "Payments related to purchase of royalty rights",
        "terseLabel": "Payments to acquire milestones and royalties"
       }
      }
     },
     "localname": "PaymentsRelatedToPurchaseOfRoyaltyRights",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Second License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, second agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Third License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, third agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PercentageOfAdditionalInterestRateOfOutstandingLoan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional interest rate in the event of default (as a percent)",
        "label": "Percentage Of Additional Interest Rate Of Outstanding Loan",
        "terseLabel": "Additional interest rate in the event of default (as a percent)"
       }
      }
     },
     "localname": "PercentageOfAdditionalInterestRateOfOutstandingLoan",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfAggregateSharesHeldRightAndOptionToSell": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of counterparty's shares held by entity that entity has right and option to sell if counterparty does not list common stock shares on national exchange by specified date.",
        "label": "Percentage Of Aggregate Shares Held, Right and Option To Sell",
        "terseLabel": "Percent of Rezolute's shares held Company has right and option to sell if Rezolute does not list common stock shares on national exchange"
       }
      }
     },
     "localname": "PercentageOfAggregateSharesHeldRightAndOptionToSell",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.",
        "label": "Percentage Of Decrease In Future Royalty Obligations",
        "terseLabel": "Percentage of decrease in future royalty obligations"
       }
      }
     },
     "localname": "PercentageOfDecreaseInFutureRoyaltyObligations",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares",
        "terseLabel": "Sales commission paid per transaction (as a percent)"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of net proceeds of each future financing upon closing of the qualified financing.",
        "label": "Percentage Of Net Proceeds Of Each Future Financing Upon Closing Of The Qualified Financing",
        "terseLabel": "Percentage of net proceeds of each future financing upon closing of the qualified financing"
       }
      }
     },
     "localname": "PercentageOfNetProceedsOfEachFutureFinancingUponClosingOfTheQualifiedFinancing",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of royalty rights entity has option to  purchase in future license agreements.",
        "label": "Percentage Of Optional Royalty Rights Purchase On Future License Agreements",
        "terseLabel": "Percentage of option to purchase royalty right on future license agreements"
       }
      }
     },
     "localname": "PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of royalty on net sales upon commercialization.",
        "label": "Percentage Of Royalty On Net Sales Upon Commercialization",
        "terseLabel": "Percentage of royalty on worldwide net sales of each product upon commercialization"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PeriodOfMonthlyPaymentsOfPrincipalAndInterest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of monthly payments of principal and interest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period Of Monthly Payments Of Principal And Interest",
        "terseLabel": "Period of monthly payments of principal and interest"
       }
      }
     },
     "localname": "PeriodOfMonthlyPaymentsOfPrincipalAndInterest",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock conversion price per share.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred stock conversion price per share"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xoma_ProceedsFromRepaymentsForDisgorgement": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from disgorgement.",
        "label": "Proceeds from (Repayments for) Disgorgement",
        "terseLabel": "Proceeds from disgorgement of stockholder's short-swing profits"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsForDisgorgement",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ProceedsFromUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash proceeds from upfront payment received as consideration in transaction.",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Upfront payment received",
        "verboseLabel": "Initial payment received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Purchase of Rights to Future Milestones and Royalties [Abstract]",
        "terseLabel": "Purchase of Rights to Future Milestones and Royalties"
       }
      }
     },
     "localname": "PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesUseOfEstimatesAndPurchaseOfRightsToFutureMilestonesAndRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.",
        "label": "Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones",
        "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchasedPercentageOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased percentage of milestones.",
        "label": "Purchased Percentage Of Milestones",
        "terseLabel": "Purchased percentage of milestones"
       }
      }
     },
     "localname": "PurchasedPercentageOfMilestones",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased percentage of non-royalties on net sales of products.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products",
        "terseLabel": "Non-royalties to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage",
        "terseLabel": "Future non-royalty payments to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased percentage of royalties on net sales of products.",
        "label": "Purchased Percentage Of Royalties On Net Sales Of Products",
        "terseLabel": "Royalties on net sales of products (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of proceeds third party received from issuance of capital stock which triggered a Qualified Financing event under the terms of the agreement.",
        "label": "Qualified Financing Event Trigger, Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Gross proceeds received by third party from preferred stock financing"
       }
      }
     },
     "localname": "QualifiedFinancingEventTriggerProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReimbursableTechnologyTransferExpensesReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursable technology transfer expenses received.",
        "label": "Reimbursable Technology Transfer Expenses Received",
        "terseLabel": "Reimbursable technology transfer expense received"
       }
      }
     },
     "localname": "ReimbursableTechnologyTransferExpensesReceived",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReleaseOfRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of recognized equity-based compensation related to restricted stock units released during the period.",
        "label": "Release Of Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "ReleaseOfRestrictedStockUnits",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for sale of future revenue streams.",
        "label": "Revenue Recognition Deferred Revenue Policy [Text Block]",
        "terseLabel": "Sale of Future Revenue Streams"
       }
      }
     },
     "localname": "RevenueRecognitionDeferredRevenuePolicyTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_RezoluteIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rezolute, Inc.",
        "label": "Rezolute Inc [Member]",
        "terseLabel": "Rezolute"
       }
      }
     },
     "localname": "RezoluteIncMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEstimatedFairValueOfEquitySecuritiesAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RightsOffering2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Rights Offering.",
        "label": "Rights Offering2019 [Member]",
        "terseLabel": "2019 Rights Offering"
       }
      }
     },
     "localname": "RightsOffering2019Member",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltiesPeriodMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties, Period, Minimum",
        "terseLabel": "Royalty payment period"
       }
      }
     },
     "localname": "RoyaltiesPeriodMinimum",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisInternationalDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_RoyaltyInterestAcquisitionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Interest Acquisition Agreements.",
        "label": "Royalty Interest Acquisition Agreements [Member]",
        "terseLabel": "Royalty Interest Acquisition Agreements"
       }
      }
     },
     "localname": "RoyaltyInterestAcquisitionAgreementsMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementAbstract",
     "nsuri": "http://www.xoma.com/20200930",
     "xbrltype": "stringItemType"
    },
    "xoma_RoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Member]",
        "terseLabel": "Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Text Block]",
        "terseLabel": "Royalty Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTextBlock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_SecondRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Royalty Interest Acquisition Agreement.",
        "label": "Second Royalty Interest Acquisition Agreement [Member]",
        "terseLabel": "Second Royalty Interest Acquisition Agreement"
       }
      }
     },
     "localname": "SecondRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SecondRoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second royalty purchase agreement.",
        "label": "Second Royalty Purchase Agreement [Member]",
        "terseLabel": "Second Royalty Purchase Agreement"
       }
      }
     },
     "localname": "SecondRoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SecondTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second term loan from Silicon Valley Bank credit facility.",
        "label": "Second Term Loan [Member]",
        "terseLabel": "Silicon Valley Bank, Second Term Loan"
       }
      }
     },
     "localname": "SecondTermLoanMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesXAndSeriesYConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series X and series Y convertible preferred stock.",
        "label": "Series X And Series Y Convertible Preferred Stock [Member]",
        "terseLabel": "Series X and Series Y Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXAndSeriesYConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesXConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series X convertible preferred stock.",
        "label": "Series X Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesYConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series Y convertible preferred stock.",
        "label": "Series Y Convertible Preferred Stock [Member]",
        "terseLabel": "Series Y Preferred Stock"
       }
      }
     },
     "localname": "SeriesYConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum age required for employees to qualify for immediate vesting of award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award",
        "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age",
        "terseLabel": "Threshold years required for retirement age"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_SharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consideration received in shares.",
        "label": "Shares Received",
        "terseLabel": "Transaction price, Shares received (in shares)"
       }
      }
     },
     "localname": "SharesReceived",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_SharesReceivedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares received for consideration.",
        "label": "Shares Received Value",
        "terseLabel": "Transaction price, Value of common stock received"
       }
      }
     },
     "localname": "SharesReceivedValue",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_SharesReleasedOfRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Refers to release of restricted stock units (RSUs) in shares during the period.",
        "label": "Shares Released Of Restricted Stock Units",
        "terseLabel": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "SharesReleasedOfRestrictedStockUnits",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.",
        "label": "Silicon Valley Bank [Member]",
        "terseLabel": "Silicon Valley Bank Loans"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsDebtDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsInterestExpenseDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsPalobiofarmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.",
        "label": "Stock Issued During Period Value New Issues, Common Stock",
        "verboseLabel": "Issuance of common stock, fair value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_StockOptionsVestingBasedOnPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents a stock option award with vesting based on achievement of performance conditions.",
        "label": "Stock Options Vesting Based On Performance [Member]",
        "terseLabel": "Stock Options Vesting Based On Performance"
       }
      }
     },
     "localname": "StockOptionsVestingBasedOnPerformanceMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceBasedStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TenYearWarrantsIssuedThirdRangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.",
        "label": "Ten Year Warrants Issued Third Range [Member]",
        "terseLabel": "Common stock warrant, Exercise price $23.69 per share, Issued May 2018"
       }
      }
     },
     "localname": "TenYearWarrantsIssuedThirdRangeMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLongTermDebtAndOtherFinancingsSiliconValleyBankLoanAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandEighteenAtMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand eighteen at the market agreement.",
        "label": "Two Thousand Eighteen At Market Agreement [Member]",
        "terseLabel": "2018 ATM Agreement"
       }
      }
     },
     "localname": "TwoThousandEighteenAtMarketAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.",
        "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2015 ESPP"
       }
      }
     },
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_UnrecognizedFutureCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized future cash payments.",
        "label": "Unrecognized Future Cash Payments",
        "terseLabel": "Unrecognized future cash payments"
       }
      }
     },
     "localname": "UnrecognizedFutureCashPayments",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_UpfrontConsiderationToIncrementalDiscountForFuturePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront consideration to incremental discount for future payment.",
        "label": "Upfront Consideration To Incremental Discount For Future Payment",
        "terseLabel": "Upfront consideration to incremental discount for future payment"
       }
      }
     },
     "localname": "UpfrontConsiderationToIncrementalDiscountForFuturePayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteFirstAmendmentDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteSecondAndThirdAmendmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_UpfrontOptionPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payment  to be received from counterparty, if counterparty  elects option to obtain exclusive license for one of entity's products.",
        "label": "Upfront Option Payment",
        "terseLabel": "Upfront option fee"
       }
      }
     },
     "localname": "UpfrontOptionPayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_XOMA052LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "XOMA-052 license agreement with Novartis.",
        "label": "X O M A052 License Agreement [Member]",
        "terseLabel": "XOMA-052 License Agreement"
       }
      }
     },
     "localname": "XOMA052LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "XOMA-052 license agreement and IL1 target license agreement.",
        "label": "Xoma052 License Agreement And I L1 Target License Agreement [Member]",
        "terseLabel": "XOMA-052 License Agreement and I L1 Target License Agreement"
       }
      }
     },
     "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_XomaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xoma Corporation.",
        "label": "Xoma Corporation [Member]",
        "terseLabel": "Xoma Corporation"
       }
      }
     },
     "localname": "XomaCorporationMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockRightsOffering2019Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ZydusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cadila Healthcare Limited (\"Zydus\").",
        "label": "Zydus [Member]",
        "terseLabel": "Zydus"
       }
      }
     },
     "localname": "ZydusMember",
     "nsuri": "http://www.xoma.com/20200930",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsZydusDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2740-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2793-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2814-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5144-111524"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(1),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120520240&loc=SL120174030-210619"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r477": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r478": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r479": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r480": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r481": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001558370-20-012713-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-012713-xbrl.zip
M4$L#!!0    ( %8]95'/7@JUM!T  .E; 0 0    =&UB+3(P,C P.3,P+GAS
M9.T]77/C-I+O5W7_@>>7FZV*/V3/9,93F=V293G1KFUI)<TFNR];$ E)V*$
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M1+X"8%LH<?XB3U61QK*F>Y>_/#W.Q)0[LX#O4[0(?/A Z.8>+D'@,LD%^-<
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M2S1I)<D183MUSA>2)'R\Y+5@294%_&0K!%L1:3*KH5.^-LJG4F:=6.C+;/8
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MJ,2\3 1$^E!M.Z'4Q"8V+I5#@4Y$;BJ#N:,1>&>^C-B<6CRQU)2FM9$_DR8
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MUTV=#\ZZ.!^\'Z6=CS:]&W<$XXY@W!&,.X)Q1S#N"%",UL8=P;@C&'<$XXX
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MQ"JPLI6Q+:-E&F2D;"BE9JAMUP2$-:3/"<6Y'-1PXA!$X20?_7%[46 W >J
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M8\#.N'5RE3H!]G[5O(539:#"2'E*$B%6WF.F+),EDYD[O^M<PQG(%]S<&2F
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M8@#:_+BA@G7#;]F66AGHKL-I2:;L]3P? 5$W%'?=8A2T=9M;7"TD[54P]91
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M4CHZL'*Z;D%-E2V]#9YIT3!D6 '#6!S=L1*NZHIVX.*Z8:&B(RUB+.&#%2U
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M:73*E##)=N"0D)P85=H*@[5M.##2WDLL  @;3"\U&L,N8+C32(&J5 -K-YK
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M&QNZIR7=>+3')#,Q9N<B$Z6F?Q@7KA/=X6;IYZ+AK-2]M'J.:8N=28=S<N-
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M2-^BX3?8F99!U.?A%3&4."=XD."ME4E!RS*I38*L-AD\!7GT*@(2)C_]^A^
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MM;P/ $>_W:CJEI,SOE4NK-,3Z7=XE)Y?UJW;FP.01])NWM1Z(?R2]SX+Z;W
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M[F=&?+/B5['SHN#U'1@'U670Y&$WCT=Z2>ICH/4H9!J\_/N.G9+NHX-X^Q4
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M=XO/]F51!BDOY2S*Z1;*D[(2TJAY3?^O4OE[[J]3]9>O4=71MOIUQHBT/8Y
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MW^I([PS!*;"H(U.MH:C^CE8FL4N$KCY>-8J7=14O1 E#E$'-O$>ZDELP3W6
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MH+EP[DNVWH@MZ\=1"0'^>+<_QRD]+^FV]YPUSQROU\O=6:BY/=WU!*_2VWU
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M"869<4W/1.8/3=&*<(1$P:BF-7EHGF;[^MF!X5(_.?_0QS)6AQQ\HMHJSPY
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M0K?+-F8,1E<'XH-%-=-E*4/,A:9\"$HF-"_D#N[E%2P)-DPEP(2)&QRJ21K
M7,?>2&Z90GV$"-<*'-V('/N#'<L 0+NX1'H'/E%Z97K@&@:*;@IZV3+8 R.<
M#T:AA[AN0S\87_EL>)%R];6GY<-!M0=#^>H8!<&HQ !UR5=H[W1'^6S37^E<
M3,%5;6P&&@(C(+H9Z&')8 0,4#Z8 "MINAHN-NT7N5/,"%!(IT(U </XZA@
MA5'?M'_2%SN6XC=T7&[6412#\ 6)&DUPN;G<ET7)[K+2H65X9!B.!N?U<"R[
MZAOB4!QH+XGC".T>5&OH^GE'1(W('$OZ* U)1#?!/BE[Q/7H;WLSL=U@@A<]
M91': 4'L-P4?EBO#VZ^]7.S021(4Q>7FMR#/@[2\S*\ARZAJ!G5#0_"XQ+0X
M@6;WT<<7.:Z0 TWAY9.QXD0:S;08:@#21)2+QR7-0F\W[1RP@M++\>0R)QQ
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M]7-LNA9UA^%VLS@D5]?,HAJ#ULNB38"Y,02/'/D=1B+6V5.)/LV@@K(#=]5
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MC(%Q-(Z2]Q"O*J]AZ.)*::7#_.Y?!3O]7@$@1;V.)%^&&WE6T>P6SG4&1FT
M'M4F:['06X",C_:CRIA"RH!28K]S,,0$&BTOEI0JRWB/I,B49&4<[(<,6=*N
M+"*$G(*EY<2:BV6%\$B*S-E9EN%^2)(U]<DB2ZBY6V,YR1I.,LG)?/Z_3_$C
M!7]C568(SL]08"6'D,?TGFHSM 9!(OCWAC%5^_/<P'#\=T-HTT3K*X5K9?4G
M\A27#U59/Z4>Y/_XPQ^^__"N*0#Y/1%3P1O8)WJ7[X/\A7QX]_ZGA3U@DQ8
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M.,MQE,J*7_;CSX3?JM?.3)]I,!7+=)\CA3W?"RB])"S.J8[BS^;+*9UD&8-
ME*I&FZYE>ELSPB_QWI6]]I\IYKN 2FA#)<1<+OHNC%&01!%]2&J/4W[A^*]P
MGKA\&/X!IR^AC\6R_)+$]%U$S)_ES=AJU/S](LGR+TG^-YS?8S]YCL-_X> A
M3_ROA80E'\[2W#!>UZI@F[[6RL36/:Q%KKJ]]XJY43$YDCK:B@#N3[,B*&W!
M4"((8(X(&:BF S%"2@\,XTDAA?Q+G-:R\)L"P]_HO^E3KI''.B F*&.R2HK5
MJN%3WZ(G;3Q6R/Y$X62)3MM$O#'?JA2U%2<KI.#M>%L%>T!NM_6P:4W3&W/
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MNB.QEZ)YTB!TB+K,X>S5Y9KZN$!5G$,)["C4/=X3RECK,:_(LR3\?,1[]=*
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M='Q^==8F,Z)<=.,KR2995HM/O6 .CR-U7?GKF)6OD15$!IGR'/@?3H@%H.#
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MD4B@Q)-QB =C*R]4M\],JP]4QCG0SU(7UV][4-$\04)U<FA<G& T3GM#F^H
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MGDTL\O <3],Y!XH *"2N2<6GZ7E^0)N(4G/Y0.PN"J.)_>?&"9U8+YE5YLQ
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M#.6[R':#TWEEVR731 ^85AL.6(_,J*$9V90(W6$\+ B.,@J708+2PGW1-B\
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M/C'='+Q:GV R=)A(_VUJ+F1/$R]D'V.B_2G]]O$X$=B[3$+C+IV&\$_3>?'
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M$NGM$.,X!'EH[MB.Y6[]58_.RDDT13T-X57H%@DJRILJ7L]C:(9VP5\=+^[
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M*LN44?3X" G4Q9.I6_0>/7@8G WQFG*.I X+0E<Z6Y&''!"43B#JP-#>.B\
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MT3VV\/C$:_Q,(WC5%+_D476$E-A;M$P<E0-9TZL-0IES>7NUGGNR:NNF";N
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MJZ*GS/Q!2T^8!3EN9O!K='F@];+1AX\EI5S$)@XFO;UB!-L-XL<H7G8$>EY
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M(EU\>!)Q5&C'R1<QA.Y'-6$I.><33I6J:R"CEN9DK^BIT3O,.0;HC83NO2.
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MTA&@[-DA+S8/3BU[S4J+[RRU!IV@,[Z!9T'TSE<]X2Z\0=%GK^$-DEXKQG'
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M1S'4;"MX:$ <':Q.1 S+6DQ6"4[^[E2H]5$[$#A0X8"LZJJK0B<#;0WJT&>
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MWLQ+"+%_^'X"TDQ!VCQE$*%<EG?MY4.$'$X79_\.4J'IF/.)YYHI-_8IWJ0
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M( _AK,>IL>^MPLG=GV^!S#?CF1GFR')CWT*< 0$U*0+[^[GYQ7_&_[X;]NJ
MY^=W-Q#*^/W@9^9Z-])R#V )F*MI(K777PZ5EMO#<)L^Y!@2TS55QVE*I2A#
M4SE#P]412PYIC:>&#',4&EL6JF,Z&H_&-J'#^RZ[77*]$4Z%VR8RL:Y7W+P@
M$NUL@YJRF8(NC4^%V^@NY^ECD9HJD;?F(D8>IX,6#.%13T?FVFFUPMDU6]PL
M&N*8(*98;=0\58[<:5/5O.TW"YC4F8V+=7=>QC?-O?7V:"3?J(R 4C&:V59%
M6U%8QY.(-BQ<)H]"C3E_21"C BLR1)#;-H*5--0/"Y>OJK3W<:H.=LN1IVW1
MN)M_ZNZ?!V&>G*+8RPAWO#'_]Q9_QG&#SN$SSX'&T"E\_2E 6'K&188. L'2
M-9W#ZVG&?RJP/\Y8>$M3P.II'?K=Y6KO)KRO"0*^Y.5XUL([:=.=44A]=E_(
MYZWF3RFJ_0WID:S.F6;L98GY!EK88\_?G*D("/K&_.S^.^Y#*UW&]SE'G>"V
MY-6PB*.,OCN#QB#YB@M'.&;[WXV7?3LT8([)_=ID0_V4.P?1 I(,URP9WL4A
M\G.>PPO@DM_+,DA$.^F=,(PW/Q,%EFL&P;TPK-4Q#'.6Q8["E!6M.Z.:C;$$
M\PRH=W'V*X&&#RE#3)X ^'M7*WW"O_V^RE=$S>^FYKM]+\3;GMWM^CU5,Y-N
MSE%%KZE8)KV@"H,1Q;6;*GDZ"^JW8U5_D":5-%'V3<57\G?E$L'A;%OV#5+4
M?CMV_;#_I=$+46)86WPRM&V-3J6CQ$DHP)AQO3B') IV$68PF]V-2B>Z\'M^
M_%W.!G[YR@)?#;XVY8+%>U#U QL9&T>NYNJ6YD!G&FS3&2?[AYIK:+X1I&!W
M$,MXL2Z3_*D]SGA[%#%.W6/U%>8)Q>D&P01V.=J?:NHG.*LX[+_K*?Z&H/I]
M9LWN9]\,3B5V?+6<E^$J'XGW. 6GMA@.QU:^T5&BVH;-!1.ETA%/9M9]E' _
M8Z[,"WKS5R$*]';%N2-U;[F[6XS872UV<PP21FI/)?DX:PH@0>1:.R)0P M5
MWG.U&DPTWPQ47YYLJ\2J)=I$2!/9/C7K-HWQCT<WL;G1S/!"P]0M8+7\2 5
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ML\7W3<7MRMY'7PE&\^O$;_PU#'Z]^^R70_!GRMQ$Z9!7@H!G7F"",05IB-]
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MYAXB?3+1:$^^0:&\*(,:*927!YE(H40*Y177^C[2",BF(M3;I;;0+G5$H B
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MHPGFM+L)\:7R6<3.B)V3(Z>3P,[GOQWI57[.E1=*O9\NL>+"HZONG GJQ;8
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MZSQ=B3)"45:Z@FT2FW)[11ECR-M[OP)]E:D>W;AGCVFD-# O;6SN? Q!*@K
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MD 6(_BR(GJJ Z:FV%[W8"2^@ZY667:K?(0S.9>I3C)-M4@2=IJD__OX8 OB
MF'_BH?TS"GVR8/P4:>)$GL,K!XEG.X=WCB&?U?*\C2C3%<.T.HZ6XX,YI96L
MTE@;#;X8:L:MT% T _7#1JAH"J13WFX&Z$IC7*J_Y*V2V V-$$"<WPQ#H?@G
M&3@^F_C?&"2&5NBLQ_#:4.49C^%=PY+O6*%MB9T5EIR*H;I<+>2;0Q\IN#>V
M'$O5'%*HK7!HL-F[NY+<9+3A#%@.^AW+D>*:]6CE$ DL#T V7]8GHV[!SVJJ
MDRZP'/T>"E!3E3I+#$P*2ZJ3>Z)A2?65MC'UZ&!Z*X*O<:13@R>F1C.EZT@G
M)O:#Y:UW#DTRRB+P?# G;^#\XINC0%/Z.=#LJ>%+>.%^]U5WK<OJ(3+MJ;(S
MLZ.G1$'JB7#4E!;*"$7* 5IQB8Y9W',YHK41J&/I+/5!+!.JGGLHF[V\ZDD/
M+ I/]#W4?%[C1$.$]6P(ZPT,H-*T5D1NISGL#J/J^+!O#7J5+C" ]/L&,/DU
MI27=FSGN+')T0%VI]T^A[?_[+X+^R\MX<\<-__4FG$9FZ3J:[GL9F">"I:B/
MO9<)PECO%TI-VC%\G%+4LVY*ZO'/%,.<]XMF)DTY)/(<)B:<@A!DNB'(;;B@
M'PJ_7@<4)\(I3T0F]26_[_/(+I!V6VV$]E<S(7_ $R]5G_]HDI^L;HAWT?P0
M&JX[*JA,WBM#F/ ,,.&YC%35K>I#A:I9*%[6RK@P9GD#WP C1;]CI%)<@]E6
M_8SI>%XFW-JH"--5YZKMZ6LU^CC5.9";E6 FAQ8;EF@F*]-U>\[TFY1PID8@
M[B+W>[,2S]1L,ZP O4$%Z&,IO@.FFAJ)N O%ERZ1N'W;Z9M4F$*1@"+Q!GSY
M6"*13T!$<&56T;-F07[!,<IZN#BHDM;>L+;Y>L?98",CU_WM K2VZM=LV;'4
MIN-Y;]&+KIB^JA"2QAB-#<9,*TASN)K,!#JB%\T^4;EXV1BD%KUJF>FCJ1>
M+T/]<KG:U ^K!M.NY[QI;[!!53_+<CET/-JN(M5 ?T U)+^D]&,-Z%JB*\]C
MW>=P-+7]&,_,6/JCJ!*AJ"I.()EJ F3U6HV)?M<5.-EKCBV.)HC6[J&\E=VZ
MWHZCI5[U"UP?'VA-1%<X>2$:[(@/LM2R6^E:77/8%3#TX\WFDG;JDY<XO70A
M;O+>^!20GFC]D*):B$M7^*9HUY*FU>/TL]Z.V5G6JJ+S>G?$.A8YF"X&E^TV
MEPW8SFZ_W*H\V3!'3-VH>I72#*CT0[LY$H<,L^FHH4[>*Y_*$]R#AOA<#XGD
MJH>/M*#H^Z6>(0]9C^T/%Q75&^X1#X_TPR<ZT"7-*"9/5"Y>V9Z\5SZ5,H':
MX3PU\MYV*[KX9K1D.<&O;.VFUVRV+ZPI.+TX';K+EL8WRF5[U*V*6J^QB33%
MH2E=%GW"(%,P+(C_4D%\@O7%)1#?KRF)7Z20EHNM/ICN-C(ZFI/3/HYSDT5P
M9NWP2["XU-^-35M@751TN_GMH-TLXIN#FCCVJ:.?L&P\ZCB93()Z MX\^%!F
M*%&*XLJ.A9?W\'(>Q89HG[%]M["GNKO*A9T!2D8'I&2CGE&QZ1U9LVBR/F(B
M*0<YH5#,L;?:TZ;XU@&[55U9]]07[I&,LP1O!^\;I)M<!)9,0<YGR/F<N!,-
M.9\OV64O^ZK.A!0(]#PX9DU;T$56E#1CA#<6#6*!SIWMI;KL@5]R!PO\;)J5
M4^B%W9^7FD-QSC80;MOIZ&U[B,P$# -YD(_E0.#U"DBP?6>4-*DQ ^DZTHDA
ML8$$VY^KNSR'/7P;N1>*:*=/!G:.YV9K<:<UN^WR[/?+N]_LX/1!TZAYJMZS
MN'4)+6X(K].MKZ<D$YG&"-A'(5\VY,N&?-GP1$.^[(<FPCEM&UL]WM$5W=!1
MTD&:(YG9+ OR;>T95N<:E8FXQ] BUBTS5C<@HPP4=F##><N>)?^N E@;<!\!
MP,]R%'D?46A7-4/O1,GX3H;M=SIIR*9=^D9"<F0R107%R<OW)0@IOE] .&G'
M\'&8JR&\^P:\RUI+T]FI!]O?"5QY+GIJQQ1M[X3A;X\;/8)?%?<\8N(3EQ#7
M"Z3+"!@.,%X,UKFGH\X=<H4G4!TG\APF)I2$:.K]HZF_M$0G#!$[YD=9$VG[
M*-(2F"61VS212F2( ***PYNT*:F1OIP*2 \,"H]AFD!-B%TF$[O\C/78"MOU
MW!.G*E_A EM;]#K(8CZ+K ?]CO5(<5WM1X#-?OB4\ LFF>4S8<9Q3+CIX>MX
MX6+ 3,YU,CFW1E@_<QGG5M#)25J7PE*:E16?MPV5;*B=?5MDM.J%T)/BBUAP
MVN%G7Y=,M:_*X5 _%*6W+O*0[4)'M^KK!EMI,X5);:)9HU6HA@A !A-'4R 9
MW)T43J=H*5*$KT-)@(7:#XWD?\06Q3SAG,DZQ)3ET%U^T^&,I4_LW0TP051T
MXSSW,7H*6+B=PL+M%*U%TO(*2<9S;Z6$HBC\=W108:=XNX9K(KR*;.6FA.Q+
MQ7T7Z"! D .K8^^WSCY%:W'KC-)GHO''3B-]*227:9=".]2"Y3FQS:UJ2ZQB
M2I$_](M*?1B4WTNI?HK6XM*YK6@IWE9&B5T;*#/W15USKY<(8DA6\BOC(ZN+
M2**G'KK!JK87^0\9=0M^5M.0W(85\0G<E"16',"*^(<[AH]3$7_634D]2IDT
M8!;69R=0.23R'*:U*N[6:%J:\/RK FN,L@@\'\S)&SB_^.8HVQA% <5704!/
M#5_""_>[K[IK758/B%Q/E9V9'3TE N=.0&YC5V6Q>F$W,,B-6,UED7'%6VP$
M+!M!;A0DR(>UW+"6^YZ.(:SE3J75.G,M]PTL37E$D>OMM)TUN,ZTOUQQ/F$9
MW<C2T.]9FA37?;=5/V,ZGI<)ST.$V[GJ/%Q+?:U&'Z<:C+\9JW)RV^;"DLG;
M%P\_5B/I4]TGH43<G>([U:X2;G/JT<_SUJL^EN8[U9\1B@3T!7Y :!]+)$XU
M)80B 47B!Q3RL43B1-N])$E$XDN+?]&$;]A#]K3$6 S+]7J.+BSEX8Z;_38@
MU5;]FBT[EMITO#=KA,OMH8VA[3[#<VAI+4^+"%TL=@4L%_7?(YYR1!Q(@F7"
M5RUY?#3]$F_7]^ *YLQ@]8=U@S=8=#QOVYORQ<&JWAE7I*ZY/>@&^@.Z(?DU
MH/^1?GCD1@5['<[*5,)?%D03$(P\9>J!K1[./8$^'7X V_*??TNI2-Y>NDCT
M_CIK?N+&]:&YYED9/W)R79QYZUZ-%_MKH=%IR5W"^,(%Q^AEN,#WP.N%BW_J
MHE! K1UIY.*HF-MZ&%?*>GB-"3T P-V1@R4+YZO"O:6P)&])3F'MB58@*2J6
MN'3];XIV+6EJ/WZI?;[5&G5&8-:HM9\6O9&NXBK]A9[,']#Y+2;(=O;(D#=$
MOF@UO 6^T<P9T/F + -[0K$\I, ^8XDUU/SOY1KN08=\KBE[<A7(1YJZEQL6
MRR_93<"N*MD-:<]U2U]$&@107>1AJ>LY*^.A^G@O+P/5QWF*\+,,C9!+(9_E
M]1(ZPHNYJ4C17V2W>$^55.N+(M&K%;M&95=4I]GM8J&KW4B5$!%U5Q9]HO,4
MU"AG+)Z'&N6=M%:B%,HE8.>O:9%?)++FYKBTZI8EBM<;QLIJZ!N+D\ZL/GZ)
M6%>:LWZMH[41E%MYR]6P2-%E+@*R0#8KU",H_D12<43K9$8+*I+?R4]!11+/
M7R5*DUS9-6&RY1VU'UHVBTO:I-M!ZY- OW!D$E1T::SJ#155%;/D!E[!W38/
MD0E(7.6?"/HM5#O%UR.>&YT"6OP#U[USZ(":ZI3]S2Y&)$=*8677]2\^W-V)
M3@N72FI.],TN+B1G&R_(8DZ]JH:ASP:5CE:M&8.0*FDTK/ULVC;J9 G]_4J[
M-UG,/]J#'&45C644M,17S"FE+^5@PZPW D:!9$P6LI;?*VOYS6YY)$=_W(,9
M2->13@QCP;W065^+RN <]O = AZ$)/1^KJJS7'NHS5>#U1#K7X;9^J.F<;GJ
M!Z/=M%UF+7<VQQ6ONEEC76 :H]3 QYJC0DV20@[K6UUN28XB@;;Q!M<M[NU$
M/P;-SVG;N,\+9E#?+PJHR@T6)9*M5,;UL\=ZG[)G[K['> PYS*)!1][EA879
M#)"#/:/?L6?)OU !2;7O!%-.VJ8D+\^7((3X?H'@I!U#2*H-*[Y3AAO>+SR8
M-.60R'.8F( &8GKW@>G=@.H46:XJR]QLS:.XTN7W;47(J=Q&P/('4FWT4A>5
M'DU=) G1NUO@#A[#-,%P$&V['=IV TOC9H<]=["@BGREM:J@I=ILB^%,9&GH
M]RQ-BJM&(:GV!6I'DTMA!--,MZ\M?2Q2+TBJ_1"*#Y)JWR7Z"4FU(:EVFC1?
MND3BX1@^(:DV% E(J@U)M<^8 ?D%%T$-$\K#YKA+H$B^IM.]9987"U<@U68Y
MV]H1Q5*5K[2G+1G;;B;,8"-@])&& *7B5":05!N2:D-2[=2"U1_6#8S4Z*FD
M.#!YL95GM,;,;XWSLT@WT!_0#<FO ?T8J79?7?J1DH;,VI!9^]<4J[_K$)QD
MUNYQ?7<]XDF2U>=RGM\&0U9;7Y99NRGFT"ZR1%JLVIBC^^W4"7B:"=\(,FO?
M$;-V3!'\-R3'3O09AN38B=7<<<*&ZFS#3<@>SANKQL0=8^7&<-F_+#GVJJ_/
MQWG$8 VDB9MT=X23!:D+U/:1'!O'(3GVG9!C7T1Y0W[K9.N C[#(X:@OJ;V:
M,#0L5-8$9];T:N,-4 *0W_JN^*TOH@$@1?57-,#;)>WS(<NI\YPX9:T>CHTQ
M>9^?? '7_9 V,/L^GG<LFT1U8C^2YH/I:'R(Y)XIJK$G"L.@4K@3BNJ+*(7'
M99D^<V9G-MHA9&6#BBPB,\.:EU\5,.0+4,ZG6*8]@9EX;L&KL7J6(T*-4%EV
M_8-C<&29)IZH7#Q"@"S37[@/<&NIN8 N@$31K_4"VRVYNECAYZQ5K*&.@HT*
M4__,(OVS)&\9?:A7^XT1NEL1Y7ZQ':!+X2#)!Z)H-/M6H!\E8_[MB^%^75[R
M/BAK"9F&&"VQH& BG4-E29!$$1>R-"4)=#8G"S1%X5E)SJIY)1]^P;_%YW\1
M;DICX5G4V/?F1J Z+K:M(;.ZT05)O)]'HA9EMQ8=LL^J/;FR1Q?N6-^$/EE\
MI+T=91M;(]=&^[@H55I+3C>#63@2BPVE-V-AO,-YD^>Z7F/K4>)*4S9@:&RF
M-E9"3$\4<V@CEU=Z@536.',F$/'O+Q6R<[$U4T2TT557V5F+S!(&$XZD?AY)
M.K,JUF5L%BV:PZZ-[)?B8+0)1\9GJK4Q)6CF*SEV116UR;+9UDPW&IJ+/;75
MJ_9; U9D*WJ9Y -?&C3E:&CLI8PU,R+F5K=@D$7,4QK68+68SX1L_*7V EJI
MDMR8-=0LLS$YMA.47"8<F8V-9&<\Z<YVOH',N%IH*\OV2NB&(V.OWR+-<:$Y
M11MHP"ZV/;)7-/K<)AQ)QXX),V+5NMJWC!7NS.4F:Q([!\PSOE HDS<XKS ?
M&IRY6+4;;9KU2M'0V$*A7*W:KTNU+EO95ZI5Q5F0K %F&E\H5?:;;6K0GK%B
M>#I,H8KU^^V-D!/0GT>*6U[S'8VW0F^E219G)0Q!VMUP9&RAJ-HTU#.U\8P?
MB>OJ/-O9<(S$A"-C$RV32[[ESQ8U'EE7A^Y.PE?5!?CVV$)Y/6?9K>$VSP8Y
M+="0[@B7:[-P9'RA3);EVZ61MV-W[F1LUH?82!N!B<87BK"FG$\0XPD_LN5E
MJ2#T:7T'OC^^4%U)ZNR7M3K&XSMTU:'W3&'$S 0ROE RU]HKKK>F#(Z?5LK+
MXKX=RH- QL\>G]OR\DP(6H9%3(1\MBL,A>8F'!F;Z"383Z9UG"JB19\.QBLY
M-*);,!*+?7U;K(_L]I+:LQS!BWAAM&V0 OAZX-?]M%+E74U?FCK"ZH1.F%Y6
M0\;+KD#%WZFXV*(+><]W66Z(CJLHUIK7HI&Q=Q)RVGJXTGJ^H8\6C?%L035+
M=3 R]D[(N,*QF&WF#<LJ4[R'!H1>VX!*A]C7&RK6+>2;N1*+5+N]3EW*K\I[
M\-#X.]'EP":ZWD!%1;]&"0MC,&'R72$??R>RE^>H9;^0-\2-WUYY\F;K5,#(
MV#L%_;*S6.S1$HLW7(/V2(0WVK-P9.R=\CBI#]1NOHNNM@M/YX;[-M[=A"/C
M[R32S;U0H32>MUI"T C&O=7.  \%H?B/0[%*1<5J-CI%5P42F<]7H=[%&# T
M]OHCKN"LFFMESB,333?X?K79-*.GQD2J-BX[$L4[/3YH*3N[6RR27*A0Z/A*
MK?;]J<4U5)*MU,E-UV_EL9;"A"-C*U59LV-[2MD"6RR;M*RN2OD-#9X96ZE]
MO<9/%[U5R0B08K@ J#8L9L$S8]I46@7=[;!2$MF WN?GZ$3L. P8&5_3GN^;
MA= G<]%@CQ868H'HEQ7P]?&%JA;5+-WNZ66^V*U,)[6N73>+3/C,^.N7"\,I
M0A4ESR@2]GHF!8LNT8R&QD]*T6X;,T;.L:->3:KO^[LRUNJ"H;$%X/T^7>WZ
M=AX5VX;$[?F16Q6BH;$5,)O*=+O=N@*J%MJ*U"W0DU)E X;&EX M;]U*PS::
MO&7N1WZ]+RM^/7IL? UXO-CD5^-U:%!W6&]O-0PD(,/G8O$U&#EK3UL,RSQ;
M0:Q];6TN-M@J&AI;@W7@B4Z/<3S>VA>"RJ"<'^'U:&AL#1HEUURCR(1'&YOQ
M,$=2C7P?K"P67X-B65N7F9+J\:*RH8W^PLCJC2X8&E\#+N HDIK,&131<+;2
MR7GL&(UF$)<M&7>W*":'$ETT.4%BLZO2?!8^%X^O ;9V?$+*-NHL5Q@U@J*3
M8_8Y!@R-&[;]3L16<SO'DH3<-CM&?:4NPZ%$_*E3JXV+_2UK&X'56!MKE,70
MT%7#3CA@S# @>9Z?#?D&VG5I(=17_6$7#(U-H%>8C%2\*7%LT,;,Q0@=TZ-<
M-($3RU5L%?:+>G[#B]-6*2>W:24\Q-'8V)&9E\N#K$[*-2,HHEBY(E#-<3M\
M;C;^8I69-<[K8EE"5;/BL>Q8,+5I%PR-O9A$52H47]K-T%&W/Z&6 T.3_6AH
M[,46C:I?**ZR0U;,&JY98>==CY^!H?$7J^?68E"<SUH\1_<,OEBOF>9F$XV-
MO=BLM1Z/2J4EQH8!H;4AL%W- SMVPA/:-JV [RA2"=UIJ+&8[\S=8-X%0V,O
MUE;'DWQG-5+XAH/R[1RE=*3"!@R-O=@(VPP7_:E*H94]5<1Z)&L7[.BI,5EH
M+_::,Z'9)<IU&FZO).KDK!T]]81*'*Y$N5/FFBA)5;=Y9;-H=V:'L;$UH,K=
MA3+M6"N4G"_*&VNJBB30,R><G'J/;B]RG-KA1<S:#FOM%=VH1MV)8FM09E -
MV5A%WD *_6(!P0Q^R$5/C1N%F2BL\>[ 04EI7:BV&HMFI;XY]G/^<:B/+LG%
MO%?1V=W*["/=6@6;.2^-6W\<.QPB>4*KSE4TJ%7$NC#)LG3_I3/CCV,[]MQM
M&<0*8T?5H%&98SNG8T;4EG')%<H(T0VV$CJBI].2)^TYCHJ&QEZLY4TF73''
M%_D^L92(^L@U7#5B?XD]E>_U\8+++:IL<3S>XJ[2$DTBNKX?6UENKGC;<=M3
M42Y;PY:>%1J\9O34V 0PU96<4!U9;%!Q!W21+)-[]D *$)M!RY4DJ^Q0?18I
MH#JG#ZJE2>A!8J?\#7[8]O?!?L#PEE"@U@1*8THNJ@2-/5893+I,J5UU^9V%
M8)5IF=6*I6AHW(0L.<EP[5:-)><U>9VC^ZW^,JH]C^N# E88,#JR8$/7RQ[3
MJQFY"AUI[(0CH30Q6ZSX00VU,'/I#25VLI$.%>UQL5DWAZTEVB!0?3?3RU5B
MA._#& 8[Y4JX%E8<U.L-VK"<9K\0!.A0SD:%%K''Y@O+0B-+"7-V1(V907TV
M09KJYEA*]Y/!ZY6];F48^ ;NF^N<8SG]0C5Z:FP-.H)9:&^X2L5HU)EE+Z>2
MFMJ8'2L]?@H-:P6)TP379O'Z7E+'N14[P[O/^>"?9A &16Q3L8I&8YH;3%2R
M6^ FL^=LT4^.#[_.(0VS+AO%S;8Q8=MH=A"J#OR$*R&(2A>I[779&$UF\Z&9
MZU:-\'B%0V.1)-;-+[)3J;%F=XL)@\F%E46$?C]^PI4@E4UGIO?M+#]:3#EK
M.!GE=WHT-.;X(GA_@ O]M<TV5O24DF82QEK1!.+!Y-3.+HA>W5=8/3]0*[L]
MCA.KZ+WBT20]8WF%I4<JJF*Z9C',HEGD#\]]#B<CF.VE,/X F\J.:8I+3_W^
M_,-K'(M<^G_-#]7'EKA%(NS1?H:V$%/5_.]BX#O/'T3PY^&3(]!Z&/,*>3V.
M 9\<H6D4_1\ D/GN\\2.7X@=@+./%VF3;X'ZBKX^\7PG?*9F.IMG'.[Y[P@
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M5C6K@;(J5@P]DB*U*-,;,/1YKA%$^(*%'"!?V3%-<>FIWY]_>.VQ ^C@"!N
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MZ$,0X=Z$]>H@PF\*J^,']( =YWEC-V]M7<F;-?E.%P@K0!/(W"-@"<_X"Z!
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M\< %!_^!+LCKT,F.,%'/=W795Q7P"\96?OS@U<A.N%Q.Z+,?)+ITE.SP[V8
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M<:1;&/P^$?,?B)KW3E1'&+?8H?M.16 VL^_&Y@LA4 ("(8$6%O_ZR9.9VI#
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MV0C*1G;5G;"64SM&7?!CB>)0P,I^9V8C@<YL<(X-E:@5]@A0#01K9=XJT-#
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M8 ]0Q9UI<M+W8N 3H4M6=DDVQT;(&4GZ<J2[,:T#[AR"E+=E*?/'##M+Z4/
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MY!-X,I6#^016\UM/K2@O';L41!/1=H[@SI$@(*W9J/5*DJX@]LVK05:1*6O
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M=>TA>#(9S)"=UT,8=9IQ.E"0]!(FST2UJUNBI49@ VX]3QP'2@L. +"NWC9
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MZY%<,96*6#R9-3CFW5GPL%@9BZL-"87*R+K(Y/0O[?[N/&T93.XX0<#P/M"
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M.V_-F:7O\/>:=MIY-V=IH!',T4^B*@2<ER( =E;1\AI:9I"2(V@+!I+;9TZ
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M !^0"#)1@)^HB* O\!-69[]^KE?302X69CA'@;3YF+6>@8^B!K!F'4U=^YI
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M%JQS]9TAE(KY]1;M]1 X51QY&PV_</W%*,L92Z.$!J-V<]W!<CUT-%4 5')
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M&;\#/7*C?C"J3E@P!'$MHG?"T^<T)>]51ZB.VH^.<Y%QJ+3YQNDDF79T#BS
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M\1_*@Q_*@Y>@//AXS7WT0S7WL6?6W'\,O]SD30UJ%3J"M<I7  T<BL,OA!:
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MF<-BY,T).F5_Y!40QV JN"#5AWM#.O>\^X;=)8-4DKG?=<)H&_!EJN92)HE
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MP$9/ SM(<=$.-^I6T4Z%VM:NR,='ZM>XQU'O8G_96MLP8FI15@:;Z9SEM-5
M5+/MG;9Z<#$[HK2:6KH!K9V>R"]48-//#SUB<.3W:T3U?G6YP\<UMPM'AFMV
MU=W-2L/BLEH<[>!R1Z]FG77/JT.F\VZW)YA(WH[AO3ZKYUHO!)<'Q%^9'W3^
M.)W#(#7^F3%WCNSRF*S@#J^QZOV CYEHI$#ES$R;BN8.1GY<C(]*"EBP=9#N
M9D,,Q4 ?PK-SHJ_F,P2#C>^ #&&*3\BO;Z'U084AQO-:O/VN77V?!I]V"OMD
MC$X)^96:KM:Z_6-3C3W<Y,TS, ,')P)/Y:R@\W0^6U3D0Z>K6K-\;IV  8C
MQFX>2Q7(+L]9!@(%D_X2?LH4O%,-,"!<O"6I>$V ->F4!R)(.2J;O;7E;1;S
M#[8R=#K1>49^VLW02S:#L9NFW;6"M"W$Y;R.C^IM=>IW4VT;V'MSH.OJ(68A
M[[RC\R&,@WRHM=ZI!KI>T&![QFX1&M*I3@4 #B-ZEEW'KM"?=@1_UF;]  Z:
M5'CYX,\]#7P%)I#@E)QD(!U9T'1<:WFM#*S>7_6R_5:_16W8 Z4FA6*B/;W@
MT]K57V?1#'\0&0@/#HM@)PH5GT.#SAD@HN""(W3.4%)\"T0);OV++7JNG/)W
MB.K%;4#*?'REDW]"K4\P=]>Y<7#=%'%TE*_/36!$ LWU'V=F/VF/7['"3T?0
M<Z>_!6<_<"<;Z6:RKFX;99FI+W:5U)15&LDY+.A,7K2[[:,$[6AD99* Y5,C
M'=][&3\WT-'=+PJ=66$XD9FD,,^(TJ0NYW:?$NC8<HJ%L5$_6_*7MZ1_*?MP
M:H-CQ+MM+-NC$F-Y-8NW5M$VFVG.T]?+JI\(G?_W+-#-,%15- 9:>R>V92F3
M;5&FR?1@F.1F& H7-^ $U+T1BN>&%O\M2_H)P:BJM&E3"[I%R5*A1,]KS>Y(
M[;2O!Z/>0Q]MKWQB005W*3^WH;Z@3WG2UPOYA>1$JL:%O9++QN6B5:J-*NE"
M>VG^?M)A.I[HT+O$M$V%*RESP/;$5B'3OFY$>5N5(^B OV[B2EK;^.6\-O;A
M2<I80J@%'1_\=R1"8+F!G9[&L4;@I(G8BT&,5-"<%UP66K@:P1GMDS:?T-V2
M;!>-I.S.Q?^4YYN$]N#.FUN2 -VT$^)=?('+A^A^-QJ>[]LA*D-2MZ)AVI0!
MUV>#/ 3SLN%>TZ&_B4+_YPVQ0B B1QA(]$R"@&O6'^QI_3?L5?^/W=KZ9;S$
M&Q'US^DN?+8<?W9[X:]K*@S_YF[DH"KU/Z'%L"\-8GYZBV%=7&NZZ6*"'^DU
MC)[YI<V&OW]Q7>*GN.ZGN.Z;%M?%/U1<QWS:HOT6=HPN!E.]!CU&0)B[PH&%
MTP]XN E/C^-@PHP9+EO^#.*,'@(=Z)A,Q2%T 0>*PA$"<4CNPA%2EJ\.V44F
M":>6P_GWR[B%2;4T&113T3#;I:=TALL9E;KQ8/C@4[D42J5EOYC4-VU9!%^N
M[!G9&D]NE8Z!9<< #>05$HP)9+</+ -"&53.2P9_4E2$V&^?AG?X[H+Q$;R#
M78"!\Z,P=&C3)4*21((&:LZNE!5Z8_B[>+_>; ARCMHPBVBENQML#\+\K__.
M@,R="P=Q%! $T<M_B23%U* "!\+PL_]_>?\_OKC>C9\<]_?A15ID94FMMC;%
M58<OI.:W-CYAY'6Z+MHP1IKR52;C(8;@&$/V(.T*97R0</;YBGT:0KF-'4]@
MS@ ?R<:W$4<OZ)&AOS457(G;1L"+7ENZX/4=*%'H(OA3G=M#OO5G2Y_8MY3,
MD5UEY>K(ZB1*N:E47SR(I#R7ON:,1"D[CK<<*''*L+QOZMU5ECWD$J5N73I(
M^DV)0]V%@.,J"J@D'AP54(L$*QFG,OUY+.;?7,D\1''>$$V;-:$YRX.UP"+@
MJ!>?]@%[^XH"\E&@5WM+DVW/"TG6$C-)=KA:52PAC1N>GE&@$RT PY4.C8(=
MTSAKZ373%$7;V=@VCX$"?PPP4=ZPC8*9]3U2-04WZZ(@H6JB.22-Q82AP(H!
M/Z#..BHB$ Q43I)* FXBJ7K% Y#TDY@:BDDCBD6;E^'MDIGN*$WP8 3\<PD-
M3SJ!N0VY4*P7\1IZ0W4.HL\;J7>I2DF3B3?G14A!&Q)N&^#OP'$6\"2-AH ?
M8'<:PKA'^$BT>[TMAFQJ1E&1,,,J!O^>HY.X]5J3X"2$5KCA;]"KIQK8V/#C
M!/#YO*GI+T2WVKM=X(.!_K:K!IVKE;9UVZEY%L$3V#SUO.#:FP='*T(B$A1/
M0W]W(.(J^&K?\^:<[L!!+\ESH%B^AVJ<84+B@#M*F$Z_D!S\]]=K8_[T)^)X
M(AY2 "?#^!0M?X=*9PIA-4IS!TVVN.*L/8\P>B;W:'W2@^79D]*BFUUN2PTY
MNS/6G6)X*1>T^9WEV=>34Z07$+#A['IE)+(P&NJ+A;]VY7(*%=>!]]I_#47/
MT)9H]%CD P;\T&#M,;Z'V*_9$Z1),/TP4\8M QC^IFLG&;M S7!@WIUK[5\4
M-*#:@<;YU(VV6=*;5").S2BQ5Z+'O>2HFI\]2G_XX$:K<HFVW*F'PS*W[Z]S
M%7JYM5C8=N M?F.CK;@#-%8,#6ZBT\U#:D;A^Z $>* ?<!%?YWP\#6Y&J;--
M!$TYU!![K8ND4!SO&:_MIY_2;3T7CX*+((E+8/_P,C[!2#Q8>RK<++/@N5R'
M8K:-H_"@ZW=NV.-&WN"LGHNZEUFM3,R1YJQE+Q0:)1@S_@6T#M%O CU%8177
MF50N690'P\F.81>J,*73-UIDVYA?$P^'&,=! 4E,;&277GL0W\0LN67"8/P_
M?))-;.-/?!)H"3K*?F3O<V3/5Q;2 CX7]#HO"&2@3"U7/6JQV.Q'<C7.K0<L
MM9*+;6C%7(D^!#AE'BP<KIWW%6VB,/=]8,H?R?@DR?@$-.6F4Z,BRI"U\AMQ
M8FAS1J]J\?0M-"7RY\YW_TF5K"T/GEI/1W: ^BB(4]T]\I Q^3('<OH"@8KO
M1':8,6 E\;T\%P]RZ]NEA3=ZESX;?)IZ41K"=G%8; GB<0_VTR(\2O2SA_'Q
M&FG,TY,,N<YFU%[/]P6VV&YR0XW.3J7NS9"O&AQ_N)I\D%Q%C0OS#I=;MITU
MY@Y"]\&PF ,(NUF,'SA@#H'!KD$#N:FDD%@-8OSU=9SCUA#UX'SV6933RT[N
M@Y/"5MG$_+D S7)P60Y(-?@#P"1<H(^ZACP\AQNBLLE;>$.4R_GLO9LV)LW9
M*V[6'"4U1+8Z9-C5L962U?TVO^$>)'?,:=;4G%F*DX?!\QZ4!P[<IO%:>3,>
M2:,C=6AN)^:VTZDN>]#>OM%0 <$.86;7CD%?HMQ*D3"S@Z9\-G?PJZKH9$I+
MF8UMN4)5,Y-\:1]--!K6QPV?SRX/8,U8M\E,V%F^NPNGA/TXPJ;"[1L"8&]S
MNV<SX9]Z'?NE#.N?%6):00%,6W/P%-?4\M@Q+CVV5P/#%E1$_3X-GY+P2&SR
M]21V6B]G<\9@%96EXJ++-(K%<$N[&H&^2LCAM#,G(3+/"/Q.G!$8(FN&^<G6
M*([';+8]');$?%HOXG;D@3W///;DS._^&^?A@C/8P=.4U+=?\@^ U>"DDL.G
M.6-5]PRX\VP:Z:,J6*<1Q3:+.[VX;+?"M<7NK_]&WV,WSR9+?>*1@RT+YO6<
MZYH<33$S-MVA5NU$9K^E6]E9]$&LT0,+)G&Q3*373^AYAC:RXUA,*XSSNQO-
MMN""(4,BR Z])PSS5/1/RAM.2;W>BE>8V)8:I=BI/,CNZH-U,;Y8MC\-778U
M=$(5F_5V=[HSY'!I.M!GK40CQZ-VVU<L!P?X *R'$V_.#?K[HJP<$8^OTLHO
MN,C'82>]*U/+N=P-;ZET3^TF]J-/\^ZO+G)WMBNF8F.AFQ^TJ6+%4.6.7 %N
M?.P]=7F1D?5T(4QJUTY"0NL3WM*4WYG5Q3!'C%=<QVB9D+U.> :6%&OT%SR0
MXTIF+<CCM9QO#IGP85>@8DO^-_F*@MZ9JALZ/)&+K=5LKZ<E5ARWX7G,7%7O
M=P<8;L423KFK2;;EG-9(A BVZT:@KYKQFE!>+(3_T4:_I(T^VY'E^TQ%60F3
M+&LU:O7\8B;UHL"_OFY\>.K<3V!5+M#OHEV""\AAE<U-F7$M%0,"6BWEF?(3
MH;X,Q_28!'5&Z5@E31UT-CL_E!FVVU9X_M- R5?/,RO!#A6SH:=9.J?FN8HV
MV^_BN^MD-D$2<,+8^MT;0_>0YGN-RC>,!T&1Q%!PYZ 'RMP0&M8421;)MD+M
MS>C0+[B[_HEARJB+J/K2UD/DSI5:&YM2NDOGLX>J$(_$!G2)^C27X=Z2@-C>
M6-1F<\[*5X6IM<N'\Y-C&06>KQ@3%_)#IW4E1(7;JXQ[>T/K >&RC;5F\YV>
M&@ZJ:$-31<BF2I*\G$N?;X<7LLU^.1>.I, [@-"M)![)Y"ZH>0P=C<QH"@@U
MYZV=]/=G>0^14E_X'5A.(?#Z5$KMYI$2N(DWSV/PP!YZ"TTM2 UBF"(GO(4,
M\"7<DUWD'X'&P8]HJUQIC.(ZQ44K\V1E:_'3]?RF0-^/WH2+RBD*'-0D<:RR
MQT4MO*>85,Z*%GN'ZO1BZ<HW6*!'*AW;V.9R8HS!8>.NV,F843UKLH-6=59:
MUSN%\1 X+09<U/.%V=@//:T&0<4>9WGH$ Y:T!&/"O+2IGN 8Z@LP[BJ(4B:
MU=N#[PQM85PHM>5P?0KBFK9YU?UGJ(.A$ AY![)?8><_^UL]21%C 4$=X/<(
MW('UB^%SP6$Y 1BJS5%P5RO'%Y7#.YLU$CEKH<1UP2XTN@J,</MT%K;C>J92
M7+'%5K[%Y _=\2+=#FXWYLC#3)J9<!T%[N!R0?C[/%Z7IX]60SGGT"<:?S[#
M+N0;+ZQ P3"(_^#F;. *>!93T?_UCN/[4\ D?RA@?BA@7H("AD,J:<()7"PA
M1&>3Q'0J3F(QCII,8['91.!$(9&<4I$8 SNEP[=^X(X)_< ]47+/Q\EIF ^1
MTR2>V?G]NCMKQXI0VRY?J.C4L_WR4-'D-YW(=[;!+61*A7%G79:K,;$:-KH3
M841_37:+V^_3:3Y52>?I=$1,UM*T>L3<NE>2S[<#1;X,APC)<5#0\;Q6#I6Y
MDQWL!5=Y0B+^/AXNJQIQ#R^YJF^GL7?'TG4%;BH>(!72F9U+81BSI2J2+&(V
M.U@IC9M%HHH*!?)Y>@N2[8[1VA05LGI -C,+69(V'&/!>8""NK^+H_/5OK"]
M';5!?0=#YRT'+X2/8 Q?%_[(;47N+ P$SF@WQ2DKQ3+;'#4\"ISU.!5MRRX6
M+FBZG41*$^;28.+^S2Q5S,7E$EN<,:L.,ZLQ0@01]U_9/$ XIAP4S*GI5$J<
M!.4O!W]^EP*->5:: $)>28%.E=BVWAZW(VR1WB?"ZFX;&>R_1H%*[7B2S=3B
MEES-'/C&-K?:1>KM&PH4:J8GY]7P6J5>;ZVZ9DI*)5:<08DT+>J:/JU$EE^3
MY:=:"WX@5J,E=A,3S<%J(NEJ[X'#S@A.]I,NI3C^X$FQ&JX1Y&]8ZM_1/A0
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MJV-[%!E3JXZT:[%&LD8O'FSN1$*@ ?LW<'_6%K.:6AO,1Y0X&4SZ!R%9G%/
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MDL R^)6QT'0S!"Z$?@1B$"BX5TIN;)?4DHI[HI=P0UP,#=<L1?!98"B[:8C
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M**W:(TZA>;N9/VJ/T//]67Y0U ^*?F<5T ^*^D%1G[3]H*BW*=L/BEX[*+J
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M_U2]=#,SAB:[4G2,IQL509#GK78Q>L<A@70_.^;ZN%1FN$*=8^<*L6I*0V?
M:#A*^#UTKYF_]' ^O;4X<FS#AQ_3\^+H.K*C3=<3Q44N-6.696&VR!F]<&AR
MQ^'$$T(8)B=3/<^$"[DQ,0E8QFBZ'C!Z7GA\HV"F/U_4CVC^](BFI\'S'>Q_
M/^CY/8.>G@:/?^'X<5&/QD6]#!V?;_S0J5=#I]>#SO-%5_T)HWZ0]5L&6?TQ
MC'[T])M&3V],VC]0:/MA4:]2MA\6O7I8].L# IN#2*$0P(5Q4ZQ56MF>I9<9
MONJ/&/7#HWYX]&>$1[\N0_ QL:P4J],63LX6?:(H% ;RXN-#1MUE)7,"L<H_
M^=#1NVR>"A\S-=JD2]I)$U$+9HP _$\# (.DC"FB K )?,U(QP!\C(#5P=2P
M*0JC\!<,#<9]0=_1 &:A_]UX!B]336HBEVZ.F F=Q56!:"=ZAK5'Q:$]*@[H
M@$>4;$$QHP/E,,J_(5FG"->^SHF&:O]+-C1.T0= T^,3U52,#2V''5HN<9K&
MSCJ=%A583 V&S"2R?0MOIZJD!0GCA\%!3%(1NAB/19OM"K>BLB.] 9H0#HIZ
M@J$//L",]0NP/C L !3,?C%&O+@_D"^8JKD_4QAG[Q'3P%35#$B2G($-X/ZQ
M.3H !H'-P;^YT@_K<[JHOUZ1RYQ?T8-^BP;D-OZ?HXKUMYG,K6FH[]<T[(FR
M/;Q#IK1%*TNPA(/YAKI#!L'60DSIEC3#)U2\5L+E<#C6JUY KGM+"&5E<T<D
M$)!VN\G:VBW\LZKP4'K96VC /25DE9=<2=YG@T5JF2I+XY8$^GW+PJ?5I<%#
MP@60/J;P_89F@EM<T^\0;A#4#2C(!JHLJY8MUNRQSE--G</K2H<4HIL3N'R)
MJ0.,'W'P,M,Q4;&E'X!/AVP#"6N7J@;VWVAU H7VTC:[(__H&Y(<B H'0<7)
M:^*$K&=_ 0E0IQ3G@A3%_K)?KYHZ% WZW[^O2+%OWU@_?B9VE'P]VP!<$.<G
M'J_"1PX@8:V!MOX]@+3;WWT-<%( "=I_IJHN(M[YK0&90\W=#Y[IJ@KVB]=+
MN;ZNRJ8!#L[Y%#/XX-$V__^2;4#:8]A\O'@-+] </QO ]/'R(+Q0%Y(0?,1\
M"3$?C.]>NE:^H]?JDLCV]IG?WW3+(>;0*_&MYH26D*%?=%14QE91_]O7L/_\
M.594;].'Z_$<D^!DJ,(#9$V>F8)ZRX28Y^:@Z^>-/3A5ZJ2/^VK'NW1A/\"Y
MO8?]W9U/-6!K!,@!;E>R?"W[Z?&\3ML6/S+XMR;^C[\"OV(1// BO B3M]L#
M?8YG'WW6Z_,T\1*-O8NKG_]JW^@S[MV.;^YVI-GX=_L=[_:'1WX???D_' #7
MER3D2RA"GI8D?N#VNK$-<-@>R\GCUE'@0AU@\'3BIH09:3HUL++=,9O8!:].
M)BJ"@<I+=K"7TP#&RYRNBP,1A=5T3%:580#:E9-U6$-U0B3P37!G.A#L=Z+;
MSXZ7]%TYJX\ 6@P? #=R(M2!7G9D8V'(O'K%=H[F$! D%][.-S Y-WQHNV5V
MG$^\##@-,=WHGWU,4L?A@AL/!B&#:V&RX1LR>.A2^M__V7.='0D5E_MWCN6Z
M[$A;$ Q!P/',<0/XYM^<;'%+?9U3$WO=2-;?&P&"X( 1^"L5^C>V\S."QQ$P
M4;QF!V1[\1CW:_LAF?6'%SR$+F8,=?J;A/(?433\U3U8D'B-A&Z$JP,I3VTQ
M\U\.&VDHROI_C3)]RFUXA1"Q@D+P\EZ(V/UHAX80<!%7VV$VR#*T$R_3-Y*&
MVW5+OD7Y^W@[A0[.CMRRH0$5)L-<B.T#/L(&R1#%1OEPF W!#Z,@1$0C812W
M16_EUED[R5EO55K(E20C!NJ,F4\)^ (,68*E#E>6HI'.,FM,JDQ=JJCS95[@
MZ8X%5X8/5UIXFU\LAGJDN>QFIB0),O-TT&+)XV<.92HSG-0' [P<8@LRW1B&
M4X,A7'GTS$Z^FE[,%"LFY:GF0N'Y5;E:LEB*Q0]7<L-H:S8/-T6IG3(2_6!B
M60K&AG E>;A2#!FQ16S9&N"F65#2"R'5'H2K<&7H<*7:Q0=Y-L\#*0!*+:DY
M#9HD;K&AX[>;"9:MCABAV)Q(DU@(+)8%2[/8\/%*(2^V@^$&.VC. AH86OE5
M? [W&6:#ARN90;Q"UU;U2K.\"*3'M10_#FEH9>1PY5PHFRLK-1U(( GDY-@4
MXO4QZG-S]';#B"<6(RT786:]<*T26,;U219UM3C"4;_%X1S(TS,\D& 7.0Z(
M\]4(/?,(1_HX)JBQP'#(M-L$F197;4D/H"S2H[>O!(T5AB4J+)$92LEJ.2N6
M2<=9 C]>.BPLN4F?SEI270?!-+^JS\%BB)8>P2E0K6IL*5%,2.UDNEZI)R*4
MTJVBI4> 4K0ZM33G*14W&Q0IYY+CB36%2XGC#>1SHLAP1FW8S//AA1BICN?L
M+(Z6'H&*3W;EWKS3EIOT5._':\)P,*W83SV"U:S(YA+%:6R)SYK<(FRQ>#4?
MJ:)DD"/:DX'0T):0[T0^F*$370%/=A&'1@]7QN>42HPA63/U0+I+IL<+>JC'
M(3<=/;-<*A9&7%C-XS2YE)-LR%PVFVCE$>7/E699CN.-/)X?=IB5Q2I5=8AX
M^>CM9HYKIZ*ZH4GU>*$O1\=J(9I#*PGB<"F;'+<3@(TD<+.3$KM"K6.&\R>9
M>;A,:TR&-Q),OIW4&S/XB7J:F7.I7(ZV8B1@Q'&.L_1LICT=QT\Q,U454O7.
M?-1IY@MQJA]M$5QNB-Y^=*11JSLH%;KS47-"1*118*#E.P(2$,='$A;J(%T9
M2XMF8*1V("=Q5F\V9(/'1])*9!/*KP6!S_K=SC(>+D[E1OR4+-'"1$D/IZ)]
MILZPAM#,!+-QR'FAX\/KC6DAVHR/))Q>%.IZ=\*/HCGTS*/#*TPS$DF;\T%S
MF>R79YG 1,TQ5;CRZ/!AF1^&TH%Y4FIWZBJ?2AI<I8A6;@Y_H,&MTX=8O,D.
MITDI(-&T4,[J9$E)0(Y%2\E;I@V]G9VUHTLC75@#MF-0P #'C]QT,Y1+-(5O
M4@7,$HW1;N[03K:0!GBD@@GKE"(594C"7Z#*#;"_P&**E.>_7S %&)B,(B_0
MFIJL<XS>4*YU _YCI_:BA>K43;K5;6T:/AB:82/X-7C58W_)JJ[_[;[O%?-,
MBFG\#8/@93>WRCZ/"$^)0.D0C#X%*+<*VC:8BQ'CI %DZNL,5I1^;*,*FIC
M3L8Z;_X8&H?0Y9HW* P>@#] A=Q$VCT&%@Z>'3-)0$='Z6'PL<C,DF41;D5
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M//;C_Q^Q_H8/R,_R 4&^AF-/S0?K^+8#HK@=/GX6&>E9LHB\1JFGI@J4V^!
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MB*%BOHCQ-1E?D[F[R7B[A&VVE<RVM""S+,T7DZR<3"O%V\N959N,+O%^/L"
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M&G9^Q/X>#GAG5\RYGC27W[X$=.=7]%BX1TB5\E[[#?>C$U#^]:>I0-@ZHP&
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M<Q.1@:+@!4-Z.0;5!RP)>/=3 GU*Q# +:.C=;C:=.Q#GD2F*EU,3AXQ4!Z%
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ML"VF;8,??;1/UG"M(<KV'P"GR2+JCSB ?*'Q([=P;]UN W7?53 P=UOL"F#
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MJ<3IHL7SF@G%)6=@NK@(V-X!K)!-E&M.&S_OL_C%SHKPMA54Q89*'U[IY<$
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MK;Q:IS"J;A/JDD^5)Y*6'Z=&LF]T3;21C(^%]:92TZ8^/1B9:D.9C3^N,&V
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MCT;OX;][^._*3<ZKIS'?1FV'NI7.A,^NZVN=%2*!8GQ$>W%B/37^!TGD6XH
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M#"PP*6:0FOZ_[ZAQ1KWIAM'$'&N6(:C2(89\54/R2^A=%<LTH#<B?@LCF,P
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M3(,RC^%_([SFF!8H@L,\. R6&2H/_%B+2%I$JV",+)-$*S7=Y<5]B%JX5P]
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M&]:GIO]-GM0+%L! &M,[!9_H(GJQ_F@T+L@R?6"!5Z<%YX/+[0=V6L7UT85
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ML> Q3+ -KUR$H :(P!RR,H0!GP"B!5*5"=GJ]RI>(J$@*9#8V_6R@/K7+*;
MU< -P=.SE*DYSU91 DLCU4)__Q*HU+ ?.:]9FJH),2G1-C[QFSB+BKB Z^6O
M_ZRW>ZGY(*3/7>99FN71QL_A,O"S/T=)MN&#("'4I"KYB';.2W=0X.%F HR]
M-7@LN5&_?&^R3"XCQKO4A#O6,6UYL0_4,2-'>_CBF9IXX8M OO!+>-TR2D";
MK) ,B$:G:EP..G!(QX,3_YCN2B'>CXU)NFQW2ME$J6G!NNL&?FEUU]M_?A/\
MF(& M)S$SS5J;Y<GZ0&%'0T'H[M/]T ^)@=\>H> ;[)82^O#6S T06X%_P3S
M0ZV";Z+T?>T0=F]SWD5$P\&9W:7>G;O-7^C.LBJOWQ>)7;C',*B6L"G\1 YZ
M!,1X2->[B%;P_]^#1)_> ,G!JJ.;*$X('@ZHHP)39HD_?'ET.#BTEM7+-'@5
M@9@E8@N#6]8(^,!HP32)]%-;"SP&-J5$9D_SZ#8 Y19GTV"69PMYX&@H% R?
M=G\#[P]>P^K=KQ%*W33(TMHG>==I%LRJ'%Z5\VL+O?(VK43+IE7&C:W%15'!
M:Z*@4/#5*?!2GD>\']PQN$[P:=!HH&7R25S0V<%3;N<9_ !,"S^C/4L,S*<)
MQQ)=P[E< Q<B2QV'Y\<G03&/<E:TGJ%(:XQ2_7B%?#QA:W=X/#@;XFGP=]GB
MU<O#JQTK\S4ZIXAD#6CQ(AB3%L9KJRT=WP=+'AX&*Q7E!5\.W9BL%L\#:26@
M_<!3\8]P,D6U6+!%CEL LR6"QT03L%H8-H&V]G^O7UT.@DOZN2G=Z;SGT13W
MFU5E4<+Z4 Q:63Z.$GXW;]^:&U9L^63'5D(DCD">K_!Y-U%2R3-&@W/]C!!E
MFZ%R_#/?+0K/21(513R+D1#@7^BGP!DOLUQO.,E =I4J7^Q<Q6QIOFXEW8"H
MSX/+=Z^>4IJ=UIW]UVF@!^BQ#3 \)R%P3N1 O6MD0C#G7)9$YL"D[^%*7VIB
M?!L!63O2YAF2 D8)C@Z_;NZ:_C#\^CESUP^#JT'P*Y#K+1FSTAT8+99?!U?9
M( Q^_/$J>";/^N'J5_WE4(A.J$01RX'#"K]"FBM4D@CWP'F118W_C4H2PPXX
MAX,V,DF YS"^-)<C,N$C/*J'@!M9VR9X=&RSTT)OQX=U2)%__S</*Z7A04FD
MR]F68+0<D<:_5@<,Q1+-X,TOHN0V6A4ZB ;.A ZBO3#!LA&QP.%@=/*7P/D9
MSZ-QF(A4ZAR99V#(UWPP4OW+.R!AY&;*;(EV"I$S_%,V=@S*^N2![JHF"49.
M[4 4S',U^]L7__'N]56;8-A!I #<L464>%)%?N70$!XNK.<=J1(0BU<9(<46
M1LQ$?]^"\OU[:[N.!Q-5ZZ5M@?I\&A>37)'0M_H:^=G3V>4<N. :!,O5KZ@N
M\.\%R2>@>%1)J!A=&R!: -.48+*(E80F.;@YGLV%ST(!0V(%A9N\?XS1 ;#B
M5#D'FPB,@45<ENQ')& K35'@D:D_1BM-BT200OB,!4E1$6@LN\CM*.![X(6P
MY_:F2L0Y.QZ>X'[).0"7.F?/!#Q0UK*WL%;T]X(8G"T\$+0J*(R'^>PL):)0
M,S"$Z.]@DA6EL5+Q.TQ/09E'I/9)BM*Y+7/TA- ^A8W43X"-*C;CZ!R+I9J0
MK@:I#K_,%1F]<2XN#QPB70PM$:P9T>#\F-%?] Y!DA6%=9#@MWC.:ZPT( [7
M=6IJ'%K*/+I1=,OT\0V/V_BDA]'5(OUKCL?)]@8(L,8RB58OXC0!RCD8)["1
MAFBHAT:8SX\/Q1WV'NCKD$<58W(87_S]KT9PT7_^>O>.>4<C0:W67WOZB /?
MF"9"'6L/"G@0\,H$708;%\=X/*RJB,G6KM")F8"UCIR"3$F/0 DVF52+BH,)
M*# F,8<(AH.C8"QF=+3&UM_""_CR^&1PY@44P7L)K;T%:X[1+2@5BQ[%$J8B
M*;$ >XY<$%R^[ R=$'3#(NU"(E.7 :B> D_)BT#-LB3);O$PD UG<8(_:A\(
M7"0,F:#]WX5HDG^W)3CTJ60<X(12">>BFP_R=BFGDX(NDH!  ?^9L"H!DJ@F
M(GN_@I."6U4YZ03MT5D-B*D)2KY,X[+*63:#\HE)I9$XGMZH'-7!8@GB6\O5
MJ]?_?/GM ;CXP!E3M8@G@^#["A\@GR.J,!]"E2?2V_CST82O$MX'7\FS&]X(
MQ]'$6M!D@M\'XDVJJ;*;HXT!YW*(S?=0T2*DW24FQ(U':8/?.N -5#7&$Z&'
MV"_-0'87Q@) 9S @C_R:A'<1;I3M(3V6@Q:P+'BW]K8+CG]$G C%K><11@.<
M-\M,(604?+H\ !=/JV!=#PLHYED%Z@<8:#+/LH*H8PIJ-0LQ%C!5>*,4[,.
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M8)0+;4\=RZ$0^*WRPK2++(W+C)59-(V6I<YMT9'BFU5Z$^=92BZTE.J:E=N
M#P?E@6UT[P3%-H/):HP!);*D=5#)==JHRHG_B$)Y,L>CIR\=1&494=Q.HNWN
MJL4:4/<]^=V7R31Y8;T<O )Q-<YC>.0/*KE1V.*#CX_2XD#>L67KB?9'QR?3
MH]GQZ+?3B5+HCQ[]-CXZ/OYM=CB;C<]')T?'%\IS!7Z^?//NY<O7[W[X[LW+
MG[Y__>85^'6O?P+7X?#H_/2QW #8$JZ#F?CE2XV-?7XT' I$-BTP<%;X(-5-
M']CV(V<_G4R/U>CP]+?3T7CXVW$T&?\V'AZ=_W9^$<$W+BY.1K66!/1VAC]^
M]X_+'\FQ >?_IW^\_0UD]N%NA?8'.6!#<<!H?8&SP*>LT_HI2]7#%+9]W-4/
MS]3AZ?G1R6]'QZ=P]8?CT6_GP&J_J>.+R?AP,AF>SJ;-J[_$(,GWEU?O7K]Y
M^]O%$2CLLX?N3/$WO F W:&$2R$%7&X@ZS7([(]""4=G P=J_[3A$6QN8GB'
MWM3_LIH'%>W';\%R/_A?TA-1S+G9VRB?'B19]AZUD1N,,=XGI7>D !/3CY.2
M,[N#X!LUB2CB6%&.L")5@VJ<\RG3F&KS''N!HM(8@*J_N,#,!L?:%]%4D8]*
MJ9ZQFD?)C,I%BI ]Q4**B27+"%XA^8J5*2P!+0M;Q@2[I-#8VIE0UHE-%G?)
M,TZ&RLI=Y<S96G"P*XP42-\;)KP<JT2^1+E0''@&/V/IZS/,Z#_'9V4+KM;V
M?^,4$5\Z"=#V%!L9,4MX%QP0G.+[-+M-I5P\RTU63>X(8_E*+> 43%( +R-*
M"LK>1C'G!DU:SZ;J!\'_RRJ=K9S VF857AH5#HFI62A:H\U-EMFUHO0IETV#
MF2)N/B=578*2^YIR4NM.(HW05(/G23T7/V]9@=4W0<O3E,USI4!A8QB_#-X.
MW. E'J>QD*],"1(9N9A/>=PVGH]C;AWEHOS@U-2J1P7>--S+L[\^AS/(Y)K0
MCR@F>3S&.(L"XF1:@8M-D >*:HP5WQ0[<?-&;/Y/=5)3YYCK3]R4)PK<%%'0
MDAT*G,303H__'NJ_::CZ'O;C]T%OM^XW=!%O;%,17H-NQ[N4(D<D[A(86UVO
M.M-\=^_R^7=MY2OD+K8DZCF]B;++]5#)K?,_J[/J(OCQ]*1MF+-A4H9R8#N%
M)UCFJ'**CJ("X%**B0A*5(%4WD+?5EB;D7H!5-.GC"VF&89F2"KK"I?"Z>]$
M@569[B)>EE30M%?'..4T7F9P\->G[C1H6-NVTP=KSO2]LG !#4X03'2:%!6.
M0.O=*/+FJ:H,*S;!#8_ &4=3@!IGU22)<NH5,L1!\605_(KU$<$/"DYL'KS.
MKZ,T_I/NA)MV/%HJ%(:BG?A'H\1#V@+Y[-U(!66P%LN$SMS<N5OC=XV^. 4/
M\,IACYQVL$8&%C%.0:&C$<'Q;O@)PS0HF35QP!G@68RCE+Y;2M-79F(>5)X+
M)D)DXNQT3MTIEMLW5@Y!/19+;F.C1TTPCY DD2E<@_?&V"!777LU4[K>VJG:
M0C6=55*U%7%9$G][ K8+ IW !<,F"UUJR:O)P)XKEAFU9)%5!^O2RYKBDE)E
M2O]*%#K76N!8(>.*GBT$#JSRH%WHN&)&'V;!S%0K<UIW"6T0#/YMR#6(H=AV
M;B^(G@D'Q>0_&/9EDB74G_A"__!Q!<Q^(@CI^&LG T'L@(LX@"N!%;Z8Q7^H
M:1N'."%UG55A7>C#XDD1\ZD4,?MH.!LW4E]X#3J'E@1+W@ *=+ZLX^'\YW]<
MG)Y=?%U?1PTTIR.EX_JDO_B[U<'H><:3*M% (\ %>167NL=!I2 RJ;XXA65A
MLI,\3Y8E3:ZTUEX#BJ>GQ)X2[T6)AK1 EF+Q"Q"E* 1K$6R@WOK7"7Z$K'TI
M4O3^3CF4GGI[ZKTG]<9H9(DM.R<3>L+90-VX$-U&*[?$-)U67!A6DYSU\D3_
MR5E!]=UH@.<WDOAL$\!$S$S?^CN2'BRJI4Z:UA9R7T&^;T4A1WU12%\4THFB
MD%Z)]$JD18E048*XA4A^[]6J+M8MV%(HO3]%F^37)1KD2DL!AO4("RJ0Y/ (
M)GXH:44A-^R'3C7"DX+;AN=E.:>:G+ ,9G86RR1;*;&A*-/0&_T]Q=^3XEV:
M!*M=B,HUFSA31S$.(K);;$4;JV"632JGU/<N,\:UJL8Z!8M1Q\E[70JL7RX)
M0GP('4AL?H.)'.SQ]#Z,36HW6<QM0AA>HP13 I1'[?G5DD/8*ELFJF>0GD$^
M0B4 ATB4O9C'RR6;\!'#:$F.GN*:>906G%FL>Q=D_2<ZPZL#Q8XNX?82[2)S
MAIW"M<L\(P;34(E]U*>G[]U%?3ABHV)V:9?8[!0EUENF\H3OLXRS'-\B/5Y.
MP6V),=%%K*&AK[[_]M)"7U&=;X7XM+#K5VH:3R@Y=(FMG"OSE>]>F:]86X9?
M*8WAL(U4FT.A&$/XIR2;4+K@&N$ELAR8L"KGF9108.,_AZJ4,,LRB5(L4.Z9
MIF>:CV(:ITP>Z'TM11)?<+5U5BAK&FF*=A))\*P9\ET")PJW_1Q5 0%"4D$V
MI]0*@[C<S$E:' NI&2H)Y9$Y6]*%M;1=E!NKC=T/+$C3Y=J-#R>Z:*KGEIY;
M/E3%I*!BB@(A8<BLTA M9+ ;*8Z^;0D46P@,0*F4X^,ZA9*11@30& &Y5$ZV
M^-OMODU&O#C!CO,J3PB+!?C-NMG6R^BIOJ?Z#Z!Z7>KA5#I(B6F=_/%3H$LT
M[49CK)M5*BX6;BC(<Y&E:LC+3[""T>4<5'U24EE%1L6WQK(S*\'_B9:J*I'A
M#*Z0 RGNX(!KM?,U/KA##''8\T/W^0$KLXO(E%HCK2-!3A R#B'3(O8VZH8'
M(HJ8"C>57</1S"D@5)6%AF/PD88R!J(2&VN]<W"O5T?85>B^%+C,FFMLR>4,
M/;*.+=I30"3,3?JI*T5O!(9.785L.[8;G=I:U"!KD?0HF#)]:7U'%)?2 DVA
M>L6B>ZE45*;AOHD8Q=+(G"[W%#+X& 8>TVJA\JPJ G63)>2ZFAI_7C?:N',@
MS61EFQ/87 !/,"LQCKE$*"NZ8Y+#L*897#&CSS@QF6DECB[AC4[ I378 '(<
MH8[H(Q9-'D\LNE:144<CV->EC&Q8"Y%5VW!HSU+769+DU[]TJ]CT\38@%@P2
M'D'^;?MJ7:BI3ZP$#BC=LM<.#4C948VV1\]+VY @]8'ZU+U66*;XN8JFTJ5,
M<N,[H,O5#1 K4!$VD((T2N-(4R46D,HU+!%4DKJO'60[=B*)<O!Z"#%-8B7P
MB]5!5![,LX4RB+RHN0H]@@"L@LLD6JAI%%SA7:X,8?R#[%H6CX254PI0I;M"
MIX,%/V,[;CQ\3%VR"3M.O104-LGDTT#71A)+W<)BI8.9(ICZF=VK]EY?[^O6
M3_. "F4*G%WF80*:^C( *\%S:D;*&%Y2M90^"U?Y?=;V9F0^$;:]T+/"X"W0
M_/<(%()N>_ -&)N7\#Q-#0PN?\,)1%I</4BA/S@A"&/.X2#OKX1,0T1*1J-5
MWVMZ#:0_C7-%)<R@K^)IA7I2!(5N\R[F*L%N?986'':;L)"'4]&R59ZC:4%D
MD%=X;OP[? $5VJ=9>H ?YC)AAQ[A7<OYJB#MC;NCWX:H>^;Q."X-+JG_@.L(
MM\;[HDND2R(756> _2_PA7,!L5$Y+&^-$FO2C[\Q4T]OY;$)[U";%(VV\,KQ
M=0<^EC?H@Z.A'"G_(Z2F0_\D!5E;$4>[#R,"-'1I@3+%S'<L?UI--M'S]BAS
M0?$E[,*TL!&B@_ CG--(*]3"C.C@U?=Y*)VU]]"CX%5P30F'HZ1F'!$0GK*A
M^65:#[_A>!5JZ9,Z,[D28,W"DE%!& @.5J'IN*#6C]LL?W^ 5B=)<E V\+@5
MPPXGCIMG <'I?#1>Z#K88K&WZ(*I]:.<@W$TB_*O@WEVB]* > +'D"B"XWSO
MHE10^)#*\V$KMEO!?6"H;[MIY[&_B[\&9U<AUG6A85Z!^$J$UK7#4M",VTM<
MHU%?PM:7L'6BA.T)AENPXQ7J856AKOU(5'I-/;UB<@B0#&/,U'PAMB9JI5 U
MN&-32^+*&#&8@1MB A4'8R4O=@HU\=&=@A:_V6F%H^R0L=E#QXZC\X*#2*+<
MM0^T^BCF54D]=C8LYYUFL_"FI3W>L\RT0(?'XWBSA$TTL-</\#K=4C<9$$HU
MS&%-I<-/>%.,HLUE.=+8+A!": <7M""GOL%M67-UB&FZ(C"9LZ^]L:%W-E_I
M+WFV27=HXIUGY=OF4>L&2NMH%(SS##XE-\1%)H@;Q;/W:MA5B*&@VSSQUQJ;
MJO3,4MT'J@'SQP0VCV.2[5!4$]7(9J$/IS]6MJ6#HF5H61(I2L $Q$#)K9 )
M;G#E&ID,S<Q6H:Z8:>"$:W-QQ=*@+@0P/(=A#\93]PG(;Z!T3!8'*".)?Z]B
MX$<XG4NJ;1"HC5SCSE.KXD0P7!MPY,UK:VGNM&_S3"'J9-73X^J8]H,F"-SQ
M\<F.D9P\"_9^W@J/[9 [==U>UXFP<2=*F*VY84V7Q@^M10T8^_0/!-=$IW"J
M&]*=V<*-]9%9/<T(760%MXBX(D(,:#ASW-)K6;=]369T1%J+YS1J%9T&DF)5
ME&IA*A"]+FL")8YXBN,@^$&;V#8*I[M#72FLYZ+H@&FK%<]?XX]:H'0]*T,)
MX=7W86_ X/N'!MTFF[6X"A*:Q=&[S$R,=+I3&;H>PLGY()K#CX]=L3E.N!EK
MOSX3Q%*<!N>QV <X)<7"'YA9P^1P9=K%<F?53 V&C_DZ"^6&L-/  U,UBU!6
M8W@X2M\C>TZ,&<9:-LN?%1H'V&I>\SN+S>AD-LQL>JV!S<<)#)>L! R3.]W;
MID6[OG$1^?&,OT)EDCHX3:R&^#>\'TH3EESO)4,3QRH,S#E,R):B%1\X7V.#
M2'^5HPBD-<RO2-]@:)<%-(VE$*Q"20B8^1[P6.(7/3B&F[B\83:@%3&V;[('
M='B6+@:=FNF$1ZP<H'XME:A@Z2:&A9"(P/***G729'JNCD/49/S56O,%[$C3
MMI,W;L -V)EM3ID3@8YHEK& ,(4 PI  MLMA5/A8%ZC/<5::^3;8*JA]_J%2
MRC2AP5,2A!>&)HB@@.[?6V'LX 3X^X=CPC$#F&("*_Y:F7S*C9(S\R;=8/Q&
M_1%AI$<@/^FX]51LFG^;8.U*H8$AXH*@OG#.2I2L_M1@UA7Z!-Y20*NHR9RT
ME"OGO=@S):Z(!QT(*PS<C9T)=A@TG-@POAF>P %%-!-XO:39QBB&:3HQGK?"
M\0IX7A) ' 2O\% MZ[L'66(!/FQ4=/4"IT#PT)V8M%FHBSNE.HZN<9H9=@<W
M0WDVAUD!/%Q F@KE2V&RWL15$EH85Z9'AH([RSPN,*YV57N:D#>1SF:"8!QR
M'G5CL!]RBD]31H=F_MR2E*<G2Q812=)1[4X>P(XQVGB2'':&ITT<Z'1O^W'A
M ^ YUC3/[\98+B4!BJ):2-H0^2PWS:X&L#W4-2M$J#PR\0XEUZ;A:NFDFSBR
M0+,E35J:(I@:O1[I.TNRZY708@E?5 QWM\0:XAQM>3R#&7B;%;>!\+21-EK@
MD0WKU6K=L_* 6AS+OL6F<A!U:F95=US/MQA6;C\9W#EH,60ZGH(GTYP(C$W/
M!;L1F64-"X8W_$#;PLR]TIE!/8SS7I8&\5<3B\J+&128J 9[?:S,X+8<<PA>
M?$8@D&3@G'$R=$A%5+WF<M]';40LMH#L,<&-AG];&^KE($V#"+G6"@QL)?J2
M18EV(+K6('3YD13-D#1^+X7-_*D,0%[#C&&1U6Y2TN&A HY2LD<S9V !WS).
M+,4'M%NDQM1JY39WZ!GU(QC#HVY@;K"K04IX0P9CG@-'\<IL,HD825'/XAYS
MB8/%M+8JL7 M1W2!<5OR^K!VTK[YPT,U:HR%>23%)"=FJ:&1E;;OP7R8J'S,
M=S%7:=VDG:N$+-VJ<&I8@.(3N-!I4"TYQ $[YO@'Y_1*UDHX/@]#.K'4]F"_
MZ8V8_.0^BYR_95L1W?!EE>-H00,PSE/L3.6+L56TR45 KJSA*'-(ID.<3ZH%
MU;Y@20!1#X=R8Q!>)%C-]A AC6;?>@OE9=(L7C"MX$X1EC1XI@;7 P?''2Y#
MQFMD:;+BU1'SB(/P7+L/++IMK,<9E<=-7B9XXQ\^F%(9T3B%P%7,:76Z2<K<
MR[E5Z1H7@LY8"Y>L*I,(@U.:762<JHU%$9]Q9=IF6+&/TU;[EH([[E-P?0KN
M$TK!?50@ZI48P#4 O28 GIT66M/U;G.I,Y_4A7VJN^YF[!\&8+EPP\QQ1S5$
M^K=TRDCQH1PETN_1$];$G6'09GF/P5)TGQG>7[RUA,R<H1IKHW=._*I^5,XY
M4#@ _.-L.8^ _B940<^>"J7C0#E/2?U*:*M];JV'F/V8T:*C8W=J>Q/1^7+K
MN(PQI-P8MTG<-8RWS4;[9N*T-;U;4Z<8D5.QY;WN5@R;IJNV"G'V=%H)>[/M
M*Y7MTOGZZM)-W;;6H9,US"M2-1;1*.G^;^D+\&Z=S2/?GO)95'9#*T<63I+0
M/*&TPY;UU_%<EA3,0:_"?4,K\UJ;WKN0+;@8\;K5[Q5CO-=9NI$HT^[:U@2C
M]],2%N=8 =I2:#C5 R>;(HVU*O.:7\*Q"!0F%&V;B34F<4FL-L?T/WW:'I1D
M!6O1CWH'@?8%J'4Y!2(ML5*2S[,I$W5YI;R$C%()13'XJA>S0\[@2G@A1<,4
M'%F*T8IVMDG#O@7XHSW#VN*K;>&:>7ZX]C3T./&0!22#=S !2I6)6U6,LX12
M:MPSA9TR;UT/$1^#XSR+2UO"#X=42K*7@AH8#,+^/BJ*#6%%0*-()<Y *^O3
MF>\6)G-.V"0<A:J=%8X\J!8T?JI92]?E@-)=*L&SY]R&)=CQ ;4L??'W0$RL
ME[/[B<*5EH$T&,,*] -6LPVERE*)PR/4\V,YFE^81&.L0;P.X:8G[Z-K^M&D
M3RFX9:X:*W3 ^;M6\HDR+OB;X'IESO5,P UXKQ3!?N@I 7IE6@XY>I[(M]"\
MI\>;.YN7R;$.*+$5EMR,#8LA6>&4D58I3]* %X/86#C=@[(4KX#<W7#!!H<;
M#+756D"6.;UY(D4GXB-SU*)1=&2UJ0X%Z)?;"+<@(M,"IWET:WN_]*$9!YP?
MMW-:;R7L%F)^U+SSO;BPI;2, Q:L8O/"AGBWX!J;<';3G!$".CEA2!V@\,KZ
M&39<TV38,+I<Q21]4@Y0FH-.0,!/\+@%R4U&!W=[(J2S*G2G$F! 1U'P)LL=
M&(5ZOQXAJ!6*X/JY(MFN$<[B.@># ?3/S(IU.A[G,&/$I9>4@=:.+;X1+<.T
M68'XB'!D$(:]T<#@D3MD6LVC5*H@$W43I?5G:?GEB"]=5:=SY*V+\_4^QO8X
M-\K1*M+YJ6.E.3F6VHM\TU(31S29QXJF^NH[-<:3:+]<C5T)$7$\#F5B53QF
MM;[/+-HM=G36]U6.RVWCFO:]D_- J>G0%7)$^T!FXXIH&UB$C1_TVI"BP!.X
M\TONH OM0=#<*&(6-,>9)3G":JUX,A1UJ8<FVA9&'BO?#J\;VT[I_=JK^Y%C
MD"28W;SESLJ1-E@Z3T\W?KD$3ZQPQ:"M6-097SW=R]0HS,01($CL+22RD^Q!
M@T7=B&ESRTXF5N'! =C1F=1+%%$^/KUAI0P$@/,&.!7W'AXR1YPF2=W=N0+)
M3!76+69O!D4 EP#;#+R0^!WY'W(-G 0S41P[N%)R*0.SMW:)MSG(T'&6MU*%
M'^)(M[CBZX7E3@EZE\VOWZP+6C5"55RC0TVP@[\&3VP+-3V2M1N1A4O\+\EN
M>7AP*J, L=)48#:<6!S/#?:Z>S%KQO]5A9F!XZ2FI@IV.0TM>=FBDM"M4FC4
MER;@E'"!/%&<B']JC,S&10:+GW";)$EG] #87[6N:#V'[17+2I&JJ>DUKI>>
M+5@SCS8;C+@1=O(C@0(0>SWX)34'2K@(4O3*%A&[%0H/*YI0>!"<]9157X15
M.!KWAY.B=!O&C4A0\&$.+#.K LD!S%B$CD/!TPH4'2_**KQUFI<<B8X);>);
MXC[K Y*F7M$&@(6 V#ZEIL0)=[[7+?+"?:)7WCF6V3RH@='XU598"G;J >IZ
M1TN"+J2R+1*EI-!O5?2^3KN#_>R<.^G3=GW:[A-*VSV11M;C+\FH-MJFB]H9
M UK-_!A\&9Z%"' HI24B70]4Y]$RGI+9*UTK^EL<)I-^0RG_DZ,RAJQCB27Q
M3&V >I'4V^K.M(X;?K#Y&0VL>*M+JV$'"5<\1R82[E:6YQCDQNP&Z_B2'HH(
M ^[^QRL>\.2D@4#+HS$L>JSV6GQVZZM#7:&BZ^)E'#(K;[9Y&ADGRHFQK: _
M-PBN:M]DB\1UG2G$@'@&S6"4,UO.HF#(CNJ1#"GQ)C1OT*)^Q )K9<3A].PL
MUV#")_@8$N1N6C]#4@"YV^$CS?<:U)-]7;^;S0%WMK.5K9VHR_]TS;O]C!_Q
MU"G,]L#/KAR&TXWQ3\VHIYODE9$!7_S]RJ%-8SYR[$LJ,G6<+"NLB^]DV\AJ
MU$:<!(5?B+3B^LY^/EX/&[<.-LY#L_HZZ!#J8$\_^T _XHERK[UQ45$>S<#Q
MZPFJ)ZA[$A154OLSXBR" D:'V&[,5;P8(T(%IY_0Q  5W]-;3V_WI#>G#4MG
M '49BV-9]H35$];'6%8V&$V!5)W/HK9)!JS)TI[&>AJ[)XUYOKB=BM%34D])
M]Z0D'V)JQDF] P*:HF@*PM=+_F8<9P*KU=M;/:'=V]Y"G&LRVJ4$F[O),0SL
MU*/E?A=MJA1C&436($/=V2'J.^R)K_O$I\.DB<%)F"11O/@4Q@ILR'$Q@DMT
MHVH-_F5F(^62MZ]ASMA4/5>PV8S]_3,MKD^_0:6$C72,^B,N_(K+>A8BRYM)
MB%H1052T),LLR(W7US%5-UFI:JC.9EZK[1V![<'UR!&BSUCO1\$\&WR%JQ+P
M<P'VJVMW$P^' $/PL!;9--*HCV;N,2%[8$4:?I6?MPK;,V2Z=M!TA%C4!-V\
M89&=S+519L[/)VU?C$CUQ%0()+[RVFX]EP3;R8] 7];0GBYZ3]U&IWK#=ENS
M]H=62G8%!>U75>N2,M 8;J_66E ,TT1!_?>D626PL1E4QJF9+%=+AL"4N\OC
M!6+#$N+$Y/U!M=2TA6G%:EI'\-AJF5)IE9HF)7X2YL&08NG%!BIS93:CLV-2
M\VCV!,N=B!MD6B=KE;SX"/B&RG-=JR5;=[]<2#T]L.",Y$N99X),%4U1/NNS
M4G:9U)6"N?$"D^C7Y),M@.4IFSG3,*X(7D7E7@6"05&.?1H7RZKTT E,\P:=
M1G> ;[! X Y0(CEUW;3F=: U2-E MW"AI\;R<N6Y7TS7J"GSJQ('P7>8$-7/
MMV4+]FH->'(=O 5+C9U&8GJO7C=!?]!]4"_;1+<EH@1GL)X8GB"H:_P7)'.Z
MRBIUV]N$[@@<A3 \^*KASJC) /\;:Z <CQRGBJ$(]=ZT]G1^X]<3THQDQLSS
M#]>H=0\^D&=99@DI#P&A9J 5@QWDM(@:?BX<,8&:&]- 5:'!NEH%AI47C6U:
M[#J>'*4AD&WG<OW:'/!]UISX8/=\@2E6G E? "?,43 FX-^:\@?0B0BAWT(9
M4FB@6[:X!95!G5@(>+VN!OL*SHX@333:IZEKUX_@'A:EM:AN!:<B4[))5H/
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M8/8I33.T<*?>AT2!?/_MI1Q=+B-K>58*AMR$8Q3AAU7E' NS)-8(9XF2F6<
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M -83LBC4H4+Q4<H7LD\5WG"JL"<6AO+!)^,7+?\5,%[7S)B_-Z@3*T]>4U/
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M3URDU5GS;+LOHP42R6^0 6J7D#E'OZ;63E#T3KDK&R*&J:K\0P2/Z]285D2
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M65A /O+$S)#*ME2B)>ET0ED23F/.!+9A"IF<\1I&Z%^R&Z"6[LBE;23*%4,
M&N)TXX6K.B_!"'GWVO*B%A6]HE6RAWSH*KF5PMJ6A+1B]H!B=L59]1@9Z@1.
MKA6K[@L6%"XOVDJ05ACO+8S0(@Y<.1"U*\803 #L@QW+ZN&.+[#RHVP?_6RH
M\=.2(*\0-'#OL;*#XI!O.I48XMTP7]FIM;:Q[R6BN#QJ0$%KL+$Q<BLA>[_'
M5I A5X_5H>?U\BP>U%AE=;:V!U#[TA9\"/@XE,9'C _! <A;!O@B-A7R3>W,
M-^OY82D'6]H$2.'V #)D?+#O5R !'\<N$!IWUK1#P%,QERA_+%9L4K#?G\IK
M"8L&\1;K:R<#3#+D^+,!3=DW$IMJC&T.8;G?MR^V7:_X,[M-,V8&PC]\PLE2
M].O?XLGTI^C2&=X?(3Z 00Z@%+%SAF5QO<3[^"A.9U%\9X@@)8=0I%ZL*2X6
M9C2=\X9? S948D69IVX!QX;:-YY.(',31^_3:_S\*2;Y*/$#-K?UYK>HRR5W
M84/1&LQS!(Y27W$KV#A'>2=(Z\KO<8+(?LXU.X=X L6.K>0$3P,L!0JL@SWW
M%AQHJZ(%9@)O*[&AK1I/X#Q1+ 3NXX(JMO##%(C8@OPE^U40Y'+]-Z#DB7-G
M@*3%]@<23>+[7K 3TJ30QW5067&(!5NH8[:=MAJ/9@G&S*AUWV%L9=BJ%!3"
MEX&?I]EIA$U'A_96APMX8&7,-JO+(IZX(!CWVY1W5A&)C3G#C)%>.=^8@Y2\
M0,;#=B$=?6OIB"^LDW!#2*:BD>MRQVA[DD3G/D_1H2XO<C[+#S_5=\?#*)]/
M,4?%B-"&T**/Y3"?W"50%ET (Q=$%A%@RYCOH%X'DKY+"J6).1QJ3>P] 2%0
M^R_?JP9O/4)L%$)H!O XQD4,.=SN>O21SJ,/>.HM0HH(!-3?.>51N:N/+WF@
M64I\9))(DZ!B8^A8IN >@^QTF0]&'E6'8 8;P2'@ V2553K]?H9=O7DI"46L
M\=SXTC8HTCH(RVG3%91TR@"<S-=ET=D,3+N1&9=N76?Y4B=,KUE2D7=ZCN[A
M&?ZEE/>"T)\="!"XUV2\M!+,\L"%T;IO?=J^''9;^$8+WV@$?*.]1=I;9,4M
MHE5SN;?!P  .P-I+H*AT 8%<'Z[ZTGNK0M6!QF1/A1S*B4BM^#O\*JIDL /+
M!@K470(^(V4M\7@HL(%VFAF<6[X'VVAL>TSN>TP4'L0>"%\EN>P@5"-[Y+PE
MZ1 BE*Z*:*6;*F2G 3^NU?H#<D*A3"\"Z- 5XRK"8 03Q!+MLVHMSU@A5]&2
ME)/Z)99(2'[,"\FN*>>G/AG\\B/0[X>5*"F;O)YO'7$94S2H(:99_L;*D"HY
MGO1$I-? Y]3%':0#L O@$AJFPH?$G094.,$-Q]$SN& X=ER?9KG/F(9[RH@*
MI@72A11>UNCE,TA1I%(>YQ-A9?$5%B.9!E;)2+/NSI*2\53@Y'@)V3>QE(*[
MP\@Y-QIV01S:JF?D> C"@,+FY"\%@;:B'&GS)=E).DIZB5NE>^-5,-' X?\B
MR['D1@/J/.X)<QO-":&]G3NB<Q^2@"@.8?!A'K5A$$JJN"Q%#E5,2THK$0(S
MGV9I &6Q3X *D"WH1<"=#. ;Q(XN9D*?@J4Q-]THGP.7(M-1-RQ'8:N8BGS-
M9#K.%M)G7D"=4EP\6TPIT!7TE"\HS)H.J3=$C+N/&%="@):X[OEO0I:#22W%
MD\/5;2NRR- '8 GKI0Q86G=3DP0H5832A]D-X$-5^7R!N$40/"1WL+=$[ PD
MIR&\[G&84)?KCH&/?^:8.=PN.>/,AU)]J(_68_F"B5Y8L:3,. (^+S0(*3%)
M<!J$D:2882FC-Y<EZ),"((CS\949^ /L(A-":@&U87T_(]8-O(5S3MG4P@Y7
M:0L15PJ!E(+ 3D_;.5T1EXY<&_4Y7RS7X<6>$$9!P_Y$ZIL"=/S5JVVO3NK-
M("N>KZ7@F79:T^=H(+;$]3G.I%J52&6^8 \%,*[N!\_6[PJM$&TWA^ .@VT]
MLKHY:OH?<E$'2HJ;\837M0-.Z]3670"EL@>\_K<M/)PO@U:Q1-']5F1Y&06J
MZ<8]>8+O]HB'<5CJ/D.Q?ZQV9:0^I*/L<=:6L.&*:."=%NL%2:OB:Z 2(UN<
M4HO.,"9OD80$E'W)QB@QLA=VOV)'M%C,U$#=5QQPEA<\=&#'"W)A;ZB(06I_
M&6NN^.\=G[9CT:8OSJ7BM/1*N%A2<Y79;Y/]"2X#K/)\2@EYNJ-I$1B'O1*#
M35<,OWL[>E]9<-"F;JEU$0+;DGC?>=!]&;3A&T>1-#%IAM^V"CWOJA/>"6(
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M(I'K'9$=PP5C6""1Z:1'OUE*NZ'5H5T>RA?9)T#7>X:;]:4YAK / 4,_+5]
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M7GBAI(Y2CH%1(%Z:D34DAU =.'%[LKI^A6',I8;$\#;&CG*0JT[Y+H3HPA&
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M<I2QP09U R-?R1BA-JOM+B"#4V@</[XPDME/\OY\0F@IGV:IQ@Q<89ATV"0
MLA=2G+G=$1>1[OBC ),5:PSRRZH0DLMT*8^@%MG$TA.0UANH.C-R/H*U)K19
M\"9,UD!S&295-"/G_>%CU>L[5+@,T81D;"T1WW=C]<+.XF]&H/ZRK)XNCC<)
M<S#C^(:<G<OX6W0V9S/B[UFO4)7E1WAJX1-X@CF4/2!7CW:03R]- 4P\7V@N
M@M9%TH834DIVA$)O!!EGS-( 56G"AJBD::12QN\BLBWQ/#WU*3 Y9NA=!7QT
MU$UTX>TV*N#&]A&4M]2[%D<+*&@FGH*"H\:80QZ:/">Y9N@:@]84]RH+W+;
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M<&<0;7V-#-_6!+$:#ZH/*.")^?IY*K=;/&:(9=^8 3G_GFL@JP'0./]?47^
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M_ PR<O!ZK]N:QHTPC9]+3S=373937S53;:PZMD?;!P<OV4+>>U +^;$-VWI
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MOC75%WUK"OM'YV%^RH6HK^A$G^%)!?8O^S69)+.8>RX.HPL[(E/0O?!/Z..
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M)=G<\SOSEY@#N7^Z_'C6@*CM)<@W1FOMIZU8%97PZDK)#_>MLAUJN;M=S%&
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M4AS&[&J",[-WC%XA)\IK*\IKC'6Q1?E)6$0GS"LFS&L,>VGW>M+GW)W2Q/!
M05M2[B1[;25[C5$OEF37C0^MLBM?!(7$H!3"<+U/J11^?X..C&O P#:S'V1O
M=V6%?EY'2.OX^.IK^\2[ZOSZ^>;ZR+O^>O5;Y[?.Q:_>Y=67WSK72 'DI'P]
MI7QU72+S2OEYY_JX?7;6NFA_^;I)XKQQG#Y[>^OLZ#L)LV&12^]*9DE4S&=X
M.UE>05E>8W??KUA7+(8F>6?B?E/.CYLHPVOLYVME&31[/BYY)\"K)L!K[-L[
MQ0*EWKGX0VY68N;&D0&"&*^Q(^\B@=9O$EGK1@KP&G-*M;]C*@=60I\KYKWJ
M8GPX[F==?S%>72;Y1WOWNPCO-HD6;2/E=W7IT1[MW;6$#@C& 3LI7FLI7EVH
M\Z.]TZFBK8&,@P$GF&V,+&\<"1I&/%8W7/VX91SG82HWL6CC9HKR&D?OD-%O
M""H9I)A2?U/AYTGJE/.:2_0:Q_ ^2X$-RHY0GK,\+7R,21]Y'<Q!':8RGQ,<
MZ@1\%05\C0-\IT6:]V7JM?P-JU5ZN''4E2C):QSI4_7L/#@7DG:667[D723>
M33], ZIV-_(^R5CV0C\4Z<B[0HEQ K_F K_&,<%+F1)U5>Q+S,%J]7IA%(I\
MDZ*$FRG3:QTFS&6,'*V8AN(D>E,D>HTCAL=)06=%L#^<&"\Y\7 09L-(C#[&
M22RK=(2/S_D36F\&.9!^PEFG'XLXD"F^>F;"'D=7[.B*9UZ9CJ[X(;IBQU?L
M^(IG;IGC*W9\Q8ZO>,7XBB=:6K5O:J+@>(ZG+[X?MEX7;QS0 .%HZL-1,64[
M?*I\_/3+69CE3!Y#*C<CI7KM]V501.B[*)Z]KR'%V#_2^?J!KL[!BMO^Q^?.
MI\Z-U]K9(R%^T *BG6IO[\C[G[_^[X)F<Y$]W)^CAT2%<IRDTKL4>1UIMA+]
M_31';T]!P]DES+U.?)>$OERY3A_/T6GH([0B24<KU\N3>079CH49P-GJB73[
MM554Q:9Z_Z[YMM;G'?79I&YKI^@3^GWZA*5L,++:>K](\@6LYU<:D5^?8T2N
MI5^DH;TDUF9\/GN/#]"CXT,?J!/KE<QR@<=7^ 4.!'Z_X9W(.QDE0[H#+SE.
M!@,PD>%T&?Z;SZD+'-<%:9KKX\_MDZ]((63$Y_&!;'_WY9"/_S!R5W*8PAC%
M#!%CH_!WD<)! F$*KSL2/^X5>DV?^49[QIUSRSFWG'/KF9U;]78N6!=,"J>&
M#VU.]-7',(?;?=IHP&*A1?*;3+FB;?B<VF&Z0"IYV=_#_XUOG,^BF5_"N3BW
MU^C!C?^L<]R^N&Y[K5^OVNWS]L7-BRCL9]KP?_KE!E7J6!^\+52'2FWK#CV_
M\\RR#8L9#%60NFW4]31AM&. WD8]/Q"!]"3QW:)*%VJ7DM[!+NP^@1CAW]=@
MG\E!5Z8-;W]W[^T+=;%M6G4B\.PU<S^[(^I:5^;WN!'2$7[KZ_6V=W9VW/ $
M;&BPW4K<V%1*K]F]DO16Q/#(P*-FTD!$XIX&Y016TKU(<=N[0W:RI-=#;A%/
MY-[^SWN['N8(QS!FUSG,3-[P/LD4]DTY:GC'(("P0<>A\+86/FK8V]G'JD$C
M9?FM0#R8U!CL@$O<X,$4*2@VZYWE01.';Y;!@LX/BD!,&*N]@SWO-,6VZ8'Z
MC&L[3V+X[1Q67\/<O/C!*@GX9QVP)LC]WKO=(Q*JRMBA:"#U,QAP/9GB(H,E
MUH?5%A+7?RP&$LG1886)Q:\=\E7-W"MH5\-#, BOMPAD%IKY(HM<P<\?;VI3
MM?65PR /MO&J?=RY:9U=K]8^]OOG]E6[==U@10F60R;Q_[UAF@S34.:(^L^E
MWX]AZFY9M<+V(4E:"CS?P'5P[@&A"6HNC:P8#N'D0'9;QN<9.-L/X3Y<&[!N
MPJ2 +1140PS'!:\%YYEN$F V MY]F29!@33L6R",@>R!.*%2CY+[[2.Z@-IK
MSCO#(LT*5#8HMZERL]!U=K- -\WZWI<Y/S[_-!J-5$ZE_(XS%.*1+Z;Q@<86
M/0'SE\KQ:?/'/%$P:OT"[L%[4S&D'0'GG<<);UK1L<*QT!DP@<PPHSSOPRY%
MHG6+3J=R..E G:$]H@0:QXJN-I=TI9<E$9Z64<[AS!]BI!OK!N"+>BII[''/
M'XSWHZM"S>1I**- _W$#&T^(,1EO"[<B4N/5E=/ 2Z$G?1'?<LM\Y;. 69(9
M;,/J/6DR$A&-"RQ5Z-=0A($N<@#/C2(OX7>"PAQD2F[B(&171R9S?#@L>-X!
MFZLE'Q=??F]X-R@DIU^NVC1F/LXF[&IF@K#OPU0.PDR-V* @=>@G8 >"X&1Z
M\T=P@< I8&,+QSPA.;A-$G;YW(FH($Q$Y24-I<E\&0ZU/D4[*I2Q3V;Y?3]$
M#8<F*;P)K5[_6YS<1S*XQ9?9LJTOP%,#"D4/-OOD/OOXLKOIG-[DEN:C?T9\
MR-P;_ASM/6F?=BXZ-UP985$M?G99;V5>D4FE0D"'F9,E2Q!+"NVKM-#O0UCZ
MY+FD?40*I&JV%[QY#D(Z0:;WX'@ FB6C=0"-]H+0QUA(QJO@'M;/8L7PV4=L
M\8=[W\?T!QSTZQP6ODB#V8\H-"=98\S<8L7]M7G=]'YMM2Y9&4VY5F]H#:]S
M>G7->P8>;1# 19O*K8Q!2T712"O^+,P0YX$?@,V'3NF\GR;%;3\I<J.)1A04
M>G^4Z;,C=;_IM?'9'%[/^KBU@&DQ&.+#X@2GCA[ .E-M='36YLTWS#W>S?C$
M,FGLV#84')ICK8EXHQ1G(."3VP TM-;2\/8[T,+P6S^Y1^:O!K])ELT<H&,D
MA@:2&]T^-=/>[R>W?#(696O EH[]< A+ 3;GYFU3#:TU(3+WMU]]HUP&Z?]7
M$::P2W8NYQ9ZWFYC26GY+-;".V9C1P$.TR3"7Y4=$X\T0@DE^0V\]>^PA>Y\
M3NZ]Y![-)K20^*X(C2B0;X:#[+ @"-U8]4@O!%LNP.P[$ 28<C3].$(2P&?:
M;IC0(C(14TG^?27K('0L[?3@SB78;;#*4)8FOH2B0OB699<A%RMUL5(7*W6Q
M4A<K?69=\$RSO$01QA6TW77V_9RV"YLB,LW(K2+PF 1V)-K "5J]YB]EC&3T
M<5:S3?@S#L>@%R^)]07:%B*K10<Q3I5C"LQCF$YIE"ZYC$+V0:@!4X]IZ#97
M/\[*0$+M&VA8M9MH5:59/QQZ6W8/U6D!C&J*D@P0.EX2&6QCTWIA#PPN3"-!
MVW_K[>Z?M\VERJZ"TT,J:?/(\L3_AN'.,(\X%'.7Y*4K3D;*1$QZ:J"3%+4[
MVUMXS,%O,-8%(\,S32^;H0T2#$*X)E1D.A.>BK$S-O!&0_HDDK>PE5!C1]L-
M#Z&"1<:1(G70\C 1/N;S#]ZO_L1Q;%@/))S<+9W>X9RC?#Y:JFS)Z:OX#FDP
M'!TM)OAA-X%#4W5DX!;LUYV(\-&WID13-PE&8R/E&0\7=TD9MYZ.MN+K:(,D
MLYC>8?G40$,(U06X;YA$Z/'*'GV)END;R^ME^</46;$Z$]KU24^@ETP(:9ZI
MD*9O[!4XT*5P=4,U]WLX* 9:)@2:]4;$AU@DEJP5F AX$,F?P']AVXNA.7?H
M<DWI.-F5'KE)R.J?(&>-TM\,K2"SAOI!OT5P4$WM-O Y&OW111=4:%[DTGB)
MA^A3Q W,0YREC'V),,U%*41]FGY<'ZIC-G5H;(BTQ ZIIR!"+#AUD<$QLF6&
M'J8DY+6/1<NV4W5:&$WP)<G"O XFC"Y!1S/TJ_@8'L!#-'IB0.63,P9G@A?H
ML'R)M:[(\7$F17^T<SW S:DU@#'VA4HLR9!;[P4@ # *<T3_G0A5!X]C4W,@
M#92M@VL4-K]A#IJ!5_V6(("2P/V-'ZJL&4&;'6^<YKL&;+D!'^C@JB+6?S4T
MX@2>"*8K)AC&?."*2#\(2E@(9$[5N_'"5-[B;K)U?'*U33++_D'D* WCK+YO
MH8<47N23GZ\+<T0M@DV:_: "%18=)75CX:L=O Y?U9?B;H1+) 2[*J*=5_UA
M?;-C?0$Z;H#>QU/1A9.IN&6O_.F6Z/[E3P<_'VWO6Y\&K6Z#\"6Q=WIG?<[M
MH2'Q,OB!429Z-ERUE?FG=VICV>IN4X<R?4J] :&3N;(;L5_>70@F@B=Z9!R.
M,$7(K8?J>O@4PJD(^BW2IUC_*J!.1@)+X96\+>!TA0'=UA W4K $84ED:"KG
M2I?BPC'Z%!H0);>AGX%F#T$M'VL71,(2VHEC> AGE_BTJ/9W=W_VMDAPP%8T
M.2SP 6R=/A@D^!L:I+ED#V6>;#/$"0P'%BL5DB;Q0S'")Z&U1 N%WL4M10&D
MP5$/Q&[!+6G9R12-S)1W<F7IQC#,7V/"ZUUSV(@-L-%8S+L:IF#[E]<O1B1\
M=/_WN%N3!]:/1#C(6!L)]KFR:QA&$>Q=ZBN>T=0LA1B"A_O"@.U;LLMZ>)FR
MOS%0AKXBT#G0'.59DC;:HF'C,-C3/ $)0 W6LE$ZH/51KF6^8YL/7]DM0\E\
M^($/A%=*)[J>T)5E@ MJ_N%M&!@I#UXL!]V(P0CP][V@;B?176E/GE3Q-79[
M62;0/U;I!1U<RZXJQSHTP'I7):'VH?:I6]4IY[Z?>$F70SFUE\9X@B#=1V>;
M#*SX+N/!U>PI)^#<H^+L@KH>/)O=J#(F0:F[%/8%EV:D50B,O?;S$NSEI*7%
MKZH=ZJ%,2SU98!BX]08] ][^GCYWDOX\3@(2O%,9T+%;Z0ET23<PX9&:\FYW
MK[GOR;P)YZ=_-7G79:=N2B@.%!-0%JAL)BIPE,,_"M *& FG15X-]U0ZY$2K
M)EH%6#%X3CX1\YN=L)@1TL[+/6/M[%W#7I3"QS#!T PQ*CT+]$>L]N)287E=
M$7_CL+$H\GZ2D@:CG8RV+ZUQV;-OL+2T*_%)OX'V*>&E$R7>Y6ZE9)?0^/B#
MG$D&A<7DM10O<&)AB<4Q>J8"V-G^3P&Z6\YO?^'0ADG V@!14EL'V[2)4LX0
M3,8 'M#'# HRIA7X+<(CALJ2..>\WO\N8MFP4R821/SYZH]R=J-%."2>G<5L
M+0.<RTZ3J!NB7K#''7TFZD1K,JWGHX7;BY)[/6[Z[YW[5 P_<CSM'L;ET3B7
M$@=ZL;Y4=+,D@@/$"P>]K OGE7CU[S/R.;IA7]2P/T@.Z89]OF&?DS7;$;6N
M#E'K_DQ7.9K6I>38?F[+?AXJ=@?4J@*U7G5Z'%[+X;5F/)XYO-8\CH-_RB=$
M;6ROP;V,0']L[>U/]!MT)?0_5JZ#_Q9Q@6FU>Z262I>"]A-X!WO.P5.=)__7
MXWG3 3R_2%,,2OR*B7;'\!KB,;C$^JI,1U!Q"),#V'+XHF_X^/2*<$7OC[RW
MNPWO[2'\]ZX!T[-/,W>P=\C14Q5B0B="Y_@SQK=4Y@F\@D)2"N$C%"<<;U\P
M6[35P$\WW?7I/ONQZ3X377PV>MZ?.N$?ZE.+00>P"Z"UZDU1^9)4WH4P-9P=
MSSX^6-!60#-K.&%XLC"<_Y@PG)LP*RK:4A[LO+")TM \;5XUE4#L[^UACI8*
M^KA5OXC-N)X7]<-9CPKQ_)%@$HP#TG%U ?>DM^R4M_,186X'(KH5 _U7":IM
M,,+8)- W:*=/HC#0&=N2D X(E]4Y]DFOA^\8IN$=9H"!R,$7F$;9U9$L:%8W
MC-434CC&#(FR3", 3#H8DND+UBL<@E?P"TY$0VL$.EY$>9D;3IAH1$+WDPC:
M52(B^9YJ&ID!A>(%]LOPYH>QJ3J&FA0Y+0)Z#&&Q*?PQ][UW":=,(M:S&C-I
MZ,NAGR$>[BPZ(@TWYE&@$"PNN+'^V-WF?#N<Q6*@#IN$<DD0(&%!I\;?HK+O
MJ\,^]J[D7H'(:-^HC _3YQIL,T\)QI*C2 $,\%H\;6,[H\BZC.!?J&8RB?N*
M##E<^0B>'I\80L<1O+Q]1% =@L<$R;!<$W!.QVT+E2#F?/-!. IA&PN,/,)A
MF%R<YB9J5,..8T],Q-3P;5E;<=X67H"9PD3-99 O?D3'<UBZL J[R9W$5OO<
MZDQ$4K5%'VUXO=MDW=BX::-)7:<!M,=_2V,#,:)+@!&SP!&E(K(0APY!+<&<
M[5"O2LVZEPIKA&]@A/8LZ05Y KH!K0T9%XI0ZBE]L.'R+-!;*!7>K6!8I,X'
MJ"H,>[\4%3D/9.:G8?<AD#D%S">08[T4U93.*YYY3W&[<VUW+O<I#:IY$LRQ
M2BNGX5E;"O"'7C]E@VUK[A0^'I>:3# ^HO8DN HD*R3P.#XL"*SE6.?3<>D
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MR+I/8:*9!*Z,3[\3^\T7*)5XT?ET-0^D!,32U$RR^]08'P0GC-6AAOWS*>J
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MBSWE&<X\4@,-^K%/PT$3TZ ['M7)Z(D\8_T7>*TX#[M)$$I2L&\P15:+[):
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MCQ!>-D@2%1RF,QD:L#BT)DFO'DZ#CVA[J ?11G8(#:92E<,6V02580> %6*
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M>4K99L?XR-1'H!XJT3$=6JEFC]'75J\'RP/]_P@?R(JN*AXEJ0^"BF4'WJ7
MZM<JBI#*2-YA?M"RSZY+SG').2Y=P27GK,&PN^0<EYSCDG,>.^[]],O>NYDN
M<\DY&W'Z<LDY+CG')>>XY)PE2\[1YWA<K>P)D-^'8?I$/X!!*$>H!0SYC 'W
M;5EH_Y=Q%,V#Q:\4?W[YLK][AX<_X)0#_3NO\T@AQ2E? .:<-3_L.[0QZ(G5
M=;Q%EL/:W%'2\9M 5_!Q),*!=L60C^DX29'G+B<RO6,T\W':;;</<<FMW-C.
M,[B(M=_:V]WV1J :,I48-9M+K.[5TI-0!]:^OC-SS@'L/L&SF:/I8H#\8!9@
MKMDMCT6%FM$8#S!6 E''J*,P/HEUWT,R7I)T(JMC@[YY&'=IS0$GZ^"3[5F;
M"E;F3*XL2_R0TJE*)/5D6J.#YEZ-&Q)MKGO,.RESJ0R[XE",R(DV*2MM4E\U
M ORT2/%A#<,^6>WQ5)GC&R9R8]:S)^LR75$HW$,BA.3Q-!_4&[QJ0N[/+>0=
M)&13^44@>Y-GQ))!-,L3G[*O% &<ER5>E.#Z ,,\I%P6M,3K,EJ?A09ZV,DZ
M?_Q*D^]CPU:MG9(2U:9&2NO3CSWR,<M*8+2!)(?S$*<L@I63@N#Y5%U-L8VK
MOH8B9,4L9;!?(VGH9'6VE9(JU(BD0\HOR@A1 \];\%)^&A\\8S4A-$$H42B&
ME"EM=*#6LI,5JY8OOIYL8*DY8]DBY@ZJYS:\+73[,Y5A-*KDA?Z/.;1N:R76
M OD@L1IJYEYHMM9 JL]&BHC4%_:"P3"/1KJ/=2$D+MMJ$\JT9LIRL=]7'I#Q
MX4:UVE2XV+$)@\UYA,C,"]>!/I^T%4S+2"][I<AS QSM +]&FM^57"YR?J4Y
MEI5I\1I7?C0L3-*$^1T7KT9%L"LYS/K#^KS0<RNOV<8MF=BA]5R$#Z4&T%<?
MPQQ&V(<!,38+]NQO;\)'J1IUQB_:W-"2'J94@8ALVQ901G_TQ9T>";V:)Z]=
MNEBFDK^MF"0"DV1%EL2@^:<_8N6DL/>\4CA!A^KU.WW$ET?LO,?ESHG=<XC=
M[=QB=UUT_V 1X&,.RD52Y##B\@\0!5_2-TKWP3:A!+2TL6D7,[GL&B]BMM&@
MD.840<</<[;@ ;>1([C=J)UODH@*>"J&+PK8$:M'#.MS;196-FRR$:HM4^G;
MU0;:1/8-Z[3')YQR5?8(3O*0C3NQ_4I8]4\CF@L0,X<C<3@2AR-Q.))-&G:'
M(W$X$H<CF0%'\M[A2!R.Q.%('([$X4@<CF3!.))GI!V;RJKYHDE#$A5>=F2"
M5[K4WS)F#/U@5M;A="ZRKZ"<(Z\&]< ,QRGY0Y,"%[;'#<T).'@?6HQA KUP
M%((>B&_2L ZF/ '&9S-&&4N-PO"4(A,S/$?_IX '2W01:1B)#C!J-TYBQ:O'
MP4CU /:#"4>$?[(SCE1,GS:W>I-64#*FYNNU36BK.F,OP.?) >._B,&P7)Z\
M7N>@]R2G86/,>4>B9-Q[RC7X"IBN'_,/SY\0J"J=P2(I8A1Q.-(&)BBLUDWV
M\OFF+PX?JA(5C@W ZX#07AI>0J:PB-#3;C/>UI4\NM03Y1$OQVQ,?=J1ZNHN
ML(+Z<"HGZFG)1%FRT9?Q_^DZ2T5=:@R:M!=.&W2.VQ/);!6Y94;62.[D79')
MFQ6O,39BY;AIWRZ#D<B3.E:H>796U0X8(G!2H46FCJ FHD;EDC&U.K" 3ADL
MFCVX#HYTMWWX_9 9)282L))<5''4; D-3(/-R\I+RJJ?:E?$,_*8%!E0(Y$G
M)SF<MZMH2&B#5IKC&D$_'U<'R*DJC,T\S/!6) :'CL#+M6. OV/8HH2&CHLW
MD5N:5DVTOA@!EY6@&]WE"D=ZI9;$]%6K\';C[^C9GV*K&"4U;>A+3T=9H!5M
MW&J:_J19M0"BXT\MK>4:)[DAI8:&&L@1%D&GYR*\")H<>P/$8Q./N/W4,4U>
M1G7?-CE$>POB$A."V=N2S=LF]7YN 1&IX0JBI]8&%(WN.,'8]5V8%-G8V/9%
M4!W3R1P&;Q5&$=O22PIH\>%V_5E9"9PM)PC?7[GIH;FPGH!#B_?K,'*E6]O\
M7*P,/[$@_;!2:_ZAJ1BO.<]CN0+QYQ7E1 ZF^]L47^Y#GO3##\VW&\W(\T0Z
MW.OJ4K48<8,?GI.W>\W#G]VDS#\IK0=4876&YB$=6_<E\D2*JE8<%Y6=U;:L
MGLZFM_;"_\3AGC*B3I"=(*_6<#M!=H*\%L/M!-D)\EH,]T."_+) I:<=W)>S
M50[.[N#L&P[P=7#V)1]V!V=W<'8'9T\>A[-_<'!V!V=W<'8'9W=P=@=G7QTX
M^[ME0"J=R[R?! R"GAW(;I'F5!+]JPG^#Y&'E;GYJB2Z=X*GT32KT(_=A0(4
M*R).4A%G/7P*T@!T1?S-"V0&$T/Q1(3WI&&NR-Q$<$<L/%W&Q)C&6O0Y# ;J
M00LR#5847&R"OX%7HXX5WJ<B@U',,N]$& *S*.'*TYI-3:.=2HB-Q1*$P!G]
MNZ*RC&%*<%-   8VN?X.VB_T2U8.?_=^&:2ZY1-2&T9W#;,RWD_/RJC!PKY)
M.:2]/I*Y;, B*IC_12#>#:6]FR3?,F7'('M5-I%-#1,;S(!ZU\@J)M2UK',U
M2+'*OF+(9!KU*TO?,;U:LQ@V)X/;J!>T*,:;2V"[W(/-(6-F#J;(K*(6Q[!X
MT 2S;$$IL!FX@G(P-0=#8_8:3*"K$S% IS&ABY6V(H;#)$0ZE)@A@#'-$HS[
M: <'^3:&=Z*&#>104K-)/I0L]$*P*;>4-L7?PPJM#EPIA[FA]#/OI,E47Z*8
MH:YEZ'(16[<'(#(C>#F2H"4QHV%EL/U"I+\MD-T\2>?('($NA+%*&+%)5U7&
M$O0[AT5'NV7#2#!TCL4:T7P\LF#D5YB#M^W$*A3_-W!3+=T(WHU)3;T18P1I
M@?M$MHMV_G2XJEYSGV0/D9U="<(8TT8*SQ<X!,R<IT;#4#I+OT#.QI@W]UQ\
M8X#[(U./6Z /*P%63PHME>F ]OMR#ZV^1NDOZW2&G]KG)P1ZRGN0$3N[BIJM
M.W8S]E0ZR-$$H=6,S=-G(&.Q8.?AO:"_,CH+(N RU52*I<F3W%<1I*_(&_7#
MNF1J_H(M>'6IJZ8DA*F1:G$GPDAH_DBU*G#"=':!GA(U;S# Q-[4U;90/RF0
MZCA7)(EXQL:E0K]D(# 2A%6E*:@WP@=:M&" 07:&N5)_%G+;2*@T9J)2BF3,
MV?;B#2UA?K@Q5HV\94F$Q^SIRP[_GK[L,HOG:@+FO\%BR*]-XHAL2%P"><3L
MC"3B52TSOCG:6J/"D/DX?!WVQ# )-/&EKS=0FX#:&E7J>TG?^KBVH=Z5^9V(
MZR?+-T]#/S<K'F9E?+W#2^^4[Z7^9<0P:FVG^RA"4JM 'K&*,#8(!3TT;)B*
M>RZ&=V09*:@$!AV>[TL2?-(7V>3C##[8.%,*D$4:\W\5H4JIB<1]0TDY9TZE
M'M&KH5(C'\ *JHRI^=CC.E?E2Y:[BDX*Q7GD[%H2O!AW?=P7PKBT%HT"8HG/
MH=-VBA(.=<DVR!J\ 0N&-C1VFOG(9AM0>E,/GAPUZVDQXWL"3AZF0PC#_E9M
M6%V1"96I#(96FJD=S;P$Y&)8H,*TDI5[D_+"[,RK\G8Z4>HAY+43!Y7]D@QU
MX56,)S!J45L8HT.O5/:3J=H*ZKR;ETW$.8!!PMW.)&",3=GX7JWM -I$]9F#
M^S-Y "?F;:M6:*5LS:PF]ZX^Q"CF*!R$.<^_]9Q 3TC3P^,__\$T?JD<@-&?
MD<4)RAQUBJ7EU2<33D-V*^FZ@AH"S?0E;&:2A W/$Y7T+&]OK[FW@DM\:C;=
M.%LIYX?!XL)A*2(C;M;F#[NG%%&FS$8]120YAA\@]3!HJ?^L9-CCT]3%85!>
M";\SEV,Y@9G,::?4',TKD.#B$"D.D;+A,7J'2%GR87>(%(=(<8B4&1 I/SM$
MBD.D.$2*0Z0X1(I#I+P@(N6'S_M3,2F6/QK)1DP!!/(,953J\E["E_ SI,@(
M*I A4M]E-@D&Z23VJ>H@D_*J3BJ68 (MIE)"Z;)%ET-8=4)(=KOBG<7P7J2@
M#P,<)?(DH"O',&?HV@^ZY)WV/1(]2=;'UFO_GO(;]RSF$ZJIHKS>['A )\1$
MJIWJ.*T<F./#,H YCK$Z7>R/GHA+>@Q]Q!( XO'U6F.0]'-^1Q(8V(O!&,L4
MW5E)C(2[(OE*02Y@^#U?-;/B^==1;>4;C<<=6N:M'MYSAY$6JWF:; W=9!FN
MF#J_)O+4[/"K<5P8FH&+! 3U5GJ$\A@0Q@M&]79D2M*R=Q+7'T8]4G;;D:41
MWZZ<F/Z\#&)ZAD/]! P=:JO2&:H4"D669RW$J90A8];8-TH!)A4"X:(VDO%M
ME9IS(:/?M+01499B@<+B2RP]0XFZ,2X&** @)LI@BV26,:T5DD0Q15>8YB-O
MZV!W>R< W?<U)H_\=4ZAXH"%_*SSZ<L5/QCD3_9ZDFE730.I+P9*)ZB%M+T,
MD4PUZ_.X8(3I-(Q%3 $TED:.(DSH8,,;1D7&;'I815 1*?5AX\&NZEXJ&QJ>
M;L4RSS!NARWE4IB^R"J+4D/Z#$DF=#RK%1+$R#1[J<<:R%\&"I:%-C :C!BV
M ''I1Z.R]-;SRZL.K#PNJ@W+P0\"=9L0TL)020G?3QE#.2;'JCCAO:P. 4UV
MH28<-9(5,AB$&6M*CG,I<KN2,DS8DQM-> #=QYUCP 8"T1)0D+Z!+M&V;$7=
MU!.W5T[Q[>V^EK:[$=_E.E)>[^U6T95M-C>Q3*XIH6>"S;I\:DFQMK?;8&[/
M2X&ZT(XH5BJJHN&0B^\5.FP01&TZ*R[/J8A*KUODM/:LL"=*^4#24TF9B"'6
MXO-N*<H)GRIV/*7([/:1'P%;5+8&'GA/&$]<JHEU1S@Q[F=?T1-A1/M5KXCP
MV(^AX%&))*WU>A4%I *[1%M3H],;WF^MFX;WZS7\$R1^@;-&]<.).[ !)IPD
M$.!@2%@0T'2*.+VLILO5]'!Q*39!*M8,%NB(0M ]*0UV$.4 S+ST5N%H^0%X
M!0N ^LHJZDAG*AFKFN&$YU+[_3:*#U6!GE1J$N$3Q6!0X?RE/FOU3$$YF&?:
M$_$<UAV5-8 KQ9>G\%>"[8D[(4$+8'(CA"!$#/]!@4EE7J3QF%W=(X!#M5 O
M]K$<1!O,A>(9&M":!97PDP2V?V62U./]K8HMP""/,(9E]V]IO<ND)^!+[4/%
M>-7.E<8)@O17@()E]<B*$FP>ZNE7(X*36YL\'(Z^C(+JD:B">?E(MB5H6N3F
M+R=5>R3+E M*KU F\A$;>"Q%> 9GBMCO##6CNU*<;_R,%D4!IR.D.X4;_>VR
MK'.&-03@+Y"ITD0H7T).SF"[@GG-,EC2"D&J#E>]GBY6D'3)M2L\'\8@S$O7
M  JX>KP6UW:YA90HN?$W35#.D;A7>C<2(*30/_D=5B8O4W5F)?RP$F(#FN51
MYHV(\42(RB,0$)\Y@J0@-*_XKM!VN!JP#_ 8*KP9IJ#Q,D)TO[Y:GTV6*PBV
M'ZF:'MH [0P3DVALM%Y VOP! 5@)T-FS'5^DNNURWNS[NH2[8)2Y::2J>XVZ
MJ:MP](QEQ"9:TX8O,W-*2IOT:(E(K!YRQOQO#_M/J!J&CQ*)R"PFRT60I7:'
ML?Y[V/7B,#D.D^,P.4N.4G"8G"4?=H?)<9@<A\EY'&RSO^LP.0Z3XS Y#I/C
M,#D.D[-@3,Y3'6SF3$U+$).IPAC] 2ILQ545M=],>=8RS3%2YBUF";GF&RK<
M-N#L;/9Z*@= Q<%CN8@KGZOHIGFC"NIMJ_14E8Q)^3SJY%\)$6?% -41:QQ2
MC"9]$POQQ(E2>J;3MON"]!WZ]5[=E?0$'VDE;>I4N7W(SU>D((GHPT<A-2YI
M<O*QCX]2[!YVL'='8^X8]"M"SV.JXQ:C<U 7>^*@"V7:DW<]8;8%E"T*!ZAU
M0>$C<R-AJ?CNV,2JV F/T8=>@?$%=# V8"?)E>N*@NLF2K9ZL=2IK"J+CJ5>
M)-ZOA8#ISJ6<'3AB\D!+QZ/_+4[N(QG<*IH7EBH,TL&<]Q4]TC1W'$X_,L0$
MJ%) #E.926;Y@.4M8;@'5',J19_X']*X%:'5H1\.23!-/5UR8'(1KX;*%U61
M0JM^%K7=,,%$\DY&&6;NH6><)6\\QYJ>0ZJD#,>2ID #I<@RO3K*: ]&'@8@
MS=&(@EVQ2A(.9 ^FIMHD"Y5A:&E&==^L]NZ745!28E:_H)ECW:+@EBH39F)@
ME5"L"BHS?-$,OUI8]R)%\1CALV^UJ)2#>H(O288ZR=<:?4-&17Q36=8K(H7F
MN.)<="RJUAKBRT5D(M/UFSET@9Y>/044+:;6#W&<?2)O8,=T9FXS1=;JOF4B
MY4D&,"T(WPG_+4IA*E]N,)^KITFF\O(L'"J99/-@SR94F53%%7U0!QG'K;I4
M4; 8\-+BTHP];X+VR9"2S4_#KHH!AW$%"Z&E8@P* 1^KEQ&,+>=0-.6>R^\H
M(ED-*HRO'4B9ZX^GU10OPS/2H#CD=UQ9&<7WM*8I5<F8SED]V9O*X[+PFJ<R
MWTEZO3FD#]>[U[Y36NM$]@3&M;9(D'JAQ>1QD>1RVP:K4,'.5!VN>>\":2B(
M:TPS@Y0(-*U(].&<<#(:=&?%ZNNA?QW1?HL!905[P*9846JJBQDIM:8"U089
M7 SA5T2;$6CCD6W&?,A+CB+:L-["_&'HI^H"\V3 _OP9S&>96L&XC*-S]>YV
M=<'0ZGWZ'=Q1&Z-*NQQUM<*[0%Z15"D'CIU/H!NC5P4R"KG$\ -CO;>'U3>9
MZD'=S^_2NL7 3<<$1]D&654ZF/U#28<II*G)-$1<H3-3^U]=A+H2O^7IM?;O
M"7:74F+47VS*+6W5 99YE="H,!^5$-O:T(=QM=ZLN2[D0J2/25-CBCAA>_B$
M:.1>S\AX >X%ZKWE+"SRF.=YG@*'5S>=X[.V]]94,USN@HQ??K]H7UU_[EQZ
M7TZ]SL5-^^RL?7SSM77F75Y]N6Q?W?S3N^K\^OGF>G']>?8-\.UT;LR7W N_
MW,-)/.N'P[5#R,( 3Q_BQ0WH92IWVM_#C-3TI<C-]OEWT+P[GY/[.<_-&@/(
MD*P:)@=.2$BT5@%(>FC-$C0GL#9)>E;GLE&UA!]\>#;[TR?U$^'!O-F&I5V+
MEC(:VI2=4"4S,Z<U9I9B QJVN0AV5D[.2Z5E%.O]"I[/=>O1<E=/M)%F+T1Z
MZ  ]#M#C #T.T+-)P^X /0[0XP ]R>. GCT'Z'& '@?H<8 >!^AQ@)Y5(=E!
M_\G4\.#B_"<=V(,C=-XC/.>2\M_@%-]*.;;VE4[S-Y73_.P.%>/LH@@NNNI%
M+AJ3O1>W,J9,RZ!!&BBA> #\S@%L_#6,T:^/OV$!!D8+4;9^4/@<NA^FB(KA
M D^(.(E!5?9%U+/Y[AOD<,F0,H+\'.@R)V?-%J<E;E,HVZIDH,(["C6 $0C)
M^;C,\X_Y4MJ),B0/"!*X8^$4_A*=)9A4EZ2RO(@>-#$'M!*R;R!RI^A!IPI.
M@<7TO(GA<;SQC#L4>"W86+I)H#-Y5=A\6@2TY,NW!&&H!4'YA7(=MM6Q6DVV
M/9T*^VOSNJE2 7MJ[A(6ABWT,V"WH:.C!KV<$PVG2@?GL"V\L,MI00/=N9RY
MM$LY?+K9#)CC8<'R-#K9<IB&E$NJ=UR++V,,V&+"BZ@27JCOQD>I.C)[=1N;
M6VD"=H3Y^V<2T#(>:Z*(%.U4P=Y8#%31AJ!T=I8%9,8JWU :;;G.)V5\/P",
MFAIRPZ882;'YHE+#;*Z\O_3(K$R$9N\KU8ZYD]K1:CRK%B?\07/U2.%16*="
M#!:Y?Z%FP4%K478MQ;Z->L-TX^(%1W!O]\,/#.&6V)X]1F7%+)A7P<--,Q8*
M*5#R0Y&?GZ TF*7LHQ8FP434:#*2O,49U$YM#6E]7\8>*E0@*J69$<0/1$@T
MPI3T?%W5Z+H18:KV"3INX8?:$L"E6M:IP>[F2;D3PSIG?BM\&AYM&R:.+9BG
M!/=J4ADIWYWT)L1\5%?*<,BTOC (HM8'>\@?0HR@2M<O/^4- K>%!I%QE=1)
MM,7*@>%$L"=/3]>8QGMYC?&#\MZ=6][-&$^2><:MS"3O#]6N4EK;;!PKO AL
M#-Z4A;!:.+:WT\](+QMU3A"V8RAZS@5!B&F]4\'<&6VHE=OC]U\CQH^J<8F'
M],4W_7%N'?X<IV>?N$"Z,K]'+V+EY%KN,*:H52],D>>02EMM:>JPJH*CZI5:
MWF4I[4+MA-;D*";2I,BQIA:660/]62%4JA9_M&B?RK91:4?\D]VBG'7 !;38
MOQF4!^1Q<F#J\,.+D]2O:G&%.6UDN($,1Z"?#$.5N$"GU"YRP)#W-('] LO0
ME<PX)?+=ODZS?2E###MFLJ/(M<NGE$&8&X(7UN'J#78+%>Q1M89VEIY$:EFF
M_@JSK.#?=N1WH2MAP0?)4/O$L*$-^TA2VB7O&[JR&9_85"OPF,^0D<SL2.7X
M4(TNNW8BOBK-BUB==+DJHN:PY#2$>&PL<>?%K#)]&=SN*]0VER\K!T7<$I-N
MM>QF*8(KM_CGMX"6=?&_PDJNJQ_B<:TLZ 6N9*5&R$GV/ O:H:0<2LJAI)8<
M-^)04DL^[ XEY5!2#B4U TIJWZ&D'$K*H:0<2LJAI!Q*:FEICV;U<;4Z+707
M^%(20]&S.KU6SJODS^U5:M=+4P028UI4106!',,TI&(X/#[:LWO?3Z97LK \
M>2J_FJH%1+EFDZKGCAFTQ0-OI&1Z!3U22C\<<&H;_N3T<-LGE/5)OU>+#%SC
MWJ(?R1W W4PRO3GL;3$\'BL6_;R[S85[E+>I366)<%\XH9)$"7M R=,SZ=UE
M?0,=_"M;3U1.# Y23E7D8:&ALQ_"("'X%,MNK&"\Z!4PC:?D3_9.)#*$<,4K
MVY-XAMZ;>=@H&EY0I"KJZMW ]#6,;W74F,9&4LFA+S7.?G/O 9^JL*9>,VP1
M"0'6"H$>$P\0N6D3KH-A!3,(#T!$1NQXC. $6_D>/B3'%5< HYQ_T877)[$R
MQ)*"[#62-_(-<QD-P6[0,"]RG7KJ;2T<D-;BILV&.-58M(;"6.K9IIS@4JFA
MO[5'-/W(1%%32Q-UDA5I4,402IFBP6;?=.[!1@L#EH7?46V\TVJ#4'_:?*2B
M5L40P9ZD*I@)CW<EL$MSKA-FSYA6(#1715P&]SU=(J)RX=39;2A,@]^O](WO
M8AJ4(9G5*C+P>$R B7\>==(KD(%']#V5XI^Z?@SK8*O"D=]/0E]:5#"L8?%U
MV2Q!@6I :)S)PEZ*^ZI" 8V,=9,U,$R4J!4X_IR8X4S?:J"CN$O"0+<'JV/D
MA-/0"&#K1<AV2 <9>^&K1JDC#3)YX=:F=@ \SW#SK/VL B1"&I0Q,)&:/L83
MU7I1&1'3S?+VJEA,8F*K/J$>R:&PC.976<"CBQA+#M)XK!J8Y1%.IA<"L[ L
MSDD1AA/)[%P$KII6TI?$^H$5BV&WNY# N"R2]H2OVG0>+L-TGL@>*5C0/<>(
M/L^\3W#$1X5.Y3%#T"$J*CP?(Y?:-'AO@8F^1X*(I$?Y$F*:A1S:%Y(U@TV:
M0E X);GA_[7W+DR-(]N6\%]1]#<Q ?>J::CWXTQ'N,#5Y7,IJ %7/Z:CXX1L
MI4%=LN2C!Y3OQ/SW;[\RE9)E; .F;"I/Q.D"+$NIS)T[=^Z]<JU@!CD^E9".
M6+48:*]]+X1GX 93$N,98=#&0/!QE%N["EY(;CSQ("M)U5]3WR[Y:G4RD822
MP*(1/-AL>OJ,2)2P$%(50E;*8P&J >$<R?51%D;*5.N0D%GB.U^D:8B2>N00
M=8R"]QR0="EOQI3!&W*IN;8-[F#V%N[_JI6E9&680(AV)U&&4,#"(#=EB=%E
MV![#V[%:9)%'8N%>2RLWF,VT7"O\NVL9J&E_F$J0;-25=>PV,I''G#T>5_+K
MI7D9-C8F;:@U>](J2R)-VN@_[KDJ9K+;TCR3,#5MMB).NM*W016S0:I!6!FL
MA<Q':.,%4KC4%/#,/6\("V?;SX2>Q.BZ('IKB?>VSI<_WP1?WL71'*YX[&XF
ME[/ 3=G[H0B'TK:G@8J1JE6?(Z@'UX1UYXG!RF&VOVQ%]%@'VEC\TD=8C&+_
MS;^7O(>)QEA36&$1J'O_QB&SM6]7#[EF %W8XQ[!'SLFN%G].%4+8(O0VX(P
M;W?$!/I6;#2U+%)S+&YJ[I39?(U'QT&'-X?]!9_L^KL,+YABTCJZ:.[-P/05
MW\)!GQSTR4&?-AP,XJ!/&][M#OKDH$\.^K0$].FI@SXYZ).#/CGHDX,^.>C3
MAD*?-GQC7V4LHP1ZDT$^I"R/M]8G\RP=^O:*XW-OYT'H;3B19O  RZ=C[C/M
MRAWQH%G7>@6"9*G\F??0M.3F;88I%D/,$ZFN4^] ^Q1;=<C.7JA(BT>6G)Q*
M 2VW,9 O0>'9E0'N)Z32(FO*O<"#E3/"17%DRAIB6W5J\TKOD+**14 &N749
MZ!>;D($^4T0^L<2,L35A,OE6I>M(X\<Z8'I.U/Q"Y1*>H1M!SV#@<R5F?;D,
M16>*H_&@S')5JZ#I^E]+2=H2L0Q@B<X2-37E*$'>C<!>X.FH=*94OLM"4R)(
MTR1I([OK\!]V\/O$NX$GG=,2F?)-^\)=+7&'X,AQ$-&+BH,P/62#!'TM/Q,V
MZ?GIZS39.-J48I7F!<$5P7I-/G1;$9')/?3EN[6';MV\>+D)\T(J((@&]+H&
M*;R)]!1W1'"^G,_XT:@8MV" -=I5UZ;S E>5"W;,P6023[6ZDG'?5=%7,0Y;
MO,5$ AZ\F/%S$8LZF6=2D,@\D *N1 )%C:Q$)AT.>VP EY3 GTMQ/\@MDA\)
M2HC(\"@K8<G*<)4]U%LD6>1L2SA#Z26V&'01V/:#UZ^>23#Q0+$./'@5Q"2V
MZ;R$L: R(ZZ:N,U%J3^2]1QAC:VH9#WQ\H]J/$"?7=@,F=T2(11!XGU.=-?(
M(?H([#K(O#$$&"6,E@:V\J<";[4*^1(+U/G]A&FQ'5#@VX5W,BM1[ H]W@?G
M-D>%&B'$C$"RK%\I8Y_8!H@G!A@ZCN\6!]=:(;G"&>P0QZ@R(BX<*./.N2*3
M(L!%C;RK3DI8<1X2AB)/N?GR0D)R=4'D A.<2;1,U?G=()RG+^Y$&EA*:B_,
M?X:@";JF$=+97&4\]0C!7 $>@K*X3#.-PJ&(E7H7+B38,N,(#"4"K7,&::&U
M(S'9P(8#$ZLFC6<%FSKTJR^UA18:WIU558-G56_7\G(X*$'"YH7H(!IDO261
M P754%>LDZ@O"",\;)C>%KKLN:#[.[CLYDYS:+P$G\!AQ(PPQ$@G5_ %/M\0
MTORO\$KK=>J6+T=GK&.Q=Q$XS(MHF,]QZ+TD@5ZR??B3_?W7#^2\WWTZ['56
M1PM8_L],!I_UFIL3K>E7;Y((;^S67]8>)]Y)>PJ5VT[I#>&0M9JB>/QWQ\Q:
MV,Y\3*\.C?9B: )VN[:.'2-5*$$M3W_#G)=7ZO75B-/=WA+FN!)YK01=3: ]
MH^SJ5\Z0%)<9#RA_TQ*9-K&>IG<A6KVZR:6UME#B=;C;>G]+C?&F9V5*3L/A
M"Q#RA>9)FC7?W-Z@[QS ,Y.+X,((?9MS53#/L$2'XV @=V9%IQOI>8]3EO,1
MZYRRTDE/=FM^B)\S,2DO]ESV^0E<@\=C%=IGQFJ8O=IF$XT80H>GSP]VXMV=
M%[NU%W[KK6]V:ZM;/,%%C+OI=)O1C[UNBR7-&$+#Y]>.NP0U17%B0]*:K'+^
M+S2*L(UC,_\N80&C^@1MRFF?7Z^,V.D@^QR&[OX7SZ'[6XUMJ?>=,SMOFB7M
M:2O9'M?Z@;T2\\%5W%&FA@(CS/8>TF,J7D[)2SE DP,T.4#3AD,\'*!IP[O=
M 9H<H,D!FI8 -#US@"8':'* )@=H<H F!VC:4$ 34USD_H*--X%3*A9QOXZR
M\8+PRF9ZH#=6UN%5C;&AJ@ SCC,)A9'?J.<_A/\C"KE68)VJY2J]D$,Q9.?B
M G[1KI%R(LU\!;V1O.D6U@WF\A'TI$QTQ1UJU>$H4Y1QD<DNO=6KN>T57$XC
MKR?=O[;"9IT@?)G:YEO\3EG N_VWLM4"*4M)M&-E!G.8G[A:HC;S!AKD%RS.
M>UHYSMG3YV.EBN842,V)\UKEWD"O&%18!ZU8I8@V\A%3M,,6E%4FK]DG-=0<
M/F?K<"JO-@&GTL^"4,$[?%F![6$>$X#!) XR74NKQ"6)_<I\4_OEPCR>Z_=F
M:C0^H%])X2_'*,^PI-7)X#101)[JBQO!LLD5SN^!8<O"F2'G_ /SM_635NGC
MR!^7Z_!F%:_1\0CD-*)2IE1?>X9$X!=8M,L$<VGI,]2OE3]R=VCU1?PRNI)Z
MKUN+KD%3KG<"MNZ-!W.ZCGZ]YGAUD,8AHE[.^KW#XZ[WXA\_#1ZJB3,>887V
M'IZ>O.\==4_ZO<YQK__'^EI][Y[MQ7Q$V$-ZMD-KSPK+PUNO2V7>)6%XFBN!
M2\-U_+#ZBA$I8CE-;9NJ8 T>$H3_F'HR+6NA52.K$[Q8PJ*:2&>.\EP]',X?
M"'9P9HA/[H"/KV41*L@0X6,1\Y1?UOM,;[PI/,J56?8E'-(KQ64@E#@298P8
M0M 8#?RB49/6CYEM$B\FBL+!&^#J=:H]TV1?QW?X16\'AQJNPV,500Q?NDR+
M]"(+)K J^9Y"^HDL3?#G<7"1J )_LN^VJPOH>96#0%.,"K:V.DJ_5>#VVUC+
M$;?V%N9B%V!YS8<H/U.HQ%6)/5L"B&EFZQ_Z\X;/IP$IXT#YFD@5KX;H_C*)
M< LG6HS5>-L5VZ!Q&&$2(*10.I:9_5CO%^,5Q9-[%"%_F;8JF\;*8C33&Q]9
MA3'23PN=9:O^"+8_*F-N+4*3IGKGT>QG V&"/A@:&4BX^.'93JQIU:NZ=15#
M4&VNESPDV/\P2 @)D^,<!,>A';#R&I[*J\28YC7JS;;1-Z^N"'@=F.@N#J[1
MF.JZUN!.<S[BH$VKV8TUIE(BG(11N X:GJGEFX0R4^B9DR&/DGA%.G"0A3FL
M#1-#T),B[@\G+P2A&6_^!KAU@,95OM'@2O%"F"=P$<XD)FK#A:+=%!XFN_Y-
MQ=^N:Q@VT4^CL"-4$T6-BJ?S9HJF^)5--ZT>&B<C8]MT.,8ESIM;;O0?D*0=
M1_]")0J"#8Q-KX(HUE*:M"@0KKP>8MFJ]/)YF(XIF5944UT0[#+5<:5KG^MK
MZ&,':W*P)@=K<K"F[ZG;':S)P9H<K&DQ7NG)<P=K<K F!VMRL"8':W*PIC7#
MFNYQ9Q^NO+-'3P#[\/O;W)-:P%)[>NO\LU5O*2Y),T+SM-!S]>GS.1E$>"Q.
M"J0U:E+V(P!FV](SZE;IF<794JN3Y=1Y8O%\8=\-ZX5-OX59_3(EZ: DM;\Z
M)X>G]<),M4T+&IBU"HD0L%7? +%VIT)T)XX9;63J?EP^R#W$XR'0R_2)79])
MPI]0P:%BHM=UFEF&>5UOH:><J8LR9J:TC[I26)VCURA"^/J\9"GE.Z&GA;W
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MNL#M#VFJM8+B-1!K2R?(ZJ>7^K9U^Y5I$^=2W8@;ICZ8VI2580K=@(D;+")
MX&@$Y27BU^!V$0!D1\0TCPALET]P;+)27RNTENQ2JR29R:"9DQ%<$0AH\DXE
MAV-_,L"$N _-RP2NPUDZR079Z9^1!NYEL$VM)8GT[B((QQ"VD_XW,>UI;)%
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M01]5L()5,(20"ZM'V!+-/*%;5P$"YHP64@4561K''%21R9(=_OD??_&W\QO
M%UH$T ; <8T+O[YCP*3FCLV+\6]Y&BN&55L4//! ^.P67;J[N"NWKH*Z.L2
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MRC%G5L@1PU)PA\6$778D]T3:837B8 ^EB..0\L6D)TI+S.S*XIN_,60IRC0
M!O>+890IY#/-B0\'%A[\28A!!?6$N#_X]LZ#@)3X8 >_;:&6T5'46"6?4_+<
M8M8-LP%DT!F4SR3X51B, SH4%Q,""1F@<UF6U=<)!5BSHM)&N'BDA%NL@(Y+
MU)2_:$ZZC1C2A *\-3QV _.U]JX\IG=;I0.#+,H)H%D6PJW-F%3\FW1NU:%V
MC)N746%1LYE3A?:Y/[@;C"I\&WIB[>]^2"U9 >@VR-(28WG;=!JVZ V"7%1Z
MU[#G=L@IAYQRR"F'G/J>NMTAIQQRRB&GTL7(J0.'G'+(*8><<L@IAYQRR*GM
MX4>ZG8!$HBZ@07CJSD<6A"^8W$HPP45JXFER,2ICJJ$E JDRC!?FF)==K&SA
M0[F/?)C?5F[1#VVKSK2(9)%D#K)EY.9CJ?2U55BW[E#JZNH,Z+$KD!U56&M@
M&S(!QL),N??H]*4IM<&:$2H[X2H=V<'@)U;>R[I 4B5MW]K?</&V=?GJJ@$-
M0I>F8)*1?Q*-)3[K251,^A1UC2'#=#SAA_#C2Y@S)-!'G"@PM6#^R#TP.:XN
M@WA4G[!"=7^IQL0R(/EG<PY]G,9J2&(_1I$.=2QX#DDS\7D4E=BO=L-#JU/M
M-68C&(<OJB 6BUEB&WH?9(ZW[,UO^AH6[C(5W6;W6EGF:@9HVG>=LI[ZZ$AR
M\G51\G>932FSB@#3J:2RJ][AWQM@CY8TKC0$A0LO4AH>=( , 0U5/LRB :OW
MT*00?AMNXZN] S"TAPYV5YL)]NO[WOH2S34EG\7Y9E]B94DJ3[T*;XQ5^*;8
M#Q\@ISP^)>>5C)\$O^@!"1];&[!A3!_"ZNL3. @Q0L-=''#-4@21V985^5]M
MAA!:2VGO%I"^Y4MZ->3N-I?US(NLH[1W+$6\E<I77"&JW:^ED>NM^6Q:]%W<
M6_0]AXE0_G+_@7>=:\)%W=\FZJ91=Q'W@O]:Y%B>!MHWHD!,@6&GX27S CR=
M%3,W77/,]\3%?-L=\QUL7<RW$<=]B.DZA.W@$E'>=F'@H8/G(^;6&0MJ E.*
MP98/GCO>)]H&LS)US.#WJ!&2V^N*K$&O\$3A0_!K24N4P*)6@!^Q2[@@CD7B
MB:KI_YF7$T_!H"MR"]>7\)]F'R!LD.%,#Q/=ZS>?XIJRZJO+HH34X1AUZB24
M<(C#XWR"ES5$Q#D5CM@\9%DD0Z)T$(OLMG0(G[:5;D$)]&@$JP6\'S(,8WS/
MN2QPNYFF;S/,N7S[':I4&6;8O$"&>8Y+(7X)?=B[78-KSGRC XC\\S$2(Z/&
M7N+-& CIKN*86R*/\K# .DC;6)#!E3^UUA#HB4A=,;FZ@Z4Y6)J#I6TX4,?!
MTC:\VQTLS<'2'"PM70Q+>^)@:0Z6YF!I#I;F8&D.EK:AA%ZSN0E=]&DF":H:
M46MQ CV%FA1\UB^92=O2GI\\3LL3L8([+$K8LFO !NNA:,T'S6.E\P7UO,#N
M%N85YY;KUY>%ZN1Y.9[HY,T1UM1AB\W'+X?1A+ZT?++Q-Z$<NU98]=IYHBG'
MR*5XH8HCY!LS(V>GZ1CWU&(&XV JN28[NS=4+)Y2:;3-)(J0F0E>3K2OTE@G
MS4)^2=,*SAW1BHA*%KF*JW.K4R^'UN6(;4+%G'F/VO-ZHWGM#U/%(B>SK6$:
M-FZ.WWYGPS[!7[*_@9/*-PJ61(:BS]W.-L/4>>=/X'SN$' ;,A6-!V4FDH2S
M+<5,(K?UIF/!UI%@?128S@;3-666,5:N_0E@6HSZ(.66 D9J-)?ECDV.!,$F
M)C<:)5>I,1ULK\0OK4-:@6OYZ2SFR-*!!BJGQP+U&B=FTBBC["/<)>EUHGOC
M[0,4V?S%4U8PBG/-EJTUGV>N!OK7.DJ6CBC*)F&LB!HB! M!$&!XA:- G2]3
MSLK_MC5F[L,HSM5$02SH@U)":(%-V8IJLB\P]($R0G5T<ET D\W#[+:%,XJ2
MG<<\)]& 8)"%8!MG+6VNE7'[OB@UH4=P;5NZ"/J4NI='-"^"HJRX'NVB@'W"
M' L$0\Z=2Q?K1VGO2H!-[8/R*.1)176'4+ A&LG0;%*;+NP6KLIS"ZKKF\?G
MJBAB)F!;?O'MW[!^T/J#09D1-S1/:%D'<3TAB##19NIE%\?? CO/3A]?"DDU
M.M@RL193O/FEBD-$[\7!E(4:$7U,,3'LZEI>969Z+O\N?'-JM%SZ=QE>T(4H
M&&9;)KT4.""S6O.*I1!"@,Q/JF"75R:FN0$NB1#H<R@Q9TTD%(+%I-$^*\3[
M16-$9+/\3O6%U%;B\J3F-ONH5!/2#8T:5 X^&"/EN0OJRH-=+8_;-X_G,ENN
M;QY_!$/1XS8B?,H*/%>!M2VRAPRLJ0B^J(H"$=TY;8 T4YH%'N0K8XD<K24L
M+]1$$()#H63-&[K%&,_E-X3E=IB<J7^7$8NU4I( )]R8WYX9&04ZBA*ZD[20
M]!4SR1#+"9/+[+9"$2I^'XSU+DQMM\G1AN<&] I>T5#K6B^VPNQEZ; $K&(P
M,G%P;0'%2JXPU]HNS;0#U.@;<#?>$1BT$<RNYY^ZA[W.,9*D'?7.NH=]XCHC
M)C?O^/3\O'N^,A,<,YR].^MV#C\01YMPA[U 6C7\4,C3\".DA#L[$@(X)F0[
MZWKGG]_]$YO2/_4:1%[>9_C]3(CD-"=9121W<OHK_O4<?C@3+3?\"4G>X&EP
M2>_,.^OB._=[OW:]SOOWO>->I]\EOCAXZG'OL'MRWNV>^]YOO>-C[UW7@\_?
MP4.@*?!UZ1AI[ND,H5T/6>1J-ZT]VGX"=Q-\JCN>>.IZ1\AZ!\-Q> I7_>_/
M\!N-C@P3WO'3YY,>M?ZH\['S"S\%1JKO?3H[?8\-@-_/3O_H'",5G<\?'77Z
M'?S[(?X"S8%+#S^?4:/Q5VC7>;_7_]SO>K^<GAYQ;W3/?H6V8D]\Z+(Y](3,
MSL.7!M,XZW>/D-8/VMH_Z^ ;]$_/^MY.Q;=WTOWEN/=+]^2P2V9UWC_K'5)#
MCS[#O^:&N[X>9V3U.^,;]MY]QA%G\KW>F35LT&+=)C(9'@[I3IL[D*^UKOG0
M.8<Q[9YXG:-?>^?0^M/WOL.;.+R)PYML>@7>X4TVO-L=WL3A31S>9 F\R5.'
M-W%X$X<W<7@3AS=Q>),-Q9O 7KHB\__8^^5#'[;.F# YZ?<.>\B7?T3ID$^G
MY^<]20K@5AHWX.>?#S]0Z@AWY)RCV+K4W$8H>9RD7A?];+X2Y.-$5+,XLRJ.
MNEG"&!&/=<"R+0U:%G;&DE3-K:/TIJ(AT"-SKMVWV&WR<D#;\(P0&FN6X;@O
M58/76Z)JT.^>?:1T&/[0.]DV:8/7FR%M@,I';V%J3:)L13A5OZW(,<#JNQ*U
M*0Q=I"+8T(,D<%"9$".*'-FK-+)"9'_*4;Z28QZKV/+:-W ?E!.CX_&LP55"
MB!8+>D^_BZX/GJ73((:)CN\*?R!>>%U8A+]E$<&G'N9@);9A^:.4NJ\_(\)L
M]L5$M@K[@^DN,*"\44_*[EE]^/#IWH'T:EYF5S!&OH6KD %%X3/$$$7AC^6$
MR*L@."TEA(VR3%VE)#>T98O;Z\T@(>J+Z>-HX&ITB(O.HSN<#IT]W^?U1EY3
MX1(Z@NA'(BQN5INF.J^)^;.%0C"B:0RE2J#'^4OU C'A<9NP3=YD-2]'/(04
MF&D/1K)0H6#JRCC(*C 3?]6(ZI)'NC(L$,VWB!C/@17R4*,%B4V$ ((&APHM
MVY$3SJVWH?A9D2P9ONTDF&K R3A-B ND1"J)];NW3_+D=]2N5?B@H*/FO/KN
M_&%D'T7;>R.JQ[ 5O@L.IY%>;%3EHS$,(>(0P+$-R!KPOLO9@P;L\>+S$*#)
M94A)6/%50.U-@"'3R8P\FZL&(:!#>'1(Q$KT#>MCGR1B907JV:;,4)YL$!69
M.8VO3_N',T^F<_]QK! B+_9JS= D9;+'C)8JRQ'J)$XU8C-A@5[!R+.(,1"F
M9"8H@.9@ ESNRZC#JOV&C@)::C>!#OEK7(:%_=#/U;!$+:Z)3;:^;H[["]S6
MP#\TLFF2J;_+4.P,GR1 DPKQ ;T6$'0$$2Q<$<P0.A+Q9!=NA(+\&=Q8TVAL
MW3*\$;PP_?K0WT'B"X=CKN/1H\]YOH"9Z@KH?'%]+?$RAKJXR83AS52A24\#
M[YACO=#KP">#-)S^.)C^./-'AAK"9,CH<_D1$<]XBL5Z/B'XE'<)78;K$6VW
M(# ^>*5QZW48'OO(K;.UC8 :=2N7T;7B^LRSC'!YPZ/] 0XC;J;J/FQG *:&
M,4:U?=AM\:TM%F;?9<:G:X/2,4ZUCV+'!4L$MZAHGU3B3NL>'*,4458U1T)X
MQ=@R2>S7-TEBKY78"C9]8^\0;A@EL& LP=JSYVEH?T0HPD(E3(/&QYJ:0SAC
M.<11=WV9QHJ%D"DHYH@-5M<D'RDYR%))G(MV+MR*MZV^B6=)R*\(:&$-TV$Y
M-H2%'.&&.B!K^KA(CCS42:Z#C./"O!S\C8:KEW[[A0*;*&^@XO0:%]**&SO(
MZ1P%H:K+/,:S)QCN6.C2":;W6&W7UQJ]RKM( SJ7 LUDG>D #R'2 9"LG."=
M\Y*XXN":JM40#$&SF,;54BNT_JP2/'S!'$*$$P7+(%+M@CJP>O&( I +XG4,
M#$UUB,M)2S_LFAT+'N"@2!C?),>ZC)</(RZ!#?WJ>7AY1:V-WY".T-R>#Z)#
M[-!E#EWFT&4.7?8]=;M#ESETF4.7I8O19<\<NLRARQRZS*'+'+K,H<L>4&3O
MSKFC;\"U(QD5.__XUCO$P[85_TXEO(6^958_ZU9)\\X*\(56%B=35K$0)$3I
M-,+BTJC,*"$)KG7(QY*Y6N-[-=)_4UJU<T-8A$[BYJEXS'Y6E=_9'+R5;I>R
MYLR-N<FL%:"9IU@E8.9FM:P6[KIA83+4&ZW/;K:64G%5UW#3(D*JY5:&9J:(
M(<0:Q"& N6%[_'<T=5:.! ?8N05R=%OYW&=[SW?GF(E./RU,XDE&BBXVS:ZW
MVF?F;[LZV:C"+<QU^W,Q05L'L'CV+?A SE119M3/AW:\U+.B&1S(CSK'N[QK
MZ,T.76Z;\LQ -FR7B?>) (":J#//^-E_);#[_9!><\;92D&S[R"?,?=]B%0F
MN JBF-)HMHNJB^;4F[^%]O0->"G$+:Q@)U3^6CCG9XL4&BJ!]?EJ!#'TMHSL
M!A""5;WR+<RCT1Z@9'OU]WFY]^] AZSJ7.AJ1-O@XI[S3$'(B:SZE@:I^8:L
M!E[OD[=#Q9H1&)&4:G:]',:4UT]9GGPBJL'1+7/2^_P"_Z4M&DY:DB+C:("5
M/@GIJ.)X=OQN,J<WM-N*%KBGU<(&?\E%<6$,\)9W?7=JG8E?%C9G9GU^JS>>
M2[0!OHS(TB4>,V^)]DUQCS%.#^]B'US<[>YSZ<<SJ:;>.*<6BO))N4\?@=#/
MU8$[/Q^&)Y=;@-_P@D&* .,M'[35)>(>3H^S\I=+PR^]L0H2SB!A:%3=*BBH
MYDP;)!*W&[6!CG!-E:=6(G:U($NC#9OVU' .YCF8@KKI,5MG,.'F&XSE%.[+
M<'P;#%1W1&)90F1GH-(M5NPO;Q9WLKZ9QIJOWV\CM\YVU<JV2TL18B#!_- 6
M*;P8<L+ @AL*X!^Z!M-W&J%B$D"UQ$*UC.2\CN! #V0]:6=@KC9E>\V-(8[3
M2&1,\><Z\;=6'::,.WY<:\DW6:_NO(^;>XAS?0[F4".%[,11Q^B3KD;<W024
M#]MN;HF?@C&9,6<AX@H\9H+*93-E<T!5'(HR<G9D*;Y96P<?KZI%32H6%\18
M6FUY,YO$VDT:YELW5RSZ0*.H)L1'5>NP*ZW7>Z8N(+8GC*;#83D<EL-A;3@R
MQ>&P-KS;'0[+X; <#BM=C,-Z[G!8#H?E<%@.A^5P6 Z'M:$L7YVRN$PSY(,R
MQ]8,7$"KQB](.M25I$2CI^*8LE@9<!//NE*S>E0H;I0.HZI&M]RC\1;PE.L@
MXZ-7=-),I'-&$>N!H.O,12D$LSA$:$$'[LBI&3$>R:'H]X=_E>@R+-$4O'Q0
M'?[+..]"-](GG\TI..OL_3D5Q7775VFZ%HX"778GC@)A$5KF4L( X('Y(4*:
MMC./]^);X'M,WNA]A+)/J\C^U#)5$\QI%:U)*E\40]KUTF#*U))H*.BA\L)*
MC&FM$<;[P!2"$:CA?:RWZ$P0^J>A/M8'!J*$Z68KAL#SM'+JTC["K+6W3#Y1
M"J=+IQ7AWC]5A8&<:K%5M^Q:,"CS3#IZFL/7AU6)M9'NXP!%3S_2T;I.5)9?
M1A/-FB.I=G@!=9&R7IT:5Q/>.GIJ2Z9@KBE*^(RV')#E9#X^*V*@5^4& H8J
M(#&>KO4W2#N>V0Z3HQZ^*>J5+72UHQH*L!V6\VSO.5<(=F=RJ%2EEM=%3%!!
MYX#!:I3"Z@+'>SG&9<PJ@Z>5%72H)O_#Z$VC-K'WVN&3/GL>%KJ1\H5U=+B2
MLT$?RZ0E><T1PI.XI?JT]+R&L,!'U9\#)#GZ8E B(YZY."K"%2*B.++(V--#
M5D*-P>"RV 6F*A(ZD TAK77)# $ )<OE(;471&FV+)1EAF8HKX=9ZZOK#OV6
MZX,%4::VM3B1&WS(K-H/_%+S8_,!D^; ]F+X6$5#0W VLK$*BIM[+_8.3,4,
M;-O2*2/\L0U>;%4E7.*E95W8PO7TY<.OIT<0<*VN6MNR)"YG'K/5(SV)Z)1^
M;:7TY:%X61473C*EW;%/-%PU#@#S2UZ4A-NJN!,&FJEFH.#)([LHYS>UP)@N
M58J_*F?"!R$_:"NI1_R=&E:<,+^XC0Z&Z55T$<4TT>E%K"6-H/<A>+-<(\;Q
M"M3_S'=7?:Q6%:1G/)8)CR]C7%^Q*/(R4&L\3%'%^619>5&Y6I:XQ35'+RPP
M0WB;%"ISU9QU:-&PV  +KNQCL!FE+#EZK6+HSIV#)[O(AU=<YC;)G-6Q;B^R
MDN]\]?"^LY?@A$7KZ,OPK'#0R%@ONR:11)OC' U+33TV9#:[1.^Q=6M00'$1
MA+7A@L#T59!99([@3'BC/M%HID$9?_'"K+P@^ O-)9\WST)=B/XGS;[ B/Y(
MLKDYW@-\"DXA/J=@;EW%C'BC,,A")-O!>\OC*D>.+<M@PN0!:HO"99-@^(44
M[C-%XHAX@DE_IGT1IC5W^;B31(03$B;,!4"]K..OS4%K.^%FX9Q9^/H;\$P1
M>@\M.U?#TBQ)W80.V6%0O\*L-)QWJV%@S%Z_.6/9)&GNRI2N^$!A.98]ND/
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MT+6%%=W[#9H%:RSQQ4SIGU+=[=TT4/4&<--H-CO=]L (J-5I_-SM#8:=YJ"
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M)4JUS9Z6*&O?.3PR)2=^%^%N//;GD&[)DT)1 <RN)+=]6;.]5SR@DFN:%Y'
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MC=E+"IZ^]S:O&LQE71D(K>_OFJ+*.=G?%%C[HM;<,4A8.1;F_)60)9<-[B\
M\SO'G](17'J'>PGQB#ML&G,0YN+!KDB?S=)#C(#N(*" #"ET)R?IFLFI3P]^
M/G!_#LED>O/#M3!O,3Q&AXLR?5N1O 428T#S<7P9<]=Z_D.)Y<NG2R_1U]G!
MBFD]X<+LE[\V^\_OR-Y*X7[JBFPI^9L-YH] G/P/4$L#!!0    ( %8]95%@
M:GY040@  ,HH   7    =&UB+3(P,C P.3,P>&5X,S%D,2YH=&WM6FMOVS@6
M_2N<#+IM $NR\V@2.PV0)AE,!TW;[;C8W8^41$?<2**&I.QX?OV>2TJ.[;C3
M/)QN@DZ!QC9U>7D?A^=>2CK\*0C.RHR7B4C9K\/S]RQ525V(TK)$"VXQ.I$V
M8T-55;QDYT)KF>?LK9;IA6#L(-P+N^'N?A <'4+323-%E7W6ZT6[T59WJ\MZ
M6_V=7G_K-?MTSEY]&9YL.NG3CR?#_WPZ\XM^^O+V_;L3MA%$T;^V3Z+H='CJ
M+^R$W1X;:EX:::4J>1Y%9Q\VV$9F;=6/HLED$DZV0Z4OHN'G*+-%OA/E2AD1
MIC;=.#JD$?P5/#TZ+(3E+,FX-L*^V?@R_"78AX25-A='AU'[Z65CE4Z/#E,Y
M9L9.<_%FH^#Z0I:!555_NUO9 69&N+PD<Q5,9&JS?J_;?3&H>)K*\B+(Q<CV
M>[UP[_7UF)87V?6@\L[UM<BYE6-!VN?T)KG@NA\KFPV6EU@ULVKGC51I@Q$O
M9#[MOSSAN8RU?-EY^:O(Q\+*A..[06 #([0<O1PX<2/_%- -#W-9BB 3WM!P
M:W]@Q94-H.4"R]'HP,>D#V%&__?])YD0KS1A* MAV <Q89]5P4LL[T;(C#D+
M)G[)6.4I5)U=93*6EFWWPMYA%"/JU7?Q,,$.$/J[N'@BM)4C6$N9_)X^_K<V
M6'CZ%TZ2LOOYN7'TKL-^XR3U.80@SSLL<8Y.F<VX[1]&I/ 1?>T=+.[  TBL
M<-X-R3)%OOL!R331>-U$H[N>:/1"]HYE?"R8%F,I)B!)FTG#_JBY!M#R*<8K
MI2VHD_VB=,%ZW>"?3(W8OS^>'[,3I7'1 63P@P5N*V2MQP]1\Y8;5Y=8,667
MI9KD O6KXW/01#Y54%(J%#[HYK)DO)RRNK2Z%E@5=<U51:2$LP*_M.0Y&_$$
M0YJI AQEE9>[(5"*1!C#]91$"GXIL.Z<3H.Q%,9@R9QR0&N00"(U2C'$4)P-
M+$F%9I-,)ADS-?VYGC\16C1*R(%"&I0,RJ OWEJ82B3.0-);P325PLTQIJ4L
MGLZ'X4?#UW;(OHH-P4:R1/0ID=?1[@ 8$,=E/7==EB-L6[=%\3W)ZQ0ZD=&Y
MT': !DE;O4)""$N$,313,[ T>3)+2P./J2OS'9*H<P@ (0II=,L99T_"3<9&
MN9J8%CY:7$ACT3I9QFG0VPTK.W,H,*TQ-ZS]T8"P$[+A0M3^\?/^5F]O8)I4
M-]6+-I4:H5P+[0/_CG$M7.J0"AGG@D+,!/ 2Y])D)$]B!1B%6(5^I](DN3(U
MYA'7:)5[5956:,,Q;-@KI"P5P(#/R]D5&M<2'?<QMO'G.H=$;YL'O=U78M--
M[>VF<[\D-2^EAPZI9[35YQ#E,TRFW'J=T>;FIO-L&5I8;B)<:7M6-;VW'>X^
M'#1\DYT*@[41/D?*WTYMA^I%PFMS^RE$W+% GIJ5?"E0M88";..Q-(X<("5*
MIX<ZK&M:F:<F?U! XIM:<)W)3D-;=%&"8F"+4;E,W8'.U+&1J>1:D@/25RQ'
MEB5IJ@U5$;=/C"LYCDIP#(-!.%BY214:'9G4.2<&A%O.B.MJA!F^MLV79'R+
M!0F"I#!?I,^*E-8#L7@98K?>W#>0=GM:N#7@ -*Q3 E'W.!X3O3'#3!(/0N!
MB^NT332@)WDL<VFG5*)6+4NP=YAPZ?:(71"=ZWD<RUXU#E4U&F2#4%))31*E
M4V> ZWXN1(E*F0-UN"(J@C.)H+/SR +L906F"Y\+MO;7AJUD<RW-]=F8Y[7C
M"4J>&(W0Q,@QPFY6-".SLGH+WO,_5_<G#HZ8",XRO@N*56V_;L%MF)G/I 6U
M>*-OM\LL;IM'M\.$CP2=TTCYHR,*!_J'(*J[=D2E8"L?Z)L)H_-4TUZX*RM1
M<0>.HB*GDJ36E):YBK)":Z&,Q3C=U8$NDT!1<_+V:C)N9O62B,(!2*2.09T#
M#;M-<4*[%'ESD%N2[SS8IV<'FC7TW;OW[KO=[92T15OG>BL2,\QG_'I7TIZ^
M0_V\T23-;.-HE*QJ3"$9-P"512&M%8(66C$M5BB(="V5L,TI> 6(@6(,41@^
MJ55K@2S^J"5,=Z"MRX0<V'S\)OO)<0J:[&,<DZD7<?=)H8F.+(D42%A3)6;-
M[D3P2Z)]WPLXXG==C+M+TQZ9[P2#IB_UI[P5/,!33#1B1@-?A4S3^V *<H\6
MI>-KCT'A,76!\"$ASIF&+U?>7'AV%+&V+O@8Y6.DL<\ZR(APW("<NOM=3?([
MGLQE.5;PF1B]Y!?-;3O=T(DHJEQ-!:Y.,N4IA"] "U!82WU:=SO96Y6DQZ#D
M)6!0L^^1V\]DBE1#.T6CN[UP&*/G50X<;S8(,?1DS9T&&A-BX%WH(%%YSBLC
M^NV7^=70WPX:Y^@Y%P48J1OXYUT'!^'^P0ORS.I6:1L)[[%-V_$QE0S4^ :M
M5E6-DMWNB[F0M1!WX=L-=YH@NF]+C^#F5J)\TWVV-AKM[V"B>=6/01&7P03>
M?O.QWNPZCW'0KJT8T--%LFON"=]ZGN?=Q Z.(G.!6(47/_/V /"/0YN_-OT[
M'T\M'Y'5M'D>(3&/=5C^1D3N4#Y.42'Z[ .P4<2@Z]T.HS<3%L)U!\@V9!8K
M:U6!G%PQ=Z>,_=QU_YY Y/[J2?9#8QF9B/UV?'[VNWNR>W;\_D88GS32[K/W
M'KEVW@-[1$W/$7CK>VUBX>6"V6L3?^/OD?'W]"'V$&X[R:08L;,KD=34(;"/
M_H[#:H:+7(?;UMC_;XM_CZ8@F_71,4\N+[2JRY0:=*7[+9_,O7FV>*$Q<&O)
MX):!%MYY:X867GE;?IVNPCDM\+T:'R&E?3Y6,FU@M_<ZW-F;,9\?Z[HW\/QK
M>NZ]OZ/_ 5!+ P04    " !6/651IYN)GVT(    *0  %P   '1M8BTR,#(P
M,#DS,'AE>#,Q9#(N:'1M[5IK;]LX%OTKG RZ;0#+LI.X2>PT0%Y%"TS:;NO.
M[GZD)-KB1A(U)&7'\^OW7%)V%,>=YN%D&W0*-+8I\O(^#L^]5]+!+T%P5J2\
MB$7"W@W/?V.)BJM<%);%6G"+T:FT*1NJLN0%.Q=:RRQCQUHF8\'8?GNWW6GW
M]H+@\ "23NHEJNBS;C?LA5N=K0[K;O5WNOVM??;IG+WZ.CS9=+-//YX,__/I
MS&_ZZ>OQ;^]/V$80AO_:/@G#T^&IO[#3[G394//"2"M5P;,P//NPP392:\M^
M&$ZGT_9TNZWT.!Q^#E.;9SMAII01[<0F&X<'-(*_@B>'![FPG,4IUT;8-QM?
MAV^#/<RPTF;B\""<?_JYD4IFAP>)G#!C9YEXLY%S/99%8%79W^Z4=H"5(2XO
MS;D,IC*Q:;_;Z;P8E#Q)9#$.,C&R_6ZWO?OZ:DS+<7HUJ+QQ?2TR;N5$D/2&
MW#@37/<C9=/!\A:K5I;S=2-5V&#$<YG-^B]/>"8C+5^V7KX3V418&7-\-W!L
M8(26HY<#-]W(/P5DP\),%B)(A5>TO;4WL.+2!I RQG8T.O ^Z6,RH_][_I-4
MB%:J,)2Y,.R#F++/*N<%MG<CI$9#@ZG?,E)9 E%GEZF,I&7;4.$@C.#U\DDL
MC'$"A'X2$T^$MG($;2F23VGC?RN#C6=_820)NY^=&X?O6VR8XJ)AQY4N3(O%
MSLX9LRFW_8.0Y#VBJ=W]ZP=P'S-6V.Z&9)$@W/V YM3.>%T[H[,>9W3;[#U+
M^40P+2923,&1-I6&_5%Q#9QE,XR72ELP)WNK=,ZZG>"?3(W8OS^>'[$3I7'1
MX6/PDSENJ\WF%C]$S#$W+BVQ?,8N"C7-!-)7R\>@]GRB(*10R'N0S67!>#%C
M56%U); KTII+B@@)9SE^:<DS-N(QAC13.2C**C_OQH1"Q,(8KF<T)><7 OLV
M9!J,)5 &6V84 ]J#)L12(Q-C&G*S@2:)T&R:RCAEIJ(_5^NG0HM:"!F02X.,
M01'TN5L+4XK8*4AR2ZBF$I@YP;*$1;.F&WXV?&VWV3>Q(=A(%O ^!?+*VRT
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ML=>F-FH>Q[*7M4%EA0+9P)644N-8Z<0IX*J?L2B0*3.@#E=$27"F*:CL/+(
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MKY*0JLVW:ZK>7^V#[N@W4$L! A0#%     @ 5CUE4<]>"K6T'0  Z5L! !
M             ( !     '1M8BTR,#(P,#DS,"YX<V102P$"% ,4    " !6
M/651_,G0"T$0  #WZ   %               @ 'B'0  =&UB+3(P,C P.3,P
M7V-A;"YX;6Q02P$"% ,4    " !6/651#%&9HX)%   @A04 %
M    @ %5+@  =&UB+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !6/651
M**Y-)JR?   <S0@ %               @ $)=   =&UB+3(P,C P.3,P7VQA
M8BYX;6Q02P$"% ,4    " !6/651X 0 /RAU  "^(@D %
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M,BYH=&U02P$"% ,4    " !6/6518&I^4%$(  #**   %P
M@ $=L 4 =&UB+3(P,C P.3,P>&5X,S%D,2YH=&U02P$"% ,4    " !6/651
MIYN)GVT(    *0  %P              @ &CN 4 =&UB+3(P,C P.3,P>&5X
M,S%D,BYH=&U02P$"% ,4    " !6/651^?;Y+]8&  "C'@  %P
M    @ %%P04 =&UB+3(P,C P.3,P>&5X,S)D,2YH=&U02P4&      L "P#A
) @  4,@%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
